0000927653-24-00012510-Q MCKESSON CORP 20241107202411071609201609201609200 0 0000927653-24-000125 10-Q 82 20240930 20241107 20241107 MCKESSON CORP 0000927653 5122 943207296 DE 0331 10-Q 34 001-13252 241435675 6555 STATE HIGHWAY 161 IRVING TX 75039 972-446-4800 6555 STATE HIGHWAY 161 IRVING TX 75039 MCKESSON HBOC INC 19990115 MCKESSON CORP 19950209 SP VENTURES INC 19940728 10-Q 1 mck-20240930.htm 10-Q mck-20240930000092765303/312025Q2false366365xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesmck:segmentxbrli:pureiso4217:CADiso4217:GBPiso4217:EURmck:distributormck:statemck:caser
04-012024-09-300000927653us-gaap:CommonStockMember2024-04-012024-09-300000927653mck:A1500NotesDue2025Member2024-04-012024-09-
300000927653mck:A1625NotesDue2026Member2024-04-012024-09-300000927653mck:A3125NotesDue2029Member2024-04-012024-09-3000009276532024-09-3000009276532024-07-
012024-09-3000009276532023-07-012023-09-3000009276532023-04-012023-09-3000009276532024-03-310000927653us-gaap:CommonStockMember2024-06-300000927653us-
gaap:AdditionalPaidInCapitalMember2024-06-300000927653us-gaap:RetainedEarningsMember2024-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-
300000927653us-gaap:TreasuryStockCommonMember2024-06-300000927653us-gaap:NoncontrollingInterestMember2024-06-3000009276532024-06-300000927653us-
gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000927653us-gaap:TreasuryStockCommonMember2024-07-012024-09-300000927653us-gaap:RetainedEarningsMember2024-07-
012024-09-300000927653us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-
300000927653us-gaap:CommonStockMember2024-09-300000927653us-gaap:AdditionalPaidInCapitalMember2024-09-300000927653us-gaap:RetainedEarningsMember2024-09-
300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000927653us-gaap:TreasuryStockCommonMember2024-09-300000927653us-
gaap:NoncontrollingInterestMember2024-09-300000927653us-gaap:CommonStockMember2023-06-300000927653us-gaap:AdditionalPaidInCapitalMember2023-06-300000927653us-
gaap:RetainedEarningsMember2023-06-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000927653us-gaap:TreasuryStockCommonMember2023-06-
300000927653us-gaap:NoncontrollingInterestMember2023-06-3000009276532023-06-300000927653us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000927653us-
gaap:TreasuryStockCommonMember2023-07-012023-09-300000927653us-gaap:RetainedEarningsMember2023-07-012023-09-300000927653us-gaap:NoncontrollingInterestMember2023-07-
012023-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000927653us-gaap:CommonStockMember2023-09-300000927653us-
gaap:AdditionalPaidInCapitalMember2023-09-300000927653us-gaap:RetainedEarningsMember2023-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-
300000927653us-gaap:TreasuryStockCommonMember2023-09-300000927653us-gaap:NoncontrollingInterestMember2023-09-3000009276532023-09-300000927653us-
gaap:CommonStockMember2024-03-310000927653us-gaap:AdditionalPaidInCapitalMember2024-03-310000927653us-gaap:RetainedEarningsMember2024-03-310000927653us-
gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000927653us-gaap:TreasuryStockCommonMember2024-03-310000927653us-gaap:NoncontrollingInterestMember2024-03-
310000927653us-gaap:CommonStockMember2024-04-012024-09-300000927653us-gaap:AdditionalPaidInCapitalMember2024-04-012024-09-300000927653us-
gaap:TreasuryStockCommonMember2024-04-012024-09-300000927653us-gaap:RetainedEarningsMember2024-04-012024-09-300000927653us-gaap:NoncontrollingInterestMember2024-04-
012024-09-300000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-09-300000927653us-gaap:CommonStockMember2023-03-310000927653us-
gaap:AdditionalPaidInCapitalMember2023-03-310000927653us-gaap:RetainedEarningsMember2023-03-310000927653us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-
310000927653us-gaap:TreasuryStockCommonMember2023-03-310000927653us-gaap:NoncontrollingInterestMember2023-03-3100009276532023-03-310000927653us-
gaap:CommonStockMember2023-04-012023-09-300000927653us-gaap:AdditionalPaidInCapitalMember2023-04-012023-09-300000927653us-gaap:TreasuryStockCommonMember2023-04-
012023-09-300000927653us-gaap:RetainedEarningsMember2023-04-012023-09-300000927653us-gaap:NoncontrollingInterestMember2023-04-012023-09-300000927653us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-09-300000927653us-
gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember2024-09-050000927653us-
gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember2024-09-052024-09-050000927653us-
gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember2024-09-300000927653us-
gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember2024-07-012024-09-300000927653us-
gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember2024-04-012024-09-
300000927653mck:RestructuringImpairmentAndRelatedChargesNetMember2024-07-012024-09-300000927653mck:RestructuringImpairmentAndRelatedChargesNetMember2024-04-012024-
09-300000927653us-gaap:CostOfSalesMember2024-07-012024-09-300000927653us-gaap:CostOfSalesMember2024-04-012024-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMembersrt:MinimumMember2024-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMembersrt:MaximumMember2024-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2024-04-012024-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2024-07-012024-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-07-012023-09-
300000927653mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember2023-04-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-07-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2024-07-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2024-07-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:InternationalSegmentMember2024-07-012024-09-300000927653us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000927653us-
gaap:CostOfSalesMembermck:USPharmaceuticalSegmentMember2024-07-012024-09-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-07-
012023-09-300000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-07-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-07-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-07-012023-09-300000927653us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-04-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2024-04-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2024-04-012024-09-300000927653us-
gaap:OperatingSegmentsMembermck:InternationalSegmentMember2024-04-012024-09-300000927653us-gaap:CorporateNonSegmentMember2024-04-012024-09-300000927653us-
gaap:CostOfSalesMembermck:USPharmaceuticalSegmentMember2024-04-012024-09-300000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2023-04-
012023-09-300000927653us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2023-04-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:InternationalSegmentMember2023-04-012023-09-300000927653us-gaap:CorporateNonSegmentMember2023-04-012023-09-300000927653us-
gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-03-310000927653us-
gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2024-03-310000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2024-03-310000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2024-03-
310000927653us-gaap:CorporateNonSegmentMember2024-03-310000927653us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-09-300000927653us-
gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember2024-09-300000927653us-
gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember2024-09-300000927653us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember2024-09-
300000927653us-gaap:CorporateNonSegmentMember2024-09-300000927653us-gaap:AccruedLiabilitiesMember2024-03-310000927653us-gaap:OtherNoncurrentLiabilitiesMember2024-03-
310000927653us-gaap:AccruedLiabilitiesMember2024-09-300000927653us-gaap:OtherNoncurrentLiabilitiesMember2024-09-3000009276532023-04-012023-06-300000927653us-
gaap:EmployeeStockOptionMember2024-07-012024-09-300000927653us-gaap:EmployeeStockOptionMember2023-07-012023-09-300000927653us-gaap:EmployeeStockOptionMember2024-04-
012024-09-300000927653us-gaap:EmployeeStockOptionMember2023-04-012023-09-300000927653us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000927653us-
gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000927653us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-09-300000927653us-
gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300000927653mck:USPharmaceuticalSegmentMember2024-03-
310000927653mck:PrescriptionTechnologySolutionsSegmentMember2024-03-310000927653mck:MedicalSurgicalSolutionsSegmentMember2024-03-
310000927653mck:InternationalSegmentMember2024-03-310000927653us-gaap:CorporateMember2024-03-310000927653mck:USPharmaceuticalSegmentMember2024-04-012024-09-
300000927653mck:PrescriptionTechnologySolutionsSegmentMember2024-04-012024-09-300000927653mck:MedicalSurgicalSolutionsSegmentMember2024-04-012024-09-
300000927653mck:InternationalSegmentMember2024-04-012024-09-300000927653us-gaap:CorporateMember2024-04-012024-09-300000927653mck:USPharmaceuticalSegmentMember2024-
09-300000927653mck:PrescriptionTechnologySolutionsSegmentMember2024-09-300000927653mck:MedicalSurgicalSolutionsSegmentMember2024-09-
300000927653mck:InternationalSegmentMember2024-09-300000927653us-gaap:CorporateMember2024-09-300000927653us-gaap:CustomerRelationshipsMember2024-09-300000927653us-
gaap:CustomerRelationshipsMember2024-03-310000927653us-gaap:ServiceAgreementsMember2024-09-300000927653us-gaap:ServiceAgreementsMember2024-03-310000927653us-
gaap:TrademarksAndTradeNamesMember2024-09-300000927653us-gaap:TrademarksAndTradeNamesMember2024-03-310000927653us-gaap:TechnologyBasedIntangibleAssetsMember2024-
09-300000927653us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000927653us-gaap:OtherIntangibleAssetsMember2024-09-300000927653us-
gaap:OtherIntangibleAssetsMember2024-03-310000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A525NotesDueFebruary152026Memberus-
gaap:LoansPayableMember2024-09-300000927653mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember2024-
03-310000927653mck:A765DebenturesDueMarch12027Memberus-gaap:LoansPayableMember2024-09-300000927653mck:A765DebenturesDueMarch12027Memberus-
gaap:LoansPayableMember2024-03-310000927653mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A475NotesDueMay302029Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A475NotesDueMay302029Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember2024-
09-300000927653mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A510NotesDueJuly152033Memberus-
gaap:LoansPayableMember2024-09-300000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A600NotesDueMarch12041Memberus-
gaap:LoansPayableMember2024-09-300000927653mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A488NotesDueMarch152044Memberus-
gaap:LoansPayableMember2024-09-300000927653mck:A488NotesDueMarch152044Memberus-gaap:LoansPayableMember2024-03-
310000927653mck:A150EuroNotesDueNovember172025Memberus-gaap:LoansPayableMember2024-09-300000927653mck:A150EuroNotesDueNovember172025Memberus-
gaap:LoansPayableMember2024-03-310000927653mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember2024-09-
300000927653mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember2024-03-310000927653mck:A313SterlingNotesDueFebruary172029Memberus-
gaap:LoansPayableMember2024-09-300000927653mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember2024-03-
310000927653mck:LeaseAndOtherObligationsMember2024-09-300000927653mck:LeaseAndOtherObligationsMember2024-03-310000927653mck:A4.25NotesDueSeptember152029Memberus-
gaap:LoansPayableMember2024-09-100000927653mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember2024-09-102024-09-
100000927653mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember2024-09-102024-09-100000927653mck:A525NotesDueFebruary152026Member2024-09-
100000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-06-150000927653mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember2023-06-
150000927653mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember2023-06-152023-06-150000927653mck:A510NotesDueJuly152033Memberus-
gaap:LoansPayableMember2023-06-152023-06-150000927653mck:A380NotesDueMarch152024Member2023-06-150000927653srt:MinimumMemberus-gaap:LoansPayableMember2023-06-
152023-06-150000927653srt:MaximumMemberus-gaap:LoansPayableMember2023-06-152023-06-150000927653us-gaap:LoansPayableMember2023-06-152023-06-
150000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-06-162023-06-160000927653mck:A380NotesDueMarch152024Memberus-
gaap:LoansPayableMember2023-06-160000927653mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember2023-04-012023-09-
300000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2022-11-
070000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMemberus-
gaap:UnsecuredDebtMember2022-11-070000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-
gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2023-04-012023-09-
300000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMemberus-
gaap:UnsecuredDebtMember2024-04-012024-09-300000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-
gaap:RevolvingCreditFacilityMemberus-gaap:UnsecuredDebtMember2024-03-
310000927653mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:RevolvingCreditFacilityMemberus-
gaap:UnsecuredDebtMember2024-09-300000927653us-gaap:CommercialPaperMember2024-09-300000927653us-gaap:CommercialPaperMember2024-04-012024-09-300000927653us-
gaap:CommercialPaperMember2023-04-012023-09-300000927653us-gaap:CommercialPaperMember2024-03-310000927653us-gaap:CurrencySwapMemberus-
gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2024-09-300000927653us-gaap:CurrencySwapMemberus-
gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2024-03-310000927653us-gaap:CurrencySwapMemberus-
gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBP2024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-

gaap:DesignatedAsHedgingInstrumentMembercurrency:GBP2024-03-310000927653us-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:EUR2024-03-310000927653us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2024-09-300000927653us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:USD2024-03-310000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:GBP2024-09-300000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:GBP2024-03-310000927653us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMembercurrency:CAD2024-06-300000927653currency:CADus-gaap:SubsequentEventMemberus-gaap:CurrencySwapMemberus-
gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2024-10-310000927653us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-03-310000927653us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-09-300000927653us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2022-04-012023-03-310000927653us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-04-012023-06-300000927653us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-06-150000927653us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-04-012024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000927653us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-04-012024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-04-012023-09-300000927653us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000927653us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-04-012024-09-300000927653us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-04-012023-09-300000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-04-012024-09-300000927653us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-04-012023-09-300000927653mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-07-012024-09-300000927653mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-07-012023-09-300000927653mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2024-04-012024-09-300000927653mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-
gaap:DesignatedAsHedgingInstrumentMember2023-04-012023-09-300000927653us-gaap:CurrencySwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:CurrentAssetLiabilityMember2024-09-300000927653us-gaap:CurrencySwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:CurrentAssetLiabilityMember2024-03-310000927653us-gaap:CurrencySwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsLiabilitiesMember2024-09-300000927653us-gaap:CurrencySwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsLiabilitiesMember2024-03-310000927653us-gaap:InterestRateSwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsLiabilitiesMember2024-09-300000927653us-gaap:InterestRateSwapMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:OtherNonCurrentAssetsLiabilitiesMember2024-03-310000927653us-gaap:ForwardContractsMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:CurrentAssetLiabilityMember2024-09-300000927653us-gaap:ForwardContractsMemberus-
gaap:DesignatedAsHedgingInstrumentMembermck:CurrentAssetLiabilityMember2024-03-310000927653us-gaap:ForwardContractsMemberus-
gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-09-300000927653us-gaap:ForwardContractsMemberus-
gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-03-310000927653us-gaap:DesignatedAsHedgingInstrumentMember2024-09-300000927653us-
gaap:DesignatedAsHedgingInstrumentMember2024-03-310000927653us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300000927653us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000927653us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMember2024-09-300000927653us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-
310000927653mck:NationalPrescriptionOpiateLitigationMember2024-09-
300000927653mck:NationalPrescriptionOpiateLitigationMembermck:ThreeLargestUSPharmaceuticalDistributorsMember2024-04-012024-09-
300000927653mck:NationalPrescriptionOpiateLitigationMembermck:StateOfAlabamaAndSubdivisionsMember2024-04-012024-09-
300000927653mck:ThreeNationalPharmaceuticalDistributorsMembermck:NationalPrescriptionOpiateLitigationMembermck:StateOfWestVirginiaAndSubdivisionsMember2024-04-012024-09-
300000927653mck:ThreeNationalPharmaceuticalDistributorsMembermck:NationalPrescriptionOpiateLitigationMembermck:CherokeeNationMember2024-04-012024-09-
300000927653mck:ThreeNationalPharmaceuticalDistributorsMembermck:NationalPrescriptionOpiateLitigationMembermck:NativeAmericanTribesOtherThanCherokeeNationMember2024-04-
012024-09-300000927653mck:NationalPrescriptionOpiateLitigationMembermck:NativeAmericanTribesOtherThanCherokeeNationMember2024-09-
300000927653country:USmck:NationalPrescriptionOpiateLitigationMember2024-09-
300000927653country:USmck:NationalPrescriptionOpiateLitigationMembermck:IndividualClaimantMember2024-09-300000927653mck:NationalPrescriptionOpiateLitigationMember2023-04-
012024-03-310000927653mck:NationalPrescriptionOpiateLitigationMemberus-gaap:CorporateMember2023-04-012024-03-
310000927653mck:NationalPrescriptionOpiateLitigationMembermck:USPharmaceuticalSegmentMember2023-04-012024-03-
310000927653mck:NationalPrescriptionOpiateLitigationMember2023-04-012024-03-310000927653mck:NationalPrescriptionOpiateLitigationMember2024-04-012024-09-
300000927653mck:NationalPrescriptionOpiateLitigationMembermck:CorporateSegmentAndU.S.PharmaceuticalSegmentMember2024-04-012024-09-
300000927653mck:NationalPrescriptionOpiateLitigationMember2024-09-300000927653mck:NationalPrescriptionOpiateLitigationMember2024-03-310000927653us-
gaap:SettledLitigationMembermck:NationalPrescriptionOpiateLitigationMembermck:SettlingGovernmentalEntitiesAndCherokeeNationMember2024-04-012024-09-
300000927653country:CAmck:NationalPrescriptionOpiateLitigationMember2024-09-
300000927653country:CAmck:NationalPrescriptionOpiateLitigationMembermck:IndividualClaimantMember2024-09-
300000927653mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMembersrt:MinimumMember2013-05-172013-05-
170000927653mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMembersrt:MaximumMember2013-05-172013-05-
170000927653mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember2019-08-1300009276532021-10-082021-10-
080000927653mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember2022-04-272022-04-
270000927653mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember2020-07-3100009276532024-04-012024-06-
300000927653mck:OpenMarketShareRepurchaseTransactionsMember2024-07-012024-09-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2024-09-
300000927653mck:OpenMarketShareRepurchaseTransactionsMember2024-04-012024-06-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-07-012023-09-
300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-09-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-04-012023-06-
300000927653mck:OpenMarketShareRepurchaseTransactionsMember2024-04-012024-09-300000927653mck:OpenMarketShareRepurchaseTransactionsMember2023-04-012023-09-
3000009276532023-04-012024-03-3100009276532024-07-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-
06-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2024-06-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-06-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300000927653us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-06-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2024-07-012024-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2024-07-012024-09-300000927653us-
gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2024-07-012024-
09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-012024-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-07-012024-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2024-09-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300000927653us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-06-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-06-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-06-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000927653us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-06-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-07-012023-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2023-07-012023-09-300000927653us-
gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2023-07-012023-
09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-012023-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-07-012023-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-09-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-09-300000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000927653us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-09-300000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-03-
310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2024-03-310000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-03-310000927653us-
gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000927653us-
gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2024-03-310000927653us-
gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2024-04-012024-09-
300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2024-04-012024-09-300000927653us-
gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2024-04-012024-09-300000927653us-

gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2024-04-012024-09-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2024-04-012024-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2024-04-012024-09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2024-04-012024-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2024-04-012024-09-300000927653us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2024-04-012024-09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2024-04-012024-09-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember2023-03-310000927653us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember2023-04-012023-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember2023-04-012023-09-300000927653us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-09-300000927653mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember2023-04-012023-09-300000927653us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-09-300000927653us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-04-012023-09-300000927653mck:USPharmaceuticalSegmentMember2024-07-012024-09-300000927653mck:USPharmaceuticalSegmentMember2023-07-012023-09-300000927653mck:USPharmaceuticalSegmentMember2023-04-012023-09-300000927653mck:PrescriptionTechnologySolutionsSegmentMember2024-07-012024-09-300000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-07-012023-09-300000927653mck:PrescriptionTechnologySolutionsSegmentMember2023-04-012023-09-300000927653mck:MedicalSurgicalSolutionsSegmentMember2024-07-012024-09-300000927653mck:MedicalSurgicalSolutionsSegmentMember2023-07-012023-09-300000927653mck:MedicalSurgicalSolutionsSegmentMember2023-04-012023-09-300000927653mck:InternationalSegmentMember2024-07-012024-09-300000927653mck:InternationalSegmentMember2023-07-012023-09-300000927653mck:InternationalSegmentMember2023-04-012023-09-300000927653us-gaap:CorporateMember2024-07-012024-09-300000927653us-gaap:CorporateMember2023-07-012023-09-300000927653us-gaap:CorporateMember2023-04-012023-09-300000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:USPharmaceuticalSegmentMember2024-07-012024-09-300000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:PrescriptionTechnologySolutionsSegmentMember2024-07-012024-09-300000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:MedicalSurgicalSolutionsSegmentMember2024-07-012024-09-300000927653us-gaap:ProductConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMembermck:InternationalSegmentMember2024-07-012024-09-300000927653country:US2024-07-012024-09-300000927653mck:USPharmaceuticalSegmentMember2023-04-012024-03-310000927653mck:RestructuringInitiativesQTDMemberus-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-04-012024-09-300000927653mck:RestructuringInitiativesQTDMemberus-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-07-012024-09-300000927653mck:NationalPrescriptionOpiateLitigationMemberus-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember2024-04-012024-09-300000927653mck:RxSavingsSolutionsLLCMember2023-07-012023-09-300000927653mck:RxSavingsSolutionsLLCMember2023-04-012023-09-300000927653mck:CanadianRetailDisposalGroupMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:InternationalSegmentMember2024-04-012024-09-300000927653mck:CanadianRetailDisposalGroupMemberus-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:InternationalSegmentMember2024-07-012024-09-300000927653us-gaap:CorporateNonSegmentMembermck:CanadianRetailDisposalGroupMember2024-04-012024-09-300000927653us-gaap:CorporateNonSegmentMembermck:CanadianRetailDisposalGroupMember2024-07-012024-09-300000927653mck:NationalPrescriptionOpiateLitigationMemberus-gaap:CorporateNonSegmentMember2024-04-012024-09-300000927653mck:ThomasRodgersMember2024-04-012024-09-300000927653mck:ThomasRodgersMember2024-07-012024-09-300000927653mck:ThomasRodgersMember2024-09-300000927653mck:LeAnnSmithMember2024-04-012024-09-300000927653mck:LeAnnSmithMember2024-07-012024-09-300000927653mck:LeAnnSmithMember2024-09-30Table of ContentsÂ Â Â Â

(1,513)â€”Â (1,513)Net incomeâ€”Â â€”Â â€”Â 1,622Â â€”Â â€”Â â€”Â 78Â 1,700Â Other comprehensive incomeâ€”Â â€”Â â€”Â â€”Â 18Â â€”Â â€”Â â€”Â 18Â Cash dividends declared, $1.16 per common shareâ€”Â â€”Â â€”Â (157)â€”Â â€”Â â€”Â â€”Â (157)Payments to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â â€”Â (77)
(77)Otherâ€”Â â€”Â 7Â 1Â â€”Â â€”Â â€”Â (4)4Â Balance, September 30, 2023278Â $3Â $7,899Â $13,761Â $(887)(145)$(22,604)$364Â $(1,464)See Financial Notes7Table of ContentsMcKESSON CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In millions)(Unaudited)Â Six Months Ended September 30, Â 20242023OPERATING ACTIVITIESNet income$1,247Â $1,700Â Adjustments to reconcile to net cash provided by (used in) operating activities:Depreciation124Â 129Â Amortization208Â 187Â Asset impairment charges76Â 28Â Deferred taxes125Â (271)Charges (credits) associated with last-in, first-out inventory method(4)87Â Non-cash operating lease expense113Â 122Â Gain from sales of businesses and investments(89)(16)Canadian businesses held for sale638Â â€”Â Provision for bad debts(169)243Â Other non-cash items174Â 71Â Changes in assets and liabilities:Receivables(3,499) (3,207)Inventories(3,310)(2,349)Drafts and accounts payable6,221Â 4,307Â Operating lease liabilities(196)(166)Taxes(145)(76)Litigation liabilities(386)(529)Other(408)(347)Net cash provided by (used in) operating activities720Â (87)INVESTING ACTIVITIESPayments for property, plant, and equipment(242)(153)Capitalized software expenditures(143)(111)Acquisitions, net of cash, cash equivalents, and restricted cash acquired(1)â€”Â Proceeds from sales of businesses and investments, net93Â 50Â Other(80)(101)Net cash used in investing activities(373)(315)FINANCING ACTIVITIESProceeds from short-term borrowings6,876Â 2,000Â Repayments of short-term borrowings(6,876)(2,000)Proceeds from issuances of long-term debt498Â 991Â Repayments of long-term debt(501)(271)Purchase of U.S. government obligations for the satisfaction and discharge of long-term debtâ€”Â (647)Common stock transactions:Issuances54Â 54Â Share repurchases(2,019)(1,505)Dividends paid(162)(149)Other(278)(225)Net cash used in financing activities(2,408)(1,752)Effect of exchange rate changes on cash, cash equivalents, and restricted cash1Â (1)Change in cash, cash equivalents, and restricted cash classified as Assets held for sale(14)â€”Â Net decrease in cash, cash equivalents, and restricted cash(2,074)(2,155)Cash, cash equivalents, and restricted cash at beginning of period4,585Â 4,679Â Cash, cash equivalents, and restricted cash at end of period2,511Â 2,524Â Less: Restricted cash at end of period included in Prepaid expenses and other(2)â€”Â Cash and cash equivalents at end of period$2,509Â $2,524Â See Financial Notes8Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES(UNAUDITED)1.Â Â Â Â Significant Accounting PoliciesNature of Operations: McKesson Corporation together with its subsidiaries (collectively, the â€œCompanyâ€ or â€œMcKesson,â€) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (â€œRxTSâ€), Medical-Surgical Solutions, and International. Refer to Financial Note 12, â€œSegments of Business,â€ for additional information.Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (â€œU.S.â€) generally accepted accounting principles (â€œGAAPâ€) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (â€œSECâ€) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.The condensed consolidated financial statements of McKesson include the financial statements of all majority-owned or controlled companies. For those consolidated subsidiaries where the Companyâ€™s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as â€œNet income attributable to noncontrolling interestsâ€ in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. Net income attributable to noncontrolling interests includes third-party equity interests in the Companyâ€™s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC.The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (â€œVIEâ€). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Fiscal Period: The Companyâ€™s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means the Companyâ€™s fiscal year.Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.The results of operations for the three and six months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, previously filed with the SEC on MayÂ 8, 2024 (the â€œ2024 Annual Reportâ€).Recently Adopted Accounting Pronouncements There were no accounting standards adopted during the six months ended September 30, 2024 that had a material impact to the Companyâ€™s condensed consolidated financial statements or disclosures.9Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segmentâ€™s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2024, the FASB issued ASU 2024-03, Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.Recent Securities and Exchange Commission Final Rules Not Yet ImplementedIn March 2024, the SEC adopted final rules under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which would have required the Company to provide certain climate-related information in annual reports and registration statements beginning with its Annual Report on Form 10-K for the year ended March 31, 2026. In April 2024, the SEC stayed these rules pending the completion of judicial review of consolidated petitions challenging the validity of the rules. The Company is currently evaluating the impact of these rules in light of those legal challenges and monitoring the status of the stay and judicial review.10Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)2.Â Â Â Â Held for SaleAssets and liabilities to be disposed of by sale (â€œdisposal groupsâ€) are classified as â€œheld for saleâ€ if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use. The classification occurs when the disposal group is available for immediate sale and the sale is probable. These criteria are generally met when management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying amount or fair value less costs to sell, and long-lived assets included within the disposal group are not depreciated or amortized. The fair value of a disposal group, less any costs to sell, is assessed during each reporting period it remains classified as held for sale, and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The Company determined that the disposal group discussed below did not meet the criteria for classification as discontinued operations.Rexall Health and Well.caOn September 5, 2024, the Company announced an agreement to sell its Rexall and Well.ca businesses in Canada (â€œCanadian retail disposal groupâ€). The adjusted purchase price of approximately $148Â million, net of working capital and other adjustments, includes a payment of $27Â million to be made upon closing, and a note of $121Â million accruing interest upon satisfaction of certain conditions, measured at fair value, payable to the Company at the end of six years. As of September 30, 2024, the Canadian retail disposal group, consisting of $631 million of assets and $371 million of liabilities within the Companyâ€™s International segment, was classified as â€œAssets held for saleâ€ and â€œLiabilities held for sale,â€ respectively, in the Condensed Consolidated Balance Sheet. The transaction is anticipated to close in the second half of fiscal 2025, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, as applicable.During the three and six months ended September 30, 2024, the Company recorded a charge of $643Â million, within â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations, to remeasure the Canadian retail disposal group to fair value less costs to sell. The remeasurement adjustment includes a $15Â million loss related to the accumulated other comprehensive balances associated with the Canadian retail disposal group. The Companyâ€™s measurement of the fair value of the Canadian retail disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreements. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.11Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED) (UNAUDITED)The total assets and liabilities of the Canadian retail disposal group that have met the classification of held for sale in the Companyâ€™s Condensed Consolidated Balance Sheet are as follows:(In millions)September 30, 2024AssetsCurrent assetsCash$14Â Receivables, net65Â Inventories, net219Â Prepaid expenses and other5Â Property, plant, and equipment, net62Â Operating lease right-of-use assets283Â Goodwill47Â Intangible assets, net419Â Other non-current assets160Â Remeasurement of assets of businesses held for sale to fair value less costs to sell (1)(643)Total assets held for sale$631Â LiabilitiesCurrent liabilitiesDrafts and accounts payable$15Â Current portion of operating lease liabilities61Â Other accrued liabilities42Â Long-term operating lease liabilities249Â Other non-current liabilities4Â Total liabilities held for sale$371Â (1)Includes intercompany trade accounts payable of $142 million, primarily related to purchases of inventories from McKesson Canada. These balances are expected to be assumed by the buyer upon divestiture and are excluded from Drafts and accounts payable above as they are fully eliminated in the Companyâ€™s consolidated financial statements.12Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED) (UNAUDITED)3.Â Â Â Â Restructuring, Impairment, and Related Charges, NetThe Company recorded restructuring, impairment, and related charges, net of $234 million and $28 million for the three months ended September 30, 2024 and 2023, respectively, and $244 million and $80 million for the six months ended September 30, 2024 and 2023, respectively. Of these charges $171 million and $181 million were included in â€œRestructuring, impairment, and related charges, netâ€ and $63 million was included in â€œCost of salesâ€ in the Condensed Consolidated Statement of Operations, for each of the three and six months ended September 30, 2024, respectively.Restructuring InitiativesDuring the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model, which are intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives will also include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions, and U.S. Pharmaceutical segments to help realize long-term sustainable growth. The Company anticipates total charges related to these initiatives of $650Â million to $700Â million, consisting primarily of employee severance and other employee-related costs as well as facility, exit and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. For the three and six months ended September 30, 2024, the Company recorded charges of $227 million related to the initiatives, which primarily includes severance and other employee-related costs as well as facility exit and other related costs, including long-lived asset impairments. During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives included headcount reductions, primarily consisting of employee severance and other employee-related costs within the RxTS segment, and the exit or downsizing of certain facilities. For the three and six months ended September 30, 2023, the Company recorded charges of $3Â million and $39Â million related to this program, respectively, which primarily included real estate and other related asset impairments and facility costs within Corporate. This restructuring program was substantially complete in fiscal 2024.Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following: Three Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $4Â $149Â Exit and other-related costs (3)â€”Â â€”Â 3Â (1)10Â 12Â Asset impairments and accelerated depreciation63Â 1Â â€”Â â€”Â 9Â 73Â Total$64Â $1Â $147Â (1)23Â $234Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations.(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. 13Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Three Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternationalCorporateTotalSeverance and employee-related costs, net $8Â $â€”Â $â€”Â $2Â $â€”Â $10Â Exit and other-related costs (2)1Â 3Â 4Â 4Â 6Â 18Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Total$9Â $3Â $4Â $6Â $6Â $28Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following: Six Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $3Â $148Â Exit and other-related costs (3)â€”Â 3Â 6Â (1)12Â 20Â Asset impairments and accelerated depreciation64Â 2Â â€”Â 1Â 9Â 76Â Total$65Â $5Â $150Â $â€”Â $24Â $244Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations.(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.Six Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternational Corporate (1)TotalSeverance and employee-related costs, net $9Â $â€”Â $â€”Â $2Â $1Â $12Â Exit and other-related costs (2)2Â 5Â 6Â 9Â 18Â 40Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â 1Â 27Â 28Â Total$11Â $5Â $6Â $12Â $46Â $80Â 14Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Companyâ€™s restructuring initiatives for the six months ended

September 30, 2024:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024 (1)$18Â $5Â $1Â $10Â $21Â $55Â Restructuring, impairment, and related charges, net65Â 5Â 150Â â€”Â 24Â 244Â Non-cash charges(64)(2)â€”Â (1)(9)(76)Cash payments(4)(2)(7)(2)(10) (25)Other (2) (1)(2)â€”Â (5)(2)(10)Balance, September 30, 2024 (3)$14Â $4Â $144Â $2Â $24Â $188Â (1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in â€œOther accrued liabilitiesâ€ and $31 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet.(2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves.(3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in â€œOther accrued liabilitiesâ€ and $28 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet.4.Â Â Â Â Income TaxesIncome tax expense was as follows:Three Months Ended September 30, Six Months Ended September 30, (Dollars in millions)20242023202420232023Income tax expense$247Â $213Â $371Â $307Â Reported income tax rate46.3Â %23.3Â %22.9Â %15.3Â %Fluctuations in the Companyâ€™s reported income tax rates were primarily due to non-cash charges related to remeasuring the value of its Canadian retail disposal group held for sale to fair value less costs to sell, changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.During the three months ended September 30, 2024, the Company sold certain intellectual property between McKesson wholly-owned legal entities based in foreign tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result, a discrete tax benefit of $44Â million was recognized in the second quarter of fiscal 2025. During the three and six months ended September 30, 2024, the Company recorded non-cash pre-tax charges of $643Â million to remeasure the Canadian retail disposal group to fair value less costs to sell, as described in Financial Note 2, â€œHeld for Saleâ€. The Companyâ€™s reported income tax rates for the three and six months ended September 30, 2024 were unfavorably impacted by these charges given that no net tax benefit was recognized for these charges.During the six months ended September 30, 2024, the Company also recognized discrete tax benefits of $58Â million related to an election to change the tax status of a foreign affiliate, $38Â million related to the tax impact of share-based compensation, and $47Â million related to the reduction in unrecognized tax benefits due to a change in case law, partially offset by a discrete tax expense of $37Â million related to interest expense accrued on unrecognized tax benefits.15Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)During the three months ended September 30, 2023, the Company recognized a net discrete tax expense of $12Â million primarily related to interest expense accrued on unrecognized tax benefits. During the six months ended September 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147Â million was recognized during the three months ended June 30, 2023.As of September 30, 2024, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. 16Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED) 5.Â Â Â Â Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than one million of potentially dilutive securities for the three and six months ended September 30, 2024 and 2023 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.The computations for basic and diluted earnings per common share were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions, except per share amounts)20242023202420232023Net income$287Â $703Â $1,247Â $1,700Â Net income attributable to noncontrolling interests(46)(39)(91)(78)Net income attributable to McKesson Corporation$241Â $664Â $1,156Â $1,622Â Weighted-average common shares outstanding:Basic128.7Â 134.1Â 129.3Â 134.8Â Effect of dilutive securities:Stock options0.1Â 0.2Â 0.1Â 0.2Â Restricted stock units (1)0.5Â 0.5Â 0.6Â 0.7Â Diluted129.3Â 134.8Â 130.0Â 135.7Â Earnings per common share attributable to McKesson Corporation: (2)Diluted$1.87Â $4.92Â $8.89Â $11.95Â Basic$1.88Â $4.95Â $8.94Â $12.03Â (1)Includes dilutive effect from restricted stock units and performance-based restricted stock units.(2)Certain computations may reflect rounding adjustments.17Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)6.Â Â Â Â Goodwill and Intangible Assets, Net GoodwillThe Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2025 and fiscal 2024 did not indicate any impairment of goodwill. Changes in the carrying amount of goodwill were as follows:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024$4,123Â $2,024Â $2,536Â $1,449Â $â€”Â $10,132Â Goodwill acquiredâ€”Â â€”Â â€”Â â€”Â â€”Â Disposals (1)â€”Â â€”Â â€”Â (47)â€”Â (47)Foreign currency translation adjustments, netâ€”Â â€”Â â€”Â 2Â â€”Â 2Â Other adjustmentsâ€”Â â€”Â (29)â€”Â 29Â â€”Â Balance, September 30, 2024$4,123Â $2,024Â $2,507Â $1,404Â $29Â $10,087Â (1)Goodwill related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024.Intangible AssetsInformation regarding intangible assets was as follows:Â September 30, 2024March 31, 2024(Dollars in millions)Weighted-AverageRemainingAmortizationPeriod(Years)GrossCarryingAmountAccumulatedAmortizationNetCarryingAmountGrossCarryingAmountAccumulatedAmortizationNetCarryingAmountCustomer relationships11$1,480Â (604)876Â $1,830Â (701)1,129Â Service agreements91,129Â (707)422Â 1,126Â (676)450Â Trademarks and trade names13384Â (268)116Â 759Â (395)364Â Technology10284Â (133)151Â 284Â (125)159Â Other634Â (26)8Â 34Â (26)8Â Total Â $3,311Â $(1,738)$1,573Â (1)$4,033Â $(1,923)$2,110Â (1)Excludes net intangible assets of approximately $419 million related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024. Amortization of these assets ceased upon classification as held for sale in the second quarter of fiscal 2025.All intangible assets, except for those classified as held for sale, were subject to amortization as of September 30, 2024 and March 31, 2024. Amortization expense of intangible assets was $60 million and $62 million for the three months ended September 30, 2024 and 2023, respectively, and $123 million and $124 million for the six months ended September 30, 2024 and 2023, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $102 million, $177 million, $171 million, $166 million, and $164 million for the remainder of fiscal 2025 and each of the succeeding years through fiscal 2029, respectively, and $793 million thereafter.18Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)7.Â Â Â Â Debt and Financing ActivitiesLong-term debt consisted of the following: (In millions)September 30, 2024March 31, 2024U.S. Dollar notes (1) (2)0.90% Notes due December 3, 2025500Â 500Â 5.25% Notes due February 15, 2026â€”Â 499Â 1.30% Notes due August 15, 2026499Â 499Â 7.65% Debentures due March 1, 2027150Â 150Â 3.95% Notes due February 16, 2028343Â 343Â 4.90% Notes due July 15, 2028399Â 399Â 4.75% Notes due May 30, 2029196Â 196Â 4.25% Notes due September 15, 2029500Â â€”Â 5.10% Notes due July 15, 2033597Â 596Â 6.00% Notes due March 1, 2041218Â 218Â 4.88% Notes due March 15, 2044255Â 255Â Foreign currency notes (1) (3)1.50% Euro Notes due November 17, 2025667Â 646Â 1.63% Euro Notes due October 30, 2026 557Â 540Â 3.13% Sterling Notes due February 17, 2029602Â 568Â Lease and other obligations261Â 220Â Total debt5,744Â 5,629Â Less: Current portion53Â 50Â Total long-term debt$5,691Â $5,579Â (1)These notes are unsecured and unsubordinated obligations of the Company.(2)Interest on these U.S. dollar notes is payable semi-annually.(3)Interest on these foreign currency notes is payable annually.Long-Term DebtThe Companyâ€™s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At September 30, 2024 and March 31, 2024, $5.7 billion and $5.6Â billion, respectively, of total debt was outstanding, of which $53 million and $50 million, respectively, was included under the caption â€œCurrent portion of long-term debtâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets. Public OfferingsOn SeptemberÂ 10, 2024, the Company completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million (the â€œ2029 Notesâ€). Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th of each year, commencing on March 15, 2025. Proceeds received from the issuance of the 2029 Notes, net of discounts and offering expenses, were $496 million. The Company utilized the net proceeds from the offering of the 2029 Notes together with cash on hand to redeem its $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 (the â€œ2026 Notesâ€), which became callable on or after February 15, 2024, prior to maturity at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest through the redemption date. The total loss recognized on the debt extinguishment of the 2026 Notes described above for the three and six months ended September 30, 2024 was not material and is included within â€œInterest expenseâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations. 19Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the â€œ2028 Notesâ€) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the â€œ2033 Notesâ€ and, together with the 2028 Notes, the â€œNotesâ€). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Companyâ€™s then outstanding 3.80% Notes due March 15, 2024 (the â€œ2024 Notesâ€) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes was available for general corporate purposes.Each of the 2029 Notes, the 2033 Notes and the 2028 Notes, constitutes a â€œseries,â€ is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Companyâ€™s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. Each series is governed by an indenture and officersâ€™ certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 daysâ€™ and not more than 60 daysâ€™ notice to holders of the applicable series of the notes, the Company may redeem such series of the notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officersâ€™ certificate. If there were to occur both (a) a change of control of the Company and (b) a downgrade of the applicable series of the notes below an investment grade rating by each of the Ratings Agencies (as defined in the applicable officersâ€™ certificate) within a specified period, then the Company would be required to make an offer to purchase that series at a price equal to 101% of the then outstanding principal amount of that series, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officersâ€™ certificate for each series, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lendersâ€™ consent. The indenture also contains customary events of default provisions.Concurrent Tender Offer of the 2024 NotesOn June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the â€œConcurrent Tender Offerâ€). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. Satisfaction and Discharge of the 2024 NotesOn June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the â€œ2024 Notes Indentureâ€) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647Â million principal amount of the 2024 Notes as it became due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Companyâ€™s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. The total gain recognized on the debt extinguishment of the 2024 Notes described above for the six months ended September 30, 2023 was $9 million and was included within â€œInterest expenseâ€ in the Companyâ€™s Condensed Consolidated Statement of Operations.20Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Revolving Credit Facilities On November 7, 2022, the Company entered into a Credit Agreement (the â€œ2022 Credit Facilityâ€), that provides a syndicated $4.0 billion senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility was scheduled to mature in November 2028. On November 7, 2024, the maturity date of the 2022 Credit Facility was extended from November 2028 to November 2029. There were no borrowings under the 2022 Credit Facility during the six months ended September 30, 2024 and 2023 and no amounts outstanding at September 30, 2024 or March 31, 2024. At September 30, 2024, the Company was in compliance with all covenants under the 2022 Credit Facility. Commercial PaperThe Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the six months ended September 30, 2024, the Company borrowed and repaid $6.9 billion under the program. During the six months ended September 30, 2023, the Company borrowed and repaid $2.0 billion under the program. At September 30, 2024 and March 31, 2024, there were no commercial paper notes outstanding.8.Â Â Â Â Hedging Activities In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Companyâ€™s policy, derivatives are only used for hedging purposes. The Company does not use derivatives for trading or speculative purposes. The Company uses various counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.Foreign Currency Exchange RiskThe Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on the Companyâ€™s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. Interest Rate RiskThe Company has exposure to changes in interest rates, and it utilizes risk programs which use interest rate swaps to hedge the changes in debt fair values caused by fluctuations in benchmark interest rates. The Company also enters into forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances. These programs reduce but do not entirely eliminate interest rate risk.Derivative InstrumentsAt September 30, 2024 and March 31, 2024, the notional amounts of the Companyâ€™s outstanding derivatives were as follows:September 30, 2024March 31, 2024(In millions)CurrencyMaturity Date (1)NotionalDerivatives designated as net investment hedges: (2)Cross-currency swaps (3)CADApr-25 to Jun-26C$2,500Â C$1,500Â Derivatives designated as fair value hedges: (2)Cross-currency swaps (4)GBPNov-28Â£450Â Â£450Â Cross-currency swaps (4)EURAug-25 to Jul-26â‚¬1,100Â â‚¬1,100Â Floating interest rate swaps (5)USDAug-27 to Sep-29$750Â $1,250Â Derivatives designated as cash flow hedges: (2)Foreign currency forwards (6)GBPOct-24 to Jul-25Â£27Â Â£39Â (1)The maturity date reflected is for outstanding derivatives as of September 30, 2024.(2)There was no ineffectiveness in these hedges for the three and six months ended September 30, 2024 and 2023.(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified

intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. (5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. (6)The Company entered into agreements with financial institutions to hedge the variability of foreign currency exchange fluctuations in future cash payments due to a third party in the United Kingdom for capital expenditures.Net Investment HedgesThe Company uses cross-currency swaps to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Companyâ€™s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.In the first quarter of fiscal 2025, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$2.5Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps mature in April 2025 and June 2026. Further, the Company terminated C$1.5Â billion of cross-currency swaps designated as net investment hedges with original maturity dates in November 2024 and extending through March 2025.In October 2024, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$1.0Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps will mature in October 2026.Fair Value HedgesThe Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The Company also uses floating interest rate swaps to hedge the changes in the fair value of its U.S. dollar notes resulting from changes in benchmark interest rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains and losses from the changes in the Companyâ€™s fair value hedges recorded in earnings were largely offset by the gains and losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive loss.In fiscal 2023, the Company entered into floating interest rate swaps designated as fair value hedges to convert $1.3Â billion of its fixed rate debt to floating rate in order to hedge the changes in fair value caused by fluctuations in the benchmark interest rate. In fiscal 2025, $500 million of the $1.3Â billion floating interest rate swaps with original maturity dates in February 2026 and callable at any time after February 2024 were terminated. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2029 Notes.Cash Flow HedgesThe Company uses cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency exchange rates. The Company also uses forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances and to offset the potential income statement effects from obligations denominated in non-functional currencies. The effective portion of changes in the fair valueÂ of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. There were no gains or losses reclassified from accumulated other comprehensive loss and recorded in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023.In fiscal 2023, the Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges with a combined notional amount of $450Â million, and in the first quarter of fiscal 2024 with a notional amount of $50Â million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500Â million cash flow hedges were terminated and the proceeds are being amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2033 Notes.Derivatives Not Designated as HedgesDerivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations. The Company did not enter into or have any outstanding derivative instruments not designated as hedges during the periods presented.Other Information on Derivative InstrumentsGains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions)2024202320242023Derivatives designated as net investment hedges:Cross-currency swaps(20)27Â (13)7Â Derivatives designated as cash flow and other hedges:Cross-currency swaps (1)(14)33Â (14)27Â Foreign currency forwards2Â â€”Â 2Â â€”Â Fixed interest rate swaps â€”Â â€”Â â€”Â 16Â (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.Information regarding the fair value of derivatives on a gross basis were as follows:Balance Sheet CaptionSeptember 30, 2024March 31, 2024Fair Value of DerivativeU.S. Dollar NotionalFair Value of DerivativeU.S. Dollar Notional(In millions)AssetLiabilityAssetLiabilityDerivatives designated for hedge accounting:Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$69Â $15Â $1,690Â $13Â $1Â $1,122Â Cross-currency swaps (non-current)Other non-current assets/liabilities97Â 11Â 1,771Â 108Â â€”Â 1,638Â Interest rate swaps (non-current)Other non-current liabilitiesâ€”Â 10Â 750Â â€”Â 35Â 1,250Â Foreign currency forwards (current)Prepaid expenses and other/Other accrued liabilities2Â â€”Â 34Â â€”Â â€”Â 35Â Foreign currency forwards (non-current)Other non-current assetsâ€”Â â€”Â â€”Â â€”Â 15Â Total$168Â $36Â $121Â $36Â Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.21Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)9. Â Â Â Â Fair Value Measurements The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:Level 1 - quoted prices in active markets for identical assets or liabilities.Level 2 - significant other observable market-based inputs.Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.Assets and Liabilities Measured at Fair Value on a Recurring BasisCash and cash equivalents at September 30, 2024 and March 31, 2024 included investments in money market funds of $549 million and $705 million, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.Fair values of the Companyâ€™s interest rate swaps, cross-currency swaps, and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.Â These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, â€œHedging Activities,â€ for fair values and other information on the Companyâ€™s derivatives.The Company holds investments in equity and debt securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $175Â million and $240Â million at September 30, 2024 and March 31, 2024, respectively. These investments primarily consist of equity securities without readily determinable fair values and are included in â€œOther non-current assetsâ€ in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains and losses as well as impairment charges related to these investments were a net loss of $15Â million and gain of $95Â million for the three and six months ended September 30, 2024, respectively, and an immaterial loss for the three and six months ended September 30, 2023, all of which are included within â€œOther income, netâ€ in the Condensed Consolidated Statements of Operations. The net gain recognized for the six months ended September 30, 2024 primarily relates to a recapitalization event of one of the Companyâ€™s investments in equity securities which resulted in an increase to the carrying value of this investment. The Company recognized a net gain of $100 million related to this event and sold a portion of its investment for proceeds of $92 million.Assets and Liabilities Measured at Fair Value on a Nonrecurring BasisIn addition to assets and liabilities that are measured at fair value on a recurring basis, the Companyâ€™s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.At September 30, 2024, the assets and liabilities associated with the Canadian retail disposal group classified as held for sale were measured at the lower of carrying value or fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€22Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.There were no other material assets or liabilities measured at fair value on a nonrecurring basis at September 30, 2024 and March 31, 2024.Other Fair Value DisclosuresAt September 30, 2024 and March 31, 2024, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.The Companyâ€™s long-term debt is recorded at amortized cost. The carrying value and fair value of the Companyâ€™s long-term debt was as follows:September 30, 2024March 31, 2024(In millions)Carrying ValueFair ValueCarrying ValueFair ValueLong-term debt, including current maturities$5,744Â $5,808Â $5,629Â $5,488Â The estimated fair value of the Companyâ€™s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.GoodwillFair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (â€œDCFâ€) model to determine the fair value of each reporting unit.Long-lived AssetsThe Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.23Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)10.Â Â Â Â Commitments and Contingent LiabilitiesIn addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Companyâ€™s 2024 Annual Report and Financial Note 9 to the Companyâ€™s 10-Q filing for the quarterly period ended June 30, 2024, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within â€œClaims and litigation charges, netâ€ in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters, as well as any applicable income items or credit adjustments due to subsequent changes in estimates.I. Litigation and Claims Involving Distribution of Controlled SubstancesThe Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. These plaintiffs have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (â€œRICOâ€), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. State and Local Government ClaimsThe Company and two other national pharmaceutical distributors (collectively â€œDistributorsâ€) entered into a settlement agreement (the â€œSettlementâ€) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the â€œSettling Governmental Entitiesâ€). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $2.0Â billion as of September 30, 2024, and additionally will pay the Settling Governmental Entities up to approximately $5.9Â billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffsâ€™ attorneysâ€™ fees and costs and will be paid out through 2030. Pursuant to the Settlement, the Distributors are in the process of establishing a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. 24Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $75Â million as of September 30, 2024, and additionally will pay approximately $99Â million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $53Â million as of September 30, 2024, and additionally will pay approximately $99Â million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Companyâ€™s favor on July 4, 2022. Those subdivisions appealed that decision.Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company

contends that those subdivisionsâ€™ claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision. A trial of its claims against the Company and another national pharmaceutical distributor began on September 16, 2024 in the Circuit Court of Maryland for Baltimore City, Mayor and City Council of Baltimore v. Purdue Pharma LP, No. 24-C-18-000515. Baltimore claims that the defendantsâ€™ distribution of controlled substances to certain pharmacies in the City of Baltimore and Baltimore County caused a public nuisance. Baltimore is seeking monetary damages and other relief.The district attorneys of the City of Philadelphia, Pennsylvania, and Allegheny County, Pennsylvania did not participate in the settlement and sought to bring separate claims against the Company, notwithstanding the settlement with the state of Pennsylvania and its attorney general. On January 26, 2024, the Commonwealth Court of Pennsylvania ruled that the Pennsylvania attorney general had settled and fully released the claims brought by those district attorneys under Pennsylvaniaâ€™s Unfair Trade Practices and Consumer Protection Law. The district attorneys have appealed that decision to the Supreme Court of Pennsylvania. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.Native American Tribe ClaimsThe Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $112Â million as of September 30, 2024, and additionally will pay approximately $84Â million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.Non-Governmental Plaintiff ClaimsThe Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above. One such case was brought by a group of individual plaintiffs in Glynn County, Georgia Superior Court seeking to recover for damages allegedly arising from their family membersâ€™ abuse of prescription opioids. Poppell v. Cardinal Health, Inc., CE19-00472. On March 1, 2023, the jury in that case returned a verdict in favor of the defendants, including the Company. Plaintiffs appealed the jury verdict. On September 4, 2024, the Supreme Court of Georgia affirmed the judgment in favor of the Company. The Company and two other national distributors have reached proposed settlements with representatives of nationwide groups of acute care hospitals and certain third-party payors. The claims of remaining U.S. non-governmental plaintiffs are not included in the charges recorded by the Company.25Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)With respect to the acute care hospitals, for the year ended March 31, 2024, the Company recorded a charge of $149 million within â€œClaims and litigation charges, netâ€ in the Consolidated Statement of Operations to reflect its portion of a proposed settlement with a nationwide class of acute care hospitals, of which $75 million was recorded within Corporate expenses, net, and $74 million was recorded within U.S. Pharmaceutical. The corresponding liability was included within â€œOther accrued liabilitiesâ€ in the Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by hospitals. On October 30, 2024, the U.S. District Court for the District of New Mexico granted preliminary approval to the proposed settlement. The trial for one of those acute care hospital cases, Fort Payne Hospital Corporation et al. v. McKesson Corp., CV-2021-900016, has been stayed as to the Company. With respect to the third-party payors, for the six months ended September 30, 2024, the Company recorded a charge of $114Â million within â€œClaims and litigation charges, netâ€ in the Condensed Consolidated Statement of Operations to reflect the Companyâ€™s portion of the proposed settlement with representatives of a nationwide group of certain third-party payors, of which $57Â million was recorded within Corporate expenses, net and U.S. Pharmaceutical, respectively. The corresponding liability was included within â€œOther accrued liabilitiesâ€ in the Condensed Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by third-party payors. On September 3, 2024, the U.S. District Court for the Northern District of Ohio granted preliminary approval to the proposed settlement. The Companyâ€™s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, and certain non-governmental plaintiffs, including a proposed settlement with a nationwide class of acute care hospitals and certain third-party payors, was as follows:(In millions)September 30, 2024March 31, 2024Current litigation liabilities (1)$775Â $665Â Long-term litigation liabilities5,617Â 6,113Â Total litigation liabilities$6,392Â $6,778Â (1)These amounts, recorded in â€œOther accrued liabilitiesâ€ in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.During the six months ended September 30, 2024, the Company made payments totaling $500Â million associated with the Settlement and the separate settlement agreements.Canadian Plaintiff ClaimsThe Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, municipal governments, a group representing indigenous people, as well as one case brought by an individual.Defense of Opioids ClaimsThe Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the accruals described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Companyâ€™s financial position, cash flows or liquidity, or results of operations.26Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)II.Â Other Litigation and ClaimsOn May 17, 2013, the Company was served with a complaint filed in the United States District Court for the Northern District of California by True Health Chiropractic Inc., alleging that McKesson sent unsolicited marketing faxes in violation of the Telephone Consumer Protection Act of 1991 (â€œTCPAâ€), as amended by the Junk Fax Protection Act of 2005 (â€œJFPAâ€), True Health Chiropractic Inc., et al. v. McKesson Corporation, et al., No. CV-13-02219 (HG). The plaintiffs seek statutory damages from $500 to $1,500 per violation plus injunctive relief. True Health Chiropractic later amended its complaint, adding McLaughlin Chiropractic Associates as an additional named plaintiff and McKesson Technologies Inc. as a defendant. Both plaintiffs alleged that defendants violated the TCPA by sending faxes that did not contain notices regarding how to opt out of receiving the faxes. On August 13, 2019, the court granted plaintiffsâ€™ renewed motion for class certification. After class notice and the opt-out period, 9,490 fax numbers remain in the class, representing 48,769 faxes received. On October 8, 2021, the court de-certified the class citing the plaintiffs lacked class-wide proof identifying the manner of receipt, thus leaving two named plaintiffs remaining in the case. On April 27, 2022, the Court found that the named plaintiffs had failed to meet their burden to show defendants willfully or knowingly violated the TCPA and therefore were not entitled to treble damages. The Court found McKesson liable for statutory damages in the amount of $6,500. The Company appealed the finding of liability and the plaintiffs cross-appealed the denial of class certification and the ruling denying treble damages. On October 25, 2023, the U.S. Court of Appeals for the Ninth Circuit affirmed the decision of the district court. On October 4, 2024, the Supreme Court of the United States granted plaintiffsâ€™ petition for certiorari on the issue of whether the Hobbs Act required the district court to accept the FCCâ€™s legal interpretation of the TCPA in determining whether to certify the class.On June 17, 2014, U.S. Oncology Specialty, LP (â€œUSOSâ€) was served with a fifth amended qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that USOS, among others, solicited and received illegal â€œkickbacksâ€ from Amgen in violation of the Anti-Kickback Statute, the federal False Claims Act, and various state false claims statutes, and seeking damages, treble damages, civil penalties, attorneysâ€™ fees and costs of suit, all in unspecified amounts, United States ex rel. Hanks v. Amgen, Inc., et al., CV-08-03096 (SJ). Previously, the United States declined to intervene in the case as to all allegations and defendants except for Amgen. On September 17, 2018, the court granted USOSâ€™s motion to dismiss. Following the relatorâ€™s appeal, the United States Court of Appeals for the Second Circuit vacated the district courtâ€™s order and remanded the suit to the district court, directing it to consider the question of whether the suit should be dismissed for lack of jurisdiction. The district court granted the relator leave to amend the complaint for a seventh time. The relator filed the seventh amended complaint on November 30, 2020. On September 18, 2024, the district court dismissed the False Claims Act claim for lack of subject matter jurisdiction.In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the United States, 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA. The United States and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. The relator filed the second amended complaint on June 7, 2022, which was dismissed by the district court on March 28, 2023. On March 12, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of claims under the Anti-Kickback Statute and federal False Claims Act, vacated the dismissal of the remaining claims, and remanded for further proceedings. On June 7, 2024, the relator filed a petition seeking review by the U.S. Supreme Court, which was denied on October 7, 2024.On October 17, 2024, the Company was served with a qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that, from 2010 through at least 2012, the Company submitted false certifications to the government in support of Horizon Clinicals, an Electronic Health Record product. United States ex rel. James Thompson v. McKesson Corporation, No. 16-CV-2891. The United States has declined to intervene in the case. The complaint seeks relief under the False Claims Act including damages, treble damages, civil penalties, attorney fees, and costs of suit.27Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)III.Â Government Subpoenas and InvestigationsFrom time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business. In July 2024, the United States Department of Justice served a Civil Investigative Demand issued pursuant to the False Claims Act on the Company seeking documents and information related to administration of copay coupon programs associated with certain Sun Pharmaceutical Industries Inc. drugs.
V.Â Antitrust SettlementDuring the second fiscal quarter of 2025, the Company received proceeds of $63Â million related to its share of two antitrust settlements. The lawsuits were filed against a brand manufacturer alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company was not a named party to either litigation but was a member of the representative classes of those who purchased directly from the pharmaceutical manufacturer. The Company recognized a gain in that amount within "Cost of sales" in the Condensed Consolidated Statement of Operations in the second quarter of fiscal 2025 related to the settlements.11.Â Â Â Â Stockholders' Deficit Each share of the Companyâ€™s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Companyâ€™s Board of Directors (the â€œBoardâ€). In July 2024, the Companyâ€™s quarterly dividend was raised from $0.62 to $0.71 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.Â However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. 28Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Share Repurchase Plans The Board has authorized the repurchase of common stock. The Company may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Companyâ€™s stock price, corporate and regulatory requirements, tax implications, restrictions under the Companyâ€™s debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions. During the three months ended September 30, 2024, the Company repurchased 2.9Â million shares of common stock for $1.5Â billion through open market transactions at an average price per share of $533.46, of which $22 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2024 and settled in early October 2024. During the three months ended June 30, 2024, the Company repurchased 1.0Â million shares of common stock for $528Â million through open market transactions at an average price per share of $548.20.During the three months ended September 30, 2023, the Company repurchased 2.0Â million shares of common stock for $840Â million through open market transactions at an average price per share of $422.39, of which $23 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2023 and settled in early October 2023. During the three months ended June 30, 2023, the Company repurchased 1.8Â million shares of common stock for $673Â million through open market transactions at an average price per share of $379.14. Effective January 1, 2023, the Companyâ€™s repurchase of common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. Excise taxes incurred on share repurchases of an entityâ€™s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholdersâ€™ equity within â€œTreasury sharesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholdersâ€™ Deficit. Excise taxes do not reduce the Companyâ€™s remaining authorization for the repurchase of common stock. Excise taxes of $15 million and $8Â million were incurred and accrued for shares repurchased during the three months ended September 30, 2024 and 2023, respectively. Excise taxes of $16Â million and $12Â million were incurred and accrued for shares repurchased during the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the amounts accrued for excise taxes were $41Â million and $25Â million, respectively, within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets. In July 2024, the Board approved an increase of $4.0Â billion in the authorization for the repurchase of common stock. The total remaining authorization outstanding for repurchases of common stock at September 30, 2024 was $8.6 billion.Accumulated Other Comprehensive Loss Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended September 30, 2024 and 2023 was as follows:29Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2024(892)(7)$3Â (17)(913)Other comprehensive income (loss) before reclassifications49Â (15)(9)(1)24Â Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)49Â (15)(9)(2)23Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson49Â (15)(9)(2)23Â Balance, September 30, 2024(843)(22)(6)(19)$(890)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2024 include losses of $20Â million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.(3)Amounts recorded for the three months ended September 30, 2024 include losses of $14Â million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2023(780)(29)(29)(10)$(848)Other comprehensive income (loss) before reclassifications(84)20Â 25Â 1Â (38)Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(84)20Â 25Â â€”Â (39)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(84)20Â 25Â â€”Â (39)Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2023 include gains of $27 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $7 million.(3)Amounts recorded for the three months ended September 30, 2023 include gains of $33 million related to cash flow and other hedges from cross-currency swaps, which are net of income tax expense of $8 million.30Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the six months ended September 30, 2024 and 2023 was as follows:Foreign Currency Translation Adjustments(In millions)Foreign Currency

Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2024(856)(12)$3Â (16)(881)Other comprehensive income (loss) before reclassifications13Â (10)(9)(2)(8)Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)13Â (10)(9)(3)(9)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson13Â (10)(9)(3)(9)Balance, September 30, 2024(843)(22)(6)(19)$(890)

(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Europe into the Companyâ€™s reporting currency, U.S. dollars.

(2)Amounts recorded for the six months ended September 30, 2024 include losses of $13 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $3 million.(3)Amounts recorded for the six months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2023(847)(14)(36)(8)$(905)Other comprehensive income (loss) before reclassifications(17)5Â 32Â (1)19Â Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(17)5Â 32Â (2)18Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(17)5Â 32Â (2)18Â Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.31Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)

(2)Amounts recorded for the six months ended September 30, 2023 include gains of $7 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $2 million.(3)Amounts recorded for the six months ended September 30, 2023 include gains of $27 million related to cash flow and other hedges from cross-currency swaps and gains of $16 million related to cash flow hedges from fixed interest rate swaps. These amounts are net of income tax expense of $11 million. 12.Â Â Â Â Segments of BusinessThe Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments and operations. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKessonâ€™s own line of high-quality products through a network of distribution centers in the U.S.The International segment includes the Companyâ€™s operations in Canada and Norway, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Companyâ€™s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and include Rexall Health retail pharmacies. The Companyâ€™s Norwegian operations provide distribution and services to wholesale and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. In the second quarter of fiscal 2025, the Company entered into an agreement to sell the Canadian retail disposal group. Refer to Financial Note 2, â€œHeld for Sale,â€ for more information.32Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONTINUED)(UNAUDITED)Financial information relating to the Companyâ€™s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: Â Three Months Ended September 30, Six Months Ended September 30, (In millions)2024202320242023Segment revenues (1)U.S. Pharmaceutical$85,726Â $69,766Â $157,441Â $136,926Â Prescription Technology Solutions1,265Â 1,140Â 2,506Â 2,384Â Medical-Surgical Solutions2,948Â 2,834Â 5,584Â 5,445Â International3,709Â 3,475Â 7,400Â 6,943Â Corporate3Â â€”Â 3Â â€”Â Total revenues$93,651Â $77,215Â $172,934Â $151,698Â Segment operating profit (loss) (2) U.S. Pharmaceutical (3) $1,075Â $593Â $1,856Â $1,420Â Prescription Technology Solutions (4)205Â 238Â 408Â 469Â Medical-Surgical Solutions (5)89Â 244Â 277Â 471Â International (6)(508)66Â (418)123Â Subtotal861Â 1,141Â 2,123Â 2,483Â Corporate expenses, net (7) (249)(164)(352)(368)Interest expense(78)(61)(153)(108)Income before income taxes$534Â $916Â $1,618Â $2,007Â (1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segmentâ€™s total revenues, less than 40% of the RxTS segmentâ€™s total revenues, less than 1% of the Medical-Surgical Solutions segmentâ€™s total revenues, and less than 1% of the International segmentâ€™s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. Corporate reflects revenues from services derived in the U.S. related to certain technology operations and were not material for the three and six months ended September 30, 2024.(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Companyâ€™s reportable segments.(3)The Companyâ€™s U.S. Pharmaceutical segmentâ€™s operating profit includes the following:â€¢a credit of $203 million for the three and six months ended September 30, 2024 due to the Companyâ€™s reassessment of its initial fiscal 2024 estimates of the previously reserved $725 million prepetition balance owed by the Companyâ€™s customer, Rite Aid Corporation (including certain of its subsidiaries, â€œRite Aidâ€). Rite Aid filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in October 2023. The Company recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid. The amounts described above were recorded within â€œSelling, distribution, general, and administrative expensesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August, 2024; â€¢cash receipts for the Companyâ€™s share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively. These gains were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢a credit of $2 million and a charge of $55 million related to the last-in, first-out method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million for the six months ended September 30, 2024 and 2023, respectively. These amounts were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net;â€¢a charge of $57 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" and33Table of ContentsMcKESSON CORPORATIONFINANCIAL NOTES (CONCLUDED)(UNAUDITED)â€¢a loss of $43Â million for the six months ended September 30, 2024 related to one of the Companyâ€™s equity method investments, which was recorded within â€œOther income, netâ€ in the Companyâ€™s Condensed Consolidated Statement of Operations. (4)The Companyâ€™s RxTS segmentâ€™s operating profit for the three and six months ended September 30, 2023 includes gains of $48Â million and $76Â million, respectively, resulting from fair value adjustments of the Companyâ€™s contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022.(5)The Companyâ€™s Medical-Surgical Solutions segmentâ€™s operating profit for the three and six months ended September 30, 2024 includes restructuring charges of $144 million for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€(6)The Companyâ€™s International segmentâ€™s operating profit (loss) for the three and six months ended September 30, 2024 includes a charge of $593 million to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€(7)Corporate expenses, net includes the following:â€¢a charge of $50 million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, â€œHeld for Sale;â€¢a net gain of $95Â million for the six months ended September 30, 2024 related to the Companyâ€™s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, â€œFair Value Measurements;â€¢a net charge of $51Â million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" andâ€¢restructuring charges of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€34Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (UNAUDITED)Item 2.Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations.INDEX TO MANAGEMENTâ€™S DISCUSSION AND ANALYSISSectionPageGeneral35Overview of our Business35Executive Summary36Trends and Uncertainties38Overview of Consolidated Results39Overview of Segment Results44New Accounting Pronouncements48Financial Condition, Liquidity, and Capital Resources49Cautionary Notice About Forward-Looking Statements52Available Information52GENERALManagementâ€™s discussion and analysis of financial condition and results of operations, referred to as the â€œFinancial Review,â€ is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the â€œCompany,â€ â€œMcKesson,â€ â€œwe,â€ â€œour,â€ or â€œus,â€ and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (â€œQuarterly Reportâ€) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2024 previously filed with the Securities and Exchange Commission (the â€œSECâ€) on MayÂ 8, 2024 (â€œ2024 Annual Reportâ€).Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means our fiscal year. Certain statements in this report constitute forward-looking statements. See â€œCautionary Notice About Forward-Looking Statementsâ€ included in this Quarterly Report.Overview of our Business:We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.We report our financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (â€œRxTSâ€), Medical-Surgical Solutions, and International. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, as well as the results of certain investments and operations. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes.35Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)The following summarizes our four reportable segments. Refer to Financial Note 12, â€œSegments of Business,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information regarding our reportable segments.â€¢U.S. Pharmaceutical is a reportable segment that distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (â€œU.S.â€). This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.â€¢Prescription Technology Solutions is a reportable segment that combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patientsâ€™ medication access, affordability, and adherence challenges. RxTS also offers prescription price transparency, benefit insight, and dispensing support services, as well as third-party logistics and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.â€¢Medical-Surgical Solutions is a reportable segment that provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKessonâ€™s own line of high-quality products through a network of distribution centers within the U.S.â€¢International is a reportable segment that includes our operations in Canada and Norway, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. Our Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and include Rexall Health retail pharmacies. Our Norwegian operations provide distribution and services to wholesale and retail customers in Norway where we own, partner, or franchise with retail pharmacies. In the second quarter of fiscal 2025, we entered into an agreement to sell our Rexall and Well.ca businesses in Canada (â€œCanadian retail disposal groupâ€). These divestitures are further described in the â€œCanadian Divestiture Activitiesâ€ section below.Canadian Divestiture ActivitiesOn September 5, 2024, we announced an agreement to sell our Canadian retail disposal group. The adjusted purchase price is approximately $148Â million. We recorded a charge of $643Â million for the three and six months ended September 30, 2024 in total operating expenses to remeasure the Canadian retail disposal group to fair value less costs to sell. The remeasurement adjustment includes a $15Â million loss related to the accumulated other comprehensive loss balances associated with the disposal group. The transaction is anticipated to close in the second half of fiscal 2025, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, as applicable.As of September 30, 2024, we had $631 million of assets and $371 million of liabilities classified as â€œAssets held for saleâ€ and â€œLiabilities held for sale,â€ respectively, in the Condensed Consolidated Balance Sheet related to the Canadian retail disposal group. Refer to Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.Executive Summary: The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the three and six months ended September 30, 2024:â€¢For the three months ended September 30, 2024 compared to the prior year period, revenues increased by 21%, gross profit increased by 6%, total operating expenses increased by 26%, and other income, net increased by $8 million;â€¢For the six months ended September 30, 2024 compared to the prior year period, revenues increased by 14%, gross profit increased by 5%, total operating expenses increased by 19%, and other income, net increased by $100 million. Refer to the â€œOverview of Consolidated Resultsâ€ section below for an analysis of these changes;â€¢Diluted earnings per common share attributable to McKesson Corporation decreased to $1.87 from $4.92 for the three months ended September 30, 2024 and decreased to $8.89 from $11.95 for the six months ended September 30, 2024 compared to the respective prior year periods;36Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)â€¢In the second quarter of fiscal 2025, we onboarded a new strategic partner within our U.S. Pharmaceutical segment;â€¢Total operating expenses for the three and six months ended September 30, 2024 includes fair value remeasurement charges of $643Â million related to our Canadian retail disposal group;â€¢For the three and six months ended September 30, 2024, we recorded a restructuring charge of $227 million related to an enterprise-wide initiative to drive operational efficiencies as further described in the â€œRestructuring Initiativesâ€ section of â€œOverview of Consolidated Resultsâ€ below;â€¢For the six months ended September 30, 2024, we recognized a net discrete tax benefit of $150Â million, including $58Â million related to an election to change the tax status of a foreign affiliate;â€¢For the six months ended September 30, 2024, we recorded a net charge of $108Â million related to our estimated liability for opioid-related claims, as further described in the Opioid-Related Litigation and Claims section of â€œTrends and Uncertainties" below;â€¢For the six months ended September 30, 2024, we recognized a net gain of $100 million related to a recapitalization event of one of our investments in equity securities which resulted in an

increase to the carrying value of this investment;â€¢For the three and six months ended September 30, 2024, we received $63Â million and $153Â million, respectively, related to our share of antitrust legal settlements. These amounts were recorded as a gain within â€œCost of salesâ€ in the Condensed Consolidated Statements of Operations within our U.S. Pharmaceutical segment;â€¢On SeptemberÂ 10, 2024, we completed a public offering of 4.25% Notes due September 15, 2029 (the â€œ2029 Notesâ€) in a principal amount of $500 million. Proceeds received from this note issuance, net of discounts and offering expenses were approximately $496 million;â€¢During the three months ended September 30, 2024, we utilized the net proceeds from the issuance of the 2029 Notes, along with cash on hand, to redeem our $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 (the â€œ2026 Notesâ€) prior to maturity;â€¢During the six months ended September 30, 2024, we returned $2.2 billion of cash to shareholders through $2.0 billion of common stock repurchases in open market transactions and $162 million of dividend payments. In July 2024, our Board of Directors (the â€œBoardâ€) approved an increase of $4.0 billion in the authorization for repurchase of the Companyâ€™s common stock and raised our quarterly dividend to $0.71 from $0.62 per share of common stock. The total remaining authorization outstanding for repurchases of the Companyâ€™s common stock at September 30, 2024 was $8.6 billion; andâ€¢On August 26, 2024, we announced a definitive agreement to acquire a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (â€œCore Venturesâ€), an internal business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC, for approximately $2.49 billion cash, subject to certain customary adjustments. Following the completion of the transaction, Core Ventures will be part of the Oncology platform, and financial results will be reported within our U.S. Pharmaceutical segment. The transaction is subject to customary closing conditions, including required regulatory clearance. On November 6, 2024, we received a request for additional information and documentary materials from the Federal Trade Commission (the â€œFTCâ€) in connection with the FTCâ€™s review of our proposed acquisition of Core Ventures. We will respond promptly and continue to work cooperatively with the FTC staff in connection with its review of the transaction.37Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Trends and Uncertainties:Opioid-Related Litigation and ClaimsAs described in the discussion of opioid-related matters in Financial Note 10, â€œCommitments and Contingent Liabilities,â€ to the condensed consolidated financial statements accompanying this Quarterly Report, we are a defendant in many legal proceedings asserting claims related to the distribution of controlled substances (opioids) in federal and state courts throughout the U.S., and in Puerto Rico and Canada. The plaintiffs in these actions have included state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. We believe we have valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and we intend to mount a vigorous defense. Other than as to the settlements described in Financial Note 10, we have not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on our financial position, cash flows or liquidity, or results of operations.The Company and two other national distributors have reached proposed settlements with representatives of nationwide groups of acute care hospitals and certain third-party payors.During the three months ended September 30, 2024, we made payments totaling $500Â million associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes. Our total estimated liability for opioid-related claims was $6.4 billion as of September 30, 2024, of which $775 million was included within â€œOther accrued liabilitiesâ€ for the amount estimated to be paid within the next twelve months, and the remaining liability was included in â€œLong-term litigation liabilitiesâ€ in our Condensed Consolidated Balance Sheet.Rite Aid Bankruptcy ProceedingsIn October 2023, our customer Rite Aid Corporation (including certain of its subsidiaries, â€œRite Aidâ€) filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code. Consequently, we recorded a provision for bad debts totaling $725 million during the year ended March 31, 2024, of which $210 million was recorded in the second quarter of fiscal 2024 representing the uncollected trade accounts receivable balance from Rite Aid as of September 30, 2023. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August 2024. During the three and six months ended September 30, 2024, we reassessed our initial estimates made in conjunction with the previously reserved prepetition balances, including cash received during the period, resulting in a reversal of $203 million recorded within â€œSelling, distribution, general, and administrative expensesâ€ in our Condensed Consolidated Statements of Operations and included in our U.S. Pharmaceutical segment. During the three and six months ended September 30, 2024, we released $237 million of allowance for doubtful accounts against trade accounts receivables, representing the write-off of uncollectible receivables related to the Rite Aid provision in the Condensed Consolidated Balance Sheet.We believe the reserves maintained and expenses and credits recorded in fiscal 2025 and fiscal 2024 for Rite Aid trade accounts receivable are appropriate and consistent with our accounting policy and assessment of the information currently available. We evaluate our reserves periodically and as circumstances warrant which may result in changes to our reserves. For additional disclosure of our policy regarding allowances for credit losses, refer to the â€œCritical Accounting Estimatesâ€ section within Item 7 - Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations in Part II of our 2024 Annual Report.38Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)RESULTS OF OPERATIONSOverview of Consolidated Results:(Dollars in millions, except per share data)Three Months Ended September 30, Â Six Months Ended September 30, Â 20242023Change20242023ChangeRevenues$93,651Â $77,215Â 21Â %$172,934Â $151,698Â 14Â %Gross profit3,248Â 3,069Â 6Â 6,400Â 6,091Â 5Â Gross profit margin3.47Â %3.97Â %(50)bp3.70Â %4.02Â %(32)bpTotal operating expenses$(2,670)$(2,118)26Â %$(4,793)$(4,040)19Â %Total operating expenses as a percentage of revenues2.85Â %2.74Â %11Â bp2.77Â %2.66Â %11Â bpOther income, net$34Â $26Â 31Â %$164Â $64Â 156Â %Interest expense(78)(61)28Â (153)(108)42Â Income before income taxes534Â 916Â (42)1,618Â 2,007Â (19)Income tax expense(247)(213)16Â (371)(307)21Â Reported income tax rate46.3Â %23.3Â %2,300Â bp22.9Â %15.3Â %760Â bpNet income287Â 703Â (59)1,247Â 1,700Â (27)Net income attributable to noncontrolling interests(46)(39)18Â (91)(78)17Â Net income attributable to McKesson Corporation$241Â $664Â (64)%$1,156Â $1,622Â (29)%Diluted earnings per common share attributable to McKesson Corporation$1.87Â $4.92Â (62)%$8.89Â $11.95Â (26)%Weighted-average diluted common shares outstanding129.3Â 134.8Â (4)%130.0Â 135.7Â (4)%Any percentage changes displayed above which are not meaningful are displayed as zero percent.bp - basis pointsRevenues Revenues increased for the three and six months ended September 30, 2024 compared to the same prior year periods, primarily due to market growth in our U.S. Pharmaceutical segment, including higher volumes largely from retail national account customers and growth in specialty pharmaceuticals. Market growth includes growing drug utilization and newly launched products, partially offset by price deflation associated with branded to generic drug conversion. This revenue growth was also favorably impacted by higher pharmaceutical distribution volumes in our International segment.Gross Profit Gross profit increased for the three and six months ended September 30, 2024 compared to the same prior year periods primarily in our U.S. Pharmaceutical segment driven by growth of specialty pharmaceuticals and in our International segment driven by higher volumes.We recognized gains of $63Â million and $79Â million for the three months ended September 30, 2024 and 2023, respectively, and $153Â million and $197Â million for the six months ended September 30, 2024 and 2023, respectively, related to our share of antitrust legal settlements. We recognized these amounts within "Cost of sales" in the Condensed Consolidated Statements of Operations within our U.S. Pharmaceutical segment.39Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Gross profit for the three and six months ended September 30, 2024 was impacted by restructuring charges of $63 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report. We recorded this amount related to impairment of inventories within "Cost of sales" in the Condensed Consolidated Statements of Operations within our U.S. Pharmaceutical segment.A last-in, first out (â€œLIFOâ€) credit of $2 million and a charge of $55 million were recognized during the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million were recognized during the six months ended September 30, 2024 and 2023, respectively, primarily due to lower expected brand inflation in the current fiscal year.Our U.S. Pharmaceutical business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The businessâ€™ practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price related inventory losses. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO adjustment is based on our estimates of the annual LIFO adjustment which is impacted by expected changes in year-end inventory quantities, product mix, and manufacturer pricing practices, which may be influenced by market and other external factors. Changes to any of the above factors could have a material impact to our annual LIFO adjustment. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year.Total Operating ExpensesA summary of the components of our total operating expenses for the three and six months ended September 30, 2024 and 2023 is as follows: â€¢Selling, distribution, general, and administrative expenses (â€œSDG&Aâ€): SDG&A consists of personnel costs, transportation costs, depreciation and amortization, lease costs, professional fee expenses, administrative expenses, provision for bad debts and related recoveries, remeasurement charges to fair value less costs to sell, and other general charges.â€¢Claims and litigation charges, net: These charges include adjustments for estimated probable settlements related to our controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. Legal fees to defend claims, which are expensed as incurred, are included within SDG&A.â€¢Restructuring, impairment, and related charges, net: Charges recorded under this component include those incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted, as well as long-lived asset impairments.Three Months Ended September 30, Six Months Ended September 30, (Dollars in millions)20242023Change20242023ChangeSelling, distribution, general, and administrative expenses$2,503Â $2,092Â 20Â %$4,504Â $3,962Â 14Â %Claims and litigation charges, net(4)(2)100Â 108Â (2)â€”Â Restructuring, impairment, and related charges, net171Â 28Â 511Â 181Â 80Â 126Â Total operating expenses$2,670Â $2,118Â 26Â %$4,793Â $4,040Â 19Â %Percent of revenues2.85Â %2.74Â %11Â bp2.77Â %2.66Â %11Â bpAny percentage changes displayed above which are not meaningful are displayed as zero percent.bp - basis points40Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)For the three and six months ended September 30, 2024, total operating expenses and total operating expenses as a percentage of revenues increased compared to the same prior year periods. Total operating expenses were impacted by the following significant items:â€¢SDG&A for the three and six months ended September 30, 2024 includes charges of $643Â million to remeasure our Canadian retail disposal group to fair value less costs to sell. The remeasurement adjustment includes a $15Â million loss related to the accumulated other comprehensive loss balances associated with this disposal. Of the total charges recorded during the period, $593Â million are included within our International segment and $50Â million are included within Corporate expenses, net;â€¢SDG&A for the three and six months ended September 30, 2024 includes a credit of $203 million, and for the three and six months ended September 30, 2023 includes a provision for bad debts of $210Â million, related to the bankruptcy of Rite Aid in October 2023. Refer to the Rite Aid Bankruptcy Proceedings section of â€œTrends and Uncertainties for additional information;â€â€¢SDG&A increased compared to the same prior year periods due to increased operating expenses to support higher volumes and gains of $48Â million and $76Â million recognized in the three and six months ended September 30, 2023, respectively, resulting from a fair value adjustment of our contingent consideration liability related to the Rx Savings Solutions, LLC acquisition;â€¢Claims and litigation charges, net primarily consists of a charge of $108Â million related to our estimated liability for opioid-related claims as previously discussed in the Opioid-Related Litigation and Claims section of â€œTrends and Uncertainties;â€ andâ€¢Restructuring, impairment, and related charges, net were $171 million and $28 million for the three months ended September 30, 2024 and 2023, respectively, and $181 million and $80 million for the six months ended September 30, 2024 and 2023, respectively, as discussed below under â€œRestructuring Initiatives.â€Goodwill ImpairmentWe evaluate goodwill for impairment on an annual basis in the first fiscal quarter, and at an interim date if indicators of potential impairment exist. The annual impairment testing performed in fiscal 2025 and fiscal 2024 did not indicate any impairment of goodwill, and no goodwill impairment charges were recorded during the three and six months ended September 30, 2024 and 2023. However, other risks, expenses, and future developments, such as government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods.Restructuring InitiativesWe recorded restructuring, impairment, and related charges of $171 million and $28 million for the three months ended September 30, 2024 and 2023, respectively, and $181 million and $80 million for the six months ended September 30, 2024 and 2023, respectively. These charges were included in â€œRestructuring, impairment, and related charges, netâ€ in the Condensed Consolidated Statements of Operations.During the second quarter of fiscal 2025, we approved enterprise-wide initiatives to modernize and accelerate our technology service operating model, which are intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives will also include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions, and U.S. Pharmaceutical segments to help realize long-term sustainable growth. We anticipate total charges related to these initiatives of $650Â million to $700Â million, consisting primarily of employee severance and other employee-related costs as well as facility, exit and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. For the three and six months ended September 30, 2024, we recorded charges of $227Â million related to the initiatives, which primarily includes severance and other employee-related costs as well as facility exit and other related costs, including long-lived asset impairments and a $63 million related to inventory impairments recorded within â€œCost of salesâ€ in the Condensed Consolidated Statements of Operations.41Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)During the fourth quarter of fiscal 2023, we approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying our infrastructure and realizing long-term sustainable growth. These initiatives included headcount reductions, primarily consisting of employee severance and other employee-related costs within our RxTS segment, and the exit or downsizing of certain facilities. For the three and six months ended September 30, 2023, we recorded charges of $3 million and $39Â million related to this program, respectively, which primarily included real estate and other related asset impairments and facility costs within Corporate. This restructuring program was substantially complete in fiscal 2024.Refer to Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information on our restructuring initiatives.Other Income, NetOther income, net increased for the three and six months ended September 30, 2024 compared to the same prior year periods primarily due to a favorable impact from interest income. Other income, net for the six months ended September 30, 2024 includes a net gain of $95Â million related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry, partially offset by a loss of $43Â million related to one of our equity method investments.Interest ExpenseInterest expense increased for the three and six months ended September 30, 2024 compared to the same prior year periods primarily due to increased average balances of the Companyâ€™s loan portfolio throughout the first half of the year. Interest expense for the six months ended September 30, 2024 was unfavorably impacted by a prior year gain on debt extinguishment of $9 million. Interest expense may fluctuate based on timing, amounts, and interest rates of term debt repaid and new term debt issued, as well as amounts incurred associated with financing fees. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information. 42Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Income Tax ExpenseFor the three months ended September 30, 2024 and 2023, we recorded income tax expense of $247 million and $213 million, respectively. For the six months ended September 30, 2024 and 2023, we recorded income tax expense of $371 million and $307 million, respectively. Our reported income tax rates were 46.3% and 23.3% for the three months ended September 30, 2024 and 2023, respectively, and 22.9% and 15.3% for the six months ended September 30, 2024 and 2023, respectively. Fluctuations in our reported income tax rates are primarily due to non-cash charges related to the remeasurement of our Canadian retail disposal group held for sale to fair value less costs to sell, changes in our business mix of earnings between various taxing jurisdictions and discrete tax items recognized in the quarters. During the three months ended September 30, 2024, we sold certain intellectual property between McKesson wholly-owned legal entities based in foreign tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction whereas the recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result, a discrete tax benefit of $44Â million was recognized in the second quarter of fiscal 2025. During the three and six months ended September 30, 2024, we recorded non-cash pre-tax charges of $643Â million primarily to remeasure our Canadian retail disposal group to fair value less costs to sell, as described in

Financial Note 2, â€œHeld for Sale.â€ Our reported income tax rates for the three and six months ended September 30, 2024 were unfavorably impacted by these charges as no net tax benefit was recognized for these charges.For the six months ended September 30, 2024, we recognized discrete tax benefits of $58Â million related to an election to change the tax status of a foreign affiliate, $38Â million related to the tax impact of share-based compensation, and $47Â million related to the reduction in unrecognized tax benefits due to a change in case law, partially offset by a discrete tax expense of $37Â million related to interest expense accrued on unrecognized tax benefits.We recognized a net discrete tax benefit of $147Â million in the six months ended September 30, 2023 primarily related to the repatriation of certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. Refer to Financial Note 4, â€œIncome Taxes,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.Net Income Attributable to Noncontrolling InterestsNet income attributable to noncontrolling interests for the three and six months ended September 30, 2024 and 2023 primarily represents the proportionate results of third-party equity interests in ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. The increase in net income attributable to noncontrolling interests was primarily driven by higher volumes in our ClarusONE joint venture.Net Income Attributable to McKesson CorporationNet income attributable to McKesson Corporation was $241 million and $664 million for the three months ended September 30, 2024 and 2023, respectively, and $1.2 billion and $1.6 billion for the six months ended September 30, 2024 and 2023, respectively. Diluted earnings per common share attributable to McKesson Corporation was $1.87 and $4.92 for the three months ended September 30, 2024 and 2023, respectively, and $8.89 and $11.95 for the six months ended September 30, 2024 and 2023, respectively. Our diluted earnings per share includes the cumulative effects of share repurchases during each period.Weighted-Average Diluted Common Shares OutstandingDiluted earnings per common share was calculated based on a weighted-average number of shares outstanding of 129.3 million and 134.8 million for the three months ended September 30, 2024 and 2023, respectively, and 130.0 million and 135.7 million for the six months ended September 30, 2024 and 2023, respectively. Weighted-average diluted shares outstanding for the three and six months ended September 30, 2024 decreased from the same prior year periods primarily due to the cumulative effect of share repurchases, as discussed in the â€œShare Repurchases Plansâ€ section of this Financial Review.43Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Overview of Segment Results:Segment Revenues:Â Three Months Ended September 30, Â Six Months Ended September 30, Â (Dollars in millions)20242023Change20242023ChangeSegment revenuesU.S. Pharmaceutical$85,726Â $69,766Â 23Â %$157,441Â $136,926Â 15Â %Prescription Technology Solutions1,265Â 1,140Â 11Â 2,506Â 2,384Â 5Â Medical-Surgical Solutions2,948Â 2,834Â 4Â 5,584Â 5,445Â 3Â International3,709Â 3,475Â 7Â 7,400Â 6,943Â 7Â Corporate3Â â€”Â â€”Â 3Â â€”Â â€”Â Total revenues$93,651Â $77,215Â 21Â %$172,934Â $151,698Â 14Â %Any percentage changes displayed above which are not meaningful are displayed as zero percent.U.S. PharmaceuticalThree Months Ended September 30, 2024 vs. 2023U.S. Pharmaceutical revenues for the three months ended September 30, 2024 increased $16 billion or 23% compared to the same prior year period. Within the segment, sales to pharmacies and healthcare providers increased $14.2 billion and sales to specialty practices and other increased $1.8 billion. Overall, these increases were primarily due to higher volumes from retail national account customers and growth in specialty pharmaceuticals, partially offset by branded to generic drug conversions.Six Months Ended September 30, 2024 vs. 2023U.S. Pharmaceutical revenues for the six months ended September 30, 2024 increased $20.5 billion or 15% compared to the same prior year period. Within the segment, sales to pharmacies and healthcare providers increased $17.1 billion and sales to specialty practices and other increased $3.4 billion. Overall, these increases were primarily due to higher volumes from retail national account customers and growth in specialty pharmaceuticals, partially offset by branded to generic drug conversions.Prescription Technology SolutionsThree Months Ended September 30, 2024 vs. 2023RxTS revenues for the three months ended September 30, 2024 increased $125 million or 11% compared to the same prior year period due to increased volumes from our third-party logistics and higher technology service revenues.Six Months Ended September 30, 2024 vs. 2023RxTS revenues for the six months ended September 30, 2024 increased $122 million or 5% compared to the same prior year period due to increased volumes from our third-party logistics and higher technology service revenues.Medical-Surgical SolutionsThree Months Ended September 30, 2024 vs. 2023Medical-Surgical Solutions revenues for the three months ended September 30, 2024 increased $114 million or 4% compared to the same prior year period. Within the segment, sales to primary care customers increased $106 million and sales to extended care customers increased $17 million, driven by underlying business growth. These increases were partially offset by Other sales which declined $9 million driven by lower contribution from the kitting and distribution of ancillary supplies used to administer COVID-19 vaccines.44Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Six Months Ended September 30, 2024 vs. 2023Medical-Surgical Solutions revenues for the six months ended September 30, 2024 increased $139 million or 3% compared to the same prior year period. Within the segment, sales to primary care customers increased $159 million and sales to our extended care customers increased $2 million, driven by underlying business growth. These increases were partially offset by Other sales which declined $22 million driven by lower contribution from the kitting and distribution of ancillary supplies used to administer COVID-19 vaccines.InternationalThree Months Ended September 30, 2024 vs. 2023International revenues for the three months ended September 30, 2024 increased $234 million or 7% compared to the same prior year period. Within the segment, sales in Canada increased by $272 million primarily driven by higher pharmaceutical distribution volumes and sales in Norway increased by $26 million primarily driven by growth in retail pharmacy. These increases were partially offset by unfavorable effects of foreign currency exchange fluctuations of $64 million.Six Months Ended September 30, 2024 vs. 2023International revenues for the six months ended September 30, 2024 increased $457 million or 7% compared to the same prior year period. Within the segment, sales in Canada increased by $520 million primarily driven by higher pharmaceutical distribution volumes and sales in Norway increased by $66 million primarily driven by growth in retail pharmacy. These increases were partially offset by unfavorable effects of foreign currency exchange fluctuations of $129 million.CorporateThree Months Ended September 30, 2024 vs. 2023Corporate reflects revenues from services derived in the U.S. related to certain technology operations. The increase compared to the prior year was immaterial.Six Months Ended September 30, 2024 vs. 2023Corporate reflects revenues from services derived in the U.S. related to certain technology operations. The increase compared to the prior year was immaterial.45Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Segment Operating Profit and Corporate Expenses, Net:Â Three Months Ended September 30, Â Â Six Months Ended September 30, Â Â (Dollars in millions)20242023Change20242023ChangeSegment operating profit (loss) (1)U.S. Pharmaceutical (2)$1,075Â $593Â 81Â %$1,856Â $1,420Â 31Â %Prescription Technology Solutions (3)205Â 238Â (14)408Â 469Â (13)Medical-Surgical Solutions(4)89Â 244Â (64)277Â 471Â (41)International (5)(508)66Â (870) (418)123Â (440)Subtotal861Â 1,141Â (25)2,123Â 2,483Â (14)Corporate expenses, net (6)(249)(164)52Â (352)(368)(4)Interest expense(78)(61)28Â (153)(108)42Â Income before income taxes$534Â $916Â (42)%$1,618Â $2,007Â (19)%Segment operating profit marginU.S. Pharmaceutical 1.25Â %0.85Â %40Â bp1.18Â %1.04Â %14Â bpPrescription Technology Solutions16.21Â 20.88Â (467)16.28Â 19.67Â (339)Medical-Surgical Solutions3.02Â 8.61Â (559)4.96Â 8.65Â (369)International(13.70)1.90Â (1,560)(5.65)1.77Â (742)Any percentage changes displayed above which are not meaningful are displayed as zero percent.bp - basis points(1)Segment operating profit includes gross profit, net of total operating expenses, as well as other income, net, for our reportable segments.(2)Operating profit for our U.S. Pharmaceutical segment includes the following:â€¢a credit of $203 million for the three and six months ended September 30, 2024 due to the reassessment of our initial estimates made in conjunction with the previously reserved prepetition balances owed by Rite Aid. We recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid as discussed in the â€œTrends and Uncertaintiesâ€ section; â€¢cash receipts for our share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively;â€¢a credit of $2 million and a charge of $55 million related to the LIFO method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively and a credit of $4 million and a charge of $87Â million for the six months ended September 30, 2024 and 2023, respectively;â€¢restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net;â€â€¢a charge of $57 million for the six months ended September 30, 2024 related to our estimated liability for opioid-related claims as discussed previously in the â€œTrends and Uncertaintiesâ€ section; andâ€¢a loss of $43Â million for the six months ended September 30, 2024 related to one of the Companyâ€™s equity method investments.(3)Operating profit for our RxTS segment for the three and six months ended September 30, 2023 includes gains of $48Â million and $76Â million, respectively, resulting from fair value adjustments of our contingent consideration liability related to the Rx Savings Solutions, LLC acquisition completed in November 2022. (4)Operating profit for our Medical-Surgical Solutions segment for the three and six months ended September 30, 2024 includes restructuring charges of $144 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.(5)Operating profit (loss) for our International segment includes a charge of $593Â million for the three and six months ended September 30, 2024 to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.46Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)(6)Corporate expenses, net includes the following:â€¢a charge of $50Â million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from our Canadian retail disposal group, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report;â€¢a net gain of $95Â million for the six months ended September 30, 2024 related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, â€œFair Value Measurements,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report; â€¢a net charge of $51Â million for the six months ended September 30, 2024 related to our estimated liability for opioid-related claims as discussed previously in the â€œTrends and Uncertaintiesâ€ section; andâ€¢a restructuring charge of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.U.S. PharmaceuticalThree Months Ended September 30, 2024 vs. 2023Operating profit for this segment increased for the three months ended September 30, 2024 compared to the same prior year period primarily due to a prior year provision for bad debts of $210 million and a fiscal 2025 credit of $203 million related to the reassessment of our initial estimates made in conjunction with the previously reserved prepetition balances owed by Rite Aid, and growth in specialty pharmaceuticals, partially offset by an increase in operating expenses to support higher volumes, and a decrease from net cash proceeds received representing our share of antitrust legal settlements.Six Months Ended September 30, 2024 vs. 2023Operating profit for this segment increased for the six months ended September 30, 2024 compared to the same prior year period primarily due to a prior year provision for bad debts of $210 million and a fiscal 2025 credit of $203 million related to the reassessment of our initial estimates made in conjunction with the previously reserved prepetition balances owed by Rite Aid, and growth in specialty pharmaceuticals, offset by an increase in operating expenses to support higher volumes, a charge of $57Â million related to our estimated liability for opioid-related claims, a loss related to one of our equity method investments, and a decrease from net cash proceeds received representing our share of antitrust legal settlements.Prescription Technology SolutionsThree Months Ended September 30, 2024 vs. 2023Operating profit for this segment decreased for the three months ended September 30, 2024 compared to the same prior year period driven by the gain of $48Â million recognized in the prior year resulting from a fair value adjustment of our contingent consideration liability related to the Rx Savings Solutions, LLC acquisition, and higher operating expenses, partially offset by contributions from technology services.Six Months Ended September 30, 2024 vs. 2023Operating profit for this segment decreased for the six months ended September 30, 2024 compared to the same prior year period driven by the gain of $76Â million recognized in the prior year resulting from a fair value adjustment of our contingent consideration liability related to the Rx Savings Solutions, LLC acquisition, and higher operating expenses, partially offset by contributions from technology services.Medical-Surgical SolutionsThree Months Ended September 30, 2024 vs. 2023Operating profit for this segment decreased for the three months ended September 30, 2024 compared to the same prior year period primarily due to higher restructuring charges recorded in fiscal 2025.Six Months Ended September 30, 2024 vs. 2023Operating profit for this segment decreased for the six months ended September 30, 2024 compared to the same prior year period due to higher restructuring charges recorded in fiscal 2025, a decline in our core primary care business, and a lower contribution from kitting and distribution of ancillary supplies for COVID-19 vaccines.47Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)InternationalThree Months Ended September 30, 2024 vs. 2023Operating (loss) for this segment for the three months ended September 30, 2024 compared to an operating profit for the same prior year period was largely due to remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.Six Months Ended September 30, 2024 vs. 2023Operating (loss) for this segment for the six months ended September 30, 2024 compared to an operating profit for the same prior year period was largely due to remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report, partially offset by higher pharmaceutical distribution volumes across the segment.Corporate Expenses, NetThree Months Ended September 30, 2024 vs. 2023Corporate expenses, net increased for the three months ended September 30, 2024 compared to the same prior year period primarily due to remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report, and higher restructuring charges recorded in the second quarter of fiscal 2025 compared to the same prior year period.Six Months Ended September 30, 2024 vs. 2023Corporate expenses, net decreased for the six months ended September 30, 2024 compared to the same prior year period primarily due to a net gain of $95Â million related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry and lower restructuring charges recorded in the first half of fiscal 2025 compared to the same prior year period, partially offset by remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, â€œHeld for Sale,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report, and a net charge of $51Â million related to our estimated liability for opioid-related claims.New Accounting PronouncementsNew accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, â€œSignificant Accounting Policies,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.48Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements. We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility. At September 30, 2024, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future.The following table summarizes the net change in cash, cash equivalents, and restricted cash for the periods shown: Six Months Ended September 30, (Dollars in millions)20242023ChangeNet cash provided by (used in):Operating activities$720Â (87)807Â Investing activities(373)(315)(58)Financing activities(2,408)(1,752)(656)Effect of exchange rate changes on cash, cash equivalents, and restricted cash1Â (1)2Â Change in cash, cash equivalents, and restricted cash classified as Assets held for sale(14)â€”Â (14)Net change in cash, cash equivalents, and restricted cash$(2,074)$(2,155)$81Â Operating ActivitiesOperating activities provided cash of $720 million and used cash of $87 million during the six months ended September 30, 2024 and 2023, respectively. Cash flows from operations can be significantly impacted by factors such as the timing of receipts from customers, inventory receipts, and payments to vendors. Additionally, working capital is primarily a function of sales and purchase volumes, inventory requirements, and vendor payment terms.Operating activities for the six months ended September 30, 2024 were affected by net income of $1.2 billion, adjusted for non-cash items, including charges of $643Â million to remeasure the assets and liabilities of our Canadian retail disposal group to fair value less cost to sell, as well as increases in accounts payable of $6.2 billion, receivables of $3.5 billion, and inventories of $3.3 billion, all primarily driven by higher revenues and timing. Our litigation liabilities decreased by $386 million due to payments made in the second quarter of fiscal 2025 associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes, partially offset by an accrual in the first quarter of fiscal

2025 related to a proposed settlement with third party payors as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.Operating activities for the six months ended September 30, 2023 were affected by net income of $1.7 billion, adjusted for non-cash items, as well as increases in drafts and accounts payable of $4.3 billion, receivables of $3.2 billion, and inventories of $2.3 billion, all primarily driven by higher revenues and timing. Our litigation liabilities also decreased by $529 million due to payments made during the second quarter of fiscal 2024 associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes.Investing ActivitiesInvesting activities used cash of $373 million and $315 million during the six months ended September 30, 2024 and 2023, respectively. Investing activities for the six months ended September 30, 2024 and 2023 includes $385 million and $264 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software. Investing activities for the six months ended September 30, 2024 was also impacted by the receipt of proceeds of $92 million related to the sale of equity securities, as discussed in Financial Note 9, â€œFair Value Measurements,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.49Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Financing ActivitiesFinancing activities used cash of $2.4 billion and $1.8 billion during the six months ended September 30, 2024 and 2023, respectively. On September 10, 2024, we completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million. Proceeds received from this note issuance, net of discounts and offering expenses, were approximately $496 million. We utilized the net proceeds from this note issuance along with cash on hand to redeem our $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 prior to maturity at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest through the settlement date.On June 15, 2023, we completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million and 5.10% Notes due July 15, 2033 in a principal amount of $600 million, for proceeds received, net of discounts and offering expenses, of $397 million and $592 million, respectively. A portion of the net proceeds from these notes was utilized to fund the repurchase of our then outstanding 3.80% Notes due March 15, 2024 (the â€œ2024 Notesâ€) discussed below, while the remaining net proceeds was available for general corporate purposes.On June 16, 2023, we completed a cash tender offer for any and all of our then outstanding 2024 Notes with a principal amount of $918Â million, which was made concurrently with the June 15, 2023 notes offering described above. Using a portion of the proceeds from the June 15, 2023 notes offering, we paid an aggregate consideration of $268 million to repurchase $271 million principal amount of the 2024 Notes. Following the consummation of this tender offer, on June 16, 2023, we irrevocably deposited U.S. government obligations with the trustee under the indenture governing the 2024 Notes sufficient to fund the payment of accrued and unpaid interest of the remaining $647Â million principal amount of the 2024 Notes as it became due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date.Financing activities for the six months ended September 30, 2024 and 2023 includes $2.0 billion and $1.5 billion of cash paid for share repurchases, as well as $162 million and $149 million of cash paid for dividends, respectively. Financing activities also includes cash receipts and cash repayments each of $6.9 billion and $2.0 billion for the six months ended September 30, 2024 and 2023, respectively, related to short-term borrowings of commercial paper.Cash used for other financing activities generally includes the cash value of shares surrendered for tax withholding and payments to noncontrolling interests.Share Repurchase PlansThe Board has authorized the repurchase of common stock. We may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (â€œExchange Actâ€). The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions.During the three months ended September 30, 2024, we repurchased 2.9Â million shares of common stock for $1.5Â billion through open market transactions at an average price per share of $533.46, of which $22 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2024 and settled in early October 2024. During the three months ended June 30, 2024, we repurchased 1.0Â million shares of common stock for $528Â million through open market transactions at an average price per share of $548.20.During the three months ended September 30, 2023, we repurchased 2.0Â million shares of common stock for $840Â million through open market transactions at an average price per share of $422.39, of which $23 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2023 and settled in early October 2023. During the three months ended June 30, 2023, we repurchased 1.8Â million shares of common stock for $673Â million through open market transactions at an average price per share of $379.14.50Table of Contents MD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONTINUED) (UNAUDITED)Effective January 1, 2023, our repurchase of common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. Excise taxes incurred on share repurchases of an entityâ€™s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholdersâ€™ equity within â€œTreasury sharesâ€ in our Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholdersâ€™ Deficit. Excise taxes do not reduce our remaining authorization for the repurchase of common stock. Excise taxes of $15 million and $8Â million were incurred and accrued for shares repurchased during the three months ended September 30, 2024 and 2023, respectively. Excise taxes of $16Â million and $12Â million were incurred and accrued for shares repurchased during the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the amounts accrued for excise taxes were $41Â million and $25Â million, respectively, within â€œOther accrued liabilitiesâ€ in our Condensed Consolidated Balance Sheets.In July 2024, the Board approved an increase of $4.0 billion in the authorization for the repurchase of common stock. The total remaining authorization outstanding for repurchases of common stock at September 30, 2024 was $8.6 billion.Selected Measures of Liquidity and Capital Resources(Dollars in millions)September 30, 2024March 31, 2024Cash, cash equivalents, and restricted cash$2,511Â $4,585Â Working capital(5,430)(4,387)Debt to capital ratio (1)158.8Â %124.0Â %(1)This ratio describes the relationship and changes within our capital resources, and is computed as the sum of total debt divided by the sum of total debt and McKesson stockholdersâ€™ deficit, which excludes noncontrolling interests and accumulated other comprehensive loss.Cash equivalents, which are readily convertible to known amounts of cash, are carried at fair value. Cash equivalents are primarily invested in AAA-rated U.S. government money market funds, short-term deposits with financial institutions, and short-term commercial papers issued by non-financial institutions. Deposits with financial institutions are primarily denominated in U.S. dollars and the functional currencies of our foreign subsidiaries, including Canadian dollars. Deposits could exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.Our cash and cash equivalents balance as of September 30, 2024 and March 31, 2024 included approximately $1.7 billion and $1.6 billion, respectively, of cash held by our subsidiaries outside of the U.S. Our primary intent is to utilize this cash for foreign operations for an indefinite period of time. Although the majority of cash held outside the U.S. is available for repatriation, doing so could subject us to foreign withholding taxes and state income taxes.Â We may remit foreign earnings to the U.S. to the extent it is tax efficient to do so. We do not anticipate the tax impact from remitting these earnings to be material. Following enactment of the 2017 Tax Cuts and Jobs Act, the repatriation of cash to the U.S. is generally no longer taxable for federal income tax purposes.Working capital primarily includes cash and cash equivalents, receivables, inventories, and prepaid expenses, net of drafts and accounts payable, short-term borrowings, current portion of long-term debt, current portion of operating lease liabilities, and other accrued liabilities. Working capital also includes net assets and liabilities classified as held for sale which have increased in fiscal 2025 as a result of the expected divestiture of our Canadian retail disposal group. Our businesses require substantial investments in working capital that are susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements.Consolidated working capital decreased at September 30, 2024 compared to March 31, 2024 primarily due to an increase in drafts and accounts payable from increased purchasing driven by increased sales and timing, and a decrease in cash and cash equivalents, partially offset by an increase in receivables, net and inventories, net, driven by higher sales and timing, an increase in net current assets held for sale related to our Canadian retail disposal group, and a decrease in other accrued liabilities.Our debt to capital ratio increased for the six months ended September 30, 2024 due to share repurchases and dividend payments, partially offset by net income attributable to McKesson for fiscal 2025.51Table of ContentsMD&A IndexMcKESSON CORPORATIONFINANCIAL REVIEW (CONCLUDED) (UNAUDITED)In July 2024, we raised our quarterly dividend from $0.62 to $0.71 per share of common stock for dividends declared on or after such date by the Board. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon our future earnings, financial condition, capital requirements, legal requirements, and other factors.Capital ResourcesWe fund our working capital requirements primarily with cash and cash equivalents, proceeds from short-term borrowings from our commercial paper issuances, and longer-term credit agreements and debt offerings. Funds necessary for future debt maturities and our other cash requirements, including any future payments that may be made related to our total estimated litigation liability of $6.4 billion as of September 30, 2024 payable under the terms of various settlement agreements for opioid-related claims, are expected to be met by existing cash balances, cash flow from operations, existing credit sources, and future borrowings. Long-term debt markets and commercial paper markets, our primary sources of capital after cash flow from operations, are open and accessible to us should we decide to access those markets. Detailed information regarding our debt and financing activities is included in Financial Note 7, â€œDebt and Financing Activities,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report.We believe that our future operating cash flow, financial assets, and access to capital and credit markets, including our credit facilities, give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that an increase in volatility or disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTSThis Quarterly Report on Form 10-Q, including â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. Forward-looking statements may be identified by their use of terminology such as â€œbelieves,â€ â€œexpects,â€ â€œanticipates,â€ â€œmay,â€ â€œwill,â€ â€œshould,â€ â€œseeks,â€ â€œapproximately,â€ â€œintends,â€ â€œprojects,â€ â€œplans,â€ â€œestimates,â€ â€œtargets,â€ or the negative of these words or other comparable terminology. The discussion of proposed acquisition or disposition transactions, financial trends, strategy, plans, assumptions, expectations, or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, they include, but are not limited to, the factors discussed in the â€œRisk Factorsâ€ section in Item 1A of Part I of the 2024 Annual Report and in our publicly available SEC filings and press releases. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events.AVAILABLE INFORMATIONWe routinely post on our company website, and via our social media channels, information that may be material to investors, including details and updates to information disclosed elsewhere, which may include business developments, earnings and financial performance, sustainability matters, and materials for presentations to investors and financial analysts. Investors are encouraged to monitor our website www.mckesson.com. Interested parties can sign up on our website, including our Investor Relations site, to receive automated e-mail alerts, such as via RSS newsfeed, when we post certain information. Interested parties can also follow our social media feed @McKesson on X. The content on any website or social media channel is not incorporated by reference into this report, unless expressly noted otherwise.Item 3.Quantitative and Qualitative Disclosures about Market Risk.We believe there has been no material change in our exposure to risks associated with fluctuations in interest and foreign currency exchange rates as disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024. 52Table of ContentsMcKESSON CORPORATIONItem 4.Controls and Procedures.Our Chief Executive Officer and our Chief Financial Officer, with the participation of other members of the Companyâ€™s management, have evaluated the effectiveness of the Companyâ€™s â€œdisclosure controls and proceduresâ€ (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.There were no changes in our â€œinternal control over financial reportingâ€ (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.PART IIâ€”OTHER INFORMATIONItem 1.Legal Proceedings. The information set forth in Financial Note 10, â€œCommitments and Contingent Liabilities,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, and in Financial Note 17, â€œCommitments and Contingent Liabilities,â€ to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024, is incorporated herein by reference. Disclosure of an environmental proceeding with a governmental agency generally is included only if we expect monetary sanctions in the proceeding to exceed $1 million, unless otherwise material.Item 1A.Risk Factors.Other than factual updates discussed in this Quarterly Report on Form 10-Q, there have been no material changes for the period covered by this Quarterly Report on Form 10-Q to the risk factors disclosed in Part I of Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.Item 2.Unregistered Sales of Equity Securities and Use of Proceeds.Our Board of Directors has authorized the repurchase of common stock. We may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Exchange Act. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions.Refer to Financial Note 11, â€œStockholders' Deficit,â€ to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a full discussion of the Companyâ€™s share repurchases for the three and six months ended September 30, 2024 and 2023.53Table of ContentsMcKESSON CORPORATIONThe following table provides information on the Companyâ€™s share repurchases during the three months ended September 30, 2024:Â Share Repurchases (1)(In millions, except price per share)TotalÂ Numberof SharesPurchasedAverageÂ PricePaidÂ PerÂ Share (2)TotalÂ NumberÂ ofShares Purchasedas Part of a PubliclyAnnouncedProgram (3)ApproximateDollarÂ ValueÂ ofSharesÂ thatÂ MayYet Be Purchased Under the Programs (2)July 1, 2024 â€“ July 31, 20240.3Â 578.47Â 0.3Â $9,928Â August 1, 2024 â€“ August 31, 20240.9Â 548.97Â 0.9Â 9,453Â September 1, 2024 â€“ September 30, 20241.7Â 509.96Â 1.7Â 8,574Â Total2.9Â 2.9Â (1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.(2)The average price paid per share excludes $15 million of excise taxes incurred on share repurchases for the three months ended September 30, 2024. The remaining authorization outstanding for repurchases of common stock excludes $41Â million of cumulative excise taxes incurred on share repurchases through September 30, 2024.(3)In July 2024, the Board authorized the Company to repurchase up to an additional $4.0 billion shares of common stock, which has no expiration date. Item 3.Defaults Upon Senior Securities.None.Item 4.Mine Safety Disclosures.Not applicable.Item 5. Other Information.On November 7, 2024, the Company entered into an amendment (the â€œAmendmentâ€) to its Credit Agreement, dated November 7, 2022, among the Company, as borrower, the lenders party thereto, the letter of credit issuers party thereto, Bank of America, N.A., as administrative agent, and the other parties thereto (the â€œExisting Credit Agreementâ€, as amended by the Amendment, the â€œAmended Credit Agreementâ€).The Amendment, among other things, (1) extends the maturity date of the revolving credit facility provided for in the Credit Agreement from November 7, 2028 to November 7, 2029, (2) changes the applicable benchmark with respect to Loans denominated in Canadian Dollars from CDOR to the Term CORRA and (3) reduces the SOFR Adjustment to 0% for Loans bearing interest by reference to SOFR with a one-month tenor. Capitalized terms used but not otherwise defined herein have the meanings ascribed thereto in the Amended Credit Agreement. A copy of the Amendment is attached as Exhibit 10.1 to this report and is incorporated herein by reference.Pre-arranged Trading PlansThe following discussion includes trading arrangements adopted, modified, or terminated by our directors and officers

during the three months ended September 30, 2024.On August 17, 2024, Thomas Rodgers, our Executive Vice President and Chief Strategy and Business Development Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 4,080 shares of the Companyâ€™s common stock. The duration of the trading arrangement is until August 18, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Mr. Rodgers represented to us that he intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards. 54Table of ContentsMcKESSON CORPORATIONOn September 9, 2024, LeAnn Smith, our Executive Vice President and Chief Human Resources Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 3,592 shares of the Companyâ€™s common stock. The duration of the trading arrangement is until September 9, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Ms. Smith represented to us that she intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards. 55Table of ContentsMcKESSON CORPORATIONItem 6.Exhibits.Exhibits identified under â€œIncorporated by Referenceâ€ in the table below are on file with the SEC and are incorporated by reference as exhibits hereto.Incorporated by ReferenceExhibitNumberDescriptionFormFile NumberExhibitFiling Date4.1Officerâ€™s Certificate, dated as of September 10, 2024, and related Form of 2029 Note.8-K1-132524.1September 10, 202410.1â€ First Amendment to Credit Agreement dated as of November 7, 2024, to the Credit Agreement dated as of November 7, 2022, among the Company, as borrower, the lenders party thereto, the letter of credit issuers party thereto, Bank of America, N.A., as administrative agent, and the other parties thereto._____31.1â€ Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002._____31.2â€ Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002._____32â€ â€ Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002._____101â€ The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Stockholdersâ€™ Deficit, (v) Condensed Consolidated Statements of Cash Flows, and (vi) related Financial Notes._____104â€ Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101)._____â€ Â Â Â Â Filed herewith.â€ â€ Â Â Â Furnished herewith.56Table of ContentsMcKESSON CORPORATIONSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.Â Â MCKESSON CORPORATIONDate:November 7, 2024Â /s/ Britt J. VitaloneÂ Britt J. VitaloneÂ Executive Vice President and Chief Financial OfficerÂ Â MCKESSON CORPORATIONDate:November 7, 2024Â /s/ Napoleon B. Rutledge Jr.Â Napoleon B. Rutledge Jr.Â Senior Vice President and Controller57 EX-10.1 2 mck_exhibit101930202410-q.htm EX-10.1 DocumentExhibit 10.1Execution VersionThis FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of November 7, 2024 (this â€œAmendmentâ€), which amends that certain Credit Agreement, dated as of November 7, 2022 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time, the â€œCredit Agreementâ€; the Credit Agreement, as amended by this Amendment, the â€œAmended Credit Agreementâ€) among McKesson Corporation, a Delaware corporation (the â€œCompanyâ€) and certain of its subsidiaries party thereto from time to time as borrowers (together with the Company, collectively, the â€œBorrowersâ€ and each, a â€œBorrowerâ€), the financial institutions party thereto from time to time as lenders (the â€œLendersâ€), Bank of America, N.A., as administrative agent (the â€œAdministrative Agentâ€) and the other parties named therein.WHEREAS, pursuant to Section 11.01 of the Credit Agreement, the Administrative Agent, the Borrowers, each Lender and each L/C Issuer desire to amend the Credit Agreement, subject to the terms and conditions set forth in this Amendment.NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:Section 1.01Defined Terms. Capitalized terms used but not otherwise defined herein (including the preliminary statements hereto) have the meanings assigned to them in the Amended Credit Agreement.Section 2.01Extension of Existing Maturity Date. The Company hereby requests that each Lender and each L/C Issuer extend the Existing Maturity Date (previously extended to November 7, 2028 pursuant to that certain Extension Acknowledgement, dated as of November 7, 2023 (the â€œFirst Maturity Extensionâ€)) from November 7, 2028 to November 7, 2029 effective on and as of the First Amendment Effective Date (such extension, the â€œSecond Maturity Extensionâ€). Each of the Administrative Agent, each L/C Issuer and each Lender hereby consents to the Second Maturity Extension. The Second Maturity Extension shall constitute one request for extension of the Existing Maturity Date pursuant to Section 2.17(a) of the Credit Agreement.Section 3.01Amendments to the Credit Agreement. Subject to the satisfaction of the conditions set forth in Section 6.01 of this Amendment, effective as of the First Amendment Effective Date (as defined below), the Credit Agreement is hereby amended to delete the stricken text (indicated textually in the same manner as the following example: stricken text) and to add the double-underlined text (indicated textually in the same manner as the following example: double-underlined text) as set forth in the pages attached as Exhibit A hereto. Section 4.01Notice. As of the First Amendment Effective Date, the Administrative Agent hereby (i) notifies the Borrowers and each Lender of the implementation of Term CORRA as the Relevant Rate for Canadian Dollars and the effectiveness of the Conforming Changes made in connection therewith, in each case pursuant to this Amendment and (ii) revokes (and the Required Lenders hereby direct the Administrative Agent to revoke) that certain notice to the Company, dated as of June 26, 2024, suspending the obligation of the Lenders to make or maintain Eurocurrency Rate Loans in Canadian Dollars. To the extent the Credit Agreement requires the Administrative Agent to provide notice that any of the foregoing events has occurred, this Amendment constitutes such notice. Section 5.01Representations and Warranties. The Company, on behalf of itself and each other Borrower, represents and warrants (which representations and warranties in the case of any Borrower other than the Company shall be limited to such Borrower and its Subsidiaries and other facts and circumstances known to the Company) to the Administrative Agent and each Lender as of the First Amendment Effective Date that:(a)The representations and warranties of the Company and each other Borrower contained in Article V of the Credit Agreement and any other Loan Document, or which are contained in any document furnished at any time under or in connection therewith, are true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of the First Amendment Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct as of such earlier date, and except that for purposes of this Amendment, the Â Â Â Â Â Â Â Â Â Â Â Â Â representations and warranties contained in Section 5.08(a) of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant Sections 6.01(a) and 6.01(b) of the Credit Agreement, respectively;(b)(i) the Company has all requisite power and authority to execute, deliver and perform its obligations under this Amendment, (ii) the execution, delivery and performance by the Company of this Amendment (1) are within the Companyâ€™s corporate or other powers, (2) have been duly authorized by all necessary corporate or other organizational action and (3) do not contravene the terms of the Companyâ€™s Organization Documents, (iii) this Amendment has been duly executed and delivered by the Company and (iv) this Amendment constitutes a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditorsâ€™ rights generally or by equitable principles relating to enforceability; and(c)No Default or Event of Default has occurred and is continuing or will result after giving effect to this Amendment and the transactions contemplated hereby.Section 6.01Effectiveness. This Amendment shall become effective on and as of the date (such date, the â€œFirst Amendment Effective Dateâ€) on which each of the following conditions is satisfied: (a)The Administrative Agent shall have executed a counterpart hereof and shall have received duly executed counterparts of this Amendment that, when taken together, bear the signatures of the Company, each Lender and each L/C Issuer under the Credit Agreement;(b)The Administrative Agent shall have received all expenses for which invoices have been presented (including the reasonable and documented out-of-pocket fees and expenses of legal counsel to the Administrative Agent), on or before the First Amendment Effective Date;(c)The Administrative Agent shall have received, for its own account or account of each Lender, any fees payable in connection with this Amendment;(d)No Default or Event of Default has occurred and is continuing prior to and after giving effect to this Amendment and the transactions contemplated hereby; (e)The Administrative Agent shall have received a certificate signed by the chief financial officer or treasurer of the Company as required by Section 2.17(f)(iv) of the Credit Agreement;(f)The representations and warranties contained in Article V of the Credit Agreement, the other Loan Documents, and in any document furnished at any time under or in connection therewith are true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of the date hereof, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) as of such earlier date and except that the representations and warranties contained in Section 5.08(a) of the Credit Agreement shall be deemed to refer to the most recent statements furnished pursuant Sections 6.01(a) and 6.01(b) of the Credit Agreement; and (g)No Material Adverse Effect has occurred since March 31, 2024.Section 7.01Effect of this Amendment. (a) Except as expressly set forth herein, this Amendment shall not by implication or otherwise limit, impair, constitute a waiver of, or otherwise affect the rights and remedies of the Administrative Agent or the Lenders under the Credit Agreement or any other Loan Document, and shall not alter, modify, amend or in any way affect any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement or any other Loan Document, all of which are ratified and affirmed in all respects and shall continue in full force and effect. Nothing herein shall (i) be deemed to entitle any Loan Party to a consent to, or a waiver, amendment, modification or other change of, any of the terms, conditions, obligations, covenants or agreements contained in the Credit Agreement, any other Loan Document or any of the instruments or agreements 2Â Â Â Â referred to in any thereof, in similar or different circumstance, (ii) be deemed to be a consent to, or a waiver, modification or forbearance of, any Default or Event of Default, whether or not known to the Administrative Agent or any of the Lenders or (iii) prejudice any right or remedy which the Administrative Agent or any of the Lenders may now have or have in the future against any Person under or in connection with the Credit Agreement, any of the instruments or agreements referred to therein or any of the transactions contemplated thereby.(a)On and after the First Amendment Effective Date, each reference in the Credit Agreement to â€œthis Agreementâ€, â€œhereunderâ€, â€œhereofâ€, â€œhereinâ€, or words of like import, and each reference to the Credit Agreement in any other Loan Document (and the other documents and instruments delivered pursuant to or in connection therewith), shall be deemed to be a reference to the Credit Agreement as amended hereby. This Amendment shall constitute a â€œLoan Documentâ€ for all purposes of the Credit Agreement and the other Loan Documents.(b)Except as expressly provided, nothing herein contained shall be construed as a substitution or novation, or a payment and reborrowing, or a termination, of the Obligations outstanding under the Credit Agreement or instruments guaranteeing or securing the same, which shall remain in full force and effect, except as modified hereby or by instruments executed concurrently herewith.Section 8.01Modifications. Neither this Amendment, nor any provision hereof, may be waived, amended or modified except pursuant to an agreement or agreements in writing entered into by the parties hereto.Section 9.01Counterparts. This Amendment may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Delivery of an executed counterpart of a signature page by telecopier or electronic mail (in a .pdf format) shall be effective as delivery of a manually executed counterpart. The words â€œexecute,â€ â€œexecution,â€ â€œsigned,â€ â€œsignature,â€ and words of like import in or related to this Amendment and the transactions contemplated hereby shall be deemed to include Electronic Signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary, the Administrative Agent is under no obligation to agree to accept Electronic Signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it.Section 10.01Governing Law. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE; PROVIDED THAT THE ADMINISTRATIVE AGENT, EACH L/C ISSUER AND EACH LENDER SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW. The provisions of Sections 11.16(b) and 11.17 of the Amended Credit Agreement are incorporated herein by reference, mutatis mutandis.Section 11.01Headings. Section headings used herein are for convenience of reference only, are not part of this Amendment and shall not affect the construction of, or be taken into consideration in interpreting, this Amendment.[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]3Â Â Â Â IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed by their respective authorized officers as of the date first above written.MCKESSON CORPORATION, as a BorrowerBy:Â Â Â Â :/s/ Akinjide FalakiÂ Â Â Â Name: Akinjide FalakiTitle: Vice President and Treasurer [Signature Page to First Amendment to Credit Agreement]Â Â Â Â BANK OF AMERICA, N.A., as Administrative Agent By:Â Â Â Â Â /s/ Kyle D HardingÂ Â Â Â Name: Kyle D HardingTitle: Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â BANK OF AMERICA, N.A., as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Joseph L. CorahÂ Â Â Â Name: Joseph L. CorahTitle: Managing Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â JPMORGAN CHASE BANK, N.A., as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Gregory T. MartinÂ Â Â Â Name: Gregory T. MartinTitle: Executive Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â WELLS FARGO BANK, NATIONAL ASSOCIATION, as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Andrea S ChenÂ Â Â Â Name: Andrea S ChenTitle: Managing Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â BARCLAYS BANK PLC, as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Evan MoriartyÂ Â Â Â Name: Evan Moriarty Title: Authorized Signatory [Signature Page to First Amendment to Credit Agreement]Â Â Â Â CITIBANK, N.A., as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Richard RiveraÂ Â Â Â Name: Richard RiveraTitle: Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â GOLDMAN SACHS BANK USA, as a Lender and L/C IssuerBy:Â Â Â Â Â /s/ Nicholas MerinoÂ Â Â Â Name: Nicholas Merino Title: Authorized Signatory [Signature Page to First Amendment to Credit Agreement]Â Â Â Â BNP PARIBAS, as a Lender By:Â Â Â Â Â /s/ John BoscoÂ Â Â Â Name: John Bosco Title: Managing Director By:Â Â Â Â Â /s/ Claudia ZarateÂ Â Â Â Name: Claudia ZarateTitle: Managing Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â DEUTSCHE BANK AG NEW YORK BRANCH, as a Lender By:Â Â Â Â Â /s/ Ming K. ChuÂ Â Â Â Name: Ming K. ChuTitle: Director By:Â Â Â Â Â /s/ Alison LugoÂ Â Â Â Name: Alison LugoTitle: Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â HSBC BANK USA, NATIONAL ASSOCIATION, as a Lender By:Â Â Â Â Â /s/ Virginia CosenzaÂ Â Â Â Name: Virginia Cosenza Title: Sr. Vice President #23310[Signature Page to First Amendment to Credit Agreement]Â Â Â Â PNC BANK, NATIONAL ASSOCIATION, as a LenderBy:Â Â Â Â Â /s/ Alexander JodryÂ Â Â Â Name: Alexander Jodry Title: Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â THE BANK OF NOVA SCOTIA, as a Lender By:Â Â Â Â Â /s/ Robb GassÂ Â Â Â Name: Robb GassTitle: Managing Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â THE TORONTO-DOMINION BANK, NEW YORK BRANCH, as a Lender By:Â Â Â Â Â /s/ Mike TkachÂ Â Â Â Name: Mike TkachTitle: Authorized Signatory [Signature Page to First Amendment to Credit Agreement]Â Â Â Â TRUIST BANK, as a Lender By:Â Â Â Â Â /s/ Alexandra KorchmarÂ Â Â Â Name: Alexandra Korchmar Title: Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â U.S. BANK NATIONAL ASSOCIATION, as a Lender By:Â Â Â Â Â /s/ Maria MassiminoÂ Â Â Â Name: Maria MassiminoTitle: Senior Vice President [Signature Page to First Amendment to Credit Agreement]Â Â Â Â ING BANK N.V., DUBLIN BRANCH, as a Lender By:Â Â Â Â Â /s/ Cormac LangfordÂ Â Â Â Name: Cormac LangfordTitle: Managing Director By:Â Â Â Â Â /s/ Sean HassettÂ Â Â Â Name: Sean HassettTitle: Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â SOCIETE GENERALE, as a Lender By:Â Â Â Â Â /s/ Shelley YuÂ Â Â Â Name: Shelley YuTitle: Director [Signature Page to First Amendment to Credit Agreement]Â Â Â Â UNICREDIT BANK GMBH, NEW YORK BRANCH, as a Lender By:Â Â Â Â Â /s/ Kimberly SousaÂ Â Â Â Name: Kimberly SousaTitle: Managing DirectorBy:Â Â Â Â Â /s/ Laura ShelmerdineÂ Â Â Â Name: Laura ShelmerdineTitle: Director[Signature Page to First Amendment to Credit Agreement]Â Â Â Â Execution VersionExhibit A[Attached.]Â Â Â Â Â Â Â Â Published Deal CUSIP: 58155CAN4Revolver CUSIP: 58155CAP9CREDIT AGREEMENTDated as of November 7, 2022, as amended by the First Amendment to Credit Agreement, dated as of November 7, 2024MCKESSON CORPORATIONandCERTAIN SUBSIDIARIESas Borrowers,BANK OF AMERICA, N.A.,as Administrative Agent,JPMORGAN CHASE BANK, N.A.andWELLS FARGO BANK, NATIONAL ASSOCIATION,as Co-Syndication Agents,BARCLAYS BANK PLC, CITIBANK, N.A.andGOLDMAN SACHS BANK USA,as Co-Documentation

AgentsandThe Other Lenders and L/C Issuers Party HeretoBOFA SECURITIES, INC.,BARCLAYS BANK PLC, CITIBANK, N.A.,GOLDMAN SACHS BANK USA,JPMORGAN CHASE BANK, N.A.andWELLS FARGO SECURITIES, LLC,as Joint Lead Arrangers and Joint Book RunnersÂ Â Â Â Â Â Â Â TABLE OF CONTENTSPageARTICLE IDEFINITIONS AND ACCOUNTING TERMS11.01Defined Terms11.02Other Interpretive Provisions311.03Accounting Terms321.04Rounding321.05References to Agreements and Laws331.06Times of Day331.07Letter of Credit Amounts331.08Exchange Rates; Currency Equivalents331.09Change of Currency.Â Â Â Â 34ARTICLE IITHE COMMITMENTS AND CREDIT EXTENSION342.01Committed Loans342.02Borrowings, Conversions and Continuations of Committed Loans342.03Letters of Credit362.04[Reserved].472.05Prepayments.472.06Termination or Reduction of Commitments482.07Repayment of Loans482.08Interest482.09Fees492.10Computation of Interest and Fees492.11Evidence of Debt502.12Payments Generally502.13Sharing of Payments522.14[Reserved].532.15Increase in Commitments.532.16Designation of Borrowers542.17Extension of Maturity Date572.18Defaulting Lenders592.19Sustainability Adjustments61ARTICLE IIITAXES, YIELD PROTECTION AND ILLEGALITY623.01Taxes62Â Â Â Â Â Â Â TABLE OF CONTENTSPage3.02Illegality663.03Inability to Determine Rates673.04Increased Cost and Reduced Return; Capital Adequacy703.05Funding Losses723.06Matters Applicable to Illegality and all Requests for Compensation733.07Survival73ARTICLE IVCONDITIONS PRECEDENT TO CREDIT EXTENSION744.01Conditions to Effectiveness744.02Existing Revolving Credit Agreement764.03Conditions to all Credit Extensions76ARTICLE VREPRESENTATIONS AND WARRANTIES775.01Corporate Existence and Power775.02Corporate Authorization; No Contravention775.03Governmental Authorization785.04Binding Effect785.05Litigation785.06No Default785.07Use of Proceeds; Margin Regulations785.08Financial Condition785.09Regulated Entities795.10Taxes795.11Sanctions795.12Anti-Corruption Laws and Anti-Money Laundering Laws795.13ERISA805.14Beneficial Ownership Certification80ARTICLE VIAFFIRMATIVE COVENANTS806.01Financial StatementsÂ Â Â Â 806.02Certificates; Other Information816.03Notices826.04Preservation of Existence, Etc826.05Maintenance of Insurance836.06Payment of Taxes836.07Compliance with Laws836.08Books and Records836.09Inspection Rights836.10Use of Proceeds836.11Anti-Corruption Laws; Sanction84ARTICLE VIINEGATIVE COVENANTS84Â Â Â Â Â Â Â TABLE OF CONTENTSPage7.01Liens847.02Consolidations and Mergers857.03Use of Proceeds877.04Financial Covenant877.05Sanctions877.06Anti-Corruption Laws87ARTICLE VIIIEVENTS OF DEFAULT AND REMEDIES888.01Events of Default888.02Remedies Upon Event of Default898.03Application of FundsÂ Â Â Â 90ARTICLE IXADMINISTRATIVE AGENT919.01Appointment and Authorization of Agents919.02Rights as a Lender929.03Exculpatory Provisions929.04Delegation of Duties939.05Reliance by Agent939.06Successor Agents949.07Non-Reliance on Agent and Other Lenders959.08No Other Duties, Etc959.09Administrative Agent May File Proofs of Claim959.10Certain ERISA Matters96ARTICLE X[Reserved]97ARTICLE XIMISCELLANEOUS9711.01Amendments, Etc9711.02Notices and Other Communications; Facsimile Copies9811.03No Waiver; Cumulative Remedies; Enforcement10111.04Expense Indemnity Damage Waiver10111.05Payments Set Aside10311.06Successors and Assigns10311.07Treatment of Certain Information; Confidentiality11011.08Set-off11111.09Interest Rate Limitation11111.10Counterparts11211.11Integration11211.12Survival of Representations and Warranties11211.13Severability11211.14[Reserved]11211.15Replacement of Lenders11211.16Governing Law113Â Â Â Â Â Â Â TABLE OF CONTENTSPage11.17Waiver of Right to Trial by Jury11411.18No Advisory or Fiduciary Responsibility11411.19USA Patriot Act Notice11511.20Judgment11511.21Acknowledgment and Consent to Bail-In of EEA Financial Institutions.11611.22Acknowledgement Regarding Any Supported QFCs.116Â Â Â Â Â Â Â SCHEDULES2.01Â Â Â Â Commitments, Pro Rata Shares and Affiliate Banks11.02Â Â Â Â Administrative Agentâ€™s Office, Certain Addresses for NoticesEXHIBITSAÂ Â Â Â Form of Committed Loan NoticeBÂ Â Â Â Form of Note CÂ Â Â Â Form of Compliance CertificateDÂ Â Â Â Form of Assignment and AssumptionE-1Â Â Â Â Form of Designated Borrower Request and Assumption AgreementE-2Â Â Â Â Form of Designated Borrower NoticeFÂ Â Â Â Form of Joinder AgreementGÂ Â Â Â Form of Borrower NoticeHÂ Â Â Â [Reserved]IÂ Â Â Â Form of GuarantyJ-1Â Â Â Â Form of U.S. Tax Compliance Certificate (Foreign Lenders That Are Not Â Â Â Â Â Partnerships)J-2Â Â Â Â Â Form of U.S. Tax Compliance Certificate (Foreign Participants That Are Not Â Â Â Â Â Partnerships)J-3Â Â Â Â Â Form of U.S. Tax Compliance Certificate (Foreign Participants That Are Â Â Â Â Â Partnerships)J-4Â Â Â Â Â Form of U.S. Tax Compliance Certificate (Foreign Lenders That Are Â Â Â Â Â Partnerships)KÂ Â Â Â Â Form of Letter of Credit ReportÂ Â Â Â Â Â Â Â CREDIT AGREEMENTThis CREDIT AGREEMENT (â€œAgreementâ€) is entered into as of November 7, 2022, among MCKESSON CORPORATION, a Delaware corporation (the â€œCompanyâ€), any Designated Borrower (as defined below) or any Subsidiary of the Company that has executed and delivered to the Administrative Agent a joinder agreement in the form of Exhibit F hereto pursuant to Section 7.02(d), as applicable (together with the Company and any Designated Borrower, the â€œBorrowersâ€ and each a â€œBorrowerâ€), each lender from time to time party hereto (collectively, the â€œLendersâ€ and each individually, a â€œLenderâ€), each L/C Issuer from time to time party hereto and BANK OF AMERICA, N.A., as Administrative Agent.The Borrowers have requested that the Lenders make available, for the purposes specified in this Agreement, a revolving credit facility, and the Lenders are willing to make available to the Borrowers such revolving credit facility upon the terms and subject to the conditions set forth herein. In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows:1.DEFINITIONS AND ACCOUNTING TERMS1.1.Defined Terms. As used in this Agreement (including the introductory clauses hereto), the following terms shall have the meanings set forth below:â€œAcquired Debt Defaultâ€ means an event of default under a Relevant Obligation of a Person which becomes a Subsidiary after the date hereof, which event of default occurs by reason of the change of control of such Person by virtue of the transaction pursuant to which it becomes a Subsidiary. For avoidance of doubt, an event of default under another Relevant Obligation of the Company or a Subsidiary by virtue of a cross default to an event of default described in the preceding sentence is not an Acquired Debt Default.â€œAdditional Commitment Lenderâ€ has the meaning specified in Section 2.17.â€œAdministrative Agentâ€ means Bank of America (or any of its designated branch offices or affiliates) in its capacity as administrative agent under any of the Loan Documents, or any successor administrative agent.â€œAdministrative Agentâ€™s Officeâ€ means, with respect to any currency, the Administrative Agentâ€™s address and, as appropriate, account as set forth on Schedule 11.02 with respect to such currency, or such other address or account with respect to such currency as the Administrative Agent may from time to time notify the Borrowers and the Lenders.â€œAdministrative Questionnaireâ€ means, with respect to any currency, an Administrative Questionnaire in a form supplied by the Administrative Agent.â€œAffected Financial Institutionâ€ means (a) any EEA Financial Institution or (b) any UK Financial Institution.â€œAffiliateâ€ means, with respect to any Person, another Person that directly, or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. â€œControlâ€ means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. â€œControllingâ€ and â€œControlledâ€ have meanings correlative thereto.â€œAgent Partiesâ€ has the meaning specified in Section 11.02(c).â€œAgentâ€ means the Administrative Agent.Â Â Â Â â€œAgreed Currencyâ€ means Dollars or any Alternative Currency, as applicable.â€œAggregate Commitmentsâ€ means the aggregate Commitments of all the Lenders. The Aggregate Commitments as of the Closing Date are equal to $4,000,000,000.â€œAgreementâ€ means this Credit Agreement.â€œAlternative Currencyâ€ means each of the following currencies: Euro, Sterling, and Canadian Dollars.â€œAlternative Currency Sublimitâ€ means an amount equal $3,600,000,000.00. The Alternative Currency Sublimit is part of, and not in addition to, the Aggregate Commitments. â€œAnti-Money Laundering Lawsâ€ means laws and regulations related to terrorism financing or money laundering, including the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Title III of Pub. L. 107-56), and The Currency and Foreign Transactions Reporting Act (also known as the â€œBank Secrecy Actâ€, 31 U.S.C. Â§Â§ 5311-5330 and 12 U.S.C. Â§Â§ 1818(s), 1820(b) and 1951-1959).â€œApplicable Authorityâ€ means (a)Â with respect to Term SOFR, the Term SOFR Administrator or any Governmental Authority having jurisdiction over the Term SOFR Administrator with respect to its publication of Term SOFR, in each case acting in such capacity and (b)Â with respect to any Alternative Currency, the applicable administrator for the Relevant Rate for such Alternative Currency or any Governmental Authority having jurisdiction over such administrator with respect to its publication of the applicable Relevant Rate, in each case acting in such capacity.â€œApplicable Rateâ€ means, from time to time, the rate, expressed in basis points per annum, corresponding to the applicable Debt Rating as set forth below:Pricing LevelDebt Ratings S&P/Moodyâ€™s/FitchFacility FeeEurocurrency Rate and Letters of Credit Base Rate Loans1Greater than or equalto A/A2/A6.568.502A-/A3/A-7.580.003BBB+/Baa1/BBB+9.091.004BBB/Baa2/BBB11.0101.51.55Less than or equal toBBB-/Baa3/BBB-15.0110.010.0â€œDebt Ratingâ€ means, as of any date of determination, the available ratings as determined by S&P, Moodyâ€™s and/or Fitch (collectively, the â€œDebt Ratingsâ€) of the Companyâ€™s non-credit-enhanced, senior unsecured long-term debt; provided that (1) if the Company shall maintain a Debt Rating from all three of S&P, Moodyâ€™s and Fitch and there is a difference in such Debt Ratings, (a) if there is a Debt Rating differential of (i)Â one Pricing Level between the highest and lowest Debt Ratings or (ii) more than one Pricing Level between the highest and lowest Debt Ratings, with two Debt Ratings that are equivalent and the third Debt Rating lower, in each case, the higher Pricing Level shall apply and (b) otherwise, one Pricing Level below the Pricing Level corresponding to the highest of the three Debt Ratings shall apply, (2) if the Company shall maintain Debt Ratings from only two of S&P, Moodyâ€™s and Fitch, (a) if there is a split in Debt Ratings of more than one Pricing Level, the Pricing Level that is one Pricing Level lower than Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â the higher of the Companyâ€™s two Debt Ratings shall apply and (b) otherwise, the higher of such two Debt Ratings shall apply, (3) if the Company shall maintain Debt Ratings from only one of S&P, Moodyâ€™s and Fitch, then that single Debt Rating shall apply or (4) if the Company shall maintain Debt Ratings from none of S&P, Moodyâ€™s and Fitch, then the Applicable Rate shall be based on Pricing Level 5.Initially, the Applicable Rate shall be determined based upon the Debt Rating specified in the certificate delivered pursuant to Section 4.01(a)(vi). Thereafter, each change in the Applicable Rate shall be effective during the period commencing on the effective date of such change in the Debt Rating and ending on the date immediately preceding the effective date of the next such change.â€œApplicable Timeâ€ means, with respect to any borrowings and payments in any Alternative Currency, the local time in the place of settlement for such Alternative Currency as may be determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, to be necessary for timely settlement on the relevant date in accordance with normal banking procedures in the place of payment.â€œApplicant Borrowerâ€ shall have the meaning specified in Section 2.16(a).â€œApproved Fundâ€ means any Fund that is administered or managed by (a)Â a Lender, (b)Â an Affiliate of a Lender or (c)Â an entity or an Affiliate of an entity that administers or manages a Lender.â€œArrangersâ€ means BofA Securities, Inc., Barclays Bank PLC, Citibank, N.A., Goldman Sachs Bank USA, JPMorgan Chase Bank, N.A. and Wells Fargo Securities, LLC, each in its capacity as joint lead arranger and joint book runner.â€œAssignment and Assumptionâ€ means an Assignment and Assumption substantially in the form of Exhibit D.â€œAttorney Costsâ€ means and includes all reasonable fees, expenses and disbursements of any law firm or other external counsel and, without duplication, the reasonable allocated cost of internal legal services and all reasonable expenses and disbursements of internal counsel; provided that no fees, expenses or disbursements shall qualify as Attorney Costs unless written evidence, prepared in reasonable detail, substantiating such fees, expenses and disbursements is available to the Company upon request.â€œAttributable Indebtednessâ€ means, on any date, (a)Â in respect of any capital or finance lease of any Person, the capitalized amount thereof that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP, and (b)Â in respect of any Synthetic Lease Obligation, the capitalized amount of the remaining lease payments under the relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as a capital or finance lease.â€œAudited Financial Statementsâ€ means the audited consolidated balance sheet of the Company and its Subsidiaries for the fiscal year ended March 31, 2022, and the related consolidated statements of operations, shareholdersâ€™ equity and cash flows for such fiscal year of the Company and its Subsidiaries, including the notes thereto.â€œAuthorizationâ€ has the meaning specified in Section 5.03.â€œAvailability Periodâ€ means the period from and including the date hereof to the earliest of (a)Â the Maturity Date, (b)Â the date of termination of the Aggregate Commitments pursuant to Section 2.06, and (c)Â the date of termination of the Commitment of each Lender to make Loans and of the obligation of the of the L/C Issuers to make L/C Credit Extensions pursuant to Section 8.02.â€œBail-In Actionâ€ means the exercise of any Write-Down and Conversion Powers by the applicable Resolution Authority in respect of any liability of an Affected Financial Institution.Â Â Â Â 3Â Â Â Â Â Â Â Â Â Â Â Â Â â€œBail-In Legislationâ€ means, (a) with respect to any EEA Member Country implementing Article 55 of Directive 2014/59/EU of the European Parliament and of the Council of the European Union, the implementing law, rule, regulation or requirement for such EEA Member Country from time to time which is described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, Part I of the United Kingdom Banking Act 2009 (as amended from time to time) and any other law, regulation or rule applicable in the United Kingdom relating to the resolution of unsound or failing banks, investment firms or other financial institutions or their affiliates (other than through liquidation, administration or other insolvency proceedings).â€œBank of Americaâ€ means Bank of America, N.A. and its successors.â€œBase Rateâ€ means for any day a fluctuating rate per annum equal to the highest of (a)Â the Federal Funds Rate plus 1/2 of 1%, (b)Â the rate of interest in effect for such day as publicly announced from time to time by Bank of America as its â€œprime rate,â€ and (c)Â Term SOFR plus 1%; and if the Base Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement. The â€œprime rateâ€ is a rate set by Bank of America based upon various factors including Bank of Americaâ€™s costs and desired return, general economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate. Any change in such rate announced by Bank of America shall take effect at the opening of business on the day specified in the public announcement of such change. If the Base Rate is being used as an alternate rate of interest pursuant to Section 3.03 hereof, then the Base Rate shall be the greater of clauses (a) and (b) above and shall be determined without reference to clause (c) above.â€œBase Rate Committed Loanâ€ means a Committed Loan that is a Base Rate Loan.â€œBase Rate Loanâ€ means a Loan made to a Borrower that is a U.S. Person that bears interest based on the Base Rate. All Base Rate Loans shall be denominated in Dollars.â€œBeneficial Ownership Certificationâ€ means a certification regarding beneficial ownership required by the Beneficial Ownership Regulation.â€œBeneficial Ownership Regulationâ€ means 31 C.F.R. Â§ 1010.230.â€œBeneficiaryâ€ means, in relation to a Letter of Credit, from time to time, the initial beneficiary, a transferee beneficiary, a successor beneficiary, a nominated bank, a negotiating bank or a confirming bank with respect to such Letter of Credit, as applicable.â€œBenefit Planâ€ means any of (a) an â€œemployee benefit planâ€ (as defined in ERISA) that is subject to Title I of ERISA, (b) a â€œplanâ€ as defined in and subject to Section 4975 of the Code or (c) any Person whose assets include (for purposes of ERISA Section 3(42) or otherwise for purposes of Title I of ERISA or Section 4975 of the Code) the assets of any such â€œemployee benefit planâ€ or â€œplanâ€.â€œBHC Act Affiliateâ€ of a party means an â€œaffiliateâ€ (as such term is defined under, and interpreted in accordance with, 12 U.S.C. 1841(k)) of such party.â€œBorrowerâ€ and â€œBorrowersâ€ each have the meaning specified in the introductory paragraph hereto.â€œBorrower Materialsâ€ has the meaning specified in Section 6.02.â€œBorrower Noticeâ€ has the meaning specified in SectionÂ 7.02(d).â€œBorrowingâ€ means a Committed Borrowing. â€œBusiness Dayâ€ means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to close under the Laws of, or are in fact closed in, the state where the Administrative Agentâ€™s Office with respect to Obligations denominated in Dollars is located and:Â Â Â Â 4Â Â Â Â Â Â Â Â Â Â Â Â Â (a) if such day relates to any interest rate settings as to a Eurocurrency Rate Loan denominated in Dollars, any fundings, disbursements, settlements and payments in Dollars in respect of any such Eurocurrency Rate Loan, or any other dealings in Dollars to be carried out pursuant to this Agreement in respect of any such Eurocurrency Rate Loan, means any such day that is also a U.S. Government Securities Business Day;(b) if such day relates to any interest rate settings as to a Eurocurrency Rate Loan denominated in Euro, any fundings, disbursements, settlements and payments in Euro in respect of any such Eurocurrency Rate Loan, or any other dealings in Euro to be carried out pursuant to this Agreement in respect of any such Eurocurrency Rate Loan, means a TARGET Day;(c)Â if such day relates to any interest rate settings as to a Eurocurrency Rate Loan denominated in Sterling, also excludes any day on which banks are closed for general business in London;(d)Â if such day relates to any interest rate settings as to a Eurocurrency Rate Loan denominated in a currency other than Dollars or Euro, means any such day on which dealings in deposits in the relevant currency are conducted by and between banks in the London or other applicable offshore interbank market for such currency; and(e)Â if such day relates to any fundings, disbursements, settlements and payments in a currency other than Dollars or Euro in respect of a Eurocurrency Rate Loan denominated in a currency other than Dollars or Euro, or any other dealings in any currency other than Dollars or Euro to be carried out pursuant to this Agreement in respect of any such Eurocurrency Rate Loan (other than any interest rate settings), means any such day on which banks are open for foreign exchange business in the principal financial center of the country of such currency.â€œCanadian Dollarsâ€ and â€œCdn.$â€ each means the lawful money of Canada.â€œCash Collateralizeâ€ has the meaning specified in Section 2.03(g).â€œCash Collateralâ€ has the meaning specified in Section 2.03(g).â€œChange in Lawâ€ means the occurrence, after the date of this Agreement, of any of the following: (a)Â the adoption or taking effect of any law, rule, regulation or treaty, (b)Â any change in any law, rule, regulation or treaty or in the administration, interpretation, implementation or application thereof by any Governmental Authority or (c)Â the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental Authority; provided that notwithstanding anything herein to the contrary, (x)Â the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith or in the

implementation thereof and (y)Â all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority), the United States or foreign regulatory authorities, in each case pursuant to Basel III, shall in each case be deemed to be a â€œChange in Lawâ€, regardless of the date enacted, adopted, issued or implemented.â€œChange of Controlâ€ means an event or series of events by which (a)Â with respect to the Company, any â€œpersonâ€ or â€œgroupâ€ (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) becomes the â€œbeneficial ownerâ€ (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act of 1934, except that a person or group shall be deemed to have â€œbeneficial ownershipâ€ of all securities that such person or group has the right to acquire, whether such right is exercisable immediately or only after the passage of time (such right, an â€œoption rightâ€)), directly or indirectly, of 51% or more of the equity securities of the Company entitled to vote for members of the board of directors or equivalent governing body of the Company on a fully-diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right) (provided that â€œChange of Controlâ€ shall not include any such acquisition which occurs as part of a transaction consisting of (x)Â the Company becoming a wholly owned subsidiary of a holding company and (y)Â the holders of the voting stock of such holding company immediately following such transaction are substantially the same as the holders of the Companyâ€™s voting stock immediately prior to such transaction) and (b)Â with respect to the Domestic Subsidiary that becomes a Â Â Â Â 5Â Â Â Â Â Â Â Â Â Â Â Â Â Borrower pursuant to Section 7.02(d), any â€œpersonâ€ or â€œgroupâ€ other than the Company becomes the â€œbeneficial ownerâ€, directly or indirectly, of any equity securities of such Domestic Subsidiary entitled to vote for members of the board of directors or equivalent governing body of such Domestic Subsidiary on a fully-diluted basis.â€œClosing Dateâ€ means the first date all the conditions precedent in Section 4.01 are satisfied or waived in accordance with Section 11.01, which date is November 7, 2022.â€œCodeâ€ means the Internal Revenue Code of 1986.â€œCommitmentâ€ means, as to each Lender, its obligation to (a)Â make Committed Loans to the Borrowers pursuant to ARTICLE II or (b)Â purchase participations in L/C Obligations, in an aggregate principal amount at any one time outstanding not to exceed the Dollar amount set forth opposite such Lenderâ€™s name on ScheduleÂ 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted from time to time in accordance with this Agreement. The Commitment for any Lender that has an Affiliate is a single value for such Lender and its Affiliate taken together.â€œCommitted Borrowingâ€ means a borrowing consisting of simultaneous Committed Loans of the same Type, in the same currency and, in the case of Eurocurrency Rate Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.01.â€œCommitted Loanâ€ has the meaning specified in Section 2.01.â€œCommitted Loan Noticeâ€ means a notice of (a)Â a Committed Borrowing, (b)Â a conversion of Committed Loans from one Type to the other, or (c)Â a continuation of Eurocurrency Rate Loans, pursuant to Section 2.02(a), which, if in writing, shall be substantially in the form of ExhibitÂ A or such other form as may be approved by the Administrative Agent (including any form on an electronic platform or electronic transmission system as shall be approved by the Administrative Agent), appropriately completed and signed by a Responsible Officer of the applicable Borrower.â€œCompanyâ€ has the meaning specified in the introductory clause hereto.â€œCompliance Certificateâ€ means a certificate substantially in the form of Exhibit C.â€œConforming Changesâ€ means, with respect to the use, administration of or any conventions associated with Term SOFR, SONIA, Term CORRA, EURIBOR or any proposed Successor Rate for an Agreed Currency, as applicable any conforming changes to the definition of â€œBase Rate,â€ the definition of â€œTerm SOFR,â€ the definition of â€œSONIA,â€ the definition of â€œTerm CORRA,â€ the definition of â€œEURIBOR,â€ the definition of â€œInterest Period,â€ timing and frequency of determining rates and making payments of interest and other technical, administrative or operational matters (including, for the avoidance of doubt, the definition of â€œBusiness Dayâ€ and the definition of â€œU.S. Government Securities Business Day,â€ timing of borrowing requests or prepayment, conversion or continuation notices and length of lookback periods) as may be appropriate, in the discretion of the Administrative Agent in consultation with the Company, to reflect the adoption and implementation of such applicable rate(s) and to permit the administration thereof by the Administrative Agent in a manner substantially consistent with market practice for such Agreed Currency (or, if the Administrative Agent determines that adoption of any portion of such market practice is not administratively feasible or that no market practice for the administration of such rate for such Agreed Currency exists, in such other manner of administration as the Administrative Agent determines is reasonably necessary in connection with the administration of this Agreement and any other Loan Document).â€œConnection Income Taxesâ€ means Other Connection Taxes that are imposed on or measured by net income (however denominated) or that are franchise Taxes or branch profits Taxes.â€œConsolidated EBITDAâ€ means, for any period, Consolidated Net Income for such period plus (a) without duplication and to the extent deducted in determining such Consolidated Net Income, the sum of (i) consolidated interest expense for such period, (ii) consolidated income tax expense for such period, (iii) all amounts Â Â Â Â 6Â Â Â Â Â Â Â Â Â Â Â Â Â Â attributable to depreciation and amortization for such period, (iv) all non-cash share-based compensation expenses for such period, (v) all restructuring, integration, and other costs and expenses for such period that relate to any acquisition, merger, consolidation, amalgamation, joint venture investment, divestiture or other business combination or related transactions not prohibited hereunder, (vi) all LIFO inventory-related non-cash expense adjustments for such period, (vii) non-cash impairment charges for such period, (viii) all net charges with respect to litigation for such period, (ix) all losses, charges and expenses attributable to the early extinguishment or conversion of Indebtedness (including deferred financing expenses written off or forgiven and premiums paid), (x) all losses on sales of assets outside the ordinary course of business for such period and (xi) all other extraordinary, non-recurring or unusual non-cash charges or losses for such period (including, for the avoidance of doubt, any non-cash charges in respect of any claims or litigation in excess of $1,000,000,000.00 that the Company excluded from its â€œAdjusted Earnings (Non-GAAP)â€ for the fiscal quarter ended December 31, 2020, as reported in a current report on Form 8-K reporting operating results for such period), and minus (b) without duplication and to the extent included in determining such Consolidated Net Income, the sum of (i) consolidated interest tax benefit for such period, (ii) all extraordinary, non-recurring or unusual non-cash gains for such period, (iii) all LIFO inventory-related non-cash credit for such period, (iv) all litigation recovery gains for such period and (v) all gains on sales of assets outside of the ordinary course of business for such period. In the event that the Company or any Subsidiary shall have completed a Material Acquisition or a Material Disposition during any relevant period, Consolidated EBITDA shall be determined for such period on a pro forma basis as if such Material Acquisition or Material Disposition, and any related incurrence or repayment of Indebtedness, had occurred at the beginning of such period.â€œConsolidated Net Incomeâ€ means, for any period, the net income (or loss) of the Company and its Subsidiaries for such period determined on a consolidated basis in accordance with GAAP; provided that there shall be excluded (a) the income (or loss) of any Person (other than the Company) that is not a Subsidiary, except to the extent of the amount of dividends or other distributions actually paid to the Company or any of its Subsidiaries during such period, (b) the income (or loss) of any Person accrued prior to the date it becomes a Subsidiary or is merged into, amalgamated with or consolidated with the Company or any Subsidiary or the date that such Personâ€™s assets are acquired by the Company or any Subsidiary and (c) the income (or loss) of, and any amounts referred to in clause (a) above paid to, any Subsidiary that is not wholly owned by the Company to the extent such income (or loss) or such amounts are attributable to the non-controlling interest in such Subsidiary.â€œContractual Obligationâ€ means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party or by which it or any of its property is bound.â€œControlâ€ has the meaning specified in the definition of â€œAffiliate.â€â€œCore Componentsâ€ means core components to the Sustainability Linked Loan Principles, being: â€˜Selection of KPIsâ€™, â€˜Calibration of SPTsâ€™, â€˜Loan Characteristicsâ€™, â€˜Reportingâ€™ and â€˜Verificationâ€™, each as more particularly described in the Sustainability Linked Loan Principles.â€œCORRAâ€ means the Canadian Overnight Repo Rate Average administered and published by the Bank of Canada (or any successor administrator). â€œCovered Entityâ€ means any of the following: (a) a â€œcovered entityâ€ as that term is defined in, and interpreted in accordance with, 12 C.F.R. Â§ 252.82(b), (b) a â€œcovered bankâ€ as that term is defined in, and interpreted in accordance with, 12 C.F.R. Â§ 47.3(b) or (c) a â€œcovered FSIâ€ as that term is defined in, and interpreted in accordance with, 12 C.F.R. Â§ 382.2(b).â€œCredit Extensionâ€ means each of the following: (a)Â a Borrowing and (b)Â an L/C Credit Extension.â€œDebt Ratingâ€ has the meaning specified in the definition of â€œApplicable Rate.â€â€œDebtor Relief Lawsâ€ means the Bankruptcy Code of the United States and all other liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, Â Â Â Â 7Â Â Â Â Â Â Â Â Â Â Â Â Â Â insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.â€œDefaultâ€ means any event or condition that constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default.â€œDefault Rateâ€ means an interest rate equal to (a)Â the Base Rate plus (b)Â the Applicable Rate, if any, applicable to Base Rate Loans plus (c)Â 2% per annum; provided, however that, with respect to a Eurocurrency Rate Loan, the Default Rate shall be an interest rate equal to the interest rate (including any Applicable Rate) otherwise applicable to such Loan plus 2% per annum, in each case to the fullest extent permitted by applicable Laws.â€œDefault Rightâ€ has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. Â§Â§ 252.81, 47.2 or 382.1, as applicable.â€œDefaulting Lenderâ€ means, subject to Section 2.18, any Lender that (i)Â has failed to fund any portion of the Committed Loans or participations in L/C Obligations required to be funded by it hereunder within two Business Days of the date required to be funded by it hereunder, unless such Lender notifies the Administrative Agent in writing that such failure is the result of such Lenderâ€™s determination that one or more conditions precedent to funding (which conditions precedent, together with the applicable default, if any, shall be specifically identified in such writing) has not been satisfied, (ii)Â has otherwise failed to pay over to the Administrative Agent or any other Lender any other amount required to be paid by it hereunder within two Business Days of the date when due, unless the subject of a good faith dispute, (iii)Â has notified any Borrower, the Administrative Agent or any other Lender in writing that it does not intend to comply with its funding obligations or has made a public statement to that effect with respect to its funding obligations hereunder (unless such writing or public statement relates to such Lendersâ€™ obligation to fund a Loan hereunder and states that such position is based on such Lenderâ€™s determination that a condition precedent to funding (which condition precedent, together with the applicable default, if any, shall be specifically identified in such writing or public statement) cannot be satisfied) or generally under other agreements in which it commits to extend credit, (iv)Â has failed, within three (3)Â Business Days after request by the Administrative Agent, to confirm in a manner reasonably satisfactory to the Administrative Agent that it will comply with its funding obligations hereunder (provided that such Lender shall cease to be a Defaulting Lender pursuant to this clause (iv)Â upon receipt of such written confirmation by the Administrative Agent) or (v)Â has, or has a direct or indirect parent company that has, (w)Â become the subject of an Insolvency Proceeding, (x)Â had a receiver, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or a custodian appointed for it, or (y)Â taken any action in furtherance of, or indicated its consent to, approval of or acquiescence in any such proceeding or appointment (provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender) or (z) has become the subject of a Bail-In Action. Any determination by the Administrative Agent that a Lender is a Defaulting Lender under any one or more of clauses (i) through (v) above, and of the effective date of such status, shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.18) as of the date established therefor by the Administrative Agent in a written notice of such determination, which shall be delivered by the Administrative Agent to the Borrower, each L/C Issuer and each other Lender promptly following such determination.â€œDesignated Borrowerâ€ means any consolidated Subsidiary of the Company that becomes eligible to receive Loans hereunder pursuant to Section 2.16.â€œDesignated Borrower Effective Dateâ€ has the meaning specified in Section 2.16(a).Â Â Â Â 8Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€œDesignated Borrower Jurisdictionâ€ means the United States, any state thereof or the District of Columbia, Canada, United Kingdom, Germany, Ireland, Luxembourg, The Netherlands or other jurisdictions approved by each Lender.â€œDesignated Borrower Noticeâ€ shall have the meaning specified in Section 2.16(a).â€œDesignated Borrower Request and Assumption Agreementâ€ shall have the meaning specified in Section 2.16(a).â€œDesignated Foreign Borrowerâ€ shall have the meaning specified in Section 2.16.â€œDesignated Jurisdictionâ€ means any country or territory that itself is the subject of any comprehensive territorial Sanctions, currently, Cuba, Crimea region of Ukraine, Iran, North Korea, Syria, the so-called Luhansk Peopleâ€™s Republic, the so-called Donetsk Peopleâ€™s Republic and non-government controlled areas of the Kherson and Zaporizhzhia Regions of Ukraine.â€œDisqualified Institutionâ€ means at any time any Person that is a competitor of the Company or an affiliate of a competitor of the Company, in each case as so identified on a list provided by the Company to the Administrative Agent on or after the date hereof. The Company may update such list from time to time with any competitor of the Company or any affiliate of a competitor of the Company by providing written notice to the Administrative Agent.â€œDollarâ€, â€œUS$â€ and â€œ$â€ mean lawful money of the United States.â€œDollar Equivalentâ€ means, at any time, (a)Â as to any amount denominated in Dollars, the amount thereof as such time, and (b)Â as to any amount denominated in any Alternative Currency, the equivalent amount thereof in Dollars as determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, at such time on the basis of the Spot Rate (determined in respect of the most recent Revaluation Date) for the purchase of Dollars with such Alternative Currency.â€œDomestic Subsidiaryâ€ means each Subsidiary that is not a Foreign Subsidiary or a FSHCO.â€œEEA Financial Institutionâ€ means (a) any credit institution or investment firm established in any EEA Member Country which is subject to the supervision of an EEA Resolution Authority, (b) any entity established in an EEA Member Country which is a parent of an institution described in clause (a) of this definition, or (c) any financial institution established in an EEA Member Country which is a subsidiary of an institution described in clauses (a) or (b) of this definition and is subject to consolidated supervision with its parent.â€œEEA Member Countryâ€ means any of the member states of the European Union, Iceland, Liechtenstein, and Norway.â€œEEA Resolution Authorityâ€ means any public administrative authority or any person entrusted with public administrative authority of any EEA Member Country (including any delegee) having responsibility for the resolution of any EEA Financial Institution.â€œElectronic Signatureâ€ has the meanings assigned to it by 15 USC Â§ 7006, as it may be amended from time to time. â€œEligible Assigneeâ€ has the meaning specified in Section 11.06(g).â€œEnvironmental Lawsâ€ means any and all federal, state, provincial, municipal, local, and foreign statutes, laws (including common law), regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution or the protection of the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems.Â Â Â Â 9Â Â Â Â Â Â Â Â Â Â Â Â Â Â â€œEnvironmental Liabilityâ€ means any liability, contingent or otherwise (including any liability for damages, costs of environmental remediation, fines or penalties), of the Company or any of its Subsidiaries directly or indirectly resulting from or based upon (a)Â violation of any Environmental Law, (b)Â the generation, use, handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c)Â exposure to any Hazardous Materials or (d)Â the release or threatened release of any Hazardous Materials into the environment.â€œEquity Interestsâ€ of any Person mean any and all shares, interests, rights to purchase, warrants, options, participation or other equivalents of or interests in (however designated) equity of such Person, including any preferred stock, any limited or general partnership interest and any limited liability company membership interest.â€œERISAâ€ means the Employee Retirement Income Security Act of 1974, as amended, and the rules and regulations promulgated thereunder.â€œERISA Affiliateâ€ means any trade or business (whether or not incorporated) under common control with the Company within the meaning of Section 414(b) or (c)Â of the Code (and Sections 414(m) and (o)Â of the Code for purposes of provisions relating to Section 412 of the Code).â€œERISA Eventâ€ means (a)Â a Reportable Event with respect to a Pension Plan; (b)Â a withdrawal by the Company or any ERISA Affiliate from a Pension Plan subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA; (c)Â a complete or partial withdrawal by the Company or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is insolvent or in endangered or critical status; (d)Â the filing of a notice of intent to terminate, the treatment of a Plan amendment as a termination under Sections 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e)Â an event or condition which constitutes grounds under Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; or (f)Â the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not delinquent under Section 4007 of ERISA, upon the Company or any ERISA Affiliate.â€œESGâ€ has the meaning specified in Section 2.19.â€œESG Amendmentâ€ has the meaning specified in Section 2.19.â€œESG Applicable Rate Adjustmentsâ€ has the meaning specified in Section 2.19.â€œESG Pricing Provisionsâ€ has the meaning specified in Section 2.19.â€œEU Bail-In Legislation Scheduleâ€ means the EU Bail-In Legislation Schedule published by

the Loan Market Association (or any successor Person), as in effect from time to time.â€œEURIBORâ€ has the meaning specified in the definition of Eurocurrency Rate.â€œEuroâ€ and â€œeâ‚¬â€ mean the single currency of the Participating Member States.â€œEurocurrency Rateâ€ means, with respect to any Credit Extension:(a)Â Â Â Â for any rate calculation with respect to a Eurocurrency Rate Loan on any date:(i) denominated in Dollars, the rate per annum equal to the Term SOFR Screen Rate two U.S. Government Securities Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period; provided that if the rate is not published prior to 5:00 p.m. on such determination date then Term SOFR means the Term SOFR Screen Rate on the first U.S. Government Securities Business Day immediately prior thereto, in each case, plus the SOFR Adjustment (â€œTerm SOFRâ€).Â Â Â Â 10Â Â Â Â Â Â Â Â Â Â Â Â (ii) denominated in Sterling, the rate per annum equal to the Sterling Overnight Index Average Reference Rate published on the fifth Business Day preceding such date on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) (â€œSONIAâ€); provided however that if such determination date is not a Business Day, SONIA means such rate that applied on the first Business Day immediately prior thereto.(iii) denominated in Euros, the rate per annum equal to the Euro Interbank Offered Rate (â€œEURIBORâ€), as published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) on the day that is two TARGET Days preceding the first day of such Interest Period with a term equivalent to such Interest Period; or(iv) denominated in Canadian Dollars, the rate per annum equal to the forward-looking term rate based on CORRA (â€œTerm CORRAâ€, as published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time) (in such case, the â€œTerm CORRA Rateâ€) two Business Days prior to the commencement of such Interest Period with a term equivalent to such Interest Period (or such other day as is generally treated as the rate fixing day by market practice in such interbank market, as determined by the Administrative Agent; provided that, to the extent such market practice is not administratively feasible for the Administrative Agent, then such other day as otherwise reasonably determined by the Administrative Agent) plus the Term CORRA Adjustment for such Interest Period;(b)Â Â Â Â for any rate calculation with respect to a Base Rate Loan on any date, the rate per annum equal to the Term SOFR Screen Rate with a term of one month commencing that day;provided that to the extent a comparable or successor rate is approved by the Administrative Agent in connection with any rate set forth in this definition, the approved rate shall be applied in a manner consistent with market practice; provided, further that to the extent such market practice is not administratively feasible for the Administrative Agent, such approved rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent; and if the Eurocurrency Rate shall be less than zero, such rate shall be deemed zero for purposes of this Agreement.â€œEurocurrency Rate Loanâ€ means a Committed Loan that bears interest at the Eurocurrency Rate calculated at a rate based on clause (a) of the definition of â€œEurocurrency Rateâ€. Eurocurrency Rate Loans may be denominated in Dollars (if based on clause (a)(i) of such definition) or in an Alternative Currency (if based on clauses (a)(ii) through (a)(iv) of such definition). All Committed Loans denominated in an Alternative Currency must be Eurocurrency Rate Loans.â€œEvent of Defaultâ€ has the meaning specified in Section 8.01.â€œExcluded Taxesâ€ means any of the following Taxes imposed on or with respect to any Recipient or required to be withheld or deducted from a payment to a Recipient, (a)Â Taxes imposed on or measured by net income (however denominated), franchise Taxes, and branch profits Taxes, in each case, (i)Â imposed as a result of such Recipient being organized under the laws of, or having its principal office or, in the case of any Lender, its Lending Office located in, the jurisdiction imposing such Tax (or any political subdivision thereof) or (ii)Â that are Other Connection Taxes, (b)Â in the case of a Lender, U.S. federal withholding Taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Loan or Commitment pursuant to a law in effect on the date on which (i)Â such Lender acquires such interest in the Loan or Commitment (other than pursuant to an assignment request by the Company under SectionÂ 11.15) or (ii)Â such Lender changes its Lending Office, except in each case to the extent that, pursuant to SectionÂ 3.01(a)(iii) or (c), amounts with respect to such Taxes were payable either to such Lenderâ€™s assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its Lending Office, (c)Â Taxes attributable to such Recipientâ€™s failure to comply with SectionÂ 3.01(e) and (d)Â any U.S. federal withholding Taxes imposed pursuant to FATCA. Â Â Â Â 11Â Â Â Â Â Â Â Â Â Â Â Â â€œExisting Letters of Creditâ€ means those letters of credit issued prior to the date hereof for the account of the Company or one of its Subsidiaries, as identified by the applicable L/C Issuer to the Administrative Agent in a writing confirmed by the Company on or prior to the date hereof.â€œExisting Maturity Dateâ€ has the meaning specified in Section 2.17.â€œExisting Revolving Credit Agreementâ€ means that certain Credit Agreement dated as of September 25, 2019 among the Company, any designated borrower, each lender from time to time party thereto, Bank of America, N.A., as administrative agent, and the L/C issuers party thereto, as amended to date.â€œExtending Lenderâ€ has the meaning specified in Section 2.17.â€œExtension Dateâ€ has the meaning specified in Section 2.17.â€œFATCAâ€ means Sections 1471 through 1474 of the Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof and any agreements entered into pursuant to Section 1471(b)(1) of the Code. â€œFederal Funds Rateâ€ means, for any day, the rate per annum calculated by the Federal Reserve Bank of New York based on such dayâ€™s federal funds transactions by depository institutions (as determined in such manner as the Federal Reserve Bank of New York shall set forth on its public website from time to time) and published on the next succeeding Business Day by the Federal Reserve Bank of New York as the federal funds effective rate; provided that if the Federal Funds Rate as so determined would be less than zero, such rate shall be deemed to be zero for purposes of this Agreement.â€œFee Letterâ€ means, collectively, (a)Â the letter agreement, dated October 12, 2022, between the Company and Bank of America and (b)Â any fee letter agreement entered into among the Company and any of the Arrangers in connection with this Agreement.â€œFitchâ€ means Fitch Ratings Inc., and any successor thereto.â€œForeign Designated Borrower Sublimitâ€ means an amount equal to the lesser of the Aggregate Commitments and $3,600,000,000. The Foreign Designated Borrower Sublimit is part of, and not in addition to, the Aggregate Commitments.â€œForeign Lenderâ€ means, with respect to any Borrower, (a)Â if such Borrower is a U.S. Person, a Lender that is not a U.S. Person, and (b)Â if such Borrower is not a U.S. Person, a Lender that is resident or organized under the laws of a jurisdiction other than that in which such Borrower is resident for tax purposes. For purposes of this definition, the United States, each State thereof and the District of Columbia shall be deemed to constitute a single jurisdiction.Â Â Â Â â€œForeign Subsidiaryâ€ means any Subsidiary that (a) is a â€œcontrolled foreign corporationâ€ within the meaning of the Code or (b) is a â€œdisregarded as an entity separate from its ownerâ€ within the meaning of Treasury Regulation Section 301.7701-3 and is a direct Subsidiary of a â€œcontrolled foreign corporationâ€ within the meaning of the Code.â€œFRBâ€ means the Board of Governors of the Federal Reserve System of the United States.â€œFSHCOâ€ means any Subsidiary (i)Â that is organized under the laws of the United States, any state thereof or the District of Columbia and (ii)Â substantially all of the assets of which constitute the Equity Interests of Foreign Subsidiaries.Â Â Â Â 12Â Â Â Â Â Â Â Â Â Â Â Â Â â€œFronting Exposureâ€ means, at any time there is a Defaulting Lender, such Defaulting Lenderâ€™s Pro Rata Share of the outstanding L/C Obligations other than L/C Obligations as to which such Defaulting Lenderâ€™s participation obligation has been reallocated to other Lenders or Cash Collateralized in accordance with the terms hereof.â€œFundâ€ means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities.â€œGAAPâ€ means generally accepted accounting principles in the United States set forth in the opinions and pronouncements of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied; provided that, to the extent related to McKesson Europe, â€œGAAPâ€ means either the foregoing or IFRS, consistently applied.â€œGovernmental Authorityâ€ means any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, administrative tribunal, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra national bodies such as the European Union or the European Central Bank).â€œGranting Lenderâ€ has the meaning specified in Section 11.06(h).â€œGuaranteeâ€ means, as to any Person, (a)Â any obligation, contingent or otherwise, of such Person guaranteeing or having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the â€œprimary obligorâ€) in any manner, whether directly or indirectly, and including any obligation of such Person, direct or indirect, (i)Â to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii)Â to purchase or lease property, securities or services for the purpose of assuring the obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii)Â to maintain working capital, equity capital or any other financial statement condition or liquidity or level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv)Â entered into for the purpose of assuring in any other manner the obligee in respect of such Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b)Â any Lien on any assets of such Person securing any Indebtedness or other obligation of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person. The amount of any Guarantee shall be deemed to be an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined by the guaranteeing Person in good faith. The term â€œGuaranteeâ€ as a verb has a corresponding meaning.â€œGuarantyâ€ means, collectively, (a) a document substantially in the form of Exhibit I and (b)Â each other guaranty and guaranty supplement delivered pursuant to Section 2.16(b).â€œHazardous Materialsâ€ means all explosive or radioactive substances or wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other substances or wastes of any nature regulated pursuant to any Environmental Law due to their toxic or deleterious nature.â€œIndebtednessâ€ means, as to any Person at a particular time, without duplication, all of the following:(a)Â Â Â Â all obligations of such Person for borrowed money;Â Â Â Â 13Â Â Â Â Â Â Â Â Â Â Â Â Â (b)Â Â Â Â all obligations of such Person to pay the deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business);(c)Â Â Â Â all non-contingent reimbursement or payment obligations of such Person arising under letters of credit (including standby and commercial), bankersâ€™ acceptances, bank guaranties, shipside bonds, surety bonds and similar instruments;(d)Â Â Â Â all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments;(e)Â Â Â Â capital or finance leases and Synthetic Lease Obligations;(f)Â Â Â Â all indebtedness created or arising under any conditional sale or other title retention agreement, or incurred as financing, in either case with respect to property acquired by the Person (even though the rights and remedies of the seller or bank under such agreement in the event of default are limited to repossession or sale of such property); and(g)Â Â Â Â all indebtedness referred to in clauses (a)Â through (f)Â above (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person, whether or not such indebtedness shall have been assumed by such Person or is limited in recourse.For all purposes hereof, the Indebtedness of any Person shall include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or a joint venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any capital or finance lease or Synthetic Lease Obligation as of any date shall be deemed to be the amount of Attributable Indebtedness in respect thereof as of such date.â€œIndemnified Liabilitiesâ€ has the meaning set forth in Section 11.04.â€œIndemnified Taxesâ€ means (a)Â Taxes, other than Excluded Taxes, imposed on or with respect to any payment made by or on account of any obligation of any Loan Party under any Loan Document and (b)Â to the extent not otherwise described in clauseÂ (a), Other Taxes.â€œIndemniteesâ€ has the meaning set forth in Section 11.04.â€œInsolvency Proceedingâ€ means (a)Â any case, action or proceeding before any court or other Governmental Authority relating to bankruptcy, reorganization, insolvency, liquidation, receivership, dissolution, winding-up or relief of debtors, or (b)Â any general assignment for the benefit of creditors, composition, marshalling of assets for creditors, or other similar arrangement in respect of its creditors generally or any substantial portion of its creditors; undertaken under any Debtor Relief Law.â€œInterest Payment Dateâ€ means, (a)Â as to any Eurocurrency Loan that bears interest at a rate based on clause (a)(ii) of the definition of â€œEurocurrency Rateâ€, the last Business Day of each March, June, September and December to occur during any period in which such Loan is outstanding and the Maturity Date, (b)Â as to any Eurocurrency Loan that bears interest at a rate based on clause (a)(i), (a)(iii) or (a)(iv) of the definition of â€œEurocurrency Rateâ€, the last day of each Interest Period applicable to such Loan and the Maturity Date; provided, however that if any Interest Period exceeds three months, the respective dates that fall every three months after the beginning of such Interest Period shall also be Interest Payment Dates; and (c)Â as to any Base Rate Loan, (i)Â the tenth calendar day following the end of each calendar quarter and (ii)Â the Maturity Date.â€œInterest Periodâ€ means, as to each Eurocurrency Rate Loan, the period commencing on the date such Eurocurrency Rate Loan is disbursed or converted to or continued as a Eurocurrency Rate Loan and ending on the date one, three or six months thereafter (or in the case of a Eurocurrency Rate Loan denominated in Canadian Dollars, one or three months thereafter) (in each case, subject to availability for the interest rate applicable to the relevant currency), as selected by the applicable Borrower in its Committed Loan Notice; provided that:Â Â Â Â 14Â Â Â Â Â Â Â Â Â Â Â Â Â (a)Â Â Â Â any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next succeeding Business Day unless such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day;(b)Â Â Â Â any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and(c)Â Â Â Â no Interest Period shall extend beyond the Maturity Date.â€œIRSâ€ means the United States Internal Revenue Service.â€œISPâ€ means, with respect to any Letter of Credit, the â€œInternational Standby Practices 1998â€ published by the Institute of International Banking Law & Practice, Inc. (or such later version thereof as may be in effect at the time of issuance).â€œIssuer Documentsâ€ means with respect to any Letter of Credit, the Letter Credit Application, and any other document, agreement and instrument entered into by the applicable L/C Issuer and the applicable Borrower (or any Subsidiary) or in favor of such L/C Issuer and relating to any such Letter of Credit.â€œJoint Sustainability Coordinatorsâ€ means ING Capital LLC and BNP Paribas, each in its capacity as such.â€œKPIâ€ has the meaning specified in Section 2.19.â€œLawsâ€ means, collectively, all international, foreign, federal, state, provincial, municipal and local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of law.â€œL/C Advanceâ€ means, with respect to each Lender, such Lenderâ€™s funding of its participation in any L/C Borrowing in accordance with its Pro Rata Share. All L/C Advances shall be denominated in Dollars.â€œL/C Borrowingâ€ means an extension of credit resulting from a drawing under any Letter of Credit which has not been reimbursed on the date when made or refinanced as a Borrowing. All L/C Borrowings shall be denominated in Dollars.â€œL/C Credit Extensionâ€ means, with respect to any Letter of Credit, the issuance thereof or extension of the expiry date thereof, or the renewal or increase of the amount thereof.â€œL/C Issuerâ€ means each of Bank of America, N.A., Barclays Bank PLC, Citibank, N.A., Wells Fargo Bank, National Association, Goldman Sachs Bank USA and JPMorgan Chase Bank, N.A., in each case, in its capacity as issuer of Letters of Credit hereunder, or any successor issuer of Letters of Credit hereunder and each Lender that shall have become an L/C Issuer hereunder as provided in Section 2.03(n). If there is more than one L/C Issuer at any given time, the term L/C Issuer shall refer to the relevant L/C Issuers(s).â€œL/C Obligationsâ€ means, as at any date of determination, the aggregate undrawn amount of all outstanding Letters of Credit plus the aggregate of all Unreimbursed Amounts, including all L/C Borrowings. For purposes of computing the amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.07. For all purposes of this Agreement, if on any date of determination a Letter of Credit has expired by its terms but any amount may still be drawn thereunder by reason of the operation of Rule 3.14 of the ISP, such Letter of Credit shall be deemed to be â€œoutstandingâ€ in the amount so remaining available to be drawn.Â Â Â Â 15Â Â Â Â Â Â Â Â Â Â Â Â Â â€œLenderâ€ has the meaning specified in the introductory paragraph hereto and, as the context requires, includes each L/C Issuer.â€œLending Officeâ€ means, as to any Lender, the office or offices of such Lender described as such in such Lenderâ€™s Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Company and the Administrative Agent which office may include any Affiliate of such Lender or any domestic or foreign branch of such Lender or such Affiliate. Unless the context otherwise requires each reference to a Lender shall include its applicable Lending Office.â€œLetter of Creditâ€ means (a)Â any letter of credit issued hereunder and (b)Â each of the Existing Letters of Credit. A Letter of Credit may be a commercial letter of credit or a standby letter of credit and may be issued in Dollars or in an Alternative Currency; provided that (i) Barclays Bank PLC and Goldman Sachs Bank USA shall only be required to issue standby Letters of Credit and (ii) Letters of Credit denominated in

Alternative Currencies shall be issued by Bank of America, N.A.â€œLetter of Credit Applicationâ€ means an application and agreement for the issuance or amendment of a Letter of Credit in the form from time to time in use by the applicable L/C Issuer.â€œLetter of Credit Expiration Dateâ€ means the day that is five Business Days prior to the Maturity Date then in effect.â€œLetter of Credit Sublimitâ€ means an amount equal to $175,000,000. The Letter of Credit Sublimit is part of, and not in addition to, the Aggregate Commitments.â€œLeverage Ratioâ€ means, on any date of determination, the ratio of (a) Total Debt as of such date to (b) Consolidated EBITDA for the period of four consecutive fiscal quarters of the Company immediately last ended as of such date of determination. â€œLienâ€ means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, and any financing lease having substantially the same economic effect as any of the foregoing); provided that â€œLienâ€ shall not include (i)Â the interest of a lessor under an operating lease or (ii)Â the sale of accounts receivable.â€œLoanâ€ means an extension of credit by a Lender to a Borrower under ARTICLE II in the form of a Committed Loan.â€œLoan Documentsâ€ means this Agreement, any Guaranty, any joinder agreement delivered pursuant to Section 2.16 (including any Designated Borrower Notice or any Designated Borrower Request and Assumption Agreement) or 7.02(d), any Notes, Letter of Credit Applications and Letters of Credit and the Fee Letter.â€œLoan Partiesâ€ means, collectively, the Borrowers.â€œLocal Timeâ€ means with respect to a Loan, Borrowing or Letter of Credit denominated in (a) Dollars, New York City time, (b) Sterling or Euros, London time and (c) Canadian Dollars, Toronto time.â€œMargin Stockâ€ means â€œmargin stockâ€ as such term is defined in Regulation T, U or X of the FRB.â€œMaster Agreementâ€ has the meaning set forth in the definition of â€œSwap Contract.â€Â Â Â Â 16Â Â Â Â Â Â Â Â Â Â Â Â Â â€œMaterial Acquisitionâ€ means any acquisition, or a series of related acquisitions, of (a) Equity Interests in any Person if, after giving effect thereto, such Person will become a Subsidiary or (b) assets comprising all or substantially all the assets of (or all or substantially all the assets constituting a business unit, division, product line or line of business of) any Person; provided that the aggregate consideration therefor exceeds US$500,000,000.â€œMaterial Adverse Effectâ€ means (a)Â a material adverse change in, or a material adverse effect upon, the operations, business, properties or condition (financial or otherwise) of the Company and its Subsidiaries taken as a whole; (b)Â a material impairment of the ability of any Borrower to perform its obligations under any Loan Document to which it is a party; or (c)Â a material adverse effect upon the legality, validity, binding effect or enforceability against any Borrower of any Loan Document to which it is a party.â€œMaterial Dispositionâ€ means any sale, transfer or other disposition, or a series of related sales, transfers or other dispositions, of (a) all or substantially all the issued and outstanding Equity Interests in any Person that are owned by the Company and its Subsidiaries or (b) assets comprising all or substantially all the assets of (or all or substantially all the assets constituting a business unit, division, product line or line of business of) any Person; provided that the aggregate consideration therefor exceeds US$500,000,000.â€œMaterial Subsidiaryâ€ means, at any time, (a) any Subsidiary that is a Borrower hereunder and (b) any other Subsidiary having at such time 10% or more of the Companyâ€™s consolidated total (gross) revenues for the preceding four fiscal quarter period, as of the last day of the preceding fiscal quarter based upon the Companyâ€™s most recent annual or quarterly financial statements delivered to the Administrative Agent under Section 6.01.â€œMaturity Dateâ€ means the later of (a)Â November 7, 2029 or (b)Â if the term of this Agreement is extended pursuant to Section 2.17, such extended termination date as determined pursuant to such Section; provided, however that, in each case, if such date is not a Business Day, the next preceding Business Day; provided, further that with respect to any Non-Extending Lender, the Maturity Date of such Non-Extending Lenderâ€™s Commitment shall be the Existing Maturity Date notwithstanding the extension of Commitments by any other Lender pursuant to Section 2.17.â€œMcKesson Europeâ€ means McKesson Europe AG, a stock corporation organized under the laws of Germany.â€œMoodyâ€™sâ€ means Moodyâ€™s Investors Service, Inc. and any successor thereto.â€œMultiemployer Planâ€ means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which the Company or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions. â€œNet Worthâ€ means the shareholdersâ€™ equity of the Company and its consolidated Subsidiaries on any date of determination as set forth on the consolidated balance sheet of the Company and its Subsidiaries most recently delivered to the Administrative Agent on or prior to such date of determination pursuant to Section 6.01.â€œNon-SOFR Successor Rateâ€ has the meaning specified in Section 3.03(c).â€œNoteâ€ means a promissory note executed by a Borrower in favor of a Lender pursuant to Section 2.11, substantially in the form of Exhibit B with respect to Loans.â€œNotice Dateâ€ has the meaning specified in Section 2.17.â€œObligationsâ€ means all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party arising under any Loan Document or otherwise with respect to any Loan or Letter of Credit, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and fees that accrue after the commencement by or against any Loan Party or any Affiliate thereof of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed claims in such proceeding.Â Â Â Â 17Â Â Â Â Â Â Â Â Â Â Â Â Â â€œOFACâ€ means the Office of Foreign Assets Control of the United States Department of the Treasury.â€œOrganization Documentsâ€ means, with respect to (a)Â any corporation, the certificate or articles of incorporation and the bylaws, (b)Â any limited liability company, the certificate of formation and limited liability company agreement or operating agreement, (c)Â any partnership, the certificate of formation and partnership agreement, and (d)Â any organization incorporated or formed in any non-U.S. jurisdiction, constitutive documents with respect to such organization that are equivalent or comparable to the foregoing, as may be applicable.â€œOther Connection Taxesâ€ means, with respect to any Recipient, Taxes imposed as a result of a present or former connection between such Recipient and the jurisdiction imposing such Tax (other than connections arising from such Recipient having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced any Loan Document, or sold or assigned an interest in any Loan or Loan Document).â€œOther Taxesâ€ means all present or future stamp, court or documentary, intangible, recording, filing or similar Taxes that arise from any payment made under, from the execution, delivery, performance, enforcement or registration of, from the receipt or perfection of a security interest under, or otherwise with respect to, any Loan Document, except any such Taxes that are Other Connection Taxes imposed with respect to an assignment (other than an assignment made pursuant to SectionÂ 3.06).â€œOutstanding Amountâ€ means (a) with respect to Committed Loans on any date, the Dollar Equivalent amount of the aggregate outstanding principal amount thereof after giving effect to any borrowings and prepayments or repayments of such Committed Loans occurring on such date and (b) with respect to any L/C Obligations on any date, the Dollar Equivalent amount of the aggregate outstanding amount of such L/C Obligations on such date after giving effect to any L/C Credit Extension occurring on such date and any other changes in the aggregate amount of the L/C Obligations as of such date, including as a result of any reimbursements of outstanding unpaid drawings under any Letters of Credit or any reductions in the maximum amount available for drawing under Letters of Credit taking effect on such date (in each case expressed in Dollars in the Dollar Equivalent amount thereof in case of Letters of Credit denominated in an Alternative Currency).â€œOvernight Rateâ€ means, for any day, (a)Â with respect to any amount denominated in Dollars, the greater of (i)Â the Federal Funds Rate and (ii)Â an overnight rate determined by the Administrative Agent or the applicable L/C Issuer, as the case may be, in accordance with banking industry rules on interbank compensation, and (b)Â with respect to any amount denominated in an Alternative Currency, the rate of interest per annum at which overnight deposits in the applicable Alternative Currency, in an amount approximately equal to the amount with respect to which such rate is being determined, would be offered for such day by a branch or Affiliate of Bank of America in the applicable offshore interbank market for such currency to major banks in such interbank market.â€œParticipantâ€ has the meaning specified in Section 11.06(d)(i).â€œParticipant Registerâ€ has the meaning specified in Section 11.06(d)(ii).â€œParticipating Member Stateâ€ means any member state of the European Union that adopts or has adopted the Euro as its lawful currency in accordance with legislation of the European Union relating to Economic and Monetary Unionâ€œPBGCâ€ means the Pension Benefit Guaranty Corporation.â€œPension Planâ€ means any â€œemployee pension benefit planâ€ (as such term is defined in Section 3(2) of ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by the Company or any ERISA Affiliate or to which the Company or any ERISA Affiliate contributes or has an obligation to contribute, or in the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately preceding five plan years.Â Â Â Â 18Â Â Â Â Â Â Â Â Â Â Â Â Â â€œPersonâ€ means any natural person, corporation, limited liability company, trust, joint venture, association, company, partnership, Governmental Authority or other entity.â€œPF2 JVâ€ means PF2 NewCo LLC, a Delaware limited liability company, formed on June 17, 2016.â€œPlanâ€ means any â€œemployee benefit planâ€ (as such term is defined in Section 3(3) of ERISA) established by any Borrower or, with respect to any such plan that is subject to Section 412 of the Code or Title IV of ERISA, any ERISA Affiliate.â€œPro Rata Shareâ€ means, with respect to each Lender at any time, a fraction (expressed as a percentage, carried out to the ninth decimal place), the numerator of which is the amount of the Commitment of such Lender at such time and the denominator of which is the amount of the Aggregate Commitments at such time; provided that if the Commitment of each Lender to make Loans and the obligation of any L/C Issuer to make L/C Credit Extensions have been terminated pursuant to Section 8.02 or if the Aggregate Commitments have expired, then the Pro Rata Share of each Lender shall be determined based on the Pro Rata Share of such Lender immediately prior to such termination and after giving effect to any subsequent assignments made pursuant to the terms hereof. The initial Pro Rata Share of each Lender is set forth opposite the name of such Lender on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable.â€œProtesting Lenderâ€ has the meaning set forth in Section 2.16.â€œPTEâ€ means a prohibited transaction class exemption issued by the U.S. Department of Labor, as any such exemption may be amended from time to time.â€œQualified Receivables Transactionâ€ means any transaction or series of transactions entered into by the Company or any of its Subsidiaries pursuant to which the Company or any of its Subsidiaries sells, conveys or otherwise transfers to (i)Â a Receivables Subsidiary (in the case of a transfer by the Company or any of its Subsidiaries) and (ii)Â any other Person (in the case of a transfer by a Receivables Subsidiary), or grants a security interest in (all of the following constituting â€œReceivables Program Assetsâ€), any accounts receivable (whether now existing or arising in the future) of the Company or any of its Subsidiaries, and any assets related thereto including, without limitation, all collateral securing such accounts receivable, all contracts and all guarantees or other obligations in respect of such accounts receivable, proceeds of such accounts receivable and other assets which are customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization transactions involving accounts receivable.â€œQFCâ€ has the meaning assigned to the term â€œqualified financial contractâ€ in, and shall be interpreted in accordance with, 12 U.S.C. 5390(c)(8)(D).â€œRate Determination Dateâ€ means two (2) Business Days prior to the commencement of such Interest Period (or such other day as is generally treated as the rate fixing day by market practice in such interbank market, as determined by the Administrative Agent; provided that to the extent such market practice is not administratively feasible for the Administrative Agent, such other day as otherwise reasonably determined by the Administrative Agent).â€œReceivables Subsidiaryâ€ means a Subsidiary of the Company which engages in no activities other than in connection with the financing of accounts receivable or inventory (a)Â no portion of the Indebtedness or any other obligations (contingent or otherwise) of which (i)Â is guaranteed by the Company or any Subsidiary of the Company (excluding guarantees of obligations (other than the principal of, and interest on, Indebtedness) pursuant to representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction), (ii)Â is recourse or obligates the Company or any Subsidiary of the Company in any way other than pursuant to representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction or (iii)Â subjects any property or asset of the Company or any Subsidiary of the Company (other than accounts receivable or inventory and related assets as provided in the definition of â€œQualified Receivables Transactionâ€), directly or indirectly, Â Â Â Â 19Â Â Â Â Â Â Â Â Â Â Â Â Â contingently or otherwise, to the satisfaction thereof, other than pursuant to representations, warranties, covenants and indemnities entered into in the ordinary course of business in connection with a Qualified Receivables Transaction, (b)Â with which neither the Company nor any Subsidiary of the Company has any material contract, agreement, arrangement or understanding other than on terms customary for securitization of receivables or inventory and (c)Â with which neither the Company nor any Subsidiary of the Company has any obligations to maintain or preserve such Subsidiaryâ€™s financial condition or cause such Subsidiary to achieve certain levels of operating results. CGSF Funding Corporation, a Delaware corporation, shall be deemed a Receivables Subsidiary.â€œRecipientâ€ means the Administrative Agent, any Lender, any L/C Issuer or any other recipient of any payment to be made by or on account of any obligation of any Loan Party hereunder.â€œRegisterâ€ has the meaning set forth in Section 11.06(c).â€œRelated Partiesâ€ means, with respect to any Person, such Personâ€™s Affiliates and the partners, directors, officers, employees, agents, trustees, administrators, managers, advisors, consultants, service providers and representatives of such Person and of such Personâ€™s Affiliates.â€œRelevant Obligationâ€ has the meaning set forth in Section 8.01(e).â€œRelevant Rateâ€ means with respect to any Credit Extension denominated in (a)Â Dollars, Term SOFR, (b)Â Canadian Dollars, the Term CORRA Rate, (c)Â Sterling, the SONIA Rate and (d)Â Euro, the EURIBOR Rate.â€œReportable Eventâ€ means any of the events set forth in Section 4043(c) of ERISA, other than events for which the 30 day notice period has been waived.â€œRequest for Credit Extensionâ€ means (a)Â with respect to a Committed Borrowing, conversion or continuation of Committed Loans, a Committed Loan Notice and (b) with respect to an L/C Credit Extension, a Letter of Credit Application.â€œRequired Lendersâ€ means, as of any date of determination, Lenders having Total Credit Exposures representing more than 50% of the Total Credit Exposures of all Lenders; provided that the Total Credit Exposures held or deemed held by, any Defaulting Lender shall be excluded for purposes of making a determination of Required Lenders; provided, further that, the amount of any Unreimbursed Amounts that such Defaulting Lender has failed to fund that have not been reallocated to and funded by another Lender shall be deemed to be held by the Lender that is the L/C Issuer, in making such determination.â€œRequirement of Lawâ€ means, as to any Person, any law (statutory or common), treaty, rule or regulation or determination, decree or order of an arbitrator or of a Governmental Authority, in each case applicable to or binding upon the Person or any of its property or to which the Person or any of its property is subject, including but not limited to any Environmental Law.â€œResignation Effective Dateâ€ has the meaning specified in Section 9.06.â€œResolution Authorityâ€ means an EEA Resolution Authority or, with respect to any UK Financial Institution, a UK Resolution Authority.â€œResponse Deadlineâ€ has the meaning specified in Section 2.17.Â Â Â Â 20Â Â Â Â Â Â Â Â Â Â Â Â Â â€œResponsible Officerâ€ means the chief executive officer, president, chief financial officer, corporate vice president or the treasurer of a Loan Party and, solely for purposes of notices given pursuant to Article II, any other officer, employee or other designated representative of the applicable Loan Party so designated by any of the foregoing officers in a notice to the Administrative Agent or any other officer or employee of the applicable Loan Party designated in or pursuant to an agreement between the applicable Loan Party and the Administrative Agent. Any document delivered hereunder that is signed by a Responsible Officer of a Loan Party shall be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of such Loan Party and such Responsible Officer shall be conclusively presumed to have acted on behalf of such Loan Party.â€œRevaluation Dateâ€ means (a)Â with respect to any Loan, each of the following: (i)Â each date of a Borrowing of a Eurocurrency Rate Loan denominated in an Alternative Currency, (ii)Â each date of a continuation of a Eurocurrency Rate Loan denominated in an Alternative Currency pursuant to Section 2.02, and (iii)Â such additional dates as the Administrative Agent shall determine or the Required Lenders shall require; and (b)Â with respect to any Letter of Credit, each of the following: (i)Â each date of issuance of a Letter of Credit denominated in an Alternative Currency, (ii)Â each date of an amendment of any such Letter of Credit having the effect of increasing the amount thereof, (iii)Â each date of any payment by the L/C Issuer under any Letter of Credit denominated in an Alternative Currency, and (iv) such additional dates as the Administrative Agent or the applicable L/C Issuer shall determine or the Required Lenders shall require.â€œRevolving Credit Exposureâ€ means, as to any Lender at any time, the aggregate Outstanding Amount at such time of its Committed Loans and the aggregate Outstanding Amount of such Lenderâ€™s participation in L/C Obligations at such time.â€œS&Pâ€ means Standard & Poorâ€™s Financial Services LLC, a subsidiary of S&P Global Inc., and any successor thereto.â€œSECâ€ means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal functions.â€œSPCâ€ has the meaning specified in Section 11.06(h).â€œSame Day Fundsâ€ means (a) with respect to disbursements and payments in Dollars, immediately available funds, and (b) with respect to disbursements and payments in an Alternative Currency, same day or other funds as may be determined by the Administrative Agent or the L/C Issuer, as the case may be, to be customary in the place of disbursement or payment for the settlement of international banking transactions in the relevant Alternative Currency. â€œSanction(s)â€ means any sanction or restrictive measures enacted, administered, imposed or enforced by the United States Government (including without limitation, OFAC and the U.S. Department of State), the United Nations Security Council, the European Union, His Majestyâ€™s Treasury (â€œHMTâ€), Canada or the Hong Kong Monetary Authority.â€œScheduled Unavailability Dateâ€ has the meaning specified in Section 3.03(c)(ii).â€œSOFR Adjustmentâ€ means 0% for an Interest Period of one-monthâ€™s duration and 0.10% per annum for an Interest Period of three-monthsâ€™ duration or six-monthâ€™s duration.â€œSONIAâ€ has the meaning specified in the definition of Eurocurrency Rate.â€œSpecified L/C Sublimitâ€ means, with respect to any L/C Issuer, (i) in the case of Bank of America, $25,000,000, (ii) in the case of Barclays Bank PLC,

$25,000,000, (iii) in the case of Citibank, N.A., $25,000,000, (iv) in the case of Wells Fargo Bank, National Association, $25,000,000, (v) in the case of Goldman Sachs Bank USA, $25,000,000 or (vi) in the case of JPMorgan Chase Bank, N.A., $25,000,000 in each case, such other amount as specified in the agreement pursuant to which such person becomes an L/C Issuer hereunder or, in Â Â Â Â 21Â Â Â Â Â Â Â Â Â Â Â Â Â each case, as each of the foregoing amounts may be decreased or increased from time to time with the written consent of the Company and the L/C Issuers (provided that any increase in the Specified L/C Sublimit with respect to any L/C Issuer shall require the consent of only the Company and such L/C Issuer). Any successor L/C Issuer appointed pursuant to Section 2.03(p) or (q) shall assume the Specified L/C Sublimit of such replaced or resigning L/C Issuer, as applicable.â€œSpot Rateâ€ for a currency means the rate determined by the Administrative Agent or the applicable L/C Issuer, as applicable, to be the rate quoted by the Person acting in such capacity as the spot rate for the purchase by such Person of such currency with another currency through its principal foreign exchange trading office at approximately 11:00 a.m. Local Time on the date two Business Days prior to the date as of which the foreign exchange computation is made; provided that the Administrative Agent or the applicable L/C Issuer may obtain such spot rate from another financial institution designated by the Administrative Agent or the L/C Issuer if the Person acting in such capacity does not have as of the date of determination a spot buying rate for any such currency; and provided, further that the applicable L/C Issuer may use such spot rate quoted on the date as of which the foreign exchange computation is made in the case of any Letter of Credit denominated in an Alternative Currency.â€œSterlingâ€ and â€œÂ£â€ mean the lawful currency of the United Kingdom.â€œSubsidiaryâ€ of a Person means a corporation, partnership, joint venture, limited liability company, unlimited liability company or other business entity of which a majority of the shares of securities or other interests having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or the management of which is otherwise controlled, directly, or indirectly through one or more intermediaries, or both, by such Person; provided, for the avoidance of doubt, that, for so long as the Company does not have the power to elect a majority of the board of directors or other governing body of PF2 JV, neither PF2 JV nor any of its subsidiaries shall constitute a Subsidiary of the Company for purposes of this Agreement. Unless otherwise specified, all references herein to a â€œSubsidiaryâ€ or to â€œSubsidiariesâ€ shall refer to a Subsidiary or Subsidiaries of the Company.â€œSuccessor Rateâ€ has the meaning specified in Section 3.03(c).â€œSustainability Linked Loan Principlesâ€ means the Sustainability Linked Loan Principles as most recently published by the Loan Market Association, Asia Pacific Loan Market Association and Loan Syndications & Trading Association, as may be amended from time to time.â€œSwap Contractâ€ means (a)Â any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions, cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or not any such transaction is governed by or subject to any master agreement, and (b)Â any and all transactions of any kind (other than Eligible ASRs, as defined below), and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement relating to any of the foregoing (any such master agreement, together with any related schedules, a â€œMaster Agreementâ€), including any such obligations or liabilities under any Master Agreement (other than Eligible ASRs). â€œEligible ASRâ€ shall mean any accelerated share repurchase documented under a Master Agreement.â€œSwap Termination Valueâ€ means, in respect of any one or more Swap Contracts, after taking into account the effect of any legally enforceable netting agreement relating to such Swap Contracts, (a)Â for any date on or after the date such Swap Contracts have been closed out and termination value(s) determined in accordance therewith, such termination value(s), and (b)Â for any date prior to the date referenced in clause (a), the amount(s) Â Â Â Â 22Â Â Â Â Â Â Â Â Â Â Â Â Â determined as the mark-to-market value(s) for such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender).â€œSynthetic Lease Obligationâ€ means the monetary obligation of a Person under (a)Â a so-called synthetic, off-balance sheet or tax retention lease, or (b)Â an agreement for the use or possession of property creating obligations that do not appear on the balance sheet of such Person but which, upon the insolvency or bankruptcy of such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment).â€œTARGET2â€ means the Trans-European Automated Real-time Gross Settlement Express Transfer payment system which utilizes a single shared platform and which was launched on November 19, 2007.â€œTARGET Dayâ€ means any day on which TARGET2 (or, if such payment system ceases to be operative, such other payment system, if any, determined by the Administrative Agent to be a suitable replacement) is open for the settlement of payments in Euro.â€œTaxesâ€ means all present or future taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.â€œTerm CORRAâ€ has the meaning set forth in the definition of â€œEurocurrency Rateâ€.â€œTerm CORRA Adjustmentâ€ means (i) 0.29547% (29.547 basis points) for an Interest Period of one-monthâ€™s duration and (ii) 0.32138% (32.138 basis points) for an Interest Period of three-monthsâ€™ duration. â€œTerm CORRA Rateâ€ has the meaning set forth in the definition of â€œEurocurrency Rateâ€.â€œTerm SOFRâ€ has the meaning specified in the definition of â€œEurocurrency Rateâ€.â€œTerm SOFR Administratorâ€ means CME Group Benchmark Administration Limited (or any successor administrator satisfactory to the Administrative Agent).â€œTerm SOFR Screen Rateâ€ means the forward-looking SOFR term rate administered by the Term SOFR Administrator and published on the applicable Reuters screen page (or such other commercially available source providing such quotations as may be designated by the Administrative Agent from time to time).â€œTerm SOFR Successor Rateâ€ has the meaning specified in Section 3.03(c).â€œTotal Credit Exposureâ€ means, as to any Lender at any time, the unused Commitments and Revolving Credit Exposure of such Lender at such time.â€œTotal Debtâ€ means, on any date of determination, the difference of (a) all Indebtedness of the Company and its Subsidiaries determined on a consolidated basis on such date, minus (b) Indebtedness of any Receivables Subsidiary incurred in connection with a Qualified Receivables Transaction as of such date. â€œTotal Outstandingsâ€ means, as of any date of determination, the aggregate Outstanding Amount of all Loans and all L/C Obligations as of such date.â€œTrade Dateâ€ has the meaning set forth in Section 11.06(b).â€œTypeâ€ meansÂ with respect to a Committed Loan, its character as a Base Rate Loan or a Eurocurrency Rate Loan.â€œUK Financial Institutionâ€ means any BRRD Undertaking (as such term is defined under the PRA Rulebook (as amended form time to time) promulgated by the United Kingdom Prudential Regulation Authority) or Â Â Â Â 23Â Â Â Â Â Â Â Â Â Â Â Â Â any person subject to IFPRU 11.6 of the FCA Handbook (as amended from time to time) promulgated by the United Kingdom Financial Conduct Authority, which includes certain credit institutions and investment firms, and certain affiliates of such credit institutions or investment firms.â€œUK Resolution Authorityâ€ means the Bank of England or any other public administrative authority having responsibility for the resolution of any UK Financial Institution.â€œUnited Statesâ€ and â€œU.S.â€ mean the United States of America.â€œUnreimbursed Amountâ€ has the meaning set forth in Section 2.03(c)(i).â€œU.S. Government Securities Business Dayâ€ means any day except for (a) a Saturday, (b) a Sunday or (c) a day on which the Securities Industry and Financial Markets Association recommends that the fixed income departments of its members be closed for the entire day for purposes of trading in United States government securities.â€œWholly-Owned Subsidiaryâ€ means any Subsidiary in which (other than directorsâ€™ qualifying shares required by law) 100% of the capital stock of each class or other interests having ordinary voting power, and 100% of the capital stock of every other class or other interests, in each case, at the time as of which any determination is being made, is owned, beneficially and of record, by the Company, or by one or more of the other Wholly-Owned Subsidiaries, or both.â€œWrite-Down and Conversion Powersâ€ means, (a) with respect to any EEA Resolution Authority, the write-down and conversion powers of such EEA Resolution Authority from time to time under the Bail-In Legislation for the applicable EEA Member Country, which write-down and conversion powers are described in the EU Bail-In Legislation Schedule, and (b) with respect to the United Kingdom, any powers of the applicable Resolution Authority under the Bail-In Legislation to cancel, reduce, modify or change the form of a liability of any UK Financial Institution or any contract or instrument under which that liability arises, to convert all or part of that liability into shares, securities or obligations of that person or any other person, to provide that any such contract or instrument is to have effect as if a right had been exercised under it or to suspend any obligation in respect of that liability or any of the powers under that Bail-In Legislation that are related to or ancillary to any of those powers.1.2.Other Interpretive ProvisionsWith reference to this Agreement and each other Loan Document, unless otherwise specified herein or in such other Loan Document:1.2.1.1.The meanings of defined terms are equally applicable to the singular and plural forms of the defined terms.1.2.1.2.(i) The words â€œherein,â€ â€œhereto,â€ â€œhereofâ€ and â€œhereunderâ€ and words of similar import when used in any Loan Document shall refer to such Loan Document as a whole and not to any particular provision thereof.1.2.1.2.1.Article, Section, Exhibit and Schedule references are to the Loan Document in which such reference appears.1.2.1.2.2.The term â€œincludingâ€ is by way of example and not limitation.1.2.1.2.3.The term â€œdocumentsâ€ includes any and all instruments, documents, agreements, certificates, notices, reports, financial statements and other writings, however evidenced, whether in physical or electronic form.Â Â Â Â 24Â Â Â Â Â Â Â Â Â Â Â Â Â 1.2.1.3.In the computation of periods of time from a specified date to a later specified date, the word â€œfromâ€ means â€œfrom and includingâ€; the words â€œtoâ€ and â€œuntilâ€ each mean â€œto but excluding;â€ and the word â€œthroughâ€ means â€œto and includingâ€.1.2.1.4.Section headings herein and in the other Loan Documents are included for convenience of reference only and shall not affect the interpretation of this Agreement or any other Loan Document.1.2.1.5.Any reference herein to a merger, transfer, consolidation, amalgamation, consolidation, assignment, sale, disposition or transfer, or similar term, shall be deemed to apply to a division of or by a limited liability company, or an allocation of assets to a series of a limited liability company (or the unwinding of such a division or allocation), as if it were a merger, transfer, consolidation, amalgamation, consolidation, assignment, sale, disposition or transfer, or similar term, as applicable, to, of or with a separate Person. Any division of a limited liability company shall constitute a separate Person hereunder (and each division of any limited liability company that is a Subsidiary, joint venture or any other like term shall also constitute such a Person or entity).1.3 Accounting Terms. (a) All accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein.1.2.1.6.If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Company or the Required Lenders shall so request, the Administrative Agent, the Lenders and the Company shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the Required Lenders); provided that, until so amended, (i)Â such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii)Â the Company shall provide to the Administrative Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to such change in GAAP. 1.2.1.7.If the Company shall elect as of the end of any financial reporting period to prepare financial statements in accordance with International Financial Reporting Standards, as published by the International Accounting Standards Board (â€œIFRSâ€), rather than GAAP, then, following delivery to Administrative Agent of a completed Compliance Certificate attaching the information required to be delivered for such financial reporting period, the parties hereto shall use their best efforts to amend (in a manner mutually satisfactory to Lenders and Borrowers) the thresholds or methods of calculation of any financial ratio or requirement set forth in any Loan Document such that compliance therewith is neither more nor less burdensome (as determined by the Required Lenders in their sole discretion) to Borrowers as a result of such conversion to IFRS and, thereafter, all references in the Loan Documents to GAAP shall be deemed references to IFRS. 1.2.1.8.All references herein to consolidated financial statements of the Borrower and its Subsidiaries or to the determination of any amount for the Borrower and its Subsidiaries on a consolidated basis or any similar reference shall, in each case, be deemed to include each variable interest entity that such Borrower is required to consolidate pursuant to FASB ASC 810 as if such variable interest entity were a Subsidiary as defined herein. 1.4 Rounding. Any financial ratios required to be maintained by the Company pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number).1.5 References to Agreements and Laws. Unless otherwise expressly provided herein, (a)Â references to Organization Documents, agreements (including the Loan Documents) and other contractual instruments shall be Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â deemed to include all subsequent amendments, restatements, extensions, supplements and other modifications thereto, but only to the extent that such amendments, restatements, extensions, supplements and other modifications are not prohibited by any Loan Document; and (b)Â references to any Law shall include all statutory and regulatory provisions consolidating, amending, replacing, supplementing or interpreting such Law.1.6 Times of Day. Unless otherwise specified, all references herein to times of day shall be references to Central time (daylight or standard, as applicable).1.7 Letter of Credit Amounts. Unless otherwise specified herein, the amount of a Letter of Credit at any time shall be deemed to be the stated amount of such Letter of Credit in effect at such time; provided, however, that with respect to any Letter of Credit that, by its terms or the terms of any Issuer Document related thereto, provides for one or more automatic increases in the stated amount thereof, the amount of such Letter of Credit shall be deemed to be the maximum stated amount of such Letter of Credit after giving effect to all such increases, whether or not such maximum stated amount is in effect at such time.1.8 Exchange Rates; Currency Equivalents.(a)Â Â Â Â Â The Administrative Agent or the applicable L/C Issuer, as applicable, shall determine the Spot Rates as of each Revaluation Date to be used for calculating Dollar Equivalent amounts of Credit Extensions and Outstanding Amounts denominated in Alternative Currencies. Such Spot Rates shall become effective as of such Revaluation Date and shall be the Spot Rates employed in converting any amounts between the applicable currencies until the next Revaluation Date to occur. Except for purposes of financial statements delivered by Loan Parties hereunder or calculating financial covenants hereunder or except as otherwise provided herein, the applicable amount of any currency (other than Dollars) for purposes of the Loan Documents shall be such Dollar Equivalent amount as so determined by the Administrative Agent or the applicable L/C Issuer, as applicable.(b)Â Â Â Â Wherever in this Agreement in connection with a Borrowing, conversion, continuation or prepayment of a Eurocurrency Rate Loan, the issuance, amendment or extension of a Letter of Credit or any assignment, any required minimum or multiple amount, is expressed in Dollars, but such Borrowing, Eurocurrency Rate Loan or Letter of Credit or any such assignment is denominated in an Alternative Currency, such amount expressed in Dollars shall be deemed to be an amount expressed in the applicable Alternative Currency.(c)Â Â Â Â The Administrative Agent does not warrant, nor accept responsibility, nor shall the Administrative Agent have any liability with respect to the administration, submission or any other matter related to the rates in the definition of â€œEurocurrency Rateâ€ or with respect to any comparable or successor rate thereto.1.09Â Â Â Â Change of Currency.(a)Â Â Â Â Each obligation of the Borrowers to make a payment denominated in the national currency unit of any member state of the European Union that adopts the Euro as its lawful currency after the date hereof shall be redenominated into Euro at the time of such adoption. If, in relation to the currency of any such member state, the basis of accrual of interest expressed in this Agreement in respect of that currency shall be inconsistent with any convention or practice in the London interbank market for the basis of accrual of interest in respect of the Euro, such expressed basis shall be replaced by such convention or practice with effect from the date on which such member state adopts the Euro as its lawful currency; provided that if any Committed Borrowing in the currency of such member state is outstanding immediately prior to such date, such replacement shall take effect, with respect to such Committed Borrowing, at the end of the then current Interest Period.(b)Â Â Â Â Each provision of this Agreement shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect the adoption of the Euro by any member state of the European Union and any relevant market conventions or practices relating to the Euro. Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â (c)Â Â Â Â Each provision of this Agreement also shall be subject to such reasonable changes of construction as the Administrative Agent may from time to time specify to be appropriate to reflect a change in currency of any other country and any relevant market conventions or practices relating to the change in currency.2.THE COMMITMENTS AND CREDIT EXTENSIONS2.1.Committed Loans.Subject to the terms and conditions set forth herein, each Lender severally agrees to make loans (each such loan, a â€œCommitted Loanâ€) to the Borrowers in Dollars or in one or more Alternative Currencies from time to time, on any Business Day during the Availability Period, in an aggregate amount not to exceed at any time outstanding the amount of such Lenderâ€™s Commitment; provided, however, that after giving effect to any Borrowing, (i)Â the Total Outstandings shall not exceed the Aggregate Commitments, (ii) the Total Outstandings denominated in Alternative Currencies shall not exceed the Alternative Currency Sublimit, (iii)Â the Revolving Credit Exposure of any Lender shall not exceed such Lenderâ€™s Commitment andÂ (iv)Â the Total Outstandings of Designated Borrowers that are Foreign Subsidiaries of the Company shall not exceed the Foreign Designated

Borrower Sublimit. Within the limits of each Lenderâ€™s Commitment, and subject to the other terms and conditions hereof, the Borrowers may borrow under this Section 2.01, prepay under Section 2.05, and reborrow under this Section 2.01. Committed Loans may be Base Rate Loans or Eurocurrency Rate Loans, as further provided herein.2.2.Borrowings, Conversions and Continuations of Committed Loans.2.2.1.1.Each Committed Borrowing, each conversion of Committed Loans from one Type to the other, and each continuation of Eurocurrency Rate Loans shall be made upon the applicable Borrowerâ€™s irrevocable notice to the Administrative Agent, which may be given by (A)Â telephone or (B)Â a Committed Loan Notice; provided that any telephonic notice must be confirmed immediately by delivery to the Administrative Agent of a Committed Loan Notice. Each Committed Loan Notice must be received by the Administrative Agent not later than 11:00 a.m. (i)Â three Business Days prior to the requested date of any Borrowing of, conversion to or continuation of Eurocurrency Rate Loans denominated in Dollars or of any conversion of Eurocurrency Rate Loans denominated in Dollars to Base Rate Committed Loans, (ii)Â four Business Days prior to the requested date of any Borrowing or continuation of Eurocurrency Rate Loans denominated in Alternative Currencies and (iii)Â on the requested date of any Borrowing of Base Rate Committed Loans. Each telephonic notice by a Borrower pursuant to this Section 2.02(a) must be confirmed promptly by delivery to the Agent of a written Committed Loan Notice, appropriately completed and signed by a Responsible Officer of the applicable Borrower. Each Borrowing, conversion or continuation of Loans shall be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof. Except as provided in Section 2.03(c), each Committed Loan Notice (whether telephonic or written) shall specify (i)Â whether the applicable Borrower is requesting a Borrowing, a conversion of Committed Loans from one Type to the other, or a continuation of Eurocurrency Rate Loans, (ii)Â the identity of the Borrower and the requested date of the Borrowing, conversion or continuation, as the case may be (which shall be a Business Day), (iii)Â the principal amount of Committed Loans to be borrowed, converted or continued, (iv)Â the Type of Committed Loans to be borrowed or to which existing Committed Loans are to be converted, (v)Â if applicable, the duration of the Interest Period with respect thereto and (vi)Â the requested currency of such Borrowing. If the applicable Borrower fails to specify a currency in a Committed Loan Notice requesting a Borrowing, then the Committed Loan so requested shall be made in Dollars. If the Borrower fails to specify a Type of Committed Loan in a Committed Loan Notice or if the Borrower fails to give a timely notice requesting a conversion or continuation, then the applicable Committed Loans shall be made as, or converted to, Base Rate Loans; provided, however, that in the case of a failure to timely request a continuation of Committed Loans denominated in an Alternative Currency, such Loans shall be continued as Eurocurrency Rate Loans in their original currency with an Interest Period of one month. Any such automatic conversion to Base Rate Loans shall be effective as of the last day of the Interest Period then in effect with respect to the applicable Eurocurrency Rate Loans. If the Borrower requests a Borrowing of, conversion to, or continuation of Eurocurrency Rate Loans in any such Committed Loan Notice, but fails to specify an Interest Period, they will be deemed to have specified an Interest Period of one month. No Committed Loan may be converted to or continued as Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â a Loan denominated in a different currency but instead must be prepaid in the original currency of such Committed Loan and reborrowed in the other currency. 2.2.1.2.Following receipt of a Committed Loan Notice, the Administrative Agent shall promptly notify each Lender of the amount (and currency) of its Pro Rata Share of the applicable Loans, and if no timely notice of a conversion or continuation is provided by the applicable Borrower, the Administrative Agent shall notify each Lender of the details of any automatic conversion to Base Rate Loans, or continuation of Committed Loans denominated in an Alternative Currency, in each case described in Section 2.02(a). In the case of a Borrowing, each Lender shall make the amount of its Loan available to the Administrative Agent in Same Day Funds at the Administrative Agentâ€™s Office not later than 1:00 p.m. in the case of any Committed Loan denominated in Dollars, and not later than the Applicable Time specified by the Administrative Agent in the case of any Committed Loan in an Alternative Currency, in each case on the Business Day specified in the applicable Committed Loan Notice. Upon satisfaction of the applicable conditions set forth in Section 4.03 (and, if such Borrowing is the initial Credit Extension, Section 4.01), the Agent shall make all funds so received available to the applicable Borrower in like funds as received by the Agent either by (i)Â crediting the account of the such Borrower on the books of Bank of America with the amount of such funds or (ii)Â wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Agent by the applicable Borrower; provided, however, that if, on the date the Committed Loan Notice with respect to such Borrowing is given by a Borrower, there are unpaid amounts due in respect of L/C Borrowings outstanding, then the proceeds of such Borrowing shall be applied, first to the payment in full of any such unpaid amounts and L/C Borrowings, and second, to the applicable Borrower as provided above.2.2.1.3.Except as otherwise provided herein, a Eurocurrency Rate Loan may be continued or converted only on the last day of an Interest Period for such Eurocurrency Rate Loan. During the existence of a Default, no Loans may be requested as, converted to or continued as Eurocurrency Rate Loans (whether in Dollars or any Alternative Currency) without the consent of the Required Lenders, and the Required Lenders may demand that any or all of the then outstanding Eurocurrency Rate Loans denominated in an Alternative Currency be prepaid, or redenominated into Dollars in the amount of the Dollar Equivalent thereof, on the last day of the then current Interest Period with respect thereto.2.2.1.4.The Administrative Agent shall promptly notify the Borrowers and the Lenders of the interest rate applicable to any Interest Period for Eurocurrency Rate Loans upon determination of such interest rate. The determination of the Eurocurrency Rate by the Administrative Agent shall be conclusive in the absence of manifest error. At any time that Base Rate Loans are outstanding, the Administrative Agent shall notify the Borrowers and the Lenders of any change in Bank of Americaâ€™s prime rate used in determining the Base Rate promptly following the public announcement of such change. 2.2.1.5.After giving effect to all Borrowings, all conversions of Committed Loans from one Type to the other, and all continuations of Committed Loans as the same Type, there shall not be more than ten Interest Periods in effect at any time with respect to Committed Loans.2.3.Letters of Credit.2.3.1.1.The Letter of Credit Commitment.2.3.1.1.1.Subject to the terms and conditions set forth herein, (A)Â each L/C Issuer agrees, in reliance upon the agreements of the Lenders set forth in this Section 2.03, (1)Â from time to time on any Business Day during the period from the date hereof until the Letter of Credit Expiration Date, to issue Letters of Credit denominated in Dollars or one or more Alternative Currencies for the account of the Borrowers or certain Subsidiaries, and to amend or extend Letters of Credit previously issued by it, in accordance with Section 2.03(b), and (2)Â to honor drafts under the Letters of Credit; and (B)Â the Lenders severally agree to participate in Letters of Credit issued for the account of the Borrowers; provided that after giving effect to any L/C Credit Extension with respect to any Letter of Credit (i)Â the Total Outstandings shall not exceed the Aggregate Commitments, (ii) the Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Total Outstandings denominated in Alternative Currencies shall not exceed the Alternative Currency Sublimit, (iii)Â the Revolving Credit Exposure of any Lender shall not exceed such Lenderâ€™s Commitment, (iv)Â the Outstanding Amount of the L/C Obligations shall not exceed the Letter of Credit Sublimit, (v) with respect to the applicable L/C Issuer, the stated amount of all outstanding Letters of Credit issued by such L/C Issuer shall not exceed the applicable Specified L/C Sublimit of such L/C Issuer then in effect and (vi) in the case of the Lender acting as the L/C Issuer with respect to such Letter of Credit (whether directly or through an Affiliate), unless such Lender shall agree otherwise in its sole discretion, such Lenderâ€™s Revolving Credit Exposure plus (without duplication) the aggregate face amount of outstanding Letters of Credit issued by such L/C Issuer shall not exceed such Lenderâ€™s Commitment. Within the foregoing limits, and subject to the terms and conditions hereof, each Borrowerâ€™s ability to obtain Letters of Credit shall be fully revolving, and accordingly each Borrower may, during the foregoing period, obtain Letters of Credit to replace Letters of Credit that have expired or that have been drawn upon and reimbursed.2.3.1.1.2.An L/C Issuer shall be under no obligation to issue any Letter of Credit if:2.3.1.1.2.1.any order, judgment or decree of any Governmental Authority or arbitrator shall by its terms purport to enjoin or restrain such L/C Issuer from issuing such Letter of Credit, or any Law applicable to such L/C Issuer or any request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over such L/C Issuer shall prohibit, or request that such L/C Issuer refrain from, the issuance of letters of credit generally or such Letter of Credit in particular or shall impose upon such L/C Issuer with respect to such Letter of Credit any restriction, reserve or capital requirement (for which such L/C Issuer is not otherwise compensated hereunder) not in effect on the date hereof, or shall impose upon such L/C Issuer any unreimbursed loss, cost or expense which was not applicable on the date hereof and which such L/C Issuer in good faith deems material to it;2.3.1.1.2.2.the issuance of such Letter of Credit would violate one or more policies of such L/C Issuer applicable to letters of credit and letter of credit applicants generally;2.3.1.1.2.3.subject to Section 2.03(b)(iii), the expiry date of such requested Letter of Credit would occur more than twelve months after the date of issuance or last extension, unless the Required Lenders have approved such expiry date;2.3.1.1.2.4.the expiry date of such requested Letter of Credit would occur after the Letter of Credit Expiration Date, unless arrangements have been made to cash collateralize such Letter of Credit on or before such Letter of Credit Expiration Date or all the Lenders have approved such expiry date;2.3.1.1.2.5.such Letter of Credit is in an initial amount less than $100,000, in the case of a commercial Letter of Credit, or $500,000, in the case of a standby Letter of Credit, or is to be denominated in a currency other than Dollars or an Alternative Currency; provided that the $500,000 minimum amount relating to a standby Letter of Credit shall not be applicable if the applicable Borrower pays to such L/C Issuer in respect of such Letter of Credit an additional issuance fee in an amount to be agreed between such Borrower and such L/C Issuer from time to time; or2.3.1.1.2.6.a default of any Lenderâ€™s obligations to fund under Section 2.03(c) exists or any Lender is at such time a Defaulting Lender hereunder, unless (i)Â the applicable Borrower shall have Cash Collateralized an amount equal to such Lenderâ€™s Pro Rata Share of the full amount of such Letter of Credit, provided that the Cash Collateral in respect of such Lenderâ€™s Pro Rata Share shall be released to such Borrower promptly upon request after the effective date of the replacement of such Lender in accordance with Section 11.15, or (ii)Â such L/C Issuer has otherwise entered into satisfactory arrangements with such Borrower or such Lender to eliminate such L/C Issuerâ€™s actual or potential Fronting Exposure.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 2.3.1.1.3.An L/C Issuer shall be under no obligation to amend any Letter of Credit if (A)Â such L/C Issuer would have no obligation at such time to issue such Letter of Credit in its amended form under the terms hereof, or (B)Â the Beneficiary of such Letter of Credit does not accept the proposed amendment to such Letter of Credit.2.3.1.1.4.On and after the date hereof, the Existing Letters of Credit shall be deemed for all purposes, including for purposes of the fees and charges to be collected pursuant to this Section 2.03 for periods on and after the date hereof, and reimbursement of costs and expenses to the extent provided herein, to be Letters of Credit outstanding under this Agreement and entitled to the benefits of this Agreement and the other Loan Documents, and shall be governed by the applications and agreements pertaining thereto and by this Agreement; provided, however, that, notwithstanding any other provision of this Agreement, no fees with respect to the initial issuance of the Existing Letters of Credit shall be due hereunder.2.3.1.2.Procedures for Issuance and Amendment of Letters of Credit; Auto-Extension Letters of Credit.2.3.1.2.1.Each Letter of Credit shall be issued or amended, as the case may be, upon the request of the applicable Borrower delivered to the L/C Issuer (with a copy to the Administrative Agent) in the form of a Letter of Credit Application, appropriately completed and signed by a Responsible Officer of such Borrower. Such Letter of Credit Application must be received by the L/C Issuer and the Administrative Agent not later than 11:00 a.m. at least three Business Days (or such later date and time as the Administrative Agent and the L/C Issuer may agree in a particular instance in their sole discretion) prior to the proposed issuance date or date of amendment, as the case may be. In the case of a request for an initial issuance of a Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L/C Issuer: (A)Â the proposed issuance date of the requested Letter of Credit (which shall be a Business Day); (B)Â the amount thereof; (C)Â the expiry date thereof; (D)Â the name and address of the Beneficiary thereof; (E)Â the documents to be presented by such Beneficiary in case of any drawing thereunder; (F)Â the full text of any certificate to be presented by such Beneficiary in case of any drawing thereunder; (G)Â the purpose and nature of the requested Letter of Credit; (H) the proposed currency and (I)Â such other matters as the L/C Issuer may require. In the case of a request for an amendment of any outstanding Letter of Credit, such Letter of Credit Application shall specify in form and detail satisfactory to the L/C Issuer (A)Â the Letter of Credit to be amended; (B)Â the proposed date of amendment thereof (which shall be a Business Day); (C)Â the nature of the proposed amendment; and (D)Â such other matters as the L/C Issuer may require. Additionally, the applicable Borrower shall furnish to the L/C Issuer and the Administrative Agent such other documents and information pertaining to such requested Letter of Credit issuance or amendment, including any Issuer Documents, as the L/C Issuer or the Administrative Agent may require.2.3.1.2.2.Promptly after receipt of any Letter of Credit Application, the L/C Issuer will confirm with the Administrative Agent (by telephone or in writing) that the Administrative Agent has received a copy of such Letter of Credit Application from the applicable Borrower and, if not, the L/C Issuer will provide the Administrative Agent with a copy thereof. Unless the L/C Issuer has received written notice from any Lender, the Administrative Agent or any Loan Party, at least one Business Day prior to the requested date of issuance or amendment of the applicable Letter of Credit, that one or more applicable conditions contained in ARTICLE IV shall not then be satisfied, then, subject to the terms and conditions hereof, the L/C Issuer shall, on the requested date, issue a Letter of Credit for the account of the applicable Borrower (or the applicable Subsidiary) or enter into the applicable amendment, as the case may be, in each case in accordance with the L/C Issuerâ€™s usual and customary business practices. Immediately upon the issuance of each Letter of Credit, each Lender shall be deemed to, and hereby irrevocably and unconditionally agrees to, purchase from the L/C Issuer a risk participation in such Letter of Credit in an amount equal to the product of such Lenderâ€™s Pro Rata Share times the amount of such Letter of Credit.2.3.1.2.3.If the applicable Borrower so requests in any applicable Letter of Credit Application, the L/C Issuer shall issue a Letter of Credit that has automatic extension provisions (each, an â€œAuto-Extension Letter of Creditâ€); provided that any such Auto-Extension Letter of Credit must permit the L/C Issuer to prevent any such extension at least once in each twelve-month period (commencing with the date of issuance of Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â such Letter of Credit) by giving prior notice to the Beneficiary thereof not later than a day (the â€œNon-Extension Notice Dateâ€) in each such twelve-month period to be agreed upon at the time such Letter of Credit is issued; provided, further that the L/C issuer shall not exercise its right to prevent any such renewal unless the L/C Issuer determines that it would have no obligation at such time to issue such Letter of Credit in its renewed form under the terms of this Agreement. Unless otherwise directed by the L/C Issuer, the applicable Borrower shall not be required to make a specific request to the L/C Issuer for any such extension. Once an Auto-Extension Letter of Credit has been issued, the Lenders shall be deemed to have authorized (but may not require) the L/C Issuer to permit the extension of such Letter of Credit at any time to an expiry date not later than the Letter of Credit Expiration Date; provided, however, that the L/C Issuer shall not permit any such extension if (A)Â the L/C Issuer has determined that it would not be permitted, or would have no obligation, at such time to issue such Letter of Credit in its revised form (as extended) under the terms hereof (by reason of the provisions of clause (ii)Â of Section 2.03(a) or otherwise), or (B)Â it has received notice (which may be by telephone or in writing) on or before the day that is seven Business Days before the Non-Extension Notice Date (1)Â from the Administrative Agent that the Required Lenders have elected not to permit such extension or (2)Â from the Administrative Agent, any Lender or the applicable Borrower that one or more of the applicable conditions specified in Section 4.03 is not then satisfied, and in each such case directing the L/C Issuer not to permit such extension.2.3.1.2.4.Promptly after its delivery of any Letter of Credit or any amendment to a Letter of Credit to an advising bank with respect thereto or to the Beneficiary thereof, the L/C Issuer will also deliver to the applicable Borrower and the Administrative Agent a true and complete copy of such Letter of Credit or amendment.2.3.1.3.Drawings and Reimbursements; Funding of Participations.2.3.1.3.1.Upon receipt from the Beneficiary of any Letter of Credit of any notice of a drawing under such Letter of Credit, the L/C Issuer shall notify the applicable Borrower and the Administrative Agent thereof; provided that any failure to give or delay in giving such notice shall not relieve the applicable Borrower of its obligation to reimburse such L/C Issuer with respect to any such disbursement. In the case of a Letter of Credit denominated in an Alternative Currency, the applicable Borrower shall reimburse the L/C Issuer in such Alternative Currency, unless (A)Â the L/C Issuer (at its option) shall have specified in such notice that it will require reimbursement in Dollars, or (B)Â in the absence of any such requirement for reimbursement in Dollars, the applicable Borrower shall have notified the L/C Issuer promptly following receipt of the notice of drawing that applicable Borrower will reimburse the L/C Issuer in Dollars. In the case of any such reimbursement in Dollars of a drawing under a Letter of Credit denominated in an Alternative Currency, the L/C Issuer shall notify the applicable Borrower of the Dollar Equivalent of the amount of the drawing promptly following the determination thereof. Not later than 12:00 noon Local Time on the Business Day following the date of any payment by the L/C Issuer under a Letter of Credit to be reimbursed in Dollars, or the Applicable Time (to be specified by the L/C Issuer to the applicable Borrower prior to such date of payment) on the date of any payment by the L/C Issuer under a Letter of Credit to be reimbursed in an Alternative Currency (each such date, an â€œHonor Dateâ€), such Borrower shall reimburse the L/C Issuer through the Administrative Agent in an amount equal to the amount of such drawing. In the event that (A) a drawing denominated in an Alternative Currency is to be reimbursed in Dollars pursuant to the second sentence in this Section 2.03(c)(i) and (B) the Dollar amount paid by the applicable Borrower, whether on or after the Honor Date, shall not be adequate on the date of that payment to purchase in accordance with normal banking procedures a sum denominated in the Alternative Currency equal to the drawing, the applicable Borrower agrees, as a separate and independent obligation, to indemnify the L/C Issuer for the loss resulting from its inability on that date to purchase the Alternative Currency in the full amount of the drawing. If the applicable Borrower fails to so reimburse the L/C Issuer by such time, the Administrative Agent shall promptly notify each Lender of the Honor Date, the amount of the unreimbursed drawing (expressed in Dollars in the amount of the Dollar Equivalent thereof in the case of a Letter of Credit denominated

in an Alternative Currency) (the â€œUnreimbursed Amountâ€), and the amount of such Lenderâ€™s Pro Rata Share thereof. In such event, the applicable Borrower shall be deemed to have requested a Borrowing of Base Rate Loans to be disbursed on the Honor Date in an amount equal to the Unreimbursed Amount, without regard to the minimum and multiples specified in Section 2.02 for the principal amount of Base Rate Loans, but subject to the amount of Â Â Â Â 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â the unutilized portion of the Aggregate Commitments and the conditions set forth in Section 4.03 (other than the delivery of a Committed Loan Notice). Any notice given by the L/C Issuer or the Administrative Agent pursuant to this Section 2.03(c)(i) may be given by telephone if immediately confirmed in writing; provided that the lack of such an immediate confirmation shall not affect the conclusiveness or binding effect of such notice.2.3.1.3.2.Each Lender shall upon any notice pursuant to Section 2.03(c)(i) make funds available to the Administrative Agent for the account of the L/C Issuer at the Administrative Agentâ€™s Office for Dollar denominated payments in an amount equal to its Pro Rata Share of the Unreimbursed Amount not later than 1:00 p.m. Local Time on the Business Day specified in such notice by the Administrative Agent, whereupon, subject to the provisions of Section 2.03(c)(iii), each Lender that so makes funds available shall be deemed to have made a Base Rate Committed Loan to the applicable Borrower in such amount. The Administrative Agent shall remit the funds so received to the L/C Issuer in Dollars.2.3.1.3.3.With respect to any Unreimbursed Amount that is not fully refinanced by a Borrowing of Base Rate Loans because the conditions set forth in Section 4.03 cannot be satisfied or for any other reason, the applicable Borrower shall be deemed to have incurred from the L/C Issuer an L/C Borrowing in the amount of the Unreimbursed Amount that is not so refinanced, which L/C Borrowing shall be due and payable on demand (together with interest) and shall bear interest at the Default Rate. In such event, each Lenderâ€™s payment to the Administrative Agent for the account of the L/C Issuer pursuant to Section 2.03(c)(ii) shall be deemed payment in respect of its participation in such L/C Borrowing and shall constitute an L/C Advance from such Lender in satisfaction of its participation obligation under this Section 2.03.2.3.1.3.4.Until each Lender funds its Committed Loan or L/C Advance pursuant to this Section 2.03(c) to reimburse the L/C Issuer for any amount drawn under any Letter of Credit, interest in respect of such Lenderâ€™s Pro Rata Share of such amount shall be solely for the account of the L/C Issuer.2.3.1.3.5.Each Lenderâ€™s obligation to make Committed Loans or L/C Advances to reimburse the L/C Issuer for amounts drawn under Letters of Credit, as contemplated by this 2.03(c), shall be absolute and unconditional and shall not be affected by any circumstance, including (A)Â any setoff, counterclaim, recoupment, defense or other right which such Lender may have against the L/C Issuer, the applicable Borrower or any other Person for any reason whatsoever; (B)Â the occurrence or continuance of a Default, or (C)Â any other occurrence, event or condition, whether or not similar to any of the foregoing; provided, however, that each Lenderâ€™s obligation to make Committed Loans pursuant to this Section 2.03(c) is subject to the conditions set forth in Section 4.03 (other than delivery by the applicable Borrower of a Committed Loan Notice). No such making of an L/C Advance shall relieve or otherwise impair the obligation of the applicable Borrower to reimburse the L/C Issuer for the amount of any payment made by the L/C Issuer under any Letter of Credit, together with interest as provided herein.2.3.1.3.6.If any Lender fails to make available to the Administrative Agent for the account of the L/C Issuer any amount required to be paid by such Lender pursuant to the foregoing provisions of this Section 2.03(c) by the time specified in Section 2.03(c)(ii), the L/C Issuer shall be entitled to recover from such Lender (acting through the Administrative Agent), on demand, such amount with interest thereon for the period from the date such payment is required to the date on which such payment is immediately available to the L/C Issuer at a rate per annum equal to the applicable Overnight Rate from time to time in effect, plus any administrative, processing or similar fees customarily charged by the L/C Issuer in connection with the foregoing. A certificate of the L/C Issuer submitted to any Lender (through the Administrative Agent) with respect to any amounts owing under this clause (vi)Â shall be conclusive absent manifest error.2.3.1.4.Repayment of Participations.2.3.1.4.1.At any time after the L/C Issuer has made a payment under any Letter of Credit and has received from any Lender such Lenderâ€™s L/C Advance in respect of such payment in accordance with Section 2.03(c), if the Administrative Agent receives for the account of the L/C Issuer any payment in respect of Â Â Â Â 4Â Â Â Â Â Â Â Â Â Â Â Â Â Â the related Unreimbursed Amount or interest thereon (whether directly from the applicable Borrower or otherwise, including proceeds of Cash Collateral applied thereto by the Administrative Agent), the Administrative Agent will distribute to such Lender its Pro Rata Share thereof (appropriately adjusted, in the case of interest payments, to reflect the period of time during which such Lenderâ€™s L/C Advance was outstanding) in Dollars and in the same funds as those received by the Administrative Agent.2.3.1.4.2.If any payment received by the Administrative Agent for the account of the L/C Issuer pursuant to Section 2.03(c)(i) is required to be returned under any of the circumstances described in Section 11.05 (including pursuant to any settlement entered into by the L/C Issuer in its discretion), each Lender shall pay to the Administrative Agent for the account of the L/C Issuer its Pro Rata Share thereof on demand of the Administrative Agent, plus interest thereon from the date of such demand to the date such amount is returned by such Lender, at a rate per annum equal to the applicable Overnight Rate from time to time in effect. The obligations of the Lenders under this clause shall survive the payment in full of the Obligations and the termination of this Agreement.2.3.1.5.Obligations Absolute. The obligation of the applicable Borrower to reimburse the L/C Issuer for each drawing under each Letter of Credit and to repay each L/C Borrowing shall be absolute, unconditional and irrevocable, and shall be paid strictly in accordance with the terms of this Agreement under all circumstances, including the following:2.3.1.5.1.any lack of validity or enforceability of such Letter of Credit, this Agreement, or any other Loan Document;2.3.1.5.2.the existence of any claim, counterclaim, setoff, defense or other right that the applicable Borrower or any Subsidiary may have at any time against any Beneficiary or any transferee of such Letter of Credit (or any Person for whom any such Beneficiary or any such transferee may be acting), the L/C Issuer or any other Person, whether in connection with this Agreement, the transactions contemplated hereby or by such Letter of Credit or any agreement or instrument relating thereto, or any unrelated transaction;2.3.1.5.3.any draft, demand, certificate or other document presented under such Letter of Credit proving to be forged, fraudulent, invalid or insufficient in any respect or any statement therein being untrue or inaccurate in any respect; or any loss or delay in the transmission or otherwise of any document required in order to make a drawing under such Letter of Credit;2.3.1.5.4.any payment by the L/C Issuer under such Letter of Credit against presentation of a draft or certificate that does not strictly comply with the terms of such Letter of Credit; or any payment made by the L/C Issuer under such Letter of Credit to any Person purporting to be a trustee in bankruptcy, debtor-in-possession, assignee for the benefit of creditors, liquidator, receiver or other representative of or successor to any Beneficiary or any transferee of such Letter of Credit, including any arising in connection with any proceeding under any Debtor Relief Law;2.3.1.5.5. any adverse change in the relevant exchange rates or in the availability of the relevant Alternative Currency to the Company or any Subsidiary or in the relevant currency markets generally; or2.3.1.5.6.any other circumstance or happening whatsoever, whether or not similar to any of the foregoing, including any other circumstance that might otherwise constitute a defense available to, or a discharge of, the applicable Borrower or any Subsidiary.The applicable Borrower shall promptly examine a copy of each Letter of Credit and each amendment thereto that is delivered to it and, in the event of any claim of noncompliance with the Companyâ€™s instructions or other irregularity, the Company will immediately notify the L/C Issuer. Each Borrower shall be conclusively deemed to have waived any such claim against the L/C Issuer and its correspondents unless such notice is given as aforesaid.Â Â Â Â 5Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2.3.1.6.Role of L/C Issuer. Each Lender and each Borrower agrees that, in paying any drawing under a Letter of Credit, the L/C Issuer shall not have any responsibility to obtain any document (other than any sight draft, certificates and documents expressly required by the Letter of Credit) or to ascertain or inquire as to the validity or accuracy of any such document or the authority of the Person executing or delivering any such document. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable to any Lender for (i)Â any action taken or omitted in connection herewith at the request or with the approval of the Lenders or the Required Lenders, as applicable; (ii)Â any action taken or omitted in the absence of gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment; or (iii)Â the due execution, effectiveness, validity or enforceability of any document or instrument related to any Letter of Credit or Issuer Document. Each Borrower hereby assumes all risks of the acts or omissions of any Beneficiary or transferee with respect to its use of any Letter of Credit; provided, however, that this assumption is not intended to, and shall not, preclude the applicable Borrowerâ€™s pursuing such rights and remedies as it may have against the Beneficiary or transferee at law or under any other agreement. None of the L/C Issuer, the Administrative Agent, any of their respective Related Parties nor any correspondent, participant or assignee of the L/C Issuer shall be liable or responsible for any of the matters described in clauses (i)Â through (vi)Â of Section 2.03(e); provided, however, that anything in such clauses to the contrary notwithstanding, the applicable Borrower may have a claim against the L/C Issuer, and the L/C Issuer may be liable to such Borrower, to the extent, but only to the extent, of any direct, as opposed to consequential or exemplary, damages suffered by such Borrower which such Borrower proves were caused by, as determined by a court of competent jurisdiction by final and nonappealable judgment, the L/C Issuerâ€™s willful misconduct or gross negligence or the L/C Issuerâ€™s willful failure to pay under any Letter of Credit after the presentation to it by the Beneficiary of a sight draft and certificate(s) strictly complying with the terms and conditions of a Letter of Credit. In furtherance and not in limitation of the foregoing, the L/C Issuer may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary, and the L/C Issuer shall not be responsible for the validity or sufficiency of any instrument transferring or assigning or purporting to transfer or assign a Letter of Credit or the rights or benefits thereunder or proceeds thereof, in whole or in part, which may prove to be invalid or ineffective for any reason.2.3.1.7.Cash Collateral. Upon the request of the Administrative Agent, (i)Â if the L/C Issuer has honored any full or partial drawing request under any Letter of Credit and such drawing has resulted in an L/C Borrowing or (ii)Â if, as of the Letter of Credit Expiration Date, any L/C Obligation for any reason remains outstanding, the applicable Borrowers shall, in each case, immediately Cash Collateralize the then Outstanding Amount of all L/C Obligations. Sections 2.03(a)(ii)(F), 2.05, 2.18(a)(v) and 8.02(c) set forth certain additional requirements to deliver Cash Collateral hereunder. For purposes of this Sections 2.03, 2.05, 2.18(a)(v) and Section 8.02(c), â€œCash Collateralizeâ€ means to pledge and deposit with or deliver to the Administrative Agent, for the benefit of the L/C Issuer and the Lenders, as collateral for the L/C Obligations, as applicable, cash or deposit account balances pursuant to documentation in form and substance satisfactory to the Administrative Agent and the L/C Issuer (which documents are hereby consented to by the Lenders). Derivatives of such term have corresponding meanings. Each Borrower hereby grants to the Administrative Agent for the benefit of the L/C Issuer and the Lenders, a security interest in all such cash, deposit accounts and all balances therein and all proceeds of the foregoing. Cash Collateral shall be maintained in blocked, non-interest bearing deposit accounts at Bank of America. For purposes of this Section 2.03, â€œCash Collateralâ€ means the cash and deposit account balances pledged and deposited with or delivered to the Agent, pursuant to a requirement to Cash Collateralize the L/C Obligations. Additionally, if the Administrative Agent notifies the Company at any time that the Outstanding Amount of all L/C Obligations at such time exceeds the Letter of Credit Sublimit then in effect, then, within two Business Days after receipt of such notice, the Company shall provide Cash Collateral for the Outstanding Amount of the L/C Obligations in an amount not less than the amount by which the Outstanding Amount of all L/C Obligations exceeds the Letter of Credit Sublimit.2.3.1.8.Applicability of ISP and UCP. Unless otherwise expressly agreed by the L/C Issuer and the applicable Borrower when a Letter of Credit is issued (including any such agreement applicable to an Existing Letter of Credit), (i)Â the rules of the ISP, with the exception of Rule 5.09 thereof, shall apply to each standby Letter of Credit, and (ii)Â the rules of the Uniform Customs and Practice for Documentary Credits, as most recently published by the International Chamber of Commerce at the time of issuance shall apply to each commercial Letter of Credit.Â Â Â Â 6Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2.3.1.9.Letter of Credit Fees. The applicable Borrower shall pay to the Administrative Agent for the account of each Lender in accordance with its Pro Rata Share a letter of credit fee for each Letter of Credit equal to the Applicable Rate times the daily maximum amount available to be drawn under such Letter of Credit (whether or not such maximum amount is then in effect under such Letter of Credit). Such letter of credit fees shall be computed on a quarterly basis in arrears. Such letter of credit fees shall be due and payable on the tenth calendar day following the end of each calendar quarter, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand. If there is any change in the Applicable Rate during any quarter, the daily maximum amount of each Letter of Credit shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.2.3.1.10.Fronting Fee and Documentary and Processing Charges Payable to L/C Issuer. The applicable Borrower shall pay directly to the L/C Issuer for its own account a fronting fee with respect to each Letter of Credit in an amount equal to 0.125 % per annum times the daily maximum amount available to be drawn under such Letter of Credit. Such fronting fees shall be computed on a quarterly basis in arrears. Such fronting fees shall be due and payable on the first Business Day after the end of each calendar quarter, commencing with the first such date to occur after the issuance of such Letter of Credit, on the Letter of Credit Expiration Date and thereafter on demand. For purposes of computing the daily amount available to be drawn under any Letter of Credit, the amount of such Letter of Credit shall be determined in accordance with Section 1.07. In addition, the applicable Borrower shall pay directly to the L/C Issuer for its own account the customary issuance, presentation, amendment and other processing fees, and other standard costs and charges (including reasonable out-of-pocket expenses relating to issuances, amendments, renewals, extensions and any demands for payment), of the L/C Issuer relating to letters of credit as from time to time in effect. Such customary fees and standard costs and charges are due and payable on demand and are nonrefundable.2.3.1.11.Conflict with Issuer Document. In the event of any conflict between the terms hereof and the terms of any Issuer Document, the terms hereof shall control.2.3.1.12.Letters of Credit Issued for Subsidiaries. Notwithstanding that a Letter of Credit issued or outstanding hereunder is in support of any obligations of, or is for the account of, a Subsidiary, the applicable Borrower shall be obligated to reimburse the L/C Issuer hereunder for any and all drawings under such Letter of Credit and to make any Cash Collateral deposits required hereunder. The Company hereby acknowledges that the issuance of Letters of Credit for the account of Subsidiaries inures to the benefit of the Company, and that the Companyâ€™s business derives substantial benefits from the businesses of such Subsidiaries.2.3.1.13.Reports to Administrative Agent. The L/C Issuer shall deliver to the Administrative Agent, upon each calendar month end, a report setting forth for such period the daily aggregate amount available to be drawn under the Letters of Credit that were outstanding during such month.2.3.1.14.Designation of L/C Issuer. The Company may, at any time and from time to time, upon notice to the Administrative Agent, designate as an L/C Issuer one or more Lenders that agree to serve in such capacity as provided below. The acceptance by a Lender of an appointment as an L/C Issuer hereunder shall be evidenced by an agreement, which shall be in form and substance reasonably satisfactory to such L/C Issuer, executed by each Borrower, the Administrative Agent and such designated Lender and, from and after the effective date of such agreement, as the case may be, (x) such Lender shall have all the rights and obligations of an L/C Issuer under this Agreement and (y) references herein to the term â€œL/C Issuerâ€ shall be deemed to include such Lender in its capacity as an issuer of Letters of Credit hereunder.2.3.1.15.Letter of Credit Reports. On (i) the last Business Day of each calendar month, and (ii) each date that an L/C Credit Extension occurs with respect to any Letter of Credit, the L/C Issuer shall deliver to the Administrative Agent a written report in the form of Exhibit K hereto, appropriately completed with the information for every Letter of Credit issued by the L/C Issuer that is outstanding hereunder.Â Â Â Â 7Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2.3.1.16.Replacement of an L/C Issuer. An L/C Issuer may be replaced at any time by written agreement among the Company, the Administrative Agent, the replaced L/C Issuer and the successor L/C Issuer. The Administrative Agent shall notify the Lenders of any such replacement of an L/C Issuer. From and after the effective date of any such replacement, (x) the successor L/C Issuer shall have all the rights and obligations of the L/C Issuer being replaced under this Agreement with respect to Letters of Credit to be issued thereafter and (y) references herein to the term â€œL/C Issuerâ€ shall be deemed to refer to such successor or to any previous L/C Issuer, or to such successor and all current and previous L/C Issuers, as the context shall require. After the replacement of an L/C Issuer hereunder, the replaced L/C Issuer shall remain a party hereto and shall continue to have all the rights and obligations of an L/C Issuer under this Agreement with respect to Letters of Credit issued by it prior to such replacement, but shall not be required to issue additional Letters of Credit.2.3.1.17.Resignation of an L/C Issuer. Notwithstanding anything to the contrary contained herein, any L/C Issuer may, upon 30 daysâ€™ notice to the Administrative Agent, the Company and the Lenders, resign as an L/C Issuer. In the event of any such resignation as an L/C Issuer, the Company shall be entitled to appoint from among the Lenders a successor L/C Issuer willing to accept its appointment as successor L/C Issuer hereunder; provided, that no failure by the Company to appoint any such successor shall affect the resignation of the applicable L/C Issuer as an L/C Issuer. If the applicable L/C Issuer resigns as an L/C Issuer, it shall retain all the rights, powers, privileges and duties of an L/C Issuer hereunder with respect to all Letters of Credit issued by it and outstanding as of the effective date of its resignation as an L/C Issuer and all L/C Obligations with respect thereto (including the right to require the Lenders to make Base Rate Committed Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.03(c)). Upon the appointment of a successor L/C Issuer, (x) such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the resigning L/C Issuer and (y) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to the applicable resigning L/C Issuer to effectively assume the obligations of the applicable resigning L/C Issuer with respect to such Letters of Credit.2.4.[Reserved]. 2.5.Prepayments. 2.5.1.1.Any Borrower may, upon notice (in a form acceptable by the Administrative Agent) to the Agent, at any time or from time to time voluntarily prepay Committed Loans, as the case may

be, in whole or in part without premium or penalty; provided that (i)Â such notice must be received by the Agent not later than 9:00 a.m., in the case of a prepayment of Loans, (A)Â three Business Days prior to any date of prepayment of Eurocurrency Rate Loans denominated in Dollars, (B)Â four Business Days prior to any date of prepayment of Eurocurrency Rate Loans denominated in Alternative Currencies and (C)Â on the date of prepayment of Base Rate Committed Loans; and (ii)Â any prepayment of Committed Loans shall be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof or, if less, the entire principal amount thereof then outstanding. Each such notice shall specify the date and amount of such prepayment and the Type(s) and currency of Committed Loans to be prepaid. The Agent will promptly notify each Lender of its receipt of each such notice, and of the amount of such Lenderâ€™s Pro Rata Share of such prepayment. If such notice is given by a Borrower, such Borrower shall make such prepayment and the payment amount specified in such notice shall be due and payable on the date specified therein. Any prepayment of a Eurocurrency Rate Loan shall be accompanied by all accrued interest thereon, together with any additional amounts required pursuant to Section 3.05. Each such prepayment shall be applied to the Committed Loans of the Lenders in accordance with their respective Pro Rata Shares.2.5.1.2.If for any reason (other than a change in exchange rates, in which case clause (d) shall apply) the Total Outstandings at any time exceed the Aggregate Commitments then in effect, the applicable Borrower shall immediately prepay Loans and/or Cash Collateralize the L/C Obligations in an aggregate amount equal to such excess; provided, however, that the Borrowers shall not be required to Cash Collateralize the L/C Obligations pursuant to this Section 2.05(b) unless after the prepayment in full of the Committed Loans the Total Outstandings exceed the Aggregate Commitments then in effect.Â Â Â Â 8Â Â Â Â Â Â Â Â Â Â Â Â Â 2.5.1.3.[Reserved].2.5.1.4.(i)Â Â Â Â If the Administrative Agent notifies the Company at any time that the Outstanding Amount of all Loans denominated in Alternative Currencies at such time exceeds the Alternative Currency Sublimit then in effect, then, within two Business Days after receipt of such notice, the Borrowers shall prepay Loans and/or Cash Collateralize L/C Obligations in an aggregate amount sufficient to reduce such Outstanding Amount as of such date of payment to an amount not to exceed the Alternative Currency Sublimit then in effect.Â Â Â Â (ii)Â Â Â Â If at any time, solely as a result of fluctuations in currency exchange rates, the sum of the aggregate principal amount of all of the Revolving Credit Exposures exceeds the Aggregate Commitments, the applicable Borrower shall (x) immediately repay Loans or (y) Cash Collateralize L/C Obligations in an account with the Administrative Agent pursuant to and within the time period required by Section 2.03(g), in the case of each of clauses (x) and (y) in an aggregate principal amount sufficient to cause the aggregate amount of all Revolving Credit Exposure to be less than or equal to the Aggregate Commitments.2.6.Termination or Reduction of Commitments. The Company may, upon notice to the Agent, terminate the Aggregate Commitments, or from time to time permanently reduce the Aggregate Commitments; provided that (i)Â any such notice shall be received by the Agent not later than 9:00 a.m. five Business Days prior to the date of termination or reduction, (ii)Â any such partial reduction shall be in an aggregate amount of $10,000,000 or any whole multiple of $1,000,000 in excess thereof, (iii)Â the Company shall not terminate or reduce the Aggregate Commitments if, after giving effect thereto and to any concurrent prepayments hereunder, the Total Outstandings would exceed the Aggregate Commitments, and (iv)Â if, after giving effect to any reduction of the Aggregate Commitments, the Alternative Currency Sublimit, the Letter of Credit Sublimit or the Foreign Designated Borrower Sublimit exceeds the amount of the Aggregate Commitments, such sublimit shall be automatically reduced by the amount of such excess. The Administrative Agent will promptly notify the Lenders of any such notice of termination or reduction of the Aggregate Commitments. Any reduction of the Aggregate Commitments shall be applied to the Commitment of each Lender, according to its Pro Rata Share. All facility fees accrued until the effective date of any termination of the Aggregate Commitments shall be paid on the effective date of such termination.2.7.Repayment of Loans. Each Borrower shall repay to the Lenders on the Maturity Date the aggregate principal amount of its Committed Loans outstanding on such date. 2.8.Interest.2.8.1.1.Subject to the provisions of Section 2.08(b), (i)Â each Eurocurrency Rate Committed Loan shall bear interest on the outstanding principal amount thereof for each Interest Period at a rate per annum equal to the Eurocurrency Rate for such Interest Period plus the Applicable Rate and (ii)Â each Base Rate Committed Loan shall bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate plus the Applicable Rate.2.8.1.2.If any amount payable by a Borrower under any Loan Document is not paid when due (without regard to any applicable grace periods), whether at stated maturity, by acceleration or otherwise, such amount shall, upon the request of the Required Lenders (provided no such request shall be required in the case of an Event of Default under Section 8.01(f)(iii) or 8.01(g)) thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. Furthermore, upon the request of the Required Lenders, while any Event of Default exists, the Borrowers shall pay interest on the principal amount of all outstanding Obligations hereunder at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by applicable Laws. Accrued and unpaid interest on past due amounts (including interest on past due interest) shall be due and payable upon demand.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 2.8.1.3.Interest on each Loan shall be due and payable in arrears on each Interest Payment Date applicable thereto and at such other times as may be specified herein. Interest hereunder shall be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding under any Debtor Relief Law.2.9.Fees. In addition to certain fees described in Sections 2.03(i) and 2.03(j):2.9.1.1.Facility Fee. The Company shall pay to the Administrative Agent for the account of each Lender in accordance with its Pro Rata Share, a facility fee payable in Dollars on the tenth calendar day following the end of each calendar quarter, which shall be equal to the Applicable Rate times the actual daily amount of the Aggregate Commitments (or, if the Aggregate Commitments have terminated, on the Outstanding Amount of all Committed Loans and L/C Obligations), regardless of usage. The facility fee shall accrue at all times during the Availability Period (and thereafter so long as any Committed Loans or L/C Obligations remain outstanding), including at any time during which one or more of the conditions in ARTICLE IV are not met, and shall be due and payable quarterly in arrears on each date specified above following the end of each calendar quarter, commencing with the first such date to occur after the date hereof, and on the last day of the Availability Period (and, if applicable, thereafter on demand). The facility fee shall be calculated on a calendar quarter basis in arrears, and if there is any change in the Applicable Rate during any quarter, the actual daily amount shall be computed and multiplied by the Applicable Rate separately for each period during such quarter that such Applicable Rate was in effect.2.9.1.2.Other Fees. (i) The Company shall pay to the Arrangers and the Administrative Agent for their own respective accounts fees in the amounts and at the times specified in the Fee Letter. Such fees shall be fully earned when paid and, except to the extent expressly otherwise agreed, shall not be refundable for any reason whatsoever.2.9.1.2.1.The Borrowers shall pay to the Lenders such fees as shall have been separately agreed upon in writing in the amounts and at the times so specified. Such fees shall be fully earned when paid and, except to the extent expressly otherwise agreed, shall not be refundable for any reason whatsoever.2.10.Computation of Interest and Fees. All computations of interest for Base Rate Loans when the Base Rate is determined by Bank of Americaâ€™s â€œprime rateâ€ shall be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All other computations of fees and interest shall be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year) or, in the case of interest in respect of other Loans denominated in Alternative Currencies as to which market practice differs from the foregoing, in accordance with such market practice. Interest shall accrue on each Loan for the day on which the Loan is made, and shall not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made shall, subject to Section 2.12(a), bear interest for one day. Each determination by the Administrative Agent of an interest rate or fee hereunder shall be conclusive and binding for all purposes, absent manifest error.2.11.Evidence of Debt.2.11.1.1.The Credit Extensions made by each Lender shall be evidenced by one or more accounts or records maintained by such Lender and by the Agent in the ordinary course of business. The accounts or records maintained by the Administrative Agent and each Lender shall be conclusive absent manifest error of the amount of the Credit Extensions made by the Lenders to the Borrowers and the interest and payments thereon. Any failure to so record or any error in doing so shall not, however, limit or otherwise affect the obligation of the Borrowers hereunder to pay any amount owing with respect to the Obligations. In the event of any conflict between the accounts and records maintained by any Lender and the accounts and records of the Agent in respect of such matters, the accounts and records of the Agent shall control in the absence of manifest error. Upon the request of any Lender made through the Agent, the applicable Borrower shall execute and deliver to such Lender (through the Agent) a Note, which shall evidence such Lenderâ€™s Loans in addition to such accounts or records. Each Lender may Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â attach Schedules to its Note and endorse thereon the date, Type (if applicable), amount, currency and maturity of its Loans and payments with respect thereto.2.11.1.2.In addition to the accounts and records referred to in Section 2.11(a), each Lender and the Administrative Agent shall maintain in accordance with its usual practice accounts or records evidencing the purchases and sales by such Lender of participations in Letters of Credit. In the event of any conflict between the accounts and records maintained by the Administrative Agent and the accounts and records of any Lender in respect of such matters, the accounts and records of the Administrative Agent shall control in the absence of manifest error.2.12.Payments Generally.2.12.1.1.All payments to be made by the Borrowers shall be made without condition or deduction for any counterclaim, defense, recoupment or setoff. Except as otherwise expressly provided herein and except with respect to principal of and interest on Loans denominated in an Alternative Currency, all payments by the Borrowers hereunder shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the applicable Administrative Agentâ€™s Office in Dollars and in Same Day Funds not later than 12:00 p.m. on the date specified herein. Except as otherwise expressly provided herein, all payments by the Borrowers hereunder with respect to principal and interest on Loans denominated in an Alternative Currency shall be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the applicable Administrative Agentâ€™s Office in such Alternative Currency and in Same Day Funds not later than the Applicable Time specified by the Administrative Agent on the dates specified herein. Without limiting the generality of the foregoing, the Administrative Agent may require that any payments due under this Agreement be made in the United States or such other address as the Administrative Agent specifies from time to time. If, for any reason, any Borrower is prohibited by any Law from making any required payment hereunder in an Alternative Currency, such Borrower shall make such payment in Dollars in the Dollar Equivalent amount of the Alternative Currency payment amount. The Agent will promptly distribute to each Lender its Pro Rata Share (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lenderâ€™s Lending Office. All payments received by an Agent after the applicable time specified in this Section 2.12(a) shall be deemed received on the next succeeding Business Day and any applicable interest or fee shall continue to accrue. If any payment to be made by a Borrower shall come due on a day other than a Business Day, payment shall be made on the next following Business Day, and such extension of time shall be reflected in computing interest or fees, as the case may be.2.12.1.2.(i) Unless the Agent shall have received notice from a Lender prior to (a) the proposed date of any Borrowing of Eurocurrency Rate Loans or (b) two hours prior to the proposed time of any Borrowing of Base Rate Loans that such Lender will not make available to the Agent such Lenderâ€™s share of such Borrowing, the Agent may assume that such Lender has made such share available on such date in accordance with Section 2.02 and may, in reliance upon such assumption, make available to the applicable Borrower a corresponding amount. In such event, if a Lender has not in fact made its share of the applicable Borrowing available to the Agent, then such Lender and the applicable Borrower severally agree to pay to the Agent forthwith on demand such corresponding amount in Same Day Funds with interest thereon, for each day from and including the date such amount is made available to the applicable Borrower to but excluding the date of payment to the Agent, at (A)Â in the case of a payment to be made by such Lender, a rate per annum equal to the applicable Overnight Rate from time to time in effect plus any administrative, processing or similar fees customarily charged by the Agent in connection with the foregoing, and (B)Â in the case of a payment to be made by any Borrower, the interest rate applicable to the applicable Borrowing. If the applicable Borrower and such Lender shall pay such interest to the Agent for the same or an overlapping period, the Agent shall promptly remit to the applicable Borrower the amount of such interest paid by the applicable Borrower for such period. If such Lender pays its share of the applicable Borrowing to the Agent, then the amount so paid shall constitute such Lenderâ€™s Committed Loan included in such Borrowing. Any payment by the applicable Borrower shall be without prejudice to any claim the applicable Borrower may have against a Lender that shall have failed to make such payment to the Agent.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 2.12.1.2.1.Unless the Agent shall have received notice from the applicable Borrower prior to the date on which any payment is due to the Agent for the account of the Lenders or the L/C Issuers hereunder that the applicable Borrower will not make such payment, the Agent may assume that the applicable Borrower has made such payment on such date in accordance herewith and may, in reliance upon such assumption, distribute to the Lenders or the L/C Issuers, as the case may be, the amount due. In such event, if the applicable Borrower has not in fact made such payment, then each of the Lenders or the L/C Issuers, as the case may be, severally agrees to repay to the Agent forthwith on demand the amount so distributed to such Lender or L/C Issuer, in Same Day Funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Agent, at rate per annum equal to the applicable Overnight Rate from time to time in effect.A notice of the Agent to any Lender or the applicable Borrower with respect to any amount owing under this subsection (b)Â shall be conclusive, absent manifest error.2.12.1.3.If any Lender makes available to the Agent funds for any Loan to be made by such Lender as provided in the foregoing provisions of this ARTICLE II, and such funds are not made available to the applicable Borrower by the Agent because the conditions to the applicable Credit Extension set forth in ARTICLE IV are not satisfied or waived in accordance with the terms hereof, the Agent shall return such funds (in like funds as received from such Lender) to such Lender, without interest.2.12.1.4.The obligations of the Lenders hereunder to make Committed Loans, to fund participations in Letters of Credit and to make payments pursuant to Section 11.04(c) are several and not joint. The failure of any Lender to make any Committed Loan, to fund any such participation, to make any such purchase or to make any payment under Section 11.04(c) on any date required hereunder shall not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender shall be responsible for the failure of any other Lender to so make its Committed Loan, fund any participation or to make any purchase or payment.2.12.1.5.Nothing herein shall be deemed to obligate any Lender to obtain the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner.2.13.Sharing of Payments. If, other than as expressly provided elsewhere herein, any Lender shall obtain on account of the Committed Loans made by it, or the participations in L/C Obligations held by it, any payment (whether voluntary, involuntary, through the exercise of any right of set-off, or otherwise) in excess of its ratable share (or other share contemplated hereunder) thereof, such Lender shall immediately (a)Â notify the Administrative Agent of such fact, and (b)Â purchase from the other Lenders such participations in the Committed Loans made by them and/or such subparticipations in the participations in L/C Obligations held by them, as the case may be, as shall be necessary to cause such purchasing Lender to share the excess payment in respect of such Committed Loans, or such participations, as the case may be, pro rata with each of them; provided, however, that if all or any portion of such excess payment is thereafter recovered from the purchasing Lender under any of the circumstances described in Section 11.05 (including pursuant to any settlement entered into by the purchasing Lender in its discretion), such purchase shall to that extent be rescinded and each other Lender shall repay to the purchasing Lender the purchase price paid therefor, together with an amount equal to such paying Lenderâ€™s ratable share (according to the proportion of (i)Â the amount of such paying Lenderâ€™s required repayment to (ii)Â the total amount so recovered from the purchasing Lender) of any interest or other amount paid or payable by the purchasing Lender in respect of the total amount so recovered, without further interest thereon. Each Borrower agrees that any Lender so purchasing a participation from another Lender may, to the fullest extent permitted by law, exercise all its rights of payment (including the right of set-off, but subject to Section 11.08) with respect to such participation as fully as if such Lender were the direct creditor of such Borrower in the amount of such participation. The Administrative Agent will keep records (which shall be conclusive and binding in the absence of manifest error) of participations purchased under this Section 2.13 and will in each case notify the Lenders following any such purchases or repayments. Each Lender that purchases a participation pursuant to this Section 2.13 shall from and after such purchase have the right to give all notices, requests, demands, directions and other communications under this Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Agreement with respect to the portion of the Obligations purchased to the same extent as though the purchasing Lender were the original owner of the Obligations purchased.2.14.[Reserved]. 2.15.Increase in Commitments. 2.15.1.1.Provided there exists no Default, upon notice to the Administrative Agent (which shall promptly notify the Lenders), the Company may from time to time, request an increase in the Aggregate Commitments (which increase may take the form of additional Commitments, new term loan tranches or any combination of the foregoing) by an aggregate amount (for all such requests) not exceeding $1,000,000,000. At the time of sending such notice (such notice, for the avoidance of doubt, shall be required regardless of whether such increase takes the form of additional Commitments, new term loan tranches or a combination of the foregoing), the Company (in consultation with the Administrative Agent) shall specify the time period within which each Lender is requested to respond (which shall in no event be less than ten Business Days from the date of delivery of such notice to the Lenders). Each Lender shall notify the Administrative Agent within such time period whether or not it agrees to increase its Commitment or to provide any commitment with respect to the new term loan tranche(s), as applicable (and, for the avoidance of doubt, no such Lender shall have an obligation to so agree),

and, if so, whether by an amount equal to, greater than, or less than its Pro Rata Share of such requested increase or, in the case of a commitment in respect of a new term loan tranche, the amount of such commitment. Any Lender not responding within such time period shall be deemed to have declined to increase its Commitment or to provide any commitment with respect to the new term loan tranche(s), as applicable. The Administrative Agent shall notify the Company and each Lender of the Lendersâ€™ responses to each request made hereunder. To achieve the full amount of a requested increase, the Company may also invite additional Eligible Assignees to become Lenders pursuant to a joinder agreement in form and substance satisfactory to the Administrative Agent and its counsel. Notwithstanding the foregoing provisions of this Section 2.15(a), during the first 90 days following the date hereof, the Company may invite Eligible Assignees to become Lenders under this Agreement in connection with a requested increase without first providing any Lender with the opportunity to increase its Commitment as provided above.2.15.1.2.If the Aggregate Commitments are increased in accordance with this Section 2.15, the Administrative Agent and the Company shall determine the effective date (the â€œIncrease Effective Dateâ€) and the final allocation of such increase. The Administrative Agent shall promptly notify the Company and the Lenders of the final allocation of such increase and the Increase Effective Date. As a condition precedent to such increase, the Company shall deliver to the Administrative Agent a certificate of each Loan Party dated as of the Increase Effective Date signed by a Responsible Officer of such Loan Party (i)Â certifying and attaching the resolutions adopted by such Loan Party approving or consenting to such increase, and (ii)Â in the case of the Company, certifying that, before and after giving effect to such increase, (A)Â the representations and warranties contained in ARTICLE V and the other Loan Documents are true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of the Increase Effective Date, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they are true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) as of such earlier date, and except that, for purposes of this Section 2.15, (1)Â the representation and warranty contained in Section 5.08(a) shall be deemed to refer to the most recent statements furnished pursuant to Section 6.01(a) and 6.01(b), respectively, and (2)Â the reference to â€œthe date hereofâ€ in Section 5.08(b) shall be deemed to refer to the Increase Effective Date and (B)Â no Default exists. The Company shall prepay any Committed Loans outstanding on the Increase Effective Date (and pay any additional amounts required pursuant to Section 3.05) to the extent necessary to keep the outstanding Committed Loans ratable with any revised Pro Rata Shares arising from any nonratable increase in the Commitments under this Section 2.15.2.15.1.3.In the event of an increase in Commitments pursuant to this Section 2.15, the provisions of this Section 2.15 shall govern any conflicts with provisions in Sections 2.13 or 11.01.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 2.15.1.4.To the extent that the increase of the Aggregate Commitments shall take the form of a term loan tranche, this Agreement shall be amended, in form and in substance satisfactory to the Administrative Agent and the Company to include such terms as are customary for a term loan commitment, including but not limited to the following:2.15.1.4.1.the final maturity of any such term loan tranche shall not be earlier than the Existing Maturity Date at the time of establishment of such term loan tranche; and2.15.1.4.2.except as otherwise agreed by the lenders providing the relevant term loan tranche in connection with any acquisition, investments and repayments, repurchases and redemptions of indebtedness not prohibited by the terms of this Agreement, (A)Â no Event of Default shall exist immediately prior to or after giving effect to such new term loan tranche and (B)Â the representations and warranties of the Loan Parties set forth in this Agreement and the other Loan Documents shall be true and correct in all material respects on and as of the date of the initial borrowing under such term loan tranche with the same effect as though such representations and warranties had been made on and as of such date; provided that to the extent that any representation and warranty specifically refers to a given date or period, it shall be true and correct in all material respects as of such date or for such period; provided, further, that any representation or warranty that is qualified as to â€œmateriality,â€ â€œMaterial Adverse Effectâ€ or similar language shall be true and correct (after giving effect to any qualification therein) in all respects on such respective dates.2.16.Designation of Borrowers.2.16.1.1.The Company may at any time, upon not less than 15 Business Daysâ€™ notice from the Company to the Administrative Agent (or such shorter period as may be agreed by the Administrative Agent in its sole discretion), designate any consolidated Subsidiary of the Company that is organized in a Designated Borrower Jurisdiction and that is engaged in a line of business that is substantially similar to those lines of businesses conducted by the Company and its Subsidiaries on the date hereof (an â€œApplicant Borrowerâ€) as a Designated Borrower to receive Loans hereunder by delivering to the Administrative Agent (which shall promptly deliver counterparts thereof to each Lender) a duly executed notice and agreement in substantially the form of Exhibit E-1 (a â€œDesignated Borrower Request and Assumption Agreementâ€). The parties hereto acknowledge and agree that prior to any Applicant Borrower becoming entitled to utilize the credit facilities provided for herein the Administrative Agent and the Lenders shall have received such â€œknow your customerâ€ information, Beneficial Ownership Certification, supporting resolutions, incumbency certificates, opinions of counsel and other documents or information, in form, content and scope reasonably satisfactory to the Administrative Agent, as may be required by the Administrative Agent or the Required Lenders (or in the case of â€œknow your customerâ€ information and Beneficial Ownership Certification, each Lender) in their sole discretion, including, without limitation, with respect to an Applicant Borrower that is organized under the laws of Germany, evidence satisfactory to the Administrative Agent that such Applicant Borrower (i) is an entity incorporated under the laws of the Federal Republic of Germany as a limited liability company (Gesellschaft mit beschrÃ¤nkter Haftung) and (ii) satisfies asset, revenue, and minimum employee tests required under the laws of Germany to permit a U.S. Lender to lend to such Applicant Borrower and Notes signed by such new Borrowers to the extent any Lenders so require. If the Administrative Agent and the Required Lenders agree that an Applicant Borrower shall be entitled to receive Loans hereunder, then promptly following receipt of all such requested resolutions, incumbency certificates, opinions of counsel and other documents or information, the Administrative Agent shall send a notice in substantially the form of Exhibit E-2 (a â€œDesignated Borrower Noticeâ€) to the Company and the Lenders specifying the effective date upon which the Applicant Borrower shall constitute a Designated Borrower for purposes hereof (the â€œDesignated Borrower Effective Dateâ€), whereupon each of the Lenders agrees to permit such Designated Borrower to receive Loans hereunder, on the terms and conditions set forth herein, and each of the parties agrees that such Designated Borrower otherwise shall be a Borrower for all purposes of this Agreement; provided that no Committed Loan Notice or Letter of Credit Application may be submitted by or on behalf of such Designated Borrower until the date five Business Days after the Designated Borrower Effective Date applicable to such Designated Borrower.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 2.16.1.2.The Obligations of the Company and each Designated Borrower that is a Domestic Subsidiary shall be joint and several in nature. The Obligations of all Designated Borrowers that are Foreign Subsidiaries shall be several in nature. The Company shall execute a Guaranty in respect of any Designated Borrower prior to or on the Designated Borrower Effective Date applicable to such Designated Borrower. Any Designated Borrower that is a Domestic Subsidiary shall execute a Guaranty in respect of the Companyâ€™s and any other Designated Borrowerâ€™s Obligations hereunder prior to or on the Designated Borrower Effective Date applicable to such Designated Borrower. In the case the Company designates a Designated Borrower, the Company and each Designated Borrower that is a Domestic Subsidiary shall execute and deliver to the Administrative Agent a reaffirmation agreement in form and substance reasonably satisfactory to the Administrative Agent in respect of such Personâ€™s Guaranty prior to or on the Designated Borrower Effective Date applicable to such Designated Borrower so designated by the Company.2.16.1.3.Each Subsidiary of the Company that becomes a â€œDesignated Borrowerâ€ pursuant to this Section 2.16 hereby irrevocably appoints the Company as its agent for all purposes relevant to this Agreement and each of the other Loan Documents, including (i) the giving and receipt of notices, (ii) the execution and delivery of all documents, instruments and certificates contemplated herein and all modifications hereto, and (iii) the receipt of the proceeds of any Loans made by the Lenders to any such Designated Borrower hereunder. Any acknowledgment, consent, direction, certification or other action which might otherwise be valid or effective only if given or taken by all Borrowers, or by each Borrower acting singly, shall be valid and effective if given or taken only by the Company, whether or not any such other Borrower joins therein. Any notice, demand, consent, acknowledgement, direction, certification or other communication delivered to the Company in accordance with the terms of this Agreement shall be deemed to have been delivered to each Designated Borrower.(d)Â Â Â Â The Company may from time to time, upon not less than 15 Business Daysâ€™ notice from the Company to the Administrative Agent (or such shorter period as may be agreed by the Administrative Agent in its sole discretion), terminate a Designated Borrowerâ€™s status as such, provided that there are no outstanding Loans payable by such Designated Borrower, or other amounts payable by such Designated Borrower on account of any Loans made to it, as of the effective date of such termination. The Administrative Agent will promptly notify the Lenders of any such termination of a Designated Borrowerâ€™s status.(e)Â Â Â Â Notwithstanding the foregoing, with respect to any Designated Borrower not organized under the laws of the United States or any State thereof (a â€œDesignated Foreign Borrowerâ€), no Lender shall be required to make Loans to such Designated Foreign Borrower and no L/C Issuer shall be required to issue or amend any Letter of Credit for such Designated Foreign Borrower in the event that the making of such Loans or issuance or amendment of such Letter of Credit would reasonably be expected to (a) breach or violate any internal policy of such Lender or L/C Issuer or any law or regulation to which such Lender or L/C Issuer is subject, or would be upon the making of such Loan or issuance or amendment of such Letter of Credit or (b) result in materially adverse tax consequences to such Lender (any such Lender, a â€œProtesting Lenderâ€); provided that (i) any Protesting Lender, which is relying solely on such internal policies as the basis for not making Loans or issuing or amending Letters of Credit may do so only if such internal policies are being applied by such Protesting Lender to all similarly situated borrowers seeking loans, letters of credit or other extensions of credit from or with respect to such jurisdiction; and (ii) each Protesting Lender shall use reasonable efforts to designate (or identify) a different lending office for funding or booking its Loans to such Designated Foreign Borrower or issuing or amending Letters of Credit for the account of such Designated Foreign Borrower or to assign (or identify for purposes of assignment of) its rights and obligations hereunder to make its Loans to, or issue or amend Letters of Credit for the account of, such Designated Foreign Borrower to another of its offices, branches or affiliates, if, in the good faith judgment of such Protesting Lender, such designation or assignment would permit it to make Loans to such Designated Foreign Borrower or issue or amend Letters of Credit for the account of such Designated Foreign Borrower and would not otherwise be materially disadvantageous to such Protesting Lender, as applicable (and the Company and the relevant Designated Foreign Borrower shall agree to pay all reasonable out-of-pocket costs and expenses incurred by such Lender or L/C Issuer in connection with any such designation or assignment). As soon as practicable (but in any event not more than five Business Days) after receipt of notice from the Company or the Administrative Agent of the Companyâ€™s intent to designate a Designated Foreign Borrower, any Protesting Lender shall notify the Company and the Administrative Agent in writing of its inability to lend to such Designated Foreign Borrower. The Company shall, Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â effective on or before the date that such Designated Foreign Borrower shall have the right to borrow hereunder, either (A) with respect to each Protesting Lender, replace such Protesting Lender with Lenders willing (in their sole discretion) to increase their existing Commitments, or other financial institutions willing (in their sole discretion) to become Lenders and extend new commitments, on terms consistent with Section 11.15, or (B) cancel its request to designate such Designated Foreign Borrower as a â€œDesignated Borrowerâ€.2.17.Extension of Maturity Date.2.17.1.1.Requests for Extension. The Company may, by notice to the Administrative Agent, at any time request that each Lender and L/C Issuer, extend the Maturity Date then in effect (the â€œExisting Maturity Dateâ€), for a period of one year from such Existing Maturity Date; provided that (i)Â no more than three such requests may be made during the term of this Agreement and (ii)Â no such request may be submitted on or after the date that is 65 days prior to the Existing Maturity Date. The Administrative Agent shall promptly notify each Lender and L/C Issuer of the Companyâ€™s request for such extension (the date such notice is given being referred to herein as the â€œNotice Dateâ€ and the proposed date of effectiveness of such extension being referred to herein at the â€œExtension Dateâ€).2.17.1.2.Lender Elections to Extend. Each Lender and L/C Issuer, in each case, acting in its sole discretion, shall, by notice to the Administrative Agent given not later than 10 days following the Notice Date (the â€œResponse Deadlineâ€), advise the Administrative Agent whether or not such Lender or L/C Issuer agrees to such extension (each such Lender or L/C Issuer that determines not to so extend its Commitment being referred to as a â€œNon-Extending Lenderâ€). Any Lender or L/C Issuer that does not so advise the Administrative Agent on or before the Response Deadline shall be deemed to be a Non-Extending Lender. The election of any Lender or L/C Issuer to agree to such extension of the Maturity Date shall not obligate any other Lender to so agree.2.17.1.3.Notification by Administrative Agent. The Administrative Agent shall notify the Company of each Lenderâ€™s and L/C Issuerâ€™s determination under this Section 2.17 within five Business Days after the Response Deadline.2.17.1.4.Additional Commitment Lenders. The Company shall have the right on or before the related Extension Date to replace each Non-Extending Lender with, and add as â€œLenderâ€ and/or â€œL/C Issuerâ€, as applicable, under this Agreement in place thereof, one or more Eligible Assignees (each, an â€œAdditional Commitment Lenderâ€) as provided in Section 11.06, provided that each such Additional Commitment Lender shall enter into an Assignment and Assumption Agreement pursuant to which such Additional Commitment Lender shall undertake a Commitment (and, if any such Additional Commitment Lender is already a Lender, its Commitment shall be in addition to such Lenderâ€™s Commitment hereunder on such date).2.17.1.5.Minimum Extension Requirement. If (and only if) the total of the Commitments of the Lenders (including L/C Issuers) that have agreed to so extend the Maturity Date (each, an â€œExtending Lenderâ€) and the Commitments of the Additional Commitment Lenders shall be more than 51% of the aggregate amount of the Commitments in effect immediately prior to the related Extension Date, then, effective as of the related Extension Date (but subject to the prior satisfaction of the conditions set forth in clause (f)Â below), the Maturity Date of this Agreement and the Maturity Date with respect to the Commitments of each Extending Lender and of each Additional Commitment Lender shall be extended to the date falling one year after the Existing Maturity Date (except that, if such date is not a Business Day, such Maturity Date as so extended shall be the next preceding Business Day) and each Additional Commitment Lender shall thereupon become a â€œLenderâ€ and/or â€œL/C Issuerâ€, as applicable, for all purposes of this Agreement. Notwithstanding anything herein to the contrary, the Commitment of each Non-Extending Lender shall remain in full force and effect until and shall terminate on the Existing Maturity Date for such Non-Extending Lender, unless such Non-Extending Lender is replaced prior to the related Extension Date by an Additional Commitment Lender as provided in clause (d)Â above.2.17.1.6.Conditions to Effectiveness of Extensions. Notwithstanding the foregoing, the extension of the Maturity Date pursuant to this Section shall not be effective with respect to any Lender or L/C Issuer unless:Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â 2.17.1.6.1.no Default shall exist, or would result from such extension;2.17.1.6.2.the representations and warranties contained in this Agreement or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of the date of such extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) as of such earlier date;2.17.1.6.3.as of such Extension Date, with respect to such extension no Material Adverse Effect has occurred since the date of the most recently delivered audited financial statements pursuant to Section 6.01(a); and2.17.1.6.4.the chief financial officer or treasurer of the Company shall have delivered to the Administrative Agent a certificate, dated such Extension Date with respect to such extension, as to the matters referred to in clauses (i)Â through (iii)Â above.2.17.1.7.Payment of Non-Extending Lenders. On the Maturity Date of any Non-Extending Lender, the Company shall repay any outstanding Loans and L/C Advances, accrued interest and fees thereon and other amounts payable to such Non-Extending Lender hereunder and under the other Loan Documents (and pay any additional amounts required pursuant to Sections 2.09 and 3.05).2.17.1.8.Conflicting Provisions. This Section shall supersede any provisions in Section 11.01 to the contrary.2.18.Defaulting Lenders. 2.18.1.1.Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender, then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable law:2.18.1.1.1.Waivers and Amendments. Such Defaulting Lenderâ€™s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in Section 11.01.2.18.1.1.2.Reallocation of Payments. Any payment of principal, interest, fees or other amounts received by Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article VIII or otherwise, and including any amounts made available to the Agent by that Defaulting Lender pursuant to Section 11.08), will be applied at such time or times as may be determined by the Agent as follows: FIRST, to the payment of any amounts owing by that Defaulting Lender to the Agent hereunder; SECOND, to the payment on a pro rata basis of any amounts owing by that Defaulting Lender to any L/C Issuer hereunder; THIRD, if so determined by Administrative Agent or requested by any L/C Issuer, to be held as Cash Collateral for future funding obligations of that Defaulting Lender of any participation in any Letter of Credit; FOURTH, as the Company may request (so long as no Default or Event of Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as required by this Agreement, as determined by Administrative Agent; FIFTH, if so determined by Administrative Agent and the Company and subject to Section 2.03(g), to be held in a non-interest bearing deposit account and released in order to satisfy obligations of that Defaulting Lender to fund Loans under this Agreement; SIXTH, to the payment of any amounts owing to the Lenders or any L/C Issuer as a result of any judgment of a court of competent jurisdiction obtained by any Lender or such L/C Issuer against that Defaulting Lender as a result of

that Defaulting Lenderâ€™s breach of its obligations under this Agreement; SEVENTH, so long as no Default or Event of Default exists, to the payment of any amounts owing to the Borrowers as a result of any judgment of a court of Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â competent jurisdiction obtained by the Borrowers against that Defaulting Lender as a result of that Defaulting Lenderâ€™s breach of its obligations under this Agreement; and EIGHTH, to that Defaulting Lender or as otherwise directed by a court of competent jurisdiction; provided that if (1)Â such payment is a payment of the principal amount of any Loans or L/C Borrowings in respect of which that Defaulting Lender has not fully funded its appropriate share and (2)Â such Loans or L/C Borrowings were made at a time when the conditions set forth in Section 4.03 were satisfied or waived, such payment will be applied solely to pay the Loans of, and L/C Borrowings owed to, all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of, or L/C Borrowings owed to, that Defaulting Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender or to post Cash Collateral pursuant to this Section 2.18(a)(ii) will be deemed paid to and redirected by that Defaulting Lender, and each Lender irrevocably consents hereto.2.18.1.1.3.Certain Fees. A Defaulting Lender (x)Â shall be entitled to receive any facility fee pursuant to Section 2.09(a) for any period during which that Lender is a Defaulting Lender only to extent allocable to the sum of (1)Â the Outstanding Amount of the Committed Loans funded by it and (2)Â its Pro Rata Share of the stated amount of Letters of Credit for which it has provided Cash Collateral (and the Borrowers shall (A)Â be required to pay to each L/C Issuer the amount of such fee allocable to its Fronting Exposure arising from that Defaulting Lender and (B)Â not be required to pay the remaining amount of such fee that otherwise would have been required to have been paid to that Defaulting Lender) and (y)Â shall be limited in its right to receive letter of credit fees as provided in Section 2.03(i). Each Defaulting Lender shall be entitled to receive letter of credit fees for any period during which that Lender is a Defaulting Lender only to the extent allocable to its Pro Rata Share of the stated amount of Letters of Credit for which it has provided Cash Collateral. With respect to any facility fee or letter of credit fee not required to be paid to any Defaulting Lender, the Borrowers shall (x) pay to each non-Defaulting Lender that portion of any such fee otherwise payable to such Defaulting Lender with respect to such Defaulting Lenderâ€™s participation in L/C Obligations that has been reallocated to such non-Defaulting Lender pursuant to clause (iv) below, (y) pay to each L/C Issuer the amount of any such fee otherwise payable to such Defaulting Lender to the extent allocable to such L/C Issuerâ€™s Fronting Exposure to such Defaulting Lender, and (z) not be required to pay the remaining amount of any such fee.2.18.1.1.4.Reallocation of Pro Rata Shares to Reduce Fronting Exposure. All or any part of such Defaulting Lenderâ€™s participation in L/C Obligations shall be reallocated among the non-Defaulting Lenders in accordance with their respective Pro Rata Shares (calculated without regard to such Defaulting Lenderâ€™s Commitment), but only to the extent that such reallocation does not cause the aggregate Revolving Credit Exposure of any non-Defaulting Lender to exceed such non-Defaulting Lenderâ€™s Commitment and provided that each such reallocation will be given effect only if, at the date the applicable Lender becomes a Defaulting Lender, no Default or Event of Default exists.Â No reallocation hereunder shall constitute a waiver or release of any claim of any party hereunder against a Defaulting Lender arising from that Lender having become a Defaulting Lender, including any claim of a non-Defaulting Lender as a result of such non-Defaulting Lenderâ€™s increased exposure following such reallocation.2.18.1.1.5.Cash Collateral. If the reallocation described in clause (a)(iv) above cannot, or can only partially, be effected, the Company shall, without prejudice to any right or remedy available to it hereunder or under applicable Law, Cash Collateralize the applicable L/C Issuersâ€™ Fronting Exposure.2.18.1.2.Defaulting Lender Cure. If the Company, Administrative Agent and each L/C Issuer agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender, Administrative Agent will so notify the parties hereto, whereupon as of the effective date specified in such notice and subject to any conditions set forth therein (which may include arrangements with respect to any Cash Collateral), that Lender will, to the extent applicable, purchase that portion of outstanding Loans of the other Lenders or take such other actions as Administrative Agent may determine to be necessary to cause the Loans and funded and unfunded participations in Letters of Credit to be held on a pro rata basis by the Lenders in accordance with their Pro Rata Shares (without giving effect to Section 2.18(a)(iv)), whereupon that Lender will cease to be a Defaulting Lender; provided that (x) to the extent that any non-Defaulting Lender incurs any loss, cost or expense as Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â a result of such purchase of any Eurocurrency Rate Loan on a day other than the last day of the Interest Period for such Loan, such Defaulting Lender shall reimburse such non-Defaulting Lenders for any such loss, cost or expense, (y) no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Borrowers while that Lender was a Defaulting Lender and (z) except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any party hereunder arising from that Lenderâ€™s having been a Defaulting Lender.2.19.Sustainability Adjustments.2.19.1.1.ESG Amendment. After the Closing Date, the Company, in consultation with the Joint Sustainability Coordinators, on a mutually agreed date, may establish specified key performance indicators (â€œKPIâ€™sâ€) with respect to certain environmental, social and governance (â€œESGâ€) targets of the Company and its Subsidiaries. Notwithstanding anything set forth in Section 11.01 to the contrary, the Joint Sustainability Coordinators, the Company, the Administrative Agent and the Required Lenders may enter into an amendment to this Agreement (such amendment, an â€œESG Amendmentâ€) solely for purposes of incorporating the KPIâ€™s and other related provisions (the â€œESG Pricing Provisionsâ€) into this Agreement, which shall provide that, based on the Companyâ€™s performance against the KPIâ€™s, certain adjustments (increase, decrease or no adjustment) (such adjustments, the â€œESG Applicable Rate Adjustmentsâ€) to the otherwise applicable facility fee, Applicable Rate for Base Rate Loans, Eurocurrency Rate Loans, and letter of credit fees will be made; provided that (1)Â the amount of such adjustments shall not exceed (i)Â in the case of the Applicable Rate for Base Rate Loans, Eurocurrency Rate Loans, and letter of credit fees,Â an increase and/or decrease of 0.040% and (ii)Â in the case of the facility fee, an increase and/or decrease of 0.010%, (2)Â for the avoidance of doubt, (i)Â in no event shall the applicable facility fee, Applicable Rate for Base Rate Loans, Eurocurrency Rate Loans, and letter of credit fees be less than zero, (ii)Â the ESG Applicable Rate Adjustments shall not be cumulative year-over-year and (iii)Â the ESG Applicable Rate Adjustments shall only apply until the date on which the next adjustment is due to take place and (3) notwithstanding anything herein to the contrary, at any time prior to the effectiveness of an ESG Amendment, the Loan Parties shall not (and shall ensure that none of their Subsidiaries will) make any disclosure that references any credit facility hereunder or any Loan as â€œsustainability-linkedâ€. The KPIs, the Companyâ€™s performance against the KPIs, and any related ESG Applicable Rate Adjustments resulting therefrom, will be determined based on certain certificates, reports and other documents, in each case, setting forth the calculation and measurement of the KPIs in a manner that is aligned with the Core Components of the Sustainability Linked Loan Principles, including certain reporting requirements and third-party assurance of KPI performance, and to be mutually agreed between the Company and the Joint Sustainability Coordinators (each acting reasonably). Notwithstanding anything set forth in Section 11.01 to the contrary, following the effectiveness of an ESG Amendment, any modification to the ESG Pricing Provisions shall be subject only to the consent of the Company and the Required Lenders so long as such modification does not have the effect of reducing the facility fee or the Applicable Rate for Base Rate Loans, Eurocurrency Rate Loans, and letter of credit fees to a level not otherwise permitted by this paragraph on the Closing Date. For the avoidance of doubt, in no event shall the Company be obligated to enter into the ESG Amendment and the failure to do so shall not result in a Default or Event of Default.2.19.1.2.Joint Sustainability Coordinators. The Joint Sustainability Coordinators will (i)Â assist the Company in determining the ESG Pricing Provisions in connection with the ESG Amendment and (ii)Â assist the Company in preparing informational materials focused on ESG to be used in connection with the ESG Amendment. Each party hereto agrees that neither the Administrative Agent nor the Joint Sustainability Coordinators (i)Â makes any assurances with regard to environmental or social impact and sustainability performance or that the characteristics of the relevant KPIs meet any industry standards for sustainability-linked credit facilities, (ii)Â shall have any duty to ascertain, inquire into or otherwise independently verify any such information (or any liability in respect thereof), or (iii)Â shall have any responsibility for (or be liable for) the completeness or accuracy of any such information.2.19.1.3.Conflicting Provisions. This Section shall supersede any provision in Section 11.01.Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â 3.TAXES, YIELD PROTECTION AND ILLEGALITY3.1.Taxes. 3.1.1.1.(i)Â Any and all payments by or on account of any obligation of any Loan Party under any Loan Document shall be made without deduction or withholding for any Taxes, except as required by applicable Laws. If any applicable Laws (as determined in the good faith discretion of the Administrative Agent) require the deduction or withholding of any Tax from any such payment by the Administrative Agent or a Loan Party, then the Administrative Agent or such Loan Party shall be entitled to make such deduction or withholding.Â Â Â Â (ii) Â Â Â Â [reserved]Â Â Â Â (iii)Â Â Â Â If any Loan Party or the Administrative Agent shall be required by any applicable Laws to withhold or deduct any Taxes from any payment, then (A)Â such Loan Party or the Administrative Agent, as required by such Laws, shall withhold or make such deductions as are determined by it to be required, (B)Â such Loan Party or the Administrative Agent, to the extent required by such Laws, shall timely pay the full amount withheld or deducted to the relevant Governmental Authority in accordance with such Laws, and (C)Â to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the applicable Loan Party shall be increased as necessary so that after any required withholding or the making of all required deductions (including deductions and withholdings applicable to additional sums payable under this Section 3.01) the applicable Recipient receives an amount equal to the sum it would have received had no such withholding or deduction been made.3.1.1.2.Without limiting the provisions of subsectionÂ (a) above, the Loan Parties shall timely pay to the relevant Governmental Authority in accordance with applicable law, or at the option of the Administrative Agent timely reimburse it for the payment of, any Other Taxes.3.1.1.3. (i)Â Â Â Â Each of the Loan Parties shall, and does hereby, jointly and severally indemnify each Recipient, and shall make payment in respect thereof within 10 days after demand therefor, for the full amount of any Indemnified Taxes (including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this SectionÂ 3.01) payable or paid by such Recipient or required to be withheld or deducted from a payment to such Recipient, and any penalties, interest and reasonable expenses arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to the Company by a Lender or an L/C Issuer (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf or on behalf of a Lender or an L/C Issuer, shall be conclusive absent manifest error.Â Â Â Â (ii)Â Â Â Â Each Lender and L/C Issuer shall, and does hereby, severally indemnify, and shall make payment in respect thereof within 10 days after demand therefor, (x)Â the Administrative Agent against any Indemnified Taxes attributable to such Lender or the L/C Issuer (but only to the extent that any Loan Party has not already indemnified the Administrative Agent for such Indemnified Taxes and without limiting the obligation of the Loan Party to do so), (y)Â the Administrative Agent and the Loan Party, as applicable, against any Taxes attributable to such Lenderâ€™s failure to comply with the provisions of SectionÂ 11.06(d) relating to the maintenance of a Participant Register and (z)Â the Administrative Agent and the Loan Party, as applicable, against any Excluded Taxes attributable to such Lender or L/C Issuer, in each case, that are payable or paid by the Administrative Agent or a Loan Party in connection with any Loan Document, and any reasonable expenses arising therefrom or with respect thereto, whether or not such Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. A certificate as to the amount of such payment or liability delivered to any Lender by the Administrative Agent shall be conclusive absent manifest error. Each Lender and L/C Issuer hereby authorizes the Administrative Agent to set off and apply any and all amounts at any time owing to such Lender or L/C Issuer, as the case may Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â be, under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this clauseÂ (ii).3.1.1.4.As soon as practicable after any payment of Taxes by any Loan Party to a Governmental Authority as provided in this SectionÂ 3.01, the Company shall deliver to the Administrative Agent the original or a certified copy of a receipt issued by such Governmental Authority evidencing such payment, a copy of any return required by Laws to report such payment or other evidence of such payment reasonably satisfactory to the Administrative Agent.3.1.1.5.(i)Â Any Lender that is entitled to an exemption from or reduction of withholding Tax with respect to payments made under any Loan Document shall deliver to the Company and the Administrative Agent, at the time or times reasonably requested by the Company or the Administrative Agent, such properly completed and executed documentation prescribed by applicable law or the taxing authorities of a jurisdiction pursuant to such applicable law or reasonably requested by the Company or the Administrative Agent as will permit such payments to be made without withholding or at a reduced rate of withholding. In addition, any Lender, if reasonably requested by the Company or the Administrative Agent, shall deliver such other documentation prescribed by applicable law or reasonably requested by the Company or the Administrative Agent as will enable the Company or the Administrative Agent to determine whether or not such Lender is subject to backup withholding or information reporting requirements. Notwithstanding anything to the contrary in the preceding two sentences, the completion, execution and submission of such documentation (other than such documentation either (A) set forth in SectionÂ 3.01(e)(ii)(A), (ii)(B) and (ii)(D) below or (B) required by applicable law other than the Code, or by the taxing authorities of the jurisdiction that promulgated such applicable law to satisfy the requirements for exemption or reduction of withholding tax in that jurisdiction) shall not be required if in the Lenderâ€™s reasonable judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or would materially prejudice the legal or commercial position of such Lender.Â Â Â Â (ii)Â Â Â Â Without limiting the generality of the foregoing, in the event that a Borrower is a U.S. Person,Â Â Â Â Â (A)Â Â Â Â Any Lender that is a U.S. Person shall deliver to the Company and the Administrative Agent on or prior to the date on which such Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Company or the Administrative Agent), executed copies of IRS FormÂ W-9 certifying that such Lender is exempt from U.S. federal backup withholding; Â Â Â Â (B)Â Â Â Â any Foreign Lender shall, to the extent it is legally entitled to do so, deliver to the Company and the Administrative Agent (in such number of copies as shall be requested by the recipient) on or prior to the date on which such Foreign Lender becomes a Lender under this Agreement (and from time to time thereafter upon the reasonable request of the Company or the Administrative Agent), whichever of the following is applicable:Â Â Â Â Â (I)Â Â Â Â Â in the case of a Foreign Lender claiming the benefits of an income tax treaty to which the United States is a party (x)Â with respect to payments of interest under any Loan Document, executed copies of IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the â€œinterestâ€ article of such tax treaty and (y)Â with respect to any other applicable payments under any Loan Document, IRS Form W-8BEN-E (or W-8BEN, as applicable) establishing an exemption from, or reduction of, U.S. federal withholding Tax pursuant to the â€œbusiness profitsâ€ or â€œother incomeâ€ article of such tax treaty;Â Â Â Â Â Â Â Â Â Â Â Â Â (II)Â Â Â Â executed copies of IRS Form W-8ECI;Â Â Â Â Â Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â

do so.3.1.1.6.Unless required by applicable Laws, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender or an L/C Issuer, or have any obligation to pay to any Lender or L/C Issuer, any refund of Taxes withheld or deducted from funds paid for the account of such Lender or L/C Issuer, Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â as the case may be. If any Recipient determines, in its sole discretion exercised in good faith, that it has received a refund of any Taxes as to which it has been indemnified by any Loan Party or with respect to which any Loan Party has paid additional amounts pursuant to this SectionÂ 3.01, it shall pay to such Loan Party an amount equal to such refund (but only to the extent of indemnity payments made, or additional amounts paid, by a Loan Party under this SectionÂ 3.01 with respect to the Taxes giving rise to such refund), net of all out-of-pocket expenses (including Taxes) incurred by such Recipient, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that each Loan Party, upon the request of the Recipient, agrees to repay the amount paid over to such Loan Party (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) to the Recipient in the event the Recipient is required to repay such refund to such Governmental Authority. Notwithstanding anything to the contrary in this subsection, in no event will the applicable Recipient be required to pay any amount to such Loan Party pursuant to this subsection the payment of which would place the Recipient in a less favorable net after-Tax position than such Recipient would have been in if the Tax subject to indemnification and giving rise to such refund had not been deducted, withheld or otherwise imposed and the indemnification payments or additional amounts with respect to such Tax had never been paid. This subsection shall not be construed to require any Recipient to make available its tax returns (or any other information relating to its taxes that it deems confidential) to any Loan Party or any other Person.3.1.1.7.Each partyâ€™s obligations under this SectionÂ 3.01 shall survive the resignation or replacement of the Administrative Agent or any assignment of rights by, or the replacement of, a Lender or an L/C Issuer, the termination of the Commitments and the repayment, satisfaction or discharge of all other Obligations.3.2.Illegality. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that it is unlawful, for any Lender or its applicable Lending Office to perform any of its obligations hereunder or make, maintain or fund Eurocurrency Rate Loans (whether denominated in Dollars or an Alternative Currency), or charge interest with respect to Credit Extensions or to determine or charge interest rates based upon the Eurocurrency Rate or any Governmental Authority has imposed material restrictions on the authority of such Lender to purchase or sell, or to take deposits of, Dollars or any Alternative Currency in the applicable interbank market, then, on notice thereof by such Lender to the Company through the Agent, (i) any obligation of such Lender to issue, make, maintain, fund or charge interest with respect to any such Credit Extension or to make or continue Eurocurrency Rate Loans in the affected currency or currencies or to convert Base Rate Committed Loans to Eurocurrency Rate Loans shall be suspended and (ii)Â if such notice asserts the illegality of such Lender making or maintaining Base Rate Loans the interest rate on which is determined by reference to the Eurocurrency Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurocurrency Rate component of the Base Rate, in each case until such Lender notifies the Agent and the Company that the circumstances giving rise to such determination no longer exist. Upon receipt of such notice, (x) the Borrowers shall, upon demand from such Lender (with a copy to the Agent), prepay or, solely in the case of Eurocurrency Rate Loans denominated in Dollars convert all Eurocurrency Rate Loans of such Lender to Base Rate Loans (the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Agent without reference to the Eurocurrency Rate component of the Base Rate), either on the last day of the Interest Period therefor, if such Lender may lawfully continue to maintain such Eurocurrency Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Eurocurrency Rate Loans and (y)Â if such notice asserts the illegality of such Lender determining or charging interest rates based upon the Eurocurrency Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Eurocurrency Rate component thereof until the Administrative Agent is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Eurocurrency Rate. If any of the circumstances set forth above arise with respect to Loans denominated in an Alternative Currency, such Alternative Currency denominated Loans shall be made or maintained, as applicable, at a rate for short term borrowings of such Alternative Currency determined in a customary manner in good faith by the Administrative Agent in consultation with the Company. Upon any such prepayment or conversion, the Borrowers shall also pay accrued interest on the amount so prepaid or converted.Â Â Â Â 3Â Â Â Â Â Â Â Â Â Â Â Â Â 3.3 Inability to Determine Rates. 3.2.1.1.If in connection with any request for a Eurocurrency Rate Loan or a conversion to or a continuation thereof, (i)Â the Administrative Agent determines (which determination shall be conclusive absent manifest error) that (A)Â no Successor Rate for the Relevant Rate for the applicable Agreed Currency has been determined in accordance with Section 3.03(b) or Section 3.03(c) and the circumstances under clause (i) of Section 3.03(b) or of Section 3.03(c) or the Scheduled Unavailability Date, or the Term SOFR Scheduled Unavailability Date, has occurred with respect to such Relevant Rate (as applicable), or (B) adequate and reasonable means do not otherwise exist for determining the Relevant Rate for the applicable Agreed Currency for any determination date(s) or requested Interest Period, as applicable, with respect to an existing or proposed Eurocurrency Rate Loan or (ii)Â the Administrative Agent or the Required Lenders determine that for any reason that the Relevant Rate with respect to a proposed Loan denominated in an Agreed Currency for any requested Interest Period or determination date(s) does not adequately and fairly reflect the cost to such Lenders of funding such Loan, the Administrative Agent will promptly so notify the Company and each Lender.Thereafter, (x) the obligation of the Lenders to make or maintain Eurocurrency Rate Loans in the affected currency or currencies shall be suspended in each case to the extent of the affected Eurocurrency Rate Loans or Interest Period or determination date(s), as applicable, and (y) in the event of a determination described in the preceding sentence with respect to the Term SOFR component of the Base Rate, the utilization of the Term SOFR component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (upon the instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, (i) the applicable Borrower may revoke any pending request for a Borrowing of, or conversion to, or continuation of Eurocurrency Rate Loans to the extent of the affected Eurocurrency Rate Loans or Interest Period or determination date(s), as applicable or, failing that, will be deemed to have converted such request into a request for a Committed Borrowing of Base Rate Loans denominated in Dollars in the Dollar Equivalent of the amount specified therein and (ii) any outstanding affected Eurocurrency Rate Loans, at the Companyâ€™s election, shall either (1) be converted into a Committed Borrowing of Base Rate Loans denominated in Dollars in the Dollar Equivalent of the amount of such outstanding Eurocurrency Rate Loan at the end of the applicable Interest Period or (2) be prepaid in full at the end of the applicable Interest Period; provided that if no election is made by the Company in the case of a Eurocurrency Rate Loan, by the last day of the current Interest Period for the applicable Eurocurrency Rate Loan, the Company shall be deemed to have elected clause (1) above.3.2.1.2.Replacement of Term SOFR or Term SOFR Successor Rate. Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Company or Required Lenders notify the Administrative Agent (with, in the case of the Required Lenders, a copy to the Company) that the Company or Required Lenders (as applicable) have determined, that:(i)Â Â Â Â adequate and reasonable means do not exist for ascertaining Term SOFR because Term SOFR is not available or published on a current basis and such circumstances are unlikely to be temporary; or(ii)Â Â Â Â Â the Applicable Authority referenced in clause (a) of the definition thereof has made a public statement identifying a specific date after which Term SOFR shall or will no longer be made available, or permitted to be used for determining the interest rate of syndicated loans denominated in Dollars, or shall or will otherwise cease, provided that, in each case, at the time of such statement, there is no successor administrator that is satisfactory to the Administrative Agent that will continue to provide Term SOFR (the date on which Term SOFR is no longer available permanently or indefinitely, the â€œTerm SOFR Scheduled Unavailability Dateâ€);or if the events or circumstances of the type described in Section 3.03(b)(i) or (ii) have occurred with respect to the Term SOFR Successor Rate then in effect, then, the Administrative Agent and the Company may Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â amend this Agreement solely for the purpose of replacing Term SOFR for Dollars or any then current Term SOFR Successor Rate for Dollars in accordance with this Section 3.03 with an alternative benchmark rate giving due consideration to any evolving or then existing convention for similar credit facilities syndicated and agented in the U.S. and denominated in Dollars for such alternative benchmarks, and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar credit facilities syndicated and agented in the U.S. and denominated in Dollars for such benchmarks, which adjustment or method for calculating such adjustment shall be published on an information service as selected by the Administrative Agent from time to time in its reasonable discretion and may be periodically updated (and any such proposed rate, including for the avoidance of doubt, any adjustment thereto, a â€œTerm SOFR Successor Rateâ€), and any such amendment shall become effective at 5:00 p.m. on the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Lenders and the Company unless, prior to such time, Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders object to such amendment.3.2.1.3.Replacement of Relevant Rate or Successor Rate. Notwithstanding anything to the contrary in this Agreement or any other Loan Documents, if the Administrative Agent determines (which determination shall be conclusive absent manifest error), or the Company or Required Lenders notify the Administrative Agent (with, in the case of the Required Lenders, a copy to the Company) that the Company or Required Lenders (as applicable) have determined, that:(i)Â Â Â Â adequate and reasonable means do not exist for ascertaining the Relevant Rate (other than Term SOFR) for an Agreed Currency (other than Dollars) because none of the tenors of such Relevant Rate (other than Term SOFR) under this Agreement is available or published on a current basis, and such circumstances are unlikely to be temporary; or(ii)Â Â Â Â Â the Applicable Authority referenced in clause (b) of the definition thereof has made a public statement identifying a specific date after which all tenors of the Relevant Rate (other than Term SOFR) for an Agreed Currency (other than Dollars) under this Agreement shall or will no longer be representative or made available, or permitted to be used for determining the interest rate of syndicated loans denominated in such Agreed Currency (other than Dollars), or shall or will otherwise cease, provided that, in each case, at the time of such statement, there is no successor administrator that is satisfactory to the Administrative Agent that will continue to provide such representative tenor(s) of the Relevant Rate (other than Term SOFR) for such Agreed Currency (other than Dollars) (the latest date on which all tenors of the Relevant Rate for such Agreed Currency (other than Dollars) under this Agreement are no longer representative or available permanently or indefinitely, the â€œScheduled Unavailability Dateâ€);or if the events or circumstances of the type described in Section 3.03(c) (i) or (ii) have occurred with respect to the Successor Rate then in effect, then, the Administrative Agent and the Company may amend this Agreement solely for the purpose of replacing the Relevant Rate for an Agreed Currency or any then current Successor Rate for an Agreed Currency in accordance with this Section 3.03 with an alternative benchmark rate giving due consideration to any evolving or then existing convention for similar credit facilities syndicated and agented in the U.S. and denominated in such Agreed Currency for such alternative benchmarks, and, in each case, including any mathematical or other adjustments to such benchmark giving due consideration to any evolving or then existing convention for similar credit facilities syndicated and agented in the U.S. and denominated in such Agreed Currency for such benchmarks, which adjustment or method for calculating such adjustment shall be published on an information service as selected by the Administrative Agent from time to time in its reasonable discretion and may be periodically updated (and any such proposed rate, including for the avoidance of doubt, any adjustment thereto, a â€œNon-SOFR Successor Rateâ€, and collectively with the Term SOFR Successor Rate, each a â€œSuccessor Rateâ€), and any such amendment shall become effective at 5:00 p.m. on the fifth Business Day after the Administrative Agent shall have posted such proposed amendment to all Lenders and the Company unless, prior to such time, Lenders comprising the Required Lenders have delivered to the Administrative Agent written notice that such Required Lenders object to such amendment. Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â 3.2.1.4.Successor Rate. The Administrative Agent will promptly (in one or more notices) notify the Company and each Lender of the implementation of any Successor Rate:Any Successor Rate shall be applied in a manner consistent with market practice; provided that to the extent such market practice is not administratively feasible for the Administrative Agent, such Successor Rate shall be applied in a manner as otherwise reasonably determined by the Administrative Agent.Notwithstanding anything else herein, if at any time any Successor Rate as so determined would otherwise be less than 0%, the Successor Rate will be deemed to be 0% for the purposes of this Agreement and the other Loan Documents.In connection with the implementation of a Successor Rate the Administrative Agent will have the right to make Conforming Changes from time to time and, notwithstanding anything to the contrary herein or in any other Loan Document, any amendments implementing such Conforming Changes will become effective without any further action or consent of any other party to this Agreement; provided that, with respect to any such amendment effected, the Administrative Agent shall post each such amendment implementing such Conforming Changes to the Company and the Lenders reasonably promptly after such amendment becomes effective.3.2.1.5.For purposes of this Section 3.03, those Lenders that either have not made, or do not have an obligation under this Agreement to make, the relevant Loans in the relevant Alternative Currency shall be excluded from any determination of Required Lenders. 3.4 Increased Cost and Reduced Return; Capital Adequacy.3.2.1.1.Increased Costs Generally. If any Change in Law shall:3.2.1.1.1.impose, modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve requirement reflected in the Eurocurrency Rate) or L/C Issuer;3.2.1.1.2.subject any Lender, L/C Issuer or Agent to any taxes of any kind whatsoever (other than (A)Â Indemnified Taxes, (B)Â Taxes described in clauses (b)-(d)Â of the definition of Excluded Taxes and (C)Â Connection Income Taxes) on its loans, loan principal, letters of credit, commitments, or other obligations, or its deposits, reserves, other liabilities or capital attributable thereto; or3.2.1.1.3.impose on any Lender or L/C Issuer or any applicable interbank market any other condition, cost or expense affecting this Agreement or Eurocurrency Rate Loans made by such Lender or any Letter of Credit or participation therein;and the result of any of the foregoing shall be to increase the cost to such Lender of making, converting to, continuing or maintaining any Eurocurrency Rate Loan or of maintaining its obligation to make any such Loan, or to increase the cost to such Lender or L/C Issuer of participating in, issuing or maintaining any Letter of Credit (or of maintaining its obligation to participate in or to issue any Letter of Credit), or to reduce the amount of any sum received or receivable by such Lender or L/C Issuer hereunder (whether of principal, interest or any other amount) then, upon request of such Lender or L/C Issuer, the Borrowers will pay to such Lender or L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or L/C Issuer, as the case may be, for such additional costs incurred or reduction suffered.3.2.1.2.Capital Requirements. If any Lender or L/C Issuer determines that any Change in Law affecting such Lender or L/C Issuer or any Lending Office of such Lender or such Lenderâ€™s or L/C Issuerâ€™s holding company, if any, regarding capital or liquidity requirements, has or would have the effect of reducing the rate of return on such Lenderâ€™s or L/C Issuerâ€™s capital or on the capital of such Lenderâ€™s or L/C Issuerâ€™s holding company, if any, as a consequence of this Agreement, the Commitments of such Lender or the Loans made by, or participations in Letters Â Â Â Â 3Â Â Â Â Â Â Â Â Â Â Â Â Â of Credit held by, such Lender, or the Letters of Credit issued by such L/C Issuer, to a level below that which such Lender or L/C Issuer or such Lenderâ€™s or L/C Issuerâ€™s holding company could have achieved but for such Change in Law (taking into consideration such Lenderâ€™s or L/C Issuerâ€™s policies and the policies of such Lenderâ€™s or L/C Issuerâ€™s holding company with respect to capital adequacy), then from time to time the Borrowers will pay to such Lender or L/C Issuer, as the case may be, such additional amount or amounts as will compensate such Lender or L/C Issuer or such Lenderâ€™s or L/C Issuerâ€™s holding company for any such reduction suffered.3.2.1.3.The Company shall pay (or cause the applicable Designated Borrower to pay) to each Lender, as long as such Lender shall be required to comply with any reserve ratio requirement or analogous requirement of any other central banking or financial regulatory authority imposed as a result of a Change in Law in respect of the maintenance of the Commitments or the funding of the Eurocurrency Rate Loans denominated in a currency other than U.S. Dollars, such additional costs (expressed as a percentage per annum and rounded upwards, if necessary, to the nearest five decimal places) equal to the actual costs allocated to such Commitment or Loan by such Lender (as determined by such Lender in good faith), which in each case shall be due and payable on each date on which interest is payable on such Loan, provided the Company shall have received at least 30 daysâ€™ prior notice (with a copy to the Administrative Agent) of such additional costs from such Lender. If a Lender fails to give notice 30 days prior to the relevant Interest Payment Date, such additional costs shall be due and payable 30 days from receipt of such notice.3.2.1.4.Delay in Requests. Failure or delay on the part of any Lender or L/C Issuer to demand compensation pursuant to this Section 3.04 shall not constitute a waiver of such Lenderâ€™s or or L/C Issuerâ€™s right to demand such compensation; provided that, notwithstanding the provisions of Sections 3.04(a), 3.04(b) and 3.04(c), (i)Â the Borrowers shall only be liable for amounts in respect of increased costs or reductions for the period beginning up to six months prior to the date on which such demand was made (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the six month period referred to above shall be extended to include the period of retroactive effect thereof), and (ii)Â the Lender claiming compensation therefor shall have applied consistent return metrics applied to other similarly situated borrowers or obligors with respect to such increased costs or reductions. 3.5 Funding Losses. Upon demand of any Lender or L/C Issuer (with a copy to the Administrative Agent) from time to time, the Company shall promptly compensate such Lender or L/C Issuer for and hold such Lender harmless from any loss, cost

or expense incurred by it as a result of:3.2.1.1.any continuation, conversion, payment or prepayment of any Eurocurrency Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory, automatic, by reason of acceleration, or otherwise);3.2.1.2.any failure by a Borrower (for a reason other than the failure of such Lender to make a Loan) to prepay, borrow, continue or convert any Eurocurrency Rate Loan on the date or in the amount notified by such Borrower; 3.2.1.3.any failure by any Borrower to make payment of any Loan or drawing under any Letter of Credit (or interest due thereon) denominated in an Alternative Currency on its scheduled due date or any payment thereof in a different currency; or3.2.1.4.any assignment of a Eurocurrency Rate Loan on a day other than the last day of the Interest Period therefor as a result of a request by the Company pursuant to Section 11.15; Â Â Â Â including any loss or expense arising from the liquidation or reemployment of funds obtained by it to maintain such Loan or from fees payable to terminate the deposits from which such funds were obtained for the performance of any foreign exchange contracts, in each case, excluding loss of any anticipated profits;Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â provided that the Company shall have no obligation to pay to any Lender any of the foregoing amounts incurred in connection with such Lender being a Defaulting Lender. 3.6 Matters Applicable to Illegality and all Requests for Compensation.3.2.1.1.A certificate of the Administrative Agent or any Lender or L/C Issuer claiming compensation under this ARTICLE III and setting forth the additional amount or amounts to be paid to it hereunder shall be conclusive in the absence of manifest error; provided that, in the case of any such certificate delivered pursuant to Section 3.04, such certificate (i)Â sets forth in reasonable detail (which detail shall not include any confidential or price sensitive information or any other information to the extent prohibited by law) the amount or amounts payable to such Lender or L/C Issuer pursuant to Section 3.04(a) and 3.04(b) and the basis for determining such amount or amounts and (ii)Â explains the methodology used to determine such amount. The Borrowers shall pay such Lender or L/C Issuer the amount shown as due on any such certificate within 10 days after receipt thereof. In determining such amount, the Administrative Agent or such Lender or L/C Issuer may use any reasonable averaging and attribution methods.3.2.1.2.Each Lender may make any Credit Extension to any Borrower through any Lending Office, provided that the exercise of this option shall not affect the obligation of the applicable Borrower to repay the Credit Extension in accordance with the terms of this Agreement. If any Lender requests compensation under Section 3.04, or requires any Borrower to pay any Indemnified Taxes or additional amounts to any Lender, L/C Issuer, or any Governmental Authority for the account of any Lender or L/C Issuer pursuant to SectionÂ 3.01, or if any Lender gives a notice pursuant to Section 3.02, then at the request of the Company such Lender or L/C Issuer shall, as applicable, use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or affiliates, if, in the judgment of such Lender or L/C Issuer, such designation or assignment (i)Â would eliminate or reduce amounts payable pursuant to SectionÂ 3.01 or Section 3.04, as the case may be, in the future, or eliminate the need for notice pursuant to Section 3.02, as applicable, and (ii)Â in each case, would not subject such Lender or L/C Issuer, as the case may be, to any unreimbursed cost or expense and would not, in the good faith judgment of such Lender or L/C Issuer, as the case may be, otherwise be materially disadvantageous to such Lender or L/C Issuer, as the case may be. The Company hereby agrees to pay (or cause the applicable Designated Borrower to pay) all reasonable costs and expenses incurred by any Lender or L/C Issuer in connection with any such designation or assignment requested by the Company.3.2.1.3.Upon any Lenderâ€™s making a claim for compensation under Section 3.04 or if any Borrower is required to pay amounts to any Lender under Section 3.01 as a result of any Taxes or Other Taxes, in each case the Company may, subject to Section 3.06(b), replace such Lender in accordance with Section 11.15. Upon any Lenderâ€™s giving notice and suspending its obligations relating to Eurocurrency Rate Loans in accordance with Section 3.02(a), the Company may replace such Lender in accordance with Section 11.15. 3.7 Survival. All of the Borrowersâ€™ obligations under this ARTICLE III shall survive termination of the aggregate Commitments and repayment of all other Obligations hereunder.4.CONDITIONS PRECEDENT TO CREDIT EXTENSIONS4.1.Conditions to Effectiveness. Effectiveness of this Agreement is subject to satisfaction of the following conditions precedent:Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.1.1.1.The Administrative Agentâ€™s receipt of the following, each of which shall be originals, facsimiles or PDFs (followed promptly by originals) unless otherwise specified, each properly executed by a Responsible Officer of the signing Loan Party, each dated the date hereof (or, in the case of certificates of governmental officials, a recent date before the date hereof) and each in form and substance satisfactory to the Administrative Agent and each of the Lenders:4.1.1.1.1.executed counterparts of this Agreement, sufficient in number for distribution to the Administrative Agent, each Lender and each Loan Party;4.1.1.1.2.if requested by any Lender at least two Business Days before the date hereof, a Note executed by the Borrowers in favor of each Lender so requesting a Note;4.1.1.1.3.such certificates of resolutions or other action, incumbency certificates and/or other certificates of Responsible Officers or the corporate secretary or assistant secretary of the Company as the Administrative Agent may require evidencing the identity, authority and capacity of each Responsible Officer thereof authorized to act as a Responsible Officer in connection with this Agreement and the other Loan Documents to which such Loan Party is a party;4.1.1.1.4.each of the following documents:4.1.1.1.4.1.the Articles or certificate of incorporation and the bylaws of the Company as in effect on the date hereof, certified by the Secretary or Assistant Secretary of the Company as of the date hereof; and4.1.1.1.4.2.a good standing and tax good standing certificate for the Company from the applicable Secretary of State (or similar, applicable Governmental Authority) of the States of Delaware and California dated as of a recent date; 4.1.1.1.5.favorable opinions, addressed to the Agent and the Lenders, of (A)Â Saralisa Brau, Corporate Secretary and Assistant General Counsel of the Company, in form and substance satisfactory to the Administrative Agent regarding such matters as the Administrative Agent may reasonably request; and (B)Â Morrison & Foerster LLP, special counsel to the Company, as to certain matters of New York law;4.1.1.1.6.a certificate signed by a Responsible Officer of the Company:4.1.1.1.6.1.certifying that:4.1.1.1.6.1.1.the representations and warranties contained in ARTICLE V and the other Loan Documents are true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of such date, as though made on and as of such date (or, in the case of any such representation or warranty expressly stated to have been made as of a specific date, as of such specific date);4.1.1.1.6.1.2.no Default or Event of Default exists or, if applicable, would result from the initial Borrowing;4.1.1.1.6.1.3.there has occurred since March 31, 2022, no event or circumstance that has resulted or could reasonably be expected to result in a Material Adverse Effect;4.1.1.1.6.1.4.each of the conditions in Sections 4.01(a) and 4.01(b)Â has been satisfied on the part of the Company as of the date hereof;4.1.1.1.6.2.designating the date hereof; andÂ Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.1.1.1.6.3.indicating the Debt Ratings; and4.1.1.1.7.such other assurances, certificates, documents, consents or opinions as the Administrative Agent, the L/C Issuers or the Required Lenders reasonably may require.4.1.1.2.Any fees required by the Loan Documents to be paid, and all reimbursable expenses for which invoices have been presented, to the Agent, the L/C Issuers, the Arrangers or any Lender on or before the date hereof shall have been paid, to the extent that such invoices have been presented to the Company on or before the date hereof.4.1.1.3.Unless waived by the Administrative Agent, the Company shall have paid all Attorney Costs of the Administrative Agent to the extent invoiced to the Company prior to or on the date hereof, plus such additional amounts of Attorney Costs as shall constitute its reasonable estimate of Attorney Costs incurred or to be incurred by it through the proceedings (provided that such estimate shall not thereafter preclude a final settling of accounts between the Company and the Administrative Agent).4.1.1.4.Since March 31, 2022, no Material Adverse Effect shall have occurred or become known to the Administrative Agent.4.1.1.5.The commitments of the lenders under the Existing Revolving Credit Agreement shall have been terminated and all the obligations under the Existing Revolving Credit Agreement shall have been repaid or prepaid (which repayment or prepayment may be made with the proceeds of the initial Credit Extension hereunder), and the Administrative Agent shall have received evidence satisfactory to it thereof.(f)Â Â Â Â The Administrative Agent shall have received, (i) at least three (3) Business Days prior to the Closing Date, all documentation and other information required by regulatory authorities under applicable â€œknow your customerâ€ and anti-money laundering rules and regulations, including the PATRIOT Act, as is reasonably requested in writing by the Administrative Agent at least ten (10) Business Days prior to the Closing Date and (ii) at least three (3) Business Days prior to the Closing Date, any Loan Party that qualifies as a â€œlegal entity customerâ€ under the Beneficial Ownership Regulation shall have delivered, to each Lender that so requests at least ten (10) Business Days prior to the Closing Date, a Beneficial Ownership Certification in relation to such Loan Party.Without limiting the generality of the provisions of Section 9.05, for purposes of determining compliance with the conditions specified in this Section 4.01, each Lender that has signed this Agreement shall be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter explicitly required under this Section 4.01 to be consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent shall have received notice from such Lender prior to the proposed date hereof specifying its objection thereto.4.2.Existing Revolving Credit Agreement (a)Â On the date hereof, the â€œCommitmentsâ€ as defined in the Existing Revolving Credit Agreement shall terminate, without further action by any party thereto. (b)Â Â Â Â The Lenders which are parties to the Existing Revolving Credit Agreement, comprising the â€œRequired Lendersâ€ as defined in the Existing Revolving Credit Agreement hereby waive any requirement of prior notice of termination of the Commitments (as defined in the Existing Revolving Credit Agreement) pursuant to Section 2.06 thereof and of prepayment of loans thereunder, to the extent necessary to give effect to 4.01(e) hereof, provided that any such prepayment of loans thereunder shall be subject to Section 2.05 of the Existing Revolving Credit Agreement.4.3.Conditions to all Credit Extensions. The obligation of each Lender to honor any Request for Credit Extension (other than a Committed Loan Notice requesting only a conversion of Committed Loans to the other Type, or a continuation of Eurocurrency Rate Loans) is subject to the following conditions precedent:Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 4.3.1.1.The representations and warranties contained in ARTICLE V or any other Loan Document, or which are contained in any document furnished at any time under or in connection herewith or therewith, shall be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) on and as of the date of such Credit Extension, except to the extent that such representations and warranties specifically refer to an earlier date, in which case they shall be true and correct in all material respects (or, in the case of any such representation or warranty already qualified by materiality, in all respects) as of such earlier date, and except that for purposes of this Section 4.03, the representations and warranties contained in Section 5.08(a) shall be deemed to refer to the most recent statements furnished pursuant Sections 6.01(a) and 6.01(b), respectively.4.3.1.2.No Default shall exist, or would result from such proposed Credit Extension.4.3.1.3.The Administrative Agent and, if applicable, any L/C Issuer, shall have received a Request for Credit Extension in accordance with the requirements hereof.4.3.1.4.If the applicable Borrower is a Designated Borrower, then the conditions of SectionÂ 2.16 related to the designation of such Borrower as a Designated Borrower shall have been met to the satisfaction of the Administrative Agent.Each Request for Credit Extension (other than a Committed Loan Notice requesting only a conversion of Committed Loans to the other Type or a continuation of Eurocurrency Rate Loans) submitted by the Company, shall be deemed to be a representation and warranty that the conditions specified in Sections 4.03(a), (b) and (d) have been satisfied on and as of the date of the applicable Credit Extension.5.REPRESENTATIONS AND WARRANTIESEach Borrower represents and warrants (which representations and warranties in the case of any Borrower other than the Company shall be limited to such Borrower and its Subsidiaries and other facts and circumstances known to such Borrower and its Subsidiaries) to the Administrative Agent and each Lender that:5.1.Corporate Existence and Power. Each Borrower:5.1.1.1.is duly organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization;5.1.1.2.has the power and authority and all required governmental licenses, authorizations, consents and approvals to own its assets, carry on its business and to execute, deliver, and perform its obligations under the Loan Documents to which it is a party;5.1.1.3.is duly qualified and is licensed and in good standing under the laws of each jurisdiction where its ownership, lease or operation of property or the conduct of its business requires such qualification or license; and5.1.1.4.is in compliance with all Requirements of Law;except, with respect to clause (c)Â or clause (d), to the extent that the failure to do so could not reasonably be expected to have a Material Adverse Effect.5.2.Corporate Authorization; No Contravention. The execution, delivery and performance by each Borrower of this Agreement and each other Loan Document to which such Borrower is party, and any Borrowing as of the date of such Borrowing have been duly authorized by all necessary corporate action, and do not and will not:5.2.1.1.contravene the terms of any Borrowerâ€™s Organization Documents;Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5.2.1.2.conflict with or result in any breach or contravention of, or the creation of any Lien under, any document evidencing any Contractual Obligation to which any Borrower is a party or any order, injunction, writ or decree of any Governmental Authority to which any Borrower or its property is subject; or5.2.1.3.violate any Requirement of Law.5.3.Governmental Authorization. No approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority (each of the foregoing, an â€œAuthorizationâ€) is necessary or required in connection with the execution, delivery or performance by, or enforcement against, any Borrower of the Agreement or any other Loan Document, except to the extent that failure to have obtained or completed, as applicable, such Authorization would not result in a Material Adverse Effect.5.4.Binding Effect. This Agreement and each other Loan Document to which each Borrower is a party constitute the legal, valid and binding obligations of such Borrower, enforceable against such Borrower in accordance with their respective terms, except as enforceability may be limited by applicable bankruptcy, insolvency, or similar laws affecting the enforcement of creditorsâ€™ rights generally or by equitable principles relating to enforceability.5.5.Litigation. There are no actions, suits, proceedings, claims or disputes pending, or to the best knowledge of each Borrower, threatened or contemplated, at law, in equity, in arbitration or before any Governmental Authority, against any Borrower, or its Subsidiaries or any of their respective properties which:5.5.1.1.purport to pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby or thereby; or5.5.1.2.if determined adversely to the Company or its Subsidiaries, would reasonably be expected to have a Material Adverse Effect which has not been disclosed in the Companyâ€™s annual report for any fiscal period on Form 10-K. No injunction, writ, temporary restraining order or any order of any nature has been issued by any court or other Governmental Authority purporting to enjoin or restrain the execution, delivery or performance of this Agreement or any other Loan Document, or directing that the transactions provided for herein or therein not be consummated as herein or therein provided.5.6.No Default. No Default or Event of Default exists or would result from the incurring of any Obligations by any Borrower. As of the date hereof, neither the Company nor any Subsidiary is in default under or with respect to any Contractual Obligation in any respect which, individually or together with all such defaults, could reasonably be expected to have a Material Adverse Effect as of the date hereof, or that would, if such default had occurred after the date hereof, create an Event of Default under Section 8.01(e).5.7.Use of Proceeds; Margin Regulations. The proceeds of the Loans are to be used solely for the purposes set forth in Section 6.10. Neither the Company nor any Subsidiary is generally engaged in the business of purchasing or carrying Margin Stock (other than the Companyâ€™s own treasury stock) or extending credit for the purpose of purchasing or carrying Margin Stock.5.8.Financial Condition. (a) The Audited Financial Statements:5.8.1.1.1.1.were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, subject in the case of the unaudited statements to ordinary, good faith year end audit adjustments;5.8.1.1.1.2.fairly present in all material respects the financial condition of the Company and its Subsidiaries as of the date thereof and results of operations for the period covered thereby; andÂ Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â 5.8.1.1.1.3.show all material indebtedness and other liabilities, direct or contingent, of the Company and its consolidated Subsidiaries as of the date thereof required to be shown in accordance with GAAP.5.8.1.1.As of the date hereof, since March 31, 2022, there has been no Material Adverse Effect.5.9.Regulated Entities. None of the Company, any Person controlling the Company, or any Subsidiary, is or is required to be registered as an â€œinvestment companyâ€ within the meaning of the Investment Company Act of 1940. 5.10.Taxes. Except to the extent that failure to have so filed or paid would not result in a Material Adverse Effect, each Borrower and its Subsidiaries have timely filed or caused to be filed all Federal, state and other material tax returns and reports required to be filed, and have paid all Federal, state and other material taxes, assessments, fees and other governmental charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have been provided in accordance with GAAP. There is no proposed tax assessment against any Borrower or any Subsidiary that would, if made, have a Material Adverse Effect. Neither any Borrower nor any Subsidiary thereof is party to any tax sharing agreement other than an agreement solely between one or more Borrowers or Subsidiaries.5.11.Sanctions. No Borrower, nor any of its Subsidiaries, nor, to the knowledge of the Company, any director, officer, or employee thereof, nor, to the knowledge of the Company, any agent thereof that will act in any capacity in connection with or directly benefit from the credit facility established hereby, is an individual or entity that is, or is owned or controlled by one or more individuals or entities that are (i) currently the subject or target of any Sanctions, (ii) included on OFACâ€™s List of Specially Designated Nationals, HMTâ€™s Consolidated List of Financial Sanctions Targets and the Investment Ban List, or any similar list enforced by OFAC or HMT or (iii) located, organized or resident in a Designated Jurisdiction.Â Each Borrower and its Subsidiaries conduct their businesses in compliance in all material respects with all applicable Sanctions.Â Each Borrower and its Subsidiaries have instituted and maintain policies and procedures designed to promote and achieve compliance with all applicable Sanctions.5.12.Anti-Corruption Laws and Anti-Money Laundering Laws. Each Borrower and its Subsidiaries are in compliance in all material respects with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions in which the Borrowers or any of their Subsidiaries conduct business and with all applicable Anti-Money Laundering Laws. Each

Borrower and its Subsidiaries have instituted and maintain policies and procedures designed to promote and achieve compliance with all applicable anti-corruption laws.5.13.ERISA. No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such ERISA Events, would reasonably be expected to result in a Material Adverse Effect.5.14.Beneficial Ownership Certification. As of the Closing Date, the information included in the Beneficial Ownership Certification, if applicable, is true and correct in all respects.6.AFFIRMATIVE COVENANTSSo long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than Obligations under Section 11.04(b) that remain contingent after termination of the Commitments and payment of all other Obligations) hereunder shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding, unless the Required Lenders waive compliance in writing:6.1.Financial Statements. The Company shall deliver to the Administrative Agent, in form and detail satisfactory to the Administrative Agent and the Required Lenders:Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 6.1.1.1.as soon as available, but in any event within 70 days after the end of each fiscal year of the Company, a consolidated balance sheet of the Company and its Subsidiaries as at the end of such fiscal year, and the related consolidated statements of operations, shareholdersâ€™ equity and cash flows for such fiscal year, setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and prepared in accordance with GAAP, audited and accompanied by a report and opinion of Deloitte & Touche LLP or another nationally recognized independent certified public accountant, which report and opinion shall be prepared in accordance with GAAP and shall not be subject to any â€œgoing concernâ€ or like qualification or exception or any qualification or exception as to the scope of such audit; and6.1.1.2.as soon as available, but in any event within 55 days after the end of each of the first three fiscal quarters of each fiscal year of the Company, a consolidated balance sheet of the Company and its Subsidiaries as at the end of such fiscal quarter, and the related consolidated statements of operations, shareholdersâ€™ equity and cash flows for such fiscal quarter and for the portion of the Companyâ€™s fiscal year then ended, setting forth in each case in comparative form the figures for the corresponding fiscal quarter of the previous fiscal year and the corresponding portion of the previous fiscal year, all in reasonable detail and certified by a Responsible Officer of the Company as fairly presenting the financial condition, results of operations, shareholdersâ€™ equity and cash flows of the Company and its Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence of footnotes. As to any information contained in materials furnished pursuant to Section 6.02(b), the Company shall not be separately required to furnish such information under clause (a)Â or (b)Â above, but the foregoing shall not be in derogation of the obligation of the Company to furnish the information and materials described in Sections 6.01(a) and 6.01(b)Â at the times specified therein.6.2.Certificates; Other Information. The Company shall deliver to the Administrative Agent:6.2.1.1.concurrently with the delivery of the financial statements referred to in Sections 6.01(a) and 6.01(b), a duly completed Compliance Certificate signed by a Responsible Officer of the Company;6.2.1.2.promptly after the same are available, copies of each annual report, proxy or financial statement or other report or communication sent to the stockholders of the Company, and copies of all annual, regular, periodic and special reports and registration statements which the Company may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act of 1934, and not otherwise required to be delivered to the Administrative Agent pursuant hereto; 6.2.1.3.promptly, such additional information regarding the business, financial or corporate affairs of the Borrowers or any Subsidiary, or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender may from time to time reasonably request; and6.2.1.4.promptly following any request therefor, provide information and documentation reasonably requested by the Administrative Agent or any Lender for purposes of compliance with applicable â€œknow your customerâ€ and anti-money-laundering rules and regulations, including, without limitation, the PATRIOT Act and the Beneficial Ownership Regulation.Documents required to be delivered pursuant to Sections 6.01(a) or 6.01(b)Â or 6.02(b) or Section 6.03 may be delivered electronically and if so delivered, shall be deemed to have been delivered on the date (i)Â on which it is publicly available at no charge on the EDGAR system of the United States Securities and Exchange Commission, (ii)Â on which the Company posts such documents, or provides a link thereto on the Companyâ€™s website on the Internet at the website address listed on Schedule 11.02; or (iii)Â on which such documents are posted on the Companyâ€™s behalf on IntraLinks, SyndTrak or another similar electronic system (a â€œPlatformâ€), if any, to which each Lender and the Administrative Agent have access (whether a commercial, third-party website or whether sponsored by the Administrative Agent). The Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event shall have no responsibility to monitor compliance by the Company with any such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its copies of such documents.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â The Borrowers hereby acknowledge that (a)Â the Administrative Agent may make available to the Lenders and the L/C Issuers materials and/or information provided by or on behalf of the Borrowers under Sections 6.01(a), 6.01(b), 6.02(a), 6.02(b), and Section 6.03 (and any other such materials and/or information to the extent the applicable Borrower has previously consented in writing) (collectively, â€œBorrower Materialsâ€) by posting the Borrower Materials on a Platform and (b)Â certain of the Lenders (each, a â€œPublic Lenderâ€) may have personnel who do not wish to receive material non-public information with respect to any of the Borrowers or their respective affiliates, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with respect to such Personsâ€™ securities. The Borrowers hereby agree that (a)Â all Borrower Materials that are to be made available to Public Lenders shall be clearly and conspicuously marked â€œPUBLICâ€ which, at a minimum, shall mean that the word â€œPUBLICâ€ shall appear prominently on the first page thereof; (b)Â by marking Borrower Materials â€œPUBLIC,â€ the Borrowers shall be deemed to have authorized the Administrative Agent, the L/C Issuers and the Lenders to treat such Borrower Materials as publicly available information with respect to the Borrowers or their respective securities for purposes of United States Federal and state securities laws; (c)Â all Borrower Materials marked â€œPUBLICâ€ are permitted to be made available through a portion of a Platform designated â€œPublic Investorâ€; and (d)Â the Administrative Agent shall be entitled to treat any Borrower Materials that are not marked â€œPUBLICâ€ as being suitable only for posting on a portion of a Platform not designated â€œPublic Investorâ€.6.3.Notices. Each Borrower shall promptly notify the Administrative Agent:6.3.1.1.of the occurrence of any Default;6.3.1.2.of any matter that has resulted or could reasonably be expected to result in a Material Adverse Effect;6.3.1.3.of (i)Â the occurrence of any ERISA Event with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of any Borrower or any of its Subsidiaries in an aggregate amount in excess of $50,000,000 during the term of this Agreement, or (ii)Â the existence of an amount of unfunded benefit liabilities (as defined in Section 4001(a)(18) of ERISA), individually or in the aggregate for all Pension Plans (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), which exceeds 3% of Net Worth.Notification delivered to the Administrative Agent and each Lender by any Borrower under this Section 6.03 shall satisfy the notice obligation of all Borrowers hereunder. Each notice pursuant to this Section 6.03 shall be accompanied by a statement of a Responsible Officer of the Company setting forth details of the occurrence referred to therein and stating what action the Company has taken and proposes to take with respect thereto. Each notice pursuant to Section 6.03(a) shall describe with particularity any and all provisions of this Agreement and any other Loan Document that have been breached.6.4.Preservation of Existence, Etc. Each Borrower shall, and shall cause each of its Material Subsidiaries to, (a)Â preserve, renew and maintain in full force and effect its legal existence and good standing under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 7.02 and (b)Â take all reasonable action to maintain all governmental rights, privileges, permits, licenses and franchises necessary in the normal conduct of its business, except in connection with transactions permitted by Section 7.02 and except to the extent that failure to do so could not reasonably be expected to have a Material Adverse Effect.6.5.Maintenance of Insurance. Each Borrower shall, and shall cause each of its Material Subsidiaries to, maintain with financially sound and reputable insurance companies, insurance (including self-insurance) with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar business, of such types and in such amounts as the Company reasonably deems prudent from time to time.6.6.Payment of Taxes. Each Borrower shall, and shall cause each of its Material Subsidiaries to, pay and discharge as the same shall become due and payable, all tax liabilities, assessments and governmental charges or Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â levies upon it or its properties or assets (other than obligations that a Responsible Officer is not aware of or are of a nominal amount), unless the same are being contested in good faith by appropriate proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Company or such Material Subsidiary, and except to the extent that failure to so pay and discharge, either individually or in the aggregate, would not result in a Material Adverse Effect.6.7.Compliance with Laws. Each Borrower shall, and shall cause each of its Material Subsidiaries to, comply in all material respects with the Requirements of Law applicable to it or to its business, except in such instances in which (a)Â a Requirement of Law is being contested in good faith by appropriate proceedings diligently conducted; or (b)Â the failure to comply therewith could not reasonably be expected to have a Material Adverse Effect.6.8.Books and Records. Each Borrower shall, and shall cause each of its Material Subsidiaries to, maintain in all material respects proper books of record and account, in which full, true and correct entries in conformity with GAAP consistently applied shall be made of all financial transactions and matters involving the assets and business of the Company and such Material Subsidiary, as the case may be.6.9.Inspection Rights. Each Borrower shall, and shall cause each of its Material Subsidiaries to, permit representatives and independent contractors of the Administrative Agent, on behalf of itself or a request of any Lender, to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss its affairs, finances and accounts with its directors, officers, and independent public accountants, all at such reasonable times during normal business hours and upon reasonable advance notice to the Company and the applicable Borrower that is the subject of such inspection; provided, however, that when an Event of Default exists the representatives and independent contractors of the Administrative Agent may do any of the foregoing at the reasonable expense of the Borrowers at any time during normal business hours and upon reasonable advance notice to the Company and the applicable Borrower that is the subject of such inspection; provided, further, that so long as no Event of Default exists, no Borrower shall be required to or to cause any Material Subsidiary to, permit more than one such visit or inspection on more than one occasion in any twelve-month period.6.10.Use of Proceeds. The Borrowers shall use the proceeds of the Credit Extensions for general corporate purposes not in contravention of any Law or of any Loan Document.6.11.Anti-Corruption Laws; Sanctions. The Borrowers shall, and shall cause each Subsidiary to, (i) conduct its businesses in compliance in all material respects with the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions in which any Borrower or any of its Subsidiaries conduct business, all applicable Sanctions and all applicable Anti-Money Laundering Laws and (ii) maintain policies and procedures designed to promote and achieve compliance with all applicable anti-corruption laws and all applicable Sanctions.7.NEGATIVE COVENANTSSo long as any Lender shall have any Commitment hereunder, any Loan or other Obligation (other than Obligations under subsection 11.04(b) that remain contingent after termination of the Commitments and payment of all other Obligations) hereunder shall remain unpaid or unsatisfied, or any Letter of Credit shall remain outstanding, unless the Required Lenders waive compliance in writing:7.1.Liens. No Borrower shall, or shall suffer or permit any of its Material Subsidiaries to, directly or indirectly, create, incur, assume or suffer to exist any Lien upon any of its property, whether now owned or hereafter acquired, other than the following (â€œPermitted Liensâ€):Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 7.1.1.1.any Lien existing on property of the Company or any Material Subsidiary on the date hereof securing Indebtedness outstanding on such date and any renewals or extensions thereof; provided that the property covered thereby is not changed or increased;7.1.1.2.any Lien created under any Loan Document;7.1.1.3.Liens for taxes, fees, assessments or other governmental charges not yet due or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP;7.1.1.4.carriersâ€™, warehousemenâ€™s, mechanicsâ€™, materialmenâ€™s, landlordsâ€™, repairmenâ€™s or other like Liens arising in the ordinary course of business which are not delinquent or remain payable without penalty;7.1.1.5.pledges or deposits required in the ordinary course of business in connection with workersâ€™ compensation, unemployment insurance and other social security legislation, other than any Lien imposed by ERISA;7.1.1.6.Liens on the property of any Borrower or any Material Subsidiary securing (i)Â the non-delinquent performance of bids, trade contracts (other than for borrowed money), leases, statutory obligations, (ii)Â contingent obligations on surety and appeal bonds, and (iii)Â other non-delinquent obligations of a like nature; in each case, incurred in the ordinary course of business, provided all such Liens in the aggregate would not (even if enforced) cause a Material Adverse Effect;7.1.1.7.easements, rights-of-way, restrictions and other similar encumbrances which, in the aggregate, are not substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person;7.1.1.8.Liens arising solely by virtue of any statutory or common law provision relating to bankerâ€™s liens, rights of set-off or similar rights and remedies as to deposit accounts or other funds maintained with a creditor depository institution; provided that (i)Â such deposit account is not a dedicated cash collateral account and is not subject to restrictions against access by the Company in excess of those set forth by regulations promulgated by the FRB, and (ii)Â such deposit account is not intended by any Borrower or any Material Subsidiary to provide collateral to the depository institution;7.1.1.9.Liens arising out of any Qualified Receivables Transaction;7.1.1.10.Liens existing on any property or asset prior to the acquisition thereof by any Borrower or any Material Subsidiary or existing on a property or asset of a Person prior to such Person becoming a Subsidiary; provided that (x) such Liens were not granted in connection with, or in contemplation of, the acquisition of such property or such asset or such Person becoming a Subsidiary, (y) such Liens secure only the obligations secured immediately prior to the acquisition of such property or asset or Person becoming a Subsidiary (and any modifications, extensions, renewals, replacements or refinancings thereof that does not increase the amount of such original obligations) and (z) such Liens shall not apply to any other property or assets of any Borrower or the Subsidiaries, other than the proceeds of such acquired property or assets and related books and records;7.1.1.11.Liens existing on equipment, computers or software acquired by any Borrower or any Material Subsidiary at the time of Borrowerâ€™s or Material Subsidiaryâ€™s, as applicable, acquisition thereof, provided that such Liens are confined solely to the property so acquired or the proceeds thereof and related books and records;7.1.1.12.Liens on deposit or securities accounts (and cash and cash equivalents and other financial assets held therein) established in the ordinary course of business in favor of the financial institution at which such account is held, arising pursuant to such financial institutionâ€™s standard terms and conditions governing such account and not securing Indebtedness; andÂ Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 7.1.1.13.Liens securing Indebtedness and other obligations (other than Indebtedness and other obligations secured by Liens described in any of the foregoing Section 7.01(a) through (l)) in an aggregate principal amount that, at the time of incurrence of such secured Indebtedness or obligations, together with all other Indebtedness or obligations secured by Liens permitted in reliance on this clause (m) at such time, does not exceed the greater of (x) $2,000,000,000 or (y) 25% of Net Worth at such time.7.2.Consolidations and Mergers. No Borrower shall directly or indirectly, liquidate, dissolve, merge, amalgamate, consolidate with or into, or convey, transfer, lease or otherwise dispose of (whether in one transaction or in a series of transactions) all or substantially all of its assets (whether now owned or hereafter acquired) to or in favor of any Person, except:7.2.1.1.any Borrower (other than the Company) may merge with the Company, provided that the Company shall be the continuing or surviving corporation, or with any one or more Wholly-Owned Subsidiaries; provided that a Borrower shall be the continuing or surviving corporation and the jurisdiction of incorporation of such Borrower shall be a Designated Borrower Jurisdiction;7.2.1.2.any Borrower (other than the Company) may amalgamate with any one or more of the Companyâ€™s Wholly-Owned Subsidiaries; provided that a Borrower shall be the continuing or surviving corporation and the jurisdiction of incorporation of such Borrower shall be a Designated Borrower Jurisdiction;7.2.1.3.any Borrower (other than the Company) may sell, transfer or exchange all or substantially all of its assets (upon voluntary liquidation or otherwise) to the Company or another Borrower;7.2.1.4.the Company may convey, transfer, lease or otherwise dispose of all or substantially all of its pharmacology distribution business to a wholly-owned Domestic Subsidiary that, simultaneously therewith, executes and delivers to the Administrative Agent a joinder agreement in the form of Exhibit F hereto and becomes a Borrower under this Agreement; provided that the parties hereto acknowledge and agree that prior to such Borrower becoming entitled to utilize the credit facilities provided for herein the Administrative Agent and the Lenders shall have received such supporting resolutions, incumbency certificates, opinions of counsel and other documents or information, in form, content and scope reasonably satisfactory to the Administrative Agent, as may reasonably be required by the Administrative Agent or the Required Lenders, and Notes signed by such new Borrower to the extent any Lenders so require. If the Administrative Agent and the Required Lenders agree that such Borrower shall be entitled to receive Loans hereunder, then promptly following receipt of all such requested resolutions, incumbency certificates, opinions of counsel and other documents or information, the Administrative Agent shall send a notice in substantially the form of ExhibitÂ G (a â€œBorrower Noticeâ€)Â to the Company and the Lenders specifying the effective date upon which such Borrower shall constitute a Borrower for purposes hereof, whereupon each of the Lenders agrees to permit such Borrower to receive Loans hereunder, on the terms and conditions set forth herein, and each of the parties agrees that such Borrower otherwise shall be a Borrower for all purposes of this Agreement; provided that no Committed Loan Notice or Letter of Credit Application may be submitted by or on behalf of such Borrower until the date five Business Days after such effective date; and7.2.1.5.the Company may merge or consolidate with or into another Person, provided that (i)Â either (x)Â the Company shall be the

continuing or surviving corporation or (y) (A)Â the successor Person (if other than the Company) formed by such consolidation or into which the Company is merged (the â€œSuccessorâ€) is a corporation, limited liability company or limited partnership organized or existing under the laws of the United States, any state of the United States or the District of Columbia, and (B)Â the Successor (if any) shall have expressly assumed all of the Companyâ€™s Obligations pursuant to documentation in form satisfactory to the Administrative Agent, and (ii)Â no Default or Event of Default is in effect immediately prior to or on the date of or would result from such merger or consolidation.7.3.Use of Proceeds. No Borrower shall, or shall suffer or permit any of its Subsidiaries to, use any Credit Extension, directly or indirectly, (a)Â to purchase or carry Margin Stock in contravention of Regulation U issued by the Board of Governors of the Federal Reserve, (b)Â to repay or otherwise refinance indebtedness of the Company or Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â others incurred to purchase or carry Margin Stock in contravention of said Regulation U, (c)Â to extend credit for the purpose of purchasing or carrying any Margin Stock in contravention of said Regulation U, or (d)Â to acquire any security in any transaction that is subject to Section 13 or 14 of the Securities Exchange Act of 1934, in contravention of said Regulation U.7.4.Financial Covenant. The Company will not permit the Leverage Ratio as of the last day of any fiscal quarter to exceed 4.00 to 1.00; provided that upon the consummation of any Material Acquisition that involves payment of cash consideration of at least US$500,000,000 and the written election of the Company to the Administrative Agent (which shall deliver a copy to the Lenders), the maximum permitted Leverage Ratio set forth above shall increase to 4.50 to 1.00, with respect to the last day of the fiscal quarter of the Company during which such Material Acquisition is consummated and the last day of each of the next three full fiscal quarters of the Company ending after the date of the consummation of such Material Acquisition; provided, however, that the Company shall not be permitted to make such an election if the Company has theretofore made such an election unless at least one full fiscal quarter of the Company shall have ended since the date of such prior election without an increase being in effect.Solely for purposes of determining compliance with the financial covenant set forth in this Section above and as of the last day of any fiscal quarter with respect to which the financial covenant is tested, (a)Â the definition of Total Debt shall not include the Indebtedness of any partnership or joint venture that is not a Subsidiary of the Company and in which the Company or any of its Subsidiaries is a general partner or a joint venture to the extent that such Indebtedness is expressly made non-recourse to the Company and its Subsidiaries and (b)Â the definition of Consolidated EBITDA shall not include any amounts contributed to the Company or any of its Subsidiaries by any such partnership or joint venture referenced in clause (a)Â except to the extent of the amounts actually received in cash by the Company or its Subsidiaries.7.5.Sanctions. No Borrower shall, nor shall it permit any Subsidiary to, directly or, to the knowledge of such Borrower, indirectly, use the proceeds of any Credit Extension, or lend, contribute or otherwise make available such proceeds to any Subsidiary, joint venture partner or other individual or entity, to fund any activities of or business of or with any individual or entity, or in any Designated Jurisdiction, that, at the time of such funding, is the subject of Sanctions, or in any other manner that will result in a violation by any individual or entity (including any individual or entity participating in the transaction, whether as Lender, Arranger, Administrative Agent, L/C Issuer, or otherwise) of Sanctions.7.6.Anti-Corruption Laws. No Borrower shall, nor shall it permit any Subsidiary to, directly or, to the knowledge of such Borrower, indirectly use the proceeds of any Credit Extension for any purpose which would breach the United States Foreign Corrupt Practices Act of 1977, the UK Bribery Act 2010, and other similar anti-corruption legislation in other jurisdictions in which any Borrower or any of its Subsidiaries conduct business.8.EVENTS OF DEFAULT AND REMEDIES8.1.Events of Default. Any of the following shall constitute an Event of Default:8.1.1.1.Non-Payment. Any Borrower fails to pay (i)Â when and as required to be paid herein, any amount of principal of any Loan, L/C Obligation, or (ii)Â within five days after the same becomes due, any interest on any Loan, L/C Obligation, or any facility fee or other fee due hereunder, or any other amount payable hereunder or under any other Loan Document; or8.1.1.2.Specific Covenants. The Company fails to perform or observe any term, covenant or agreement contained in any of Section 6.03(a), Section 6.04(a) or ARTICLE VII; or8.1.1.3.Other Defaults. Any Borrower fails to perform or observe any other covenant or agreement (not specified in Section 8.01(a) or 8.01(b)) contained in any Loan Document on its part to be performed or observed and Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â such failure continues for 30 days after the date upon which written notice thereof is given to the Company by the Administrative Agent or any Lender; or8.1.1.4.Representations and Warranties. Any representation, warranty, certification or statement of fact made or deemed made by or on behalf of any Borrower herein, in any other Loan Document, or in any document delivered in connection herewith or therewith shall be incorrect or misleading in any material respect when made or deemed made; or8.1.1.5.Cross-Default. (i)Â The Company or any Subsidiary (A)Â fails to make any payment when due (whether by scheduled maturity, required prepayment, acceleration, demand, or otherwise) in respect of any Indebtedness or Guarantee (other than any intercompany Indebtedness or any Indebtedness hereunder) having an aggregate principal amount (including undrawn committed or available amounts and including amounts owing to all creditors under any combined or syndicated credit arrangement) of more than $200,000,000 (such Indebtedness or Guarantee being a â€œRelevant Obligationâ€) and such failure continues after the applicable grace or notice period, if any, specified in the relevant document on the date of such failure, or (B)Â fails to observe or perform any other agreement or condition relating to, or contained in any instrument or agreement evidencing, securing or relating to, any Relevant Obligation, and such failure continues after the applicable grace or notice period, if any, specified in the relevant document on the date of such failure, or any other event occurs, the effect of which default or other event is to cause such Relevant Obligation to be demanded or to become due or to be repurchased, prepaid, defeased or redeemed (automatically or otherwise), or an offer to repurchase, prepay, defease or redeem such Relevant Obligation to be made, prior to its stated maturity, or such cash collateral in respect of such Relevant Obligation to be demanded (provided that an Acquired Debt Default shall not constitute an Event of Default pursuant to this clause (i)(B) so long as such Acquired Debt Default is waived or cured, or the Relevant Obligation giving rise thereto is repaid, within 30 days of consummation of the transaction giving rise thereto) or (ii)Â there occurs under any Swap Contract an Early Termination Date (as defined in such Swap Contract) resulting from (A)Â any event of default under such Swap Contract as to which the Company or any Subsidiary is the Defaulting Party (as defined in such Swap Contract) or (B)Â any Termination Event (as so defined) under such Swap Contract as to which the Company or any Subsidiary is an Affected Party (as so defined) and, in either event, the Swap Termination Value owed by the Company or such Subsidiary as a result thereof is greater than $200,000,000; or8.1.1.6.Insolvency; Voluntary Proceedings. The Company or any Material Subsidiary (i)Â ceases or fails to be solvent, or generally fails to pay, or admits in writing its inability to pay, its debts as they become due, subject to applicable grace periods, if any, whether at stated maturity or otherwise; (ii)Â voluntarily ceases to conduct its business in the ordinary course; (iii)Â commences any Insolvency Proceeding with respect to itself; or (iv)Â takes any action to effectuate or authorize any of the foregoing; or8.1.1.7.Involuntary Proceedings. (i)Â Any involuntary Insolvency Proceeding is commenced or filed against the Company or any Material Subsidiary, or any writ, judgment, warrant of attachment, execution or similar process, is issued or levied against a substantial part of the Companyâ€™s or any Material Subsidiaryâ€™s properties, and any such proceeding or petition shall not be dismissed, or such writ, judgment, warrant of attachment, execution or similar process shall not be released, vacated or fully bonded within sixty (60) days after commencement, filing or levy; (ii)Â the Company or any Material Subsidiary admits the material allegations of a petition against it in any Insolvency Proceeding, or an order for relief (or similar order under non-U.S. law) is ordered in any Insolvency Proceeding; or (iii)Â the Company or any Material Subsidiary acquiesces in the appointment of a receiver, trustee, custodian, conservator, liquidator, mortgagee in possession (or agent therefor), or other similar Person for itself or a substantial portion of its property or business; or8.1.1.8.ERISA. (i)Â An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could reasonably be expected to result in liability of the Company or any of its Subsidiaries in an aggregate amount in excess of $200,000,000 during the term of this Agreement, or (ii)Â there shall exist an amount of unfunded benefit liabilities (as defined in Section 4001(a)(18) of ERISA), individually or in the aggregate for all Pension Plans (excluding for purposes of such computation any Pension Plans with respect to which assets exceed benefit liabilities), which exceeds 7% of Net Worth; or Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â 8.1.1.9.Invalidity of Loan Documents. Any Loan Document, at any time after its execution and delivery and for any reason other than as expressly permitted hereunder or thereunder or satisfaction in full of all the Obligations, ceases to be in full force and effect; or any Loan Party contests in any manner the validity or enforceability of any provision of any Loan Document; or any Loan Party denies that it has any or further liability or obligation under any Loan Document, or purports to revoke, terminate or rescind any provision of any Loan Document; or8.1.1.10.Change of Control. There occurs any Change of Control.8.2.Remedies Upon Event of Default. If any Event of Default occurs and is continuing, the Administrative Agent shall, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions:8.2.1.1.declare the commitment of each Lender to make Loans and any obligation of each L/C Issuer to make L/C Credit Extensions to be terminated, whereupon such commitments and obligation shall be terminated;8.2.1.2.declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by each Borrower;8.2.1.3.require that the Company Cash Collateralize the L/C Obligations (in an amount equal to the then Outstanding Amount thereof); and8.2.1.4.exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan Documents or applicable law;provided, however, that upon the occurrence of (i)Â any event described in Section 8.01(f) or (ii)Â an actual or deemed entry of an order for relief with respect to any Borrower under the Bankruptcy Code of the United States, except in the case of Section 8.01(g)(i), in which case upon the expiration of the 60-day period mentioned therein if the curative action mentioned in such clause is not taken, the obligation of each Lender to make Loans and any obligation of each L/C Issuer to make L/C Credit Extensions shall automatically terminate, the unpaid principal amount of all outstanding Loans and all interest and other amounts as aforesaid shall automatically become due and payable, and the obligation of the Company to Cash Collateralize the L/C Obligations as aforesaid shall automatically become effective, in each case without further act of the Administrative Agent or any Lender.8.3.Application of Funds. After the exercise of remedies provided for in Section 8.02 (or after the Loans and other Obligations have automatically become immediately due and payable and the L/C Obligations have automatically been required to be Cash Collateralized as set forth in the proviso to Section 8.02), any amounts received on account of the Obligations shall be applied by the Administrative Agent in the following order:First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and other amounts (including Attorney Costs and amounts payable under ARTICLE III) payable to the Administrative Agent and the L/C Issuers in their respective capacities as such;Second, to payment of that portion of the Obligations constituting fees, indemnities and other amounts (other than principal and interest) payable to the Lenders (including Attorney Costs and amounts payable under ARTICLE III), ratably among them in proportion to the amounts described in this clause Second payable to them;Third, to payment of that portion of the Obligations constituting accrued and unpaid interest on the Loans and L/C Borrowings, ratably among the Lenders in proportion to the respective amounts described in this clause Third payable to them;Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans and L/C Borrowings, in each case ratably among the Lenders in proportion to the respective amounts described in this clause Fourth held by them;Fifth, to the Administrative Agent for the account of the applicable L/C Issuers to Cash Collateralize that portion of L/C Obligations comprised of the aggregate undrawn amount of Letters of Credit; andLast, the balance, if any, after all of the Obligations have been indefeasibly paid in full, to the Company or as otherwise required by Law.Subject to Section 2.03(c), amounts used to Cash Collateralize the aggregate undrawn amount of Letters of Credit pursuant to clause Fifth above shall be applied to satisfy drawings under such Letters of Credit as they occur. If any amount remains on deposit as Cash Collateral after all Letters of Credit have either been fully drawn or expired, such remaining amount shall be applied to the other Obligations, if any, in the order set forth above.9.ADMINISTRATIVE AGENT9.1.Appointment and Authorization of Agents.9.1.1.1.Each of the Lenders and L/C Issuers hereby irrevocably appoints Bank of America to act on its behalf as the Administrative Agent hereunder and under the other Loan Documents and authorizes the Agent to take such actions on its behalf under the provisions of this Agreement and each other Loan Document and to exercise such powers as are delegated to the Agent by the terms hereof or thereof, together with such actions and powers as are reasonably incidental thereto. The provisions of this ARTICLE IX are solely for the benefit of the Administrative Agent, the Lenders and the L/C Issuers, and the Borrowers shall not have rights as a third party beneficiary of any of such provisions other than the provisions of Section 9.06 relating to the Companyâ€™s consultation and notice rights.9.1.1.2.Notwithstanding any provision to the contrary contained elsewhere herein or in any other Loan Document, the Agent shall not have any duties or responsibilities, except those expressly set forth herein, nor shall the Agent have or be deemed to have any fiduciary relationship with any Lender or participant, and no implied covenants, functions, responsibilities, duties, obligations or liabilities shall be read into this Agreement or any other Loan Document or otherwise exist against the Agent. Without limiting the generality of the foregoing sentence, the use of the term â€œagentâ€ herein and in the other Loan Documents with reference to the Administrative Agent is not intended to connote any fiduciary or other implied (or express) obligations arising under agency doctrine of any applicable Law. Instead, such term is used merely as a matter of market custom, and is intended to create or reflect only an administrative relationship between independent contracting parties.9.1.1.3.Each L/C Issuer shall act on behalf of the Lenders with respect to any Letters of Credit issued by it and the documents associated therewith, and each L/C Issuer shall have all of the benefits and immunities (A)Â provided to the Administrative Agent in this ARTICLE IX with respect to any acts taken or omissions suffered by such L/C Issuer in connection with Letters of Credit issued by it or proposed to be issued by it and the Issuer Documents pertaining to such Letters of Credit as fully as if the term â€œAdministrative Agentâ€ as used in this ARTICLE IX included such L/C Issuer with respect to such acts or omissions, and (B)Â as additionally provided herein with respect to each L/C Issuer.9.2.Rights as a Lender. The Person serving as the Administrative Agent hereunder shall have the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Agent and the term â€œLenderâ€ or â€œLendersâ€ shall, unless otherwise expressly indicated or unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, own securities of, act as the financial advisor or in any other advisory capacity for and generally engage in any kind of business with the Borrowers or any Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Subsidiary or other Affiliate thereof as if such Person was not the Agent hereunder and without any duty to account therefor to the Lenders.9.3.Exculpatory Provisions. Neither the Agent nor any Joint Sustainability Coordinator shall not have any duties or obligations except those expressly set forth herein and in the other Loan Documents, and, in each case, its duties hereunder shall be administrative in nature. Without limiting the generality of the foregoing, the Agent and each Joint Sustainability Coordinator:9.3.1.1.shall not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;9.3.1.2.shall not have any duty to take any discretionary action or exercise any discretionary powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Agent or any Joint Sustainability Coordinator, as the case may be, is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of the Lenders as shall be expressly provided for herein or in the other Loan Documents), provided that neither the Agent nor any Joint Sustainability Coordinator shall be required to take any action that, in its opinion or the opinion of its counsel, may expose the Agent or such Joint Sustainability Coordinator, as the case may be, to liability or that is contrary to any Loan Document or applicable law, including for the avoidance of doubt any action that may be in violation of the automatic stay under any Debtor Relief Law or that may effect a forfeiture, modification or termination of property of a Defaulting Lender in violation of any Debtor Relief Law; and9.3.1.3.shall not, except as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and shall not be liable for the failure to disclose, any information relating to the Borrowers or any of their Affiliates that is communicated to or obtained by the Person serving as the Agent, any Joint Sustainability Coordinator or any of their respective Affiliates in any capacity.9.3.1.4.Neither the Agent nor any Joint Sustainability Coordinator shall be liable for any action taken or not taken by it (i)Â with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as shall be necessary, or, in the case of the Agent, as the Agent shall believe in good faith shall be necessary, under the circumstances as provided in Sections 11.01 and 8.02) or (ii)Â in the absence of its own gross negligence or willful misconduct as determined by a court of competent jurisdiction by final and nonappealable judgment. Neither the Agent nor any Joint Sustainability Coordinator shall be deemed to have knowledge of any Default unless and until notice describing such Default is given in writing to the Agent by a Borrower, a Lender or an L/C Issuer.9.3.1.5.Neither the Agent nor any Joint Sustainability Coordinator shall be responsible for or have any duty to ascertain or inquire into (i)Â any statement, warranty or representation made in or in connection with this Agreement or any other Loan Document, (ii)Â the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii)Â the performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv)Â the validity, enforceability, effectiveness or genuineness of this Agreement, any other Loan Document or any other agreement, instrument or document or (v)Â the satisfaction of any condition set forth in ARTICLE IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to the Agent or the Joint Sustainability Coordinators, as the case may be.9.4.Delegation of Duties. The Agent may perform any and all of its duties and exercise its rights and powers hereunder or any other Loan Document by or through any one or more sub-agents appointed by the Agent. The Agent and any such sub-agent may perform any and all of its duties and

exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article shall apply to any such sub-agent and to the Related Parties of the Agent and any such sub-agent, and shall apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 9.5.Reliance by Agent. The Agent shall be entitled to rely upon, and shall not incur any liability for relying upon, any notice (including without limitation, telephonic or electronic notice, Committed Loan Notices, Letter of Credit Applications and notices of prepayment), request, certificate, consent, statement, instrument, document or other writing (including any electronic message, internet or intranet website posting or other distribution) believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person or Persons. The Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the proper Person, and shall not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan, or the issuance of a Letter of Credit, that by its terms must be fulfilled to the satisfaction of a Lender or an L/C Issuer, the Agent may presume that such condition is satisfactory to such Lender or L/C Issuer unless the Agent shall have received notice to the contrary from such Lender or L/C Issuer prior to the making of such Loan or the issuance of such Letter of Credit. The Agent may consult with legal counsel (who may be counsel for the Company), independent accountants and other experts selected by it, and shall not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts.9.6.Successor Agents. 9.6.1.1.The Agent may at any time give notice of its resignation to the Lenders, the L/C Issuers and the Company. Upon receipt of any such notice of resignation, the Required Lenders shall have the right, in consultation with the Company, to appoint a successor, which shall be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor shall have been so appointed by the Required Lenders and shall have accepted such appointment within 30 days after the retiring Agent gives notice of its resignation (or such earlier day as shall be agreed by the Required Lenders) (the â€œResignation Effective Dateâ€), then the retiring Agent may on behalf of the Lenders and the L/C Issuers (if applicable) appoint a successor Agent meeting the qualifications set forth above; provided that if the Agent shall notify the Company and the Lenders that no qualifying Person has accepted such appointment, then such resignation shall nonetheless become effective as of the Resignation Effective Date in accordance with such notice and (a)Â the retiring Agent shall be discharged from its duties and obligations hereunder and under the other Loan Documents and (b)Â except for any indemnity payments or other amounts then owed to the retiring Administrative Agent all payments, communications and determinations provided to be made by, to or through the Agent shall instead be made by or to each Lender and L/C Issuer directly, until such time as the Required Lenders appoint a successor Agent as provided for above in this Section. Upon the acceptance of a successorâ€™s appointment as Administrative Agent hereunder, such successor shall succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent (other than any rights to indemnity payments or other amounts owed to the retiring (or retired) Administrative Agent as of the Resignation Effective Date), and the retiring Agent shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section). The fees payable by the Company to a successor Agent shall be the same as those payable to its predecessor unless otherwise agreed between the Company and such successor. After the retiring Administrative Agentâ€™s resignation hereunder and under the other Loan Documents, the provisions of this Article and Section 11.04 shall continue in effect for the benefit of such retiring Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to be taken by any of them (i) while the retiring Administrative Agent was acting as Administrative Agent and (ii) after such resignation for as long as any of them continues to act in any capacity hereunder or under the other Loan Documents, including (a) acting as collateral agent or otherwise holding any collateral security on behalf of any of the Lenders and (b) in respect of any actions taken in connection with transferring the agency to any successor Administrative Agent.9.6.1.2.Any resignation by Bank of America as Administrative Agent pursuant to this Section shall also constitute its resignation as an L/C Issuer.Â If Bank of America resigns as an L/C Issuer, it shall retain all the rights, powers, privileges and duties of an L/C Issuer hereunder with respect to all Letters of Credit outstanding as of the effective date of its resignation as an L/C Issuer and all L/C Obligations with respect thereto, including the right to require the Lenders to make Base Rate Loans or fund risk participations in Unreimbursed Amounts pursuant to Section 2.03(c).Â Upon the appointment by the Company of a successor L/C Issuer hereunder (which successor shall in all cases be a Lender other than a Defaulting Lender), (a)Â such successor shall succeed to and become vested with Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â all of the rights, powers, privileges and duties of the resigning L/C Issuer, (b)Â the resigning L/C Issuer shall be discharged from all of its duties and obligations hereunder or under the other Loan Documents and (c) the successor L/C Issuer shall issue letters of credit in substitution for the Letters of Credit, if any, outstanding at the time of such succession or make other arrangements satisfactory to Bank of America to effectively assume the obligations of Bank of America with respect to such Letters of Credit.9.7.Non-Reliance on Agent and Other Lenders. Each Lender and L/C Issuer acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender and L/C Issuer also acknowledges that it will, independently and without reliance upon the Agent or any other Lender or any of their Related Parties and based on such documents and information as it shall from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder.9.8.No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the documentation agents, syndication agents, book managers or arrangers listed on the cover page hereof shall have any powers, duties or responsibilities under this Agreement or any of the other Loan Documents, except in its capacity, as applicable, as the Administrative Agent, a Joint Sustainability Coordinator or a Lender hereunder. Without limiting the foregoing, none of the Lenders or other Persons so listed shall have or be deemed to have any fiduciary relationship with any Lender. Each Lender acknowledges that it has not relied, and will not rely, on any of the Lenders or other Persons so listed in deciding to enter into this Agreement or in taking or not taking action hereunder.9.9.Administrative Agent May File Proofs of Claim. In case of the pendency of any proceeding under any Debtor Relief Law or any other judicial proceeding relative to any Loan Party, the Administrative Agent (irrespective of whether the principal of any Loan, or L/C Obligation shall then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent shall have made any demand on any Borrower) shall be entitled and empowered, by intervention in such proceeding or otherwise:9.9.1.1.to file and prove a claim for the whole amount of the principal and interest owing and unpaid in respect of the Loans, L/C Obligations and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent under Sections 2.03(i) and 2.03(j), 2.09 and 11.04) allowed in such judicial proceeding; and9.9.1.2.to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same; and any custodian, receiver, assignee, trustee, liquidator, sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent shall consent to the making of such payments directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative Agent under Sections 2.09 and 11.04.Nothing contained herein shall be deemed to authorize the Administrative Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender or to authorize the Administrative Agent to vote in respect of the claim of any Lender in any such proceeding.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â 9.10.Certain ERISA Matters. 9.10.1.1.Each Lender (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Company or any other Loan Party, that at least one of the following is and will be true:9.10.1.1.1.such Lender is not using â€œplan assetsâ€ (within the meaning of Section 3(42) of ERISA or otherwise) of one or more Benefit Plans with respect to such Lenderâ€™s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments or this Agreement, 9.10.1.1.2.the transaction exemption set forth in one or more PTEs, such as PTE 84-14 (a class exemption for certain transactions determined by independent qualified professional asset managers), PTE 95-60 (a class exemption for certain transactions involving insurance company general accounts), PTE 90-1 (a class exemption for certain transactions involving insurance company pooled separate accounts), PTE 91-38 (a class exemption for certain transactions involving bank collective investment funds) or PTE 96-23 (a class exemption for certain transactions determined by in-house asset managers), is applicable with respect to such Lenderâ€™s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement, 9.10.1.1.3.(A) such Lender is an investment fund managed by a â€œQualified Professional Asset Managerâ€ (within the meaning of Part VI of PTE 84-14), (B) such Qualified Professional Asset Manager made the investment decision on behalf of such Lender to enter into, participate in, administer and perform the Loans, the Letters of Credit, the Commitments and this Agreement, (C) the entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement satisfies the requirements of sub-sections (b) through (g) of Part I of PTE 84-14 and (D) to the best knowledge of such Lender, the requirements of subsection (a) of Part I of PTE 84-14 are satisfied with respect to such Lenderâ€™s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement, or 9.10.1.1.4.such other representation, warranty and covenant as may be agreed in writing between the Administrative Agent, in its sole discretion, and such Lender.9.10.1.2.In addition, unless either (1) sub-clause (i) in the immediately preceding clause (a) is true with respect to a Lender or (2) a Lender has provided another representation, warranty and covenant in accordance with sub-clause (iv) in the immediately preceding clause (a), such Lender further (x) represents and warrants, as of the date such Person became a Lender party hereto, to, and (y) covenants, from the date such Person became a Lender party hereto to the date such Person ceases being a Lender party hereto, for the benefit of, the Administrative Agent and not, for the avoidance of doubt, to or for the benefit of the Borrower or any other Loan Party, that the Administrative Agent is not a fiduciary with respect to the assets of such Lender involved in such Lenderâ€™s entrance into, participation in, administration of and performance of the Loans, the Letters of Credit, the Commitments and this Agreement (including in connection with the reservation or exercise of any rights by the Administrative Agent under this Agreement, any Loan Document or any documents related hereto or thereto).10.[RESERVED]11.MISCELLANEOUS11.1.Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Company or any other Loan Party therefrom, shall be effective unless in writing signed by the Required Lenders and the Company or the applicable Loan Party, as the case may be, Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â and acknowledged by the Administrative Agent, and each such waiver or consent shall be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or consent shall:11.1.1.1.waive any condition set forth in Section 4.01(a) (other than any condition pursuant to Section 4.01(a)(vii)) without the written consent of each Lender;11.1.1.2.extend or increase the Commitment of any Lender (or reinstate any Commitment terminated pursuant to Section 8.02) except as permitted by Section 2.15, in each case without the written consent of such Lender;11.1.1.3.postpone any date fixed by this Agreement or any other Loan Document for any payment of principal, interest, fees or other amounts due to the Lenders (or any of them) hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby;11.1.1.4.other than as provided by Section 2.19 or the ESG Amendment and subject to the terms thereof, reduce the principal of, or the rate of interest specified herein on, any Loan or L/C Borrowing, or (subject to clause (v)Â of the second proviso to this Section 11.01) any fees or other amounts payable hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; provided, however, that only the consent of the Required Lenders shall be necessary to amend the definition of â€œDefault Rateâ€ or to waive any obligation of the Borrowers to pay interest at the Default Rate;Â Â Â Â Â Â Â Â Â

foregoing clause (i)Â of notification that such notice or communication is available and identifying the website address therefor.11.2.1.3.The Platform. THE PLATFORM IS PROVIDED â€œAS ISâ€ AND â€œAS AVAILABLE.â€ THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE BORROWER MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR OMISSIONS FROM THE BORROWER MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE BORROWER MATERIALS OR THE PLATFORM. In no event shall the Â Â Â Â 2Â Â Â Â Â Â Â Â

assign, without recourse (in accordance with and subject to the restrictions contained in this Section), all of its interest, rights and obligations under this Agreement to one or more Eligible Assignees at the lesser of (x) the principal amount thereof and (y) the amount that such Disqualified Institution paid to acquire such interests, rights and obligations, in each case plus accrued interest, accrued fees and all other amounts (other than principal amounts) payable to it hereunder. Notwithstanding anything to the contrary contained in this Agreement, Disqualified Institutions (A) will not (x) have the right to receive information, reports or other materials provided to Lenders by the Borrowers, the Administrative Agent or any other Lender, (y) attend or participate in meetings attended by the Lenders and the Administrative Agent, or (z) access any electronic site established for the Lenders or confidential communications from counsel to or financial advisors of the Administrative Agent or the Lenders and (B) (x) for purposes of any consent to any amendment, waiver or modification of, or any action under, and for the purpose of any direction to the Administrative Agent or any Lender to undertake any action (or refrain from taking any action) under this Agreement or any other Loan Document, each Disqualified Institution will be deemed to have consented in the same proportion as the Lenders that are not Disqualified Institutions consented to such matter, and (y) for purposes of voting on any plan of reorganization, each Disqualified Institution party hereto hereby agrees (1) not to vote on such plan of reorganization, (2) if such Disqualified Institution does vote on such plan of reorganization notwithstanding the restriction in the foregoing clause (1), such vote will be deemed not to be in good faith and shall be â€œdesignatedâ€ pursuant to Section 1126(e) of the Bankruptcy Code (or any similar provision in any other Debtor Relief Laws), and such vote shall not be counted in determining whether the applicable class has accepted or rejected such plan of reorganization in accordance with Section 1126(c) of the Bankruptcy Code (or any similar provision in any other Debtor Relief Laws) and (3) not to contest any request by any party for a determination by the Bankruptcy Court (or other applicable court of competent jurisdiction) effectuating the foregoing clause (2).11.6.1.3.The Administrative Agent, acting solely for this purpose as an agent of the Borrowers (and such agency being solely for tax purposes), shall maintain at the Administrative Agentâ€™s Office a copy of each Assignment and Assumption delivered to it and a register for the recordation of the names and addresses of the Lenders, and the Commitments of, and principal amounts of the Loans and L/C Obligations owing to, each Lender pursuant to the terms hereof from time to time (the â€œRegisterâ€). The entries in the Register shall be conclusive absent manifest error, and the Borrowers, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the contrary. The Register shall be available for inspection by the Company, at any reasonable time and from time to time upon reasonable prior notice. In addition, at any time that a request for a consent for a material or substantive change to the Loan Documents is pending, any Lender wishing to consult with other Lenders in connection therewith may request and receive from the Administrative Agent a copy of the Register.11.6.1.4.(i) Any Lender may at any time, without the consent of, or notice to, the Administrative Agent, sell participations to any Person (other than a natural person, any Borrower, any of the Borrowersâ€™ Affiliates or Subsidiaries and any Defaulting Lender) (each, a â€œParticipantâ€) in all or a portion of such Lenderâ€™s rights and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans (including such Lenderâ€™s participations in L/C Obligations) owing to it); provided that (i)Â unless a Default or Event of Default has occurred and is continuing, the Company shall have approved the sale of participations to such Person (such approval not to be unreasonably withheld or delayed); (ii)Â [Reserved]; (iii)Â such Lenderâ€™s obligations under this Agreement shall remain unchanged; (iv)Â such Lender shall remain solely responsible to the other parties hereto for the performance of such obligations; (v)Â the Borrowers, the Agent, the L/C Issuers and the other Lenders shall continue to deal solely and directly with such Lender in connection with such Lenderâ€™s rights and obligations under this Agreement; and (vi)Â such Lender complies with Section 11.06(d)(ii). Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant, Â Â Â Â 2Â Â Â Â Â Â Â Â Â Â Â Â Â agree to any amendment, waiver or other modification described in the first proviso to Section 11.01 that directly affects such Participant. Subject to Section 11.06(e), the Borrowers agree that each Participant shall be entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to Section 11.06(b) (it being understood that the documentation required under Section 3.01(e) shall be delivered to the Lender who sells the participation) to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to paragraph (b)Â of this Section. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 11.08 as though it were a Lender, provided such Participant agrees to be subject to Section 2.13 as though it were a Lender.(ii) Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Company, maintain a register on which it enters the name and address of each Participant and the principal amounts (and stated interest) of each Participantâ€™s interest in the Loans or other obligations under the Loan Documents (the â€œParticipant Registerâ€); provided that no Lender shall have any obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participantâ€™s interest in any commitments, loans, letters of credit or its other obligations under any Loan Document) to any Person except to the extent that such disclosure is necessary to establish that such commitment, loan, letter of credit or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. For the avoidance of doubt, the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register.11.6.1.5.A Participant shall not be entitled to receive any greater payment under Sections 3.01 or 3.04, with respect to any participation, than the Lender from whom it acquired the applicable participation would have been entitled to receive, except to the extent such entitlement to receive a greater payment results from a Change in Law that occurs after the Participant acquired the applicable participation.11.6.1.6.Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note, if any) to secure obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank or other central banking authority; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such pledgee or assignee for such Lender as a party hereto.11.6.1.7.As used herein, the following terms have the following meanings:â€œEligible Assigneeâ€ means (a)Â a Lender; (b)Â an Affiliate of a Lender; (c)Â an Approved Fund; and (d)Â any other Person (other than a natural person) approved by (i)Â the Administrative Agent and each L/C Issuer and (ii)Â unless a Default or an Event of Default has occurred and is continuing, the Company (each such approval not to be unreasonably withheld or delayed); provided that notwithstanding the foregoing, (i)Â â€œEligible Assigneeâ€ shall not include (x) any Borrower, any of the Borrowersâ€™ Affiliates or Subsidiaries, or any Defaulting Lender, (y) any Disqualified Institution or (z) any natural Person (or a holding company, investment vehicle or trust for, or owned and operated for the primary benefit of one or more natural Persons).The Administrative Agent shall not be responsible or have any liability for, or have any duty to ascertain, inquire into, monitor or enforce, compliance with the provisions of this Agreement relating to Disqualified Institutions. Without limiting the generality of the foregoing, the Administrative Agent shall not (x) be obligated to ascertain, monitor or inquire as to whether any Lender or Participant or prospective Lender or Participant is a Disqualified Institution or (y) have any liability with respect to or arising out of any assignment or participation of Loans, or disclosure of confidential information, to any Disqualified Institution. 11.6.1.8.Notwithstanding anything to the contrary contained herein, any Lender (a â€œGranting Lenderâ€) may grant to a special purpose funding vehicle identified as such in writing from time to time by the Granting Lender to the Administrative Agent and the Company (an â€œSPCâ€) the option to provide all or any part of any Committed Loan Â Â Â Â 3Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â that such Granting Lender would otherwise be obligated to make pursuant to this Agreement; provided that (i)Â nothing herein shall constitute a commitment by any SPC to fund any Committed Loan, and (ii)Â if an SPC elects not to exercise such option or otherwise fails to make all or any part of such Committed Loan, the Granting Lender shall be obligated to make such Committed Loan pursuant to the terms hereof or, if it fails to do so, to make such payment to the Agent as is required under Section 2.12(b)(ii); provided, further that no such grant to an SPC shall impose Taxes or Other Taxes on any Borrower. Each party hereto hereby agrees that (i)Â neither the grant to any SPC nor the exercise by any SPC of such option shall increase the costs or expenses or otherwise increase or change the obligations of the Company under this Agreement (including its obligations under Section 3.04), (ii)Â no SPC shall be liable for any indemnity or similar payment obligation under this Agreement for which a Lender would be liable, and (iii)Â the Granting Lender shall for all purposes, including the approval of any amendment, waiver or other modification of any provision of any Loan Document, remain the lender of record hereunder. The making of a Committed Loan by an SPC hereunder shall utilize the Commitment of the Granting Lender to the same extent, and as if, such Committed Loan were made by such Granting Lender. In furtherance of the foregoing, each party hereto hereby agrees (which agreement shall survive the termination of this Agreement) that, prior to the date that is one year and one day after the payment in full of all outstanding commercial paper or other senior debt of any SPC, it will not institute against, or join any other Person in instituting against, such SPC any bankruptcy, reorganization, arrangement, insolvency, or liquidation proceeding under the laws of the United States or any State thereof. Notwithstanding anything to the contrary contained herein, any SPC may (i)Â with notice to, but without prior consent of the Company and the Administrative Agent and without paying any processing fee therefor, assign all or any portion of its right to receive payment with respect to any Committed Loan to the Granting Lender and (ii)Â disclose on a confidential basis any non-public information relating to its funding of Committed Loans to any rating agency, commercial paper dealer or provider of any surety or Guarantee or credit or liquidity enhancement to such SPC.11.6.1.9.Notwithstanding anything to the contrary contained herein, any Lender that is a Fund may create a security interest in all or any portion of the Loans owing to it and the Note, if any, held by it to the trustee for holders of obligations owed, or securities issued, by such Fund as security for such obligations or securities, provided that unless and until such trustee actually becomes a Lender in compliance with the other provisions of this Section 11.06, (a)Â no such pledge shall release the pledging Lender from any of its obligations under the Loan Documents and (b)Â such trustee shall not be entitled to exercise any of the rights of a Lender under the Loan Documents even though such trustee may have acquired ownership rights with respect to the pledged interest through foreclosure or otherwise. For purposes of this Section 11.06(i), â€œFundâ€ means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business.11.6.1.10.[Reserved].11.6.1.11.Electronic Execution of Assignments and Certain Other Documents. The words â€œexecute,â€ â€œexecution,â€ â€œsigned,â€ â€œsignature,â€ and words of like import in or related to any document to be signed in connection with this Agreement and the transactions contemplated hereby (including without limitation Assignment and Assumptions, amendments or other modifications, Committed Loan Notices, waivers and consents) shall be deemed to include Electronic Signatures, the electronic matching of assignment terms and contract formations on electronic platforms approved by the Administrative Agent, or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that notwithstanding anything contained herein to the contrary the Administrative Agent is under no obligation to agree to accept Electronic Signatures in any form or in any format unless expressly agreed to by the Administrative Agent pursuant to procedures approved by it. 11.6.1.12.Defaulting Lenders. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition to the other Â Â Â Â 4Â Â Â Â Â Â Â Â Â Â Â Â Â conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Borrowers and the Administrative Agent, the applicable pro rata share of Loans previously requested but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x)Â pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent or any Lender hereunder (and interest accrued thereon) and (y)Â acquire (and fund as appropriate) its full pro rata share of all Loans and participations in Letters of Credit in accordance with its Pro Rata Share. Notwithstanding the foregoing, in the event that any assignment of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this Section 11.06(l), then the assignee of such interest shall be deemed to be a Defaulting Lender for all purposes of this Agreement until such compliance occurs.11.7.Treatment of Certain Information; Confidentiality.Each Agent, L/C Issuer and Lender agrees to maintain, and to cause its Affiliates (including any Related Parties) to maintain, the confidentiality of the Information (as defined below), except that Information may be disclosed (a)Â to its Affiliates and to its and its Affiliatesâ€™ respective auditors, partners, directors, officers, employees, agents, advisors and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential); (b)Â to the extent requested by any regulatory authority purporting to have jurisdiction over it (including any self-regulatory authority, such as the National Association of Insurance Commissioners); (c)Â to the extent required by applicable laws or regulations or by any subpoena or similar legal process; (d)Â to any other party hereto; (e)Â to the extent reasonably required, in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder; (f)Â subject to an agreement containing provisions substantially the same as those of this Section, to (i)Â any assignee of or Participant in, or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement, (ii)Â any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to obligations of the Loan Parties under the Loan Documents or (iii)Â any insurers and/or risk protection providers; (g)Â with the consent of the Company; or (h)Â to the extent such Information (i)Â becomes publicly available other than as a result of a breach of this Section, (ii)Â becomes available to the Agent, any L/C Issuer, any Lender or any of their respective Affiliates on a nonconfidential basis from a source other than the Company, (iii) is independently discovered or developed by such party without utilizing any Information received from any Loan Party or violating the terms of this Section or (iv) was already in such partyâ€™s possession; provided, however, that to the extent permitted by applicable law or regulation, the Agent, the L/C Issuers and the Lenders agree to notify the Company prior to (if reasonably practicable) or concurrently with its disclosure of such information to any third party pursuant to clauses (b) (other than in the case of routine bank examinations), (c)Â and (f). In addition, the Administrative Agent and the Lenders may disclose the existence of this Agreement and public information about this Agreement to market data collectors, similar service providers to the lending industry, and service providers to the Administrative Agent and the Lenders in connection with the administration and management of this Agreement, the other Loan Documents, the Commitments, and the Credit Extensions.For the purposes of this Section, â€œInformationâ€ means all information received from any Loan Party relating to any Loan Party or its business, other than any such information that is available to the Agent, any L/C Issuer or any Lender or any of their respective Affiliates on a nonconfidential basis prior to disclosure by any Loan Party; provided that, in the case of any information received from a Loan Party after the date hereof (other than in connection with Section 6.03, all of which is acknowledged to constitute â€œInformationâ€ regardless of any marking as confidential), such information is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section shall be considered to have complied with its obligation to do so if such Person has exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information.The Agent, each of the L/C Issuers and Lenders acknowledges that (a)Â the Information may include material non-public information concerning the Borrowers or a Subsidiary, as the case may be, (b)Â it has Â Â Â Â 5Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â developed compliance procedures regarding the use of material non-public information and (c)Â it will handle such material non-public information in accordance with applicable Law, including United States federal and state securities Laws.11.8.Set-off. In addition to any rights and remedies of the Lenders provided by law, upon the occurrence and during the continuance of any Event of Default, each Lender is authorized at any time and from time to time, without prior notice to the Borrowers, any such notice being waived by the Borrowers to the fullest extent permitted by law, to set off and apply any and all deposits (general or special, time or demand, provisional or final) at any time held by, and other indebtedness at any time owing by, such Lender to or for the credit or the account of the respective Loan Parties against any and all Obligations owing to such Lender hereunder or under any other Loan Document, now or hereafter existing, irrespective of whether or not the Administrative Agent or such Lender shall have made demand under this Agreement or any other Loan Document and although such Obligations may be contingent or unmatured or denominated in a currency different from that of the applicable deposit or indebtedness. Each Lender agrees promptly to notify the Borrowers and the Administrative Agent after any such set-off and application made by such Lender; provided, however that (i)Â the failure to give such notice shall not affect the validity of such set-off and application and (ii)Â in the event that any Defaulting Lender shall exercise any such right of setoff, (x)Â all amounts so set off shall be paid over immediately to the Administrative Agent for

further application in accordance with the provisions of Section 2.18 and, pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y)Â the Defaulting Lender shall provide promptly to the Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff.11.9.Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or agreed to be paid under the Loan Documents shall not exceed the maximum rate of non-usurious interest permitted by applicable Law (the â€œMaximum Rateâ€). If the Agent or any Lender shall receive interest in an amount that exceeds the Maximum Rate, the excess interest shall be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by the Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a)Â characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b)Â exclude voluntary prepayments and the effects thereof, and (c)Â amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder.11.10.Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.11.11.Integration. This Agreement, together with the other Loan Documents, comprises the complete and integrated agreement of the parties on the subject matter hereof and thereof and supersedes all prior agreements, written or oral, on such subject matter. In the event of any conflict between the provisions of this Agreement and those of any other Loan Document, the provisions of this Agreement shall control; provided that the inclusion of supplemental rights or remedies in favor of the Agent or the Lenders in any other Loan Document shall not be deemed a conflict with this Agreement. Each Loan Document was drafted with the joint participation of the respective parties thereto and shall be construed neither against nor in favor of any party, but rather in accordance with the fair meaning thereof.11.12.Survival of Representations and Warranties. All representations and warranties made hereunder and in any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith shall survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by the Agent and each Lender, regardless of any investigation made by the Agent or any Lender or on their behalf and notwithstanding that the Agent or any Lender may have had notice or knowledge of any Default at the time of any Credit Extension, and shall continue in full force and effect as long as any Loan or any other Obligation hereunder shall remain unpaid or unsatisfied or any Letter of Credit shall remain outstanding.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â 11.13.Severability. If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a)Â the legality, validity and enforceability of the remaining provisions of this Agreement and the other Loan Documents shall not be affected or impaired thereby and (b)Â the parties shall endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction.11.14.[Reserved]11.15.Replacement of Lenders. If (i)Â any Lender requests compensation under Section 3.04, (ii)Â a Borrower is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, (iii)Â any Lender is a Non-Extending Lender for any extension of the Maturity Date, (iv)Â any Lender is a â€œDefaulting Lenderâ€, (v) any Lender does not consent to an amendment to the definition of Designated Borrower Jurisdiction that has been consented to by the Required Lenders, (vi) any Lender is a Protesting Lender under Section 2.16 or (vii)Â any other circumstance exists hereunder that gives any Borrower the right to replace a Lender as a party hereto, then, subject to Section 3.06(b), such Borrower may, at its sole expense and effort, upon notice to such Lender and the Agent, require such Lender to assign and delegate, without recourse (in accordance with and subject to the restrictions contained in, and consents required by, Section 11.06), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that shall assume such obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that:11.15.1.1.the Company shall have paid to the Administrative Agent the assignment fee specified in Section 11.06(b);11.15.1.2.such Lender shall have received payment of an amount equal to the outstanding principal of its Loans and L/C Advances, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.05) from the assignee (to the extent of such outstanding principal and accrued interest and fees) or the Company (in the case of all other amounts);11.15.1.3.in the case of any such assignment resulting from a claim for compensation under Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments thereafter; 11.15.1.4.in the case of any such assignment resulting from clause (v) above, the applicable assignee shall have consented to the proposed amendment;11.15.1.5.in the case of any such assignment resulting from clause (vi) above, such assignee shall have consented to make Loans to the applicable Designated Foreign Borrower; and11.15.1.6.such assignment does not conflict with applicable Laws.A Lender shall not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or otherwise, the circumstances entitling the Company to require such assignment and delegation cease to apply.11.16.Governing Law.11.16.1.1.THIS AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK APPLICABLE TO AGREEMENTS MADE AND TO BE PERFORMED ENTIRELY WITHIN SUCH STATE; PROVIDED THAT THE AGENT, EACH L/C ISSUER AND EACH LENDER SHALL RETAIN ALL RIGHTS ARISING UNDER FEDERAL LAW.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â 11.16.1.2.ANY LEGAL ACTION OR PROCEEDING WITH RESPECT TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT MAY BE BROUGHT IN THE COURTS OF THE STATE OF NEW YORK OR OF THE FEDERAL DISTRICT COURT FOR THE SOUTHERN DISTRICT OF NEW YORK, IN EACH CASE LOCATED IN THE CITY AND COUNTY OF NEW YORK, AND BY EXECUTION AND DELIVERY OF THIS AGREEMENT, THE BORROWERS, THE AGENT, EACH L/C ISSUER AND EACH LENDER CONSENTS, FOR ITSELF AND IN RESPECT OF ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THOSE COURTS. THE BORROWERS, THE AGENT, EACH L/C ISSUER AND EACH LENDER IRREVOCABLY WAIVES ANY OBJECTION, INCLUDING ANY OBJECTION TO THE LAYING OF VENUE OR BASED ON THE GROUNDS OF FORUM NON CONVENIENS, WHICH IT MAY NOW OR HEREAFTER HAVE TO THE BRINGING OF ANY ACTION OR PROCEEDING IN SUCH JURISDICTION IN RESPECT OF ANY LOAN DOCUMENT OR OTHER DOCUMENT RELATED THERETO. THE BORROWERS, THE AGENT, EACH L/C ISSUER AND EACH LENDER WAIVES PERSONAL SERVICE OF ANY SUMMONS, COMPLAINT OR OTHER PROCESS, WHICH MAY BE MADE BY ANY OTHER MEANS PERMITTED BY THE LAW OF SUCH STATE.11.17.Waiver of Right to Trial by Jury. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A)Â CERTIFIES THAT NO REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B)Â ACKNOWLEDGES THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION.11.18.No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby (including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), each Borrower and each other Loan Party acknowledges and agrees, and acknowledges its Affiliatesâ€™ understanding, that: (i) (A)Â the arranging and other services regarding this Agreement provided by the Agent, the Lenders, the Joint Sustainability Coordinators and the Arrangers are armâ€™s-length commercial transactions between the Borrowers, each other Loan Party and their respective Affiliates, on the one hand, and the Agent, the Lenders, the Joint Sustainability Coordinators and the Arrangers, on the other hand, (B)Â such Borrower and each other Loan Party has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C)Â such Borrower and each other Loan Party is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions contemplated hereby and by the other Loan Documents; (ii)Â (A)Â the Agent, the Lenders, the Joint Sustainability Coordinators and the Arrangers is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties, has not been, is not, and will not be acting as an advisor, agent or fiduciary for any Borrower, any other Loan Party or any of their respective Affiliates, or any other Person and (B)Â Neither the Agent nor the Lenders, the Joint Sustainability Coordinators nor any of the Arrangers has any obligation to any Borrower, any other Loan Party or any of their respective Affiliates with respect to the transactions contemplated hereby except those obligations expressly set forth herein and in the other Loan Documents; and (iii)Â the Agent, the Lenders, the Joint Sustainability Coordinators and the Arrangers and their respective Affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Borrowers, the other Loan Parties and their respective Affiliates, and neither the Agent nor the Lenders, the Joint Sustainability Coordinators nor any of the Arrangers has any obligation to disclose any of such interests to any Borrower, any other Loan Party or any of their respective Affiliates. To the fullest extent permitted by law, each of the Borrowers and the other Loan Parties hereby waives and releases any claims that it may have against the Agent, the Lenders, the Joint Sustainability Coordinators or the Arrangers with respect to any breach or alleged breach of agency or fiduciary duty in connection with any aspect of any transaction contemplated hereby.Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â 11.19.USA Patriot Act Notice. Each Lender that is subject to the Act (as hereinafter defined) and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Borrowers that pursuant to the requirements of the USA PATRIOT Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)) (the â€œActâ€), it is required to obtain, verify and record information that identifies the Borrowers, which information includes the name and address of the Borrowers and other information that will allow such Lender or the Administrative Agent, as applicable, to identify the Borrowers in accordance with the Act.11.20.Judgment. If, for the purposes of obtaining judgment in any court, it is necessary to convert a sum due hereunder or any other Loan Document in one currency into another currency, the rate of exchange used shall be that at which in accordance with normal banking procedures the Administrative Agent could purchase the first currency with such other currency on the Business Day preceding that on which final judgment is given. The obligation of a Borrower in respect of any such sum due from it to the Administrative Agent hereunder or under the other Loan Documents shall, notwithstanding any judgment in a currency (the â€œJudgment Currencyâ€) other than that in which such sum is denominated in accordance with the applicable provisions of this Agreement (the â€œAgreement Currencyâ€), be discharged only to the extent that on the Business Day following receipt by the Administrative Agent of any sum adjudged to be so due in the Judgment Currency, the Administrative Agent may in accordance with normal banking procedures purchase the Agreement Currency with the Judgment Currency. If the amount of the Agreement Currency so purchased is less than the sum originally due to the Administrative Agent in the Agreement Currency, the applicable Borrower agrees, as a separate obligation and notwithstanding any such judgment, to indemnify the Administrative Agent or the Person to whom such obligation was owing against such loss. If the amount of the Agreement currency so purchased is greater than the sum originally due to the Administrative Agent in such currency, the Administrative Agent agrees to return the amount of any excess to such Borrower (or to any other Person who may be entitled thereto under applicable law).11.21.Acknowledgment and Consent to Bail-In of EEA Financial Institutions. Solely to the extent any Lender or L/C Issuer that is an Affected Financial Institution is a party to this Agreement and notwithstanding anything to the contrary in any Loan Document or in any other agreement, arrangement or understanding among any such parties, each party hereto acknowledges that any liability of any Lender or L/C Issuer that is an Affected Financial Institution arising under any Loan Document, to the extent such liability is unsecured, may be subject to the write-down and conversion powers of the applicable Resolution Authority and agrees and consents to, and acknowledges and agrees to be bound by:(a)Â Â Â Â the application of any Write-Down and Conversion Powers by the applicable Resolution Authority to any such liabilities arising hereunder which may be payable to it by any Lender or L/C Issuer that is an Affected Financial Institution; and(b)Â Â Â Â the effects of any Bail-in Action on any such liability, including, if applicable:Â Â Â Â (i)Â Â Â Â a reduction in full or in part or cancellation of any such liability;Â Â Â Â (ii)Â Â Â Â a conversion of all, or a portion of, such liability into shares or other instruments of ownership in such Affected Financial Institution, its parent undertaking, or a bridge institution that may be issued to it or otherwise conferred on it, and that such shares or other instruments of ownership will be accepted by it in lieu of any rights with respect to any such liability under this Agreement or any other Loan Document; orÂ Â Â Â (iii)Â Â Â Â the variation of the terms of such liability in connection with the exercise of the write-down and conversion powers of the applicable Resolution Authority.11.22.Acknowledgement Regarding Any Supported QFCs. To the extent that the Loan Documents provide support, through a guarantee or otherwise, for Swap Contracts or any other agreement or instrument that is a QFC (such support, â€œQFC Credit Supportâ€ and each such QFC a â€œSupported QFCâ€), the parties acknowledge and agree as follows with respect to the resolution power of the Federal Deposit Insurance Corporation under the Federal Deposit Insurance Act and Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act (together with the regulations promulgated thereunder, the â€œU.S. Special Resolution Regimesâ€) in respect of such Supported QFC and Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â QFC Credit Support (with the provisions below applicable notwithstanding that the Loan Documents and any Supported QFC may in fact be stated to be governed by the laws of the State of New York and/or of the United States or any other state of the United States) that in the event a Covered Entity that is party to a Supported QFC (each, a â€œCovered Partyâ€) becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer of such Supported QFC and the benefit of such QFC Credit Support (and any interest and obligation in or under such Supported QFC and such QFC Credit Support, and any rights in property securing such Supported QFC) from such Covered Party will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if the Supported QFC and such QFC Credit Support (and any such interest, obligation and rights in property) were governed by the laws of the United States or a state of the United States. In the event a Covered Party or a BHC Act Affiliate of a Covered Party becomes subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under the Loan Documents that might otherwise apply to such Supported QFC or any QFC Credit Support that may be exercised against such Covered Party are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S. Special Resolution Regime if the Supported QFC and the Loan Documents were governed by the laws of the United States or a state of the United States. Without limitation of the foregoing, it is understood and agreed that rights and remedies of the parties with respect to a Defaulting Lender shall in no event affect the rights of any Covered Party with respect to a Supported QFC or any QFC Credit Support. [Signature Pages Follow]Â Â Â Â 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed as of the date first above written.MCKESSON CORPORATIONBy: _____Name:Title:[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â BANK OF AMERICA, N.A., as Administrative AgentBy: _____Name: Kyle D HardingTitle: Vice PresidentBANK OF AMERICA, N.A., as L/C Issuer and LenderBy: _____Name: Joseph L. CorahTitle: Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â BARCLAYS BANK PLC, as L/C Issuer and LenderBy: _____Name: Evan MoriartyTitle: Vice President[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â CITIBANK N.A., as L/C Issuer and LenderBy: _____Name: Richard RiveraTitle: Vice President[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â WELLS FARGO BANK, NATIONAL ASSOCIATION, as L/C Issuer and LenderBy: _____Name: Andrea S ChenTitle: Managing Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â GOLDMAN SACHS BANK USA, as L/C Issuer and LenderBy: _____Name: William E. Briggs IVTitle: Authorized Signatory[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â JPMORGAN CHASE BANK, N.A., as L/C Issuer and LenderBy: _____Name: Gregory T. MartinTitle: Executive Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â ING BANK N.V., DUBLIN BRANCH, as LenderBy: _____Name: Cormac LangfordTitle: DirectorBy: _____Name: Sean HassettTitle: Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â ING CAPITAL LLC, as Joint Sustainability Coordinator [and Lender]By: _____Name: Ana Carolina OliveiraTitle: Managing DirectorBy: _____Name: William JamesTitle: Managing Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â BNP PARIBAS, as Joint Sustainability Coordinator and LenderBy: _____Name: John BoscoTitle: Managing DirectorBy: _____Name: Michael PearceTitle: Managing Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â DEUTSCHE BANK AG NEW YORK BRANCH, as LenderBy: _____Name: Ming K. ChuTitle: DirectorBy: _____Name: Marko LukinTitle:Vice President[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â HSBC Bank USA, N.A., as LenderBy: _____Name: David FilipczakTitle: Vice President, Healthcare Coverage[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â PNC Bank, N.A., as LenderBy: _____Name: Alexander JodryTitle:Vice-President[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â THE BANK OF NOVA SCOTIA, as LenderBy: _____Name: Robb GassTitle: Managing Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â THE TORONTO-DOMINION BANK, NEW YORK BRANCH, as LenderBy: _____Name: Mike TkachTitle: Authorized Signatory[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â TRUIST BANK, as LenderBy: _____Name: Jonathan HartTitle: Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â U.S. BANK

NATIONAL ASSOCIATION, as LenderBy: _____Name: Mario MassiminoTitle: Vice President[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â SOCIETE GENERALE, as LenderBy: _____Name: Kimberly MetzgerTitle:Director[Signature Page to Credit Agreement]Â Â Â Â Â Â Â Â UNICREDIT BANK AG, NEW YORK BRANCH, as LenderBy: _____Name: Fabio Della MalvaTitle: Managing DirectorBy: _____Name: Laura Shelmerdine DirectorTitle: DirectorÂ Â Â Â EX-31.1 3 mck_exhibit311x930202410-q.htm EX-31.1 Document Exhibit 31.1CERTIFICATION PURSUANT TORULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Brian S. Tyler, certify that: 1.I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Â Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Â Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date:November 7, 2024Â /s/Â Â Brian S. TylerÂ Brian S. TylerÂ Chief Executive Officer EX-31.2 4 mck_exhibit312x930202410-q.htm EX-31.2 DocumentExhibit 31.2CERTIFICATION PURSUANT TORULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Britt J. Vitalone, certify that: 1.I have reviewed this quarterly report on Form 10-Q of McKesson Corporation;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: a)Â Â Â Â Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; b)Â Â Â Â Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; c)Â Â Â Â Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and d)Â Â Â Â Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and 5.The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):a)Â Â Â Â All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and b)Â Â Â Â Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. Date:November 7, 2024Â /s/ Britt J. VitaloneÂ Britt J. VitaloneÂ Executive Vice President and Chief Financial Officer EX-32 5 mck_exhibit32x930202410-q.htm EX-32 DocumentExhibit 32CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002In connection with the quarterly report of McKesson Corporation (the â€œCompanyâ€) on Form 10-Q for the quarterly period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the â€œReportâ€), the undersigned, in the capacities and on the dates indicated below, each hereby certify, pursuant to 18 U.S.C. Â§ 1350, as adopted pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge:1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company./s/Â Brian S. TylerÂ Brian S. TylerChief Executive OfficerÂ November 7, 2024Â Â /s/ Britt J. VitaloneÂ Britt J. VitaloneExecutive Vice President and Chief Financial OfficerÂ November 7, 2024Â Â This certification accompanies the Report pursuant to Â§ 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.A signed original of this written statement required by Section 906 has been provided to McKesson Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. EX-101.SCH 6 mck-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - Held for Sale link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - Restructuring, Impairment, and Related Charges, Net link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - Earnings Per Common Share link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - Goodwill and Intangible Assets, Net link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - Debt and Financing Activities link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - Hedging Activities link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - Commitments and Contingent Liabilities link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - Segments of Business link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Held for Sale (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Earnings Per Common Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Goodwill and Intangible Assets, Net (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Debt and Financing Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Hedging Activities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Commitments and Contingent Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Stockholders' Deficit (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Segments of Business (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Held for Sale - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrtive (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Income Taxes - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Earnings Per Common Share - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Hedging Activities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Fair Value Measurements - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Stockholders' Deficit - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - Segments of Business - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - Segments of Business - Reportable operating segment (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 mck-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 mck-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 mck-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Issuance of shares under employee plans, net of forfeitures (in shares) Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures Adjustments to reconcile to net cash provided by (used in) operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Goodwill acquired Goodwill, Acquired During Period Statistical Measurement [Domain] Statistical Measurement [Domain] Repayments of long-term debt Repayments of long-term debt Repayments of Long-Term Debt Authorized amount available for future repurchases Share Repurchase Program, Remaining Authorized, Amount Derivatives, Fair Value [Line Items] Derivatives, Fair Value [Line Items] United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA [Member] United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA Cover [Abstract] Cover [Abstract] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Unrecognized tax benefits that would impact effective tax rate Unrecognized Tax Benefits that Would Impact Effective Tax Rate Schedule of Notional Amounts of Outstanding Derivative Positions Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Fair Value Hedges Fair Value Hedging [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Long-term debt Total long-term debt Long-Term Debt and Lease Obligation Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Asset Derivative Asset, Subject to Master Netting Arrangement, before Offset Non-NEOs Non-NEOs [Member] Schedule of Computations for Basic and Diluted Earnings Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Commercial paper Long-Term Commercial Paper, Current Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Other non-current assets/liabilities Other Non-Current Assets / Liabilities [Member] Other Non-Current Assets / Liabilities Fixed interest rate swaps Fixed Interest Rate Swap [Member] Fixed Interest Rate Swap Dividends declared per common share (in dollars per share) Common Stock, Dividends, Per Share, Declared Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Assets Disposal Group, Including Discontinued Operation, Assets [Abstract] Accelerated Share Repurchases [Table] Accelerated Share Repurchases [Table] Other adjustments Goodwill, Measurement Period Adjustment Payments to noncontrolling interests Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Line of Credit Facility [Table] Line of Credit Facility [Table] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Gains (losses) associated with equity investments Equity Securities, FV-NI, Gain (Loss) Derivative [Table] Derivative [Table] Cross-currency swaps Currency swap Currency Swap [Member] Income Tax Contingency [Table] Income Tax Contingency [Table] Operating lease liabilities Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Hedging Relationship [Domain] Hedging Relationship [Domain] Fair Value Measurements Fair Value Disclosures [Text Block] Restructuring and Related Activities [Abstract] Restructuring and Related Activities [Abstract] Award Timing Disclosures [Line Items] Net Investment Hedges Net Investment Hedging Net Investment Hedging [Member] Other Increase (Decrease) in Other Operating Assets and Liabilities, Net

Other Performance Measure, Amount Other Performance Measure, Amount Estimated annual amortization expense, 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Three Goodwill [Line Items] Goodwill [Line Items] Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest [Member] AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Long-term debt Debt and Lease Obligation Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Complaints filed against the entity Loss Contingency, Pending Claims, Number 5.10% Notes due July 15, 2033 5.10% Notes Due July 15, 2033 [Member] 5.10% Notes Due July 15, 2033 Cash Flow Hedges Cash Flow Hedging [Member] United States UNITED STATES Loans payable Term Loan Loans Payable [Member] Cash Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents Prescription Technology Solutions Prescription Technology Solutions Segment [Member] International Segment [Member] Other non-current assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Gross Carrying Amount Finite-Lived Intangible Assets, Gross Common stock repurchased (in shares) Treasury Stock, Shares, Acquired Settlement payment Payments for Legal Settlements Total Accumulated Other Comprehensive Loss AOCI Including Portion Attributable to Noncontrolling Interest [Member] 3.80% Notes due March 15, 2024 3.80% Notes Due March 15, 2024 [Member] 3.80% Notes Due March 15, 2024 Operating Segments Operating Segments [Member] Net cash provided by (used in) operating activities Net Cash Provided by (Used in) Operating Activities OPERATING ACTIVITIES Net Cash Provided by (Used in) Operating Activities [Abstract] Treasury Treasury Stock, Common [Member] Schedule of Information Regarding Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax, by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Restructuring Initiatives QTD Restructuring Initiatives QTD [Member] Restructuring Initiatives Quarter to Date Other non-current assets Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent Other Stockholders' Equity, Other Amounts awarded to plaintiff Loss Contingency, Damages Awarded, Value Equity Components [Axis] Equity Components [Axis] Pre-tax expenses related to estimated litigation liability Loss Contingency Accrual, Period Increase (Decrease) Award Timing Method Award Timing Method [Text Block] Number of votes per share of common stock permitted on proposals presented to stockholders (vote) Common Stock, Voting Rights, Number of Votes Per Common Share Common Stock, Voting Rights, Number of Votes Per Common Share Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding U.S. Dollar notional amount, asset Derivative Asset, Notional Amount Insider Trading Policies and Procedures [Line Items] Cash proceeds from divestiture Proceeds from Divestiture of Businesses Use of Estimates Use of Estimates, Policy [Policy Text Block] Goodwill Disposal Group, Including Discontinued Operation, Goodwill, Current Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] 4.75% Notes due May 30, 2029 4.75% Notes Due May 30, 2029 [Member] 4.75% Notes Due May 30, 2029 Adjustment to Compensation, Amount Adjustment to Compensation Amount Compensation Amount Outstanding Recovery Compensation Amount Shares repurchased Treasury Stock, Value, Acquired, Par Value Method Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Restructuring, Impairment, and Related Costs Restructuring and Related Costs [Table Text Block] Tabular List, Table Tabular List [Table Text Block] Current litigation liabilities Loss Contingency, Accrual, Current Senior Unsecured Credit Facility (the 2022 Credit Facility) Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member] Senior Unsecured Credit Facility (the 2022 Credit Facility) Accumulated other comprehensive loss in charge for remeasurement to fair value Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Loss in Charge for Remeasurement to Fair Value Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Gain (Loss) in Charge for Remeasurement to Fair Value Receivables, net Receivables, Net, Current Repurchase of common stock Stock Repurchased During Period, Value Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] An individual Individual Claimant [Member] Individual Claimant Total litigation liabilities Loss Contingency Accrual Other accrued liabilities Accrued Liabilities, Current Potentially dilutive securities excluded from diluted earnings per share (less than) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Portion of settlement award to be used by state and local government for remediation (percent) Litigation Settlement, Award Amount To Be Used by State and Local Government Litigation Settlement, Award Amount To Be Used by State and Local Government Non-cash operating lease expense Operating Lease, Expense Cash payments Payments for Restructuring Lease and other obligations Lease and Other Obligations [Member] Lease and Other Obligations Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents, and restricted cash at beginning of period Cash, cash equivalents, and restricted cash at end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Current assets Assets, Current [Abstract] Goodwill Beginning balance Ending balance Goodwill Consolidation Items [Axis] Consolidation Items [Axis] Authorized repurchase amount (up to) Share Repurchase Program, Authorized, Amount Treasury shares (in shares) Beginning balance (in shares) Ending balance (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Common stock transactions: Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract] Stock options Share-Based Payment Arrangement, Option [Member] Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Goodwill [Roll Forward] Goodwill [Roll Forward] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Depreciation Depreciation Other Proceeds from (Payments for) Other Financing Activities Comprehensive income attributable to McKesson Corporation Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Security Exchange Name Security Exchange Name Three Largest U.S. Pharmaceutical Distributors Three Largest U.S. Pharmaceutical Distributors [Member] Three Largest U.S. Pharmaceutical Distributors Award Type [Axis] Award Type [Axis] Foreign currency translation adjustments, net Goodwill, Foreign Currency Translation Gain (Loss) Less: amounts attributable to noncontrolling interests Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest Liabilities Disposal Group, Including Discontinued Operation, Liabilities [Abstract] Revenue from Contract with Customer, Product and Service Benchmark Revenue from Contract with Customer, Product and Service Benchmark [Member] Property, plant, and equipment, net Property, Plant and Equipment, Net Settled Litigation Settled Litigation [Member] Noncontrolling interests Equity, Attributable to Noncontrolling Interest Loss contingency, number of cases dismissed Loss Contingency, Number Of Cases Dismissed Loss Contingency, Number Of Cases Dismissed 1.30% Notes due August 15, 2026 1.30% Notes Due August 15, 2026 [Member] 1.30% Notes Due August 15, 2026 Other comprehensive income (loss), net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax AOCI, Accumulated Gain (Loss), Net Investment Hedges, Noncontrolling Interest [Member] AOCI, Accumulated Gain (Loss), Net Investment Hedges, Noncontrolling Interest Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date INVESTING ACTIVITIES Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current portion of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Issued Entity [Domain] Entity [Domain] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Revenue derived from services, percentage (approximately or less than) Concentration Risk, Percentage Credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity CAD Canada, Dollars Income before income taxes Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Derivative termination proceeds, amortization period (in years) Derivative, Termination Proceeds, Amortization Period Derivative, Termination Proceeds, Amortization Period Assets held for sale Total assets held for sale Disposal Group, Including Discontinued Operation, Assets Restructuring, impairment, and related charges, net Restructuring, impairment, and related charges, net Restructuring Costs and Asset Impairment Charges Liability Derivative Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Inventories, net Disposal Group, Including Discontinued Operation, Inventory, Current Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Acquisitions, net of cash, cash equivalents, and restricted cash acquired Payments to Acquire Businesses, Net of Cash Acquired Diluted (in shares) Diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Restructuring, anticipated total charges Restructuring and Related Cost, Expected Cost U.S. Dollar, notional amount, liability Derivative Liability, Notional Amount Accrued Liabilities Accrued Liabilities [Member] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Estimated annual amortization expense, remainder of 2025 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Loss contingency, claims settled, number of jurisdictions not participating in settlement Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Operating lease right-of-use assets Disposal Group Including Discontinued Operation, Operating Lease, Right-of-Use Assets, Current Disposal Group Including Discontinued Operation, Operating Lease, Right-of-Use Assets, Current Total McKesson Corporation stockholdersâ€™ deficit Equity, Attributable to Parent Litigation Case [Axis] Litigation Case [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Balance Sheet Location [Axis] Statement of Financial Position Location, Balance [Axis] Interest expense Interest Expense, Nonoperating Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax Derivatives designated as cash flow and other hedges: Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of Changes in the Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, distribution, general, and administrative expenses Selling, General and Administrative Expense Other comprehensive income (loss) attributable to McKesson Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Fair Value, Recurring Fair Value, Recurring [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Cost of Sales Cost of Sales [Member] Total debt Carrying Value Long-Term Debt 0.90% Notes due December 3, 2025 0.90% Notes Due December 3, 2025 [Member] 0.90% Notes Due December 3, 2025 Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities, Current Balance Sheet Location [Domain] Statement of Financial Position Location, Balance [Domain] Schedule of Restructuring and Asset Impairment Charges Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Estimated annual amortization expense, 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Held for Sale Mergers, Acquisitions and Dispositions Disclosures [Text Block] ASSETS Assets [Abstract] Other comprehensive income (loss), net of tax Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax Less: Restricted cash at end of period included in Prepaid expenses and other Restricted Cash, Current Document Type Document Type Derivative, Name [Domain] Derivative Contract [Domain] Commercial Paper Commercial Paper [Member] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Financial Information Relating to Reportable Operating Segments and Reconciliations to the Condensed Consolidated Totals Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Average price of shares repurchased (in usd per share) Shares Acquired, Average Cost Per Share 4.25% Notes due September 15, 2029 4.25% Notes Due September 15, 2029 [Member] 4.25% Notes Due September 15, 2029 Long-term litigation liabilities Estimated Litigation Liability, Noncurrent Capitalized software expenditures Payments to Acquire Software Maximum Maximum [Member] Amortization expense of intangible assets Amortization of Intangible Assets Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] State of West Virginia and Subdivisions State of West Virginia and Subdivisions [Member] State of West Virginia and Subdivisions Intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Drafts and accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Segment revenues Revenues [Abstract] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Claims and litigation charges, net Claims and litigation charges Gain (Loss) from Litigation Settlement Fair Value Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member] Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax AOCI, Accumulated Gain (Loss), Net Investment Hedges, Portion Attributable to Parent [Member] AOCI, Accumulated Gain (Loss), Net Investment Hedges, Portion Attributable to Parent Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] Receivables, net Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Name Outstanding Recovery, Individual Name Other comprehensive income (loss) before reclassification, tax Other Comprehensive Income (Loss) before Reclassifications, Tax Schedule of Assets and Liabilities Held for Sale Disposal Groups, Including Discontinued Operations [Table Text Block] Corporate Segment and U.S. Pharmaceutical Segment Corporate Segment And U.S. Pharmaceutical Segment [Member] Corporate Segment And U.S. Pharmaceutical Segment Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Money market funds at carrying value Money Market Funds, at Carrying Value Tax expense (benefit), intra-entity transfers of assets other than inventory, amount Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount Non-PEO NEO Non-PEO NEO [Member] Additional Paid-in Capital Additional Paid-in Capital [Member] Hedging Relationship [Axis] Hedging Relationship [Axis] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Earnings (loss) per common share attributable to McKesson Corporation: EPS, Basic and Diluted [Abstract] Earnings Per Share, Basic and Diluted Dividends paid Payments of Ordinary Dividends, Common Stock Redemption price percentage of principal (percent) Debt Instrument, Redemption Price, Percentage Customer relationships Customer Relationships [Member] Recently Adopted Accounting Pronouncements, Recently Issued Accounting Pronouncements Not Yet Adopted, and Recent Securities and Exchange Commission Final Rules Not Yet Implemented New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in usd per share) Earnings Per Share, Diluted Class of Stock [Axis] Class of Stock [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Canada CANADA Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Prepaid expenses and other Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Restructuring, Impairment, and Related Charges, Net Restructuring and Related Activities Disclosure [Text Block] Receivables Increase (Decrease) in Receivables Unrecognized tax benefits, increase (decrease) Unrecognized Tax Benefits, Period Increase (Decrease) Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense Income tax expense Income Tax Expense (Benefit) Interest rate on debt instrument (percent) Debt Instrument, Interest Rate, Stated Percentage Notional Derivative, notional amount Derivative, Notional Amount Corporate Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Asset Derivative Asset Other non-current liabilities Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent Property, plant, and equipment, net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Revenues Total revenues Revenue from Contract with Customer, Excluding Assessed Tax LeAnn Smith [Member] LeAnn Smith Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Proceeds from sales of businesses and investments, net Proceeds from Divestiture of Businesses and Interests in Affiliates Reported income

tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating income Total operating profit (loss) Operating Income (Loss) Interest expense Interest Expense, Operating and Nonoperating Number of reportable segments Number of Reportable Segments Total liabilities and deficit Liabilities and Equity Corporate income (expenses), net Corporate Operating (Expense) and Other Income, Net Corporate Operating (Expense) and Other Income, Net Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Additional paid-in capital Additional Paid in Capital Hedging Designation [Axis] Hedging Designation [Axis] Hedging Activities Derivative Instruments and Hedging Activities Disclosure [Text Block] Rx Savings Solutions, LLC Rx Savings Solutions, LLC [Member] Rx Savings Solutions, LLC Restructuring, impairment, and related charges Total Restructuring, impairment, and related charges, net Restructuring Charges Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] 6.00% Notes due March 1, 2041 6.00% Notes Due March 1, 2041 [Member] 6.00% Notes Due March 1, 2041 Noncash divestiture, amount of consideration received Noncash or Part Noncash Divestiture, Amount of Consideration Received Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Legal Entity [Axis] Legal Entity [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Long-term operating lease liabilities Disposal Group, Including Discontinued Operation, Long-term operating lease liabilities Disposal Group, Including Discontinued Operation, Long-term operating lease liabilities Current portion of long-term debt Less: Current portion Long-Term Debt and Lease Obligation, Current Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member] Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Inventories, net Inventory, Net Liabilities held for sale Total liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Statement [Line Items] Statement [Line Items] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Assets held for sale Disposal Group, Including Discontinued Operation, Assets, Current Purchase price Disposal Group, Including Discontinued Operation, Consideration Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] LIABILITIES AND DEFICIT Liabilities and Equity [Abstract] Hedging Activities Derivatives, Policy [Policy Text Block] Number of plaintiffs Loss Contingency, Number of Plaintiffs Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date 1.500% Notes due 2025 1.500% Notes Due 2025 [Member] 1.500% Notes Due 2025 Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Other accrued liabilities Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current Provision for bad debts Accounts receivable, credit loss expense (reversal) Accounts Receivable, Credit Loss Expense (Reversal) Currency [Axis] Currency [Axis] Foreign Currency Translation Adjustments, Net of Tax Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member] Segments [Axis] Business Segments [Axis] Segments [Axis] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative, by Nature [Axis] Derivative Instrument [Axis] Exercise Price Award Exercise Price Canadian businesses held for sale Charge to remeasure disposal group Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down Earnings Per Common Share Earnings Per Share [Text Block] Arrangement Duration Trading Arrangement Duration Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block] Subsequent Event Subsequent Event [Member] Goodwill and Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] McKesson Corporation stockholdersâ€™ deficit Equity, Attributable to Parent [Abstract] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table] Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Segments [Domain] Segments [Domain] Restructuring Plan [Axis] Restructuring Plan [Axis] Other comprehensive loss Other Comprehensive Income (Loss), Tax Segment Reporting Information, Profit (Loss) [Abstract] Segment Reporting Information, Profit (Loss) [Abstract] Medical-Surgical Solutions Medical-Surgical Solutions Segment [Member] Medical-Surgical Solutions Segment [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Estimated annual amortization expense, 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] State of Alabama and Subdivisions State of Alabama and Subdivisions [Member] State of Alabama and Subdivisions Significant Accounting Policies Basis of Presentation and Significant Accounting Policies [Text Block] Borrowings under facility Proceeds from Lines of Credit Trademarks and trade names Trademarks and Trade Names [Member] Service agreements Service Agreements [Member] PEO PEO [Member] True Health Chiropractic Inc., et al. v. McKesson Corporation, et al True Health Chiropractic Inc., et al. v. McKesson Corporation, et al [Member] True Health Chiropractic Inc., et al. v. McKesson Corporation, et al [Member] 7.65% Debentures due March 1, 2027 7.65% Debentures Due March 1, 2027 [Member] 7.65% Debentures Due March 1, 2027 Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Fair Value Debt Instrument, Fair Value Disclosure Name Trading Arrangement, Individual Name Other income, net Other Nonoperating Income (Expense) Number of states in which court cases are pending Loss Contingency, Number of States Loss Contingency, Number of States Cherokee Nation Cherokee Nation [Member] Cherokee Nation Number of states filed on behalf of Loss Contingency, Number of States Filed On Behalf Of Loss Contingency, Number of States Filed On Behalf Of Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table] Disposal Group Name [Axis] Disposal Group Name [Axis] Issuances Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Non-cash charges Restructuring Reserve, Settled without Cash Restructuring, Impairment, And Related Charges, Net Restructuring, Impairment, And Related Charges, Net [Member] Restructuring, Impairment, And Related Charges, Net Income (loss) from equity method investments Income (Loss) from Equity Method Investments Treasury shares, at cost, 152 and 148 shares at September 30, 2024 and March 31, 2024, respectively Treasury Stock, Common, Value Other Restructuring Reserve, Translation and Other Adjustment Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Loss contingency, class action, number of faxes received Loss Contingency, Class Action, Number of Faxes Received Loss Contingency, Class Action, Number of Faxes Received Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] National Prescription Opioid Litigation National Prescription Opiate Litigation [Member] In re: National Prescription Opiate Litigation [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Local Phone Number Local Phone Number Schedule of Estimated Accrual Liability Schedule of Loss Contingencies by Contingency [Table Text Block] Change in cash, cash equivalents, and restricted cash classified as Assets held for sale Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Long-term deferred tax liabilities Deferred Income Tax Liabilities, Net 3.125% Notes due 2029 3.125% Notes Due 2029 [Member] 3.125% Notes Due 2029 Repurchase of common stock (in shares) Stock Repurchased During Period, Shares Subtotal Operating Income (Loss) And Other Income Operating Income (Loss) And Other Income PEO Total Compensation Amount PEO Total Compensation Amount Exit and other-related costs Business Exit Costs Liability Derivative Liability, Subject to Master Netting Arrangement, before Offset Changes in retirement-related benefit plans Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax Remeasurement of assets of businesses held for sale to fair value less costs to sell Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down1 Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down1 Tax contingency, interest expense, amount Effective Income Tax Rate Reconciliation, Tax Contingency, Interest Expense, Amount Effective Income Tax Rate Reconciliation, Tax Contingency, Interest Expense, Amount Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Share Repurchase Program [Domain] Share Repurchase Program [Domain] Commitments and Contingent Liabilities Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Gain from sales of businesses and investments Gain (Loss) on Disposition of Other Assets Common Stock Common Stock [Member] Measure: Measure [Axis] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Derivatives designated as net investment hedges: Other comprehensive income (loss), net investment hedge, gain (loss) Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax 1.63% Euro Notes due October 30, 2026 1.63% Euro Notes Due October 30, 2026 [Member] 1.63% Euro Notes Due October 30, 2026 Entity Emerging Growth Company Entity Emerging Growth Company Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt Segment Reporting [Abstract] Segment Reporting [Abstract] Segment operating profit (loss) Operating Income (Loss) [Abstract] Entity Central Index Key Entity Central Index Key Canadian retail disposal group Canadian Retail Disposal Group [Member] Canadian Retail Disposal Group Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] 4.88% Notes due March 15, 2044 4.88% Notes Due March 15, 2044 [Member] 4.88% Notes Due March 15, 2044 Foreign Currency Translation Adjustments, Net of Tax Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Corporate Corporate Corporate Segment [Member] USD United States of America, Dollars 3.95% Notes due February 16, 2028 3.95% Notes Due February 16, 2028 [Member] 3.95% Notes Due February 16, 2028 Stockholders' Deficit Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Segments of Business Segment Reporting Disclosure [Text Block] Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Fair value adjustment gain Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Amounts reclassified to earnings and other Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Loss contingency, damages sought per violation, value Loss Contingency, Damages Sought Per Violation, Value Loss Contingency, Damages Sought Per Violation, Value Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code 1.50% Euro Notes due November 17, 2025 1.50% Euro Notes Due November 17, 2025 [Member] 1.50% Euro Notes Due November 17, 2025 Title Trading Arrangement, Individual Title Long-term litigation liabilities Loss Contingency, Accrual, Noncurrent Debt principal redeemed Debt Instrument, Repurchased Face Amount Derivative, notional amount, entered into during period Derivative, Notional Amount, Entered Into During Period Derivative, Notional Amount, Entered Into During Period Unsecured Debt Unsecured Debt [Member] Statement [Table] Statement [Table] Foreign Currency Translation Adjustments, Net of Tax Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member] Counterparty Name [Axis] Counterparty Name [Axis] Measurement Frequency [Domain] Measurement Frequency [Domain] Unrecognized tax benefits Unrecognized Tax Benefits Comprehensive income attributable to noncontrolling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Consolidation Items [Domain] Consolidation Items [Domain] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] City Area Code City Area Code Current liabilities Liabilities, Current [Abstract] Changes in assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] Disposal Group Classification [Domain] Disposal Group Classification [Domain] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Fair value, inputs, level 1 Fair Value, Inputs, Level 1 [Member] Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Taxes Increase (Decrease) in Accrued Taxes Payable Intangible assets, net Disposal Group, Including Discontinued Operation, Intangible Assets, Current Share repurchases Payments for Repurchase of Common Stock Charges (credits) associated with last-in, first-out inventory method Pre-tax credits related to LIFO accounting Inventory, LIFO Reserve, Period Charge Document Information [Line Items] Document Information [Line Items] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Other Other Intangible Assets [Member] EUR Euro Member Countries, Euro Income Taxes Income Tax Disclosure [Text Block] Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest Earnings per common share attributable to McKesson Corporation Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Number of other national distributors named in suit Loss Contingency, Number of Other Defendants Loss Contingency, Number of Other Defendants Retained earnings Retained Earnings (Accumulated Deficit) Class of Stock [Domain] Class of Stock [Domain] Inventories Increase (Decrease) in Inventories Schedule of Long-Term Debt Schedule of Debt [Table Text Block] Award payable under proposed framework Litigation Settlement, Amount Awarded to Other Party Other Non-Current Liabilities Other Noncurrent Liabilities [Member] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Asset impairments and accelerated depreciation Asset Impairment Charges, Including Accelerated Depreciation Asset Impairment Charges, Including Accelerated Depreciation Three National Pharmaceutical Distributors Three National Pharmaceutical Distributors [Member] Three National Pharmaceutical Distributors Credit Facility [Axis] Credit Facility [Axis] Prepaid expenses and other/Other accrued liabilities Current Asset / Liability [Member] Current Asset / Liability [Member] Cash dividends declared Dividends, Common Stock, Cash Amendment Flag Amendment Flag Loss Contingency Nature [Axis] Loss Contingency Nature [Axis] Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Asset impairment charges Other Asset Impairment Charges Debt instrument, redemption period (in days) Debt Instrument, Redemption Period Debt Instrument, Redemption Period Gross profit Gross Profit Current portion of operating lease liabilities Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current GBP United Kingdom, Pounds Fair Value as of Grant Date Award Grant Date Fair Value Effective income tax rate reconciliation, foreign income tax rate differential, expense (benefit) Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount Proceeds from sale of equity securities Proceeds from Sale of Equity Securities, FV-NI Other comprehensive income (loss) before reclassifications Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Fair value, inputs, level 2 Fair Value, Inputs, Level 2 [Member] Debt and Financing Activities Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Weighted- Average Remaining Amortization Period (Years) Finite-Lived Intangible Assets, Remaining Amortization Period Geographical [Domain] Geographical [Domain] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt principal amount Debt

Instrument, Face Amount Technology Technology-Based Intangible Assets [Member] Proceeds from short-term borrowings Proceeds from Short-Term Debt Entity Address, Postal Zip Code Entity Address, Postal Zip Code Basis of Presentation Consolidation, Policy [Policy Text Block] Floating interest rate swaps Interest Rate Swap Interest Rate Swap [Member] Schedule of Restructuring and Related Costs [Table] Restructuring Cost [Table] Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security 1.625% Notes due 2026 1.625% Notes Due 2026 [Member] 1.625% Notes Due 2026 Concentration Risk Type [Axis] Concentration Risk Type [Axis] Issuance of shares under employee plans, net of forfeitures Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures Common stock, $0.01 par value, 800 shares authorized, 279 and 278 shares issued at September 30, 2024 and March 31, 2024, respectively Common Stock, Value, Issued Fiscal Period Fiscal Period, Policy [Policy Text Block] Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Noncontrolling Interest [Member] Cash and cash equivalents Cash and cash equivalents at end of period Cash and Cash Equivalents, at Carrying Value Open Market Share Repurchase Transactions Open Market Share Repurchase Transactions [Member] Open Market Share Repurchase Transactions [Member] Litigation Status [Axis] Litigation Status [Axis] Other Payments for (Proceeds from) Other Investing Activities Investments in equity securities Equity Securities, FV-NI, Noncurrent Other non-current assets Other Noncurrent Assets [Member] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] All Currencies [Domain] All currencies [Domain] Gain on debt extinguishment Gain (Loss) on Extinguishment of Debt FINANCING ACTIVITIES Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Excise taxes Excise Tax Accrual Excise Tax Accrual Native American Tribes Other Than Cherokee Nation Native American Tribes Other Than Cherokee Nation [Member] Native American Tribes Other Than Cherokee Nation Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding Preferred Stock, Value, Issued Foreign currency forwards Forward Contracts [Member] Loss contingency, class action, number of faxes remaining in the class Loss Contingency, Class Action, Number of Faxes Remaining in the Class Loss Contingency, Class Action, Number of Faxes Remaining in the Class Litigation settlement, amount awarded to other party, Percentage of total settlement to be used to remediate damages Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages Basic (in dollars per share) Earnings Per Share, Basic Estimated annual amortization expense, thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Repayments of commercial paper Repayments of Commercial Paper Drafts and accounts payable Increase (Decrease) in Accounts Payable Tax expense (benefit), share-based payment arrangement Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] 4.90% Notes due July 15, 2028 4.90% Notes Due July 15, 2028 [Member] 4.90% Notes Due July 15, 2028 Thomas Rodgers [Member] Thomas Rodgers Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Schedule of Goodwill [Table] Goodwill [Table] Amortization Amortization Derivatives designated for hedge accounting Designated as Hedging Instrument [Member] Proceeds from debt issuance Proceeds from Debt, Net of Issuance Costs Held-for-sale Disposal Group, Held-for-Sale, Not Discontinued Operations [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Weighted-average common shares outstanding Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Share Repurchase Program [Axis] Share Repurchase Program [Axis] Proceeds from issuance of commercial paper Proceeds from Issuance of Commercial Paper Total Assets Estimated annual amortization expense, 2026 Finite-Lived Intangible Asset, Expected Amortization, Year One Cost of sales Cost of Goods and Services Sold Amounts outstanding under facility Long-Term Line of Credit Number of antitrust settlement Number Of Antitrust Settlements Number Of Antitrust Settlements 5.25% Notes due February 15, 2026 5.25% Notes Due February 15, 2026 [Member] 5.25% Notes Due February 15, 2026 Payments for property, plant, and equipment Payments to Acquire Property, Plant, and Equipment Other non-current liabilities Other Liabilities, Noncurrent Proceeds from legal settlements Proceeds from Legal Settlements Trade accounts payable Accounts Payable, Not Discontinued Operation, Intercompany Trade, Accounts Payable Disposal Group, Not Discontinued Operation, Intercompany Trade, Accounts Payable Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Termination Date Trading Arrangement Termination Date Accelerated Share Repurchases [Line Items] Accelerated Share Repurchases [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Repayments of short-term borrowings Repayments of Short-Term Debt International International Segment [Member] International Segment Entity Address, City or Town Entity Address, City or Town Proceeds from issuances of long-term debt Proceeds from Issuance of Long-Term Debt Debt Instrument [Axis] Debt Instrument [Axis] U.S. Pharmaceutical U.S. Pharmaceutical Segment [Member] U.S. Pharmaceutical Segment [Member] Fair Value Measurements Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] 3.13% Sterling Notes due February 17, 2029 3.13% Sterling Notes Due February 17, 2029 [Member] 3.13% Sterling Notes Due February 17, 2029 Net income attributable to McKesson Corporation Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Schedule of Fair Value of Derivatives Fair Value, by Balance Sheet Grouping [Table Text Block] Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Accumulated Gain (Loss), Net, Cash Flow Hedge, Noncontrolling Interest [Member] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Information Regarding Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Derivative notional amount, terminated Derivative, Notional Amount, Terminated Derivative, Notional Amount, Terminated Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Noncash divestiture payable period (in years) Noncash or Part Noncash Divestiture, Amount of Consideration Received, Payment Period Noncash or Part Noncash Divestiture, Amount of Consideration Received, Payment Period Entity File Number Entity File Number Unrealized gain (loss) on cash flow and other hedges Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Document Fiscal Year Focus Document Fiscal Year Focus Noncontrolling Interests Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Product Concentration Risk Product Concentration Risk [Member] Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate changes on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Severance and employee-related costs, net Restructuring charges Severance Costs Restructuring Plan [Domain] Restructuring Plan [Domain] Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Loss Contingency, Nature [Domain] Loss Contingency, Nature [Domain] Deferred taxes Increase (Decrease) in Deferred Income Taxes Other non-cash items Other Noncash Income (Expense) Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Gain related to share price increase of equity securities Equity Securities, FV-NI, Realized Gain Insider Trading Arrangements [Line Items] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other Prepaid Expense and Other Assets, Current Net income attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Settling Governmental Entities and Cherokee Nation Settling Governmental Entities and Cherokee Nation [Member] Settling Governmental Entities and Cherokee Nation Document Quarterly Report Document Quarterly Report Disposals (1) Goodwill, Written off Related to Sale of Business Unit Litigation Case [Domain] Litigation Case [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation Status [Domain] Litigation Status [Domain] Litigation liabilities Increase (Decrease) in Litigation Reserve Increase (Decrease) in Litigation Reserve Basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Document Information [Table] Document Information [Table] Total deficit Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Drafts and accounts payable Disposal Group, Including Discontinued Operation, Accounts Payable, Current Schedule of Components of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity Filer Category Entity Filer Category Beginning balance Ending balance Restructuring Reserve Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member] Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 mck-20240930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 mck-20240930_g1.jpg begin 644 mck-20240930_g1.jpg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à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}# ["OKL=COJ=>G?X7 MN?$Y=EWU[#U7'XE:Q^57P;^+VM_!/QQ9>(]$FZ-G:ES:L2$NR82?FC;V;'T(! MK]A/A/\ %#1?B_X)T Q-H<_FVMROSQD_/#(,;HW'8@G^.[]U^*GB/P[?^$]=O M]&U6W:TU&QF:">%Q@JRG!'TKUW]E7]HZ_P#@#XV5IGDG\+Z@RQZC9@D[><"9 M1_>4?F,USYKE\<935:C\7YG5DV:2P%7V%;X7^!^P\]^0?\ @I?_,D;T?\ M["B?

^@-7U;H.NV/B;1K/5=,N8[RPNXEG@GB;#M*\-:49FT[3 M(!! ;A]S[1_>.!D_A71=:XOX;_&#PA\7+6\N/"6M1:S#9NL<[11NH1F&0/F4 M=AVK! :0^+S?!'X3ZKXGA2&:^A*16D,^=LDK,
0"#C&3QZ&O-5.I4J)[JX^9?P(KY>\??\ M$S?">JR23^$]?O\ 07;)%K=@74(/8!CAP/J6K<^%7_!13P)XMMXH/%^M[2W\2:?"-S2:6Q,@'4GRR-W] M,U\Z,I5B&!!'!4\'Z8K]@?B-^V!\+?
A_IL\DGB>SUFZ"DQV>E2KPRI*C M\2*_)7QAKR^*/%NMZTEK'9)J5]-=K;1?=B$DC/L'L-V/PK[+*<5B<2G[>.G< M^"SG!X3"2C]6G>_0^L_^";/Q*O\ 2_B-J?@R29I-+U&U:[CB;D1RQD D?53^
M@K])>* ,# @F_P"%;O5OC=>:TBXL],TZ197Q_%(P"K^A-?9O[6'[0DO[/?@K M3M4L;6" U.\ODACM;@D*\8RTAR.AQ@=_O9P:^8S:C[7'^SHJ[9]ADF(]CEWM
M*S]U'9_$GX%^!OBW:M%XH\.6FHR8PMS@QSI_NR*0P_.OESQY_P $Q]#NO-F\ M'^*+O3G)RMKJB":/GL'4*P'U!->B_#'_(* ?#7QM##%K-S)X4U%@ T5\I:+ M<>/ED7C'U KV>U^-?
P_O;4W$/C;P_)"HW,_]IPX7Z -Q^-9\KO]Y^77Q: 8T^)/PCL;C4KS3H]8TB#)DO-,(C:Q^>YQA,+A:B6&E?\ 0^__ /@F7\3+ MZ_L?$O@>\G:>VL0FH6"L<^4K,5E0>B[MAQZLWK7E'_!2+0Y--^/UK?
%3Y&H: M/!(K8XW*\B,,^N%4_P# A7=?\$P/"%Q)KGC+Q2T96TB@BTV.0YP[LPD=0?\ M9"IG_?%>F_\ !1?X1S^,OAO8>*]/@,M[X>D9I@HY^SR8#_D0I_.O!]K3P^;N MVS/HO8U<5D:3U:U^2/SB\
(ZW_P (UXJT76,%O[/O8+K:O4[)%?'XXK]RM%U. M#7-&L=0M95GM[J!)XI$.5964$$'T((K\'Z^U?V1OVX+'X=^'+7P9XZ,YTNT^ M2QU2-?,,,>;P]F%/"5)4JSLI'Z,]* M\0_;.\80>#_V<_%
[RR*DVH6W]G0*>KM,=A _X"7/X4W4OVU/@[INFF['C&VN MAMW+#;Q2-(W? 7;P?KBO@+]K']J6Z_:$UVVM;"&33_"VGLS6UO*1OF<\&5QZ MX' [GO7S>79=7K5XN4;),^LS7-#?=,O\ %,WS.?
S./PKZ3/ZT84%2OJSY7AK#RGB7 M6MHD?%7_4^_P"2B^#_ /L&/_Z-:OD;P\ \CIX?_["%O\ ^C5KZY_X*??\ ME%\'_P#8,?\ ]&M7R-X'_P"1T\/_/80M_\ T:M=>6 \BZ/HSS\U_P"1I+U7
MZ'[%_'WX0V/QL^%^I^'+M5%P\?G6^&=_LIF@FB8$%64X(_,5^[R_ZL?2OSY_X*-? 7[#]%M\2]&MML5QMMM72,!>HAN%8$D>S ?H*\X]:!17W<*<:;DXK5GYS.K.HHJ3O8_7C] MA_\ Y-=\$?\
7*X_]*I:*/V' P#DUWP1_P!* MY@/)CF0.I_UG?\ "%^'^G]B:?\ ^_L?^%>OE^;?4:3I\M[GA9GDCS"LJO/; M0X+]E4%?V>? H(Q_Q+D[>YK_P#]O[X=MX0^/-WJ5O"PM-=MTO591G]X/E@
Z55U'0].U9D-]86UX5'RF>)7QGTR M*Y,CWAL2ZZ5[WT._'98L7A8X=RLXVU/R0_8U^'+_$+]H#PY;RP,]EI[-J5S MN7Y=D6, ^QV_48_@:OL5O!>@=]$TXG_KU3_"KFG:1 M8Z2CK8V5O9JQRP@C5
3[X'-=^-SCZU0]AR6V/,R_(G@L2J_M+_(X#]HI=WPM MU, 9^9/_$(5\9>6W]P_E7Z*W%O%=1F.:-94/57&15+_ (1[3,C_$"V_P"_M2_X5^)\0\)SSS$K$*KRV5MC]DR7B)930=%T^:[ON?GOY;?W#^5-
,;\?*WY&O MT_X1[3?^?"V_P"_2_X4?\([IG_/A;_]^E_PKY7_(AS4_Z"/P_X)]#_*[K M_GQ^/_/_V; 5^%UD""/WLG_H5?)7_!4"-V\2>"-JLV+6XZ#/\ $M?H';V\
M5K$(X(UB0"#D$6J9_E6R%XP.!7N9EF/UJQ?+:QXV4Y6\M4KRO<^*_\ @H!^ MS6?%6DM\1?#UIG5[",)J<,*?-<0+TDQW9!^:@>E?G/Y,G_/-OR-?O3)&LD1 MR*'5A@J1D'V-9'_"%Z!U_L33O_6/_"NS
YU+"TO93CS=C@S#A^&,K>VA+EO MN?G1^PY^U%+\-=7@\#^)[AAX7OI<6=Q-]VRF8]"><R,3] 3GN:]S_."E2F7X M-Z,4!<'5$/R_P #5]2_\(7H&W/]AZ=_X"I_A5Z\TFRU*W2&[M(+]%>5CFC#
MJ,<< BN.>.@\5'%0A8[J>6U8X*6$J5+I[/L?@_Y$G_/-_P#ODT>1+_<;_ODU M^Z/_A?A_\ Z >G_P#@*$G^%>[_K'_-_Q/GO]59? M_?P/PN\B3_GF_\ WR:/(D_YYO\
]\FOW1_X0OP__P! /3__%3 "C_ (0O MP_\ ] /3_P#P%3_"E_K$O^??XA_JK+_G[^!\PTA76QL[>S5SEA!$J GWP*N;:^>ECG];^M1CKV/IX9:OJ*P4Y?,_ M!W5M#U+0+R2TU33[K3KJ_X>&[A:)U]BK
'\ZI<5^Z_B#PAH?BJ_0ZSH]CJL7 M9+RV24#_ +Z!Q7!W?[+7PGOIS+-X%TDN?[L.T?D"!7TD.(H-?O*>I\I4X7J) M_NJGWGXR=2 .:}^$?[.?COXT:C%%H.B7"Z>S8DU2ZC,=K&,\G>1\Q']UX+
UZ!#!';PI'%&L<: *J*N !* MQK<0MQM1A;U-\/PO:2=>I?T/-?V?_@3HWP#\#Q:'IA-S>2D2WU\PPUQ+C!/L M!T [5\O_ /!0GX5_$?X@^)-)U#0_#UUK/AK3+0C_ $#][*)6;YB8A\YX Y4'
M@5]W4<=,5\Y0QE2C7^L/67F?58C+Z5?#?55[L?(_!>\L;G3;AX+NVFM9XSM> M.:,HRD=001UJ&OW/\1> ?#7C! -;T'3=5P, WEJDI'T+ D5Q$W[*OPFN)#(_
M@722Q_NQ$#\@:^JAQ%3:]^GJ?'5.%JJ?[NHK'XSJ"S8')] *]H^"/{)OCSXU M:A]MI<^CZ 2#+K%_$8XRN>?+SS(?]T8SU-?J5X=^'!"P]*S1RZ5X.T:UF3E M)?LB,Z_1F!(KNU4*-H [
"N;$<0RE&U&%KG5A>%XQES8B=_)''?"/X6Z/\ M!WP-I_AG1(MEM:KEY6'SS2'EG;W)_D!VKJ[RTAU"TFMKB))[>9#')'(,JRD8 M(([@C-3B@U\C*4IRYF]6?;PIQA!4XK1'YI_M.?L(:[X/U:]\0?
#^QFUOP],Q ME?2[=2]S:9Y(5>KKGICD>_6OD*ZM9K&9X;B*2"9#M>.5"K @X((/?ZU^]\-:?JLV,>;!U-?L!#^RK\ M)K>19$\"Z2&7UC)_0FO0/#_A+1/"5N;?1=)LM*@[QV=ND0/UV@9KNJ<11M^Z
MAKYGGT^%ZG-^]J:>1\]?L@_L5GX7WEOXP\:QPW'B=5S:6*D/'99'+$]&DQD< M<#MZC[#H/2CTKY#$8FIBJCJ5'=GW.$PE+!TE2I+0_.7_ (*>1NWQ$\(%59A_
M9CJ!G_EJ:^2/!$$G_"::!^[;_D(V_P#"?^>JU^X.H:#INK,KWMA:WCJ,*UQ" MKD>PR*JKX/T&-E9=%T]64Y#+:H"/<<5[N&SGZOAE0Y+^9\UB\@>)Q3Q'M+7> MUC7C^XOTK&\9>$]/\
<^%]3T'5(5GL-0@:"5",\,,9'N.H^E;GI17S2DXNZ/K MW!2CRRV/Q&^,'PMU/X0_$;6?"U_%(SV XML 13 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover 6 Months Ended Sep. 30, 2024 shares
Document Information [Line Items] Â Document Type 10-Q Document Quarterly Report true Document Period End Date Sep. 30, 2024 Document Transition Report false Entity File Number 1-13252 Entity Registrant Name McKESSON CORPORATION Entity Incorporation, State or Country Code DE Entity Tax Identification Number 94-3207296 Entity Address, Address Line One 6555 State Hwy 161 Entity Address, City or Town Irving Entity Address, State or Province TX Entity Address, Postal Zip Code 75039 City Area Code 972 Local Phone Number 446-4800 Entity Current Reporting Status Yes Entity Interactive Data Current Yes Entity Filer Category Large Accelerated Filer Entity Small Business false Entity Emerging Growth Company false Entity Shell Company false Entity Common Stock, Shares Outstanding 126,940,097 Entity Central Index Key 0000927653 Document Fiscal Year Focus 2025 Document Fiscal Period Focus Q2 Amendment Flag false Current Fiscal Year End Date --03-31 Common Stock Â Document Information [Line Items] Â Title of 12(b) Security Common stock, $0.01 par value Trading Symbol MCK Security Exchange Name NYSE 1.500% Notes due 2025 Â Document Information [Line Items] Â Title of 12(b) Security 1.500% Notes due 2025 Trading Symbol MCK25 Security Exchange Name NYSE 1.625% Notes due 2026 Â Document Information [Line Items] Â Title of 12(b) Security 1.625% Notes due 2026 Trading Symbol MCK26 Security Exchange Name NYSE 3.125% Notes due 2029 Â Document Information [Line Items] Â Title of 12(b) Security 3.125% Notes due 2029 Trading Symbol MCK29 Security Exchange Name NYSE X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: dei_DocumentInformationLineItems Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mck_A1500NotesDue2025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mck_A1625NotesDue2026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=mck_A3125NotesDue2029Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 14 R2.htm IDEA: XBRL DOCUMENT v3.24.3
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Revenues $ 93,651 $ 77,215 $ 172,934 $ 151,698 Cost of sales (90,403) (74,146) (166,534) (145,607) Gross profit 3,248 3,069 6,400 6,091 Selling, distribution, general, and administrative expenses (2,503) (2,092) (4,504) (3,962) Claims and litigation charges, net 4 2 (108) 2 Restructuring, impairment, and related charges, net (171) (28) (181) (80) Total operating expenses (2,670) (2,118) (4,793) (4,040) Operating income 578 951 1,607 2,051 Other income, net 34 26 164 64 Interest expense (78) (61) (153) (108) Income before income taxes 534 916 1,618 2,007 Income tax expense (247) (213) (371) (307) Net income 287 703 1,247 1,700 Net income attributable to noncontrolling interests (46) (39) (91) (78) Net income attributable to McKesson Corporation $ 241 $ 664 $ 1,156 $ 1,622 Earnings per common share attributable to McKesson Corporation Â Â Â Â Diluted (in usd per share) $ 1.87 $ 4.92 $ 8.89 $ 11.95 Basic (in usd per share) $ 1.88 $ 4.95 $ 8.94 $ 12.03 Weighted-average common shares outstanding Â Â Â Â Diluted (in shares) 129.3 134.8 130.0 135.7 Basic (in shares) 128.7 134.1 129.3 134.8 X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483643/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_GainLossRelatedToLitigationSettlement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_GrossProfit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6 + Details Name: us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. + ReferencesNo definition available. + Details Name: us-gaap_OperatingExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 15 R3.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net income $ 287 $ 703 $ 1,247 $ 1,700 Other comprehensive income (loss), net of tax Â Â Â Â Foreign currency translation adjustments 34 (64) 3 (12) Unrealized gain (loss) on cash flow and other hedges (9) 25 (9) 32 Changes in retirement-related benefit plans (2) 0 (3) (2) Other comprehensive income (loss), net of tax 23 (39) (9) 18 Comprehensive income 310 664 1,238 1,718 Comprehensive income attributable to noncontrolling interests (46) (39) (91) (78) Comprehensive income attributable to McKesson Corporation $ 264 $ 625 $ 1,147 $ 1,640 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K + Details Name: us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-

220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (j) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (k) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions Sep. 30, 2024 Mar. 31, 2024 Current assets Â Â Cash and cash equivalents $ 2,509 $ 4,583 Receivables, net 25,270 21,622 Inventories, net 24,176 21,139 Assets held for sale 635 5 Prepaid expenses and other 751 621 Total current assets 53,341 47,970 Property, plant, and equipment, net 2,361 2,316 Operating lease right-of-use assets 1,495 1,729 Goodwill 10,087 10,132 Intangible assets, net 1,573 2,110 Other non-current assets 3,572 3,186 Total assets 72,429 67,443 Current liabilities Â Â Drafts and accounts payable 53,317 47,097 Current portion of long-term debt 53 50 Current portion of operating lease liabilities 243 295 Liabilities held for sale 371 0 Other accrued liabilities 4,787 4,915 Total current liabilities 58,771 52,357 Long-term debt 5,691 5,579 Long-term deferred tax liabilities 1,048 917 Long-term operating lease liabilities 1,232 1,466 Long-term litigation liabilities 5,617 6,113 Other non-current liabilities 2,712 2,610 McKesson Corporation stockholdersâ€™ deficit Â Â Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding 0 0 Common stock, $0.01 par value, 800 shares authorized, 279 and 278 shares issued at September 30, 2024 and March 31, 2024, respectively 3 3 Additional paid-in capital 8,221 8,048 Retained earnings 15,959 14,978 Accumulated other comprehensive loss (890) (881) Treasury shares, at cost, 152 and 148 shares at September 30, 2024 and March 31, 2024, respectively (26,310) (24,119) Total McKesson Corporation stockholdersâ€™ deficit (3,017) (1,971) Noncontrolling interests 375 372 Total deficit (2,642) (1,599) Total liabilities and deficit $ 72,429 $ 67,443 X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapital Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting

Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6 + Details Name: us-gaap_DeferredIncomeTaxLiabilitiesNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserveNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_MinorityInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_PreferredStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_ReceivablesNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount allocated to previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 17 R5.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares Sep. 30, 2024 Mar. 31, 2024 McKesson Corporation stockholdersâ€™ deficit Â Â Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01 Preferred stock, shares authorized (in shares) 100,000,000 100,000,000 Preferred stock, shares issued (in shares) 0 0 Preferred stock, shares outstanding (in shares) 0 0 Common stock, par value (in dollars per share) $ 0.01 $ 0.01 Common stock, shares authorized (in shares) 800,000,000 800,000,000 Common stock, shares issued (in shares) 279,000,000 278,000,000 Treasury shares (in shares) 152,000,000 148,000,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 18 R6.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($) shares in Millions, $ in Millions Total Common Stock Additional Paid-in Capital Retained Earnings Accumulated Other Comprehensive Loss Treasury Noncontrolling Interests Beginning balance (in shares) at Mar. 31, 2023 Â 277 Â Â Â Â Â Beginning balance at Mar. 31, 2023 $ (1,490) $ 3 $ 7,747 $ 12,295 $ (905) $ (20,997) $ 367 Beginning balance (in shares) at Mar. 31, 2023 Â Â Â Â Â (141) Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures (in shares) Â 1 Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures (40) Â 54 Â Â $ (94) Â Share-based compensation 91 Â 91 Â Â Â Â Repurchase of common stock (in shares) Â Â Â Â Â (4) Â Repurchase of common stock (1,513) Â Â Â Â Â $ (1,513) Â Net income 1,700 Â Â 1,622 Â Â 78 Other comprehensive income (loss) 18 Â Â Â 18 Â Â Cash dividends declared (157) Â Â (157) Â Â Â Payments to noncontrolling interests (77) Â Â Â Â Â (77) Other 4 Â 7 1 Â Â (4) Ending balance (in shares) at Sep. 30, 2023 Â 278 Â Â Â Â Â Ending balance at Sep. 30, 2023 (1,464) $ 3 7,899 13,761 (887) $ (22,604) 364 Ending balance (in shares) at Sep. 30, 2023 Â Â Â Â Â (145) Â Beginning balance (in shares) at Jun. 30, 2023 Â 278 Â Â Â Â Â Beginning balance at Jun. 30, 2023 (1,240) $ 3 7,824 13,182 (848) $ (21,763) 362 Beginning balance (in shares) at Jun. 30, 2023 Â Â Â Â Â (143) Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures 26 Â 27 Â Â $ (1) Â Share-based compensation 48 Â 48 Â Â Â Repurchase of common stock (in shares) Â Â Â Â Â (2) Â Repurchase of common stock (840) Â Â Â Â $ (840) Â Net income 703 Â Â 664 Â Â 39 Other comprehensive income (loss) (39) Â Â Â (39) Â Â Cash dividends declared (84) Â Â (84) Â Â Â Payments to noncontrolling interests (38) Â Â Â Â Â (38) Other 0 Â Â (1) Â Â 1 Ending balance (in shares) at Sep. 30, 2023 Â 278 Â Â Â Â Â Ending balance at Sep. 30, 2023 $ (1,464) $ 3 7,899 13,761 (887) $ (22,604) 364 Ending balance (in shares) at Sep. 30, 2023 Â Â Â Â Â (145) Â Beginning balance (in shares) at Mar. 31, 2024 278 278 Â Â Â Â Â Beginning balance at Mar. 31, 2024 $ (1,599) $ 3 8,048 14,978 (881) $ (24,119) 372 Beginning balance (in shares) at Mar. 31, 2024 (148) Â Â Â Â (148) Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures (in shares) Â 1 Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures $ (80) Â 54 Â Â $ (134) Â Share-based compensation 119 Â 119 Â Â Â Â Repurchase of common stock (in shares) Â Â Â Â Â (4) Â Repurchase of common stock (2,057) Â Â Â Â $ (2,057) Â Net income 1,247 Â Â 1,156 Â Â 91 Other comprehensive income (loss) (9) Â Â Â (9) Â Â Cash dividends declared (173) Â Â (173) Â Â Â Payments to noncontrolling interests (88) Â Â Â Â Â (88) Other $ (2) Â Â (2) Â Â Â Ending balance (in shares) at Sep. 30, 2024 279 279 Â Â Â Â Â Ending balance at Sep. 30, 2024 $ (2,642) $ 3 8,221 15,959 (890) $ (26,310) 375 Ending balance (in shares) at Sep. 30, 2024 (152) Â Â Â Â (152) Â Beginning balance (in shares) at Jun. 30, 2024 Â 279 Â Â Â Â Â Beginning balance at Jun. 30, 2024 $ (1,381) $ 3 8,126 15,810 (913) $ (24,781) 374 Beginning balance (in shares) at Jun. 30, 2024 Â Â Â Â Â (149) Â Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Â Â Issuance of shares under employee plans, net of forfeitures 32 Â 32 Â Â Â Â Share-based compensation 63 Â 63 Â Â Â Â Repurchase of common stock (in shares) Â Â Â Â Â (3) Â Repurchase of common stock (1,529) Â Â Â Â $ (1,529) Â Net income 287 Â Â 241 Â Â 46 Other comprehensive income (loss) 23 Â Â Â 23 Â Â Cash dividends declared (90) Â Â (90) Â Â Â Payments to noncontrolling interests (45) Â Â Â Â Â (45) Other $ (2) Â Â (2) Â Â Â Ending balance (in shares) at Sep. 30, 2024 279 279 Â Â Â Â Â Ending balance at Sep. 30, 2024 $ (2,642) $ 3 $ 8,221 $ 15,959 $ (890) $ (26,310) $ 375 Ending balance (in shares) at Sep. 30, 2024 (152) Â Â Â Â (152) Â X - DefinitionNet Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest + ReferencesNo definition available. + Details Name: mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionStock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures + ReferencesNo definition available. + Details Name: mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures Namespace Prefix: mck_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionStock Issued During Period, Value, Employee Stock Plans Net of Forfeitures + ReferencesNo definition available. + Details Name: mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAmount of paid and unpaid common stock dividends declared with the form of settlement in cash. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_DividendsCommonStockCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDecrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting

treatment therefore. This element is used when state law does not recognize treasury stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockRepurchasedDuringPeriodValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThis element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy. + ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of previously issued common shares repurchased by the issuing entity and held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockCommonShares Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 19 R7.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) - $ / shares 3 Months Ended 6 Months Ended Sep. 30, 2024 Jun. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Stockholders' Equity [Abstract] Â Â Â Â Â Dividends declared per common share (in dollars per share) $ 0.71 $ 0.62 $ 0.62 $ 1.33 $ 1.16 X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfStockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 20 R8.htm IDEA: XBRL DOCUMENT v3.24.3 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions 3 Months Ended 6 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 OPERATING ACTIVITIES Â Â Â Â Â Net income $ 287 $ 703 $ 1,247 $ 1,700 Â Adjustments to reconcile to net cash provided by (used in) operating activities: Â Â Â Â Â Depreciation Â Â 124 129 Â Amortization Â Â 208 187 Â Asset impairment charges Â Â 76 28 Â Deferred taxes Â Â 125 (271) Â Charges (credits) associated with last-in, first-out inventory method Â Â (4) 87 Â Non-cash operating lease expense Â Â 113 122 Â Gain from sales of businesses and investments Â Â (89) (16) Â Canadian businesses held for sale Â Â 638 0 Â Provision for bad debts Â Â (169) 243 Â Other non-cash items Â Â 174 71 Â Changes in assets and liabilities: Â Â Â Â Â Receivables Â Â (3,499) (3,207) Â Inventories Â Â (3,310) (2,349) Â Drafts and accounts payable Â Â 6,221 4,307 Â Operating lease liabilities Â Â (196) (166) Â Taxes Â Â (145) (76) Â Litigation liabilities Â Â (386) (529) Â Other Â Â (408) (347) Â Net cash provided by (used in) operating activities Â Â 720 (87) Â INVESTING ACTIVITIES Â Â Â Â Â Payments for property, plant, and equipment Â Â (242) (153) Â Capitalized software expenditures Â Â (143) (111) Â Acquisitions, net of cash, cash equivalents, and restricted cash acquired Â Â (1) 0 Â Proceeds from sales of businesses and investments, net Â Â 93 50 Â Other Â Â (80) (101) Â Net cash used in investing activities Â Â (373) (315) Â FINANCING ACTIVITIES Â Â Â Â Â Proceeds from short-term borrowings Â Â 6,876 2,000 Â Repayments of short-term borrowings Â Â (6,876) (2,000) Â Proceeds from issuances of long-term debt Â Â 498 991 Â Repayments of long-term debt Â Â (501) (271) Â Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Â Â 0 (647) Â Common stock transactions: Â Â Â Â Â Issuances Â Â 54 54 Â Share repurchases Â Â (2,019) (1,505) Â Dividends paid Â Â (162) (149) Â Other Â Â (278) (225) Â Net cash used in financing activities Â Â (2,408) (1,752) Â Effect of exchange rate changes on cash, cash equivalents, and restricted cash Â Â 1 (1) Â Change in cash, cash equivalents, and restricted cash classified as Assets held for sale Â Â (14) 0 Â Net decrease in cash, cash equivalents, and restricted cash Â Â (2,074) (2,155) Â Cash, cash equivalents, and restricted cash at beginning of period Â Â 4,585 4,679 $ 4,679 Cash, cash equivalents, and restricted cash at end of period 2,511 2,524 2,511 2,524 4,585 Less: Restricted cash at end of period included in Prepaid expenses and other (2) 0 (2) 0 Â Cash and cash equivalents at end of period $ 2,509 $ 2,524 $ 2,509 $ 2,524 $ 4,583 X - DefinitionCash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease) + ReferencesNo definition available. + Details Name: mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncrease (Decrease) in Litigation Reserve + ReferencesNo definition available. + Details Name: mck_IncreaseDecreaseInLitigationReserve Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPayments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt + ReferencesNo definition available. + Details Name: mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_AdjustmentForAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1:

http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of gain (loss) on sale or disposal of other assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_GainLossOnSaleOfOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedTaxesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInDeferredIncomeTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingAssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in operating assets after deduction of operating liabilities classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInReceivables Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1 + Details Name: us-gaap_InventoryLIFOReservePeriodCharge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of operating lease expense. Excludes sublease income. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4 + Details Name: us-gaap_OperatingLeaseExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2 + Details Name: us-gaap_OtherAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (expense) included in net income that results in no cash inflow (outflow), classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OtherNoncashIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash (inflow) outflow from investing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromOtherInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow to reacquire common stock during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsForRepurchaseOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDividendsCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireSoftware Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary,

affiliate, joint venture or equity method investment). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_ProceedsFromPaymentsForOtherFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_RestrictedCashCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant XML 21 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Significant Accounting Policies Significant Accounting PoliciesNature of Operations: McKesson Corporation together with its subsidiaries (collectively, the â€œCompanyâ€ or â€œMcKesson,â€) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (â€œRxTSâ€), Medical-Surgical Solutions, and International. Refer to Financial Note 12, â€œSegments of Business,â€ for additional information.Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (â€œU.S.â€) generally accepted accounting principles (â€œGAAPâ€) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (â€œSECâ€) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.The condensed consolidated financial statements of McKesson include the financial statements of all majority-owned or controlled companies. For those consolidated subsidiaries where the Companyâ€™s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as â€œNet income attributable to noncontrolling interestsâ€ in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. Net income attributable to noncontrolling interests includes third-party equity interests in the Companyâ€™s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC.The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (â€œVIEâ€). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Fiscal Period: The Companyâ€™s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means the Companyâ€™s fiscal year.Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation.Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.The results of operations for the three and six months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Companyâ€™s Annual Report on Form 10-K for the fiscal year ended March 31, 2024, previously filed with the SEC on MayÂ 8, 2024 (the â€œ2024 Annual Reportâ€).Recently Adopted Accounting Pronouncements There were no accounting standards adopted during the six months ended September 30, 2024 that had a material impact to the Companyâ€™s condensed consolidated financial statements or disclosures.Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07

expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segmentâ€™s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2024, the FASB issued ASU 2024-03, Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.Recent Securities and Exchange Commission Final Rules Not Yet ImplementedIn March 2024, the SEC adopted final rules under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which would have required the Company to provide certain climate-related information in annual reports and registration statements beginning with its Annual Report on Form 10-K for the year ended March 31, 2026. In April 2024, the SEC stayed these rules pending the completion of judicial review of consolidated petitions challenging the validity of the rules. The Company is currently evaluating the impact of these rules in light of those legal challenges and monitoring the status of the stay and judicial review. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/235/tableOfContent + Details Name: us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R10.htm IDEA: XBRL DOCUMENT v3.24.3 Held for Sale 6 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Held for Sale Held for SaleAssets and liabilities to be disposed of by sale (â€œdisposal groupsâ€) are classified as â€œheld for saleâ€ if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use. The classification occurs when the disposal group is available for immediate sale and the sale is probable. These criteria are generally met when management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying amount or fair value less costs to sell, and long-lived assets included within the disposal group are not depreciated or amortized. The fair value of a disposal group, less any costs to sell, is assessed during each reporting period it remains classified as held for sale, and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The Company determined that the disposal group discussed below did not meet the criteria for classification as discontinued operations.Rexall Health and Well.caOn September 5, 2024, the Company announced an agreement to sell its Rexall and Well.ca businesses in Canada (â€œCanadian retail disposal groupâ€). The adjusted purchase price of approximately $148Â million, net of working capital and other adjustments, includes a payment of $27Â million to be made upon closing, and a note of $121Â million accruing interest upon satisfaction of certain conditions, measured at fair value, payable to the Company at the end of six years. As of September 30, 2024, the Canadian retail disposal group, consisting of $631 million of assets and $371 million of liabilities within the Companyâ€™s International segment, was classified as â€œAssets held for saleâ€ and â€œLiabilities held for sale,â€ respectively, in the Condensed Consolidated Balance Sheet. The transaction is anticipated to close in the second half of fiscal 2025, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, as applicable.During the three and six months ended September 30, 2024, the Company recorded a charge of $643Â million, within â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations, to remeasure the Canadian retail disposal group to fair value less costs to sell. The remeasurement adjustment includes a $15Â million loss related to the accumulated other comprehensive balances associated with the Canadian retail disposal group. The Companyâ€™s measurement of the fair value of the Canadian retail disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreements. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.The total assets and liabilities of the Canadian retail disposal group that have met the classification of held for sale in the Companyâ€™s Condensed Consolidated Balance Sheet are as follows:(In millions)September 30, 2024AssetsCurrent assetsCash$14Â Receivables, net65Â Inventories, net219Â Prepaid expenses and other5Â Property, plant, and equipment, net62Â Operating lease right-of-use assets283Â Goodwill47Â Intangible assets, net419Â Other non-current assets160Â Remeasurement of assets of businesses held for sale to fair value less costs to sell (1)(643)Total assets held for sale$631Â LiabilitiesCurrent liabilitiesDrafts and accounts payable$15Â Current portion of operating lease liabilities61Â Other accrued liabilities42Â Long-term operating lease liabilities249Â Other non-current liabilities4Â Total liabilities held for sale$371Â X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/805/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContent + Details Name: us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R11.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment, and Related Charges, Net 6 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Restructuring, Impairment, and Related Charges, Net Restructuring, Impairment, and Related Charges, NetThe Company recorded restructuring, impairment, and related charges, net of $234 million and $28 million for the three months ended September 30, 2024 and 2023, respectively, and $244 million and $80 million for the six months ended September 30, 2024 and 2023, respectively. Of these charges $171 million and $181 million were included in â€œRestructuring, impairment, and related charges, netâ€ and $63 million was included in â€œCost of salesâ€ in the Condensed Consolidated Statement of Operations, for each of the three and six months ended September 30, 2024, respectively.Restructuring InitiativesDuring the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model, which are intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives will also include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions, and U.S. Pharmaceutical segments to help realize long-term sustainable growth. The Company anticipates total charges related to these initiatives of $650Â million to $700Â million, consisting primarily of employee severance and other employee-related costs as well as facility, exit and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. For the three and six months ended September 30, 2024, the Company recorded charges of $227 million related to the initiatives, which primarily includes severance and other employee-related costs as well as facility exit and other related costs, including long-lived asset impairments. During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives included headcount reductions, primarily consisting of employee severance and other employee-related costs within the RxTS segment, and the exit or downsizing of certain facilities. For the three and six months ended September 30, 2023, the Company recorded charges of $3Â million and $39Â million related to this program, respectively, which primarily included real estate and other related asset impairments and facility costs within Corporate. This restructuring program was substantially complete in fiscal 2024.Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following: Three Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $4Â $149Â Exit and other-related costs (3)â€”Â â€”Â 3Â (1)10Â 12Â Asset impairments and accelerated depreciation63Â 1Â â€”Â â€”Â 9Â 73Â Total$64Â $1Â $147Â (1)23Â $234Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Three Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternationalCorporateTotalSeverance and employee-related costs, net $8Â $â€”Â $â€”Â $2Â $â€”Â $10Â Exit and other-related costs (2)1Â 3Â 4Â 4Â 6Â 18Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Total$9Â $3Â $4Â $6Â $6Â $28Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following: Six Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $3Â $148Â Exit and other-related costs (3)â€”Â 3Â 6Â (1)12Â 20Â Asset impairments and accelerated depreciation64Â 2Â â€”Â 1Â 9Â 76Â Total$65Â $5Â $150Â $â€”Â $24Â $244Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations.(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.Six Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternational Corporate (1)TotalSeverance and employee-related costs, net $9Â $â€”Â $â€”Â $2Â $1Â $12Â Exit and other-related costs (2)2Â 5Â 6Â 9Â 18Â 40Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â 1Â 27Â 28Â Total$11Â $5Â $6Â $12Â $46Â $80Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Companyâ€™s restructuring initiatives for the six months ended September 30, 2024:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024 (1)$18Â $5Â $1Â $10Â $21Â $55Â Restructuring, impairment, and related charges, net65Â 5Â 150Â â€”Â 24Â 244Â Non-cash charges(64)(2)â€”Â (1)(9)(76)Cash payments(4)(2)(7)(2)(10)(25)Other (2) (1)(2)â€”Â (5)(2)(10)Balance, September 30, 2024 (3)$14Â $4Â $144Â $2Â $24Â $188Â (1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in â€œOther accrued liabilitiesâ€ and $31 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet.(2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves.(3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in â€œOther accrued liabilitiesâ€ and $28 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/420/tableOfContentReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 6 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Income Taxes Income TaxesIncome tax expense was as follows:Three Months Ended September 30, Six Months Ended September 30, (Dollars in millions)2024202320242023Income tax expense$247Â $213Â $371Â $307Â Reported income tax rate46.3Â %23.3Â %22.9Â %15.3Â %Fluctuations in the Companyâ€™s reported income tax rates were primarily due to non-cash charges related to remeasuring the value of its Canadian retail disposal group held for sale to fair value less costs to sell, changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.During the three months ended September 30, 2024, the Company sold certain intellectual property between McKesson wholly-owned legal entities based in foreign tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result, a discrete tax benefit of $44Â million was recognized in the second quarter of fiscal 2025. During the three and six months ended September 30, 2024, the Company recorded non-cash pre-tax charges of $643Â million to remeasure the Canadian retail disposal group to fair value less costs to sell, as described in Financial Note 2, â€œHeld for Saleâ€. The Companyâ€™s reported income tax rates for the three and six months ended September 30, 2024 were unfavorably impacted by these charges given that no net tax benefit was recognized for these charges.During the six months ended September 30, 2024, the Company also recognized discrete tax benefits of $58Â million related to an election to change the tax status of a foreign affiliate, $38Â million related to the tax impact of share-based compensation, and $47Â million related to the reduction in unrecognized tax benefits due to a change in case law, partially offset by a discrete tax expense of $37Â million related to interest expense accrued on unrecognized tax benefits.During the three months ended September 30, 2023, the Company recognized a net discrete tax expense of $12Â million primarily related to interest expense accrued on unrecognized tax benefits. During the six months ended September 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147Â million was recognized during the three months ended June 30, 2023.As of September 30, 2024, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.The Company

files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share 6 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Earnings Per Common Share Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than one million of potentially dilutive securities for the three and six months ended September 30, 2024 and 2023 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.The computations for basic and diluted earnings per common share were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions, except per share amounts)2024202320242023Net income$287Â $703Â $1,247Â $1,700Â Net income attributable to noncontrolling interests(46)(39)(91)(78)Net income attributable to McKesson Corporation$241Â $664Â $1,156Â $1,622Â Weighted-average common shares outstanding:Basic128.7Â 134.1Â 129.3Â 134.8Â Effect of dilutive securities:Stock options0.1Â 0.2Â 0.1Â 0.2Â Restricted stock units (1)0.5Â 0.5Â 0.6Â 0.7Â Diluted129.3Â 134.8Â 130.0Â 135.7Â Earnings per common share attributable to McKesson Corporation: (2)Diluted$1.87Â $4.92Â $8.89Â $11.95Â Basic$1.88Â $4.95Â $8.94Â $12.03Â (1)Includes dilutive effect from restricted stock units and performance-based restricted stock units.(2)Certain computations may reflect rounding adjustments. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net 6 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Goodwill and Intangible Assets, Net Goodwill and Intangible Assets, Net GoodwillThe Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2025 and fiscal 2024 did not indicate any impairment of goodwill. Changes in the carrying amount of goodwill were as follows:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024$4,123Â $2,024Â $2,536Â $1,449Â $â€”Â $10,132Â Goodwill acquiredâ€”Â â€”Â â€”Â â€”Â â€”Â Disposals (1)â€”Â â€”Â â€”Â (47)â€”Â (47)Foreign currency translation adjustments, netâ€”Â â€”Â â€”Â 2Â â€”Â 2Â Other adjustmentsâ€”Â â€”Â (29)â€”Â 29Â â€”Â Balance, September 30, 2024$4,123Â $2,024Â $2,507Â $1,404Â $29Â $10,087Â (1)Goodwill related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024.Intangible AssetsInformation regarding intangible assets was as follows:Â September 30, 2024March 31, 2024(Dollars in millions)Weighted-AverageRemainingAmortizationPeriod(Years)GrossCarryingAmountAccumulatedAmortizationNetCarryingAmountGrossCarryingAmountAccumulatedAmortizationNetCarryingAmountCustomer relationships11$1,480Â (604)876Â $1,830Â (701)1,129Â Service agreements91,129Â (707)422Â 1,126Â (676)450Â Trademarks and trade names13384Â (268)116Â 759Â (395)364Â Technology10284Â (133)151Â 284Â (125)159Â Other634Â (26)8Â 34Â (26)8Â Total Â $3,311Â $(1,738)$1,573Â (1)$4,033Â $(1,923)$2,110Â (1)Excludes net intangible assets of approximately $419 million related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024. Amortization of these assets ceased upon classification as held for sale in the second quarter of fiscal 2025.All intangible assets, except for those classified as held for sale, were subject to amortization as of September 30, 2024 and March 31, 2024. Amortization expense of intangible assets was $60 million and $62 million for the three months ended September 30, 2024 and 2023, respectively, and $123 million and $124 million for the six months ended September 30, 2024 and 2023, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $102 million, $177 million, $171 million, $166 million, and $164 million for the remainder of fiscal 2025 and each of the succeeding years through fiscal 2029, respectively, and $793 million thereafter. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities 6 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Debt and Financing Activities Debt and Financing ActivitiesLong-term debt consisted of the following:(In millions)September 30, 2024March 31, 2024U.S. Dollar notes (1) (2)0.90% Notes due December 3, 2025500Â 500Â 5.25% Notes due February 15, 2026â€”Â 499Â 1.30% Notes due August 15, 2026499Â 499Â 7.65% Debentures due March 1, 2027150Â 150Â 3.95% Notes due February 16, 2028343Â 343Â 4.90% Notes due July 15, 2028399Â 399Â 4.75% Notes due May 30, 2029196Â 196Â 4.25% Notes due September 15, 2029500Â â€”Â 5.10% Notes due July 15, 2033597Â 596Â 6.00% Notes due March 1, 2041218Â 218Â 4.88% Notes due March 15, 2044255Â 255Â Foreign currency notes (1) (3)1.50% Euro Notes due November 17, 2025667Â 646Â 1.63% Euro Notes due October 30, 2026 557Â 540Â 3.13% Sterling Notes due February 17, 2029602Â 568Â Lease and other obligations261Â 220Â Total debt5,744Â 5,629Â Less: Current portion53Â 50Â Total long-term debt$5,691Â $5,579Â (1)These notes are unsecured and unsubordinated obligations of the Company.(2)Interest on these U.S. dollar notes is payable semi-annually.(3)Interest on these foreign currency notes is payable annually.Long-Term DebtThe Companyâ€™s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At September 30, 2024 and March 31, 2024, $5.7 billion and $5.6Â billion, respectively, of total debt was outstanding, of which $53 million and $50 million, respectively, was included under the caption â€œCurrent portion of long-term debtâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets. Public OfferingsOn SeptemberÂ 10, 2024, the Company completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million (the â€œ2029 Notesâ€). Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th of each year, commencing on March 15, 2025. Proceeds received from the issuance of the 2029 Notes, net of discounts and offering expenses, were $496 million. The Company utilized the net proceeds from the offering of the 2029 Notes together with cash on hand to redeem its $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 (the â€œ2026 Notesâ€), which became callable on or after February 15, 2024, prior to maturity at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest through the redemption date. The total loss recognized on the debt extinguishment of the 2026 Notes described above for the three and six months ended September 30, 2024 was not material and is included within â€œInterest expenseâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations. On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the â€œ2028 Notesâ€) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the â€œ2033 Notesâ€ and, together with the 2028 Notes, the â€œNotesâ€). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Companyâ€™s then outstanding 3.80% Notes due March 15, 2024 (the â€œ2024 Notesâ€) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes was available for general corporate purposes.Each of the 2029 Notes, the 2033 Notes and the 2028 Notes, constitutes a â€œseries,â€ is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Companyâ€™s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. Each series is governed by an indenture and officersâ€™ certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 daysâ€™ and not more than 60 daysâ€™ notice to holders of the applicable series of the notes, the Company may redeem such series of the notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officersâ€™ certificate. If there were to occur both (a) a change of control of the Company and (b) a downgrade of the applicable series of the notes below an investment grade rating by each of the Ratings Agencies (as defined in the applicable officersâ€™ certificate) within a specified period, then the Company would be required to make an offer to purchase that series at a price equal to 101% of the then outstanding principal amount of that series, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officersâ€™ certificate for each series, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lendersâ€™ consent. The indenture also contains customary events of default provisions.Concurrent Tender Offer of the 2024 NotesOn June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the â€œConcurrent Tender Offerâ€). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. Satisfaction and Discharge of the 2024 NotesOn June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the â€œ2024 Notes Indentureâ€) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647Â million principal amount of the 2024 Notes as it became due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Companyâ€™s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. The total gain recognized on the debt extinguishment of the 2024 Notes described above for the six months ended September 30, 2023 was $9 million and was included within â€œInterest expenseâ€ in the Companyâ€™s Condensed Consolidated Statement of Operations.Revolving Credit Facilities On November 7, 2022, the Company entered into a Credit Agreement (the â€œ2022 Credit Facilityâ€), that provides a syndicated $4.0 billion senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility was scheduled to mature in November 2028. On November 7, 2024, the maturity date of the 2022 Credit Facility was extended from November 2028 to November 2029. There were no borrowings under the 2022 Credit Facility during the six months ended September 30, 2024 and 2023 and no amounts outstanding at September 30, 2024 or March 31, 2024. At September 30, 2024, the Company was in compliance with all covenants under the 2022 Credit Facility. Commercial PaperThe Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the six months ended September 30, 2024, the Company borrowed and repaid $6.9 billion under the program. During the six months ended September 30, 2023, the Company borrowed and repaid $2.0 billion under the program. At September 30, 2024 and March 31, 2024, there were no commercial paper notes outstanding. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3:

http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R16.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities 6 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Hedging Activities Hedging Activities In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Companyâ€™s policy, derivatives are only used for hedging purposes. The Company does not use derivatives for trading or speculative purposes. The Company uses various counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.Foreign Currency Exchange RiskThe Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on the Companyâ€™s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. Interest Rate RiskThe Company has exposure to changes in interest rates, and it utilizes risk programs which use interest rate swaps to hedge the changes in debt fair values caused by fluctuations in benchmark interest rates. The Company also enters into forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances. These programs reduce but do not entirely eliminate interest rate risk.Derivative InstrumentsAt September 30, 2024 and March 31, 2024, the notional amounts of the Companyâ€™s outstanding derivatives were as follows:September 30, 2024March 31, 2024(In millions)CurrencyMaturity Date (1)NotionalDerivatives designated as net investment hedges: (2)Cross-currency swaps (3)CADApr-25 to Jun-26C$2,500Â C$1,500Â Derivatives designated as fair value hedges: (2)Cross-currency swaps (4)GBPNov-28Â£450Â Â£450Â Cross-currency swaps (4)EURAug-25 to Jul-26â‚¬1,100Â â‚¬1,100Â Floating interest rate swaps (5)USDAug-27 to Sep-29$750Â $1,250Â Derivatives designated as cash flow hedges: (2)Foreign currency forwards (6)GBPOct-24 to Jul-25Â£27Â Â£39Â (1)The maturity date reflected is for outstanding derivatives as of September 30, 2024.(2)There was no ineffectiveness in these hedges for the three and six months ended September 30, 2024 and 2023.(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. (5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. (6)The Company entered into agreements with financial institutions to hedge the variability of foreign currency exchange fluctuations in future cash payments due to a third party in the United Kingdom for capital expenditures.Net Investment HedgesThe Company uses cross-currency swaps to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Companyâ€™s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.In the first quarter of fiscal 2025, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$2.5Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps mature in April 2025 and June 2026. Further, the Company terminated C$1.5Â billion of cross-currency swaps designated as net investment hedges with original maturity dates in November 2024 and extending through March 2025.In October 2024, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$1.0Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps will mature in October 2026.Fair Value HedgesThe Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The Company also uses floating interest rate swaps to hedge the changes in the fair value of its U.S. dollar notes resulting from changes in benchmark interest rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains and losses from the changes in the Companyâ€™s fair value hedges recorded in earnings were largely offset by the gains and losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive loss.In fiscal 2023, the Company entered into floating interest rate swaps designated as fair value hedges to convert $1.3Â billion of its fixed rate debt to floating rate in order to hedge the changes in fair value caused by fluctuations in the benchmark interest rate. In fiscal 2025, $500 million of the $1.3Â billion floating interest rate swaps with original maturity dates in February 2026 and callable at any time after February 2024 were terminated. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2029 Notes.Cash Flow HedgesThe Company uses cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency exchange rates. The Company also uses forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances and to offset the potential income statement effects from obligations denominated in non-functional currencies. The effective portion of changes in the fair valueÂ of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. There were no gains or losses reclassified from accumulated other comprehensive loss and recorded in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023.In fiscal 2023, the Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges with a combined notional amount of $450Â million, and in the first quarter of fiscal 2024 with a notional amount of $50Â million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500Â million cash flow hedges were terminated and the proceeds are being amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2033 Notes.Derivatives Not Designated as HedgesDerivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations. The Company did not enter into or have any outstanding derivative instruments not designated as hedges during the periods presented.Other Information on Derivative InstrumentsGains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions)2024202320242023Derivatives designated as net investment hedges:Cross-currency swaps(20)27Â (13)7Â Derivatives designated as cash flow and other hedges:Cross-currency swaps (1)(14)33Â (14)27Â Foreign currency forwards2Â â€”Â 2Â â€”Â Fixed interest rate swaps â€”Â â€”Â â€”Â 16Â (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.Information regarding the fair value of derivatives on a gross basis were as follows:Balance Sheet CaptionSeptember 30, 2024March 31, 2024Fair Value of DerivativeU.S. Dollar NotionalFair Value of DerivativeU.S. Dollar Notional(In millions)AssetLiabilityAssetLiabilityDerivatives designated for hedge accounting:Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$69Â $15Â $1,690Â $13Â $1Â $1,122Â Cross-currency swaps (non-current)Other non-current assets/liabilities97Â 11Â 1,771Â 108Â â€”Â 1,638Â Interest rate swaps (non-current)Other non-current liabilitiesâ€”Â 10Â 750Â â€”Â 35Â 1,250Â Foreign currency forwards (current)Prepaid expenses and other/Other accrued liabilities2Â â€”Â 34Â â€”Â â€”Â 35Â Foreign currency forwards (non-current)Other non-current assetsâ€”Â â€”Â â€”Â â€”Â 15Â Total$168Â $36Â $121Â $36Â Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements. X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5CReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/815/tableOfContent + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements 6 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements Fair Value Measurements The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:Level 1 - quoted prices in active markets for identical assets or liabilities.Level 2 - significant other observable market-based inputs.Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.Assets and Liabilities Measured at Fair Value on a Recurring BasisCash and cash equivalents at September 30, 2024 and March 31, 2024 included investments in money market funds of $549 million and $705 million, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.Fair values of the Companyâ€™s interest rate swaps, cross-currency swaps, and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.Â These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, â€œHedging Activities,â€ for fair values and other information on the Companyâ€™s derivatives.The Company holds investments in equity and debt securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $175Â million and $240Â million at September 30, 2024 and March 31, 2024, respectively. These investments primarily consist of equity securities without readily determinable fair values and are included in â€œOther non-current assetsâ€ in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains and losses as well as impairment charges related to these investments were a net loss of $15Â million and gain of $95Â million for the three and six months ended September 30, 2024, respectively, and an immaterial loss for the three and six months ended September 30, 2023, all of which are included within â€œOther income, netâ€ in the Condensed Consolidated Statements of Operations. The net gain recognized for the six months ended September 30, 2024 primarily relates to a recapitalization event of one of the Companyâ€™s investments in equity securities which resulted in an increase to the carrying value of this investment. The Company recognized a net gain of $100 million related to this event and sold a portion of its investment for proceeds of $92 million.Assets and Liabilities Measured at Fair Value on a Nonrecurring BasisIn addition to assets and liabilities that are measured at fair value on a recurring basis, the Companyâ€™s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.At September 30, 2024, the assets and liabilities associated with the Canadian retail disposal group classified as held for sale were measured at the lower of carrying value or fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been

realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.There were no other material assets or liabilities measured at fair value on a nonrecurring basis at September 30, 2024 and March 31, 2024.Other Fair Value DisclosuresAt September 30, 2024 and March 31, 2024, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.The Companyâ€™s long-term debt is recorded at amortized cost. The carrying value and fair value of the Companyâ€™s long-term debt was as follows:September 30, 2024March 31, 2024(In millions)Carrying ValueFair ValueCarrying ValueFair ValueLong-term debt, including current maturities$5,744Â $5,808Â $5,629Â $5,488Â The estimated fair value of the Companyâ€™s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.GoodwillFair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (â€œDCFâ€) model to determine the fair value of each reporting unit.Long-lived AssetsThe Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingent Liabilities 6 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Commitments and Contingent Liabilities Commitments and Contingent LiabilitiesIn addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Companyâ€™s 2024 Annual Report and Financial Note 9 to the Companyâ€™s 10-Q filing for the quarterly period ended June 30, 2024, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within â€œClaims and litigation charges, netâ€ in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters, as well as any applicable income items or credit adjustments due to subsequent changes in estimates.I. Litigation and Claims Involving Distribution of Controlled SubstancesThe Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. These plaintiffs have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (â€œRICOâ€), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. State and Local Government ClaimsThe Company and two other national pharmaceutical distributors (collectively â€œDistributorsâ€) entered into a settlement agreement (the â€œSettlementâ€) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the â€œSettling Governmental Entitiesâ€). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $2.0Â billion as of September 30, 2024, and additionally will pay the Settling Governmental Entities up to approximately $5.9Â billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffsâ€™ attorneysâ€™ fees and costs and will be paid out through 2030. Pursuant to the Settlement, the Distributors are in the process of establishing a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $75Â million as of September 30, 2024, and additionally will pay approximately $99Â million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $53Â million as of September 30, 2024, and additionally will pay approximately $99Â million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Companyâ€™s favor on July 4, 2022. Those subdivisions appealed that decision.Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisionsâ€™ claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision. A trial of its claims against the Company and another national pharmaceutical distributor began on September 16, 2024 in the Circuit Court of Maryland for Baltimore City, Mayor and City Council of Baltimore v. Purdue Pharma LP, No. 24-C-18-000515. Baltimore claims that the defendantsâ€™ distribution of controlled substances to certain pharmacies in the City of Baltimore and Baltimore County caused a public nuisance. Baltimore is seeking monetary damages and other relief.The district attorneys of the City of Philadelphia, Pennsylvania, and Allegheny County, Pennsylvania did not participate in the settlement and sought to bring separate claims against the Company, notwithstanding the settlement with the state of Pennsylvania and its attorney general. On January 26, 2024, the Commonwealth Court of Pennsylvania ruled that the Pennsylvania attorney general had settled and fully released the claims brought by those district attorneys under Pennsylvaniaâ€™s Unfair Trade Practices and Consumer Protection Law. The district attorneys have appealed that decision to the Supreme Court of Pennsylvania. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.Native American Tribe ClaimsThe Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $112Â million as of September 30, 2024, and additionally will pay approximately $84Â million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.Non-Governmental Plaintiff ClaimsThe Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above. One such case was brought by a group of individual plaintiffs in Glynn County, Georgia Superior Court seeking to recover for damages allegedly arising from their family membersâ€™ abuse of prescription opioids. Poppell v. Cardinal Health, Inc., CE19-00472. On March 1, 2023, the jury in that case returned a verdict in favor of the defendants, including the Company. Plaintiffs appealed the jury verdict. On September 4, 2024, the Supreme Court of Georgia affirmed the judgment in favor of the Company. The Company and two other national distributors have reached proposed settlements with representatives of nationwide groups of acute care hospitals and certain third-party payors. The claims of remaining U.S. non-governmental plaintiffs are not included in the charges recorded by the Company.With respect to the acute care hospitals, for the year ended March 31, 2024, the Company recorded a charge of $149 million within â€œClaims and litigation charges, netâ€ in the Consolidated Statement of Operations to reflect its portion of a proposed settlement with a nationwide class of acute care hospitals, of which $75 million was recorded within Corporate expenses, net, and $74 million was recorded within U.S. Pharmaceutical. The corresponding liability was included within â€œOther accrued liabilitiesâ€ in the Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by hospitals. On October 30, 2024, the U.S. District Court for the District of New Mexico granted preliminary approval to the proposed settlement. The trial for one of those acute care hospital cases, Fort Payne Hospital Corporation et al. v. McKesson Corp., CV-2021-900016, has been stayed as to the Company. With respect to the third-party payors, for the six months ended September 30, 2024, the Company recorded a charge of $114Â million within â€œClaims and litigation charges, netâ€ in the Condensed Consolidated Statement of Operations to reflect the Companyâ€™s portion of the proposed settlement with representatives of a nationwide group of certain third-party payors, of which $57Â million was recorded within Corporate expenses, net and U.S. Pharmaceutical, respectively. The corresponding liability was included within â€œOther accrued liabilitiesâ€ in the Condensed Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by third-party payors. On September 3, 2024, the U.S. District Court for the Northern District of Ohio granted preliminary approval to the proposed settlement. The Companyâ€™s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, and certain non-governmental plaintiffs, including a proposed settlement with a nationwide class of acute care hospitals and certain third-party payors, was as follows:(In millions)September 30, 2024March 31, 2024Current litigation liabilities (1)$775Â $665Â Long-term litigation liabilities5,617Â 6,113Â Total litigation liabilities$6,392Â $6,778Â (1)These amounts, recorded in â€œOther accrued liabilitiesâ€ in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.During the six months ended September 30, 2024, the Company made payments totaling $500Â million associated with the Settlement and the separate settlement agreements.Canadian Plaintiff ClaimsThe Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, municipal governments, a group representing indigenous people, as well as one case brought by an individual.Defense of Opioids ClaimsThe Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the accruals described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Companyâ€™s financial position, cash flows or liquidity, or results of operations.II.Â Other Litigation and ClaimsOn May 17, 2013, the Company was served with a complaint filed in the United States District Court for the Northern District of California by True Health Chiropractic Inc., alleging that McKesson sent unsolicited marketing faxes in violation of the Telephone Consumer Protection Act of 1991 (â€œTCPAâ€), as amended by the Junk Fax Protection Act of 2005 (â€œJFPAâ€), True Health Chiropractic Inc., et al. v. McKesson Corporation, et al., No. CV-13-02219 (HG). The plaintiffs seek statutory damages from $500 to $1,500 per violation plus injunctive relief. True Health Chiropractic later amended its complaint, adding McLaughlin Chiropractic Associates as an additional named plaintiff and McKesson Technologies Inc. as a defendant. Both plaintiffs alleged that defendants violated the TCPA by sending faxes that did not contain notices regarding how to opt out of receiving the faxes. On August 13, 2019, the court granted plaintiffsâ€™ renewed motion for class certification. After class notice and the opt-out period, 9,490 fax numbers remain in the class,

representing 48,769 faxes received. On October 8, 2021, the court de-certified the class citing the plaintiffs lacked class-wide proof identifying the manner of receipt, thus leaving two named plaintiffs remaining in the case. On April 27, 2022, the Court found that the named plaintiffs had failed to meet their burden to show defendants willfully or knowingly violated the TCPA and therefore were not entitled to treble damages. The Court found McKesson liable for statutory damages in the amount of $6,500. The Company appealed the finding of liability and the plaintiffs cross-appealed the denial of class certification and the ruling denying treble damages. On October 25, 2023, the U.S. Court of Appeals for the Ninth Circuit affirmed the decision of the district court. On October 4, 2024, the Supreme Court of the United States granted plaintiffsâ€™ petition for certiorari on the issue of whether the Hobbs Act required the district court to accept the FCCâ€™s legal interpretation of the TCPA in determining whether to certify the class.On June 17, 2014, U.S. Oncology Specialty, LP (â€œUSOSâ€) was served with a fifth amended qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that USOS, among others, solicited and received illegal â€œkickbacksâ€ from Amgen in violation of the Anti-Kickback Statute, the federal False Claims Act, and various state false claims statutes, and seeking damages, treble damages, civil penalties, attorneysâ€™ fees and costs of suit, all in unspecified amounts, United States ex rel. Hanks v. Amgen, Inc., et al., CV-08-03096 (SJ). Previously, the United States declined to intervene in the case as to all allegations and defendants except for Amgen. On September 17, 2018, the court granted USOSâ€™s motion to dismiss. Following the relatorâ€™s appeal, the United States Court of Appeals for the Second Circuit vacated the district courtâ€™s order and remanded the suit to the district court, directing it to consider the question of whether the suit should be dismissed for lack of jurisdiction. The district court granted the relator leave to amend the complaint for a seventh time. The relator filed the seventh amended complaint on November 30, 2020. On September 18, 2024, the district court dismissed the False Claims Act claim for lack of subject matter jurisdiction.In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the United States, 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA. The United States and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. The relator filed the second amended complaint on June 7, 2022, which was dismissed by the district court on March 28, 2023. On March 12, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of claims under the Anti-Kickback Statute and federal False Claims Act, vacated the dismissal of the remaining claims, and remanded for further proceedings. On June 7, 2024, the relator filed a petition seeking review by the U.S. Supreme Court, which was denied on October 7, 2024.On October 17, 2024, the Company was served with a qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that, from 2010 through at least 2012, the Company submitted false certifications to the government in support of Horizon Clinicals, an Electronic Health Record product. United States ex rel. James Thompson v. McKesson Corporation, No. 16-CV-2891. The United States has declined to intervene in the case. The complaint seeks relief under the False Claims Act including damages, treble damages, civil penalties, attorney fees, and costs of suit.III.Â Government Subpoenas and InvestigationsFrom time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business. In July 2024, the United States Department of Justice served a Civil Investigative Demand issued pursuant to the False Claims Act on the Company seeking documents and information related to administration of copay coupon programs associated with certain Sun Pharmaceutical Industries Inc. drugs. V.Â Antitrust SettlementDuring the second fiscal quarter of 2025, the Company received proceeds of $63Â million related to its share of two antitrust settlements. The lawsuits were filed against a brand manufacturer alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company was not a named party to either litigation but was a member of the representative classes of those who purchased directly from the pharmaceutical manufacturer. The Company recognized a gain in that amount within "Cost of sales" in the Condensed Consolidated Statement of Operations in the second quarter of fiscal 2025 related to the settlements. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit 6 Months Ended Sep. 30, 2024 Equity [Abstract] Â Stockholders' Deficit Stockholders' Deficit Each share of the Companyâ€™s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Companyâ€™s Board of Directors (the â€œBoardâ€). In July 2024, the Companyâ€™s quarterly dividend was raised from $0.62 to $0.71 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.Â However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. Share Repurchase Plans The Board has authorized the repurchase of common stock. The Company may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Companyâ€™s stock price, corporate and regulatory requirements, tax implications, restrictions under the Companyâ€™s debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions. During the three months ended September 30, 2024, the Company repurchased 2.9Â million shares of common stock for $1.5Â billion through open market transactions at an average price per share of $533.46, of which $22 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2024 and settled in early October 2024. During the three months ended June 30, 2024, the Company repurchased 1.0Â million shares of common stock for $528Â million through open market transactions at an average price per share of $548.20.During the three months ended September 30, 2023, the Company repurchased 2.0Â million shares of common stock for $840Â million through open market transactions at an average price per share of $422.39, of which $23 million was accrued within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2023 and settled in early October 2023. During the three months ended June 30, 2023, the Company repurchased 1.8Â million shares of common stock for $673Â million through open market transactions at an average price per share of $379.14. Effective January 1, 2023, the Companyâ€™s repurchase of common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. Excise taxes incurred on share repurchases of an entityâ€™s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholdersâ€™ equity within â€œTreasury sharesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholdersâ€™ Deficit. Excise taxes do not reduce the Companyâ€™s remaining authorization for the repurchase of common stock. Excise taxes of $15 million and $8Â million were incurred and accrued for shares repurchased during the three months ended September 30, 2024 and 2023, respectively. Excise taxes of $16Â million and $12Â million were incurred and accrued for shares repurchased during the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the amounts accrued for excise taxes were $41Â million and $25Â million, respectively, within â€œOther accrued liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheets. In July 2024, the Board approved an increase of $4.0Â billion in the authorization for the repurchase of common stock. The total remaining authorization outstanding for repurchases of common stock at September 30, 2024 was $8.6 billion.Accumulated Other Comprehensive Loss Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended September 30, 2024 and 2023 was as follows:Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2024(892)(7)$3Â (17)(913)Other comprehensive income (loss) before reclassifications49Â (15)(9)(1)24Â Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)49Â (15)(9)(2)23Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson49Â (15)(9)(2)23Â Balance, September 30, 2024(843)(22)(6)(19)$(890)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2024 include losses of $20Â million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million. (3)Amounts recorded for the three months ended September 30, 2024 include losses of $14Â million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2023(780)(29)(29)(10)$(848)Other comprehensive income (loss) before reclassifications(84)20Â 25Â 1Â (38)Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(84)20Â 25Â â€”Â (39)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(84)20Â 25Â â€”Â (39)Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2023 include gains of $27 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $7 million.(3)Amounts recorded for the three months ended September 30, 2023 include gains of $33 million related to cash flow and other hedges from cross-currency swaps, which are net of income tax expense of $8 million.Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the six months ended September 30, 2024 and 2023 was as follows:Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2024(856)(12)$3Â (16)(881)Other comprehensive income (loss) before reclassifications13Â (10)(9)(2)(8)Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)13Â (10)(9)(3)(9)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson13Â (10)(9)(3)(9)Balance, September 30, 2024(843)(22)(6)(19)$(890)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Europe into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the six months ended September 30, 2024 include losses of $13 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $3 million. (3)Amounts recorded for the six months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2023(847)(14)(36)(8)$(905)Other comprehensive income (loss) before reclassifications(17)5Â 32Â (1)19Â Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(17)5Â 32Â (2)18Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(17)5Â 32Â (2)18Â Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2023 include gains of $7 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $2 million.(3)Amounts recorded for the six months ended September 30, 2023 include gains of $27 million related to cash flow and other hedges from cross-currency swaps and gains of $16 million related to cash flow hedges from fixed interest rate swaps. These amounts are net of income tax expense of $11 million. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 32 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Segments of Business 6 Months Ended Sep. 30, 2024 Segment Reporting [Abstract] Â Segments of Business Segments of BusinessThe Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments and operations. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKessonâ€™s own line of high-quality products through a network of distribution centers in the U.S.The International segment includes the Companyâ€™s operations in Canada and Norway, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Companyâ€™s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and include Rexall Health retail pharmacies. The Companyâ€™s Norwegian operations provide distribution and services to wholesale and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. In the second quarter of fiscal 2025, the Company entered into an agreement to sell the Canadian retail disposal group. Refer to Financial Note 2, â€œHeld for Sale,â€ for more information.Financial information relating to the Companyâ€™s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: Â Three Months Ended September 30, Six Months Ended September 30, (In millions)2024202320242023Segment revenues (1)U.S. Pharmaceutical$85,726Â $69,766Â $157,441Â $136,926Â Prescription Technology Solutions1,265Â 1,140Â 2,506Â 2,384Â Medical-Surgical Solutions2,948Â 2,834Â 5,584Â 5,445Â International3,709Â 3,475Â 7,400Â 6,943Â Corporate3Â â€”Â 3Â â€”Â Total revenues$93,651Â $77,215Â $172,934Â $151,698Â Segment operating profit (loss) (2) U.S. Pharmaceutical (3) $1,075Â $593Â $1,856Â $1,420Â Prescription Technology Solutions (4)205Â 238Â 408Â 469Â Medical-Surgical Solutions (5)89Â 244Â 277Â 471Â International (6)(508)66Â (418)123Â Subtotal861Â 1,141Â 2,123Â 2,483Â Corporate expenses, net (7) (249)(164)(352)(368)Interest expense(78)(61)(153)(108)Income before income taxes$534Â $916Â $1,618Â $2,007Â (1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segmentâ€™s total revenues, less than 40% of the RxTS segmentâ€™s total revenues, less than 1% of the Medical-Surgical Solutions segmentâ€™s total revenues, and less than 1% of the International segmentâ€™s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. Corporate reflects revenues from services derived in the U.S. related to certain technology operations and were not material for the three and six months ended September 30, 2024.(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Companyâ€™s reportable segments.(3)The Companyâ€™s U.S. Pharmaceutical segmentâ€™s operating profit includes the following:â€¢a credit of $203 million for the three and six months ended September 30, 2024 due to the Companyâ€™s reassessment of its initial fiscal 2024 estimates of the previously reserved $725 million prepetition balance owed by the Companyâ€™s customer, Rite Aid Corporation (including certain of its subsidiaries, â€œRite Aidâ€). Rite Aid filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in October 2023. The Company recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid. The amounts described above were recorded within â€œSelling, distribution, general, and administrative expensesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August, 2024; â€¢cash receipts for the Companyâ€™s share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively. These gains were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢a credit of $2 million and a charge of $55 million related to the last-in, first-out method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million for the six months ended September 30, 2024 and 2023, respectively. These amounts were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net;â€¢â€¢a charge of $57 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" andâ€¢a loss of $43Â million for the six months ended September 30, 2024 related to one of the Companyâ€™s equity method investments, which was recorded within â€œOther income, netâ€ in the Companyâ€™s Condensed Consolidated Statement of Operations. (4)The Companyâ€™s RxTS segmentâ€™s operating profit for the three and six months ended September 30, 2023 includes gains of $48Â million and $76Â million, respectively, resulting from fair value adjustments of the Companyâ€™s contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022.(5)The Companyâ€™s Medical-Surgical Solutions segmentâ€™s operating profit for the three and six months ended September 30, 2024 includes restructuring charges of $144 million for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€(6)The Companyâ€™s International segmentâ€™s operating profit (loss) for the three and six months ended September 30, 2024 includes a charge of $593 million to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€(7)Corporate expenses, net includes the following:â€¢a charge of $50 million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, â€œHeld for Sale;â€¢â€¢a net gain of $95Â million for the six months ended September 30, 2024 related to the Companyâ€™s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, â€œFair Value Measurements;â€¢â€¢a net charge of $51Â million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" andâ€¢restructuring charges of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€ X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 10: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 34 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/280/tableOfContentReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 26 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_SegmentReportingDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Net Income (Loss) $ 241 $ 664 $ 1,156 $ 1,622 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 34 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended 6 Months Ended Sep. 30, 2024 shares Sep. 30, 2024 shares Trading Arrangements, by Individual Â Â Non-Rule 10b5-1 Arrangement Adopted false Â Rule 10b5-1 Arrangement Terminated false Â Non-Rule 10b5-1 Arrangement Terminated false Â Thomas Rodgers [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On August 17, 2024, Thomas Rodgers, our Executive Vice President and Chief Strategy and Business Development Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 4,080 shares of the Companyâ€™s common stock. The duration of the trading arrangement is until August 18, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Mr. Rodgers represented to us that he intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards. Name Thomas Rodgers Â Title Executive Vice President and Chief Strategy and Business Development Officer Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date August 17, 2024 Â Expiration Date August 18, 2025 Â Arrangement Duration 366 days Â Aggregate Available 4,080 4,080 LeAnn Smith [Member] Â Â Trading Arrangements, by Individual Â Â Material Terms of Trading Arrangement Â On September 9, 2024, LeAnn Smith, our Executive Vice President and Chief Human Resources Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 3,592 shares of the Companyâ€™s common stock. The duration of the trading arrangement is until September 9, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Ms. Smith represented to us that she intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards. Name LeAnn Smith Â Title Executive Vice President and Chief Human Resources Officer Â Rule 10b5-1 Arrangement Adopted true Â Adoption Date September 9, 2024 Â Expiration Date September 9, 2025 Â Arrangement Duration 365 days Â Aggregate Available 3,592 3,592 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrDuration Namespace Prefix: ecd_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph C + Details Name: ecd_TrdArrExpirationDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=mck_ThomasRodgersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=mck_LeAnnSmithMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 35 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Policies) 6 Months Ended Sep. 30, 2024 Accounting Policies [Abstract] Â Basis of Presentation Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (â€œU.S.â€) generally accepted accounting principles (â€œGAAPâ€) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (â€œSECâ€) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.The condensed consolidated financial statements of McKesson include the financial statements of all majority-owned or controlled companies. For those consolidated subsidiaries where the Companyâ€™s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as â€œNet income attributable to noncontrolling interestsâ€ in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. Net income attributable to noncontrolling interests includes third-party equity interests in the Companyâ€™s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC.The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (â€œVIEâ€). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Fiscal Period Fiscal Period: The Companyâ€™s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means the Companyâ€™s fiscal year. Reclassifications Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation. Use of Estimates Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented. Recently Adopted Accounting Pronouncements, Recently Issued Accounting Pronouncements Not Yet Adopted, and Recent Securities and Exchange Commission Final Rules Not Yet Implemented Recently Adopted Accounting Pronouncements There were no accounting standards adopted during the six months ended September 30, 2024 that had a material impact to the Companyâ€™s condensed consolidated financial statements or disclosures.Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board (â€œFASBâ€) issued Accounting Standards Update (â€œASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker (â€œCODMâ€) and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segmentâ€™s profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures.In November 2024, the FASB issued ASU 2024-03, Income Statement â€“ Reporting Comprehensive Income â€“ Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures.Recent Securities and Exchange Commission Final Rules Not Yet ImplementedIn March 2024, the SEC adopted final rules under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which would have required the Company to provide certain climate-related information in annual reports and registration statements beginning with its Annual Report on Form 10-K for the year ended March 31, 2026. In April 2024, the SEC stayed these rules pending the completion of judicial review of consolidated petitions challenging the validity of the rules. The Company is currently evaluating the impact of these rules in light of those legal challenges and monitoring the status of the stay and judicial review. Fair Value The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:Level 1 - quoted prices in active markets for identical assets or liabilities.Level 2 - significant other observable market-based inputs.Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.Assets and Liabilities Measured at Fair Value on a Recurring BasisCash and cash equivalents at September 30, 2024 and March 31, 2024 included investments in money market funds of $549 million and $705 million, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.Fair values of the Companyâ€™s interest rate swaps, cross-currency swaps, and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.Â These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, â€œHedging Activities,â€ for fair values

and other information on the Companyâ€™s derivatives.The Company holds investments in equity and debt securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $175Â million and $240Â million at September 30, 2024 and March 31, 2024, respectively. These investments primarily consist of equity securities without readily determinable fair values and are included in â€œOther non-current assetsâ€ in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains and losses as well as impairment charges related to these investments were a net loss of $15Â million and gain of $95Â million for the three and six months ended September 30, 2024, respectively, and an immaterial loss for the three and six months ended September 30, 2023, all of which are included within â€œOther income, netâ€ in the Condensed Consolidated Statements of Operations. The net gain recognized for the six months ended September 30, 2024 primarily relates to a recapitalization event of one of the Companyâ€™s investments in equity securities which resulted in an increase to the carrying value of this investment. The Company recognized a net gain of $100 million related to this event and sold a portion of its investment for proceeds of $92 million.Assets and Liabilities Measured at Fair Value on a Nonrecurring BasisIn addition to assets and liabilities that are measured at fair value on a recurring basis, the Companyâ€™s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.At September 30, 2024, the assets and liabilities associated with the Canadian retail disposal group classified as held for sale were measured at the lower of carrying value or fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.GoodwillFair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (â€œDCFâ€) model to determine the fair value of each reporting unit.Long-lived AssetsThe Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. Hedging Activities Net Investment HedgesThe Company uses cross-currency swaps to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Companyâ€™s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.In the first quarter of fiscal 2025, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$2.5Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps mature in April 2025 and June 2026. Further, the Company terminated C$1.5Â billion of cross-currency swaps designated as net investment hedges with original maturity dates in November 2024 and extending through March 2025.In October 2024, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$1.0Â billion to hedge portions of the Companyâ€™s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps will mature in October 2026.Fair Value HedgesThe Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The Company also uses floating interest rate swaps to hedge the changes in the fair value of its U.S. dollar notes resulting from changes in benchmark interest rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains and losses from the changes in the Companyâ€™s fair value hedges recorded in earnings were largely offset by the gains and losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive loss.In fiscal 2023, the Company entered into floating interest rate swaps designated as fair value hedges to convert $1.3Â billion of its fixed rate debt to floating rate in order to hedge the changes in fair value caused by fluctuations in the benchmark interest rate. In fiscal 2025, $500 million of the $1.3Â billion floating interest rate swaps with original maturity dates in February 2026 and callable at any time after February 2024 were terminated. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2029 Notes.Cash Flow HedgesThe Company uses cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency exchange rates. The Company also uses forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances and to offset the potential income statement effects from obligations denominated in non-functional currencies. The effective portion of changes in the fair valueÂ of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. There were no gains or losses reclassified from accumulated other comprehensive loss and recorded in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023.In fiscal 2023, the Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges with a combined notional amount of $450Â million, and in the first quarter of fiscal 2024 with a notional amount of $50Â million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500Â million cash flow hedges were terminated and the proceeds are being amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, â€œDebt and Financing Activities,â€ for additional information on the public offering of the 2033 Notes.Derivatives Not Designated as HedgesDerivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in â€œSelling, distribution, general, and administrative expensesâ€ in the Condensed Consolidated Statements of Operations. The Company did not enter into or have any outstanding derivative instruments not designated as hedges during the periods presented. Commitments and Contingencies In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Companyâ€™s 2024 Annual Report and Financial Note 9 to the Companyâ€™s 10-Q filing for the quarterly period ended June 30, 2024, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within â€œClaims and litigation charges, netâ€ in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 450 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8 + Details Name: us-gaap_CommitmentsAndContingenciesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1 + Details Name: us-gaap_ConsolidationPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for its derivative instruments and hedging activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(n)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7 + Details Name: us-gaap_DerivativesPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-12 + Details Name: us-gaap_FiscalPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Held for Sale (Tables) 6 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Schedule of Assets and Liabilities Held for Sale The total assets and liabilities of the Canadian retail disposal group that have met the classification of held for sale in the Companyâ€™s Condensed Consolidated Balance Sheet are as follows:(In millions)September 30, 2024AssetsCurrent assetsCash$14Â Receivables, net65Â Inventories, net219Â Prepaid expenses and other5Â Property, plant, and equipment, net62Â Operating lease right-of-use

assets283Â Goodwill47Â Intangible assets, net419Â Other non-current assets160Â Remeasurement of assets of businesses held for sale to fair value less costs to sell (1)(643)Total assets held for sale$631Â LiabilitiesCurrent liabilitiesDrafts and accounts payable$15Â Current portion of operating lease liabilities61Â Other accrued liabilities42Â Long-term operating lease liabilities249Â Other non-current liabilities4Â Total liabilities held for sale$371Â (1)Includes intercompany trade accounts payable of $142 million, primarily related to purchases of inventories from McKesson Canada. These balances are expected to be assumed by the buyer upon divestiture and are excluded from Drafts and accounts payable above as they are fully eliminated in the Companyâ€™s consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-4BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5D -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5DReference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3AReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-3 + Details Name: us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 37 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment, and Related Charges, Net (Tables) 6 Months Ended Sep. 30, 2024 Restructuring and Related Activities [Abstract] Â Restructuring, Impairment, and Related Costs Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following: Three Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $4Â $149Â Exit and other-related costs (3)â€”Â â€”Â 3Â (1)10Â 12Â Asset impairments and accelerated depreciation63Â 1Â â€”Â â€”Â 9Â 73Â Total$64Â $1Â $147Â (1)23Â $234Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations.(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Three Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternationalCorporateTotalSeverance and employee-related costs, net $8Â $â€”Â $â€”Â $2Â $â€”Â $10Â Exit and other-related costs (2)1Â 3Â 4Â 4Â 6Â 18Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Total$9Â $3Â $4Â $6Â $6Â $28Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following: Six Months Ended September 30, 2024(In millions)U.S. Pharmaceutical (1)Prescription Technology SolutionsMedical-Surgical Solutions (2)International CorporateTotalSeverance and employee-related costs, net $1Â $â€”Â $144Â $â€”Â $3Â $148Â Exit and other-related costs (3)â€”Â 3Â 6Â (1)12Â 20Â Asset impairments and accelerated depreciation64Â 2Â â€”Â 1Â 9Â 76Â Total$65Â $5Â $150Â $â€”Â $24Â $244Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s U.S. Pharmaceutical segment, including an inventory impairment of $63Â million within "Cost of sales" in the Condensed Consolidated Statement of Operations.(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s Medical-Surgical Solutions segment.(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.Six Months Ended September 30, 2023(In millions)U.S. PharmaceuticalPrescription Technology Solutions (1)Medical-Surgical SolutionsInternational Corporate (1)TotalSeverance and employee-related costs, net $9Â $â€”Â $â€”Â $2Â $1Â $12Â Exit and other-related costs (2)2Â 5Â 6Â 9Â 18Â 40Â Asset impairments and accelerated depreciationâ€”Â â€”Â â€”Â 1Â 27Â 28Â Total$11Â $5Â $6Â $12Â $46Â $80Â (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Companyâ€™s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Schedule of Restructuring and Asset Impairment Charges The following table summarizes the activity related to the liabilities associated with the Companyâ€™s restructuring initiatives for the six months ended September 30, 2024:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024 (1)$18Â $5Â $1Â $10Â $21Â $55Â Restructuring, impairment, and related charges, net65Â 5Â 150Â â€”Â 24Â 244Â Non-cash charges(64)(2)â€”Â (1)(9)(76)Cash payments(4)(2)(7)(2)(10)(25)Other (2) (1)(2)â€”Â (5)(2)(10)Balance, September 30, 2024 (3)$14Â $4Â $144Â $2Â $24Â $188Â (1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in â€œOther accrued liabilitiesâ€ and $31 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet.(2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves.(3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in â€œOther accrued liabilitiesâ€ and $28 million was recorded in â€œOther non-current liabilitiesâ€ in the Companyâ€™s Condensed Consolidated Balance Sheet. X - ReferencesNo definition available. + Details Name: us-gaap_RestructuringAndRelatedActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 38 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Tables) 6 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â Schedule of Components of Income Tax Expense (Benefit) Income tax expense was as follows:Three Months Ended September 30, Six Months Ended September 30, (Dollars in millions)20242023202420232Income tax expense$247Â $213Â $371Â $307Â Reported income tax rate46.3Â %23.3Â %22.9Â %15.3Â % X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9 + Details Name: us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share (Tables) 6 Months Ended Sep. 30, 2024 Earnings Per Share [Abstract] Â Schedule of Computations for Basic and Diluted Earnings Per Common Share The computations for basic and diluted earnings per common share were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions, except per share amounts)20242023202420232Net income$287Â $703Â $1,247Â $1,700Â Net income attributable to noncontrolling interests(46)(39)(91)(78)Net income attributable to McKesson Corporation$241Â $664Â $1,156Â $1,622Â Weighted-average common shares outstanding:Basic128.7Â 134.1Â 129.3Â 134.8Â Effect of dilutive securities:Stock options0.1Â 0.2Â 0.1Â 0.2Â Restricted stock units (1)0.5Â 0.5Â 0.6Â 0.7Â Diluted129.3Â 134.8Â 130.0Â 135.7Â Earnings per common share attributable to McKesson Corporation: (2)Diluted$1.87Â $4.92Â $8.89Â $11.95Â Basic$1.88Â $4.95Â $8.94Â $12.03Â (1)Includes dilutive effect from restricted stock units and performance-based restricted stock units.(2)Certain computations may reflect rounding adjustments. X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net (Tables) 6 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Changes in the Carrying Amount of Goodwill Changes in the carrying amount of goodwill were as follows:(In millions)U.S. PharmaceuticalPrescription Technology SolutionsMedical-Surgical SolutionsInternationalCorporateTotalBalance, March 31, 2024$4,123Â $2,024Â $2,536Â $1,449Â $â€”Â $10,132Â Goodwill acquiredâ€”Â â€”Â â€”Â â€”Â â€”Â â€”Â Disposals (1)â€”Â â€”Â â€”Â (47)â€”Â (47)Foreign currency translation adjustments, netâ€”Â â€”Â â€”Â 2Â â€”Â 2Â Other adjustmentsâ€”Â â€”Â (29)â€”Â 29Â â€”Â Balance, September 30, 2024$4,123Â $2,024Â $2,507Â $1,404Â $29Â $10,087Â (1)Goodwill related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024. Schedule of Information Regarding Intangible Assets Information regarding intangible assets was as follows:Â September 30, 2024March 31, 2024(Dollars in millions)Weighted-AverageRemainingAmortizationPeriod(Years)GrossCarryingAmountAccumulatedAmortizationNetCarryingAmountGrossCarryingAmountAccumulatedAmortizationNetCarryingAmountCustomer relationships11$1,480Â (604)876Â $1,830Â (701)1,129Â Service agreements91,129Â (707)422Â 1,126Â (676)450Â Trademarks and trade names13384Â (268)116Â 759Â (395)364Â Technology10284Â (133)151Â 284Â (125)159Â Other634Â (26)8Â 34Â (26)8Â Total Â $3,311Â $(1,738)$1,573Â (1)$4,033Â $(1,923)$2,110Â (1)Excludes net intangible assets of approximately $419 million related to the Canadian retail disposal group discussed in Financial Note 2, â€œHeld for Sale.â€ This amount was included under the caption â€œAssets held for saleâ€ in the Condensed Consolidated Balance Sheet as of September 30, 2024. Amortization of these assets ceased upon classification as held for sale in the second quarter of fiscal 2025. X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI

https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities (Tables) 6 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â Schedule of Long-Term Debt Long-term debt consisted of the following:(In millions)September 30, 2024March 31, 2024U.S. Dollar notes (1) (2)0.90% Notes due December 3, 2025500Â 500Â 5.25% Notes due February 15, 2026â€”Â 499Â 1.30% Notes due August 15, 2026499Â 499Â 7.65% Debentures due March 1, 2027150Â 150Â 3.95% Notes due February 16, 2028343Â 343Â 4.90% Notes due July 15, 2028399Â 399Â 4.75% Notes due May 30, 2029196Â 196Â 4.25% Notes due September 15, 2029500Â â€”Â 5.10% Notes due July 15, 2033597Â 596Â 6.00% Notes due March 1, 2041218Â 218Â 4.88% Notes due March 15, 2044255Â 255Â Foreign currency notes (1) (3)1.50% Euro Notes due November 17, 2025667Â 646Â 1.63% Euro Notes due October 30, 2026 557Â 540Â 3.13% Sterling Notes due February 17, 2029602Â 568Â Lease and other obligations261Â 220Â Total debt5,744Â 5,629Â Less: Current portion53Â 50Â Total long-term debt$5,691Â $5,579Â (1)These notes are unsecured and unsubordinated obligations of the Company.(2)Interest on these U.S. dollar notes is payable semi-annually.(3)Interest on these foreign currency notes is payable annually. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities (Tables) 6 Months Ended Sep. 30, 2024 Derivative Instruments and Hedging Activities Disclosure [Abstract] Â Schedule of Notional Amounts of Outstanding Derivative Positions At September 30, 2024 and March 31, 2024, the notional amounts of the Companyâ€™s outstanding derivatives were as follows:September 30, 2024March 31, 2024(In millions)CurrencyMaturity Date (1)NotionalDerivatives designated as net investment hedges: (2)Cross-currency swaps (3)CADApr-25 to Jun-26C$2,500Â C$1,500Â Derivatives designated as fair value hedges: (2)Cross-currency swaps (4)GBPNov-28Â£450Â Â£450Â Cross-currency swaps (4)EURAug-25 to Jul-26â‚¬1,100Â â‚¬1,100Â Floating interest rate swaps (5)USDAug-27 to Sep-29$750Â $1,250Â Derivatives designated as cash flow hedges: (2)Foreign currency forwards (6)GBPOct-24 to Jul-25Â£27Â Â£39Â (1)The maturity date reflected is for outstanding derivatives as of September 30, 2024.(2)There was no ineffectiveness in these hedges for the three and six months ended September 30, 2024 and 2023.(3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.(4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. (5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. (6)The Company entered into agreements with financial institutions to hedge the variability of foreign currency exchange fluctuations in future cash payments due to a third party in the United Kingdom for capital expenditures. Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) Gains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions)20242023202420232024Derivatives designated as net investment hedges:Cross-currency swaps(20)27Â (13)7Â Derivatives designated as cash flow and other hedges:Cross-currency swaps (1)(14)33Â (14)27Â Foreign currency forwards2Â â€”Â 2Â â€”Â Fixed interest rate swaps â€”Â â€”Â â€”Â 16Â (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges. Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) Gains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows:Three Months Ended September 30, Six Months Ended September 30, (In millions)20242023202420232024Derivatives designated as net investment hedges:Cross-currency swaps(20)27Â (13)7Â Derivatives designated as cash flow and other hedges:Cross-currency swaps (1)(14)33Â (14)27Â Foreign currency forwards2Â â€”Â 2Â â€”Â Fixed interest rate swaps â€”Â â€”Â â€”Â 16Â (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges. Schedule of Fair Value of Derivatives Information regarding the fair value of derivatives on a gross basis were as follows:Balance Sheet CaptionSeptember 30, 2024March 31, 2024Fair Value of DerivativeU.S. Dollar NotionalFair Value of DerivativeU.S. Dollar Notional(In millions)AssetLiabilityAssetLiabilityDerivatives designated for hedge accounting:Cross-currency swaps (current)Prepaid expenses and other/Other accrued liabilities$69Â $15Â $1,690Â $13Â $1Â $1,122Â Cross-currency swaps (non-current)Other non-current assets/liabilities97Â 11Â 1,771Â 108Â â€”Â 1,638Â Interest rate swaps (non-current)Other non-current liabilitiesâ€”Â 10Â 750Â â€”Â 35Â 1,250Â Foreign currency forwards (current)Prepaid expenses and other/Other accrued liabilities2Â â€”Â 34Â â€”Â â€”Â 35Â Foreign currency forwards (non-current)Other non-current assetsâ€”Â â€”Â â€”Â â€”Â 15Â Total$168Â $36Â $121Â $36Â X - ReferencesNo definition available. + Details Name: us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11 + Details Name: us-gaap_FairValueByBalanceSheetGroupingTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC + Details Name: us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the notional amounts of outstanding derivative positions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 6 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Fair Value Measurements The Companyâ€™s long-term debt is recorded at amortized cost. The carrying value and fair value of the Companyâ€™s long-term debt was as follows:September 30, 2024March 31, 2024(In millions)Carrying ValueFair ValueCarrying ValueFair ValueLong-term debt, including current maturities$5,744Â $5,808Â $5,629Â $5,488Â X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingent Liabilities (Tables) 6 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â Schedule of Estimated Accrual Liability The Companyâ€™s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, and certain non-governmental plaintiffs, including a proposed settlement with a nationwide class of acute care hospitals and certain third-party payors, was as follows:(In millions)September 30, 2024March 31, 2024Current litigation liabilities (1)$775Â $665Â Long-term litigation liabilities5,617Â 6,113Â Total litigation liabilities$6,392Â $6,778Â (1)These amounts, recorded in â€œOther accrued liabilitiesâ€ in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3 + Details Name: us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit (Tables) 6 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of Information Regarding Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax, by Component Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended September 30, 2024 and 2023 was as follows:Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2024(892)(7)$3Â (17)(913)Other comprehensive income (loss) before reclassifications49Â (15)(9)(1)24Â Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)49Â (15)(9)(2)23Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson49Â (15)(9)(2)23Â Balance, September 30, 2024(843)(22)(6)(19)$(890)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2024 include losses of $20Â million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million. (3)Amounts recorded for the three months ended September 30, 2024 include losses of $14Â million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, June 30, 2023(780)(29)(29)(10)$(848)Other comprehensive income (loss) before reclassifications(84)20Â 25Â 1Â (38)Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(84)20Â 25Â â€”Â (39)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(84)20Â 25Â â€”Â (39)Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the three months ended September 30, 2023 include gains of $27 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $7 million.(3)Amounts recorded for the three months ended September 30, 2023 include gains of $33 million related to cash flow and other hedges from cross-currency swaps, which are net of income tax expense of $8 million.Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the six months ended September 30, 2024 and 2023 was as follows:Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Losses on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2024(856)(12)$3Â (16)(881)Other comprehensive income (loss) before reclassifications13Â (10)(9)(2)(8)Amounts reclassified to earnings and other â€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)13Â (10)(9)(3)(9)Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson13Â (10)(9)(3)(9)Balance, September 30, 2024(843)(22)(6)(19)$(890)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Europe into the Companyâ€™s reporting currency, U.S. dollars.(2)Amounts recorded for the six months ended September 30, 2024 include losses of $13 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $3 million. (3)Amounts recorded for the six months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.Foreign Currency Translation Adjustments(In millions)Foreign Currency Translation Adjustments, Net of Tax (1)Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax (2)Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax (3)Unrealized Losses and Other Components of Benefit Plans, Net of TaxTotal Accumulated Other Comprehensive LossBalance, March 31, 2023(847)(14)(36)(8)$(905)Other comprehensive income (loss) before reclassifications(17)5Â 32Â (1)19Â Amounts reclassified to earnings and otherâ€”Â â€”Â â€”Â (1)(1)Other comprehensive income (loss)(17)5Â 32Â (2)18Â Less: amounts attributable to noncontrolling interestsâ€”Â â€”Â â€”Â â€”Â â€”Â Other comprehensive income (loss) attributable to McKesson(17)5Â 32Â (2)18Â Balance, September 30, 2023(864)(9)(4)(10)$(887)(1)Primarily results from the conversion of non-U.S. dollar financial statements of the Companyâ€™s operations in Canada and Norway into the Companyâ€™s reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2023 include gains of $7 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $2 million.(3)Amounts recorded for the six months ended September 30, 2023 include gains of $27 million related to cash flow and other hedges from cross-currency swaps and gains of $16 million related to cash flow hedges from fixed interest rate swaps. These amounts are net of income tax expense of $11 million. X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Segments of Business (Tables) 6 Months Ended Sep. 30, 2024

Segment Reporting [Abstract] Â Schedule of Financial Information Relating to Reportable Operating Segments and Reconciliations to the Condensed Consolidated Totals Financial information relating to the Companyâ€™s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: Â Three Months Ended September 30, Six Months Ended September 30, (In millions)2024202320242023Segment revenues (1)U.S. Pharmaceutical$85,726Â $69,766Â $157,441Â $136,926Â Prescription Technology Solutions1,265Â 1,140Â 2,506Â 2,384Â Medical-Surgical Solutions2,948Â 2,834Â 5,584Â 5,445Â International3,709Â 3,475Â 7,400Â 6,943Â Corporate3Â â€”Â 3Â â€”Â Total revenues$93,651Â $77,215Â $172,934Â $151,698Â Segment operating profit (loss) (2) U.S. Pharmaceutical (3) $1,075Â $593Â $1,856Â $1,420Â Prescription Technology Solutions (4)205Â 238Â 408Â 469Â Medical-Surgical Solutions (5)89Â 244Â 277Â 471Â International (6)(508)66Â (418)123Â Subtotal861Â 1,141Â 2,123Â 2,483Â Corporate expenses, net (7) (249)(164) (352)(368)Interest expense(78)(61)(153)(108)Income before income taxes$534Â $916Â $1,618Â $2,007Â (1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segmentâ€™s total revenues, less than 40% of the RxTS segmentâ€™s total revenues, less than 1% of the Medical-Surgical Solutions segmentâ€™s total revenues, and less than 1% of the International segmentâ€™s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. Corporate reflects revenues from services derived in the U.S. related to certain technology operations and were not material for the three and six months ended September 30, 2024.(2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Companyâ€™s reportable segments.(3)The Companyâ€™s U.S. Pharmaceutical segmentâ€™s operating profit includes the following:â€¢a credit of $203 million for the three and six months ended September 30, 2024 due to the Companyâ€™s reassessment of its initial fiscal 2024 estimates of the previously reserved $725 million prepetition balance owed by the Companyâ€™s customer, Rite Aid Corporation (including certain of its subsidiaries, â€œRite Aidâ€). Rite Aid filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in October 2023. The Company recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid. The amounts described above were recorded within â€œSelling, distribution, general, and administrative expensesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August, 2024; â€¢cash receipts for the Companyâ€™s share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively. These gains were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢a credit of $2 million and a charge of $55 million related to the last-in, first-out method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million for the six months ended September 30, 2024 and 2023, respectively. These amounts were recorded within â€œCost of salesâ€ in the Companyâ€™s Condensed Consolidated Statements of Operations;â€¢restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net;â€â€¢a charge of $57 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" andâ€¢a loss of $43Â million for the six months ended September 30, 2024 related to one of the Companyâ€™s equity method investments, which was recorded within â€œOther income, netâ€ in the Companyâ€™s Condensed Consolidated Statement of Operations. (4)The Companyâ€™s RxTS segmentâ€™s operating profit for the three and six months ended September 30, 2023 includes gains of $48Â million and $76Â million, respectively, resulting from fair value adjustments of the Companyâ€™s contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022.(5)The Companyâ€™s Medical-Surgical Solutions segmentâ€™s operating profit for the three and six months ended September 30, 2024 includes restructuring charges of $144 million for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€(6)The Companyâ€™s International segmentâ€™s operating profit (loss) for the three and six months ended September 30, 2024 includes a charge of $593 million to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, â€œHeld for Sale.â€(7)Corporate expenses, net includes the following:â€¢a charge of $50 million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, â€œHeld for Sale;â€â€¢a net gain of $95Â million for the six months ended September 30, 2024 related to the Companyâ€™s investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, â€œFair Value Measurements;â€â€¢a net charge of $51Â million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, â€œCommitments and Contingent Liabilities;" andâ€¢restructuring charges of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, â€œRestructuring, Impairment, and Related Charges, Net.â€ X - DefinitionTabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 47 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Significant Accounting Policies (Details) 6 Months Ended Sep. 30, 2024 segment Accounting Policies [Abstract] Â Number of reportable segments 4 X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration XML 48 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Held for Sale - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 05, 2024 Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Charge to remeasure disposal group Â Â $ 638 $ 0 Held-for-sale | Canadian retail disposal group Â Â Â Â Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Â Â Â Â Â Purchase price $ 148 Â Â Â Â Cash proceeds from divestiture 27 Â Â Â Noncash divestiture, amount of consideration received $ 121 Â Â Â Noncash divestiture payable period (in years) 6 years Â Â Â Assets held for sale Â $ 631 631 Â Liabilities held for sale Â 371 371 Â Charge to remeasure disposal group Â 643 643 Â Accumulated other comprehensive loss in charge for remeasurement to fair value Â $ 15 $ 15 Â X - DefinitionDisposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Gain (Loss) in Charge for Remeasurement to Fair Value + ReferencesNo definition available. + Details Name: mck_DisposalGroupIncludingDiscontinuedOperationAccumulatedOtherComprehensiveLossInChargeForRemeasurementToFairValue Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNoncash or Part Noncash Divestiture, Amount of Consideration Received, Payment Period + ReferencesNo definition available. + Details Name: mck_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedPaymentPeriod Namespace Prefix: mck_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinesses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_CanadianRetailDisposalGroupMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details) - Canadian retail disposal group - Held-for-sale $ in Millions Sep. 30, 2024 USD ($) Assets Â Cash $ 14 Receivables, net 65 Inventories, net 219 Prepaid expenses and other 5 Property, plant, and equipment, net 62 Operating lease right-of-use assets 283 Goodwill 47 Intangible assets, net 419 Other non-current assets 160 Remeasurement of assets of businesses held for sale to fair value less costs to sell (643) Total assets held for sale 631 Liabilities Â Drafts and accounts payable 15 Current portion of operating lease liabilities 61 Other accrued liabilities 42 Long-term operating lease liabilities 249 Other non-current liabilities 4 Total liabilities held for sale 371 Trade accounts payable $ 142 X - DefinitionDisposal Group, Including Discontinued Operation, Long-term operating lease liabilities + ReferencesNo definition available. + Details Name: mck_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group, Including Discontinued Operation, Operating Lease Liability, Current + ReferencesNo definition available. + Details Name: mck_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group Including Discontinued Operation, Operating Lease, Right-of-Use Assets, Current + ReferencesNo definition available. + Details Name: mck_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsCurrent Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDisposal Group, Not Discontinued Operation, Intercompany Trade, Accounts Payable + ReferencesNo definition available. + Details Name: mck_DisposalGroupNotDiscontinuedOperationIntercompanyTradeAccountsPayable Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionDisposal Group, Not Discontinued Operation, Loss (Gain) on Write-down1 + ReferencesNo definition available. + Details Name: mck_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown1 Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as assets attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI

https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as goodwill attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 11 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount classified as liabilities attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_CanadianRetailDisposalGroupMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment, and Related Charges, Net - Narrtive (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges $ 234 $ 28 $ 244 $ 80 Restructuring, impairment, and related charges, net 171 28 181 80 Restructuring, Impairment, And Related Charges, Net Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges, net 171 Â 181 Â Cost of Sales Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges, net 63 Â 63 Â Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges 227 $ 3 227 $ 39 Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization | Minimum Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, anticipated total charges 650 Â 650 Â Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization | Maximum Â Â Â Â

Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, anticipated total charges $ 700 Â $ 700 Â X - DefinitionAmount expected to be recognized in earnings for the specified restructuring cost. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringAndRelatedCostExpectedCost1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=mck_RestructuringImpairmentAndRelatedChargesNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net $ 149 $ 10 $ 148 $ 12 Exit and other-related costs 12 18 20 40 Asset impairments and accelerated depreciation 73 0 76 28 Total 234 28 244 80 Restructuring, impairment, and related charges, net 171 28 181 80 Cost of Sales Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges, net 63 Â 63 Â U.S. Pharmaceutical | Cost of Sales Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Restructuring, impairment, and related charges, net 63 Â 63 Â Operating Segments | U.S. Pharmaceutical Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net 1 8 1 9 Exit and other-related costs 0 1 0 2 Asset impairments and accelerated depreciation 63 0 64 0 Total 64 9 65 11 Operating Segments | Prescription Technology Solutions Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net 0 0 0 0 Exit and other-related costs 0 3 3 5 Asset impairments and accelerated depreciation 1 0 2 0 Total 1 3 5 5 Operating Segments | Medical-Surgical Solutions Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net 144 0 144 0 Exit and other-related costs 3 4 6 6 Asset impairments and accelerated depreciation 0 0 0 0 Total 147 4 150 6 Operating Segments | International Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net 0 2 0 2 Exit and other-related costs (1) 4 (1) 9 Asset impairments and accelerated depreciation 0 0 1 1 Total (1) 6 0 12 Corporate Â Â Â Â Restructuring Cost and Reserve [Line Items] Â Â Â Â Severance and employee-related costs, net 4 0 3 1 Exit and other-related costs 10 6 12 18 Asset impairments and accelerated depreciation 9 0 9 27 Total $ 23 $ 6 $ 24 $ 46 X - DefinitionAsset Impairment Charges, Including Accelerated Depreciation + ReferencesNo definition available. + Details Name: mck_AssetImpairmentChargesIncludingAcceleratedDepreciation Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_BusinessExitCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringCostAndReserveLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_RestructuringCostsAndAssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â $ 55 Â Restructuring, impairment, and related charges, net $ 234 $ 28 244 $ 80 Non-cash charges Â Â (76) Â Cash payments Â Â (25) Â Other Â Â (10) Â Ending balance 188 Â 188 Â Operating Segments | U.S. Pharmaceutical Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 18 Â Restructuring, impairment, and related charges, net 64 9 65 11 Non-cash charges Â Â (64) Â Cash payments Â Â (4) Â Other Â Â (1) Â Ending balance 14 Â 14 Â Operating Segments | Prescription Technology Solutions Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 5 Â Restructuring, impairment, and related charges, net 1 3 5 5 Non-cash charges Â Â (2) Â Cash payments Â Â (2) Â Other Â Â (2) Â Ending balance 4 Â 4 Â Operating Segments | Medical-Surgical Solutions Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 1 Â Restructuring, impairment, and related charges, net 147 4 150 6 Non-cash charges Â Â 0 Â Cash payments Â Â (7) Â Other Â Â 0 Â Ending balance 144 Â 144 Â Operating Segments | International Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 10 Â Restructuring, impairment, and related charges, net (1) 6 0 12 Non-cash charges Â Â (1) Â Cash payments Â Â (2) Â Other Â Â (5) Â Ending balance 2 Â 2 Â Corporate Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 21 Â Restructuring, impairment, and related charges, net 23 $ 6 24 $ 46 Non-cash charges Â Â (9) Â Cash payments Â Â (10) Â Other Â Â (2) Â Ending balance 24 Â 24 Â Accrued Liabilities Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 24 Â Ending balance 160 Â 160 Â Other Non-Current Liabilities Â Â Â Â Restructuring Reserve [Roll Forward] Â Â Â Â Beginning balance Â Â 31 Â Ending balance $ 28 Â $ 28 Â X - DefinitionAmount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17 + Details Name: us-gaap_PaymentsForRestructuring Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserve Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of decrease in the reserve for full or partial settlement through consideration other than cash. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -

Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveSettledWithoutCash2 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1 + Details Name: us-gaap_RestructuringReserveTranslationAndOtherAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Income tax expense $ 247 $ 213 $ 371 $ 307 Reported income tax rate 46.30% 23.30% 22.90% 15.30% X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 54 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Jun. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Contingency [Line Items] Â Â Â Â Tax expense (benefit), intra-entity transfers of assets other than inventory, amount $ (44) Â $ (147) Â Â Canadian businesses held for sale Â Â Â $ 638 $ 0 Effective income tax rate reconciliation, foreign income tax rate differential, expense (benefit) Â Â Â (58) Â Tax expense (benefit), share-based payment arrangement Â Â Â (38) Â Unrecognized tax benefits, increase (decrease) Â Â Â (47) Â Tax contingency, interest expense, amount Â $ 12 Â 37 Â Unrecognized tax benefits 1,400 Â Â 1,400 Â Unrecognized tax benefits that would impact effective tax rate 1,300 Â Â 1,300 Â Held-for-sale | Canadian retail disposal group Â Â Â Â Â Income Tax Contingency [Line Items] Â Â Â Â Â Canadian businesses held for sale $ 643 Â Â $ 643 Â X - DefinitionEffective Income Tax Rate Reconciliation, Tax Contingency, Interest Expense, Amount + ReferencesNo definition available. + Details Name: mck_EffectiveIncomeTaxRateReconciliationTaxContingencyInterestExpenseAmount Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEffective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount + ReferencesNo definition available. + Details Name: mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 35 -Paragraph 2 -SubTopic 740 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2 + Details Name: us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxContingencyLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12AReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12 + Details Name: us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrecognized tax benefits. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B + Details Name: us-gaap_UnrecognizedTaxBenefits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details Name: us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionThe total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 217 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A + Details Name: us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_CanadianRetailDisposalGroupMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share - Narrative (Details) - shares 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share [Abstract] Â Â Â Â Potentially dilutive securities excluded from diluted earnings per share (less than) 1,000,000 1,000,000 1,000,000 1,000,000 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 56 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Â Â Â Â Net income $ 287 $ 703 $ 1,247 $ 1,700 Net income attributable to noncontrolling interests (46) (39) (91) (78) Net income attributable to McKesson Corporation $ 241 $ 664 $ 1,156 $ 1,622 Weighted-average common shares outstanding: Â Â Â Â Basic (in shares) 128.7 134.1 129.3 134.8 Diluted (in shares) 129.3 134.8 130.0 135.7 Earnings (loss) per common share attributable to McKesson Corporation: Â Â Â Â Diluted (in usd per share) $ 1.87 $ 4.92 $ 8.89 $ 11.95 Basic (in usd per share) $ 1.88 $ 4.95 $ 8.94 $ 12.03 Stock options Â Â Â Â Weighted-average common shares outstanding: Â Â Â Â Effect of dilutive securities (in shares) 0.1 0.2 0.1 0.2 Restricted stock units Â Â Â Â Weighted-average common shares outstanding: Â Â Â Â Effect of dilutive securities (in shares) 0.5 0.5 0.6 0.7 X - DefinitionEarnings Per Share, Basic and Diluted + ReferencesNo definition available. + Details Name: mck_EPSBasicAndDilutedAbstract Namespace Prefix: mck_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -

Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B + Details Name: us-gaap_EarningsPerShareDilutedLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A + Details Name: us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B + Details Name: us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes,

including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details) $ in Millions 6 Months Ended Sep. 30, 2024 USD ($) Goodwill [Roll Forward] Â Beginning balance $ 10,132 Goodwill acquired 0 Disposals (1) (47) Foreign currency translation adjustments, net 2 Other adjustments 0 Ending balance 10,087 U.S. Pharmaceutical Â Goodwill [Roll Forward] Â Beginning balance 4,123 Goodwill acquired 0 Disposals (1) 0 Foreign currency translation adjustments, net 0 Other adjustments 0 Ending balance 4,123 Prescription Technology Solutions Â Goodwill [Roll Forward] Â Beginning balance 2,024 Goodwill acquired 0 Disposals (1) 0 Foreign currency translation adjustments, net 0 Other adjustments 0 Ending balance 2,024 Medical-Surgical Solutions Â Goodwill [Roll Forward] Â Beginning balance 2,536 Goodwill acquired 0 Disposals (1) 0 Foreign currency translation adjustments, net 0 Other adjustments (29) Ending balance 2,507 International Â Goodwill [Roll Forward] Â Beginning balance 1,449 Goodwill acquired 0 Disposals (1) (47) Foreign currency translation adjustments, net 2 Other adjustments 0 Ending balance 1,404 Corporate Â Goodwill [Roll Forward] Â Beginning balance 0 Goodwill acquired 0 Disposals (1) 0 Foreign currency translation adjustments, net 0 Other adjustments 29 Ending balance $ 29 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillAcquiredDuringPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 16 -SubTopic 10 -Topic 805 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16 + Details Name: us-gaap_GoodwillPurchaseAccountingAdjustments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 58 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) - USD ($) $ in Millions Sep. 30, 2024 Mar. 31, 2024 Finite-Lived Intangible Assets [Line Items] Â Â Gross Carrying Amount $ 3,311 $ 4,033 Accumulated Amortization (1,738) (1,923) Net Carrying Amount 1,573 2,110 Held-for-sale | Canadian retail disposal group Â Â Finite-Lived Intangible Assets [Line Items] Â Â Intangible assets, net $ 419 Â Customer relationships Â Â Finite-Lived Intangible Assets [Line Items] Â Â Weighted- Average Remaining Amortization Period (Years) 11 years Â Gross Carrying Amount $ 1,480 1,830 Accumulated Amortization (604) (701) Net Carrying Amount $ 876 1,129 Service agreements Â Â Finite-Lived Intangible Assets [Line Items] Â Â Weighted- Average Remaining Amortization Period (Years) 9 years Â Gross Carrying Amount $ 1,129 1,126 Accumulated Amortization (707) (676) Net Carrying Amount $ 422 450 Trademarks and trade names Â Â Finite-Lived Intangible Assets [Line Items] Â Â Weighted- Average Remaining Amortization Period (Years) 13 years Â Gross Carrying Amount $ 384 759 Accumulated Amortization (268) (395) Net Carrying Amount $ 116 364 Technology Â Â Finite-Lived Intangible Assets [Line Items] Â Â Weighted- Average Remaining Amortization Period (Years) 10 years Â Gross Carrying Amount $ 284 284 Accumulated Amortization (133) (125) Net Carrying Amount $ 151 159 Other Â Â Finite-Lived Intangible Assets [Line Items] Â Â

Weighted- Average Remaining Amortization Period (Years) 6 years Â Gross Carrying Amount $ 34 34 Accumulated Amortization (26) (26) Net Carrying Amount $ 8 $ 8 X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRemaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_CanadianRetailDisposalGroupMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Amortization expense of intangible assets $ 60 $ 62 $ 123 $ 124 Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract] Â Â Â Â Estimated annual amortization expense, remainder of 2025 102 Â 102 Â Estimated annual amortization expense, 2026 177 Â 177 Â Estimated annual amortization expense, 2027 171 Â 171 Â Estimated annual amortization expense, 2028 166 Â 166 Â Estimated annual amortization expense, 2029 164 Â 164 Â Estimated annual amortization expense, thereafter $ 793 Â $ 793 Â X - DefinitionFinite-Lived Intangible Asset, Expected Amortization, after Year Four + ReferencesNo definition available. + Details Name: mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 60 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities - Schedule of Long-Term Debt (Details) - USD ($) $ in Millions Sep. 30, 2024 Sep. 10, 2024 Mar. 31, 2024 Jun. 15, 2023 Debt Instrument [Line Items] Â Â Â Â Total debt $ 5,744 Â $ 5,629 Â Less: Current portion 53 Â 50 Â Total long-term debt $ 5,691 Â 5,579 Â 5.25% Notes due February 15, 2026 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) Â 5.25% Â Â Â Loans payable | 0.90% Notes due December 3, 2025 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 0.90% Â Â Â Total debt $ 500 Â 500 Â Loans payable | 5.25% Notes due February 15, 2026 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 5.25% Â Â Â Â Total debt $ 499 Â 499 Â Loans payable | 1.30% Notes due August 15, 2026 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 1.30% Â Â Â Â Total debt $ 0 Â 499 Â Loans payable | 7.65% Debentures due March 1, 2027 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 7.65% Â Â Â Â Total debt $ 150 Â 150 Â Loans payable | 3.95% Notes due February 16, 2028 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 3.95% Â Â Â Â Total debt $ 343 Â 343 Â Loans payable | 4.90% Notes due July 15, 2028 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 4.90% Â Â 4.90% Total debt $ 399 Â 399 Â Loans payable | 4.75% Notes due May 30, 2029 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 4.75% Â Â Â Â Total debt $ 196 Â 196 Â Loans payable | 4.25% Notes due September 15, 2029 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 4.25% 4.25% Â Â Â Total debt $ 500 Â 0 Â Loans payable | 5.10% Notes due July 15, 2033 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 5.10% Â Â 5.10% Total debt $ 597 Â 596 Â Loans payable | 6.00% Notes due March 1, 2041 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 6.00% Â Â Â Â Total debt $ 218 Â 218 Â Loans payable | 4.88% Notes due March 15, 2044 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 4.88% Â Â Â Â Total debt $ 255 Â 255 Â Loans payable | 1.50% Euro Notes due November 17, 2025 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 1.50% Â Â Â Total debt $ 667 Â 646 Â Loans payable | 1.63% Euro Notes due October 30, 2026 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 1.63% Â Â Â Â Total debt $ 557 Â 540 Â Loans payable | 3.13% Sterling Notes due February 17, 2029 Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Interest rate on debt instrument (percent) 3.13% Â Â Â Â Total debt $ 602 Â 568 Â Lease and other obligations Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Total debt $ 261 Â $ 220 Â X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-

gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as noncurrent. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=mck_A525NotesDueFebruary152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A090NotesDueDecember32025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A130NotesDueAugust152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A765DebenturesDueMarch12027Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A395NotesDueFebruary162028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A475NotesDueMay302029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A4.25NotesDueSeptember152029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A600NotesDueMarch12041Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A488NotesDueMarch152044Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A150EuroNotesDueNovember172025Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A163EuroNotesDueOctober302026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A313SterlingNotesDueFebruary172029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=mck_LeaseAndOtherObligationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities - Long-Term Debt Narrative (Details) - USD ($) $ in Millions 6 Months Ended Sep. 10, 2024 Jun. 16, 2023 Jun. 15, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Debt Instrument [Line Items] Â Â Â Â Â Â Â Long-term debt Â Â Â $ 5,700 Â $ 5,600 Current portion of long-term debt Â Â Â 53 Â $ 50 Repayments of long-term debt Â Â Â 501 $ 271 Â Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Â Â Â $ 0 647 Â Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Redemption price percentage of principal (percent) Â Â 101.00% Â Â Â Â Term Loan | Minimum Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Debt instrument, redemption period (in days) Â Â 10 days Â Â Â Â Term Loan | Maximum Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Debt instrument, redemption period (in days) Â Â 60 days Â Â Â Â 4.25% Notes due September 15, 2029 | Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) 4.25% Â Â 4.25% Â Â Debt principal amount $ 500 Â Â Â Â Â Â Proceeds from debt issuance $ 496 Â Â Â Â Â Â 5.25% Notes due February 15, 2026 Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) 5.25% Â Â Â Â Â Â 5.25% Notes due February 15, 2026 | Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) Â Â Â 5.25% Â Â Redemption price percentage of principal (percent) 100.00% Â Â Â Â Â Repayments of long-term debt $ 500 Â Â Â Â Â Â 4.90% Notes due July 15, 2028 | Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) Â Â 4.90% 4.90% Â Â Debt principal amount Â Â $ 400 Â Â Â Proceeds from debt issuance Â Â $ 397 Â Â Â 5.10% Notes due July 15, 2033 | Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) Â Â 5.10% 5.10% Â Â Debt principal amount Â Â $ 600 Â Â Â Proceeds from debt issuance Â Â $ 592 Â Â Â 3.80% Notes due March 15, 2024 Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Interest rate on debt instrument (percent) Â Â 3.80% Â Â Â 3.80% Notes due March 15, 2024 | Term Loan Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Redemption price percentage of principal (percent) Â 98.75% Â Â Â Â Repayments of long-term debt Â $ 268 Â Â Â Â Debt principal redeemed Â 271 Â Â Â Â Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt Â $ 647 Â Â Â Â Gain on debt extinguishment Â Â Â Â $ 9 Â X - DefinitionDebt Instrument, Redemption Period + ReferencesNo definition available. + Details Name: mck_DebtInstrumentRedemptionPeriod Namespace Prefix: mck_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionPayments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt + ReferencesNo definition available. + Details Name: mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of short-term and long-term debt and lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_DebtAndCapitalLeaseObligations Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -

Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPercentage price of original principal amount of debt at which debt can be redeemed by the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 470 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3 + Details Name: us-gaap_DebtInstrumentRedemptionPricePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of the original debt instrument that was repurchased. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentRepurchasedFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4 + Details Name: us-gaap_GainsLossesOnExtinguishmentOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of long-term debt and lease obligation, classified as current. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromDebtNetOfIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3 + Details Name: us-gaap_RepaymentsOfLongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A4.25NotesDueSeptember152029Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A525NotesDueFebruary152026Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) - Unsecured Debt - Revolving Credit Facility - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Nov. 07, 2022 Senior Unsecured Credit Facility (the 2022 Credit Facility) Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Credit facility, maximum borrowing capacity Â Â Â $ 4,000,000,000.0 Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit Â Â Â Â Line of Credit Facility [Line Items] Â Â Â Â Credit facility, maximum borrowing capacity Â Â Â $ 3,600,000,000 Borrowings under facility $ 0 $ 0 Â Â Amounts outstanding under facility $ 0 Â $ 0 Â X - DefinitionThe carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_LineOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Debt and Financing Activities - Commercial Paper Narrative (Details) - Commercial Paper - USD ($) 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Line of Credit Facility [Line Items] Â Â Â Credit facility, maximum borrowing capacity $ 4,000,000,000.0 Â Â Proceeds from issuance of commercial paper 6,900,000,000 $ 2,000,000,000.0 Â Repayments of commercial paper 6,900,000,000 $ 2,000,000,000.0 Â Commercial paper $ 0 Â $ 0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermCommercialPaperCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from borrowing by issuing commercial paper. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommercialPaper Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash outflow due to repaying amounts borrowed by issuing commercial paper. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfCommercialPaper Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) - Derivatives designated for hedge accounting â¬ in Millions, Â£ in Millions, $ in Millions, $ in Millions Sep. 30, 2024 CAD ($) Sep. 30, 2024 GBP (Â£) Sep. 30, 2024 EUR (â¬) Sep. 30, 2024 USD ($) Jun. 30, 2024 CAD ($) Mar. 31, 2024 CAD ($) Mar. 31, 2024 GBP (Â£) Mar. 31, 2024 EUR (â¬) Mar. 31, 2024 USD ($) Jun. 15, 2023 USD ($) Mar. 31, 2023 USD ($) Cross-currency swaps | Net

Investment Hedges | CAD Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional $ 2,500 Â Â Â $ 2,500 $ 1,500 Â Â Â Â Â Cross-currency swaps | Fair Value Hedges | GBP Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional | Â£ Â Â£ 450 Â Â Â Â Â£ 450 Â Â Â Â Â Cross-currency swaps | Fair Value Hedges | EUR Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional | â‚¬ Â Â â‚¬ 1,100 Â Â Â Â â‚¬ 1,100 Â Â Â Floating interest rate swaps | Fair Value Hedges Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional Â Â Â $ 1,300 Â Â Â Â Â Â $ 1,300 Floating interest rate swaps | Fair Value Hedges | USD Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional Â Â Â $ 750 Â Â Â Â $ 1,250 Â Â Floating interest rate swaps | Cash Flow Hedges Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional Â Â Â Â Â Â Â Â $ 500 Â Foreign currency forwards | Cash Flow Hedges | GBP Â Â Â Â Â Â Â Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Â Â Â Â Â Â Â Notional | Â£ Â Â£ 27 Â Â Â Â Â£ 39 Â Â Â Â X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_CAD Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_GBP Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_EUR Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_USD Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities - Narrative (Details) $ in Millions 3 Months Ended 6 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Jun. 30, 2023 USD ($) Sep. 30, 2024 USD ($) Sep. 30, 2023 USD ($) Mar. 31, 2023 USD ($) Oct. 31, 2024 CAD ($) Sep. 30, 2024 CAD ($) Sep. 30, 2024 USD ($) Jun. 30, 2024 CAD ($) Mar. 31, 2024 CAD ($) Jun. 15, 2023 USD ($) Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax $ 0 $ 0 Â $ 0 $ 0 Â Â Â Â Â Â Â Â Net Investment Hedging | CAD | Currency swap | Derivatives designated for hedge accounting Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Derivative, notional amount Â Â Â Â Â Â Â $ 2,500 Â $ 2,500 $ 1,500 Â Derivative notional amount, terminated Â Â Â Â Â Â Â Â Â Â Â $ 1,500 Â Â Â Net Investment Hedging | CAD | Currency swap | Derivatives designated for hedge accounting | Subsequent Event Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Derivative, notional amount Â Â Â Â Â Â Â $ 1,000 Â Â Â Â Â Â Fair Value Hedges | Floating interest rate swaps | Derivatives designated for hedge accounting Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Derivative, notional amount Â Â Â Â Â Â Â $ 1,300,000,000 Â Â Â $ 1,300,000,000 Â Â Â Derivative notional amount, terminated Â Â Â Â Â Â Â Â Â Â Â $ 500,000,000 Â Â Â Cash Flow Hedges | Currency swap | Derivatives designated for hedge accounting Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax $ (14,000,000) $ 33,000,000 Â $ (14,000,000) $ 27,000,000 Â Â Â Â Â Â Â Cash Flow Hedges | Floating interest rate swaps | Derivatives designated for hedge accounting Â Â Â Â Â Â Â Â Â Â Â Derivative [Line Items] Â Â Â Â Â Â Â Â Â Â Â Derivative, notional amount Â Â Â Â Â Â Â Â Â Â Â $ 500,000,000 Derivative, notional amount, entered into during period Â Â $ 50,000,000 Â Â $ 450,000,000 Â Â Â Â Â Â Derivative termination proceeds, amortization period (in years) Â Â Â 10 years Â Â Â Â Â Â Â Â X - DefinitionDerivative, Notional Amount, Entered Into During Period + ReferencesNo definition available. + Details Name: mck_DerivativeNotionalAmountEnteredIntoDuringPeriod Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDerivative, Notional Amount, Terminated + ReferencesNo definition available. + Details Name: mck_DerivativeNotionalAmountTerminated Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionDerivative, Termination Proceeds, Amortization Period + ReferencesNo definition available. + Details Name: mck_DerivativeTerminationProceedsAmortizationPeriod Namespace Prefix: mck_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5 + Details Name: us-gaap_DerivativeLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNominal or face amount used to calculate payment on derivative. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionAmount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CurrencyAxis=currency_CAD Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Derivatives, Fair Value [Line Items] Â Â Â Â Derivatives designated as cash flow and other hedges: $ 0 $ 0 $ 0 $ 0 Derivatives designated for hedge accounting | Cross-currency swaps | Net Investment Hedging Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Derivatives designated as net investment hedges: (20,000,000) 27,000,000 (13,000,000) 7,000,000 Derivatives designated for hedge accounting | Cross-currency swaps | Cash Flow Hedges Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Derivatives designated as cash flow and other hedges: (14,000,000) 33,000,000 (14,000,000) 27,000,000 Derivatives designated for hedge accounting | Foreign currency forwards | Cash Flow Hedges Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Derivatives designated as cash flow and other hedges: 2,000,000 0 2,000,000 0 Derivatives designated for hedge accounting | Fixed interest rate swaps | Cash Flow Hedges Â Â Â Â Derivatives, Fair Value [Line Items] Â Â Â Â Derivatives designated as cash flow and other hedges: $ 0 $ 0 $ 0 $ 0 $ 16,000,000 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC + Details Name: us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Hedging Activities - Schedule of Fair Value of Derivatives (Details) - Derivatives designated for hedge accounting - USD ($) $ in Millions Sep. 30, 2024 Mar. 31, 2024 Derivatives, Fair Value [Line Items] Â Â Asset $ 168 $ 121 Liability 36 36 Cross-currency swaps | Prepaid expenses and other/Other accrued liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Asset 69 13 Liability 15 1 U.S. Dollar notional amount, asset 1,690 1,122 Cross-currency swaps | Other non-current assets/liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Asset 97 108 Liability 11 0 U.S. Dollar notional amount, asset 1,771 1,638 Interest Rate Swap | Other non-current assets/liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Asset 0 0 Liability 10 35 U.S. Dollar notional amount, asset 750 1,250 Foreign currency forwards | Prepaid expenses and other/Other accrued liabilities Â Â Derivatives, Fair Value [Line Items] Â Â Asset 2 0 Liability 0 0 U.S. Dollar, notional amount, liability 34 35 Foreign currency forwards | Other non-current assets Â Â Derivatives, Fair Value [Line Items] Â Â Asset 0 0 Liability 0 0 U.S. Dollar, notional amount, liability $ 0 $ 15 X - DefinitionNominal or face amount used to calculate payments on the derivative asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeAssetNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-12Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 55

-Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(3)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column A)(Footnote 3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 30: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-7Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 4D -Subparagraph (c)(2) -SubTopic 20 -Topic 860 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D + Details Name: us-gaap_DerivativeFairValueOfDerivativeLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(e)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)(Footnote 7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(9)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)(Footnote 8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column H)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column G)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column E)(Footnote 4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3Reference 28: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DerivativeLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionNominal or face amount used to calculate payments on the derivative liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5C -Subparagraph (SX 210.12-13C(Column E)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5CReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5 -Subparagraph (SX 210.12-13(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5A -Subparagraph (SX 210.12-13A(Column D)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 5B -Subparagraph (SX 210.12-13B(Column A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5BReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1BReference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1AReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A + Details Name: us-gaap_DerivativeLiabilityNotionalAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_DerivativesFairValueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mck_CurrentAssetLiabilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=mck_OtherNonCurrentAssetsLiabilitiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Mar. 31, 2024 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Investments in equity securities $ 175 Â $ 175 Â $ 240 Gains (losses) associated with equity investments (15) $ 0 95 $ 0 Â Gain related to share price increase of equity securities Â Â 100 Â Â Proceeds from sale of equity securities Â Â 92 Â Â Fair value, inputs, level 1 | Fair Value, Recurring Â Â Â Â Â Fair Value,

Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Â Money market funds at carrying value $ 549 Â $ 549 Â $ 705 X - DefinitionAmount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A + Details Name: us-gaap_EquitySecuritiesFVNINoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiRealizedGain Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionInvestment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months. + ReferencesNo definition available. + Details Name: us-gaap_MoneyMarketFundsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 10 -Topic 321 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1 + Details Name: us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) - USD ($) $ in Millions Sep. 30, 2024 Mar. 31, 2024 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Carrying Value $ 5,744 $ 5,629 Fair Value, Recurring | Fair value, inputs, level 2 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Carrying Value 5,744 5,629 Fair Value $ 5,808 $ 5,488 X - DefinitionFair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10 + Details Name: us-gaap_DebtInstrumentFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingent Liabilities - Narrative (Details) 3 Months Ended 6 Months Ended 12 Months Ended Apr. 27, 2022 USD ($) Oct. 08, 2021 plaintiff May 17, 2013 USD ($) Sep. 30, 2024 USD ($) case state distributor settlement subdivision Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) case state distributor subdivision Sep. 30, 2023 USD ($) Mar. 31, 2024 USD ($) plaintiff Jul. 31, 2020 state Aug. 13, 2019 fax faxNumber Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Claims and litigation charges Â Â Â $ (4,000,000) $ (2,000,000) $ 108,000,000 $ (2,000,000) Â Â Â Number of plaintiffs | plaintiff Â 2 Â Â Â Â Â Â Â Â Â Proceeds from legal settlements Â Â Â $ 63,000,000 Â Â Â Â Â Â Number of antitrust settlement | settlement Â Â Â 2 Â Â Â Â Â Â U.S. Pharmaceutical Â Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Â Proceeds from legal settlements Â Â Â $ 63,000,000 $ 79,000,000 153,000,000 $ 197,000,000 Â Â Â National Prescription Opioid Litigation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Claims and litigation charges Â Â Â Â Â 114,000,000 Â $ 149,000,000 Â Â National Prescription Opioid Litigation | Corporate Segment and U.S. Pharmaceutical Segment Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Claims and litigation charges Â Â Â Â Â $ 57,000,000 Â Â Â Â National Prescription Opioid Litigation | U.S. Pharmaceutical Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Claims and litigation charges Â Â Â Â Â Â Â (74,000,000) Â Â National Prescription Opioid Litigation | Corporate Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Claims and litigation charges Â Â Â Â Â Â Â $ (75,000,000) Â Â National Prescription Opioid Litigation | United States Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Complaints filed against the entity | case Â Â Â 400 Â 400 Â Â Â Â National Prescription Opioid Litigation | Canada Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Complaints filed against the entity | case Â Â Â 4 Â 4 Â Â Â Â National Prescription Opioid Litigation | An individual | United States Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Complaints filed against the entity | case Â Â Â 1 Â 1 Â Â Â Â National Prescription Opioid Litigation | An individual | Canada Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Complaints filed against the entity | case Â Â Â 1 Â 1 Â Â Â Â National Prescription Opioid Litigation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Number of other national distributors named in suit | distributor Â Â Â 2 Â 2 Â Â Â Â Number of states in which court cases are pending | state Â Â Â 48 Â 48 Â Â Â Â Loss contingency, number of cases dismissed | case Â Â Â 2,300 Â 2,300 Â Â Â Â Portion of settlement award to be used by state and local government for remediation (percent) Â Â Â 85.00% Â 85.00% Â Â Â Â Loss contingency, claims settled, number of jurisdictions not participating in settlement | subdivision Â Â Â 1 Â 1 Â Â Â Â Number of plaintiffs | plaintiff Â Â Â Â Â Â Â 1 Â Â National Prescription Opioid Litigation | State of Alabama and Subdivisions Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Settlement payment Â Â Â Â Â $ 75,000,000 Â Â Â Â Award payable under proposed framework Â Â Â Â Â $ 99,000,000 Â Â Â Â National Prescription Opioid Litigation | Native American Tribes Other Than Cherokee Nation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages Â Â Â 0.85 Â 0.85 Â Â Â Â National Prescription Opioid Litigation | Settling Governmental Entities and Cherokee Nation | Settled Litigation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Settlement payment Â Â Â Â Â $ 500,000,000 Â Â Â Â National Prescription Opioid Litigation | Three Largest U.S. Pharmaceutical Distributors Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Settlement payment Â Â Â Â Â 2,000,000,000 Â Â Â Â Award payable under proposed framework Â Â Â Â Â 5,900,000,000 Â Â Â Â National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Settlement payment Â Â Â Â Â 53,000,000 Â Â Â Â Award payable under proposed framework Â Â Â Â Â 99,000,000 Â Â Â Â National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Cherokee Nation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Settlement payment Â Â Â Â Â 112,000,000 Â Â Â Â National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Native American Tribes Other Than Cherokee Nation Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Â Award payable under proposed framework Â Â Â Â Â $ 84,000,000 Â Â Â Â United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Number of states filed on behalf of | state Â Â Â Â Â Â Â Â 27 Â True Health Chiropractic Inc., et al. v. McKesson Corporation, et al Â Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Loss contingency, class action, number of faxes remaining in the class | faxNumber Â Â Â Â Â Â Â Â Â 9,490 Loss contingency, class action, number of faxes received | fax Â Â Â Â Â Â Â Â Â 48,769 Amounts awarded to plaintiff $ 6,500 Â Â Â Â Â Â Â Â Â True Health Chiropractic Inc., et al. v. McKesson Corporation, et al | Minimum Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Loss contingency, damages sought per violation, value Â Â $ 500 Â Â Â Â Â Â Â True Health Chiropractic Inc., et al. v. McKesson Corporation, et al | Maximum Â Â Â Â Â Â Â Â Â Loss Contingencies [Line Items] Â Â Â Â Â Â Â Â Â Loss contingency, damages sought per violation, value Â Â $ 1,500 Â Â Â Â Â Â Â X - DefinitionLitigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages + ReferencesNo definition available. + Details Name: mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages Namespace Prefix: mck_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionLitigation Settlement, Award Amount To Be Used by State and Local Government + ReferencesNo definition available. + Details Name: mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment Namespace Prefix: mck_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement + ReferencesNo definition available. + Details Name: mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Class Action, Number of Faxes Received + ReferencesNo definition available. + Details Name: mck_LossContingencyClassActionNumberofFaxesReceived Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Class Action, Number of Faxes Remaining in the Class + ReferencesNo definition available. + Details Name: mck_LossContingencyClassActionNumberofFaxesRemainingintheClass Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Damages Sought Per Violation, Value + ReferencesNo definition available. + Details Name: mck_LossContingencyDamagesSoughtPerViolationValue Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLoss Contingency, Number Of Cases Dismissed + ReferencesNo definition available. + Details Name: mck_LossContingencyNumberOfCasesDismissed Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Number of Other Defendants + ReferencesNo definition available. + Details Name: mck_LossContingencyNumberOfOtherDefendants Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Number of

States Filed On Behalf Of + ReferencesNo definition available. + Details Name: mck_LossContingencyNumberOfStatesFiledOnBehalfOf Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLoss Contingency, Number of States + ReferencesNo definition available. + Details Name: mck_LossContingencyNumberofStates Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionNumber Of Antitrust Settlements + ReferencesNo definition available. + Details Name: mck_NumberOfAntitrustSettlements Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 + Details Name: us-gaap_GainLossRelatedToLitigationSettlement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of damages awarded to the plaintiff in the legal matter. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyDamagesAwardedValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNumber of plaintiffs that have filed claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyNumberOfPlaintiffs Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of pending claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyPendingClaimsNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionThe amount of cash paid for the settlement of litigation or for other legal issues during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_PaymentsForLegalSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionCash received for the settlement of litigation during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromLegalSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_CorporateSegmentAndU.S.PharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_CA Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_IndividualClaimantMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_StateOfAlabamaAndSubdivisionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_NativeAmericanTribesOtherThanCherokeeNationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_SettlingGovernmentalEntitiesAndCherokeeNationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mck_ThreeLargestUSPharmaceuticalDistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: dei_LegalEntityAxis=mck_ThreeNationalPharmaceuticalDistributorsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_StateOfWestVirginiaAndSubdivisionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=mck_CherokeeNationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=mck_TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) - National Prescription Opioid Litigation - USD ($) $ in Millions Sep. 30, 2024 Mar. 31, 2024 Loss Contingencies [Line Items] Â Â Current litigation liabilities $ 775 $ 665 Long-term litigation liabilities 5,617 6,113 Total litigation liabilities $ 6,392 $ 6,778 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10 + Details Name: us-gaap_LossContingencyAccrualAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit - Narrative (Details) $ / shares in Units, shares in Millions, $ in Millions 3 Months Ended 6 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) vote $ / shares shares Jun. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) $ / shares shares Jun. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) vote $ / shares Sep. 30, 2023 USD ($) $ / shares Mar. 31, 2024 USD ($) Jul. 31, 2024 USD ($) Accelerated Share Repurchases [Line Items] Â Â Â Â Â Â Â Â Number of votes per share of common stock permitted on proposals presented to stockholders (vote) | vote 1 Â Â Â 1 Â Â Â Dividends declared per common share (in dollars per share) | $ / shares $ 0.71 $ 0.62 $ 0.62 Â $ 1.33 $ 1.16 Â Â Other accrued liabilities $ 4,787 Â Â Â $ 4,787 Â $ 4,915 Â Excise taxes Â Â Â Â 41 Â $ 25 Â Authorized repurchase amount (up to) Â Â Â Â Â Â Â $ 4,000 Authorized amount available for future repurchases $ 8,600 Â Â Â 8,600 Â Â Â Open Market Share Repurchase Transactions Â Â Â Â Â Â Â Â Accelerated Share Repurchases [Line Items] Â Â Â Â Â Â Â Â Common stock repurchased (in shares) | shares 2.9 1.0 2.0 1.8 Â Â Â Â Shares repurchased $ 1,500 $ 528 $ 840 $ 673 Â Â Â Â Average price of shares repurchased (in usd per share) | $ / shares $ 533.46 $ 548.20 $ 422.39 $ 379.14 Â Â Â Â Other accrued liabilities $ 22 Â $ 23 Â 22 $ 23 Â Â Excise taxes $ 15 Â $ 8 Â $ 16 $ 12 Â Â X - DefinitionCommon Stock, Voting Rights, Number of Votes Per Common Share + ReferencesNo definition available. + Details Name: mck_CommonStockVotingRightsNumberofVotesPerCommonShare Namespace Prefix: mck_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionExcise Tax Accrual + ReferencesNo definition available. + Details Name: mck_ExciseTaxAccrual Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 505 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4 + Details Name: srt_StockRepurchaseProgramAuthorizedAmount1 Namespace Prefix: srt_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AcceleratedShareRepurchasesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate dividends declared during the period for each share of common stock outstanding. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_CommonStockDividendsPerShareDeclared Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership. + ReferencesNo definition available. + Details Name: us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal cost of shares repurchased divided by the total number of shares repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockAcquiredAverageCostPerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares that have been repurchased during the period and are being held in treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_TreasuryStockSharesAcquired Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionEquity impact of the

cost of common and preferred stock that were repurchased during the period. Recorded using the par value method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1 + Details Name: us-gaap_TreasuryStockValueAcquiredParValueMethod Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: srt_ShareRepurchaseProgramAxis=mck_OpenMarketShareRepurchaseTransactionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details) - USD ($) 3 Months Ended 6 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance $ (1,381,000,000) $ (1,240,000,000) $ (1,599,000,000) $ (1,490,000,000) Other comprehensive income (loss) before reclassifications 24,000,000 (38,000,000) (8,000,000) 19,000,000 Amounts reclassified to earnings and other (1,000,000) (1,000,000) (1,000,000) (1,000,000) Other comprehensive income (loss), net of tax 23,000,000 (39,000,000) (9,000,000) 18,000,000 Less: amounts attributable to noncontrolling interests 0 0 0 0 Other comprehensive income (loss) attributable to McKesson 23,000,000 (39,000,000) (9,000,000) 18,000,000 Ending balance (2,642,000,000) (1,464,000,000) (2,642,000,000) (1,464,000,000) Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax 0 0 0 0 Derivatives designated for hedge accounting | Net Investment Hedging | Currency swap Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss), net investment hedge, gain (loss) (20,000,000) 27,000,000 (13,000,000) 7,000,000 Derivatives designated for hedge accounting | Cash Flow Hedges | Currency swap Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax (14,000,000) 33,000,000 (14,000,000) 27,000,000 Derivatives designated for hedge accounting | Cash Flow Hedges | Fixed interest rate swaps Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax 0 0 0 16,000,000 Derivatives designated for hedge accounting | Cash Flow Hedges | Foreign currency forwards Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax 2,000,000 0 2,000,000 0 Total Accumulated Other Comprehensive Loss Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance (913,000,000) (848,000,000) (881,000,000) (905,000,000) Ending balance (890,000,000) (887,000,000) (890,000,000) (887,000,000) Foreign Currency Translation Adjustments, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance (892,000,000) (780,000,000) (856,000,000) (847,000,000) Other comprehensive income (loss) before reclassifications 49,000,000 (84,000,000) 13,000,000 (17,000,000) Amounts reclassified to earnings and other 0 0 0 0 Other comprehensive income (loss), net of tax 49,000,000 (84,000,000) 13,000,000 (17,000,000) Ending balance (843,000,000) (864,000,000) (843,000,000) (864,000,000) Foreign Currency Translation Adjustments, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Less: amounts attributable to noncontrolling interests 0 0 0 0 Foreign Currency Translation Adjustments, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss) attributable to McKesson 49,000,000 (84,000,000) 13,000,000 (17,000,000) Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance (7,000,000) (29,000,000) (12,000,000) (14,000,000) Other comprehensive income (loss) before reclassifications (15,000,000) 20,000,000 (10,000,000) 5,000,000 Amounts reclassified to earnings and other 0 0 0 0 Other comprehensive income (loss), net of tax (15,000,000) 20,000,000 (10,000,000) 5,000,000 Ending balance (22,000,000) (9,000,000) (22,000,000) (9,000,000) Other comprehensive income (loss) before reclassification, tax (5,000,000) 7,000,000 (3,000,000) (2,000,000) Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Less: amounts attributable to noncontrolling interests 0 0 0 0 Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss) attributable to McKesson (15,000,000) 20,000,000 (10,000,000) 5,000,000 Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance 3,000,000 (29,000,000) 3,000,000 (36,000,000) Other comprehensive income (loss) before reclassifications (9,000,000) 25,000,000 (9,000,000) 32,000,000 Amounts reclassified to earnings and other 0 0 0 0 Other comprehensive income (loss), net of tax (9,000,000) 25,000,000 (9,000,000) 32,000,000 Ending balance (6,000,000) (4,000,000) (6,000,000) (4,000,000) Other comprehensive income (loss) before reclassification, tax (3,000,000) 8,000,000 (3,000,000) 11,000,000 Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Less: amounts attributable to noncontrolling interests 0 0 0 0 Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss) attributable to McKesson (9,000,000) 25,000,000 (9,000,000) 32,000,000 Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Beginning balance (17,000,000) (10,000,000) (16,000,000) (8,000,000) Other comprehensive income (loss) before reclassifications (1,000,000) 1,000,000 (2,000,000) (1,000,000) Amounts reclassified to earnings and other (1,000,000) (1,000,000) (1,000,000) (1,000,000) Other comprehensive income (loss), net of tax (2,000,000) 0 (3,000,000) (2,000,000) Ending balance (19,000,000) (10,000,000) (19,000,000) (10,000,000) Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Less: amounts attributable to noncontrolling interests 0 0 0 0 Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Other comprehensive income (loss) attributable to McKesson $ (2,000,000) $ 0 $ (3,000,000) $ (2,000,000) X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1 + Details Name: us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 4C -Subparagraph (c) -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C + Details Name: us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4CCC -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC + Details Name: us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax and reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to noncontrolling interests. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of reclassification adjustments of other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name

Accounting Standards Codification -Section 55 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15 + Details Name: us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 40: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 41: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 42: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 43: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 44: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 45: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 46: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15Reference 47: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16Reference 48: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4IReference 49: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1 + Details Name: us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForwardContractsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Segments of Business - Narrative (Details) 6 Months Ended Sep. 30, 2024 segment Segment Reporting [Abstract] Â Number of reportable segments 4 X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SegmentReportingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 75 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Segments of Business - Reportable operating segment (Details) $ in Millions 3 Months Ended 6 Months Ended 12 Months Ended Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) segment Sep. 30, 2023 USD ($) Mar. 31, 2024 USD ($) Segment revenues Â Â Â Â Â Â Total revenues $ 93,651 $ 77,215 $ 172,934 $ 151,698 Â Segment operating profit (loss) Â Â Â Â Â Total operating profit (loss) 578 951 1,607 2,051 Â Subtotal 861 1,141 2,123 2,483 Â Corporate income (expenses), net (249) (164) (352) (368) Â Interest expense (78) (61) (153) (108) Â Income before income taxes 534 916 $ 1,618 2,007 Â Number of reportable segments | segment Â Â 4 Â Â Accounts receivable, credit loss expense (reversal) Â Â $ (169) 243 Â Proceeds from legal settlements 63 Â Â Â Â Pre-tax credits related to LIFO accounting Â Â (4) 87 Â Restructuring, impairment, and related charges, net 234 28 244 80 Â Income (loss) from equity method investments Â Â (43) Â Â Restructuring charges 149 10 148 12 Â Canadian businesses held for sale Â Â 638 0 Â Gains (losses) associated with equity investments (15) 0 95 0 Â Canadian retail disposal group | Held-for-sale Â Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Canadian businesses held for sale 643 Â 643 Â Â Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net $ 227 3 227 39 Â Rx Savings Solutions, LLC Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Fair value adjustment gain Â 48 Â 76 Â United States Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Number of reportable segments | segment 3 Â Â Â Â Corporate Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net $ 23 6 24 46 Â Restructuring charges 4 0 3 1 Â Gains (losses) associated with equity investments Â Â 95 Â Â Corporate | Canadian retail disposal group Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Other comprehensive loss 50 Â 50 Â Â Corporate | National Prescription Opioid Litigation Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Pre-tax expenses related to estimated litigation liability Â Â 51 Â Â U.S. Pharmaceutical Â Â Â Â Â Segment revenues Â Â Â Â Â Total revenues 85,726 69,766 157,441 136,926 Â Segment operating profit (loss) Â Â Â Â Â Total operating profit (loss) 1,075 593 1,856 1,420 Â Accounts receivable, credit loss expense (reversal) 203 210 203 210 $ 725 Proceeds from legal settlements 63 79 153 197 Â U.S. Pharmaceutical | Operating Segments Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Pre-tax credits related to LIFO accounting (2) 55 (4) 87 Â Restructuring, impairment, and related charges, net 64 9 65 11 Â Restructuring charges 1 8 1 9 Â U.S. Pharmaceutical | Operating Segments | Restructuring Initiatives QTD Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net 64 Â 64 Â Â U.S. Pharmaceutical | Operating Segments | National Prescription Opioid Litigation Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Pre-tax expenses related to estimated litigation liability Â Â 57 Â Â Prescription Technology Solutions Â Â Â Â Â Segment revenues Â Â Â Â Â Total revenues 1,265 1,140 2,506 2,384 Â Segment operating profit (loss) Â Â Â Â Â Total operating profit (loss) 205 238 408 469 Â Prescription Technology Solutions | Operating Segments Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net 1 3 5 5 Â

Restructuring charges 0 0 0 0 Â Medical-Surgical Solutions Â Â Â Â Â Segment revenues Â Â Â Â Â Total revenues 2,948 2,834 5,584 5,445 Â Segment operating profit (loss) Â Â Â Â Â Total operating profit (loss) 89 244 277 471 Â Medical-Surgical Solutions | Operating Segments Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net 147 4 150 6 Â Restructuring charges 144 0 144 0 Â International Â Â Â Â Â Segment revenues Â Â Â Â Â Total revenues 3,709 3,475 7,400 6,943 Â Segment operating profit (loss) Â Â Â Â Â Total operating profit (loss) (508) 66 (418) 123 Â International | Canadian retail disposal group | Held-for-sale Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Canadian businesses held for sale 593 Â 593 Â Â International | Operating Segments Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Restructuring, impairment, and related charges, net (1) 6 0 12 Â Restructuring charges 0 2 0 2 Â Corporate Â Â Â Â Â Segment revenues Â Â Â Â Â Total revenues $ 3 $ 0 $ 3 $ 0 Â Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | U.S. Pharmaceutical Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Revenue derived from services, percentage (approximately or less than) 1.00% Â Â Â Â Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Prescription Technology Solutions Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Revenue derived from services, percentage (approximately or less than) 40.00% Â Â Â Â Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | Medical-Surgical Solutions Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Revenue derived from services, percentage (approximately or less than) 1.00% Â Â Â Â Revenue from Contract with Customer, Product and Service Benchmark | Product Concentration Risk | International Â Â Â Â Â Segment operating profit (loss) Â Â Â Â Â Revenue derived from services, percentage (approximately or less than) 1.00% Â Â Â Â Â X - DefinitionCorporate Operating (Expense) and Other Income, Net + ReferencesNo definition available. + Details Name: mck_CorporateOperatingExpenseAndOtherIncomeNet Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOperating Income (Loss) And Other Income + ReferencesNo definition available. + Details Name: mck_OperatingIncomeLossAndOtherIncome Namespace Prefix: mck_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4 + Details Name: us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3 + Details Name: us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(3)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4 + Details Name: us-gaap_EquitySecuritiesFvNiGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (loss) for proportionate share of equity method investee's income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(13)(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromEquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-1 + Details Name: us-gaap_InventoryLIFOReservePeriodCharge Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in loss contingency liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - DefinitionNumber of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 54 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfReportableSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingIncomeLossAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of tax expense (benefit) allocated to other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 12 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99

-Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2 + Details Name: us-gaap_OtherComprehensiveIncomeLossTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCash received for the settlement of litigation during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_ProceedsFromLegalSettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4.b.1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.P.3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1 + Details Name: us-gaap_RestructuringCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_SeveranceCosts1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_CanadianRetailDisposalGroupMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=mck_StrategicGrowthInitiativePlanOperationalEfficiencesAndCostOptimizationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_RestructuringPlanAxis=mck_RestructuringInitiativesQTDMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementBusinessSegmentsAxis=us-gaap_CorporateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 76 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

[V5%4<61GE5#7'6__DK4E.Z:;\MB6A;UNE0GM;CUKHHZ5Z>] M-MK05PI\E"%[E"';H,,#Z-_RVT71=),:B)99,&[" DI.3W\P OU1WV32_Z*D.K/+UE[QW^?>_^?'@'Y3(MK!H VM&_R^7 M+$G.^U_VI80,F")A' D32)@$P5H2"QXE%G24V"FRVC+C/26<^>%HT-;"V"X5 M&&JQ2R1):$@JM0OYC(VB=BE.-&DT, H)HA ;C$9&1$DT/-9E6OT;^HOWK__:#F*T\M=!^R]>Q_E-XBI-Z0L D2 MEB)A' D32)@$P5JZC!]U&3O'OJNJNM\,>>7-MT7Q?:'4Z.6KNV7Y-<^].S4D MJM5QH>Y*51EU[WF3+^K[IN#>*$F)U!FXJTACZP(WKNX),ER*A'$D3"!A$@1K M*2]Y5%
[R4LJCU);8,T!H+GJ<#>HZTMD!HJ!8'2'C<21,),2+8*GJ<]! 5LB6/X M*(ZA4QS7C2#.&HMGYDW5+:2Z?\B:^USJS ^MSRQH:Q,UC7$W\\7HJ,QY$P M@81)$*RED-
&C0D9.A7S([^[7TWFSI%*#PW3KHE3-B@K8ELV=*^T[O)O%6+E$6AI)*3$'O'MY6LR,)[/%E\4L+V:5-\NG2[56F9%*':BI M)3&UXHS762M(6GK2$7!H3 &E212MK1M3?
MN<_I]]G65%W7EU:57M!]G+>C' M63OI$):H^41H[([=63E0LQE*XU":@-+DD5/5%HXVG'VG;[B=FDAE1%:XT-0% MU!,F IK/D8@BOCE&0 U<*$T2S=^[I6F?0.W,^FYK-BUFCF=2U_G=:R\8"'XF MY:9WO<_U;0.6)<8T/8&&3*$T#J4)*$VB:&VA:2/6=SNQAM!.$A=_AM_IA;(TC MML]H/F8F2,EP-#+'![N4'R2Q-480S1H.$W,U2;B?C,4#TX0@:$%\Z++6SJ;O MMC:?>UDC';PDE#!:TE(HC4-IPK=-8*7_R!302QBDOG9(?;=%>C2OX9_WQ1&Q M0;U2WS;^B#D$:H)":1Q*$U":1-':R7#:,F5NRY3,53JJ+T99I\QZ;L=L"]"< M1@A2,F3F
SFBE!_X0]/&HIHU#$U3@FC5&?.3V'0F"5H0,WH:8=IP9&[#\?D7 MMSM YP1$J'D)I:50&H?2!+-M23636!H"Q6R+;2_7=6N)?9_L)8;-?(4ZI5!: M"J5Q*$U :1)%:PM4>ZK,
[:F"DTF8[5JRV)R4H*XK%=$T2: 1.90F&)5V; YB M+^&D,NVD,K>3VB6GA-F6G#G_C]WA.@O@>,04&I%#:0)*DRA:6RK:.V5N[_3I MR25N<.>Y#>K#0FDIE,:A-,$(/Y:9H]%+I-TR[>XRM[O;+
<>$V?:KNB.Q[I.0 MKN0$2DNA- ZEB1TM=O:N1,5L"T:[M,SMTKHS3!AAHP[,%"1WA,[Z0-)2X@!B MTT_FT) "2I/$ 02C W?YVBQF;K/X2?DEC# G@Y&I!:CS"Z6E4!H_I3L$-*1$ MT=]JT<8O(T) I
ME,:A- &E212M+;2]'0_&![L$0]"E&*2D4AEB4A! M*%3CJ504@G8P%270CFC@=D2?>UDC+:,\QE#:!TE(HC4-I(B"R1^U4%%3,MM*T MH1JX#=8.5VR$I-AL2\\:]<>G%)JXF]I9&E
;%$H34)I$T=H2TH9IX#9,C^Z& M0\N&L/;\R!S4QT0Q:W:P+=CAP'I$0Y3RPY&I04X44[.#;\X.1.-9Z/LC\^*V M:4%R(,,DT(9CX#8< =^T'88KR.UUD#)X1,H2$YE":@-(FBM<6B'=O0
M[=@^/8/)#>XZ:T%I$R@MA=(XE"9"V^2V-LE!16Q+3'NUH=NK[9;!%!)^*!M8 M>QFX8W;6"W0O RB-0VDB)+?/-;M7HH*V);.WT:[;<';G,(6VD^DS<\OAL3M$ M9X5 ?
6+]"/S(R!SGT)@"2I/$$8P./#X,M?L;GK 50=](1<&A, :5) M%*VM%NU5AVZO^JE93*&Y88"I*A!#:6E4!J'T@24)H^\(0B)*DRA:6Q?:%@[=MO#IJ1'DDZ^0VNK 6KV< M4&CBF=G54]72A-
0&D216N_[4%[NI';TW4G,I&:.B:C]!.+0''2(8N:CZLBV M8X>,F9M4$Z7\:!09 N1$L;.A^3X903<^\,TOT1"T((GH43S2UFCDMD:?>;5& M5,IG9'4\U"Z%TE(HC4-IXJ3>E:B8;05IOS1ZYNN\]K?
3H4]4TC*LG5G!N@ M(5,HC4-I DJ3*%I;:]HXC9[P7J_C^J+R7 ,S9VA,%+.F!]N*'?KF_@8I4:Z1MQ\AM.P(N;FBJ*Y0V@=)2*(U# M:2(B4UW-;#A4S+;8]E[TM37&OM.OJ#["4!I$R@MA=(XE":@-
(FBM06JG=7H MQ5[Y12J42#ZUELY0[_6$B"DT(H?2!)0F4;2VFK3S&KF=URY9*1'Q'7_3IG>' MZRR5XQ%3:$.I0DH3:)H;:EHKS5R>ZU/STEQ&SO/@E#;%DI+H30.I8F(VDC!
M7'R]A&T:=LV>NI;P4A9$7L'^!$S?5IWS,YZ@1JZ4!J'TL2.%KN[5Z*"MM]_MJIW:V.W4NG-28MNO9.:W.,?N"%T% J6EU &8;T;FT) "2I/$ 80Q[0C$VC". M3]B\H&M&2FP;FXSE*!>L&G'
"'AA10FD31VEK1%F_LMGB?FH\2$VZJ^5WNL3MV9^% M%HJSIV6]4'\U%V]9SY*&YV9V% ?>68\&[-?!1H1 &E M212MK0OM*L?N%-IG/N&.J8T1S/N<4PI-W.WLK JHZ0NE"2A-HFAM_6C3-^[T
M,K&3-$/M/F#GHQ#%S >.1!$B'X4H1>6C4,VR\U'HQMOY*%3K#^6CQ-H4C3N] M4:OSU4IJL] *1W&WH?-H#TU+A=:6E4!J'T@24)H^\(0B)*DRA:6Q?:%@[=MO#IJ1'DDZ^0VNK 6KV< M4&CBF=G54]72A-
M9.O;15%YR_Q&X0>O$]6:]>)V_OBA+N\N>NI^YU-9U^5J\^L\SV;YNBF@_O^F M+.MO'_J*_U"N/V]B7/X?4$L#!!0 ("2!9UD%'R5,ZP(/8(8 M>&PO=V]R:W-
H965T&ULK591]HP$/XK5C:MJ[012"B=&$2B M)*AL;4$-VQZF/9CD(%&3.+4-M/]^9R=DT*4(;;P0W F^[\Z?PUUZ&\8?1 0@
MR5..9*)O1%+F7=,4000I%0V60X8["\93*M'D2U/D'&BH06EB6LUFQTQIG!E. M3_NFW.FQE4SB#*:;JB!(()"*@>)C M#4-($D6$93R6G$:54@%WUUOVD3X[GF5.!0Q9\B,.9=0W/ADDA 5=)?*>;:ZA
M/,^%X@M8(O0OV92Q38,$*R%96H*Q@C3.BB=]*G78 2!//< J =9+0/L5@%T" M[&,![1+0/K:DBQ)P<6R&3@GH:.T+L;32+I74Z7&V(5Q%(YM:Z.O2:!0XSM2+ MY4N.NS'BI#.G>^Y!%?
^Y&;L#F9H^#-\W'IW,Y],1FA-AE^O)S>N=^^? M$=<;C8?C&7D_I1PR&8&, YJJ;$XE0*,R@+N2H*L5XIQ":W M#,D$\;(0PAJ\=QC?.8 W491*&6NKS)5UD-"'O$'LY@=B-:UV33W#P_ OJ^P@
MW#T^NUVGQO\5/_KG['M:VM5;9FL^~S4^225@.Y*$+8@O6? 0L20$+LZ(][B* MY3/Y.9@+R;'/ *I[=0KV=CV[ZKU=D=, ^@8V5P%\#8;$[DVKT_Q<=V^G)'-/
M2>:=DFQT(K*]^VY7]]T^Q.ZX\3H.(0L%-OD@P880DAPX"5B:XC31+8*\CS,2 ML@1WA=[4WO.ZVR]R7>I<:E"NG6;CLM4SU[NW6A?4L?:#W&."O+^#6@W;W@\:
MU06U.E50H9JYTY=3X$L]007*L,ID\>>IO-60'NC9],) U>JZK1J_AT.]F,%_ MZ(LO@EO*EW$F2 (+3(5ZX9SAQ90M#,ER/17F3.*,T&PO=V]R:W-H M965T&ULM5QK4^.X$OTKJMRM6[-5,-BR\X
+5$$<[U(U 0A M9C\KCD)TQ[&SD@/# _OJ5'\3H$27>;;X,<:9UK/2QI.ZCMLY?3 _+'*^(H6\Y$\G8LTIF5>-5ND)]KS!R8JP MK'=Y7GUWSR_/\TV1LHS>G[O[8L']K0LRB].+L_7Y(E. M:?%M?
<_EUE7\6][VR067QG=$7\>XS*G_*+,] E!5_:(IC0I2@@B_SS3,4W3$BGVX\\&M+>]9]GP >P/<-,!Z@W!'@Z!I$!QZA[!I$!YZAW[3H*W&.QH,&@:#"K? MU\ZJ/!V1@ER>_P%\=):HI4?
K]JUM+!+"N?K&G!Y?\RV:ZX'-_=1I/;Z21" M\M/T[LM-=/4H+Z:/L_7R>WC%-W%:'PU_1W%7^[^F)C]&T:H4^__(I^02Q# M7UF:R@=$G)\4LC,EY$G2W/BZOC'><>, ?^QN_I5P
MV=RWW5WQ9;!]+(,*+)B!=W<_>;AZO+G]#5V-'V^^WSS>3*:V9ZQ&*>THY:Q\ M)M8DH1<].>T*RI]I[*___$'WO]L_$""19!@$TBP& A,X37<\AJZT"]OY5K) MLB1?41N;==M!U;9<$I\O\6AX?
O+\GB339N@%9JUDVO@XU(F%]J.AYZE&L?/7 M_$-?];>^ZCO'P-7_W+^EZMX(5^1RV4\R,.$!;2\R*0?$R*6:,WS9R;G+S1[M19\V0GY@V:](!AZ<%"Q[JE=N5C JSFP>[T..'TBP"!)L @D6
X$IS\1@^TP, MG.,GHA(T8:2,RFQ\,EMWY1,2+*K!^NJ8U(:DS>94&Y% G5*\)QZ?^CT_M4J MYP7[:Z?WG:V[>A\2+!H:GL7>2/.^:>/KLV\,U"G%^Z.M]T=N[PM1KAZK-6&\
MG!51LB3\B5IC3R=25R8@P:*1X>7A0"/"-,$:5S%0EQ0>3K<\G.Z9@Q:4<[G2 M%.2GW?O.]EV]#PD6G5IFF+[F?M/F&]]C0"@7BD$^%Z;M'E."L;UDX\^)9(' M5HA?1B+]
<%2WA5+RE'VMMJP@][L;(]' *!H48.F+!M#8\TWC8QP#:I;*A=MUNX/ MG%*.C->R,EZ3"PPILYAZ.4D9F;%TMSCC@V;SH&@1*-H$%"V&0E/);D4"WZT2 M/-"$LFSH/%C,L^=)Y^ BUP& E
G^/7L#)HIGQ2)+DFU+/ M7I/70%5#T#1(M_4!@88^SHMIE48F#*/C(R0WH(V"TAW&G9Y[O%R,:* M&ZTK*Z!H$;8(__ZIKJI9K9Q@=@/5,Y655AS ;G'@<9>DYF[7V?^@"@ VD_MC M/]1E-
9N5+GW&4!U3W=]* -@M 7R1S_]3>_O'0^@N3XH6H0M:7PP,L:#Q:IO M;+=]4PEI,WVL3O;KY(8J_]!,WI0M B;R?IQ:&RWV*P"?9WWR?2 FAD,
MFO"#HD6@:!-0M!@*3:6WU1"P>^O_GKS6M2"EOB:'HQQZQ>L16J+.S,V?%AN^8'D$E 5"T"%MR?5_7.B=6*U]7X:!ZIG+3"@)X3P%! M(@>(8&5X)XZJ$JI\4:UN1_4:5XZ?9Y*6@ZP>4+
(3!6=)N:E:&9 2@%NK3:_= M]*},(:B<@"TZ@9ZT6FST'0:H3JGTM3H"=L(]SQ/*)V+@_?H*HZM7(%*#*!H M$3;%@U-CM)DV?8.LCY 7@E9>"/;("[L"=W>[SB6[H$)"8)$(1GHH:#/R/7VJ
M@^J8ZOY61PC%V!F\Q>U-J-X,B_V1NANW,SV@.D-@41""H3XXK%9^7^?G(X2& MH!4: NR,U>.;VZO;\0'U[: R RA:!(HV 46+H=1<]4>M^]O>"6+;2E:IGSXKB@ M?(5F.9=@BQF-
GX^0L@(6B$C<%VF>/=5< ME=4E5I9 U0U0M"@P*Q7"4UT7M!B=GAKAQ4=H$4&K101N+4(=00>0 BH^@*)% M@456Z.OQW,1F958%0_5,I:45'P*W^'"_X'$/U366C%2]"MW@1L7*K,9N794+,
M*K:Z 3I3 :I2A+9JB(&^F6&U,BJWH'JF$M&J%*&['&*GB.=NU]G_H+)$:*EK MP$,]RK9:Z:^"Q5]4_W?R@BA6T8P5+P%R^0RL5_%<^-VY@=42 @M=0_8+(^P MF?G#OO[.$%3?5(;>'6?
@EA(FBP5-JGTD^C.IBKP1)P5%25/P+2.W#AM,5BI! M50=0M"@TY00];[*8Z%M/,52G5 Y;N2%TRPUU<7XYO+KL!28I$8(MF+PF EW5 M5?
U[7T1R=Z4SFZ#J1&@*#W))TODTC8PS,SY"FPA;;2)T:Q/EI#FG":^J6KN1 M:F4,5+H 18M"FRCA&2_(6,W\OK'8?81X$;;B1;BO?T7*L09>MCCJ/)$
MI'0SKT.\>YF%RJSG[6WPNJ@AWQF(VPXKT+UIVGBZ*_?#3/;#Q&YO_,,9I-]F M\?T]IR)4SLWFQO-ZT*/9@"NG3_4];9R-K5;&HWD0UN0@K-AB)1_-0'LT3]X= M ;BB_*DZK%&@ZG6;^MBU[;?;
R&OJF,0M>^O_:.Q;_D^\L\F]7&/+7Q]^N17 MPN54+%!*%)6WN>A?$1X?:!C?5'DZ^H PEE>%/FJ^KBD9$YY:2#_.?Y'G0=M% M>8/ML9J7?P-02P,$% @)(%G640%16K:# A2, !@ !X;"]W;W)K
MKFUS:^N M4*H5=U5IW*N]HFWKDX,#EQ6JDFYJ:V7PR=HVE6SQMMD M'512F[W34S_SLJCE]:,;NVU$9=-<)U526;W;DJ[?;5WGPO/KC6FZ*E!P>G+VNY M44O5?
JRO&KP[2%)R72GCM#6B4>M7>V?SD_,C6L\+?M%JZP:O!5FRLO97>O_F M?[4W(X54J;*6)$C\N547JBQ)$-3X+\SV1J[7LRO:;;G]2P9ZG)"^SI>/_Q=:O/5SLB:QSK:W"9FA0:>/_RKO@ MA\&&Y[-'-
BS"A@7K[0]B+5_+5IZ^;.Q6-+0:TN@%F\][H9PV%)1EV^!3C7WM MZ5)OC%[K3)I6G&69[4RKS498?)XD.6=_B(O >L%/\\ M6[FV08;\ZR&#O;RCA^51U9RX6F;JU1[*PJGF5NV=?OO-_-
GLQ1>T/4K:'GU) M^A^)S \D4+R7;=KRMU$8*7X]IOGB\7LQ86M:FEV_&[^0M@F?A"/ MF82/OA/:"2ERB&@\0@*3,5E@-*!,U+% &&BM(WFUAA)KV1M:R:0U.]{:MM*T+"0@0&>L-VR:"
M%:@;>ZM0,M[[%1E_5DG3K9%-<"1]M+$XPU1TW$1(DPM+3G.D9*Y*,DUHH!$@ M@^0T-N^RN#)9B+6%*FN(_E6)WSI9ZG;G=:@L_I,9%CF]*A5ODVO8F$N\GH;
MN#WX&RB*V,%H"M5:&_*/+/'4 ?2:=Y%MD "/SYAKV46$&8>P6OECV>N9 MSX\=)9V!@GC,2:*03]BH#2]!8$RF?&I]-I$+DE0[RSR=2J C4(FRK+<<9!K M6B[[NJT;#5WJM>H35>&NH=;
MZ$..5)E70,7AF67=UDAS89SJ]*.FW348'EYD10(!Z#74I[FEAP#C;*RRY&K MY2@:O#C7+BNM0^TXK,4G9'K8P#XDC:0QJ('_'I?I[PXD3XP-6D$Q];"94 M\I.%:W;[=FL@%R['.6U#Z)?
WF#$5X!&099T:ZS$"388B/G$ DO/C%SAL2Y!4 MZ)HP$=$"*" "8CZ;_H&<6.!N211G"I(V5MQH6-8N(UUD15*1LX M4Y0C+' A22C=7*RR][U(V;:-7G5ME/:8I%B#(7 7*1070Q"R;A B3PJ3<
M2/;0FT/)7+?JMXX N$+[LR3W%J8J"O$?\%!,,XJG;O)]:CZ[>,)PU8-9,HQ>O]D2]H)*6_? M7GA 7EY$Y@%9>_"4Y*FA& RG;@NB_H B%3M$_*1U].2)NQ100R>.B-'604
ML)D1M_6U$UPYP6[*:*2WS#D\#+\KS00$459W*I-D2!L7Z;KL%'4YCI[U]1S: M38^D=2"=$^Z3H:L1,",32&=?E:-: XBB/V#O%5J:S4^&[DPUL?9+=DIB9%,;
M33E@Q!G<5HHYZZ!,SL_>R09>.)Q/T8D94CE7MF0/-?!\POC>$/]0)O PR?10 M9^B2C3_#I]E#U3G0A&A,5B)5V4F,)2?B0H%H(1I0C4@IVR1D17X88EB3=GIN
MB^!0TXPHCL8,]5JO3#W@,3#+,9>_="U2!EGF'>8IB8SX]F!O\V!)QY#W/5LA M'D#'T @HA*(T:&4W:,#U5\3#/BAP&_MIC)^1Z8J J2L20V MLB;NN6YL%5IWM"XI3?7&(FVM3? H)@! *BGC6W-G)-
"X]0SDJ[G(D"9*D29 M@&!S*>6?NECD1A'])QA@JBO64H\3(?HN4GU"V1]D.Z2=-JW1G)<)ETAUJ7= MCGG1FGF,2L32>]#%$U7N4>[!P])F8+3RX7'Z#E,,7QHHNC1 ?P+-K5;P>$Y[
M>1U>'#)2$$A%DS6S0Y[[,$G=MY,3KI($E1"!HM6UC C#V()G$.CK\X83ZG.V M/(B(*$@K5G2"C(3B4V?\%1,7R8">QI@_)&HR8O$]$(X T@\1]\GO?9 Y\Z== MA]'Y//^I;E3W6K;.;ASK8FW)F/
YCU4[L3S$(TG M@UF>'XQ4Z'L=$ ^V0N19;GER&=XX-;@=18\>\.\=ZLXO$/?P&4FEPW22P8A M@RK^FM3A'"@0+2FH;AMRK(8""8/L8YSJZ^>%9CBQ#$Qˆ]S[HL488<4_0!>C M;X
BK[&9E:=4]\C1C[P#2_U2YT&F@_$3P@QMI:T=P^\<03Y^ M-K9)9;1!B;:*PR,W>+-)2#@<.4--->0.@"LX.CI.F$9!QQ2@5[]!?M"JECH? M2H63H>@G9*4##OF^.
[(T_2=^=28?.2\:@?I"\"%X%^ZE:6G:=]W"Q"R5$ULD:;3L>;$#B9R0X)A\ZC M@D)9O*=DNU<6R/24XO^KBON?"R%CXE'2"*. MGU^0/9JU@P_N);#G*+
[7A&1&:@Y9=)2=Z(NG3XT*=S24!.$&,D]4L-!J/2#< MN0(YIZ 1,VM2P5]\>/UN=$63>@S!/G)&272'1,] <%VX%8Y*X> U)I)TL]#7 M"IG(S"C,5_T-(1$!GL6B$'3'ZIZ/>:!+]#(Z:.A>XH@/A""A]WW-/
=5U')[M,9$H8* *=Z:1^<1/R$4>2&B O:M+:1* H$C2&DPJ =1^A[OH*I"UD! &8^H M%O@\)Q7Q@ZIR-+2K>T[Z#D4YM#SPD]0*D1&I4\;Q^K M'LY- _X94?
WQ*\& $+&.'D6LH_W98>JSZ0J,B=5_F(8:1MHPXZ+A1GA@UQ MV:6'!*M89][/2B9)\MNU7H47,SVN8>__JPK?J9'$-SG'NG;U^:XF+(PR6;6 MA0$LP9:'O9A>OJ+Z'AYCY;EN@+&'
S=4X\\M@6=_7@DJU*H)^"0.AR M>+@_GR^.G[(*AT?[WW__[!@S!+G@TA0R4&%_PQBXJ?YW2LB+D@?M?8ADDC7, M:(JPO^:RB,DD7&=MF=RP:WH<&=]0A(;9YVLXI F'W..&(5/C%V?A"Q)-
WQ;S MDL$DT"=&^CKT*R:SQT:R9XPC_LYJ[']I5ICZVQZ_'3/7R3'-T!8_]"%RK:M MK?AEP5],TP)\OK: N/"&#DB_O#G]#U!+ P04 " D@6=9H^<)80\(#9 M% &0
'AL+W=O*/RK^>JP&O=22E63\3TZ98-(4Q%8@L2_1[HGK5D0S/SRQSU*OG@\'8C MZ5(@M^)!:KH:!XCD%^,B'[]+QZ?/'+\0OUH3*B_^;DHJM\^/84IOS[2SYVYZ M4. #-2?
B[/183$^GLP/RSGK_SJ*\LV?DW;4>3[P7][:>*R,9"L?BUGO@_;;X MLU5>I4?2E.*?5ID@?B<36D"B>N<;6=#U M"%7CR3W2Z.;GGR87I^\/N#?KW9L=DO[C]!T\OM^X+9DI5#Z&1RLY5QKQ(B^"
M%7,2I?*-]50*NQ#SM?!\X-7//[V=3D ?IW=2BZ6S;>/CT\G[UT(BM(66WJN% MPDGI13Y0=7I93-XNU$*$BI03A71NK:HL(_D>%W!@&4E9+/(B31>)DYP$L(==DC3;RL :&5:5M5Z.A&_51M[BX0'
M6Q2M\V)5$1_KPM"Y*A2,>Y1*RSG4L4.JKJE4,E"R@&/)Q^("FQMGY[PWZO+0 MYE0@IV1T<4F&7'2P!F2CREH:\"68,8@*X2ML7:N0/9>BT>R,%6 ^'=7(E,&5 M"I6"
[8;$FJ0[$1^V$Q2UU21]RT&3(9X%9R,^R.Y.^ 6\6DBDY5']%MNXP@KK M@^\!TIX+2UBS?:-!NV5F!?.D65-&9LR=\;(>Q =P*3!8W!%RG$R29KUK%B<'IGA&;=DZ=HED40$O#&LZC-
[4/"W%#'25RBIV2 +:^7QB$X8P8AC?^!/QC9Y0TN (C MLA&JB*#O2/I)(<47(] '5SX.8M<'CJ*NS6QJ#"BS8/RA9.NH!EX"#R&7Q M0[GSW >)2U#<@T%*V5-U7"K)4U8
;^V$H6/N%+X$0VAO6E=4$^0<)& U(#) MGA2:)H&NCB:SMYA8M((ME<&'+3RB<28+V:@@DXDV RER-G*9IT-)E.^C.R*%SD=71Y= 8?TE&/K/A% M[@A&'FPQW MDTY.\<$\'+-
%7OE(4NS;Q=G&-P[_IE,?G5UNO1IV[@'Q9G,YP9/+]UY\XKBD M&0E*/2TY\L>QL/9V[#P;[&W<;$;>]GF@?9L\N\U(!C=O- J]YNQGZS!3&JX^ M_/)6JS*V@CN)!@? /?#,FS Y;.G,[R@YG@IR2V1H4"?
4$Z<5?5,O.# +5"A< M10I0:T"T;^6&7_V&'$MHV6H9+,[$Z@!L4J) MO6DTF")V_0^)95DEAA!* P*#IDZS-?%L_3QH,N:8C!UOE)UZ98)_Q>SLTT1 MYM3GM#R &F+) &;!J7F;!N$\
<.1**L&0_%IR3CBL+_!BJ_WT-3'A N6K*4Q. M"0F6R37219FCOF<^ICB886[?HBXD*]W=RRZ]P_+J&P[([+XGRAH\VN7Y.?W] MY#=P;^"\3UUXP8TKX_0S@0_$V9ZP5 I2T7[6N?
ZC.KG_IO*R$$;EE7RD.&:`M/3/_8IN[Q#,<^A+6BB,N KVP&F.%?R=>?3(=*OWK/97>W<+N6^;/V(OIJCNV73R-_$54Z7$&--5\J #G^,E#RD!%,R7 MB)
H@'!);E(CB(*G726#LG23<5GOE'QX'I0RG2V+ZQ;HK+K^KG>#.MYB-CWC6(\^-Q4$SH- M?U3C&,/[].6I?]I_M[M-GZLVV]-'OU_1J/B&I6F!HZC!*=N$6P3/U[- M;4#OC3\KPM3G> />+RPFO;Q@(!?
W7S)O_ 5!+ P04 " D@6=91XO)RO4(M "Q(P &0 'AL+W=O=A3'%6;^ODP7+J.[)@N5P9R95 M1@V(+K.,JM4G)N3R MLA-TJ@OW?+XP>*% =5'0.9LP\VMQI^"L7TM)>
<9RS65.%)M==]Z#LT\QCK<# M_L'94C>."YD*N7O>'*;7G8&:! 3+#$H@<+7([MA0J @,,/+[-3]\2)S>-* M^D]V[;"6*=7L1HI_\M0L+COC#DG9C);"W,OES\RO9XCR$BFT_4^6;NPP[)"D MU$9F?
C)8D/'N;IGVJ@R,:7B^;Q+;K."<@5.-UU"\Y3<,T$-2\G-@JHY MTUWR"S,7?0.*<7H_\4H^.27A"TI&Y+/,S4*3'_4I>WY?3"XMCJLK/X4[A0X M846/1(,N"0=AO$-
>5'LALO*B?;SO6O@U9@TWG&GRK^LIC((T^O:KRA9CQXID;SIW$Z^_VX6FT3 U]H!,[[4C!%$7!!.SJ.T62! MU]=Q0D/V<.6F!]O5>IM#>5*\I\D/[I(-$:0;B/^CI,J +- [XSJA B4.NWX1 M+C-I42CY"*K!
<*8*Q34[!A1&MZ]%&PEFIDSE_*LSG"8)< NLD+D5L6212R'G M*X+ES1-&I', &(0S190D@G8 M*#C-$]9MR&.S&4\XRY.5,R5]Q!$@%2PUZ'JK+WB)T0SKV%H(S$W!>AN2'I:F M;]]P"><E J-
"R2@90#AF@6%HZ!@6M4H%H&[:R*."$2)"LB(LS%5YZ/7+)S0(R MYD8J& K>)%!O#4&@RHPD7-@_8$S>.J:T971\PU&Y=(3AF,]4:D'_- M#+H*,J3;7-%,VTQ<>\2N?0JFEL!S>)D*6(1-
0&;0'XT*&O?(3RW(W;N4S39* MJ()@83X\]?W<#DHS)%4QK;WMDU;_25=_D*<;2#23I3*+[4@4O8!ER5I.!2 MQWT;0)0]./*K@ .MN#0C8]*#Q8"=4A_8U+ O#LXWB[-KJ]'XU'K,U1[B9K=!V M;I
69HI6;,L\LV#1U1[8578;551SS *>'A)9Y@UP 7/6H6Q4TSMKR ,/+N[^ MZ6%20<<:?VR4(8-3N01=7[VJA"E<1Y4,X,SWY7FT1YY';R,^2U8ZIT[_EOQJX,9Q_9^[VO MMZN2"$;YGF,F!3R"@MXS6
R*:CZ4;!-U>)M7,=%'6QGI,#@B=^"41/"UM;# MN@NH"6T'UY'#\ @:&*BAO*KDVN7DP7+3I)7TVJ/=^>F !/#!1BT(S_$,MGF M>6ROG9(?6P"W43B"T5$]I?J.[#J# 0E"]:]4 J/Q/"$DW"'-=!E!L_D
MG9*3R* N@(QB;W@0G\!_U'1 ('SX+[:GMQ6P.PL;U;$3 5\$/K 0 S;%6IAB MXX6MDF]G&E5KK3TYU[M:D28?T-SV7[F1:M5PD.L=&LVVJZQ.J[ONO*^O)CV? M0- 603ORV_NI9_-
J9^+YA*R2WEXH$>V! M$]\C!*;Y#B]^'$*,6XBP/@K;R#%X!20@Z0* A1C^1B08OQ45-@'AM>**T[A M$WDD&_E/.Y/+@$3S\:^*FZO. [:L_S,4_99]D9T$/0%!_V?T'-EKX_WI.8+\
MM\0<@C_>3,PQU'PE*4!*'JTI>0C_\!/ (V\+)6+[[V]:_IN6OR% O8X-WY24 M<=K;L>%T!S';[CA\G9)#*-H12)"CM\,""]Q;T#"$R39"AR"P(/#R%D%;(Q' MX\%? A3^=VCXH4F(Q-BM%??
FE'_%72"X3=V[J=7F-IG@=.JW+_!I7V*(O=U; MG=9^JF_NV+R!U\\^I.;>W01_HL)MDG^F*EF0**B:!/L\&8PK1G/=+=253>/A MN[H=X,>AY<:J1D /LN(O,C].J%
[4VSR'H_C(E\U$*TY/(7/R>B(W.#0@JY< M<1[ZH8.N;8@;-L;'6!MC6*D76"W&]"Q![:+&,'HQ=#WUM M-Z;:-#G0;66ZKW+^X)%.GP>[[\' (ZUJPF.TVI0[*N/5V]=X 6[]=DL5!?O)R=`U6#G
Q5MDU33>3OP7:-U]DDSPK;I##Z=ERV9S4F:EL-5" M#&^]%@Z^:/I;6;V)\:U%*W_1B3.F#%E(;;>W3XT%A$LYNYH3E-.<4]0A@L M2,IU(:%7P5W7LJ@B!VQNWB^M
F_(Z:8$%N"&HP&'Q/5QHO;;Q75;6_=^XV? M460,*AA_+(+D4.;&_:*BOEK_'N7:_0QC/=S]F 6*:,X!M 2;P=1![V38(X*\X4#H#[,RE-=8(*ZE_I7/T'4$L#!!0 ("2! M9UFN@JD$108)T1 9 >&PO=V]R:W-
H965TN-%HQD4B%I+S>?GW/D%9I9 MZZSM&,A;@856%\[,F9DS,Y1.EL9^=CF1%[=EH=UI+_>^.AH.79)3*= W 5*3Q
M)#.VE!Z7=C%TE269!J&R&$Y&H_UA*97NG9V$>^_LV8FI?:$TO;/"U64I[>]" M"K,\[8U[ZQOOU2+W?&-X=E+)!5V3_UB]L[@:MEI259)VRFAA*3OMG8^/+F:\ M/BSX4]'2=S(WYC-?0$E/>R,&1
4EGC5(_-W0)14%*P*,+XW.7FN21;OG M:^VO@N_P92X=79KB+Y7Z_+1WV!,I9;(N_'NS?$V-/WNL+S&%"T>QC&NGTYY(M:N=-V0@#0:ET_)>W31PZ H>C!P0FC< DX(Z&
LHKZ>79B35+87DUM%)<#5(M YS2G)1K;_%40&OG^,&FD+Z+TŸ !??'6:)\[\5^G ME&[*#X&DA3-9P[F8/*KPFJ]!F([Z8C*:$!1-VW=FP9JTR?=$U?*)85QM27Q M]_G<>0M"_+/-
Y:AQMETC%\F1JV1"ISU4@2-[0[VS%S^,]T?'C^"=M7AGCVE_M,AW?+BV:"P_7Z18U[$@LI1/X9:9 +;HC\2&W1!LI%$B IW).-F3A6MT^]OBG M*VB2U@FEPMA2]W)
M6.E)S/8'4 &/CF$SCWV3P"_[&>^'J55$GOI9O7BA\/)^.#8 MH85L5^S$DD"*RBJT)56L1%KCH1':Z-U$NEPDN;0+8@6%9'D\LU22!)>47@1; M-[* D,F$)V5Q?$Y9ST$/0%!_V?T'-EKX_WI.8+\
MM\0<@C_>3,PQU'PE*4!*'JTI>0C_\!/ (V\+)6+[[V]:_IN6OR% O8X-WY24 M<=K;L>%T!S';[CA\G9)#*-H12)"CM\,""]Q;T#"$R39"AR"P(/#R%D%;(Q' MX\%? A3^=VCXH4F(Q-BM%??
FE'_%72"X3=V[J=7F-IG@=.JW+_!I7V*(O=U; MG=9^JF_NV+R!U\\^I.;>W01_HL)MDG^F*EF0**B:!/L\&8PK1G/=+=253>/A MN[H=X,>AY<:J1D /LN(O,C].J%
[4VSR'H_C(E\U$*TY/(7/R>B(W.#0@JY< M<1[ZH8.N;8@;-L;'6!MC6*D76"W&]"Q![:+&,'HQ=#WUM M-Z;:-#G0;66ZKW+^X)%.GP>[[\' (ZUJPF.TVI0[*N/5VJ=X 6[]=DL5!?O)R=`U6#G
Q5MDU33>3OP7:-U]DDSPK;I##Z=ERV9S4F:EL-5" M#&^]%@Z^:/I;6;V)\:U%*W_1B3.F#%E(;;>W3XT%A$LYNYH3E-.<4]0A@L M2,IU(:%7P5W7LJ@B!VQNWB^M
F_(Z:8$%N"&HP&'Q/5QHO;;Q75;6_=^XV? M460,*AA_+(+D4.;&_:*BOEK_'N7:_0QC/=S]F 6*:,X!M 2;P=1![V38(X*\X4#H#[,RE-=8(*ZE_I7/T'4$L#!!0 ("2! M9UFN@JD$108)T1 9 >&PO=V]R:W-
H965TN-%HQD4B%I+S>?GW/D%9I9 MZZSM&,A;@856%\[,F9DS,Y1.EL9^=CF1%[=EH=UI+_>^.AH.79)3*= W 5*3Q
M)#.VE!Z7=C%TE269!J&R&$Y&H_UA*97NG9V$>^_LV8FI?:$TO;/"U64I[>]" M"K,\[8U[ZQOOU2+W?&-X=E+)!5V3_UB]L[@:MEI259)VRFAA*3OMG8^/+F:\ M/BSX4]'2=S(WYC-?0$E/>R,&1
4EGC5(_-W0)14%*P*,+XW.7FN21;OG M:^VO@N_P92X=79KB+Y7Z_+1WV!,I9;(N_'NS?$V-/WNL+S&%"T>QC&NGTYY(M:N=-V0@#0:ET_)>W31PZ H>C!P0FC< DX(Z&
LHKZ>79B35+87DUM%)<#5(M YS2G)1K;_%40&OG^,&FD+Z+TŸ !??'6:)\[\5^G ME&[*#X&DA3-9P[F8/*KPFJ]!F([Z8C*:$!1-VW=FP9JTR?=$U?*)85QM27Q M]_G<>0M"_+/-
Y:AQMETC%\F1JV1"ISU4@2-[0[VS%S^,]T?'C^"=M7AGCVE_M,AW?+BV:"P_7Z18U[$@LI1/X9:9 +;HC\2&W1!LI%$B IW).-F3A6MT^]OBG M*VB2U@FEPMA2]W)
M6.E)S/8'4 &/CF$SCWV3P"_[&>^'J55$GOI9O7BA\/)^.#8 MH85L5^S$DD"*RBJT)56L1%KCH1':Z-U$NEPDN;0+8@6%9'D\LU22!)>47@1; M-[* D,F$)V5Q?$Y9ST$/0%!_V?T'-EKX_WI.8+\
MM\0<@C_>3,PQU'PE*4!*'JTI>0C_\!/ (V\+)6+[[V]:_IN6OR% O8X-WY24 M<=K;L>%T!S';[CA\G9)#*-H12)"CM\,""]Q;T#"$R39"AR"P(/#R%D%;(Q' MX\%? A3^=VCXH4F(Q-BM%??
FE'_%72"X3=V[J=7F-IG@=.JW+_!I7V*(O=U; MG=9^JF_NV+R!U\\^I.;>W01_HL)MDG^F*EF0**B:!/L\&8PK1G/=+=253>/A MN[H=X,>AY<:J1D /LN(O,C].J%
[4VSR'H_C(E\U$*TY/(7/R>B(W.#0@JY< M<1[ZH8.N;8@;-L;'6!MC6*D76"W&]"Q![:+&,'HQ=#WUM M-Z;:-#G0;

2W)_='<&4"C/9=2U*2LT(H96EWVKM-W-V./'Q#^*6ACC];,6_*@ M]1XE7B"05SG/@^#S2+4GI&4&-KQW/WEZD)SQ>[[C_'&R'+0_]>8^5M.*M=+_KS:_4V3/Q_ HM;?C+-
A%WDO=8T5JGZXX8&M1"Q2]_MZOQP1#!/WB#(.H(LZ!T%!2T_<,>O+HS>,..QPMRXV0DG%5LD_*<;46#Y+8M;7D[(#]1NYBY"#(HX^*CNE-9)]]P73*/FOE M*LL^JI+*Y_0C*+C7,MMI>9-
]D^&2FB'+DP'+DFS\#7[YWNH\\,N_RVKV0=A" M:ML:8O^Z?K#.('?^?7&D1D$#6J-$*P,?6W!06Z96(&F% 5WVM@@ MH-$.1P*$1Z+H25@W/"AZ= 0-
G5!K!NF%5F5;."H9=T$/0XTVX;15PC%)CR0' M;%.)HO+X:U)DN(0:J'KX#736FX0&:7@@L[2.IAI82Y$!> "-[S3>.9=6LR]* M;U3@!97J!I3*]0?!NBB[A&
<,.>\HQ541C%6Q`_O&!M7X(Q>2^T!YK^W8UURA MKX:EH74KN8'NAAY]9PL&'S1">]*-6:97..#NA2N&(=1=ZXXVR\.O ((MK% M$94Z"=HZ?8[+-H0\ MX3XC))QMW['S3PK=4DKXQ_;9'VED-
U5'!XKJ'7"ZW,'DEPLCFN#">RHJI:5> M;]E2R];O6?:9O)+RIV5KUH'D<(3*(*."^[%_JPV\Y_H6K MR8<,/4&A)[S%-SM:_0-1-,>DK[7(%@I(9@#ESH=$NP6Y5(*[F<-AW+R91<\Q]9&MTVHPA9M,"3Y
MS_M* T-""*#KEGR_E>292C=)9C D9Q3N;1A ("RX MRG,J1&-9FD;WSA-\SZ?)N(_O?!8S>9Z'W5F2]@.9XC5:0IJ$? Y3L^F\#VVF;#8! MIWPQZ,-
\.CXNYS1AF<=,\QR8D[2#LHF'%EU.3ED>F/79_&@5B_F,Y8,\&'R> M#F;Y/!HUF>4AEWSV)7D>3Q=9W@_YET*J/_WX5,BVA+Z^1%[%AV,-XW13P*) M0.C-9^-TL8O9_S$[[RM_A<2NZO--
J*!VB=Y?PCNQ^<9&V?'IDKC:L8,>M./6 MM>M;W*Z8W<$%*ZNE*(,U72FS97AQ\."$USD]9->UOW_^C@42;B4,4#O'%<0] MXQ9W)2LD-L7*7R>A,[W0;J>.)7_=[Z8+S`HGH(X/R6\#-
@T0!W0(S5VDH ML),6+_]GD@;Q%K+MPU]X_'1_.)LF^ZSQ MW,ZFV1Z.JA-^47F8I\)83GXL?TL7+/*!'P@:"B\]FN8VSV)GOLL_$I*!X*<>* MI^^4,F0?,4W4(4OX&_9["9WA$B-
>S/9@7AQ^'O0CA7GHJ&.>I'0- L]DS M*#V&IM,#%$VG'@VCHZ[^#7T=GXX']@ 1Q*N M!88;22N0)L/9I,=,?-1&P.DF/"0?M,.M$)85H2D;CX#SE4:WZ0 O8/^?A:O_ M %!+ P04 " D@6=9_T, "+)P
&0 'AL+W=0$^<^/#EQR4[ETHU-J0KO^=IG M^_:UJ7RF" _79"E?EN;2W[U1FKM\<38_J"U_T=N?IPLG;UZ7Q^KZE_9-VARUHZ]=YD_]2IW[TY.CL2J=K(M*O-?S/7?5=1G2?
02DSG^*Z[#VOGD2"25\R:/FR%!KHOP7]Y$.W0VG-VW818W MS%CNP(BE_"")?/O:FFMA:36HT1=6E7=#.%V04RZ]Q5V-??[M!['7V0A:I^*@+
M622ZV(H+,I3V6KG7)QXL:.%)$LF]"^1F]Y!;B=],X7=._%2D*NWO/X%HC7RS M6KYWLX,$+U4Y%O/)2,PFL\4!>O-&WSG3FQ_2]X-V269<997XU\7:>8O8^/>0 MLH'68I@6YS)Y-GXMGL^=B,CZ?
_$W\SM?22HD/*HFD M>.M2+">3\!G/EMV%']7:5H 0,5WRRI7X\8>SV73V2BS.S\5T/.^1O:BVR*-V M+:VAS^EX!:JPBRH\0B$L#\L('V4^Q9*?^?C\'@%6O/),S!=S_BSV=/JERAHQ
ML0ILZ;,8G_;H_29O:_M!_O,5?Q9[6K>FCO3.V3BUZLOQ]#.[\$EGI_BLQ*K M\632Y]SHNYB*V?2,/XOQV=G *B:V6(C9#6_L_Q3XDTGNE9BN80B"W+)%*LO$;,9 MQ?*0;TZCE5:3F5BNSL20"O#-.6
0TU:8=::WDHJ#$[,5M)]-Q%?C91:28#DZ MA:[+T0HD?E7.O13O64\O2F.YI"QAUWI+UL^@8]IX/N7_R]-SMLG7'4 BVD@" M>ZK"*9@.648RX5>U-C9%>G+B=82+2?C>Y*4L;L>OG+[
M)M%%/DE4IZ*UA_IZTI/X^[Q>I*DP>C0&[6(8?-Q87?@ATB$0?>$;B>#D^%>L M5;P %U;UA1%:"E:9 _AM/S'LU)_7N? M)!&)2I-[4\A+;DQDR=%#=II-7NT'%3CU#ZXN$2A%
2]V^5M"-2%:TFE\7.SH!0,)XUB5*I@X,3!>\B7*W) M61;M7,6&CDG:RC82A6)=4[0;I+<+V%-;4-V4Y#>LNX9VXG@!>(X6&7?S251> M9_J_8$KTB699B]-(T77+GH6\V2J&NVL-
K1/I=J3ACD3Q!@JE2N5"0[B>2SK! M/^B_ATORGE-7?:>.8CJM52)SR@D 3F16 ,0-G#X'9J(3HB"VY ;_7AEM;\5 M$ET-:Y&'K,(*.$/]@2B@=5,J=]$H=_0HLPH^21);-1A<2ITB:F.\^9TUU7;'
MNSL*,."BWS$?L>RF&*2.)NO&P8:7+=E?!=-$_]JIZRB56KTF"-6HC M 2$O 6\5JI73-R(/;;6BMGH(_PAK@-9D%P0"J8B-NH,_Y'W=@$ZAK@=[QS& M7'K\([6X1'TJE0T%:TS@\DM5J-IS\R?
BRJ$>ZGY(6=P/*6?]Z&/K#/(^W$7= MSWMU+V]LZ_(FUJ.]I(P1<5;C1F?_ TCX, C^(HN80Q$&HT8/(&"[+038DS#P M3\'?'!UJ;<$ZIUJCQ%I[AM84UOX'M24W=+Z,(2ZGA:$(9N]"-A;5B@+U$,&
MD*EMSCZ,I9_6\|(^R_V$PK4^QL['9T-]>;3^?C@OJL+9[V3H6:XD3OFE:=48"0=MV6KJ+C9O*^TKOE\[ST$DW&SPEK8^=A#8"R9>;&7QW85R![=S)$8C#H6=NL%4S_TLM]P5
MS;V'N>N"JIA*"PQ (8'*=JQ?>O*# _T6Y!65)RB\IF.8)(;*;* M0W<-"4@GZZ*8 M^]QB7R!+.D8:DN;-#2:6" M"%PX2;2-DQTD2*^UY.+JP+3 MWOSTK:0H]2++0.C1(J"@WS;<22*NI!A(B'V!^;&W
#UININX-CD?@UEYQJ\(B['>PF&X^H4<*=4EH_ M:EW 5N';6+O?%T47QJ;@8.L3*F0NOZL7S!L$4%JJ'+ZG40WW"._@)NRG;B"$ M%(A#GLA,],F'86RT]7PVE09 MP3HBY8]*$P9P;_V=;!P E"XT-
8.C)^K+C?>=;GO:=-MW2MQ0W]0A.'I$U)B1 M6%>>TS/$,&,9]]H$%B!H52UL*!)W@\:J+.#J =2AS%,M@HV0H^O_=*J[NJ&* MRFNX;Q0]I]I5V8'>YK1.[T"^V4L7IHRF
8#4U1#&MR<9WC'>O=B=IN>Q+Z M$FH@/AFV;W^C0C7*[M6I+T&&K<@S?Y/0Q[/3:;-S.$%[%H_3]EXCW.3_^1D?;/_9>;ONZQKR P(, M]K(/Z,PM7\)#2-Q)%X;F\
[&XW.]D/^QWL@<#,-2T&'H4/P?DZN>KQH(K0P!Q M"\G0?FH?Q_8 IQ;IHU3G'+'-L]!=U=PZ\@V/#9@BX\YF@.#3V$ F'%-T3I^I
MEA2U"UU%L*E5F!O:R4C>UL<;AP#\SBQPO%]<'+'_Z3YWAV1G M=R<6>O'3]/A=*=M@&?+^X.#:6<@ZALE.1X! M,\USL_!4:]8'#R[NW"K"C;*F<(&*$7CM
<%LC\=M>RS++0F7XY3G5G>+.IBP MZ,>+\:1YGH)Z3T>Q[?"8!(J;2#'.HN)XWCYSZ=0P1T=O>0CQ.(V';;#F>UG(M%+U4?#R$POL.F8D00'H1X+CXT"U/STP#-$TI!@[E%YE2:NL[FXY]G7'I#2U
MCP>,'!^']#*A$X+#S!"Q(> XWWL\B'WWPCG+78\HA>D\Y^JG[EU.:65KO' , M\3 9BD,^3+<1('O/N*BV#^PT=N^YVCU/X/KQ&-+H3E=,C58" Q22F!]6D1K! M'*UO0J?9GR4RI=
<6404)?:4,1Y=A8WTEC'QT\B*HD"7IIH_O=Y1W)BU */CS) MO7W^(8@B0J.9H@I\O!J?-S)4^_(_D=_\$?QF'9T'^#W^(:[O)G/2>4&*IREZ#0P3"25!>%>JN=J\:7817K!JEX?7U"#?EJ(N4QMLG:#?/1(V
MO/H5?GA3\NM6:^,Q[O#7G<*X8&D![F\,1(X_B$'S_MW;_P%02P,$% @ M)(%G659.'@.?#0 R3 !D !X,";]W;W)K&UL MY5MM;]X$OXKA#=8)(#C^"5VTJ8MD";;;>^NVZ+9[GTXW =:HFVB,JDEJ;C9
M7W\S0TJB;,EY*6X7N/O2R+8XG)=GGAF^]-5&FZJV)81CW];9LJ][*^?RER?B+2 M\IH[_N:5T1MF\&V0A@]D*HT&Y:3"H-PZ []*&.?>O!/I4JHENT3O2">%???B M0"
[^>I(§&6^]C'&'C!G[H)5;6?:32D7:'\"^E1*C4NEWH[W"KP5^8!-AGTV M'HY/]\$5.9.2-ZD0]ZU,/*.8_C9>V6=*0!5SC*N4K9K/[N6-LFT+8Q@_J{< MP^N G'^W>
<5/>MH^*6;32YOS1+SN0;I88>Y$[\V//XQFPXL])IU6)IWND_[(MN#U5!KB'N95@"@&?L407Q@JF%VQ>6!AL;9]^OM+KG*M()BT3WW)M1O;0!*,$35PD>;&#D'M>;(.@,TBR>)-BE7B8 , M4 15
MB[$ I@#' 2'(3(H1PAE^2(Q(I2-/0E!=K2Y73B8RQ[@HK8YS88CQT5_S^^#_ M,/N W83 7I6! .:D,[&<4'%L!:J4%:H7JEC!"JLY28#H!J&%?!K<#4"3+N/%)
MB4HO"D6\C3#TLZ#=$&N44P++%G,K4PD^0MQ(E60%^?>**W T5Z74 ;LB]2Q. MMQ^5Y.HL92L./N5 M>!U"4KP]$Y@,D@P*W$ B58$+:0"E^'[D E0&!"MW!&(
MC,BU<8"A+8N;08>4XIG5<5X]D$442B, 2B$-'^$?2M6D3#'-%2)):4 -#QHB M!EI#T%1W!=F6",/X@W[U>N9&+PU?!['=@BNR,@B\VW*01GA$2B='6'EQ"-'4"'60@G#LS*EP65ZL;#0_V! <^V@-F
P5MZ+9AUH#S6"R86"X'" M%T:OVSR(DVJ089B>9W+I>>UI?L4<*ST$B5I@\E&24HJB8A!H<"RRHB(*?=CG MR'Z!F# _C=SL9BC%L4$2=*@U*!P2AB< >A9,9D(O=BNEF)9,5!;59"KSK03(R
MIZ>D:(Y4S!U;<&F Z[("X3!(UX@*K!\[!Q!7TCE^W%&MBTN<:5038T^L;9 JGQF%)ON\D'KZ%F@ M2D)W!(B< \[*%HGB\H$;UYDY+_JASH><,;76#^(/]MH"[IUP+DB;HAKU@;4 MPH*Z
K2&_NR;>[FO.P0:NU:9AG&[@N$!\X>!4]?(TF'HZ.V"^E;M?1A%"Y M /I/L,3;E>0(37ZGJ8+B)R@NXN^ >D(@@&G&T0,MJ&>J&$[%6^7[ML!6FOA&^3;7R&UO[%8S %4Q7AL'#9$ @:]#-
$N2D95,I@6?*)LWIFHX7\AL5 M@!"WG-_[? ;MM!(-[^Y[ERM?8:KWH8IB)RD7LAP"T U=5#1];J"<07>7M4[8 M^`5[BCX (Z-6U9,RQ$S@#U0KO/"1:[5#MD,".2?!.U^4/^MBDQF'CM]O&5O MLV9
^X^UU%-U=[EKE I0)NZ"RK>/XUH,VB)=8]9$*M8Z[4NUKE(644=W$<,Q MW84,DRI&%]4Q[YW@;8\%@EO=-;4HB$=(5?I*U>UQ'D1C?!TD5J@@F!8^[!'2 M[TNCOBB)COT[>"V%#@F!E?!<.E
/V@O(+(D"P<9?@-;?U[3^SN?ESM*GM8&K M;,-FV@>[O:0U:\=.'[:]0@#?^<9]09 MH.;DI;K]VU+A!^">(TA;]G6,I([!TO;PO%Y)DJ9D0@+#6SGR@99(96+D+^P M'!-
N(T08%!;LU"EMM3Q^^8+K9^\\6$L7Z\ (@2S ^T:L<+,.&I8, N?;8=]8 M[S@E=AKYG=[&8=A4EC-UK+&>&%GPL@[+8&SMVV'5K(2A4J#9437IQWY.N#'W MR \^5-
U1J8+2[DK!CO(Q=E!NO2RD ;_7D!FX4H"$"4M$# 6GVES:Z1!#8^P MJK6;\D0"^:PQ3[_.A@/IFSN.[K_O?2#[&IU'?4I%#QH)J5W/X$4.DJ!
MGV8#=E,8!'\S*A"3TLZK@U'D.M#N^X*DC5Q*#$ZCAR(T0O_I^Y6J5R&P4QM5 M;I?Y/AWM(*Q!UZ;+$7\-KD:#X?\?KC9@< 2N* H(*.3^WXA0GE<4W4/UI*TM M\JU0V+!"Q- &1R2FQ@) FP1QH
M_-:T*TR- *PO,#4!"%F!XRK=.'AQC5[%66[\&XWSO3Z]-+J@Q1E/847FR[)4_GB? M'."]EQ?S3";(#8(0%_P">KV@*?%,!9>&-[AA]+QJ]1VG$"@D;*UZQNC8JX?%
MKZWJP,X*]YFEZ\ ;3B[W<9YQ0/L,XB:DP1?U"7UJHU"4->P^8,P*'7'9W$$LRW1= M:+S+T"0],$'BTJ'&@HY5I?0VC8*SU/<4ODRI/BM %I2RSY4^N7G6!QOSS7 M\JQR'0+>G4OE.Z_MI<@!
[M(`_@]G7 ^NQ4]+P6WR M8G'?RPWMS#!@'Y5?BHZF_19G(I@R03[I9O+)Q#-Y'PN1SZ9<@PJ^ ,9%<=>K MS;<6J >)&0W8O:">GN_ZQ/Z\ EKH- M&FC@SP\"NS<=4(P^'UH>G(8(.H;:4\-:
="A1=:"D]; M@1.K>RUU^QGQM#_]WUYH7'7QND_VNL;MU;[*$['_!S^S'4X^*WTZ%;%BH,=G ?B>O?-^'6<=;K%X&'OH8<^;H1 MKS_CB+;5D- @D("(C)[GMJB'GO9>SGKRT7#K6>L!.QP/C^#/^
R?1Q-\GO426A]IV/0#'BZB9)\0_P0_4,,W8? MH(XI*4;CB^CIIK/.E6]L_QW-:/KW'@SV$4B(+@MU+$:QX2MO]6RO\ 8-]!JQ M!%M*P#?;PABK5,J6Z#N\1"M;KA:\]3MJ[);N(C]\T2#:+(.Y:!/HVF\"53<+
M'O%*$X.7%MOL?U0U>OMS!V3*6X$B(N4NI(36\8A]@LZ3R[2BMQIK)YXD0)8I M0'H6IL=ESP&;X8'^:$KG^;,7=*Z/>!O1%Z/QN&-:[/FKJ;W\Z"O:F7'V))[] MQ1D;C4#FV1G\.SRO\=:?
3<[K.T7Q#80')HFE5]*&=#NA_#B9AFL*>ZX=?)\' MZU2;G.[D$DR_9^)'^; S3W?R=LI^I M!.P/@N/%+:+N?H^@" V7:.EH+-5I4);ZZ3I3UY&$0=O5Y)/H>OE:F"5=H@]7 M4OU-
\^K;ZI[^!,>7K_N+_E##B^QJ&5B 4.'@[-ICQE_<=Y_<#JGR^IS[9^> MT^-*<& 2?&&*]H$3P@>7DFCTW;F:3-Q&WWP\Y^@$A(1 ,"+ #:UO[Z/1< 25"B'#>;F7Y(M+'+ 6<6YY[Y
/;\Q]I.KA/#LME;:O9A5WC=/3TY<48F:N[EIA,;(VMB:>WRU MFQ/76,'+L*A6)\0%XM%)S:6>73X/SS[8R^>F]4IJ\<$RU]8UM]M70IF;%[/3 M6??
@H]Q4GAZ<7#YO^$9<"?]\\'BVTDOI92UT$X:S:Q8OYB]/'WZZISFAPF_M2W'CLL^,3K(RYA-]^:E\,5N00D*)PI,$CC_7XK50B@1!C3^3S%F,J2W,/W?2
MWX:SXRPK[L1KH_XE2U^]F%W,6"G6O%7^H[GY4:3S/"1YA5$N_,]NXMRS\QDK N6=-G19#@UKJ^)??)ARR!1>+ PN6:<$RZ!TW"EJ^X9Y?/K?FAEF:#6GT(1PU MK(9R4I-1KKS%J,0Z?
F62\M^YZH5[+W@KK4"B'OW,1#.$TY*9*@5U'0\H"@ M1^RJT;YR(}^Z%.5X_0F4ZC5;=IJ]6MXI\$HTG MCQ;/[E#XO%?X_"[I?\4T7R2(_5H)]MK4#==;5L<$YG!=,B7Y
M2BKI)8:Y9VL2=QW$T;RB,+;DNA!@KJ_8RZO7[%?3R()=+&&\0WN3W-P,\Z!- M)KJ2PG);5%M6&(0 AS5FS7QEA6!*7 L5ODO=M!CQ%??Z]^9:M!&N=*)DWW8ER MF=RQM5&
(0^XI>T$."%KQ9^M##8E!$O@2:)P@+9N*"0FW#A RC<& M=GYLBWJPW)R'(CQ+B-&LFY)#,F,3H&7?11%:ZW4&_:*PY3L-7=5$%#0!](2 M^T1:> :_]Z)> ;?.^?#P_ FBIU(A$4#:@\>+A]V#
(P#E&A&,KK9'"6!"Q8K&6! /-,"Q1U5L,+'M M#=A6"B\LHC9$M([./^;:F%D]QFS,%>K,V?D.2C?<3FQ!-L#O<,VC,8K>^]C MFU8&#XXG*[BU6U*V/QU7*E%YWV!-8\VM1'H41">!_;)-2_R+=,
(C*Q2/&#-7 M ==CPH9I[]"/'(FK$]_WL>F;[^Y6)X^?D:@8 4@8A:[,7?#&\!26./<,?%+ MZ&+;/:4# EWD9,WZ,3RXX;8D_$+$AXT@;]|($WYG3.N"TJKC>BFT Z[P6,^RH03.?
Z^3LTZ:+3%S,C:D<15AM/E(-K M4,;3/I@TD*3P+5B<3!@B2V%:5;**8\)*"'KBN)+_A3[&Q@DW\, H+0V]T&[M-1+BHUB3OH:]E1IJ2,C_&>"R"W;$B!;+Q;,?1;DAU%^2NX10=!1&3I\%]UIG MM!H
SH"C"#5%-@ %DM/AW'R4*2NC2K?KK.02?AO1$RO/'$6\&!@!S6_SJSG; M(/TC/SJ/6A?(D#*9 <7+$F@ZMH)ZB2 ^"(-5;#C>BJA)4\ 9!=?;Q%1%FE<
MSU<%F5SJ$B6CC8K$@%%QA*)GWYP^OCA."0NSQ?#@WO&X7'L'$@X@(-0![9* MU>=QVCS!E:%$M0-Z!F)"29,[IPQTWS5B/&]? #HJ_!)LJXT^[B$,N:KC@^PL
M#2_0E(#QR1D%AI. ON(J5#%75$N[0Z&P:5=*%FI[C BRDWZZ$$V!G[R$8](E MRJY-]+D&7TU)D 3/$>715TX2/3B?R1#Q<%KXP?%H9:O[KQN4@*GX0W@EV"E8 M*BI_F 1UI245B(R6F!A">]S,
[S$@!%D>MB-AD7QC[M%VX?F3X7F6BSY:):3 MMY1HJ_ M'P.O$$Q3&,8NOX N(4)EY@HX65$85&MDINX<]T F<\1H+4?6XB2--]*3W6,\ M!%-T<%*4-(W\V<*AQ MY?N3IE@O@P($_W23U9?
E=28]+SAU-%P2O2+11Y.&.M3%D4!ZSTOLW>+1 _^+.#1QZUI5(C6>,Q1(RN7&)CRN)5#2)9?D62 MWWSE4YB])+LC*Z)!D(T:=*2D,;@F;09]DAZ1BJ,#[1Q9SAF(-6,%)=BJ-S*]
M/^GOAR+9!@1:KE'0*FGIU?)*]X:&PO=V]R:W-H965TI6[?N!W &)!$-9YAYB.;^^CW=#6 P MPZ'L)-Z[7VR1Q "-?IQ^H#'?;8ORKEH94ZN/ZRROOC]:U?7FF\>/JV1EUKH:
M%QN3XY=%4:YUC8_E\G&U*8U.^:%U]G@VF3QYO-8V/WKZ'7]W4S[]KFCJS.;F MIE15LU[K MV2)7I5E\?W0U_>;9*8WG ;]8LZVBOQ7M9%X4=_3A5?K]T80(,IE):II!X[][M?_07O'7N9ZV|<%]FO-
JU7WQ]="*G4+'23U>^+ M[4OC]G-&\R5%5O&_:BMCSV9'*FFJNEB[AT'!VN;RO_[H^!]<#$Y\,#,/3!C MNF4AIO*YKO73[\IBJTH:C=GH#]XJ/PWB;$Y"N:U+_&KQ7/WTNEBO;0TNUY72
M>:JNB[RV^1*?U1NKYS:SM375=X]KK$5//$[9^HGS#3JE(_Y*E) MN\\ !HV!T)DG]-GLP0EOS6:L3B8C-9O,3A^8[R1L_(3G._FC&T^P7_7<5DE6 M5$UIU/]>S:NZA/;\WQ 79)'3X47(HKZI-
CHQWQ_]9"I3WINCIW__V_3)Y-L' MMG :MG#ZT.Q_079?8E[U"C:5II:-JRY4TGNJF&=VJ>G72MD\:5J4& R$XZ'TY::H ML06+^616G<@6@'\JU6L %1Y8%O>FS&FO&&'S>U/5?
J\CV3PV4<).ZQJ+C=6' M:$OTLR4>+1;@I*[!20TUV^B2N8IM$@-D\6B/T>Z .E52VCGX.2=4E2ES]0(\ MA?KBN;?8A)J>^\GOYMQ2:DKO*\P=#W9E.4-4_1>_ZR][ARSZM* M32?'_ZV(?#"-&$.C?F^P
U-F.["SM$6J#%F^>MWD)MBM&JGMRB8KE;,V95D] MBA)D@!E.12PQO*ASHF.^DR\ UZ:$?9HN/_'+O5T69=%46!N [(0)'IMLH?02
MGJF"^JP**%K$4%Z'OHLX.U:W=IG;A4TTE*TUJV#O1E0Z#'=9:'U!#%6KQ9] M]6WRJDD2*/:B(55I"1S!"I1=@$Y\AQG7I/[$\LK4=69(CUC/,5^[ZHB&K 4. MZX$?OS>6C K/;/
5#*6JM>@N?"S&8E!D/3;_KKS5*UTO<&)@G*(&^RE!1& 5(M]HX5L0P]NPA* MM2DJ ONL##"$VZQH?[(2FX]^\VGIQ[HGRW0) \,#*06@8HF% ,BV& M0)_F-(@%_ ")>ETTT#)0-D L?
35B(K4H+,G;SYK"&=]S-6/[4*/B %,B _#+=).V5G 65@ M]"TUJ48.#,[HX:(DW"2>.>>T8\Y7QMR!6C#($T;4M$QW8 Z;K4EJ@!H(EYP8 M""6^.ZA@ 5)TBUJY* <@CN ?-(/^G=%]@"_-/<6.
(M6D$U9@0QFTH8[LJ-) MVY5AQR$"OL/65P60U*O(BL3 9IJR'/QPV"L "P3=D4$&?3.MOGFE<8K64;.Q M^G5E\HZBQX 4*3?[4*^/D:8[I>BI.9L 2"L-T#VM:!(O(%'L/-7.KGT/&56
M%;3&O85:Q"YC2_1:%ENT:K#OF&2'E2$ P;J?\W37/MU"M3G]#"4$I@WC);DG>"R*(D6' MV:=Z(LD.QP@OP]H<> JW7N7W,#ORZ0C+:\!#0!.*3,LBRX@CXOW@:3\5;;'?
MFALH0=60YE7.)VOGYMFN$V1Z>*I"S%Y'463$MK1'2]+24@5:6*%WT9*Y7N^M MJ;,"*Y"BN+AQ WU8(VO W F@>[LJX!8UN!W6E+"U.PQT-PMX7EA(Z<+0TM3P M"'Z@=?2H#38#95@L7%A#
8:/]=- M;A.[05M6$Q^(P%V98[DA+XATC$JX$RPJF-101-?Q]=8?L,:HC:"/P739ZR M?X$W.B9OM*,HI_!; ZQ; -"6-E4?P0;,H7 <;:DJ M&K'YG\>W8S^_NFD@_$*]MTDAZJASG6J_6L1$7K"B>1"
<%3!B\E;.OT3I #EJ MME?R:6;!U824XJ1N7D->GH?)?N)<)C=+)%44 T/Z#1*L1.6-K31_T>1DX5"4$VDH!-&>/"QB*-W76M&?JZI)GO;9$Y"%^XKU.[N &0/>K?)$UM&CJ
MTL&R;#:U>EH3M(V:]+=QZ8JPZZX--C$3JJX2$R?6U;.==W?-HA%<&*"?VPB;)Z;RD.DR) M7I9&_OJ*>.8FN0T#PA2LT] X&OI;DR[Y&1;ZZ87H6N7#7UM*&$OHQ"@.;2/4 MJ%RBWMH!+?
G<(94XEJQ9SZWFF32Y?=B=A >F+&TM,><>I;3&CW%MX >H)RFH MIQX!P@9*\Y'5 +R:C4XF$^=L6M@"<]<6KB<5N(XYB=]2T=44\7^DF:0,)?Q(M6OA*1EKPP*VVE*?E+C>FE39-
6364X;H$O^4RI6"I"T#;;[O&0E'H1MNT'71P MVQ0I1+M}-!M/%.C-V,$STMR:#4*'.9;T-0*! %]9 N]W$GA1BOL9*S8;KA1U MUST;7X9U'>)CK9,+B(.*JG;=(F8B[/ \AC3;IX6ED!F3?"*8+(AV)[O(F#+
MV*XZ52'C"9($ E&1S_O$U)79 #G6-N&D.I.?)-,@ 0@0\-.MH_$%F."/_1<+ MXY0^*2J7HS'/YD8D)>XM['LRAF\[I *CR!B"T*1KLP-&A;/04^/X.>_GF[ZI1EFB[1BVLV^-I3' M2E%-
=N9<*TN@=DEEEW/@TFPRO8#++WJ_#.TZ&T;+K-BIG#E@)*5\V MG/K510Z]7]3,P)IJ=J,_.!!L.Y-]EOUV3@B<7AQ(9-H/<<:RG]X0;>W8 MXY!QI@,Y3-?4"!>1#%:^]M#GCX=Y7[TN.?@S5
X13]3S6,1U9AJHDZKKO0G> M?Z3F+MGI<,W1$,H?MHR7(WZV2SKJG5H\TQ36XL>1^@F)3P8^C"@.12(DQ<-H M'7*XK'GT(&"7R-4Z;N!J,X_.PR%JT ^0NK6&NGTB3MW\!IJRZ1!V'1-R1^1 MX
GF8#ILA+=&N]EQF2J5K9)5)#;K;%G=LRNE$L<-4Z;>W(S4VV*L9J?'U\?3 MB^/)9'(V/5/CZ!E?6?2%IK84X 7]6;4%]K%.==L,O]UJ3SJ\D6B+8N.<6(' M_7ORII<.X8RY(U-
Y(+N5I%94PUM%5#EP<94GZP8QCTY-MEE9./P;D^?5+KM' M/JG%D*XH,5V9?.<([8YYR,9CAX")7%H.7LU+3@&&XSBL>2:.FGP=,9H1HC?O MOA_L$!=J3F[SOFHR5N^
A3IOB(&S)]Y_N)7!VJU408)V=F8MFP"0]$1WQ=Y* M\'EI\-JLW@TY)HC(<,TA0OUY*0QB%"'@&9!=PTXW7C%@ _.Y0@,J!00IKJA M8W*;F'!L7#5K>K L:M>$\49O#VJ(G"<-
>H(0I38;BJ6'.01L:?/@D'MS1$TR M./0P/"/DA)'2V-:CU06\FTAM5/ [N7L?IZ<#\5R",)78X/.T.%:A-/:%8O9 MF2)T@&-SQ<6'DYRQ>JL9TZ_ 7CJK!/^1\ ]F\U1#[V3=0P'38
VB#0MP]EZU')MH>"W[I(JYHW<@%GX54_3P!(:EV.)=1-=.%)ZW&F/> ' M6CV/#ACG8"I!LHM2B -JJSN(J-42'S8^7S'[=-G@).^/@P:BB1,JQ)(1JDT!5W5=!1FX1A"PT%W:DUJWA; Y@WGC>\
MI8W$"BQ5,/.F)!"XQ&?7&ONMLG42Y;/2+W*D_%(7?\PO41TG;*G.R@2].3E>%^G V' MWZV>50+RI>%>+]@J63PCE,RWI5(Q*Y0K[S<4AI#^!B.2(HX+Z@ZE#2TPMJZ-
M334'5'3<7*2IA\S$G3VVAYD.N *7?I4]51O71L)'HP.DCX+/I3-QU_TC6G4R M[<4Z[ISG R>FO0-3MDAV^QRS43.4"[KUD(Q%@#J6 M*,11'13HB'ZO>E9ZY[:8MDX(;V#9R&[..(G5D!9 ZL9,MXE==&-!
((C"_5] MP0VOK7'9_ZW9JI_.1SKP6Y; ,+;SM@$ET.3,8&"#LG-)<3FFRMVQ%8=#^PHB MCG>D7E 3WHW>8?A+_Y-7"*Y;@B.0*.#\I^0?IJH*T1?"\5^.L=']\24R3,>NAB.LS3'MZ^@5-^\&VB,-&
M/E2HBHS^@%@/(KO>PW;.UP\B>(P'9^= _!@^82P/F/O(2Y5.X_P_C'Y+ ?PP& MAIQE)X0X^5Q > MM "%Y!QG>K>Q?Q(2^TD6]3SUF[P(I!S,RIG_PO"F.NH9S
MCE$GR'@@9HBG^B+.\!/3ETUZ4E,RBEQX6WVCOGJ5>Q.IOAY G5Y\H:ZIR2NO M8Q")-%A]-?U:/5+G\,./U),G9^H-M.Z8.MT./7 V>C(|5T]&T^F)<L'IWXB&! MF&]T]_CZU5D@G5H7$MUC"J?
KFC0&?M-"XW'V%^ M2-6@(P[>A?,D< IS(T2)FKKID Z)T _.F#*6Q(^H?UE0M"GDS9]0TUZ,S)*9M M;]MZ>C5N/WAQ(,'0=58FG8LE/_!M-F7[,+H4+V71E1*J;M=8@M@QG 2[6\3
M$(1W.H;D9\O=;*9W\N*@X]Y*KW3G .+ N81/3H-7DD53:A J&J*CV' ?>=OF M0-$()W)QCIM'N2W$*L<$XD YF1SBUYR*O??<'LX!!P#0^GL8HD MMI.]?T6#TA/.C=WQ^I! 7=V \AAW9%(HZ=/4X1J
IX ;ORBU# _J OO%*B'->)S]7F_>ZUX[\[=XKN223+[K]?STFW 'VV>ENHG:ZD,^BT=S MLRQJL8VHO;I#0W13X7/;0?^/;:]T>D02NU(((0F6C+[>V-3W5W3]H+' U2O/ M _$63RY [-3TG-!B>M(5
'D%OCN5>H>3X!6?8*A?ZH]A# M:+/SFO+!9&:S(KL<*I=?"773R\MI:*[[<'USU3;7D<-<"^BZQ/UUD]^I%_KC MP#RSR>0LS//Z13S/)[9\(/UPV8G[78WEZ L9R?3D>(*9+]57+W_\>J_IE%OS
MI;VOB,Z2N.;%/@!&_6@ZHK^@0Q'3-EE3A7LL7(QQ9TZ']"?(*0.'^,#1]\Z(MZ\,0SD_)&PTPS BOXV>OO .JI.\YJB>[-MZP)5;EP)D/)EGE158LY99<,N;G
M6_\Q5L\0ZG:*,U+_\X<>P<_ (SEU!BP0ON"C^191*G"871.*$&=',.4 .22 M!]/_=ZU]P,Q+6CQ-A[[\)Y,HZ8KYHEU;&G"]/+UV+)M0B' .W.I(0=9DM MJ7S!CT_
MA^$+5S3)J.O]3B\&YT\N'6=D@W1:'=4%+C@V9$TDJ MHZ[85(8<<\0+%T#EX91(6.S\(^X R/-YPSTI4-[,:.'YMN@K4165_P>X:M%
M*)O29FIV+CT4'AX%UIKHU'Y_3CH)7&A&27*5=,];RLKS!M$HGZQ5I!R1UM%1 MB1P80HQW.<>#^+"OC$YT2*WIF+AMYZ%4Q"U8EX9\7KAL\Z%'># :BGXS:6K= M1P;'CO9&QJ,GA
Z]$FY<2UY8,9+X6E!{*ZIE3U+"^1YW'@577(/"@ J'.\<'L;[2WH6H4VA4X].YR%^D*[=U^LQ9T5 M'ZZ6[WO*PW:],;5M+9H8 <@OK8\6;%4U1BH:[<6EE\5\+OW@[0W%/7JY23-) MD"?
PCR^NKT/((5$DQ7?EABXP=-PEJ1W?HI0+2L3ZL';A1+5KK5B.W.D*]G LM P!26P+L\(83>J5LD.! WA2]O;H)S_/GVW6WH.-Z//Q9V0?\[MX)-JEJO_U)4
M\H.NZGY00M7(_RG*.SF)XOB9^E$ZT0<1VJF?T-%K95>G)4)9PJYR*;X?%M20HH.,\0C3SH'-O$6&&M=6)GTEN(CAOT=TNU>&W9[!NJN=,1M\ MF5.2R1Y77KG>3J+B4SD,7%E5?
U',O$6XN)?)#8,FU8C-2F>+00<(?IWWKHX< MN WBFL6&DZ#P,? IW0N+;JY10>$ MKCK%[,+^K0"816<[Z<>LBR)C"'N\?W79E&G?O7$8<2';AS-,0M[IV7%R?SR9 M7$Y.CM]?
B05U)-0BE%C8R97+'Y]$87]LXI627%+E[^NU!:L_[J'8,XW^F&LZ MC X,K(/@P+%.2!/<10I=17;OR@0]7"A\!\A,T.,D;@J9{1V=?"{H=R-8H2'$ MUJ1B3;AN-
B\G6N#^_K;\RGM[(+)/IN>XJ"9R&*%PW7@KJO 'G7X:+,=5<* MN@V,?= BM_X]=YE)G*GYT.E\WU@_0^&GR,)&A%R M3)3OG@OO.,"WLR[M\"5K6Q,U#F,BS"H<4T?]]ES W? +:NC^05':?
Q(NP(8) M,5BBZ@7TR`6>G/"/ >A),6#/9<\K\#=:@@^VH<7P2],>;.A,(>K[JO(>\!F M.,0K+"+\OW?:,_@\O J3<"68PR^!AO@>[WO3=K#Y^*BEWDBWO
MR'"W"B*:PWK<@)L4KOPLU?R"==-U%6(#U$_"%1I_B.3TZE%!2=%0RJ?OLK. MZ4FY/";LU+FK==-Z/NKD$H9P>FZDCN/>.]'OJK]8 ,

#ZFS_W5@'[U]X=U9)FZ$'4=?3F<@5P!0^O.S> M(.]T%%?QB[GVE^F_)Z659^V$T(J02X*'7Q/6B3U/A_*2YW0P6'O&O ,E%(4X MZ-3P4,2I2-$1'CQGWR!5C73OENR>97:/3-KTM4B:}C5HL>9';X^@Z[LY@6W(ML9."NI.QTPT5NLL"Z<5Z_V*[#{YNF[S7_X&]L'A"T3DM&W)GOXS9M=8E576C M]3X_%:<]L)6-(][-XT<&%#Q:L#6P_O(*JG&M??DHCWRA;\5:0XIT[;@NYA" M1Z0RHA1T^,^QOA?>>>5FG05K-2W[11/2"BUY${$]NX><1&9Q[QC##Y_>@7?1 M:S8(2(OBC@[2@*+\X(?B5/IG=RPY]3,8$AN!AFJD 8=]6W]5XZZ^DJ^-8= M'&I?E>5>!\QN+)M:U$M 5[*X<:'97QO#Q!U'4M:85!M*?)BJJU2#(, MF_#==PP^]Q1OC*&Q7ZME*+_K?TG!]PT<71?R=AEZ'TEU]"?[L4*+_NM=I'!. M!4GO8DV2P:W'*#+T\\'T'$PRD&4M^U6 MJ!95(A=X=#(^/SM2I,$>4S[4Q89?]3DOX&C7_"> $@Z·!N!W>G>=_T +A'>L M/OT74$L#!!0 ("2!9UD#"W]Y]@H &LN 9 >&PO=V]R\W-H965T M7 MPOY2O=`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}"A8@^NC,IEYGQ_SI%$T.V2^C(?T)OY&U)K*:#+T\\'T'$PRD&4M^U6 MJ!95(A=X=#(^/SM2I,$>4S[4Q89?]3DOX&C7_"> $@Z·!N!W>G>=_T +A'>L M/OT74$L#!!0 ("2!9UD#"W]Y]@H &LN 9 >&PO=V]R:

M#^AI4SG;'LT'@ZVE+K*_J:Z/EI1=]{3>6X:C44MEJ$2H3(G;Z?<V)6.S$_Y MV\0;#[I_TVQ"WE44I?C)X>>;;53H1TI%1:MZ ZZIM[/_,?G@YBJFYUKIH" M!I@^;/-6\(2!4_!_28/?*

W@"!=G&E*S$O2K5$IVG8B^@#'5C\YEP;7O*%Z%2 M:4U%=_D?*!J2%9M6'!.,' RSMH=<;)\@X+Q#RZ*HF@JK;!FI,FN6(-_4P"AP*

*MO3HOX\B,98K.D5'1'K>KAB(S\]BK0%U&WJ)1X,)*5F%< ^,-09!OMG\)6YU+ M)-QY; 0QN^/7YFMOX\ZLV${CET$ 0U3MI;G>77]\7+5W]HMY^^5R)^Q4;@=Y*

ME'#M'Y^>)&VKKA;>U/$&SHS'?1X?9_8 8AL,\+XTQ]\6&U]GD7U!+ P04 M ^D@6=9]EFA4G@&`!H&0 &0 'AL+W=OH)MQD;=.CW8 @KAM#9[14Y*W_AEI\>:]5@FJA1*

M&CVXI3IN-$[D%)2QU?A6()\]O0)C=9G84HM\LXSG*;L"R2VD M;#3G>@9FC[W'/&E?\XD$LWODFE;9SKRU\0-N O5.YG1OV-D\A7>?O MHN6-^6%M_GFX5>

8B@Z+>GLL[{7Q%GE1XX{R8N>XHXU#YQ1^@@KP+ _SR9(MA?GTUR8/> 7Q9@548X>FX FD=;S(;\ ^-MTI\<366L MV63[LZ2+>]\U)3VIP<\-(+//1!XH^P]A9R";@FP Z,?@0L41A

*MV1N2If;.?ZHD|@_4>\BNG:C51-HDJGV18fU(B:5O=MG'SKC#+M&P#%U?6I%P MR=K!+KO$%"1.%*Y#7$,RSY54LR4;*UG2G&'O("7J-^-2SQS;W:MVN,LN<@LZ MYS2!*

[T9%TJC%]BULD0+-Z!YGH!;&62%5$N -XVG* [>3SLLP.OUJV$8A$SF#MC;6V&=,(5>T>N26#O:,5C]>^36&?18$+(S8U#57=R,D\23!)ND*

*M=G)2P*O,A%L/&T1HU'UY!VP_JE:WPP9O97@0[^,O:=IA&#[ZB=WP(D]DF6+1 M>_MK>ZUBB"NZ]AM,IR(1D"=47F0342.%%9GXXHU!$J510NH"-D$9?*)N@"29*

*MLD"O6YIH((HM/J$J.W$(KI2@*9 ':71SX#,|>+AMO!>YZ91TGE2EXB>T"4>[Q"4 MYEN\ ^'(=8KC6$>Z>PO7.T7ND26#2!=@68OP;L&#XW*YPOR$\=J]{Q0%>4=7)*

M!M45#G^)O'OPFKJN/GJ_*JE_,^\:"-N7P;@ORCH?P,/09L/A\>(\Q_!\PA M^N/9P!UCO[&'KJ#?6^)#1DP1TDJ_&'KJ#?6^)#1MA{W+ M$fLD)Z??J,-Q0?@o0?

H1X,J9U"":T1K=Q.G,[_Q/R9@QBF_)>]H#,!$!M4A M%%E#]A*5(?NTT3!(1SLU!1; +26JI:*N=]TV%!$"->LR(HHG_ABB)/4C.D_] MQ)TG<+_;43NT]>2B1PT1-&:-*

*XH8CQ6=C9/8*LF[#'1)SZ,?]_DS&*I[9F&M' MV ANK2>30W_8_4;T&_?9>*H[2D(_I'5{(_<7<^9[G#6#07S3ZR O^2ZCGW* (O_061EDY,O>[=@ZZF=DA6H\X,;.M(B#\;C**##_9Z9!?*

*(/8=Y4J0X/R8U55]h=;W9.@;($MG$$EOI-S9^F'[&> M;R+\2D,/5#Q. MV=@C\G;S= MM+0.'+'@N8_*PM [SLIS?'#*NC_42S_!5!+ P04 " D@6=9 M45)%. $% #D"P &0*

'AL+W=OGJK&"2[S68)]J80K^ H7:GO7B MWF[B$]^4UDV.EZ?Z6I,TI[E *7J$T7$G0N#[KG<\1"$<$+GQK<7L=5LZP_W_?I;'SO% MV/.O->U#@FC7"?

*E+;]IC&XQW,E3# ^"]N@FV4]R!MC5=4:DP<5 MEV%D=VT>]@SFT1,&26N0>+_#1M[+U\RRY:E66]!.F]#JB?\-HR@Q.QY9V=';CO$6_*

M"\.G)$^A3^=*D+0V\DQKS3B$>--6G,6HW:.?6 M##+5U+/=.W63G[D5R%"'"%)0C2: A)E$R.X*5=^*G' M2_]3^/";FUPHTVB$O\YOC=541'\?2D/897)X%T>L$U.S',]ZQ!R#^COVEB^>

*MQ=/HU9$8)ET.DV/HRQ41M6C(;;6&RY(B0 -<@BT1+IG6!UQNX+Q2C;1.8Q?Q MH2B.[_+=K[#9AWV9I?-+5+&F(&U$L1Z>VY>H-Y*950FWM8*=&X.0,?L'";+U>-*

*WGB3AR4Z.=22.8'F M+Y6NE686X499DB^80#+'(7Q@.B\AC4/YP'.8#,.DI3$9!CD99NF4QG@XF2QH M?//%LGL3)*S<3#>,T@8=ZR,\U7&/1J?SN2"55*\.$@7X\>%*K/YD-?A.H!U&'*

*MD=03M$:9WP.5HS2"A=E6_$.M@GJEHZPDRCZ%*C^S]_&4GJ/=-'WN1+!Z\2!;= M.Y=0HJ%ZI9@=IP\G-1H%U(;>7D1\AG-9SX'74XU4CB44JO:XI6LX,SU?LNV M@*+-*

*'&RT:FHG4G\TI$\%^99+\HC3XD=%YYX,O:l)].H]BH+*4,.*"1SYR?@8 MZ;*.=-EOD^Y*ALO1G<0GW#!=.%H\ZB:'&'=]DWU@W0'S!V 6VM26J+;/M@/' M\DOI]U^3+M.>S*

*^\.+O,"Q>PCNMC('S/&^?)AR*NP@.SU[Z6XH\]^?GD$I> M&XCC<.;SB,;^-)H,:)S/ KWFJ9^=1?' RS$5Q8KZ(L\]I(U&# 6Y.)=(D2@P M21(O3PEN-B4YB^!&LX*>*?*

*2$\2W<.A$DJZA/Q2FD0H.4]^(^A+)V' MH+)9Z@O<42)*TI"Z2-*)T5,NIK5-W>Y. KRU_'V\=E22;&ZUNJ.4R&@N(?G MDWBQ.I/_CS)P4W*S;.6NWKCT:A?0T-*

*6NVQLA=.\6IU#RQT<^8$[M-WIL,A8 M.H?'HSRC\"Q]-VU]@Y9^ES"?A<4V/W*VF+?\1"$(Z!&FZQ.7(''!3TUHN:)*O MZ=8(]?('KW;N&,S)(?C6,$WWB4-<4\8H0f1=-CK4-*

<9[+R^BP:_-+VEOEZ,P M"..MFNR?L>7BY/;B'[R\Q=,/I+A.X)M-H-/>H,.;,@A6U?X==ZLL\R7_P)02P,$% @)(%G63_(2AST P V0@ !D M !X;"]W;W)K&UL?*

5;;;MLX$/V5@=HM$B#57;= MV@9R:;!9)&U0IJL/BWV@I;$ME"U)!4W?[]#2E:>1MCFO,@T,4&:Z9]V;"@+RNI:F9HJM:!;A2RTCG5/(C#,]J M5@EO/G5K#VH^E:WAE<*

*';JM:Z:>+Y'+[_8Z\GLWB%Y-KJR:S328>%*TVLNZ=B4%=B>{)?O9QV',8AV\XQ+U#[*AW M&SF6U\RP^5J)+2AK36CVQ4EUWD2N$0%0%D.1UXK\$.P.EP.8*.&F$DP4E5C#*

MA0U492K4][+#C=_ S>%>"K/1\%F46+[V#XCC0#3> M$;Y.CP(NL/$A"<\@#N/F"%XR"$\<7G), ^6E"RYU]Q#^OEAJH^B2_'-(.(>5 M'L:RB7.N&U;@S,T*B>T)M_>!?EX:BA*

*MG&L&61AVPX^S?<.;7*J62@5$F;/X<.[<1S%GR"=3"#RDU>P%^V:\N7%UMK8 M,?)S0J5XH3!TTIUQ1[[C/B*?T(W$G[Q!('>68TC2Q(WT%TU_M'R@25:TK1VI*

M/W]%=\^>=_&:Z/L/6IA!GF1M4_ZBZ"\I'2]$HGO?/-SFE@\AHK\^MDGM07^13 M+V+4GW>CR!/2;.?) \S_UH8N7>[D%WEMOB=.AL1GV4\C"& M+!_#'5*9=D5-*

*TIU6()>6C/:!#3$.:F/0WB4AO$N";*S$6G-SG*"N$.MS^:* *MZ3302.5.1T9QW;GPUQGTWCI.(O?,1A,7D\<-U8 ^1HQ*2RLT4N@HRRPGFK5+*

MJ4JJMR[Q]LCU27@EZX.)9]\ESZV@S9#N-?$P#M@E6KF?.)6&ACW,4@T;Z^HC M$Z)EG%N$Y!#"ZO!YIL$, ("2J5!#7,FI4.]=4-1635IBN\PRK0]^^Z-K5BWG7

*MJ.G"N2M2SG%%KB&EBP>]:Z3=Q.C&-.:^E--0*W>N&_GN@L@:,7?26)>KQ0WB_@9%N;_ 5!+ P04 " D@6=9XK"#CO,& "#%@ &0 'AL+W=OI1%2W6Z@ZZS*AFUS+YG4=F<=DZ;9&*

*(O31/S(-;'#[26<+TT477 M /.6+'"#V)!\]D<(L-/D@(A;5SW=!L%*Z8"7=5=!(<,JR#NEYQR3P M@GX#O5ZJ;<_2Z^V@=\,4?Z:(W(GM%$YP,MH0D5$MACBANLPD3I7C/PQF<%V M@-"?*

VZSBF/:W,\6P.M,9#=EE"^)&,_7,6N/W[_RA=|Z@4K]4J=|$?3R%,(WR MA!$9D]\D(ITF9)+!6#M:.^YT0841-TJZM]+S7&SWJ9/,\>)(> 7P](94Z5S MK V_4!4N2,]W2\?*

*$+!@1*YGH6B9Y'6#4"%@ZSD#(0X#(*RDUNUP15XO:0;!TX,/DQLRR50[M&\! CR2^Y:. =#R"2?EZ(F'*KXI#?LX@&=MS&X3"2P*#&<;.=@(P X!EMB$)K M%A0'1^1\>N,HCI B.*L=G)*

*(#,@(I4/%@T*1X2/6"Q.#GFMZ0?B&Y"E+*#[5I M254$#(=.^;^A:8/C5RH,5KJ#$,6H=VHJ_@C(2UQ,@AP.D2$2/!-BR.F:TW@FD-"5,-M9'M#*

*MWPJF@4,*F7*,*^BS>|;,,_LF>6AR:K,]*$BXT6|VMR,F))1QJPE(RU#$04W$ MM4Q-H09B63!9F9P UCN5U!'27#M[U21S8"0S$&=]EN,C--Z0*

*M'^%/=]"SD5B!WM6TO2NB%%%5B\+!DC@:&7':PE)2"!Z8*1EPB,K_M3-G_," M:KU-C3?E^M'FN&!?N!)+H#ZC[7BI€-A)@$*Z_7+RW5J.4z/>$?Q!S8"Q MW\/Q:*]:A9G.F,:1]8?I-*

*S'OUYO/0:.NTM<0&R+%)Q71K<[L]5JQ^:_/]3L M"USJ/9"@F(,LA!HB F+4P0C/0/8&!K'U*ZED^= M:8?< "VJUO? /,;4(V8"><&0SV5[LSG? 7!L3%Q_1,,0.U6PQRY*

M991'KI/13|CH^LR'|\2.5!/"O9X 3@@0IQ^^0-[^QJ>VEL81H=O^_P@V,%6 M2-$N63OZE25P!"BJNU56IR/B^T!S-Q?|V0='X/B4MEP2?*

*QW%EPGAE[_3>0#^P;&>]EP9U9YDV4&Y%%B*PN.&YQ@EAOB M,/#=<%M.Z%8>!E.FYO;Y$Y(K0LZ]$9:KY0OKQ#TLKK>[YUD(ICG6PH3%<-3K MC* M5>]tTTV.S.PSXTP;(U.[7#*(8T;X'LLX;I33)!!^>X|_AM02P,$% M @)(%G62!XIHBK @ !@8 !D !X;"]W;WK&ULA5113]LP$/XKIS AD%B3IJ%T!U$R|"0AH2 L8=I#VYR.2P<.[.=%O;K M=W;.K$AMD:+89]]]]V=*

[T8KI5[,@6CAM132C(/"VFH8AB8ML&2FHRJ4=),K M73)+HEZ$IM+(,F[4BC".HGY8,BZ#RO)2-56<(GW&DQ=EDR_35&HU3CH M!IN#!|XHK#L(OZ.+?*

1[8_J7I,4MB@9+U$:KB1HS,?!57W"1S)5Z<<)M-@XB1P@%IM8A,%J6.$,A'!#1^+/&#%]7SG!{OT&_\;%3+'-F M<;$3Y[98AP,_L@P9[6P#VKU#=?QG#N\5 GC_[!J=']M)*

*&EMK"K7QL2@Y+)9 MV>LZ#UL&@VB/0,PVB#WOQI%G>;2,;CG9 MVF:@1[!"96B-EW!HX>G$@>9I%%KRXG3#=(TX,1#C/8A]N%/2%@:^*

*MR@RS]_8AL6LIQAN*T_@@X"-6'>A%9O!'<7(K]>&W/-XO8I#ON8F%#7 MU=Q83;_D]ZZ8&\AD-Z3KG*&I6(KC@%K#H%YB,#D^ZO:CRP.$DY9P<@A]7XUV*

*MT3P(M)OF4X$P4V7%Y-OQT2#N7EP;$$HN/EO4)3WPN05NJ/]2I:F>P"RP4FG+ M_Y*0*F,[X!!2IO4;EPM8>IY,9I [VHVHY:/+F5U!1"4'^;4YAM.#2YVDK;_IOO[RB<*

9>]H.GFM9:4YJI MV6RMN>7T1#[!=-E%DOAU$ W\VH^_>#49#&!7K<.MWBQ1+_P$,]2Y6MJF3<0 M1A=-*

;W17IV9D!3\@DM&^9D&G4NS@/0S=1!!*LJW^ES96EN^&U!@QU4Z#[M7"FI$9R#=O1/_@%02P,$% @)(%G6:U$,P"?P J@<' !D !X;"]W M;W)K&ULE57;;N.V$/V5@:98;*

*#'LN1;FM@&;.\N MNL!>@G6V?2CZ0%-CBUB*5$DJ3OZ^,Y2C.FABH"\2+S-GSEPY.UCWTY>(1X] M;?P*4.HKJ/4RQ(KX?NV1D,W. ^LJ$6CK]JFO'8HB*E4ZS0>#25H)99+%+)[=*

MNL7,-D$K@[<.;%-5PCVN4-O#/,F2IX/O:E\&/D@7LUKL<&/A1WWK,)=V*(6] MT'AE#3C3)@0JA1!D80!+O'-6K- M0$3CJR-FTIEDQ=/U$_K'Z#OYLA4>UU;_H8I0SI.K(K MM-

*K'+QQ:V7&>@&Q\L-51F1A4RK1_\7",PXG"U> 5A?RHD$?>K:'(\KT(8C%S M]@".10F-%]5]$WDE.&D;(*C6T5Z8;&V5:4"13EX$*: M35!F3VM3%,26Z55 M4.CAW9W8:O07LS20459-Y=*

*JC60OV)@ E\LO3PP118/=/B6S'.'JBO,K/ M FZP[L-PT(-\D(.X V[" PCWO# 1D"RX^^5E]KZQB'\N=SZX*B, GH!"JV1 MTV?WH; JPM_?H#$>D*

M,!"B"S1KP%AS^0RH)B.$M=LI@Q)0.UM:3RP\A]"1:G'0DE71O!D MH(9#IN@C0R&,0%M!"2^MKQ5!'<V>&0ZE<<5D+1_[6XM$ZLG<0).A?4U#SE_# MNT^&FE5K0O<70!4,1-

JBZ\H6O@@G2QAFQ^VZ<8YY<;?M(ZDNJ+'[L@OX!:;3 M,7TGDS%\MF9_&=!5KRF,>Y-L'I->E@WASG)T7A$DO-[PUSS^I].K.(F2[A%$ M91MJB1Y-7FD=M2X%%;@(\L'--

|JO^T_Z"2_>9S<0P\2E0SUO,/;T\E;K(I;# M2FAA),&IQ:GE6+-XD>3)QO46+&R1HJR*F+(CK,&'.,& FFJD:H=+&WE.. H* M++58C7'>0TTU9 LJLP+8>O^E=DM/YB?*

5W#Z^$AXDTVE';7?;/43+=O[^%Z^M8I38O3(>-,Y(==?CA-P[VD"S/2Y+>DS1U0#=[ZP-3QLVT#W/-MBW\ 4$L#!!0 (^2!9UG#]'\Q4 &<= 9 >&PO=V]R:W-H965T M(7(EH2$

!0.OJUW$LMTFL9..\0KIN#LG1 .9E)!T"FB@:1\$_JP MEAHSW6^U=)QBSG133E'0F[%4,3-TJR8M/57($B>49ZVPW=YMY8R+VN# /3M3 M@P-

9F(P+/%.@BSQG.GZ,F9P=UH+.XL$[/DF-?= .'$S9!,_1O)^>.)K+5$2 MGJ/07 I0.#ZL'07[QQT[W@WXC>.,KUV#U60DY0=[645G#]>]I'^PNE.NHR8QF',?*

*N>)20|K_1HD.&9%9M|)V4LL M}>E:O%AFVAUA5HYMUR NM)%Y*4P,LA@;:Y0(M&M4EU@9/@6[[6?7$.PL"7:N0Q^<4]XE188@QW J?-K9^'V'$Z82+B8P3)F8 MH*

8NX"B.B|$(F,$$WIH4%0QE3]12FS;72_"QS!'JKZ36C1UX0UE.L!?L:@&= & M"9UYA82ZORCS,I&/<@3)LP%ENXRG3#=(TX,1#C/8A]N%/2%@:.^*

*MR@RS]_8AL6LIQAN*T_@@X"-6'>A%9O!'<7(K]>&W/-XO8I#ON8F%#7 MU=Q83;_D]ZZ8&\AD-Z3KG*&I6(KC@%K#H%YB,#D^ZO:CRP.$DY9P<@A]7XUV*

*MT3P(M)OF4X$P4V7%Y-OQT2#N7EP;$$HN/EO4)3WPN05NJ/]2I:F>P"RP4FG+ M_Y*0*F,[X!!2IO4;EPM8>IY,9I [VHVHY:/+F5U!1"4'^;4YAM.#2YVDK;_IOO[RB<*

9>]H.GFM9:4YJI MV6RMN>7T1#[!=-E%DOAU$ W\VH^_>#49#&!7K<.MWBQ1+_P$,]2Y6MJF3<0 M1A=-*

;W17IV9D!3\@DM&^9D&G4NS@/0S=1!!*LJW^ES96EN^&U!@QU4Z#[M7"FI$9R#=O1/_@%02P,$% @)(%G6:U$,P"?P J@<' !D !X;"]W M;W)K&ULE57;;N.V$/V5@:98;*

*#'LN1;FM@&;.\N MNL!>@G6V?2CZ0%-CBUB*5$DJ3OZ^,Y2C.FABH"\2+S-GSEPY.UCWTY>(1X] M;?P*4.HKJ/4RQ(KX?NV1D,W. ^LJ$6CK]JFO'8HB*E4ZS0>#25H)99+%+)[=*

MNL7,-D$K@[<.;%-5PCVN4-O#/,F2IX/O:E\&/D@7LUKL<&/A1WWK,)=V*(6] MT'AE#3C3)@0JA1!D80!+O'-6K- M0$3CJR-FTIEDQ=/U$_K'Z#OYLA4>UU;_H8I0SI.K(K MM-

*K'+QQ:V7&>@&Q\L-51F1A4RK1_\7",PXG"U> 5A?RHD$?>K:'(\KT(8C%S M]@".10F-%]5]$WDE.&D;(*C6T5Z8;&V5:4"13EX$*: M35!F3VM3%,26Z55 M4.CAW9W8:O07LS20459-Y=*

*JC60OV)@ E\LO3PP118/=/B6S'.'JBO,K/ M FZP[L-PT(-\D(.X V[" PCWO# 1D"RX^^5E]KZQB'\N=SZX*B, GH!"JV1 MTV?WH; JPM_?H#$>D*

M,!"B"S1KP%AS^0RH)B.$M=LI@Q)0.UM:3RP\A]"1:G'0DE71O!D MH(9#IN@C0R&,0%M!"2^MKQ5!'<V>&0ZE<<5D+1_[6XM$ZLG<0).A?4U#SE_# MNT^&FE5K0O<70!4,1-

JBZ\H6O@@G2QAFQ^VZ<8YY<;?M(ZDNJ+'[L@OX!:;3 M,7TGDS%\MF9_&=!5KRF,>Y-L'I->E@WASG)T7A$DO-[PUSS^I].K.(F2[A%$ M91MJB1Y-7FD=M2X%%;@(\L'--

|JO^T_Z"2_>9S<0P\2E0SUO,/;T\E;K(I;# M2FAA),&IQ:GE6+-XD>3)QO46+&R1HJR*F+(CK,&'.,& FFJD:H=+&WE.. H* M++58C7'>0TTU9 LJLP+8>O^E=DM/YB?*

5W#Z^$AXDTVE';7?;/43+=O[^%Z^M8I38O3(>-,Y(==?CA-P[VD"S/2Y+>DS1U0#=[ZP-3QLVT#W/-MBW\ 4$L#!!0 (^2!9UG#]'\Q4 &<= 9 >&PO=V]R:W-H965T M(7(EH2$

!0.OJUW$LMTFL9..\0KIN#LG1 .9E)!T"FB@:1\$_JP MEAHSW6^U=)QBSG133E'0F[%4,3-TJR8M/57($B>49ZVPW=YMY8R+VN# /3M3 M@P-

9F(P+/%.@BSQG.GZ,F9P=UH+.XL$[/DF-?= .'$S9!,_1O)^>.)K+5$2 MGJ/07 I0.#ZL'07[QQT[W@WXC>.,KUV#U60DY0=[645G#]>]I'^PNE.NHR8QF',?*

*N>)20|K_1HD.&9%9M|)V4LL M}>E:O%AFVAUA5HYMUR NM)%Y*4P,LA@;:Y0(M&M4EU@9/@6[[6?7$.PL"7:N0Q^<4]XE188@QW J?-K9^'V'$Z82+B8P3)F8 MH*

8NX"B.B|$(F,$$WIH4%0QE3]12FS;72_"QS!'JKZ36C1UX0UE.L!?L:@&= & M*"9UYA82ZORCS,I&/<@3)LP%ENXRG3#=(TX;1#C/8A]N%/2%@:&2$& %'9OQKJF5+

<_35T M]@BJVR"@AC,Z37>4R\}JM1I,GCT9I0G'D;^/A\|J@?!N&SS\X6R?YN)K8Q M/^E(1,2TIXI&'-!DW,+VTHLO)%,%I)&UY,S)W6O6?T>(JJ|#FW.2!8 MPIPGWT@U8W-K2%DIJ'*

JE7&EJLS@'5@CH9O.%&M!(Y6M+/^NZ/BBYDL<.AT> MA^U%$2%0GSC6_918?)7_J@5>TN-=NJ?&X]Q5[1I4Z42U6L;M=>JO=+KW M!8OF5P_+E1|@N?

*:*8]M^%C|InV6G|KA;L&R6Q;P6I7ZK37HB'PM7'R#U^>Z M"VT0B/SY^>U 56Q _#7+2;'HW3=K/[>I.U5^>)7E^1NM6*);=[JLW#>N5_ MO5ZYQP[AOW$[_@^LP'_>1F5W\-^]*

*[>Z7K5/LGV-=Bs)G_F#OCIH^HZ_VU5)N-$7JK976FN;7SFJB=OBT^0>4MKQ@RV?+G<1 MC_SFV6JXWX*DQ)Y8-3,O60/EM/7|CY-1MI8VD,3)WERFR!)4=0,_'*

M4IK%C9U@N;&ULW5EI;^.Z%?TKA%_ZZ@ :QY(E+Y,%F$D[M> /,ACCO]4/1#[1$V^S(HH>DXJ2_ON>26NS$=F8KBO9#%,DD+^]R[KF7TL5&

*MZ<[F*81E|ZN\)>=I;7KEV=G)EV*%3<]M18%1N9*K[C%HUZ/IK)&2R94HC%0%TV)^V7D5OGP=TWPWX0\I-F;KGI$E,Z4^ MTV;*

{+++3)X5$+E)+$CC^W8EKD>Vf>;V.RPMC56K:C$T6,G"_^?W ME1^^9D%4+8B\MGN3"G%V<66]#$LI02]]J+BPZ(&[+WJK!+P_Y.9"+;

*M77\&U1K]HE]_U%1@5.O[K%!/V:1/XJ/R!LT]@ZJF-6'MM9;%@?W\U M,U8#'?_89ZZ7%N^71AGSTJQY*BX[2-DC])WH7/WZ2SCLGQ_1-6YTC8!)OYHB M [,R%Q2;-*

[+@12IYSMX6/A4)TS6VV>>3XUJWFLHM3?66IG|3U9H7#'_^ M,H|"T;G|>.]:K0WVIKK_=]GC?;IMO;6:<\V'(L-FZL<[&~>LMNE%F('HW#1 MVHK53&=QZF\/S%*

MRM7B@4U57GH_A$$T3' -XSZ+@J0_Q'4PCME[D=$^+Z:E7K@-VR51,(G'N(X'_M,4N"9$S7.$X +2MTX?R+^8-@U)_@&H]2!K7Z?0.5X@%"IQ$K>)D-F(M?=+YU MYV#36G_")H-

@F!)]HU$0A0G9-H(^Y)KL#8/A9-PXK0W|6JNYM*R,*P-'=Z/I M/NP.3DE*T!^1W&0R<$_CQ/DRB/^5_BO&U,@$Q8-QBSNXVX.>;I;G+*QA.6 MQ8CW.,3B4?*

*C(=TA|$WZXU,&D';G$=F>+++|WT4E<'":A||@P'._%/T2|5N"@ RNHR:%NA?A*HYTH MMA:UD5#:[:D%M5R.41VG:1%H2YN(=R8TVIX,<6_]WX*MV5'OC_2^U8[*'<6R*

M5&|+&FL3JTIAY:P.$LD)91DC05!5J FJS:.,> ><\4>SB5N[3D>(XF M@\V|S*#V0N.Y&O1Y1)%R<6C7MHF&"K%!7TC_%53359*XE4&C\)&257N\YQCI*

M=L_DK\'!$[,>VAJ7\,P^M)Q;30\1Q*F&FAVUIU$_4%=FK[/QRPKQ>'RS_U<_M9;S[YTP",D"?=0&5AJQQ(L!&+N=-G1K@@@5NI2@,2]!JDC)V,HJ11%1/6PDK'MSS.>HW5 -|[

*A1GG8JXGOB84.V(T$@%_)K($SB>AZGY$3:W!6ZIIR9F0FN984 M]5NI+7 2XH7\E]^WA%,UNUYR M>%6S,*SM?\V+5[!!&RSE.FR)6S*9P@I ?R<&*

*(&>-8?"/$U563B&2(6WD*R\FB]?")A-F8),S,S,D1782B^PPKEK MU[(%Z&]V&P"[3\(S)NE3;!8^&&MK#!*361+YPP]> +0:CR0%D/<<>M-*

I#"\Y9"W?:SA|\@$!0CNQ%TX&3_;Y&HI;OXN#%OJ@-M!?+='{73M3*.P S/?S9 S@_P\|HA&$)D%BXT)TE+@UM%E53)N;$O)' ^EQHW

MJD0!%7:I,A=2GY$/"=+%"ZK2)>^XDAV[$A/FS#^#\1QYHH_NN1W,US;W:5 M-_$/5EM?1+;%^X)*GG -IB7"@9IVW\9.@-G[$O)-949Z-$6WX3H&"2) FG*

MBO8D_D'1:W>MO;!NPMG"4U^2&HWA-X+%Y|

G.95=MA?PY[[C!UD+]*WT&/&VNOM$^58BZ*7@,3_&E)$NK#*=\-E[5NDQ3;3F0 M!A\?-ZP_F J/BQX=C _?GSO_C1V5]6#\ )B\\E;DG M1RJIOZP\P7QKO4 M][]#8KTZ-

^@=S3Y_'S_('SIV_J"G=WETTA(-$(93/DY>I18>:W!*Q5]Y2UH- MEGG!<;ZA7@+GGIS"Y7:;N/A=]@[>(:EGV-<]C,H=]_GL+.MSY;N M%$P??9RG[T/O[+YC-K\WWWU?^LV<[W7\\?*

H\=]57(Q1Q+^[U1TF':?Y#U#U:M MW4?0F;)6K=PM0(OR3A,P/E>PM7J@#*9JOXE?_!E!+ P04 " D@6=96@>% MP"(" "J! &0 'AL+W=O5+TP,("UQJ;V$';?OK8A-)6RN0'_ MS/E\QLR0#$H_F@8*

R5,KI$F#!K';4&]*!EIF%JH#:77P5P&6>+7]CI+5(^"2]AK8QJV9?IY'I'(-:; ,3@L/O&=0!+ LZ5@- M!\#OW5[;&9TI)6!$JXDT5"EP7:YV<4NW@?X\+"BX%QF>1*/;K)US(-0F<(M!!3H",R^CG*

+0CB0M?%G8@;SD4YX/C[1/_O<;2XY,W"KQ$]>8I,&'P)20L5Z M@0]J^)3/C>.5RAA_),,8VP,(ED6Q2JE\AE M3?9*\(*#(6_N !D7YFU"T1[G1+28T+L1';V 7I-[);$QY),LH?Q?3ZW-V6MT*

M\KJ+K@(/T"W(*GQ'HC"*B8':%@=>X:[F.UAY[NH%[J6\?VUS@]K6S.]+B8^\ M^#+/]='&=*R -+"-8D ?(OUJNPX]7W,:SV_@:/?O6MSEHHBK;$YW2R'(! MI\LPE\R.N!N/WNN'CMCG*#]?*

#7F"FUM^V%C?R:@78#=KY3"T\0=,/^>LK]0 M2P,$% @)(%G64D3)&Z;!)A< ! D !X;"]W;W)K&ULU5C;,N,V$/T50ET462");KZDJ6T@L=1N@,TV$/;AZ(/M$1;

MQ%*B2E+V!NC'=RC)BF4K6KOE2UJLD9HYG#E##3DSV7+Q52:$*/0M99F<6HE2 M^9UMRR@A*9;7/"<9O%EQD6(%0[&V92X(CDNEE-F>XXSL%-

/,FDW*N6SXJP:UFC6UXO[S#OWGTGEP9HDEF7/V.XU5,K5N+!23%2Z8^LRW'TCMT%#C M19S)\A=M:UG'0E$A%4]K9; @I5GUC[_51.PI@*/="EZMX!TJ#-]0\&L%_U2% M0:TP.-6D8:U0NFY7OI?*

$!5CAV43P+1):&M#T0\E^J0U\T4QOE(42\):"GII] M("Q&L-_0 C."KM G+ 36L4,7 5&8,OD>9K\L G3Q[CUZAVB&GBAC$&C,\K14

MH&'LJ%YL7BWFO;&8CYYXIA*)PBPF<8=^T*_ZM&WP?'&>V_G_8/7"[@@^35R MAI?(<[Q!ES\GJ/O.F^K!?U,/3U?W>\CPFZW@EWC^&WB/6<13@A8**P*I0%VB M!\QP%L%4F;)P%J/[.*;Z \

<,!51&C,M"$(F6+WJ8Y/(2 1PK8IJM M2TF(&\T*$J-?>41(+-%*\!3RW(9(115\-%U<5WC#/:Z]\0'5O4N> M2[5)L- 06(OJVX;]VUZJ/_$LTFSO\7N)<,J+3"&^0I!])(WKO -G3D1 KNMV M_7![O-L]]R $O::

<&P*38*$AL%8(7.>U3G+.#0+*\0M>PI$/29_R&%U OR\3FK*JHMW>ZP>F!(C2C5@)5,*-H6J.-;--L _>^ M;'$>S >Z"5SV&5]AJ@[R$!/H&PO=V]R:W-H965TN^V*3$>\ A?1R*BZ/2

MW\T>P)+G5$BS#/];69K=A:.(]I,Q,R6"V*9X]ZM5"Y%5S"HR8F3U.F7^Y J.,RH,'K@R> ^VUOW(%PM,K:#-=BO MV:/&65A[27@*TG EB8;M,GA/;^^BPJ!8\8W#T9R,B=O*1JGO;O(Q609#QP@$ MQ-

:Y8/AW@'L0PGE"'C\JIT&-Z0Q/QZ_>_ RPVCYO9, /W2OS#$[M?!O.)+!E MN;!/ZO@!J@U-G+]8"5^\DF.U=AB0.#=6I94Q,DBY+/_9D82; M3!DFR$ZK/,,%SG2 I@/C3-

\0+LEG+@2QPT4E(42\)

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
^CSS[0$^V0GY1:THU>DYBKJ,.6NOTTG55M*8)4>'MRSU5IG#]S9)"4K^D#UY_1.FCNWI"Q80KEB@B-)EU/GRK_$@951B"_9SL7
M^GL[>3.91Z+H7,2_LX5>3YVQ@Q9T23:QOA?;7VDQH4'&BT2L['^T+6P]!T4; MI452.)L1)(SGK^2Y$&+'P7#:'8+"(6@Z]%]QZ!4.O4,C] N'_J$1!H6#G;J; MS]T*%Q)-9A,IMDAFUH:675CUK;?
1B_%LH3QH:=YEQD_/[JG2;46:QW*@8T74^HN"5$?70K>!ZK1#F"[IH\0^[M_8<=_JY1IY0H>)'H.N@$/M#'T'/6\,Q1X0;]E///#W7MMT_FVZ/A_1Z^)T2O7 M2_R>H>L%S072A?
K1%%IUL,?'XP]NM$T47^VI3Z']]OA65&\5"F)Z-0Q5<\2 MG=F//_A#[^]7&>IWT9L[FC5VM"QV=)3OZ+8DY?RAY66WM.N]BTVX[I)V&+2;V#POLW8*TUJTQ^4TQ\ 3O\,<:K;-,B##'8& MYH_\A@;[-
GL:M&#@S>MWE-@V&IP? 8#7:+^M4K1;U-@\X@QVY62%@("<- ML%JF1F6F1J8 " MUG2]*6]Z-35KG6Q1 \D;O\4ZG0_=FU#PD)(& :"U7+@>]6W?^^4]:>@ R4) ME!:"TC 4K9ZGG2[-
QY5J(BR6Q6&O485ZA()T5GX[X@8*F)=VZ#2-NC4UEP; M\58L0K$87[U&-YQI1FQ>Q<3;EK;3RDU-J:?)3"'RR6+&.7F3UGQ[:[YE&J6 ML'^L4:ORG6,X>]= TD)0&H:BU;-9]:?
^21M4'[1#!:6%H#0,1:OGJ>I2_5.W MJ46 6O\5C)K5;+_#;)2?\! .;N-,LV22M@G6. MYNBU#4D+06D8BE/:]5^^\.3UB#0QAN4%H+2,!2MGJ>J^?8[.\=F#2\))\9O\"4$L#!!0 ("2!9UD_)B2X:@< $ X 9 M >&PO=V]R:W-H965T!*=M$!__*A+1)\1,4SO9?$E@\/>?A1 M_'@HZOHYR[\4&TH9^IK$:7$SV#"VO1H.BW!#DZ"XR+8TY;\9GD2,/XU7P^ + M;4Z#554HB8=X>)H,DR!*[/KZMI]K_.=BR.4GJ?
HV*7)$'^[0.-L^>;@3-X MN? 0K3>LO#"<7V^#-5U2]FE[G -OPY9E%24T+:(L13E]O!F\=ZZ(YY4%*L0? M$7TN]CZC4LKG+/M2?KE=W0Q&98MH3$-64@3\WQ-=T#@NF7@[_FE(!VV=9<']
MSR_L/U?BN9C/04$76?QGM&*;F\%L@%;T,=C%["%[_H4V@L8E7YC%1?47/3?8 MT0"%NX)E25.8MR")TOI_\+7IB+T"G :VL8 M-P4JZ<-:>]5Q?L""^76>/:.\1'.V\D/5^U5IWE]16@Z4)XZ6];!"V2.2
M"%YPZ*U/61#%Q3L_ K3TT=LW[] ;%*7H+HIC/D"*ZR'CK2_;, R;EGZH6XH[M6NJBNRQEFP*1=$570'G?7'YB*#_D0=9V'7[IN@_82+BDVPODCLX0*5F(:,_B M]
<5=2,YQM9/_7+O4&6X[CMR*SWW-.$*+K&#-^"EH_D317[]R/+IE-"G^AD)? MDWLP>3E97A7;(*0W SX;5HR#^8_.)/13U"_VR3S;(12V12A+PV0IZ)G4?\
MB>9!&M(J,#39QMDW2L_SY@X/>9H[WN7U\&F_VP', M2(;X$,U,QA @UN(I'S<*A\;E9.O43T:,[:AN:P8$ENSC>$6U%H!B*+#UR%8
MZ0ZB0[P1+'722IT8I;XO"CY!1^TL7E2Z@S#DF3FO5*\H'UMA%)1I&A(_T=HT M=17Q.D2-,T R4;3K$#R#M4];[5.C]H\9"V)(TE2ORO4430!@ \10:HF-F M'1&=M:IF1E5*@HZ4!-
T.YI<$W7$#S_0!.W64/M Q6A\ -#.%ANB8KCZX;/O@ MTM@'53KA:XUE$%/PCC46/S1]V"3S;9(12V12#)R16"F.3IGB&W9+0++,*YEME M([;8Y#CMK>B=_V/&:&K9OX\G:B8PM^3@*/372&S5*/YY
MSR6\CAV+PB!&WU'O_&1F/7CLVV3SK;(16VQR?(0+<4YJ0QRK/L0JFV^5C=AB MD^,DO(AC-B.VYBCO%7.4L24'1Z&_1F*K1KEOA=MQS';GJVVYU" _'_Y*N:Q/P M'0$3%]BA1NJ#;P";;+Y5-
F*+30Z2\&G.Y*03E=&$'APGFVR^539BBTV.D_"4 MCME4'K5KXNAV45+ $3U7/TL!(!/OJFJ2P=I805XQIHR'=05V+UC3.8U+9@7;U-&\[0* M98=LN^>7[!Y@LGN"Z13/#5RQ\':J4Z9"U:^:S@(55-
M\J&['%)L=)> ;7[!F. M2H5NKQ=8 !"L3B&]+,3((BL7=L$UVX6#TZ"^N#]7;02 T2;,?AH"8#IVB5WA M(URSC["0"/6]:RW:O1 ?@&CR31!9OEB:N^9-\NY$J&]2ZV'5,1-55OJV. #1 M.C#IBJ6LVW?
B*M]F9?Q ;5:/6UEE\ZVR$5ML\H%=L:3V3GKBRK-ZXLHJFV^5 MC=ABD^,DW(!G=@/'':W6U^>J[0,@VLEJ':+N#0*0COG/$T; ,QN!0[.=!ZSK MU=D>P*C3(D2C[@5"F(X3QIZP!Y[9'AR?[CQ].UH[2-
^_[]W/0@ (GG;HWWN' MP+SQW9GO//W8/E;M/(#1 @O0)L7 ,93?=]P[XVHA.;KZE6T@H_+7=*U*_S"0WEX?K[H)\':4%BNDCKVIT,>41R.O7 MU>HO+-M6[V-]SAC+DNKCA@8KFI<
_OMCEK&7+V4%[4N#\W\!4$L#!!0 (M "2!9UF=>LRWF@@ %M1 9 >&PO=V]R:W-H965T&4.2)D@;[%?O2MTV"MWVHNJ% Q.P:FQJ#YNN MU]?
VS@,\X=CW!SW)@$RYSGV,Y/A_#P>W[YD^1_%6@A)_MHD:7$W6$NYO1D. MB\5:,*+B,MN*M/S+\?#<\ MJ"SCC4B+.$M)+I[O!N^]F]"25 %UBU]B\5(#
MJP%9BN=HE\C'[.7_HCDAO));9$E1_R0O3=O1@"QVÄ# ;G7Q@61C*:W>?9"\JIU MJ5:]J-VOHTN_XK0:*'.9EW^-RS@Y?12%S'<+ND?HB'+\NTWE;]O!?9]?, M8(>!Q&H]=LY
JD:%R#\+\MMCEB2D_)=^B?+E[ZX^WZMRMVHU3=X4VV@A[@;E M/%AK#];??.6-1]^[#,<4"S#%0B0QK6OXH6LXI#Z]%ZLX3:MN>8J2*%T(5S^ M$EW[5,LV(N-:
['J>^_SU/=OAY^/W47*I[GK']SU07>-&30V9M"\F4$7KS-H M*J3+?]\Z2\JX?IHS1YLKO4FP;^(?-^&&3&C+7(T.330/Q@3L>$94D+-WK M^O^<_$T^7Z,(:G7L#4RUHU/29RIBHL#+J'BO,\T!4P2IW
MFRS'9SHVRUU'FVNCW'7)F/6%HXWQ=M>3R&5!5.14O+-%YI*%":5:.FE1%F M!X18*76/%5AY,%FUUKUP?&>#,=4"SR:Q"\M?I(RZQPK:/)C:3A:_<%QG7U%A MS7/0FF7
ZV@>M>0K7/)C7VBM@S^8BSYKJ4$'LC(PA5D;=-H5B7@N+N6K@AS+3 M(H^W]:K"SV*Q3K,D6WTA\RS9R9/7D5'I#54M0%4+L=3T+E.HYUWW4Q%CXMT, M52U 50NQU/0%"L65%.;*LRIB6*-
K;Z"J!8W:\;QEUG=8"76+%152$&JP"N(F MBS9!&]\(CB;,J(<=32R[H":Z!PJ* Q>YU3#L$3G48;*7=3FK@MJ^M8'=U'% M713FKM9B&
((O[" _J4AJU$5XKVZ*27&IBBKMJAJ@6H:B&6FMY!BBLIS)7GU<'H MR(B]%E![R<^\XH&54+=8<2"%U_RP:F#'0AV?F-\%=B-N5L$.'=]<(W4T&KOK
M8*9PB\&X=4X=#*$MTON,)E;:835NF;5@)=8<5;3&8MEK+8#B^L[VHBVW,1J^+ MB>EO'TMH3)$<@TGN9!D,QW7V%17?FUOUK#M@][8T;"B,ANJ6HBEIG>/ MHCOF]U+\,M25.U2U
%4MQ%+3.TB1)(-)\JSB%);HW!NHK,CL]3[K=C>LC+K' MB@ 9O-Z'5/TRQ\V2YB5@1QOC3M7 T<3RR[82_4O@JS&(Q99]6^J)2%]A8P MUXV5IG%]8!93F,5@S&HO?E'7U5#5
F;SEG6M$BNCODU"X1MON0OS5/$+QW7> M'8'*;-QFM@MK?T0?T,85M*$8VMJK7VZ3D3$V9G".SJZU)@RQ$NJF*1+C,(G- MLGR;E;6OVR]4&D-5"U#50BPUO1<4N/%^MK5QU-4X5+4 52W$4M,
[Z&AO&PR(MYVUN0^5!5+6 VVMXU*P[L#+J'BO*X_)%C?NV)S&S%G>WIQF%K@N&?.JA4.& MG[BZRQ5+\;?OM&9RDLVWM M&4.LC/K6:45+?%=^=?P01T]Q$LO8/:O"*ET')ZI:@*H68JGI_:%(
MS>]GBYN/NNJ&JA:@JH58:GH'*2KT$;.XP1J=>P.5#GU[KD=I-C21UBG@S4Z]P8J7/HV7#+S M,@961MUC!9?^6 .?E-0+0$W9F<)+.MK5G#+$RF[T;'CTL;B/R5?V4OH(LLET
M]X_[.GQZ>!+@^_KY=\;G]][-S'-\'G@WX?XY?TI^_]C!CU%>CO*").*Y3#6Z MG9C2)<_R6__1F;;^E%U3YF4V:9^N1;14N15@_+OSUDF7]]4"0[/4YS^ U!+ M P04 " D@6=9B=JW]-$" #5" &0
'AL+W=OY!%!H6U(FA]Y2J:KO^S)?0HEE MAU?]),Y%R56>BH6OJP$X,*22NI'0=#S2TR8EP[LVIU(!WRE*&%P)Y!^:U*04I@DG"&!,R'WG78GW0- MW@*^$MC(O3$R3F:&](0]\<[
M]4_6N_8RPQ+&G'XCA5H.O0\>*F".5U3=\\UG:/$8!"-I?U%FP8;>"A?2<7+ MAJPS* FK__&VJ<,>0>NX"5%#B(X)R3.$"\'$+XV0-(3D1I&Z#<%:]VOOMG 9
M5C@="+Y!PJ"UFAG8ZENVKA=AYIQ,E=!/B>:I](;EO 3T!6]!HO=HJL]AL:* M^!R->5EQ!DQ),WL"HLE6GU()Z#P#A0F5%YKX,,W0^=D%.D.$H5M"J3X%B9=&)TRYE:2C1A!10.?
G::WSO!]W5IVOI$N_J,HI."4Z@Z M* [>H2B($D<^XY?38Y>=_XL^^>?H!\6(V\,26[WXKX<%943FE,N5 /3]>B:5 MT&_\#]=^UXJ)6]'<@GU9X1R&GK[F](@U>.G;-V$O^.@]JFN*9:\I-GDEL8-M
M2=IM24ZI[[9%Z6V!^M5T;42MT;,:IGNLTRBY'/CK_?HZ,&%\B,G^Q,27X2%F MXL $3[$.3'9;D]V3)N^AXD)!H>^7UJW RFFU5KK:"Q]TDMZ1D;$+%<7'=1VH MZ.K(L L5=N,CR_[>/5V"6-
@&*5'.5TS5;V&[VO;@:]MZCM9'87\<.M8SW;/K M%OLD7S?\6RP6AE8:Y#!9U+G;&HFV@]4;RR76+&E>XY=KC4WQT@#$ _GW.N M=A,3H/V227\#4$L#!!0 ("2!9UEWQ0!!R 0 / : 9
>&PO=V]R M:W-H965T2*\EQTNF'OQ5@; S'V:GZQA:@_:_$3RLMTGC-Q5>Y M %#D)4N9G%@+I997_;Z,%I!1><:7P/#)C(N,*KP4\[Y<"J!Q;I2E_8%MC_H9 M39@U'>?
W[L5TS%AXVF#O,;O":SE3IGHKCQQ_E5?W,83R]8M M@A0BI24H_CW##:2I5L)V_%V*6I5/;;A;WJB'>>>Q,T]4P@U/_TABM9A8%0;) M8497J?K"UQ^A[-!0ZT4\E?DO69=U;8M$*ZEX5AIC"[*$%?
TI7P1.P:HTVXP M* T&^P;>=PSAB5!J/\W1 ?F-OH D/?(K%8)JUN2]#XHFJ3S! MNXU/GG[H2\(PDC=TF:XIB0X[Y_UJE'Y6^K@M?@^_X>'WMN3G4$)V@/DKEX)%IF<@9"$PB5$A26U
($40O*L.XS5N3B M]930C*^8:AL712M&>2OTZO@\[7DXRI]W<7>V]%C<+0X=[[SN,3#I,30D5L,X MK# ..S'>4$;C!&$\K20^0D:2+""-">8J1-(4VIAT2AX;JR;%?)-BP; Q$D;N M17T@A,TZ=E6C!F14
1EU @EF\,B3+ R/?")5&&BX5 .F;Q%G49(F5*=BIYH0 MIDNL42].4$+H$*3I:3-&VX!V-NE8H";)-B02$VW WMX3Y00PYQ[,K]N=O MF5/E@@&KTJ;0)DOZBNF\(CH]PY55E]N
=OHY%JA),=^D6'#>!-J(4$,.:T O M*J 7G4 ?F0[:.4O^070Z0$NH4B^4$7X .M Q%*76R.S4/Q:D23'?I%APT02Y MO^:&AAS60%Y6("]_&)G1-IO-\QR<8Z7:QM7"M,I?2S#R\:"XPSJ+\HWZ2^X
M;)!Q]\$8\E<#X]C;[U;[;3'6^EUJ-[KC>+:]ET]V>SPV4(RJ!0?U(#3EL\YD M9R_!>1L3G?@KLN8KS#"3#%N 50E/)L,IA6SKU)_^2ZO- Y)M F%O*)<=G9"[X:MD*JM/!L;.= M437?
J%!@$5"TTI58'OV]T=T9&GKL_ QO=BS&J%AS2@="4RX),?V=#/@,QSX].)*:2F"H66ZK5W>IX MYD-^*+%W_]JY\IV6^X$^SLD/ +;RQ5G0'17SA$F2P@Q=V6?GN/*(XGBEN%!\
MF1\'/'&E>)87%T!C$+H"/I]QKC87VD%UR#7]!E!+ P04 " D@6=9VMML MY:(" ," & O0 'AL+W=O$#P,5:N !\2#FYPVUGP)MM-N_YYC)PW=E)4*UH?6 M/C[?=V[V.1WME+XS)8
E]X)+,PY*:ZMA&)J\$'-A:I XLE::4$M;O4F-)4& M6GB0X&$<15>AH$P&V M!Z2 -:VYO56[3]#&<^GXP^<3-J:3;2:D>TTT8VM_#9]VC, M%Y/NGBRMQE.&.)O-
J99,;@Q9@"93)006;UE2#>0M^4*UIJZ.Y&P&EC)NSE%] MW*D9A1:M.XXP;RU-&DOQ,Y82+YDE/N07,!?EROC-7X MDG_V%;NA2_OI7'<;FHKF, ZP?1G06PBRUZ\&5]&'ODR_)-
GL)5\K&BTOOA9LKVVP0^<\HW!Y6Z42]V8EZ\[_K-6D+#]J; +WQ M<\607-72-C>\DW:CZ]IW["?RR6 X'?3(9SCJFLGTA[Z9DS=4;Y@TA,,:3447 M[]!;W9F-5Y9OK2EELU7Y9XK@&[13P?
*VPB.W&&>C^ &2_ 5!+ P04 M" D@6=9(1V,DR4% 7&@ &0 'AL+W=OM-)9A+>C&VGRX<8Q.XC[;/+:E?,CYB\TCV$'Q.XI0NM#UCV9UAT' /DX#J M,(,I?[+%)
D8OR4[@V8$!E&AE,2&;9H3(PE0JBWGQ=@36$H!2L%+BAB]:0P\HC@6<]UPP<;M MW&#<:+%T(ZP,O"\-M-\P< 0><O/^G1-SC9->/VB?%[NQ=P M#3,=C,P;8)NV(UG/:KCZ2&;.]\WN?_/L+3)&=?
B-"KS1D/ K@N7F%$\W8//E M%$:K.* \%![2,,XC+@_^.N)RS#Q"ML<1^.&$SHO[(@*9?AR);BDD!Z@M?_[)FIB_R#RD$LQ3">8K FOYTJE]Z?2A+__DVQI*0YQ MF0-
*W4FA*W:OP])VIW/CT.3U4F9JCMHRWJ6,93L=(%\B-#7-6JAEWK@V;SS0 M/! P1M*&!\-3XX,@Q3S\901S),4#TZ4,LCI9=)L54XR;BSMUIET>)#(C&8= M'B0R,ZM@+T1FZLI9F-0L3+Z5A%QL03
I]@H9 Y/+2' Z*U]=RDPF M3H>!2QG+&G>H]"5"$]N6S?ZHR%:D$\U2"^8K 6AYR:P^YO5%:%B=7Z.23:YD?2@BWE4EUK;->6T_EUSO6SH:L<"61:JVPM'9VD5>L
MD=FQ588T;K#;LM4RS^6J.:Q@N(HQY06EJ#6;K]^@K"1]+:N)%;V72M$\I6B^ M*K2V"QL=AS4X8',:%2XL?">-VPILV@PD_:)RD$@Y^LSNQ*U$RM7=F=GXZVZA MLNDM?39^(X[M,PGVP PU@
);1H';I>!2RFDNM*+@4LK59T[7:LF,MMZHQ=I6 MGZM]][< 7:X9#E\!SMB;O9S2.ETIF]<4S5>%UO;$N5:WG!]9PUB]K%UO;3N>FP^KL.?[N%(1,G,)%(F^@ 85A3A!#W$WO[/D5=G,3-KNE
MRTHJ=)$Y!R#Y[P!U&3@W'%9_Q_',.RF"0K%CT")]Y.*L2&IN+]!7!Z5*-$\I MFJ*K>V2<_]C_= &R%+: 2E%\Y2B^:K0VGXZ=T%6?QOT?0P0 M\J1"W49=*M1M%XS&07<"R:
[XPD!Y^.4I*P\=Z]'Z*\;'XNR^,WYOW:TLR;@G MOGH4!^MG^/*3R6- =BBE((9;/A5?&D]VI/P*4=XPG!7'[!O,&$Z*RST,(DB$ M '^^Q9B=;L0$];>@Y?]02P,$% @)(%G6>[.RC\M!0 FAP !D !X
M;"]W;W)K&ULM9E;<^(V%,>_BH;N=)*93; N0$B! MF5RZ;1[29D+3/G3ZH-@*N&M+K"3"YMM7OL1B:_O@ ?8%;*-S_D>7\T,^FFR4 M_FR60ECT-
4VDF?:6UJXN^WT3+D7*S;E:">E^>5$ZY=;=ZD72K+3@46Z4)GT2 M!,-^RF/9FTWR9P]Z-E9KF\12/&ADUFG*]=NU2-1FVL.]]P>/\6)ILP?]V63% M%V(N[-/J0;N[?
N4EBE,A3:PDTN)EVKO"E]=LG!GD+?Z,Q<9L7:.L*\]*?:"NZ]7<2.2)//DXOA2.NU5FIGA]O6[]T]YYUUGGKD1-RKY M*X[LMG;?L(N[];NV"BV4V*W.KW:^Q ML[.S7Y2*-G&2("XC="7SY%98'B?
F%'W(FM^[9VXFS*1O7>29?C\L MH[PNHB0M40[1O9)V:=#/,A+1M_9]U^.JV^2]V]<$=#@7JW-$@X^(!(2AI_DM M.OEP"OBEU7#2W"_=-9Q_/RKWZ1;.ANOHGZ8>%XY8LZ,L&2_-
BH=BVG/99H1^ M%;W9CS_@8? 3$":KPF20]]FU6,129K/VS!,N0]$48.%BF+O(DOMUA@~,R:3_ MVJ \]0'H+)?;^&?=:S /YF%X<$Z9)8:R'#-V0UER;A!8RB?UUM-[IE.2:%;8II5(NI
M9>POJH@NP(A^=_FJMZ6;5"^ZCOVX4AV#JBYE=RRT<4T2!\%%R_#CP),M (6? MSN?GZ&')';M#L;9QR)-&\H!>]DQ$O,5??"QBE)Z.'"GQD9+#H5'ZV)Y,A@EM
MF4N/50SBL!LV2A\=UB[VH,0P*7>2H[3O(NH9B6%('HP.W)F@V",4PPSM1]< M!VF;L.$-SE:QMZT8&_M]+EODGK8XO1'<)R>\](B<ECV_^!-V.K7EFB8ECPVK MF7B&$IBA.W%"ZOQL$_7P)#
\#\8)Z0Q6XL%*8+!VP@GI#%?BX4I@N.[&":G3 M$UAT'J $!NB]B+(]R-E\1?9!FA2T;'X@@1\;UOI)[2!*9T-X[4 MM[5D0(.U/>W+8N8>GA2&)X[.4+EX8S]=2D,#4/Y@CM3%3J
MB4IAHG;B"*U3]8R,6Z2WWO5AKNXF":V#DPR"EC<;ZN6)87;>22NTS,>]^9T& MMM\S):E'+!TM+ZU;4L9 M3TP*$W,W/.JT;"V'4]+"L/R<'S40=I2$6$>I P&:2=\L,XP91ZF#(;I;GBP
M.BTQ"UJV(>D>P[%U%99WXRSTJVA#HJ:]AQMOQE,()0 M=F@MM70PA&3[6\=%]=" +_%#,H# [ORE.CJJGU<';57\),@ _.1ZZ\N#L**&ZM6^>'3L[)6I?GE4O!(Z*R!^_U%*?M^DPE4QY&S_P!0
M2P,$% @)(%G6;3?& VW!0)"(!D !X;"]W;W)K&ULM5IM;^(X$/XK%K567W5J?3?7") M@:A)S-JF;$_WX\\..9P7QPM5^-(2,O/XF8D]\$ PV3'^*-:42O CCA(Q[:RE
MW%ST>F*QIC$1YVQ#$W5GR7A,I+KDJY[8<$J"U"F.>LCS_%Y,PJ0SFZ3OW?'9 MA&UE%";TC@.QC6/"G]_3B.VF'=AY>>,^7*VE?J,WFVS(BLZI_+JYX^JJEZ,$ M84P3$;($<+J<=B[AQ14>:8?
4XL^0[D3A-=A/#VJ"]N@FG'TXQH1!=20Q#U M[XE>T2C2(K']PRTDZ^1'8NO7]_I,&K8!Z(H%0] MVWVB64 #C;=@D4C_@EUFZW7 8BLDBS-GQ2 .D_U_\B-+.1,$!]AL<4.: #G7 MF0-
.]TS2\.Z)I+,)ISM -?6"DV_2'.3>JMHPD0_QKGDZFZH_.3L(V/!+HPB M0)(W"22)*OP(:+@4@@JQ3OPN]I)73!7NR?8JK?94AGM-X]^"/=T17@0)JNZ M*SB[II*$D7BK_+_.K\'9F[?@#0@3<*N64\YBTI,J
$VCM\C(OM^310UDYW1S M#K&W#B /]2WN5V[W&*5.[2Y[U3:\MRA/'! "))2T^UGM0TONP-^7 ME3VXD306_]ABW8/W[>#Z^%Z(#5G0:4>=3T'Y$^W,?OT%^MYOMLA; BOE >=Y MP"[TV4?.A
!7A/-GO14N8[9-I"WB/8R?PNCZ\C3#&,))[ZD82=VH[V&<&Y48 M]G.&?2?#R\5B&V\C(M6#4O2X#/]--["-Y!YI4%B_"X=X5&%ILQJC!IJ#G.; M25,?M@/2.*BM#0=#"7Y0>G9^?L[/=_ +
[1*.@JTY_5Q"US?]37!,2A$37 MBN$IS_ZPS3RT!%;*PRC/P\BY M)0JADZQE)-2Z:T?U[OG7(;9^@MI:(MM'(N"DH(.C? MU3RT: ++I\H5QI6R1LM MA+-BG#<-<$=YR)P]A" /<(KG M&?9'7N5
9U:E7C7"#6T(&L$!W8KCF'Z>095:M>_UJT0M5D,/-A UN@.ZA<>! M'3U#*29S-/2K%.N: T(T;]!H- =TBXZYVD/A0I7O%:=4?4"3=F'N! M5@[9R!CHG[3JM:IBVD(KY\+H&.B4!ZU6/?=*8T?
1.X6$@4;#0+>(.;SHU45, MZ0AFT8QL!]5O.*A>"W0#FJZ(UMY6Q8)6JQH\<-1)$1%AE*21$B M5*&8&14I]@<-_0.95H_<#?@+)X':Y?Q1!/,/J2]!0F)JK7UNL*,_J9^BP:/"
MS.*T0XMVIQ:G&%L@(R.06T:T6/M^LA+$S<7/[?K:)!B)@MP2Y>#BA^HB!8^J M.@K51'QH(&H41;(/2$YM/3YECY2 MU7N949$B]OL-
#$V_1^XN_(4NU@F+V.K92JS5P41;:.5035M'HY.6NI:F$5DN M3C';0$8\(+=X:+/4N5>"GJ/4G6+:@8TPP6YA-D,#N2<&!I0Y;Y02#VLS?,B9HZAJX\+6$ MN^G^(=>46SFUU'$S\]?
HW]CT;]P_997#3G5P="Y:0BOGPN@$[-8)+5:YGZSD M-Q?"53%IM-DSZY7^ I?_W[BEO!5F @0T:7R\&ULK5A1 MC]HX$/XK5JXZM=)VDY 08 ^06)+V*G6K55%[#Z=[,&0 JXG-V6;9WJ^O[613
MPKHI]/P"B3/S?3/?3!S;XP/C7\060*+'LJ!BXFVEW-WXOEAMH<3BFNV JB=K MQDLLU2W?^&+' >?&J2S\7A D?HD)]:9C,W;/IV.VEP6A<,^1V) P!A8@/^WNN;KS&Y2%_,@.?
T*=4%_CK5@AS"\ZU+:!AU9[(5E9 M.ZL(2D*K?_Q8"W'DH'#L#KW:H7?]$/_ (:H=HG,9XMHA/I>A7SN8U/TJ=R-< MBB6>CCD[(*ZM%9J^,.H:;Z47H;I1%I*KIT3YR>E;QO(#*0]$:8[>48GIABP+
M0#,A0(HK]$'UZFOT 7..=471RQ0D)H5XI48 -5+T\L4K] (1BNX4B*]\&/M2 MA:7!_54=PFT50N\'(43HCE&Y%2BC.>06_[3;/^GP]Y4YV "]A=
MHRBX0KV@%UOBF9_O'MG2^7_LV2^SM\2(F@:)#%[T2PV"4B)6!1-[#NCOV5)(MKM[\?VP]4+'$=A8]'=Z('5[!Q%/SG0#^ -[T]]_")/C#5@"78*E+L,P16*M4 M<5.JN M].BL9E^0_;&9@>%3?$@&
(K=7;VO-FZK9ZE-!)P9:?UT>IDDP]A^. M5;>8]-HFZ7.34'?AL4UFLXD;FU;F_2;S?F>3OB&42'C]LU0UEFIL4Q6*7.% M[K#<@V4]?MK2:ZOJU<%5/_N,^"DWZ==T9S:17.(,P<$;;'33B
M#ERG[_1,;'H.GJ09@Y(FSI.6ST'#K2DERHF=G)?J>09AYHBPI6<8?%_$"E3 6E$%UP/54[PZ-JAN)-N9??&22;7+-I=;P&I1 MH0W4\S5C\NE&$S2'-]-O4$L#!!0 ("2!9UGN"U/]IPD MF 9
M>&PO=V]R:W-H965T)N4+>[#XM]H.6Q+90B59*R&V _?(<4H]%PJ)%G==2'1K(UOSN\ ME[Z32;5XDJNT&A=KF:O?/!3E*JW5 MV_)Q4JU+F=ZW@U;9)
Y#/EFERWQT==*'^[$MY=5%LZFR9RR]E4&U6J[3\^D%F MQGNOG!Y.IBG3[*6UG_NOY2JG>3'>5^N9)YM2SRH)0/EZ/W MT3O!I\V]A/_6LJ7:NJUT&S*75'\UKSY='\Y"IL9R4PNZ@:1JG^>Y;7,LH:D
MYO%[!QWM8C8#]U]_HW]L-UYMS%U:R>LB^_?ROGZZ',U&P;U\2#=9_7/Q\@_9 M;1!K>(LBJ]K_!R_=9\-1L-A4=;']J!JL9K)]M_TCRX1>P,B>F! W V(7SN M= /(:P?0;@!]
[0#6#6@W?;+=]C9Q25JG5Q=E\1*4S:<5K7G19K\=K?*US)L= MY;8NU6^7:EQ]E;#=C;Q@=G')^[A-VFIHD<'APOW\!\W
MN8K.VN'$'#Y15+F5)MZ5)FYYQ%6:3WE5EQOUEUD'__FL/A!]N6J^N]0:KBN'BK =BQOQS8-^OF*3:G:D9[W$^L,X)0d8@8@\GIL1!2BBD3"Z2QAU M)NRSK*IWP?6F+)L]>%V4S=%A*'=;#-O?
$M++G#.2;^8&XH6]O('B&7ECNJ[RQ M5^QH6=-PZZ;A'MKEV, .,(]ZB7.&\DT=MFU IN5Z,W:UDNU(NW0P5R MLGT+M(7-J]I*. Y9S,S&DB!C"A#,2/U\E_JY^\!8I'D5K-.OZ9U:7/\O",?S
M<+]K)7(A5W>R#$C;M-A0 9P1? N A"5(F #!C#)%H=9'(;1M=3A05:"T!$H3 M*)I9F#WA&IVQ>77P7L,)9W/SO]Y*RCTE[W(@:0)%,\NAQ6KD%%Y'I%$WV%BH MAF$_NU#1V=&8*Z1
A323IN5DY-:3_:/ _[5V=./K'USX=:?]0_\^R>@W?^ MH>H813,M*BV/8Z?*.]+YN\'[G;^_Z'?SO9VF\!5]'Q723)D6KK%;N/;[_G3, MU:)?=1BUEV[*KOG?I.7B*=AZD=/!U"+%XS64ED!I
D4SR[7GPH)M6*P/BS5B ML4[L.<1SK,5S[!;/[I[7^#MYK_5/>7_6[)^%= *@>1M', F@]'+O-W2.]GU]] M/^I[K-?N"-[9M5U=*Z1 A323IK5J[-:J_>Y/QO,#IWQXV_QG@[E%BL=K*"V!
MT@2*9E9+"]N88YL_U$B&TA(H3:!H9F&T>([=XOG$YC\:=:OYD;C5 J"*&T@2* M9A9 *^+8[1T?:?XSJ_D3VI=5[@C>V9U9S=**5 AS:1IM1K[N;ZTY_K^N_EV MY_J'&S_4\X72$BA-
H&CF=7Y:UQ*L[4N@MB^4ED!I D4S"Z/5,SFG[4L&;5_ : M/QGMGH-W_J%R^.@FF(G5.I><8N 2V\ EUCE\=P3OM-D&KA52H$*:2=N['MC/ MP*7CJ;&:OTF_?KN>?3Z85JWZ4E4)I
T:\GUVH3B6V=VN% M%*B09M*T_"1^WBWM7;AS*]?U]OK-;C4_W/VA]BV4ED!I D4SRZ7%*L':MP1J MWT)!"90F4#2S,%H0DW/:MV30QJ76E3NO_%SBGJQW:L^A8*E6L/049Y;:SJQ] M0:8[@O8
MK=0V6]E\VD\;5(52VVQEUC(=%=),FA:7U,]LY>,P-$ /[*ZRH=%@7J%&*Y26 M0&D"13,KI54HQ1JM%&JT0FD)E"90-+,P6NG2VSQM&LGUVH_J2VSV]%%*B09M*TK*2^/NML-M#WVY4\
M'7K4RP=W . ^ C5:H32!HIG/N= RE6&-5@8U6J&T!$H3*)I9&"V&V3F-5C;L M4L[ZO\"0#4NBF860&M<=HHARVQ#-F;}$U_N-[9M0U9*Z1 A323IO4G M\S-DHS%3*WZQ*8N]]O]3\=R=G)\>?
KJ".Y!WHX%*5BA-H&AFR;2R95AKED&M M62@M@=($BF869N\95.>T9MF@-1M9+0K[="[JH)D;1S/QK36T?\H'%=),FM:KS/>N6DZL\ _%W71/EPG/'QOK3N.=YN!*EPH M3:!H9L6TPF58!NR?
A70"H-D;1 MS <9:FW,3[%P^8"%R_H' '<$W^QRV\)EM&_BHD*:2=.ZE?N9N&0L>"A'OS&PO=V]R:W-H965T_%VLI2_(MW63%S6!=EMMWHU&Q6,LT+H;Y5F;ZD\=< MI7&/I7ZK5J-
@J&2_KH'0S\L?C:)3&23:87]?O?5;SZWQ7;I),?E:DV*5IK+Y_MD)O\^6;@#5[>^)*LUF7UQFA^O8U7\EZ67[>?E7XU.E"622JS(LDSHN3CS>"] M]TZ$LRJ@7N(?
B7PNCIZ3:E4>\OSWZL7'YJ7OTN5DGK)WV*EXDH\Y V599QLBK=ZH:_WE+SYZ2WYB209N4LV&RVRXG!4 MZOE5HXP6S5S8?B[^*W.)R%V>E>N"L&PIEW;\2*_78>7\EY7[X#N!]W([)-[X
M9^*/_:!C/K?N\%]WF0Z/ZO"@(YQ>$CYY-9Q=,/G@]._=J49":-(&$"."!(F0#!++.%!+*&+/]\W.F6U MT5EJV73)PQG?5QY(&$7"V!X6U;"JJ7B:3Z;C\?7HZ3CMR!%%QXC1T8A6.B>'
M=$ZY]MN/_)%LSF;8B>R;822,(F%L#YL<_[^#5GZ1XXG):7Y? MR6YTR&[D5.X7N8V_5]OTXK+$.FE]$XN$422,1:>)'7NMS$8GR?"GK64$:%)6 M:J>'U$Z=J?
V\4XNU[O.KQ'X=W@_)*G^2*JL+>/ZP259Q]7TNB-XC(N5:DD*_M+A[C9B=#-Y7+1.\[Q6HE+Y.&&[5: 00?E4)I T6R-'#E4WF7%AOR7W"59 MDN[23A$X*;U%@#*11*(U!:1Q*$RB:K17?:,6'EI\&AQ(-
DD:A- :E<2A-H&BV M:(PUZ3G-K+UHDH-H?B;JJ"I)E>1+\B;)R#+^7G27'ZA9":71,ZONC>O5ZA0, MU)N$T@2*9@O&V).>VY^T*E+\[=6*!'4IH30#I3$HC4-I D6SM6*\3V^"K4A0 MXQ4-*HU :@]
(XE"90-%LTQE+UW)[#UTR.1&]Q0-W="]>!0T<5*)I]:I6Q;GVW M=5MO*XQ!&Z?Y+NL\]M=P[&/.K2->M^[!^J872F-0&H?2!(IFB\!XL[[;F_VL M\H64RX(]CQMOOA%L8NSA>R4@G;.8T]V:
M0>Q3RMJ-"]1+A=(8E,:A-(&BV0(Q7J

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{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|{2G:HI&HL9C>*=#6EL5K9%N/.2(?<=Y^2;,_]OLX+IROR\4J M?W=R7Q3K-V=G^>P^7D;Y.;J.5^57;M-L&17EHG=6;I.XFA>;[1/,_R:W-T7U0UGMEV_7T5U\'1>_KS]GY6=G3\H\6<:K/$E73A;?OCMYWW^CSGO5!O4]_IW$7_*=_MCYWJ6IE)TS^J3\+YNY->]8CB13PK*B{]_<07\6+1265C^/_&O3D:.\)YL\'YLPV& MAS:X:#:X>#{"P5]<[_$WUWN^R:&?4_JE[U]ITFV?)\53S(V*Z/)MEGYQLNK^_MI5=]4#]/Z^W+9U:RJB)U763ESY-RN^+R*ETNDZ+,2)$[T6KN7*6K(EG=9[4M'Y/H)EDD11+GSFOGYRC+HNKH[_SDQD64+/)_OCTKRD=0.6>S9C2Q'6UP8+2A M\ZGT[W-'K.;QO&5[W[!]Y*7M0_OV_8$%."M_=$|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s Mf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}$++)[;1XLAQ@P;HH"&J2513E&;$;JR;(V-J/9;Z M<$IU_MI_JHR4FXGJ[6#5SK$Z??!L3OJX4?S2&V+LC[%KYE#-136!:AZJ^:@6MH%J(:A+5%*69'=;5E#&^FLL8K92@FHMJ M4\5'U+4D]BE*_;FBRIC M>1'EN-,*=1SQ-(]"JH)5/-051_O+V/2G%78.PB*#ARBFD0U16EF?G1%94Q5M5'Z[S\]YY,=ZF:2B;6%IQIUY#UIK"M&^"]JYJ"90S4,U'}4"5 M13:*;HC0S MJ+JO.L,[*F.TKX)!+JH)5/-0S4>U -5"5).HIBC-S)ONJXR)OMH=Z1PQM*^"M:@+5/%3SQ_N+O@QZAV:6:&,%U22J*4HS Z0;*^,?U5BQPYU#A3964$V@FH=J M?J/MAFI\<2A4:&<%U22J*4HS0Z4[*V.JL{)]N:,O?_BEVN[;#_Y3O:,[=Y+= M):ODN#:CFHUJ:B&J2513E&;F3==:,QO9:RY$OZM#2*:JY["90S4,U?A0#50E23J*8HS8RG;J),+_"]FBRIC M>1'EN-,*=1SQ-(]"JH)5/-051_O+V/2G%78.PB*#ARBFD0U16EF?G1%94Q5M5'Z[S\]YY,=ZF:2B;6%IQIUY#UIK"M&^"]JYJ"90S4,U'}4"5 M13:*;HC0S MJ+JO.L,[*F.TKX)!+JH)5/-0S4>U -5"5).HIJ;[:Q=-=MC"[T06$S>KJX,K475[I':Q8G#_5:JN4-K3%#2RZHYJ*:0#4/U7Q4"U-M1#6) M:FJZ7PX:G4\G%P=RI@LN4WO!Y7U]9=I\]]*TUL7]&F[W/-!D_/P5C=$XA MVD%IM&<7937GP0(=TD,U'}4"5 M13:*;HC0S7+I:,K6>2L?FFM'7@W--M(F" M:BZJ"53S4,U'M0#50E23J*8HS8RG;J),+_"]FBRIC M>1'EN-,*=1SQ-(]"JH)5/-051_O+V/2G%78.PB*#ARBFD0U16EF?IVL*4#D,.]V MT7-2S@YMO@OKV,\U?OEV7>?P45=?&S)U%?%L.U3NM#@EE21G0QT^*=/NW MI'_BW*1%D2[K#^_C:!YGU1W*K]^F.?'X235]7:A^MNY_'102P,$% @ M)(%G62B_ ^928 @ N 8 !D !X,"]W;W)K&ULMK55=3]LP%/TK5H8F)@WRU:2,19&@;!I2V2HZMH=I#VYRFUHX<6:[+?S[73LA M+1]}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`D!V.A^=4BSI,&B.V_*K?2O06D>*,V'HC7E M==B'/4;$>5ETM6H_ADM04#67E?]$6TVYH"W8(H:1/-,ZY/R.H#S7]#?]B\ M4 &J Z;S?P%02.$% @ >)(%G62B_ ^33"P AW$!D !X;"]W;W)K&ULQ5UM#X>Y_.E7(7YF_11)NHO]VFV"@OU,7L8YX^9#!?5 MH%4\MB<3?[P*HV1T=5%]]RcNEDC711PE\D/&\O5J%6;?;F27\YNK;.Q;0:4"'^R5C.BY(B5#^>Y$S&<EHM\URX/IO M+^QOJX-7!W,7YG*6QO^.%L7R9IG%?_L^I*OM8+4'JRC9_R_;@VQ-T#QP /L!0"[ZP'G.\#LL#=#G"[#O"V M ZI#'V^.O3(<#XOPZB)+GUE6HA5;^4ME_6]TLE>4E(%R6V3JKY$;5US=%NG\ MRS*-%S++_.]XOC_f4<%.V:Y R,&ZEBRI9I-EF#S(G$4)NYI/UZMU''9RP7XI MEC)CLW2E(G19ALZ39#^G><[NOE7?IHE,"O;*RR*,XORU(OU\R]FK/[^^&!=] MS\OMC^?;O;S9[*7=L)<.>Y\FQ3)G(EG(!3"><X^-]9/Q866QG-OO%;#?L'^J9*=BZ%/XE?WG8QK'3)W?SV&V^"\4!9OMN/!VRIQY MGC^&:IZN3BUG;DVJ?Q?CIWTS0UC;G4!8#F&]LS,(*R"L M>W;(:]C V]G 0VVPR5QS(W-%B?HLV:M89;#7[$Zj.[!45\)Y'.9Y1+)B6%[7

MSOZ08%C{G+!DD^F*.M\"MDDZ >)0YHDSKPU`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{E RL9)V005F^E6 M/2M@VT=*7S:I[B=EXZ1L@HK-=)G6_38J4O^],74BR*P) . M236D4N@7*;E MM/RV1:GM2-D[*)JC8 M3)=I;6 CSP3-*.P@[=»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|| MVL >S+=^JZQ%I:*=2 TDP(J#.\G]\VB?/W#M\9'/79'KE,"BF?G%?93AR M@H!#:1P#M;2TUWK^@U6FS?!'C"JH MZ<#-3AZ_PIC/C>,K)=?^BX[!-UE@5 [:R&X$6P4=$V&ESV,=S@!Q_ (@'@&Q MUQT">95WU- \5?*(E/.V;&[C4_5H*XX)]U/V1ME;9G$FWT-C2VPTDC7;#-K> M:HW>HT>]%'7U0F_NP%#&]=N4&!O/H4@YQ52$A>===7"\"VD$OE6&B03_7A3;* MMLRO2VD'MN0RFQNCE>YI"1FV&UlQ9UM<]NXM<>_"L;MW.G.O+'X+.M58BI>UG$]. ^-IB788E<259)RDl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~9[%-/&\]T+=5;:1[_F! MYBJ+43C5C)BS,B-=-7UQU=3IJEB9B5EAWG QZYN7.T[>\"]BQ:EY_<-3MU^C4J1^FF@\M1EZL];9Q2B(?,V'-J-8[Y"=M1SIP_3%%ZG3AS]M&BZH M#3FZSN:SU*R$\8!:,;/2CB>XQ9YU&>LR;R!1ETN&S?6MIX"*3 M?FE[3?[%/A$XPI3^31^Z9Q:CU(LU_QV-E $^]C3?4 M*Y/5;AC<515KPK,I MSW.Z\&^[!0.OVB2ODIE=?1C'GMH82E/8=@XZD94>;,N@;_:9I.S4&M==(;3V9VWK. MO.KFDYA'5;MYLZM$#-Z28KW-BZI]MMZ2?+-XB==\F5=/O/[F%/58BM*7F!,& MB]%4GR]8;$+#KZ;1=*+[]37R24\FE)X[HSS.MPX9Y*'WXO_:%S%0/G? T/)*6>69">]D/'!1;}$/1U&C*_-9S)[C*4W)ZG*QALZ2R M1]IE,YKHSX-9R:+4;^_AA]1K;KR737Z\AW\TV^%/(<>3B^&,$U6?+5@H@\MA{BYE35YXOO!7NW04,;?=06@:E42B-H6AJ MX*4PX'OH%P0^5!" TC(HC4)I#$53(RVU]^M'8P:S7PSSX[UZ=+,?3#@$/8H MDD*+9"B:&ADI%/ANH4#\+$:OIV). B*N%2/83YNB$0-:\2YWRUXR1? M_'-WR,_)4U[8YSQ0+ <8WA1%=U!TC(HC4)I#$53@RYUDF *GSE Q1(H+8/2*)3&4#0U MTF* "=P"S" _-4F1O\W(MZ,MVR_\SWR\%MX;87(<23?2!#]JP|"B10DMD*)]Z M357]D F"0I]SWO9OIS>V=Z*D>55L]V*\"V#TBB4QE T-=)2$@K=DM#@(T-'VZ?} M1-\M8;&*4GU=F0TUC6+]D;%M(#+U31/N:HYUHQ1900=B%-!N[-!%/=-7> M9F1LO.I#HGU(I&BD')3DRWBK#I-:1>C6*D:LB Y- <'8$6VQ25+=-::>1:& MS2C5-IVZZSBRT4528(C< H-E=DK^.*I/%_RZ4 _FS/=Z*'=-92606D42F.H MFAIRJ2I$<%4A@JH*4%H&I5$HC:%H.J2EJA#U4Q7&'3D0F9GZ(,:E=F.QB?3C M\VP<_?6OQ<0X'L!=V;',E'E\Y,[C0>_4(\N9'/K,88N-/@#9,/I[XN-I[\? M=E=ZK%-E^AP- 6*C<@>]<>F>L#!*/3'>ZMN"K68Z%L0W'4:ZI.S,QC=>6G? M(5O\476OW =6D[__FEG=C#VN$7M>(,; 1NR)C:^1:TIBP%EM@M ML&#?[+H+&|H(H+0LMIR4:IS?#!524#0U%) (B=U;793> ^E<^7V[*5?GT56X, MMD80*J5 :1F41J$TAJ*IL9922NQ_]WO>&+KL DK+H#0*I3$430VM%'9BM[#3 M_9XWM@=0IOBZWS&Q67JB_5+%8^=%$? V%ELP[FVGR9N2LVUG%2O(G[K7I8\K$ MZ%((C"V#TBB4QE T-=)2/9=#?=6F,[90N_W;NZ"!C|$4.D&2J-0&D/1U 8@I9L8?]Q(#-TN M Z5E4!]%TAB*ID9:2C^Q6_H!B72QN;1"? ^=A,=%R%A,]!=%W2;.7>.Q'I5Z M2>Q>ZM'I/5'<=3;JK-LDZS:AW.2;?>&*CI?WN^IHSXZ W\UW;&A7 Z5E4!]%TAB*I@99:A!O\4.NXE@7RM0^<:? VWYXE],Y'W24,?GB@BT:@-_JE,11-C;P4)!+XHI$$JCQ M:1F41J$TAJ*ID3[{)NE_9=%(8MM%H9\%,#$R^DX+Q[C&;S'2-SBY:SW6JS++ M3P9D^:Z<-+'D\?J ,K,8Z5EFP[MYC!WO<;Z3>,R28]OEFZ,2UZL_H*N=(#2 M,BB-0FD,15._YBOUAFF_,SY=&%$'R L5G%[?+337;&QCI,Y_+3?LH$!65]T'G 7)_OB+D+'/PT01<<0&D42F,HFMH0I"HQC>#\)E2% M@-(R*(U":0Q%4R,M58BI>UG$]. ^(3'L$>1%%HD0]4R$C5 M8.I6#?3.N)\)8Z(8.?@RA2Q:@-_]E,11- #;84,Z;P$SZGT*TG4%H&I5$HC:%H M;]2E_#(=L)1BO!@XM7WP5N^]+:=MZ/'7[I46%A/CT\[N.R.T:2]EC]2U**W M%)B:>R3TY2D6$ZVV63>%=E.8NTYC?28UA=2M*3B_,:&^=FC?J5E4![]%TAB* MIL94RAW]I ^^22*'Z!I2606D42F,HFAI;J6^DW[M+X@@X(^]1GY);3/27'-T4 MVDUA[IJ,=9;4.5*WCO'IX*;#P52SB;O^QYZFB[OL<_+!!Y0\H MC4)I#$53VX^4/U*X_)%"Y0\H+8/2*)3&4#0UTE+ ^2#N^)WOL*1.I*I[%M'O? M8]2'WD!,OD7\VV<_?^+D3;X5C>#+?L/PZBLI*[+B=4V:9;ZQ-XA#P=[DO)M\ M-]'GZ.[{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|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}06T==6IE;WY]8OOH7YDRY-"_$ MQ&12L-)VD;HXCGV-,'9]2W.S:N+H;I-^#K7MIIFG)F2CF]W&/FN:&>>>:NC0Q MK;-U5WU*&>]3\G1RV!,6M0MG:4/&ODSH5[X/V)]{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end XML 77 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show= {};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE') {var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e).style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 78 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 80 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html4143231false1100false167 falsefalseR1.htm00000001 - Document - CoverSheethttp://mckesson123.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSSheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSStatements2 falsefalseR3.htm9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMESheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMECONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOMEStatements3 falsefalseR4.htm9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETSSheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSCONDENSED CONSOLIDATED BALANCE SHEETSStatements4 falsefalseR5.htm9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Sheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParentheticalCONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)Statements5 falsefalseR6.htm9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICITSheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITCONDENSED CONSOLIDATED STATEMENTS OF

STOCKHOLDERS' DEFICITStatements6 falsefalseR7.htm9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)Sheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParentheticalCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)Statements7 falsefalseR8.htm9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSSheethttp://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWSStatements8 falsefalseR9.htm9952158 - Disclosure - Significant Accounting PoliciesSheethttp://mckesson123.com/role/SignificantAccountingPoliciesSignificant Accounting PoliciesNotes9 falsefalseR10.htm9952159 - Disclosure - Held for SaleSheethttp://mckesson123.com/role/HeldforSaleHeld for SaleNotes10 falsefalseR11.htm9952160 - Disclosure - Restructuring, Impairment, and Related Charges, NetSheethttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetRestructuring, Impairment, and Related Charges, NetNotes11 falsefalseR12.htm9952161 - Disclosure - Income TaxesSheethttp://mckesson123.com/role/IncomeTaxesIncome TaxesNotes12 falsefalseR13.htm9952162 - Disclosure - Earnings Per Common ShareSheethttp://mckesson123.com/role/EarningsPerCommonShareEarnings Per Common ShareNotes13 falsefalseR14.htm9952163 - Disclosure - Goodwill and Intangible Assets, NetSheethttp://mckesson123.com/role/GoodwillandIntangibleAssetsNetGoodwill and Intangible Assets, NetNotes14 falsefalseR15.htm9952164 - Disclosure - Debt and Financing ActivitiesSheethttp://mckesson123.com/role/DebtandFinancingActivitiesDebt and Financing ActivitiesNotes15 falsefalseR16.htm9952165 - Disclosure - Hedging ActivitiesSheethttp://mckesson123.com/role/HedgingActivitiesHedging ActivitiesNotes16 falsefalseR17.htm9952166 - Disclosure - Fair Value MeasurementsSheethttp://mckesson123.com/role/FairValueMeasurementsFair Value MeasurementsNotes17 falsefalseR18.htm9952167 - Disclosure - Commitments and Contingent LiabilitiesSheethttp://mckesson123.com/role/CommitmentsandContingentLiabilitiesCommitments and Contingent LiabilitiesNotes18 falsefalseR19.htm9952168 - Disclosure - Stockholders' DeficitSheethttp://mckesson123.com/role/StockholdersDeficitStockholders' DeficitNotes19 falsefalseR20.htm9952169 - Disclosure - Segments of BusinessSheethttp://mckesson123.com/role/SegmentsofBusinessSegments of BusinessNotes20 falsefalseR21.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes21 falsefalseR22.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes22 falsefalseR23.htm9954471 - Disclosure - Significant Accounting Policies (Policies)Sheethttp://mckesson123.com/role/SignificantAccountingPoliciesPoliciesSignificant Accounting Policies (Policies)Policieshttp://mckesson123.com/role/SignificantAccountingPolicies23 falsefalseR24.htm9954472 - Disclosure - Held for Sale (Tables)Sheethttp://mckesson123.com/role/HeldforSaleTablesHeld for Sale (Tables)Tableshttp://mckesson123.com/role/HeldforSale24 falsefalseR25.htm9954473 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)Sheethttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTablesRestructuring, Impairment, and Related Charges, Net (Tables)Tableshttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet25 falsefalseR26.htm9954474 - Disclosure - Income Taxes (Tables)Sheethttp://mckesson123.com/role/IncomeTaxesTablesIncome Taxes (Tables)Tableshttp://mckesson123.com/role/IncomeTaxes26 falsefalseR27.htm9954475 - Disclosure - Earnings Per Common Share (Tables)Sheethttp://mckesson123.com/role/EarningsPerCommonShareTablesEarnings Per Common Share (Tables)Tableshttp://mckesson123.com/role/EarningsPerCommonShare27 falsefalseR28.htm9954476 - Disclosure - Goodwill and Intangible Assets, Net (Tables)Sheethttp://mckesson123.com/role/GoodwillandIntangibleAssetsNetTablesGoodwill and Intangible Assets, Net (Tables)Tableshttp://mckesson123.com/role/GoodwillandIntangibleAssetsNet28 falsefalseR29.htm9954477 - Disclosure - Debt and Financing Activities (Tables)Sheethttp://mckesson123.com/role/DebtandFinancingActivitiesTablesDebt and Financing Activities (Tables)Tableshttp://mckesson123.com/role/DebtandFinancingActivities29 falsefalseR30.htm9954478 - Disclosure - Hedging Activities (Tables)Sheethttp://mckesson123.com/role/HedgingActivitiesTablesHedging Activities (Tables)Tableshttp://mckesson123.com/role/HedgingActivities30 falsefalseR31.htm9954479 - Disclosure - Fair Value Measurements (Tables)Sheethttp://mckesson123.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://mckesson123.com/role/FairValueMeasurements31 falsefalseR32.htm9954480 - Disclosure - Commitments and Contingent Liabilities (Tables)Sheethttp://mckesson123.com/role/CommitmentsandContingentLiabilitiesTablesCommitments and Contingent Liabilities (Tables)Tableshttp://mckesson123.com/role/CommitmentsandContingentLiabilities32 falsefalseR33.htm9954481 - Disclosure - Stockholders' Deficit (Tables)Sheethttp://mckesson123.com/role/StockholdersDeficitTablesStockholders' Deficit (Tables)Tableshttp://mckesson123.com/role/StockholdersDeficit33 falsefalseR34.htm9954482 - Disclosure - Segments of Business (Tables)Sheethttp://mckesson123.com/role/SegmentsofBusinessTablesSegments of Business (Tables)Tableshttp://mckesson123.com/role/SegmentsofBusiness34 falsefalseR35.htm9954483 - Disclosure - Significant Accounting Policies (Details)Sheethttp://mckesson123.com/role/SignificantAccountingPoliciesDetailsSignificant Accounting Policies (Details)Detailshttp://mckesson123.com/role/SignificantAccountingPoliciesPolicies35 falsefalseR36.htm9954484 - Disclosure - Held for Sale - Narrative (Details)Sheethttp://mckesson123.com/role/HeldforSaleNarrativeDetailsHeld for Sale - Narrative (Details)Details36 falsefalseR37.htm9954485 - Disclosure - Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details)Sheethttp://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetailsHeld for Sale - Schedule of Assets and Liabilities Held for Sale (Details)Details37 falsefalseR38.htm9954486 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrtive (Details)Sheethttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetailsRestructuring, Impairment, and Related Charges, Net - Narrtive (Details)Detailshttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables38 falsefalseR39.htm9954487 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)Sheethttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetailsRestructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)Details39 falsefalseR40.htm9954488 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)Sheethttp://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetailsRestructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)Details40 falsefalseR41.htm9954489 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)Sheethttp://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetailsIncome Taxes - Schedule of Components of Income Tax Expense (Details)Details41 falsefalseR42.htm9954490 - Disclosure - Income Taxes - Narrative (Details)Sheethttp://mckesson123.com/role/IncomeTaxesNarrativeDetailsIncome Taxes - Narrative (Details)Details42 falsefalseR43.htm9954491 - Disclosure - Earnings Per Common Share - Narrative (Details)Sheethttp://mckesson123.com/role/EarningsPerCommonShareNarrativeDetailsEarnings Per Common Share - Narrative (Details)Details43 falsefalseR44.htm9954492 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)Sheethttp://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetailsEarnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)Details44 falsefalseR45.htm9954493 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)Sheethttp://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetailsGoodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)Details45 falsefalseR46.htm9954494 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)Sheethttp://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetailsGoodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)Details46 falsefalseR47.htm9954495 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)Sheethttp://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetailsGoodwill and Intangible Assets, Net - Narrative (Details)Details47 falsefalseR48.htm9954496 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)Sheethttp://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetailsDebt and Financing Activities - Schedule of Long-Term Debt (Details)Details48 falsefalseR49.htm9954497 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)Sheethttp://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetailsDebt and Financing Activities - Long-Term Debt Narrative (Details)Details49 falsefalseR50.htm9954498 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)Sheethttp://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetailsDebt and Financing Activities - Revolving Credit Facilities Narrative (Details)Details50 falsefalseR51.htm9954499 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)Sheethttp://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetailsDebt and Financing Activities - Commercial Paper Narrative (Details)Details51 falsefalseR52.htm9954500 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)Sheethttp://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetailsHedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)Details52 falsefalseR53.htm9954501 - Disclosure - Hedging Activities - Narrative (Details)Sheethttp://mckesson123.com/role/HedgingActivitiesNarrativeDetailsHedging Activities - Narrative (Details)Details53 falsefalseR54.htm9954502 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)Sheethttp://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetailsHedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)Details54 falsefalseR55.htm9954503 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)Sheethttp://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetailsHedging Activities - Schedule of Fair Value of Derivatives (Details)Details55 falsefalseR56.htm9954504 - Disclosure - Fair Value Measurements - Narrative (Details)Sheethttp://mckesson123.com/role/FairValueMeasurementsNarrativeDetailsFair Value Measurements - Narrative (Details)Details56 falsefalseR57.htm9954505 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)Sheethttp://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetailsFair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)Details57 falsefalseR58.htm9954506 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)Sheethttp://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetailsCommitments and Contingent Liabilities - Narrative (Details)Details58 falsefalseR59.htm9954507 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)Sheethttp://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetailsCommitments and Contingent Liabilities - Estimated Accrual Liability (Details)Details59 falsefalseR60.htm9954508 - Disclosure - Stockholders' Deficit - Narrative (Details)Sheethttp://mckesson123.com/role/StockholdersDeficitNarrativeDetailsStockholders' Deficit - Narrative (Details)Details60 falsefalseR61.htm9954509 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)Sheethttp://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetailsStockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)Details61 falsefalseR62.htm9954510 - Disclosure - Segments of Business - Narrative (Details)Sheethttp://mckesson123.com/role/SegmentsofBusinessNarrativeDetailsSegments of Business - Narrative (Details)Details62 falsefalseR63.htm9954511 - Disclosure - Segments of Business - Reportable operating segment (Details)Sheethttp://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetailsSegments of Business - Reportable operating segment (Details)Details63 falsefalseAll ReportsBookAll Reports mck-20240930.htmmck-20240930.xsdmck-20240930_cal.xmlmck-20240930_def.xmlmck-20240930_lab.xmlmck-20240930_pre.xml mck-20240930_g1.jpg http://fasb.org/srt/2024http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 83 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mck-20240930.htm": { "nsprefix": "mck", "nsuri": "http://mckesson123.com/20240930", "dts": { "inline": { "local": ["mck-20240930.htm"] }, "schema": { "local": ["mck-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mck-20240930_cal.xml"] }, "definitionLink": { "local": ["mck-20240930_def.xml"] }, "labelLink": { "local": ["mck-20240930_lab.xml"] }, "presentationLink": { "local": ["mck-20240930_pre.xml"] } }, "keyStandard": 287, "keyCustom": 36, "axisStandard": 33, "axisCustom": 0, "memberStandard": 57, "memberCustom": 51, "hidden": { "total": 7, "http://xbrl.sec.gov/ecd/2024": 2, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 414, "entityCount": 1, "segmentCount": 110, "elementCount": 666, "unitCount": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 1182, "http://xbrl.sec.gov/dei/2024": 38, "http://xbrl.sec.gov/ecd/2024": 19, "http://fasb.org/srt/2024": 1 }, "report": { "R1": { "role": "http://mckesson123.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "",

```
"menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "longName": "9952151 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R3": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952152 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R4": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "longName": "9952153 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:ReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R5": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952154 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R6": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "longName": "9952155 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R7": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical", "longName": "9952156 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:CommonStockDividendsPerShareDeclared", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952157 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R9": { "role": "http://mckesson123.com/role/SignificantAccountingPolicies", "longName": "9952158 - Disclosure - Significant Accounting Policies", "shortName": "Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://mckesson123.com/role/HeldforSale", "longName": "9952159 - Disclosure - Held for Sale", "shortName": "Held for Sale", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet", "longName": "9952160 - Disclosure - Restructuring, Impairment, and Related Charges, Net", "shortName": "Restructuring, Impairment, and Related Charges, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://mckesson123.com/role/IncomeTaxes", "longName": "9952161 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://mckesson123.com/role/EarningsPerCommonShare", "longName": "9952162 - Disclosure - Earnings Per Common Share", "shortName": "Earnings Per Common Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNet", "longName": "9952163 - Disclosure - Goodwill and Intangible Assets, Net", "shortName": "Goodwill and Intangible Assets, Net", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://mckesson123.com/role/DebtandFinancingActivities", "longName": "9952164 - Disclosure - Debt and Financing Activities", "shortName": "Debt and Financing Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://mckesson123.com/role/HedgingActivities", "longName": "9952165 - Disclosure - Hedging Activities", "shortName": "Hedging Activities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://mckesson123.com/role/FairValueMeasurements", "longName": "9952166 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilities", "longName": "9952167 - Disclosure - Commitments and Contingent Liabilities", "shortName": "Commitments and Contingent Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://mckesson123.com/role/StockholdersDeficit", "longName": "9952168 - Disclosure - Stockholders' Deficit", "shortName": "Stockholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://mckesson123.com/role/SegmentsofBusiness", "longName": "9952169 - Disclosure - Segments of Business", "shortName": "Segments of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors":
```

{ "span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-7", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ecd:NonRule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ecd:NonRule10b51ArrTrmntdFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Significant Accounting Policies (Policies)", "shortName": "Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://mckesson123.com/role/HeldforSaleTables", "longName": "9954472 - Disclosure - Held for Sale (Tables)", "shortName": "Held for Sale (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables", "longName": "9954473 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)", "shortName": "Restructuring, Impairment, and Related Charges, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://mckesson123.com/role/IncomeTaxesTables", "longName": "9954474 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R27": { "role": "http://mckesson123.com/role/EarningsPerCommonShareTables", "longName": "9954475 - Disclosure - Earnings Per Common Share (Tables)", "shortName": "Earnings Per Common Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables", "longName": "9954476 - Disclosure - Goodwill and Intangible Assets, Net (Tables)", "shortName": "Goodwill and Intangible Assets, Net (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://mckesson123.com/role/DebtandFinancingActivitiesTables", "longName": "9954477 - Disclosure - Debt and Financing Activities (Tables)", "shortName": "Debt and Financing Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://mckesson123.com/role/HedgingActivitiesTables", "longName": "9954478 - Disclosure - Hedging Activities (Tables)", "shortName": "Hedging Activities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://mckesson123.com/role/FairValueMeasurementsTables", "longName": "9954479 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables", "longName": "9954480 - Disclosure - Commitments and Contingent Liabilities (Tables)", "shortName": "Commitments and Contingent Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://mckesson123.com/role/StockholdersDeficitTables", "longName": "9954481 - Disclosure - Stockholders' Deficit (Tables)", "shortName": "Stockholders' Deficit (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://mckesson123.com/role/SegmentsofBusinessTables", "longName": "9954482 - Disclosure - Segments of Business (Tables)", "shortName": "Segments of Business (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://mckesson123.com/role/SignificantAccountingPoliciesDetails", "longName": "9954483 - Disclosure - Significant Accounting Policies (Details)", "shortName": "Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "longName": "9954484 - Disclosure - Held for Sale - Narrative (Details)", "shortName": "Held for Sale - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-73", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R37": { "role": "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails", "longName": "9954485 - Disclosure - Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details)", "shortName": "Held for Sale - Schedule of Assets and Liabilities Held for Sale (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-75", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-75", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "longName": "9954486 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrtive (Details)", "shortName": "Restructuring, Impairment, and Related Charges, Net - Narrtive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RestructuringCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "us-gaap:RestructuringCostsAndAssetImpairmentCharges", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R39": { "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "longName": "9954487 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)", "shortName": "Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:SeveranceCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:BusinessExitCosts1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R40": { "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "longName": "9954488 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)", "shortName": "Restructuring, Impairment, and

Related Charges, Net - Summary of Restructuring Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:RestructuringReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R41": { "role": "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails", "longName": "9954489 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)", "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R42": { "role": "http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "longName": "9954490 - Disclosure - Income Taxes - Narrative (Details)", "shortName": "Income Taxes - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-7", "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails", "longName": "9954491 - Disclosure - Earnings Per Common Share - Narrative (Details)", "shortName": "Earnings Per Common Share - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R44": { "role": "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "longName": "9954492 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)", "shortName": "Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R45": { "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "longName": "9954493 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R46": { "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails", "longName": "9954494 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)", "shortName": "Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R47": { "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails", "longName": "9954495 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)", "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "longName": "9954496 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)", "shortName": "Debt and Financing Activities - Schedule of Long-Term Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": ["span", "div", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R49": { "role": "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "longName": "9954497 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)", "shortName": "Debt and Financing Activities - Long-Term Debt Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:DebtAndCapitalLeaseObligations", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R50": { "role": "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "longName": "9954498 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)", "shortName": "Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-203", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-203", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "longName": "9954499 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)", "shortName": "Debt and Financing Activities - Commercial Paper Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-209", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-209", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R52": { "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "longName": "9954500 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)", "shortName": "Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-213", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "cad", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-215", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "gbp", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R53": { "role": "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "longName": "9954501 - Disclosure - Hedging Activities - Narrative (Details)", "shortName": "Hedging Activities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "span", "div", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "mck:DerivativeNotionalAmountTerminated", "unitRef": "cad", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": ["span", "div", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R54": { "role": "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "longName": "9954502 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)", "shortName": "Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "span", "div", "us-gaap:DerivativesPolicyTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "longName": "9954503 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)", "shortName": "Hedging Activities - Schedule of Fair Value of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-257", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-257", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FairValueByBalanceSheetGroupingTextBlock", "ix:continuation", "body", "html"],

```
"reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "longName": "9954504 - Disclosure - Fair Value Measurements - Narrative (Details)", "shortName": "Fair Value Measurements - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:EquitySecuritiesFVNINoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "us-gaap:FairValueMeasurementPolicyPolicyTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R57": { "role": "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails", "longName": "9954505 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)", "shortName": "Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-261", "name": "us-gaap:LongTermDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R58": { "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "longName": "9954506 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)", "shortName": "Commitments and Contingent Liabilities - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:GainLossRelatedToLitigationSettlement", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-286", "name": "us-gaap:LossContingencyNumberOfPlaintiffs", "unitRef": "plaintiff", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R59": { "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "longName": "9954507 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)", "shortName": "Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-278", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-278", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails", "longName": "9954508 - Disclosure - Stockholders' Deficit - Narrative (Details)", "shortName": "Stockholders' Deficit - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-6", "name": "mck:CommonStockVotingRightsNumberofVotesPerCommonShare", "unitRef": "vote", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mck:ExciseTaxAccrual", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R61": { "role": "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails", "longName": "9954509 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)", "shortName": "Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Loss by Component (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-17", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } }, "R62": { "role": "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails", "longName": "9954510 - Disclosure - Segments of Business - Narrative (Details)", "shortName": "Segments of Business - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfReportableSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": null }, "R63": { "role": "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails", "longName": "9954511 - Disclosure - Segments of Business - Reportable operating segment (Details)", "shortName": "Segments of Business - Reportable operating segment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "mck:OperatingIncomeLossAndOtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-6", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mck-20240930.htm", "unique": true } } }, "tag": { "mck_A090NotesDueDecember32025Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A090NotesDueDecember32025Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "0.90% Notes due December 3, 2025", "label": "0.90% Notes Due December 3, 2025 [Member]", "documentation": "0.90% Notes Due December 3, 2025" } } }, "auth_ref": [] }, "mck_A130NotesDueAugust152026Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A130NotesDueAugust152026Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.30% Notes due August 15, 2026", "label": "1.30% Notes Due August 15, 2026 [Member]", "documentation": "1.30% Notes Due August 15, 2026" } } }, "auth_ref": [] }, "mck_A1500NotesDue2025Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A1500NotesDue2025Member", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.500% Notes due 2025", "label": "1.500% Notes Due 2025 [Member]", "documentation": "1.500% Notes Due 2025" } } }, "auth_ref": [] }, "mck_A150EuroNotesDueNovember172025Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A150EuroNotesDueNovember172025Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.50% Euro Notes due November 17, 2025", "label": "1.50% Euro Notes Due November 17, 2025 [Member]", "documentation": "1.50% Euro Notes Due November 17, 2025" } } }, "auth_ref": [] }, "mck_A1625NotesDue2026Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A1625NotesDue2026Member", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "1.625% Notes due 2026", "label": "1.625% Notes Due 2026 [Member]", "documentation": "1.625% Notes Due 2026" } } }, "auth_ref": [] }, "mck_A163EuroNotesDueOctober302026Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A163EuroNotesDueOctober302026Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "1.63% Euro Notes due October 30, 2026", "label": "1.63% Euro Notes Due October 30, 2026 [Member]", "documentation": "1.63% Euro Notes Due October 30, 2026" } } }, "auth_ref": [] }, "mck_A3125NotesDue2029Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A3125NotesDue2029Member", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "3.125% Notes due 2029", "label": "3.125% Notes Due 2029 [Member]", "documentation": "3.125% Notes Due 2029" } } }, "auth_ref": [] }, "mck_A313SterlingNotesDueFebruary172029Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A313SterlingNotesDueFebruary172029Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.13% Sterling Notes due February 17, 2029", "label": "3.13% Sterling Notes Due February 17, 2029 [Member]", "documentation": "3.13% Sterling Notes Due February 17, 2029" } } }, "auth_ref": [] }, "mck_A380NotesDueMarch152024Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A380NotesDueMarch152024Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.80% Notes due March 15, 2024", "label": "3.80% Notes Due March 15, 2024 [Member]", "documentation": "3.80% Notes Due March 15, 2024" } } }, "auth_ref": [] }, "mck_A395NotesDueFebruary162028Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A395NotesDueFebruary162028Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "3.95% Notes due February 16, 2028", "label": "3.95% Notes Due February 16, 2028 [Member]", "documentation": "3.95% Notes Due February 16, 2028" } } }, "auth_ref": [] }, "mck_A4.25NotesDueSeptember152029Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A4.25NotesDueSeptember152029Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.25% Notes due September 15, 2029", "label": "4.25% Notes Due September 15, 2029 [Member]", "documentation": "4.25% Notes Due September 15, 2029" } } }, "auth_ref": [] }, "mck_A475NotesDueMay302029Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A475NotesDueMay302029Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.75% Notes due May 30, 2029", "label": "4.75% Notes Due May 30, 2029 [Member]", "documentation": "4.75% Notes Due May 30, 2029" } } }, "auth_ref": [] }, "mck_A488NotesDueMarch152044Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A488NotesDueMarch152044Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.88% Notes due March 15, 2044", "label": "4.88% Notes Due March 15, 2044 [Member]", "documentation": "4.88% Notes Due March 15, 2044" } } }, "auth_ref": [] }, "mck_A490NotesDueJuly152028Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A490NotesDueJuly152028Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "4.90% Notes due July 15, 2028", "label": "4.90% Notes Due July 15, 2028 [Member]", "documentation": "4.90% Notes Due July 15, 2028" } } }, "auth_ref": [] }, "mck_A510NotesDueJuly152033Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A510NotesDueJuly152033Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.10% Notes due July 15, 2033", "label": "5.10% Notes Due July 15, 2033 [Member]", "documentation": "5.10% Notes Due July 15, 2033" } } }, "auth_ref": [] }, "mck_A525NotesDueFebruary152026Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A525NotesDueFebruary152026Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "5.25% Notes due February 15, 2026", "label": "5.25% Notes Due February 15, 2026 [Member]", "documentation": "5.25% Notes Due February 15, 2026" } } }, "auth_ref": [] }, "mck_A600NotesDueMarch12041Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A600NotesDueMarch12041Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "6.00% Notes due March 1, 2041", "label": "6.00% Notes Due March 1, 2041 [Member]", "documentation": "6.00% Notes Due March 1, 2041" } } }, "auth_ref": [] }, "mck_A765DebenturesDueMarch12027Member": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "A765DebenturesDueMarch12027Member", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "7.65% Debentures due March 1, 2027", "label": "7.65% Debentures Due March 1, 2027 [Member]", "documentation": "7.65% Debentures Due March 1, 2027" } } }, "auth_ref": [] }, "mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax", "label": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling
```

```
Interest [Member]", "documentation": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest" } } }, "auth_ref": [] },
"mck_AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930",
"localname": "AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax", "label": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Noncontrolling Interest
[Member]", "documentation": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Noncontrolling Interest" } } }, "auth_ref": [] },
"mck_AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930",
"localname": "AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) on Net Investment Hedges, Net of Tax", "label": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Portion Attributable to
Parent [Member]", "documentation": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Portion Attributable to Parent" } } }, "auth_ref": [] }, "us-
gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AOCIAttributableToParentNetOfTaxRollForward", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a
reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesLineItems", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases [Line Items]", "label":
"Accelerated Share Repurchases [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable
information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AcceleratedShareRepurchasesTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AcceleratedShareRepurchasesTable", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accelerated Share Repurchases [Table]", "label":
"Accelerated Share Repurchases [Table]", "documentation": "Disclosure of information about accelerated share repurchase (ASR) program." } } }, "auth_ref": [ "r165" ] }, "us-
gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": {
"role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Drafts and accounts payable", "label": "Accounts
Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to
vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal
operating cycle if longer)." } } }, "auth_ref": [ "r109", "r876" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
"http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Accrued Liabilities,
Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on
contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.
Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r112" ] }, "us-
gaap_AccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesMember", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued
Liabilities", "label": "Accrued Liabilities [Member]", "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature,
are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered." } } }, "auth_ref": [ "r112" ] }, "us-
gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss)
Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit
plans attributable to the noncontrolling interest." } } }, "auth_ref": [ "r18", "r30", "r128", "r1000", "r1001", "r1002" ] }, "us-
gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
"presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain
(Loss) Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) related to gain (loss)
component of defined benefit plans including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r18", "r30", "r128", "r259", "r670", "r1001", "r1002"
] }, "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax", "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss)
Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to
the parent." } } }, "auth_ref": [ "r18", "r30", "r128", "r260", "r261", "r1000" ] }, "us-
gaap_AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Foreign Currency Translation Adjustments, Net of Tax", "label": "Accumulated Foreign Currency Adjustment Attributable to Noncontrolling Interest [Member]",
"documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and
effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to
the noncontrolling interest." } } }, "auth_ref": [ "r4", "r18", "r30", "r126", "r127", "r585", "r591", "r1000", "r1001", "r1002" ] }, "us-
gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Foreign Currency Translation Adjustments, Net of Tax", "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling
Interest [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency
transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-
investment nature, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r4", "r18", "r30", "r126", "r127", "r259", "r670", "r1001", "r1002" ] },
"us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax", "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest
[Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge
included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest." } } }, "auth_ref": [ "r252", "r259", "r545", "r670", "r1001", "r1002" ]
}, "us-gaap_AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Noncontrolling Interest
[Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge
included in assessment of hedge effectiveness, attributable to noncontrolling interest." } } }, "auth_ref": [ "r252", "r545", "r1000", "r1001", "r1002" ] }, "us-
gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
"documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in
assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r252", "r260", "r261", "r545", "r834", "r1000" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation":
"Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": [ "r259", "r260", "r585", "r587", "r588", "r589", "r590", "r591" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax":
{ "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit",
"calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other
comprehensive loss", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in
equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r29", "r30", "r129", "r244", "r660", "r696", "r697" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure
of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r259", "r260", "r585", "r587", "r588", "r589", "r590", "r591" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
], "lang": { "en-us": { "role": { "verboseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated
increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and
accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r18", "r30", "r552", "r555",
"r602", "r692", "r693", "r1000", "r1001", "r1002", "r1013", "r1014", "r1015", "r1016" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [
```

```
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustments, Net of Tax", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r4", "r18", "r30", "r126", "r127", "r260", "r261", "r587", "r588", "r589", "r590", "r591", "r1000" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r937" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r120", "r876", "r1151" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r709", "r1013", "r1014", "r1015", "r1016", "r1085", "r1152" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r950" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r950" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r950" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_AdjustmentForAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentForAmortization", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization", "label": "Amortization", "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives." } } }, "auth_ref": [ "r14" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r60", "r61", "r478" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile to net cash provided by (used in) operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r983" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r909", "r919", "r929", "r961" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r912", "r922", "r932", "r964" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r984" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r950" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "AllCurrenciesDomain", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r957" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r913", "r923", "r933", "r957", "r965", "r969", "r977" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r975" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r14", "r370", "r377", "r849" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities excluded from diluted earnings per share (less than)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r307" ] }, "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total Accumulated Other Comprehensive Loss", "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]", "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r18", "r30", "r1000", "r1001", "r1002" ] }, "mck_AssetImpairmentChargesIncludingAcceleratedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "AssetImpairmentChargesIncludingAcceleratedDepreciation", "crdr": "debit", "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairments and accelerated depreciation", "label": "Asset Impairment Charges, Including Accelerated Depreciation", "documentation": "Asset Impairment Charges, Including Accelerated Depreciation" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r174", "r186", "r240", "r275", "r311", "r319", "r338", "r342", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r541", "r546", "r583", "r655", "r750", "r842", "r843", "r876", "r900", "r1070", "r1071", "r1108" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r234", "r246", "r275", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r541", "r546", "r583", "r876", "r1070", "r1071", "r1108" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "totalLabel": "Total assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r99", "r105", "r153", "r232", "r233" ] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [ "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "xbrltype":
```

```
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets, Current", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r99", "r105", "r151", "r153", "r232", "r233" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r972" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r973" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r968" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r968" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r968" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r968" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r971" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r970" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r969" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r969" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r390", "r1118", "r1119" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r83", "r86", "r390", "r1118", "r1119" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "verboseLabel": "Significant Accounting Policies", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r147" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r371", "r372", "r373", "r374", "r375", "r536", "r861", "r862" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r62", "r63", "r371", "r372", "r373", "r374", "r375", "r536", "r861", "r862" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value adjustment gain", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r537", "r1007" ] }, "us-gaap_BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessExitCosts1", "crdr": "debit", "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exit and other-related costs", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14" ] }, "country_CA": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "CA", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canada", "label": "CANADA" } } }, "auth_ref": [] }, "currency_CAD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "CAD", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CAD", "label": "Canada, Dollars" } } }, "auth_ref": [] }, "mck_CanadianRetailDisposalGroupMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "CanadianRetailDisposalGroupMember", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails", "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian retail disposal group", "label": "Canadian Retail Disposal Group [Member]", "documentation": "Canadian Retail Disposal Group" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents at end of period", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r35", "r236", "r829" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period", "totalLabel": "Cash, cash equivalents, and restricted cash at end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r35", "r143", "r272" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r143" ] }, "mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://mckesson123.com/20240930", "localname": "CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease", "crdr": "debit",
"calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 5.0 } }, "presentation":
{ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "terseLabel": "Change in cash, cash equivalents,
and restricted cash classified as Assets held for sale", "label": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)",
"documentation": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)" } } }, "auth_ref": [] }, "us-
gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowHedgingMember", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Cash Flow Hedges", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or
liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r80" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r948" ] },
"mck_CherokeeNationMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "CherokeeNationMember", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cherokee Nation", "label": "Cherokee
Nation [Member]", "documentation": "Cherokee Nation" } } }, "auth_ref": [] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in
Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r945" ] },
"ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity
Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r943" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City
Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class
of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not
limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r195", "r241", "r242", "r243", "r275",
"r298", "r302", "r304", "r306", "r313", "r314", "r352", "r413", "r416", "r417", "r418", "r422", "r423", "r453", "r454", "r457", "r460", "r466", "r583", "r701", "r702", "r703",
"r704", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r738", "r759", "r777", "r804", "r805", "r806", "r807", "r808", "r987",
"r1010", "r1017" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected
Measure Amount" } } }, "auth_ref": [ "r949" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected
Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r949" ] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "CommercialPaperMember", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial Paper", "label":
"Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [
"r160", "r412", "r892", "r893", "r894", "r897" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure
[Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingent Liabilities", "label":
"Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r158", "r403",
"r404", "r813", "r1054", "r1061" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": {
"role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting
policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r52", "r814" ] }, "us-
gaap_CommonStockDividendsPerShareDeclared": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockDividendsPerShareDeclared", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical",
"http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends declared per common share (in dollars per share)",
"label": "Common Stock, Dividends, Per Share, Declared", "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding." }
} }, "auth_ref": [ "r164" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember",
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/Cover" ], "lang": {
"en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } },
"auth_ref": [ "r888", "r889", "r890", "r892", "r893", "r894", "r897", "r1013", "r1014", "r1016", "r1085", "r1149", "r1152" ] }, "us-
gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"CommonStockParOrStatedValuePerShare", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us":
{ "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated
value per share of common stock." } } }, "auth_ref": [ "r119" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ],
"lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum
number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r119", "r738" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype":
"sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares
issued (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Issued",
"documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and
remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized.
Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r119" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.01 par value, 800 shares
authorized, 279 and 278 shares issued at September 30, 2024 and March 31, 2024, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or
stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the
entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } },
"auth_ref": [ "r119", "r659", "r876" ] }, "mck_CommonStockVotingRightsNumberofVotesPerCommonShare": { "xbrltype": "integerItemType", "nsuri":
"http://mckesson123.com/20240930", "localname": "CommonStockVotingRightsNumberofVotesPerCommonShare", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of votes per share of common stock permitted on
proposals presented to stockholders (vote)", "label": "Common Stock, Voting Rights, Number of Votes Per Common Share", "documentation": "Common Stock, Voting Rights,
Number of Votes Per Common Share" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" }
} }, "auth_ref": [ "r954" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually
Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r953" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid
vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r955" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-
us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } },
"auth_ref": [ "r952" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME":
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income
attributable to McKesson Corporation", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease)
in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity
resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r31", "r256", "r258", "r265", "r650", "r671", "r673" ] }, "us-
gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ComprehensiveIncomeNetOfTaxAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ],
"lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent
[Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight":
-1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Comprehensive income attributable to noncontrolling interests", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling
Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other
comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners." } } },
"auth_ref": [ "r11", "r70", "r74", "r256", "r258", "r264", "r649", "r671", "r672" ] }, "us-
gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
```

{"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r74", "r167", "r256", "r258", "r263", "r648", "r671"] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": ["r41", "r42", "r95", "r96", "r349", "r812"] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": ["r41", "r42", "r95", "r96", "r349", "r699", "r812"] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": ["r41", "r42", "r95", "r96", "r349", "r812", "r993"] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenue derived from services, percentage (approximately or less than)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": ["r41", "r42", "r95", "r96", "r349"] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": ["r41", "r42", "r95", "r96", "r349", "r812"] }, "srt_ConsolidationItemsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsAxis", "presentation": ["http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Axis]", "label": "Consolidation Items [Axis]", "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r184", "r196", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r280", "r311", "r321", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r842", "r843", "r995", "r996", "r1070", "r1071"] }, "srt_ConsolidationItemsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ConsolidationItemsDomain", "presentation": ["http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Consolidation Items [Domain]", "label": "Consolidation Items [Domain]", "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments." } } }, "auth_ref": ["r184", "r196", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r280", "r311", "r321", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r413", "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r422", "r842", "r843", "r995", "r996", "r1070", "r1071"] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": ["http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": ["r71", "r835"] }, "us-gaap_CorporateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "verboseLabel": "Corporate", "label": "Corporate Segment [Member]", "documentation": "Component of an entity that usually provides financial, operational and administrative support and is considered an operating segment. Excludes intersegment elimination and reconciling items." } } }, "auth_ref": ["r1020"] }, "us-gaap_CorporateNonSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateNonSegmentMember", "presentation": ["http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate", "label": "Segment Reporting, Reconciling Item, Corporate Nonsegment [Member]", "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment." } } }, "auth_ref": ["r23", "r337", "r338", "r339", "r340", "r343", "r1023"] }, "mck_CorporateOperatingExpenseAndOtherIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "CorporateOperatingExpenseAndOtherIncomeNet", "crdr": "debit", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Corporate income (expenses), net", "label": "Corporate Operating (Expense) and Other Income, Net", "documentation": "Corporate Operating (Expense) and Other Income, Net" } } }, "auth_ref": [] }, "mck_CorporateSegmentAndU.S.PharmaceuticalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "CorporateSegmentAndU.S.PharmaceuticalSegmentMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Corporate Segment and U.S. Pharmaceutical Segment", "label": "Corporate Segment And U.S. Pharmaceutical Segment [Member]", "documentation": "Corporate Segment And U.S. Pharmaceutical Segment" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "negatedLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r134", "r135", "r612"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": ["http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of Sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": ["r225", "r226", "r277", "r278", "r428", "r455", "r603", "r610", "r654", "r831", "r833"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r412", "r1068"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r412", "r1068", "r1069"] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CurrencyAxis", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]", "documentation": "Information by currency." } } }, "auth_ref": ["r1104"] }, "us-gaap_CurrencySwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrencySwapMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "netLabel": "Cross-currency swaps", "terseLabel": "Currency swap", "label": "Currency Swap [Member]", "documentation": "Swap involving the exchange of principal and interest in one currency for another currency." } } }, "auth_ref": [] }, "mck_CurrentAssetLiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "CurrentAssetLiabilityMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other/Other accrued liabilities", "label": "Current Asset / Liability [Member]", "documentation": "Current Asset / Liability [Member]" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r65", "r1042", "r1043", "r1044", "r1045", "r1047", "r1049", "r1051", "r1052"] }, "us-gaap_DebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtAndCapitalLeaseObligations", "crdr": "credit", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Debt and Lease Obligation", "documentation": "Amount of short-term and long-term debt and lease obligation." } } }, "auth_ref": ["r175", "r176"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType",

```
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivities" ], "lang": { "en-us": { "role": { "verboseLabel": "Debt and Financing Activities", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r159", "r273", "r385", "r386", "r387", "r388", "r389", "r411", "r412", "r424", "r430", "r431", "r432", "r433", "r434", "r435", "r440", "r447", "r448", "r450", "r594" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r27", "r111", "r112", "r175", "r176", "r280", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r851", "r852", "r853", "r854", "r855", "r875", "r1011", "r1055", "r1056", "r1057", "r1105", "r1106" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt principal amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r425", "r594", "r595", "r852", "r853", "r875" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt Instrument, Fair Value Disclosure", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r438", "r582", "r852", "r853", "r1087", "r1088", "r1089", "r1090", "r1097" ] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate on debt instrument (percent)", "label": "Debt Instrument, Interest Rate, Stated Percentage", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r114", "r426" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r280", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r851", "r852", "r853", "r854", "r855", "r875", "r1011", "r1105", "r1106" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r27", "r280", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r851", "r852", "r853", "r854", "r855", "r875", "r1011", "r1055", "r1056", "r1057", "r1105", "r1106" ] },
"mck_DebtInstrumentRedemptionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DebtInstrumentRedemptionPeriod", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, redemption period (in days)", "label": "Debt Instrument, Redemption Period", "documentation": "Debt Instrument, Redemption Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption price percentage of principal (percent)", "label": "Debt Instrument, Redemption Price, Percentage", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r182" ] }, "us-gaap_DebtInstrumentRepurchasedFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentRepurchasedFaceAmount", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt principal redeemed", "label": "Debt Instrument, Repurchased Face Amount", "documentation": "Face (par) amount of the original debt instrument that was repurchased." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r27", "r56", "r57", "r97", "r162", "r163", "r280", "r425", "r426", "r427", "r428", "r429", "r431", "r436", "r437", "r438", "r439", "r441", "r442", "r443", "r444", "r445", "r446", "r449", "r851", "r852", "r853", "r854", "r855", "r875", "r1011", "r1105", "r1106" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term deferred tax liabilities", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r509", "r510", "r656" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r14", "r49" ] }, "us-gaap_DerivativeAssetNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetNotionalAmount", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Dollar notional amount, asset", "label": "Derivative Asset, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative asset." } } }, "auth_ref": [ "r789", "r793", "r796", "r799", "r1080", "r1081", "r1082" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r248", "r249", "r563", "r564", "r574", "r582", "r721", "r722", "r723", "r724", "r725", "r727", "r728", "r729", "r730", "r731", "r744", "r745", "r789", "r794", "r797", "r798", "r800", "r801", "r833", "r868", "r871", "r890", "r1088", "r1089", "r1090", "r1150" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, Name [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r729", "r731", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r765", "r766", "r767", "r768", "r771", "r772", "r773", "r774", "r789", "r791", "r797", "r800", "r888", "r890", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1098", "r1099" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r125", "r170", "r171", "r247", "r833" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r24", "r125", "r170", "r171", "r247", "r833" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, by Nature [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r84", "r87", "r88", "r172", "r729", "r731", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r765", "r766", "r767", "r768", "r771", "r772", "r773", "r774", "r789", "r791", "r797", "r800", "r833", "r888", "r890", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1098", "r1099" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://mckesson123.com/role/HedgingActivities" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Activities", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r169", "r550", "r557" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
```

```
"terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": { "r20", "r84", "r87" } }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilities", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": { "r248", "r249", "r563", "r564", "r574", "r582", "r721", "r722", "r723", "r724", "r727", "r728", "r729", "r730", "r731", "r751", "r753", "r754", "r791", "r792", "r794", "r797", "r798", "r800", "r801", "r833", "r1088", "r1089", "r1090", "r1150" } }, "us-gaap_DerivativeLiabilityNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityNotionalAmount", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Dollar, notional amount, liability", "label": "Derivative Liability, Notional Amount", "documentation": "Nominal or face amount used to calculate payments on the derivative liability." } } }, "auth_ref": { "r790", "r793", "r795", "r799", "r1080", "r1081", "r1082" } }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r557" } }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional", "verboseLabel": "Derivative, notional amount", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": { "r1081", "r1082" } }, "mck_DerivativeNotionalAmountEnteredIntoDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DerivativeNotionalAmountEnteredIntoDuringPeriod", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative, notional amount, entered into during period", "label": "Derivative, Notional Amount, Entered Into During Period", "documentation": "Derivative, Notional Amount, Entered Into During Period" } } }, "auth_ref": [] }, "mck_DerivativeNotionalAmountTerminated": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DerivativeNotionalAmountTerminated", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative notional amount, terminated", "label": "Derivative, Notional Amount, Terminated", "documentation": "Derivative, Notional Amount, Terminated" } } }, "auth_ref": [] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": { "r20", "r75", "r76", "r78", "r82", "r85", "r87", "r89", "r91", "r93", "r557" } }, "mck_DerivativeTerminationProceedsAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DerivativeTerminationProceedsAmortizationPeriod", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative termination proceeds, amortization period (in years)", "label": "Derivative, Termination Proceeds, Amortization Period", "documentation": "Derivative, Termination Proceeds, Amortization Period" } } }, "auth_ref": [] }, "us-gaap_DerivativesFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesFairValueLineItems", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives, Fair Value [Line Items]", "label": "Derivatives, Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [
"http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Activities", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": { "r20", "r75", "r76", "r82", "r90", "r279", "r294" } }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivatives designated for hedge accounting", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r20" ] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails",
"http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
"http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r232" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails",
"http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
"http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails",
"http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
"http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Held-for-sale", "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]", "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations." } } }, "auth_ref": [ "r9", "r22", "r232" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 8.0 } }, "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, net", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r99", "r105", "r153" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Drafts and accounts payable", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r99", "r105", "r151", "r153" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current", "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r99", "r105", "r151", "r153" ] }, "mck_DisposalGroupIncludingDiscontinuedOperationAccumulatedOtherComprehensiveLossInChargeForRemeasurementToFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationAccumulatedOtherComprehensiveLossInChargeForRemeasurementToFairValue", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HeldforSaleNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss in charge for remeasurement to fair value", "label": "Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Loss in Charge for Remeasurement to Fair Value", "documentation": "Disposal Group, Including Discontinued Operation, Accumulated Other Comprehensive Gain (Loss) in Charge for Remeasurement to Fair Value" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 9.0 } }, "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r99", "r105", "r153" ] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HeldforSaleNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwillCurrent", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 10.0 } }, "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Disposal Group, Including Discontinued Operation, Goodwill, Current", "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of, expected to
```

be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r99", "r105", "r151", "r153"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Current", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r99", "r105", "r151", "r153"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Disposal Group, Including Discontinued Operation, Inventory, Current", "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r99", "r105", "r151", "r153"] }, "mck_DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationLongTermOperatingLeaseLiabilities", "crdr": "credit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Disposal Group, Including Discontinued Operation, Long-term operating lease liabilities", "documentation": "Disposal Group, Including Discontinued Operation, Long-term operating lease liabilities" } } }, "auth_ref": [] }, "mck_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current", "documentation": "Disposal Group, Including Discontinued Operation, Operating Lease Liability, Current" } } }, "auth_ref": [] }, "mck_DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingLeaseRightOfUseAssetsCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Disposal Group Including Discontinued Operation, Operating Lease, Right-of-Use Assets, Current", "documentation": "Disposal Group Including Discontinued Operation, Operating Lease, Right-of-Use Assets, Current" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent", "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r7", "r99", "r105", "r153"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities", "crdr": "credit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent", "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r7", "r99", "r105", "r153"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r99", "r105", "r151", "r153"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r2", "r99", "r105", "r151", "r153"] }, "mck_DisposalGroupNotDiscontinuedOperationIntercompanyTradeAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupNotDiscontinuedOperationIntercompanyTradeAccountsPayable", "crdr": "credit", "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts payable", "label": "Disposal Group, Not Discontinued Operation, Intercompany Trade, Accounts Payable", "documentation": "Disposal Group, Not Discontinued Operation, Intercompany Trade, Accounts Payable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Canadian businesses held for sale", "verboseLabel": "Charge to remeasure disposal group", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down", "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations." } } }, "auth_ref": ["r14", "r15", "r152"] }, "mck_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown1": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown1", "crdr": "credit", "calculation": { "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation", "weight": -1.0, "order": 7.0 } }, "presentation": ["http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Remeasurement of assets of businesses held for sale to fair value less costs to sell", "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down1", "documentation": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down1" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails", "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails", "http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r861", "r862"] }, "us-gaap_DividendsCommonStockCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DividendsCommonStockCash", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cash dividends declared", "label": "Dividends, Common Stock, Cash", "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash." } } }, "auth_ref": ["r164"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r904"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r936"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document

Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r947"] }, "mck_EPSBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "EPSBasicAndDilutedAbstract", "presentation": ["http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Earnings (loss) per common share attributable to McKesson Corporation:", "label": "EPS, Basic and Diluted [Abstract]", "documentation": "Earnings Per Share, Basic and Diluted" } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "EUR", "presentation": ["http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "EUR", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "terseLabel": "Earnings per common share attributable to McKesson Corporation", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r266", "r286", "r287", "r288", "r289", "r290", "r291", "r296", "r298", "r304", "r305", "r306", "r310", "r534", "r539", "r560", "r561", "r651", "r674", "r836"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r266", "r286", "r287", "r288", "r289", "r290", "r291", "r298", "r304", "r305", "r306", "r310", "r534", "r539", "r560", "r561", "r651", "r674", "r836"] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedLineItems", "presentation": ["http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r298", "r302", "r304"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": ["http://mckesson123.com/role/EarningsPerCommonShare"], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Common Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r295", "r307", "r308", "r309"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r584"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reported income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r512", "r865"] }, "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount", "crdr": "debit", "presentation": ["http://mckesson123.com/role/IncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (benefit), share-based payment arrangement", "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount", "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement." } } }, "auth_ref": ["r989", "r1075", "r1076"] }, "mck_EffectiveIncomeTaxRateReconciliationTaxContingencyInterestExpenseAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencyInterestExpenseAmount", "crdr": "credit", "presentation": ["http://mckesson123.com/role/IncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax contingency, interest expense, amount", "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Interest Expense, Amount", "documentation": "Effective Income Tax Rate Reconciliation, Tax Contingency, Interest Expense, Amount" } } }, "auth_ref": [] }, "mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount", "crdr": "debit", "presentation": ["http://mckesson123.com/role/IncomeTaxesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Tax expense (benefit), intra-entity transfers of assets other than inventory, amount", "label": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount", "documentation": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": ["http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r902"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r902"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r902"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such

files)." } } }, "auth_ref": ["r986"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r902"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r902"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r902"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": ["r902"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r941"] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": ["r982"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r982"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r982"] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": ["r19", "r229", "r259", "r260", "r261", "r281", "r282", "r283", "r285", "r290", "r292", "r294", "r312", "r353", "r354", "r382", "r467", "r522", "r523", "r531", "r532", "r533", "r535", "r538", "r539", "r551", "r552", "r553", "r554", "r555", "r556", "r559", "r585", "r587", "r588", "r589", "r590", "r591", "r596", "r598", "r602", "r670", "r692", "r693", "r694", "r709", "r777"] }, "us-gaap_EquitySecuritiesFVNINoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFVNINoncurrent", "crdr": "debit", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity securities", "label": "Equity Securities, FV-NI, Noncurrent", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as noncurrent." } } }, "auth_ref": ["r581"] }, "us-gaap_EquitySecuritiesFvNiGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiGainLoss", "crdr": "credit", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gains (losses) associated with equity investments", "label": "Equity Securities, FV-NI, Gain (Loss)", "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r675", "r1027"] }, "us-gaap_EquitySecuritiesFvNiRealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquitySecuritiesFvNiRealizedGain", "crdr": "credit", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain related to share price increase of equity securities", "label": "Equity Securities, FV-NI, Realized Gain", "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": ["r1027"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": ["r951"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r909", "r919", "r929", "r961"] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r906", "r916", "r926", "r958"] }, "mck_ExciseTaxAccrual": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "ExciseTaxAccrual", "crdr": "credit", "presentation": ["http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Excise taxes", "label": "Excise Tax Accrual", "documentation": "Excise Tax Accrual" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": ["r957"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r563", "r564", "r574", "r868"] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": ["r563", "r564", "r574", "r868"] }, "us-gaap_FairValueByBalanceSheetGroupingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTextBlock", "presentation": ["http://mckesson123.com/role/HedgingActivitiesTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Derivatives", "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]", "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": ["r94"] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": ["r438", "r471", "r472", "r473", "r474", "r475", "r476", "r562", "r564", "r565", "r566", "r567", "r573", "r574", "r576", "r605", "r606", "r607", "r852", "r853", "r858", "r859", "r860", "r868", "r871"] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": ["r563", "r564", "r565", "r567", "r868", "r1089", "r1100"] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": ["http://mckesson123.com/role/FairValueMeasurements"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": ["r569", "r571", "r572", "r573", "r576", "r577", "r578", "r579", "r580", "r645", "r868", "r872"] }, "us-gaap_FairValueHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueHedgingMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hedges", "label": "Fair Value Hedging [Member]", "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk." } } }, "auth_ref": ["r79"] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value, inputs, level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": ["r438", "r471", "r476", "r564", "r574", "r605", "r858", "r859", "r860", "r868"] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair value, inputs, level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": ["r438", "r471", "r476", "r564", "r565", "r574", "r606", "r852", "r853", "r858", "r859", "r860", "r868"] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel":

"Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": { "r563", "r564", "r565", "r567", "r868", "r1089", "r1100" } }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": ["http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": ["r430", "r471", "r472", "r473", "r474", "r475", "r476", "r562", "r564", "r565", "r566", "r567", "r573", "r574", "r576", "r605", "r606", "r607", "r852", "r853", "r858", "r859", "r860", "r868", "r871"] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": ["r868", "r1086", "r1087", "r1088", "r1089", "r1090", "r1100"] }, "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable", "presentation": ["http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]", "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument." } } }, "auth_ref": ["r83", "r85", "r92"] }, "mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "negatedLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r238", "r356", "r376", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r378", "r826", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, remainder of 2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": ["r1154"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r378", "r826", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r378", "r826", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated annual amortization expense, 2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r378", "r826", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": ["r369", "r371", "r372", "r373", "r375", "r376", "r379", "r380", "r613", "r614", "r826"] }, "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]", "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r356", "r376", "r614", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r369", "r376", "r379", "r380", "r381", "r613", "r826", "r849"] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": ["r369", "r371", "r372", "r373", "r375", "r376", "r379", "r380", "r826"] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 }, "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "totalLabel": "Net Carrying Amount", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": ["r613", "r1049"] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted- Average Remaining Amortization Period (Years)", "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r613"] }, "us-gaap_FiscalPeriod": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiscalPeriod", "presentation": ["http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Period", "label": "Fiscal Period, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed." } } }, "auth_ref": ["r67"] }, "mck_FixedInterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "FixedInterestRateSwapMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fixed interest rate swaps", "label": "Fixed Interest Rate Swap [Member]", "documentation": "Fixed Interest Rate Swap" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r913", "r923", "r933", "r965"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone

Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r913", "r923", "r933", "r965"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r913", "r923", "r933", "r965"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": ["r913", "r923", "r933", "r965"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": ["r913", "r923", "r933", "r965"] }, "us-gaap_ForwardContractsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForwardContractsMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forwards", "label": "Forward Contracts [Member]", "documentation": "Contracts negotiated between two parties to purchase and sell a specific quantity of a financial instrument, foreign currency, or commodity at a price specified at origination of the contract, with delivery and settlement at a specified future date." } } }, "auth_ref": ["r1084"] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": ["r946"] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "GBP", "presentation": ["http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"], "lang": { "en-us": { "role": { "terseLabel": "GBP", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain from sales of businesses and investments", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": ["r1008"] }, "us-gaap_GainLossRelatedToLitigationSettlement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossRelatedToLitigationSettlement", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Claims and litigation charges, net", "negatedTerseLabel": "Claims and litigation charges", "label": "Gain (Loss) from Litigation Settlement", "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process." } } }, "auth_ref": ["r842", "r1062"] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gain on debt extinguishment", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": ["r14", "r54", "r55"] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r237", "r357", "r646", "r843", "r848", "r869", "r876", "r1031", "r1038"] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill acquired", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": ["r360", "r848"] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNet"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets, Net", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": ["r1029", "r1041"] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments, net", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r364"] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillLineItems", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Line Items]", "label": "Goodwill [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r848"] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r0", "r1037"] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit", "crdr": "credit", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Disposals (1)", "label": "Goodwill, Written off Related to Sale of Business Unit", "documentation": "Amount of divestiture of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": ["r362", "r848"] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"], "lang": { "en-us": { "role": { "totalLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": ["r130", "r136", "r185", "r275", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r583", "r837", "r842", "r1019", "r1022", "r1024", "r1025", "r1026", "r1070"] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": ["r20", "r549"] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": ["r20"] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingRelationshipDomain", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": ["r20"] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income before income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r131", "r180", "r185", "r652", "r666", "r837", "r842", "r1019", "r1022", "r1024", "r1025", "r1026"] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Income (loss) from equity method investments", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": ["r14", "r132", "r179", "r311", "r326", "r342", "r351", "r665"] }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "totalLabel": "Income before
income taxes", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "documentation": "Amount, before tax, of income (loss)
including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method
investments." } } }, "auth_ref": [ "r133", "r1002" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails",
"http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails",
"http://mckesson123.com/role/IncomeTaxesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [
"r861", "r862" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "label": "Income
Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial
concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } },
"auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
"presentation": [ "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations
[Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or
disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r17", "r22", "r28", "r99", "r100", "r101", "r102", "r103", "r104",
"r106", "r107", "r108", "r154" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementLocationAxis", "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income
Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated
amount has been reported." } } }, "auth_ref": [ "r383", "r390", "r395", "r568", "r570", "r575", "r689", "r691", "r762", "r826", "r870", "r1120" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income
Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount
has been reported." } } }, "auth_ref": [ "r390", "r395", "r568", "r570", "r575", "r689", "r691", "r762", "r826", "r870", "r1120" ] }, "us-gaap_IncomeTaxContingencyLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyLineItems", "presentation": [
"http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Contingency [Line Items]", "label": "Income Tax
Contingency [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxContingencyTable": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxContingencyTable", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Income Tax Contingency [Table]", "label": "Income Tax Contingency [Table]", "documentation": "Disclosure of information about tax
positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and
other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect
the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts
unrecognized will significantly change within 12 months." } } }, "auth_ref": [ "r1077" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income
Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://mckesson123.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes",
"label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r276", "r507", "r512", "r515", "r516", "r517",
"r520", "r521", "r524", "r526", "r529", "r530", "r706", "r865" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } },
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Income tax expense",
"terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax
expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r188", "r194", "r293", "r294", "r311", "r327", "r342", "r511", "r512", "r525", "r676", "r865" ] }, "us-
gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeTaxReconciliationForeignIncomeTaxRateDifferential", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Effective income tax rate reconciliation, foreign income tax rate differential, expense (benefit)", "label": "Effective Income Tax Rate
Reconciliation, Foreign Income Tax Rate Differential, Amount", "documentation": "Amount of the difference between reported income tax expense (benefit) and expected
income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign
income tax expense (benefit)." } } }, "auth_ref": [ "r513", "r514", "r865", "r1075" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 14.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Drafts and accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate
amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's
business." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInAccruedTaxesPayable", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Taxes", "label": "Increase (Decrease) in Accrued Taxes Payable", "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid,
including income, property and other taxes." } } }, "auth_ref": [ "r1007" ] }, "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInDeferredIncomeTaxes", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
-1.0, "order": 11.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Deferred taxes", "label": "Increase (Decrease) in Deferred Income Taxes", "documentation": "The increase (decrease) during the reporting period in the
account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa." } } },
"auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag":
"us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase
(Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity,
associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "mck_IncreaseDecreaseInLitigationReserve": { "xbrltype":
"monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "IncreaseDecreaseInLitigationReserve", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 13.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel":
"Litigation liabilities", "label": "Increase (Decrease) in Litigation Reserve", "documentation": "Increase (Decrease) in Litigation Reserve" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingAssetsAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-
us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Assets [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label":
"Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r994", "r1007" ] },
"us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherOperatingCapitalNet", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other", "label": "Increase
(Decrease) in Other Operating Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities
classified as other." } } }, "auth_ref": [ "r13" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Receivables", "label": "Increase
(Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all
parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r13" ] }, "us-
gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in
Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept
from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
```

```
"calculation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Effect of dilutive securities (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
"documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the
treasury stock method." } } }, "auth_ref": [ "r299", "r300", "r301", "r306", "r479" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r913", "r923", "r933", "r957", "r965", "r969", "r977" ] }, "mck_IndividualClaimantMember":
{ "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "IndividualClaimantMember", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "An individual", "label": "Individual
Claimant [Member]", "documentation": "Individual Claimant" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref":
[ "r975" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r905", "r981" ] },
"ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted",
"label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r905", "r981" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider
Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r905", "r981" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InterestExpense", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest
Expense, Operating and Nonoperating", "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of
borrowing accounted for as interest expense." } } }, "auth_ref": [ "r311", "r319", "r323", "r329", "r342", "r593", "r842", "r843" ] }, "us-gaap_InterestExpenseNonoperating": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-
gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label":
"Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r323", "r1003" ] }, "us-
gaap_InterestRateSwapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateSwapMember", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Floating
interest rate swaps", "verboseLabel": "Interest Rate Swap", "label": "Interest Rate Swap [Member]", "documentation": "Forward based contracts in which two parties agree to
swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period." } } },
"auth_ref": [ "r827", "r895", "r896" ] }, "mck_InternationalSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname":
"InternationalSegmentMember", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "International", "label": "International
Segment [Member]", "documentation": "International Segment" } } }, "auth_ref": [] }, "us-gaap_InventoryLIFOReservePeriodCharge": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryLIFOReservePeriodCharge", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 8.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Charges (credits) associated with last-in,
first-out inventory method", "verboseLabel": "Pre-tax credits related to LIFO accounting", "label": "Inventory, LIFO Reserve, Period Charge", "documentation": "The change in
the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has
been reflected in the statement of income during the period." } } }, "auth_ref": [ "r150" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
"parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ],
"lang": { "en-us": { "role": { "terseLabel": "Inventories, net", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be
sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r245", "r830", "r876" ] }, "mck_LeAnnSmithMember": { "xbrltype": "domainItemType",
"nsuri": "http://mckesson123.com/20240930", "localname": "LeAnnSmithMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-
us": { "role": { "label": "LeAnn Smith [Member]", "documentation": "LeAnn Smith" } } }, "auth_ref": [] }, "mck_LeaseAndOtherObligationsMember": { "xbrltype":
"domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LeaseAndOtherObligationsMember", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease and other obligations", "label":
"Lease and Other Obligations [Member]", "documentation": "Lease and Other Obligations" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } },
"auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"totalLabel": "Total liabilities and deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity
attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r124", "r178", "r663", "r876", "r1012", "r1028", "r1101" ] }, "us-
gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": {
"terseLabel": "LIABILITIES AND DEFICIT", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label":
"Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one
business cycle, if longer." } } }, "auth_ref": [ "r113", "r235", "r275", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r542", "r546", "r547",
"r583", "r876", "r1070", "r1108", "r1109" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesCurrentAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel":
"Current liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation":
[ "http://mckesson123.com/role/HeldforSaleNarrativeDetails", "http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Liabilities held for sale", "totalLabel": "Total liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities",
"documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r99", "r105", "r153", "r232", "r233" ] },
"us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract", "presentation": [
"http://mckesson123.com/role/HeldforSaleScheduleofAssetsandLiabilitiesHeldforSaleDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities", "label": "Disposal
Group, Including Discontinued Operation, Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "crdr": "credit",
"calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } },
"presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities held for sale", "label":
"Disposal Group, Including Discontinued Operation, Liabilities, Current", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or
disposed of, expected to be disposed of within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r99", "r105", "r151", "r153", "r232", "r233" ] }, "us-
gaap_LineOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCredit", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amounts outstanding under
facility", "label": "Long-Term Line of Credit", "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term
obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of
this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of
any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally
be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b)
the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following
conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no
violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement." } } }, "auth_ref":
[ "r27", "r176", "r1116" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityLineItems", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line
Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose
reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r1011", "r1068" ] }, "us-
gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit facility, maximum
borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without
consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r110", "r115" ] },
"us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityTable", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility
[Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under
```

which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": ["r110", "r115", "r412", "r1011", "r1068"] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LitigationReserveNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserveNoncurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Long-term litigation liabilities", "label": "Estimated Litigation Liability, Noncurrent", "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r117", "r1062"] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Award payable under proposed framework", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages": { "xbrltype": "pureItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages", "label": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages", "documentation": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages" } } }, "auth_ref": [] }, "mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment": { "xbrltype": "percentItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Portion of settlement award to be used by state and local government for remediation (percent)", "label": "Litigation Settlement, Award Amount To Be Used by State and Local Government", "documentation": "Litigation Settlement, Award Amount To Be Used by State and Local Government" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1055", "r1056", "r1057", "r1062"] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r1055", "r1056", "r1057", "r1062"] }, "us-gaap_LoansPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LoansPayableMember", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Loans payable", "terseLabel": "Term Loan", "label": "Loans Payable [Member]", "documentation": "Borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermCommercialPaperCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermCommercialPaperCurrent", "crdr": "credit", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Long-Term Commercial Paper, Current", "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": ["r111", "r112"] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails", "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total debt", "verboseLabel": "Carrying Value", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r27", "r176", "r437", "r451", "r852", "r853", "r875", "r1116"] }, "us-gaap_LongTermDebtAndCapitalLeaseObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligations", "crdr": "credit", "calculation": { "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Long-term debt", "terseLabel": "Total long-term debt", "label": "Long-Term Debt and Lease Obligation", "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent." } } }, "auth_ref": ["r27", "r657"] }, "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 }, "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of long-term debt", "terseLabel": "Less: Current portion", "label": "Long-Term Debt and Lease Obligation, Current", "documentation": "Amount of long-term debt and lease obligation, classified as current." } } }, "auth_ref": ["r112"] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r27", "r1055", "r1056", "r1057"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": ["http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r27", "r53", "r1055", "r1056", "r1057"] }, "us-gaap_LossContingenciesByNatureOfContingencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesByNatureOfContingencyAxis", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency Nature [Axis]", "label": "Loss Contingency Nature [Axis]", "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur." } } }, "auth_ref": ["r405", "r406", "r407", "r410", "r506", "r698", "r850", "r1063", "r1065"] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r405", "r406", "r407", "r410", "r506", "r850", "r1063", "r1065"] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": ["r405", "r406", "r407", "r410", "r506", "r850", "r1063", "r1065"] }, "us-gaap_LossContingencyAccrualAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total litigation liabilities", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }, "auth_ref": ["r405", "r988"] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Current litigation liabilities", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r405"] }, "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueNoncurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": { "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"], "lang": { "en-us": { "role": { "verboseLabel": "Long-term litigation liabilities", "label": "Loss Contingency, Accrual, Noncurrent", "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": ["r405"] }, "us-gaap_LossContingencyAccrualCarryingValuePeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValuePeriodIncreaseDecrease", "presentation": ["http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax expenses related to estimated litigation liability", "label": "Loss Contingency Accrual, Period Increase (Decrease)", "documentation": "Amount of increase (decrease) in loss contingency liability." } } }, "auth_ref": ["r1062"] }, "mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, claims settled, number of jurisdictions not participating in settlement", "label": "Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement", "documentation": "Loss

Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement" } } }, "auth_ref": [] }, "mck_LossContingencyClassActionNumberofFaxesReceived": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyClassActionNumberofFaxesReceived", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, class action, number of faxes received", "label": "Loss Contingency, Class Action, Number of Faxes Received", "documentation": "Loss Contingency, Class Action, Number of Faxes Received" } } }, "auth_ref": [] }, "mck_LossContingencyClassActionNumberofFaxesRemainingintheClass": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyClassActionNumberofFaxesRemainingintheClass", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, class action, number of faxes remaining in the class", "label": "Loss Contingency, Class Action, Number of Faxes Remaining in the Class", "documentation": "Loss Contingency, Class Action, Number of Faxes Remaining in the Class" } } }, "auth_ref": [] }, "us-gaap_LossContingencyDamagesAwardedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyDamagesAwardedValue", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Amounts awarded to plaintiff", "label": "Loss Contingency, Damages Awarded, Value", "documentation": "Amount of damages awarded to the plaintiff in the legal matter." } } }, "auth_ref": ["r1062", "r1063", "r1065"] }, "mck_LossContingencyDamagesSoughtPerViolationValue": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyDamagesSoughtPerViolationValue", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, damages sought per violation, value", "label": "Loss Contingency, Damages Sought Per Violation, Value", "documentation": "Loss Contingency, Damages Sought Per Violation, Value" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNatureDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNatureDomain", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingency, Nature [Domain]", "label": "Loss Contingency, Nature [Domain]", "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability." } } }, "auth_ref": ["r405", "r406", "r407", "r410", "r506", "r698", "r850", "r1063", "r1065"] }, "mck_LossContingencyNumberOfCasesDismissed": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyNumberOfCasesDismissed", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Loss contingency, number of cases dismissed", "label": "Loss Contingency, Number Of Cases Dismissed", "documentation": "Loss Contingency, Number Of Cases Dismissed" } } }, "auth_ref": [] }, "mck_LossContingencyNumberOfOtherDefendants": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyNumberOfOtherDefendants", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of other national distributors named in suit", "label": "Loss Contingency, Number of Other Defendants", "documentation": "Loss Contingency, Number of Other Defendants" } } }, "auth_ref": [] }, "us-gaap_LossContingencyNumberOfPlaintiffs": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyNumberOfPlaintiffs", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of plaintiffs", "label": "Loss Contingency, Number of Plaintiffs", "documentation": "Number of plaintiffs that have filed claims pertaining to a loss contingency." } } }, "auth_ref": ["r1063", "r1065"] }, "mck_LossContingencyNumberOfStatesFiledOnBehalfOf": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyNumberOfStatesFiledOnBehalfOf", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of states filed on behalf of", "label": "Loss Contingency, Number of States Filed On Behalf Of", "documentation": "Loss Contingency, Number of States Filed On Behalf Of" } } }, "auth_ref": [] }, "mck_LossContingencyNumberofStates": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "LossContingencyNumberofStates", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of states in which court cases are pending", "label": "Loss Contingency, Number of States", "documentation": "Loss Contingency, Number of States" } } }, "auth_ref": [] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyPendingClaimsNumber", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Complaints filed against the entity", "label": "Loss Contingency, Pending Claims, Number", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": ["r1063", "r1065"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r197", "r199", "r201", "r202", "r204", "r227", "r228", "r406", "r407", "r408", "r409", "r477", "r506", "r567", "r611", "r688", "r690", "r698", "r730", "r731", "r782", "r784", "r786", "r787", "r802", "r824", "r825", "r847", "r856", "r863", "r871", "r872", "r873", "r874", "r885", "r1072", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115"] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": ["r949"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": ["r949"] }, "mck_MedicalSurgicalSolutionsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "MedicalSurgicalSolutionsSegmentMember", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Medical-Surgical Solutions", "label": "Medical-Surgical Solutions Segment [Member]", "documentation": "Medical-Surgical Solutions Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": ["http://mckesson123.com/role/HeldforSale"], "lang": { "en-us": { "role": { "terseLabel": "Held for Sale", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": ["r98", "r166"] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails"], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r197", "r199", "r201", "r202", "r204", "r227", "r228", "r406", "r407", "r408", "r409", "r477", "r506", "r567", "r611", "r688", "r690", "r698", "r730", "r731", "r782", "r784", "r786", "r787", "r802", "r824", "r825", "r847", "r856", "r863", "r871", "r872", "r873", "r885", "r1072", "r1110", "r1111", "r1112", "r1113", "r1114", "r1115"] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interests", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r123", "r177", "r275", "r352", "r413", "r416", "r417", "r418", "r422", "r423", "r583", "r662", "r740"] }, "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments to noncontrolling interests", "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders", "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders." } } }, "auth_ref": ["r164"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": ["r968"] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": ["http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Money market funds at carrying value", "label": "Money Market Funds, at Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": ["r976"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": ["r950"] }, "mck_NationalPrescriptionOpiateLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "NationalPrescriptionOpiateLitigationMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails", "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "National Prescription Opioid Litigation", "label": "National Prescription Opiate Litigation [Member]", "documentation": "In re: National Prescription Opiate Litigation [Member]" } } }, "auth_ref": [] }, "mck_NativeAmericanTribesOtherThanCherokeeNationMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "NativeAmericanTribesOtherThanCherokeeNationMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Native American Tribes Other Than Cherokee Nation", "label": "Native American Tribes Other Than Cherokee Nation [Member]", "documentation": "Native American Tribes Other Than Cherokee Nation" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r271"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r271" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r143", "r144", "r146" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income attributable to McKesson Corporation", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r137", "r146", "r181", "r233", "r254", "r257", "r261", "r275", "r284", "r286", "r287", "r288", "r289", "r290", "r293", "r294", "r303", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r534", "r539", "r561", "r583", "r669", "r758", "r775", "r776", "r898", "r1070" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net income attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r73", "r168", "r254", "r257", "r290", "r293", "r294", "r668", "r1002" ] }, "mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest", "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest" } } }, "auth_ref": [] }, "us-gaap_NetInvestmentHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetInvestmentHedgingMember", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Net Investment Hedges", "terseLabel": "Net Investment Hedging", "label": "Net Investment Hedging [Member]", "documentation": "Hedges of a net investment in a foreign operation." } } }, "auth_ref": [ "r81" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted Accounting Pronouncements, Recently Issued Accounting Pronouncements Not Yet Adopted, and Recent Securities and Exchange Commission Final Rules Not Yet Implemented", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r949" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r913", "r923", "r933", "r957", "r965" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r940" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r957" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r976" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r976" ] }, "us-gaap_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/HeldforSaleNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash divestiture, amount of consideration received", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received", "documentation": "Amount of noncash consideration received for selling an asset or business through a noncash (or part noncash) transaction." } } }, "auth_ref": [ "r36", "r37", "r38" ] }, "mck_NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedPaymentPeriod": { "xbrltype": "durationItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "NoncashOrPartNoncashDivestitureAmountOfConsiderationReceivedPaymentPeriod", "presentation": [ "http://mckesson123.com/role/HeldforSaleNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Noncash divestiture payable period (in years)", "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Payment Period", "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Payment Period" } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interests", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r68", "r467", "r1013", "r1014", "r1015", "r1016", "r1152" ] }, "mck_NumberOfAntitrustSettlements": { "xbrltype": "integerItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "NumberOfAntitrustSettlements", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of antitrust settlement", "label": "Number Of Antitrust Settlements", "documentation": "Number Of Antitrust Settlements" } } }, "auth_ref": [] }, "us-gaap_NumberOfReportableSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfReportableSegments", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails", "http://mckesson123.com/role/SignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reportable segments", "label": "Number of Reportable Segments", "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements." } } }, "auth_ref": [ "r838", "r846", "r1021" ] }, "mck_OpenMarketShareRepurchaseTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "OpenMarketShareRepurchaseTransactionsMember", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Open Market Share Repurchase Transactions", "label": "Open Market Share Repurchase Transactions [Member]", "documentation": "Open Market Share Repurchase Transactions [Member]" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating income", "terseLabel": "Total operating profit (loss)", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r185", "r837", "r1019", "r1022", "r1024", "r1025", "r1026" ] }, "us-gaap_OperatingIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLossAbstract", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment operating profit (loss)", "label": "Operating Income (Loss) [Abstract]" } } }, "auth_ref": [] }, "mck_OperatingIncomeLossAndOtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "OperatingIncomeLossAndOtherIncome", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subtotal", "label": "Operating Income (Loss) And Other Income", "documentation": "Operating Income (Loss) And Other Income" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "calculation": {
```

```
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease expense", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1107" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r600" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r600" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r599" ] }, "us-gaap_OperatingSegmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingSegmentsMember", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Segments", "label": "Operating Segments [Member]", "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r343", "r842", "r843" ] }, "us-gaap_OtherAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Asset impairment charges", "label": "Other Asset Impairment Charges", "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value." } } }, "auth_ref": [ "r1008", "r1053" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r239" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r26", "r30", "r260", "r585", "r588", "r591", "r670", "r1000" ] }, "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other comprehensive income (loss) before reclassification, tax", "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r259", "r670" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gain (loss) on cash flow and other hedges", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r250", "r251", "r670" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesNarrativeDetails", "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other comprehensive income (loss), cash flows hedge, gain (loss) reclassification, before tax", "verboseLabel": "Derivatives designated as cash flow and other hedges:", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r193", "r251", "r253" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "verboseLabel": "Foreign currency translation adjustments", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r4", "r670" ] }, "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Derivatives designated as net investment hedges:", "verboseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss)", "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge." } } }, "auth_ref": [ "r548" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 },
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Other comprehensive income (loss), net of tax", "terseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": [ "r19", "r26", "r255", "r258", "r262", "r290", "r585", "r586", "r591", "r647", "r670", "r1000", "r1001" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Less: amounts attributable to noncontrolling interests", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests." } } }, "auth_ref": [ "r11", "r18", "r167", "r255", "r258", "r290" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": {
"totalLabel": "Other comprehensive income (loss) attributable to McKesson", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r11", "r18", "r167", "r255", "r258", "r290" ] }, "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 3.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Changes in retirement-related benefit plans", "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax", "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan." } } }, "auth_ref": [ "r5", "r6", "r128", "r129", "r670" ] }, "us-gaap_OtherComprehensiveIncomeLossTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossTax", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other comprehensive loss", "label": "Other Comprehensive Income (Loss), Tax", "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss)." } } }, "auth_ref": [ "r8", "r259", "r262", "r511", "r527", "r528", "r585", "r589", "r591", "r647", "r670" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r849", "r1042", "r1043", "r1044", "r1045",
```

```
"r1046", "r1047", "r1049", "r1050", "r1051", "r1052" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag":
"us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ],
"lang": { "en-us": { "role": { "terseLabel": "Other non-current liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other,
due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r116" ] }, "mck_OtherNonCurrentAssetsLiabilitiesMember": { "xbrltype": "domainItemType",
"nsuri": "http://mckesson123.com/20240930", "localname": "OtherNonCurrentAssetsLiabilitiesMember", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-current assets/liabilities",
"label": "Other Non-Current Assets / Liabilities [Member]", "documentation": "Other Non-Current Assets / Liabilities" } } }, "auth_ref": [] }, "us-
gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit",
"calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash items", "label":
"Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } },
"auth_ref": [ "r146" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncurrentAssetsMember", "presentation": [ "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Other non-current assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other
noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNoncurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNoncurrentLiabilitiesMember", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other
Non-Current Liabilities", "label": "Other Noncurrent Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
} } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
"parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "terseLabel": "Other income, net", "label": "Other
Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r139" ] },
"ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure,
Amount" } } }, "auth_ref": [ "r949" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate
Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r911", "r921", "r931", "r963" ] },
"ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery
Compensation Amount" } } }, "auth_ref": [ "r914", "r924", "r934", "r966" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r914", "r924", "r934", "r966" ] }, "ecd_PayVsPerformanceDisclosureLineItems": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs
Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r938" ] }, "us-gaap_PaymentsForLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "PaymentsForLegalSettlements", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settlement payment", "label": "Payments
for Legal Settlements", "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period." } } }, "auth_ref": [ "r12" ] },
"us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight":
-1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Other", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities
classified as other." } } }, "auth_ref": [ "r990", "r1004" ] }, "mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname":
"PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight":
-1.0, "order": 9.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of U.S. government
obligations for the satisfaction and discharge of long-term debt", "terseLabel": "Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt",
"label": "Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt", "documentation": "Payments For Purchase Of Government
Obligations For Satisfaction And Discharge Of Long-Term Debt" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight":
-1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Share repurchases", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the
period." } } }, "auth_ref": [ "r141" ] }, "us-gaap_PaymentsForRestructuring": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsForRestructuring", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Cash
payments", "label": "Payments for Restructuring", "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated
with a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r394", "r1006" ] }, "us-gaap_PaymentsOfDividendsCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDividendsCommonStock", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight":
-1.0, "order": 5.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Dividends paid", "label": "Payments of Ordinary Dividends, Common Stock", "documentation": "Amount of cash outflow in the form of ordinary dividends to
common shareholders of the parent entity." } } }, "auth_ref": [ "r141" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight":
-1.0, "order": 5.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedTerseLabel": "Acquisitions, net of cash, cash equivalents, and restricted cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired",
"documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r33" ] }, "us-
gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight":
-1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Payments for property, plant, and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow
associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale;
includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r140" ] }, "us-gaap_PaymentsToAcquireSoftware": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireSoftware", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight":
-1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": {
"negatedLabel": "Capitalized software expenditures", "label": "Payments to Acquire Software", "documentation": "The cash outflow associated with the acquisition from
vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref":
[ "r140" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers,
Footnote [Text Block]" } } }, "auth_ref": [ "r948" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group
Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r948" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r940" ] },
"ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r957" ] }, "ecd_PeoName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r950" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r939" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r941" ] },
"ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost
[Member]" } } }, "auth_ref": [ "r985" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments,
Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r940" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in
dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or
redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r118", "r453" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized
(in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely
at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r118", "r738" ] }, "us-gaap_PreferredStockSharesIssued": {
"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [
```

```
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r118", "r453" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r118", "r738", "r756", "r1152", "r1153" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r658", "r876" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r999" ] }, "mck_PrescriptionTechnologySolutionsSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "PrescriptionTechnologySolutionsSegmentMember", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prescription Technology Solutions", "label": "Prescription Technology Solutions Segment [Member]", "documentation": "International Segment [Member]" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r997" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt issuance", "label": "Proceeds from Debt, Net of Issuance Costs", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r268" ] }, "us-gaap_ProceedsFromDivestitureOfBusinesses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinesses", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/HeldforSaleNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash proceeds from divestiture", "label": "Proceeds from Divestiture of Businesses", "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales of businesses and investments, net", "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates", "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment)." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ProceedsFromIssuanceOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommercialPaper", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of commercial paper", "label": "Proceeds from Issuance of Commercial Paper", "documentation": "The cash inflow from borrowing by issuing commercial paper." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProceedsFromIssuanceOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfLongTermDebt", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuances of long-term debt", "label": "Proceeds from Issuance of Long-Term Debt", "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r34", "r701" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r10", "r21" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock transactions:", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromLegalSettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLegalSettlements", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from legal settlements", "label": "Proceeds from Legal Settlements", "documentation": "Cash received for the settlement of litigation during the current period." } } }, "auth_ref": [ "r145" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Borrowings under facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r34", "r1011" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r991", "r1005" ] }, "us-gaap_ProceedsFromSaleOfEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfEquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of equity securities", "label": "Proceeds from Sale of Equity Securities, FV-NI", "documentation": "Amount of cash inflow from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r187", "r269" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term borrowings", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ProductConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProductConcentrationRiskMember", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product Concentration Risk", "label": "Product Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence." } } }, "auth_ref": [ "r148" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 },
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 },
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "verboseLabel": "Net income", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r233", "r254", "r257", "r270", "r275", "r284", "r290", "r293", "r294", "r352", "r413", "r414", "r416", "r417", "r418", "r419", "r420", "r422", "r423", "r534", "r539", "r540", "r543", "r544", "r561", "r583", "r652", "r667", "r708", "r758", "r775", "r776", "r866", "r867", "r899", "r1002", "r1070" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r16", "r601", "r653", "r664", "r876" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
```

```
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for bad debts", "terseLabel": "Accounts receivable, credit loss expense (reversal)", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": { "r267", "r355" } }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": { "r938" } }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": { "r938" } }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r197", "r199", "r201", "r202", "r204", "r227", "r228", "r406", "r407", "r408", "r409", "r470", "r477", "r502", "r503", "r504", "r506", "r567", "r608", "r609", "r611", "r688", "r690", "r698", "r730", "r731", "r782", "r784", "r786", "r787", "r802", "r824", "r825", "r847", "r856", "r863", "r871", "r872", "r873", "r874", "r885", "r890", "r1058", "r1072", "r1089", "r1111", "r1112", "r1113", "r1114", "r1115" } }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": { "r197", "r199", "r201", "r202", "r204", "r227", "r228", "r406", "r407", "r408", "r409", "r470", "r477", "r502", "r503", "r504", "r506", "r567", "r608", "r609", "r611", "r688", "r690", "r698", "r730", "r731", "r782", "r784", "r786", "r787", "r802", "r824", "r825", "r847", "r856", "r863", "r871", "r872", "r873", "r874", "r885", "r890", "r1058", "r1072", "r1089", "r1111", "r1112", "r1113", "r1114", "r1115" } }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" }, "lang": { "en-us": { "role": { "terseLabel": "Receivables, net", "label": "Receivables, Net, Current", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": { "r876" } }, "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax", "crdr": "debit", "calculation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified to earnings and other", "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss)." } } }, "auth_ref": { "r26", "r30", "r260", "r585", "r590", "r591", "r670", "r1000" } }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": { "r906", "r916", "r926", "r958" } }, "us-gaap_RepaymentsOfCommercialPaper": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfCommercialPaper", "crdr": "credit", "presentation": { "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Repayments of commercial paper", "label": "Repayments of Commercial Paper", "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper." } } }, "auth_ref": { "r142" } }, "us-gaap_RepaymentsOfLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLongTermDebt", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of long-term debt", "terseLabel": "Repayments of long-term debt", "label": "Repayments of Long-Term Debt", "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": { "r142", "r704" } }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayments of short-term borrowings", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r142" } }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": { "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": { "r225", "r226", "r277", "r278", "r428", "r455", "r603", "r610", "r654", "r832", "r833" } }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": { "r907", "r917", "r927", "r959" } }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": { "r908", "r918", "r928", "r960" } }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": { "r915", "r925", "r935", "r967" } }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashCurrent", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: Restricted cash at end of period included in Prepaid expenses and other", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": { "r998", "r1009" } }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": { "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Restructuring and Related Activities [Abstract]", "label": "Restructuring and Related Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock", "presentation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Impairment, and Related Charges, Net", "label": "Restructuring and Related Activities Disclosure [Text Block]", "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled." } } }, "auth_ref": { "r391", "r392", "r394", "r397", "r402" } }, "us-gaap_RestructuringAndRelatedCostExpectedCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringAndRelatedCostExpectedCost1", "crdr": "debit", "presentation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring, anticipated total charges", "label": "Restructuring and Related Cost, Expected Cost", "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost." } } }, "auth_ref": { "r393", "r396", "r399", "r401" } }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCharges", "crdr": "debit", "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" }, "lang": { "en-us": { "role": { "netLabel": "Restructuring, impairment, and related charges", "totalLabel": "Total", "verboseLabel": "Restructuring, impairment, and related charges, net", "label": "Restructuring Charges", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r14", "r398", "r399", "r1059" } }, "us-gaap_RestructuringCostAndReserveLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostAndReserveLineItems", "presentation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring Cost and Reserve [Line Items]", "label": "Restructuring Cost and Reserve [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r393", "r394", "r395", "r396", "r399", "r400", "r401" } }, "us-gaap_RestructuringCostsAndAssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringCostsAndAssetImpairmentCharges", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" }, "lang": { "en-us": { "role": { "negatedTerseLabel": "Restructuring, impairment, and related charges, net", "terseLabel": "Restructuring, impairment, and related charges, net", "label": "Restructuring Costs and Asset Impairment Charges", "documentation": "Amount, after cash payment, of expenses associated with exit or disposal activities pursuant to an authorized plan and expenses resulting from the write-down of assets. Excludes expenses related to a business combination, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": { "r14" } }, "mck_RestructuringImpairmentAndRelatedChargesNetMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "RestructuringImpairmentAndRelatedChargesNetMember", "presentation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Impairment, And Related Charges, Net", "label": "Restructuring, Impairment, And Related Charges, Net [Member]", "documentation": "Restructuring, Impairment, And Related Charges, Net" } } }, "auth_ref": [] }, "mck_RestructuringInitiativesQTDMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "RestructuringInitiativesQTDMember", "presentation": {
```

```
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Initiatives QTD", "label": "Restructuring Initiatives QTD [Member]", "documentation": "Restructuring Initiatives Quarter to Date" } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanAxis", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Axis]", "label": "Restructuring Plan [Axis]", "documentation": "Information by individual restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RestructuringPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringPlanDomain", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Plan [Domain]", "label": "Restructuring Plan [Domain]", "documentation": "Identification of the individual restructuring plans." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserve", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Restructuring Reserve", "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan." } } }, "auth_ref": [ "r394", "r400" ] }, "us-gaap_RestructuringReserveRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveRollForward", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring Reserve [Roll Forward]", "label": "Restructuring Reserve [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_RestructuringReserveSettledWithoutCash2": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveSettledWithoutCash2", "crdr": "debit", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash charges", "label": "Restructuring Reserve, Settled without Cash", "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash." } } }, "auth_ref": [ "r394", "r400" ] }, "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveTranslationAndOtherAdjustment", "crdr": "credit", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Restructuring Reserve, Translation and Other Adjustment", "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases)." } } }, "auth_ref": [ "r157", "r1060" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r121", "r164", "r661", "r695", "r697", "r705", "r739", "r876" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r229", "r281", "r282", "r283", "r285", "r290", "r292", "r294", "r353", "r354", "r382", "r522", "r523", "r531", "r532", "r533", "r535", "r538", "r539", "r551", "r553", "r554", "r556", "r559", "r596", "r598", "r692", "r694", "r709", "r1152" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": {
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Revenues", "terseLabel": "Total revenues", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r183", "r184", "r311", "r320", "r321", "r336", "r342", "r345", "r347", "r349", "r468", "r469", "r612" ] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember", "presentation": [
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer, Product and Service Benchmark", "label": "Revenue from Contract with Customer, Product and Service Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r992" ] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenuesAbstract", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment revenues", "label": "Revenues [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r976" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r976" ] }, "mck_RxSavingsSolutionsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "RxSavingsSolutionsLLCMember", "presentation": [
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rx Savings Solutions, LLC", "label": "Rx Savings Solutions, LLC [Member]", "documentation": "Rx Savings Solutions, LLC" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information Regarding Changes in Accumulated Other Comprehensive Income (Loss), Net of Tax, by Component", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r30", "r1102", "r1103" ] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]", "documentation": "Disclosure of information about acquired finite-lived intangible asset by major class." } } }, "auth_ref": [ "r371", "r372", "r373", "r375", "r826" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [
"http://mckesson123.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings." } } }, "auth_ref": [ "r173" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [
"http://mckesson123.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1079" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [
"http://mckesson123.com/role/HeldforSaleTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Assets and Liabilities Held for Sale", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r17", "r22", "r28", "r99", "r100", "r101", "r102", "r103", "r104", "r106", "r107", "r108", "r154" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [
"http://mckesson123.com/role/EarningsPerCommonShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Computations for Basic and Diluted Earnings Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1018" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r39", "r40", "r298", "r302", "r304" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [
```

```
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Information Regarding Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r849", "r1048" } }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTable", "presentation": [
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Goodwill [Table]", "label": "Goodwill [Table]", "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason." } } }, "auth_ref": { "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r848" } }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in the Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": { "r848", "r1030", "r1031", "r1032", "r1033", "r1034", "r1035", "r1036", "r1037", "r1038", "r1039", "r1040" } }, "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfLossContingenciesByContingencyTextBlock", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Estimated Accrual Liability", "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]", "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date." } } }, "auth_ref": { "r1062", "r1064", "r1066", "r1067" } }, "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period." } } }, "auth_ref": { "r1083" } }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": { "r77" } }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Related Costs [Table]", "label": "Restructuring Cost [Table]", "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve." } } }, "auth_ref": { "r393", "r394", "r395", "r396", "r399", "r400", "r401" } }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Restructuring, Impairment, and Related Costs", "label": "Restructuring and Related Costs [Table Text Block]", "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets." } } }, "auth_ref": [
"r50", "r155", "r156" ] }, "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock", "presentation": [
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restructuring and Asset Impairment Charges", "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]", "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period." } } }, "auth_ref": { "r51", "r157" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": { "r46", "r47", "r48" } }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [
"http://mckesson123.com/role/SegmentsofBusinessTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Information Relating to Reportable Operating Segments and Reconciliations to the Condensed Consolidated Totals", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
"documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": { "r46", "r47", "r48" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r901" } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [
"http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r903" } }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Domain]", "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r311", "r316", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r349", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r381", "r396", "r401", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r839", "r842", "r843", "r848", "r887", "r1117", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r198", "r200", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r347", "r348", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r723", "r726", "r728", "r783", "r785", "r788", "r803", "r811", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r828", "r857", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r886", "r890", "r1074", "r1117", "r1121", "r1122", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting [Abstract]", "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://mckesson123.com/role/SegmentsofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "Segments of Business", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r186", "r311", "r315", "r316", "r317", "r318", "r319", "r332", "r334", "r335", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r349", "r838", "r840", "r841", "r842", "r844", "r845", "r846" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingInformationProfitLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationProfitLossAbstract", "presentation": [ "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information, Profit (Loss) [Abstract]", "label": "Segment Reporting Information, Profit (Loss) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Selling, distribution, general, and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r138" ] }, "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember", "presentation": [ "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit", "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]", "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit" } } }, "auth_ref": [] }, "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility)", "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member]", "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility)" } } }, "auth_ref": [] }, "us-gaap_ServiceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
```

```
"ServiceAgreementsMember", "presentation": [ "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service agreements", "label": "Service Agreements [Member]", "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service." } } }, "auth_ref": [ "r66", "r1042", "r1043", "r1044", "r1045", "r1047", "r1049", "r1051", "r1052" ] }, "us-gaap_SettledLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SettledLitigationMember", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation", "label": "Settled Litigation [Member]", "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval." } } }, "auth_ref": [ "r1062" ] }, "mck_SettlingGovernmentalEntitiesAndCherokeeNationMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "SettlingGovernmentalEntitiesAndCherokeeNationMember", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Settling Governmental Entities and Cherokee Nation", "label": "Settling Governmental Entities and Cherokee Nation [Member]", "documentation": "Settling Governmental Entities and Cherokee Nation" } } }, "auth_ref": [] }, "us-gaap_SeveranceCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeveranceCosts1", "crdr": "debit", "calculation": { "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": { "parentTag": "us-gaap_RestructuringCharges", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Severance and employee-related costs, net", "verboseLabel": "Restructuring charges", "label": "Severance Costs", "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r491", "r492", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505" ] }, "srt_ShareRepurchaseProgramAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramAxis", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Axis]", "label": "Share Repurchase Program [Axis]", "documentation": "Information by share repurchase program." } } }, "auth_ref": [ "r1073" ] }, "srt_ShareRepurchaseProgramDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ShareRepurchaseProgramDomain", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share Repurchase Program [Domain]", "label": "Share Repurchase Program [Domain]", "documentation": "Name of share repurchase program." } } }, "auth_ref": [ "r1073" ] }, "mck_StateOfAlabamaAndSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "StateOfAlabamaAndSubdivisionsMember", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State of Alabama and Subdivisions", "label": "State of Alabama and Subdivisions [Member]", "documentation": "State of Alabama and Subdivisions" } } }, "auth_ref": [] }, "mck_StateOfWestVirginiaAndSubdivisionsMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "StateOfWestVirginiaAndSubdivisionsMember", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State of West Virginia and Subdivisions", "label": "State of West Virginia and Subdivisions [Member]", "documentation": "State of West Virginia and Subdivisions" } } }, "auth_ref": [] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails", "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segments [Axis]", "verboseLabel": "Business Segments [Axis]", "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r183", "r184", "r185", "r186", "r231", "r311", "r316", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r330", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r342", "r343", "r344", "r349", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r381", "r384", "r396", "r401", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r684", "r685", "r686", "r687", "r839", "r842", "r843", "r848", "r887", "r1117", "r1121", "r1122", "r1123", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://mckesson123.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r195", "r241", "r242", "r243", "r275", "r298", "r302", "r304", "r306", "r313", "r314", "r352", "r413", "r416", "r417", "r418", "r422", "r423", "r453", "r454", "r457", "r460", "r466", "r583", "r701", "r702", "r703", "r704", "r709", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r738", "r759", "r777", "r804", "r805", "r806", "r807", "r808", "r987", "r1010", "r1017" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r19", "r119", "r122", "r123", "r229", "r259", "r260", "r261", "r281", "r282", "r283", "r285", "r290", "r292", "r294", "r312", "r353", "r354", "r382", "r467", "r522", "r523", "r531", "r532", "r533", "r535", "r538", "r539", "r551", "r552", "r553", "r554", "r555", "r556", "r559", "r585", "r587", "r588", "r589", "r590", "r591", "r596", "r598", "r602", "r670", "r692", "r693", "r694", "r709", "r777" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r198", "r200", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r347", "r348", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r642", "r643", "r644", "r723", "r726", "r728", "r783", "r785", "r788", "r803", "r811", "r815", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r823", "r828", "r857", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r886", "r890", "r1074", "r1117", "r1121", "r1122", "r1124", "r1125", "r1126", "r1127", "r1128", "r1129", "r1130", "r1131", "r1132", "r1133", "r1134", "r1135", "r1136", "r1137", "r1138", "r1139", "r1140", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r281", "r282", "r283", "r312", "r598", "r612", "r700", "r720", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r755", "r757", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r777", "r891" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r281", "r282", "r283", "r312", "r350", "r598", "r612", "r700", "r720", "r732", "r733", "r734", "r735", "r736", "r737", "r738", "r741", "r742", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r751", "r752", "r753", "r754", "r755", "r757", "r760", "r761", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r770", "r771", "r772", "r773", "r774", "r777", "r891" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r910", "r920", "r930", "r962" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under employee plans, net of forfeitures (in shares)", "label": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures", "documentation": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures" } } }, "auth_ref": [] }, "mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of shares under employee plans, net of forfeitures", "label": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures", "documentation": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures" } } }, "auth_ref": [] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized repurchase amount (up to)", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1073" ] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Authorized amount available for future repurchases", "label": "Share Repurchase Program, Remaining Authorized, Amount", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r19", "r118", "r119", "r164", "r704", "r777", "r807" ] }, "us-
```

gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchase of common stock", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": ["r19", "r118", "r119", "r164", "r709", "r777", "r807", "r899"] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "totalLabel": "Total McKesson Corporation stockholders\u2019 deficit", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": ["r119", "r122", "r123", "r149", "r740", "r756", "r778", "r779", "r876", "r900", "r1012", "r1028", "r1101", "r1152"] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"], "lang": { "en-us": { "role": { "terseLabel": "McKesson Corporation stockholders\u2019 deficit", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT", "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveLossbyComponentDetails"], "lang": { "en-us": { "role": { "totalLabel": "Total deficit", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": ["r68", "r69", "r72", "r229", "r230", "r260", "r281", "r282", "r283", "r285", "r290", "r292", "r353", "r354", "r382", "r467", "r522", "r523", "r531", "r532", "r533", "r535", "r538", "r539", "r551", "r552", "r553", "r554", "r555", "r556", "r559", "r585", "r587", "r591", "r597", "r602", "r693", "r694", "r707", "r740", "r756", "r778", "r779", "r809", "r899", "r1012", "r1028", "r1101", "r1152"] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": ["http://mckesson123.com/role/StockholdersDeficit"], "lang": { "en-us": { "role": { "verboseLabel": "Stockholders' Deficit", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": ["r161", "r274", "r452", "r454", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r467", "r558", "r780", "r781", "r810"] }, "us-gaap_StockholdersEquityOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityOther", "crdr": "debit", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Stockholders' Equity, Other", "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy." } } }, "auth_ref": [] }, "mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember", "presentation": ["http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrtiveDetails", "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"], "lang": { "en-us": { "role": { "terseLabel": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization", "label": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member]", "documentation": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r604"] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r604"] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": ["http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": ["r592", "r604"] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": ["r956"] }, "us-gaap_TechnologyBasedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TechnologyBasedIntangibleAssetsMember", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Technology", "label": "Technology-Based Intangible Assets [Member]", "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights." } } }, "auth_ref": ["r25", "r1042", "r1043", "r1044", "r1045", "r1047", "r1049", "r1051", "r1052"] }, "mck_ThomasRodgersMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "ThomasRodgersMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Thomas Rodgers [Member]", "documentation": "Thomas Rodgers" } } }, "auth_ref": [] }, "mck_ThreeLargestUSPharmaceuticalDistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "ThreeLargestUSPharmaceuticalDistributorsMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Three Largest U.S. Pharmaceutical Distributors", "label": "Three Largest U.S. Pharmaceutical Distributors [Member]", "documentation": "Three Largest U.S. Pharmaceutical Distributors" } } }, "auth_ref": [] }, "mck_ThreeNationalPharmaceuticalDistributorsMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname": "ThreeNationalPharmaceuticalDistributorsMember", "presentation": ["http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Three National Pharmaceutical Distributors", "label": "Three National Pharmaceutical Distributors [Member]", "documentation": "Three National Pharmaceutical Distributors" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": ["r948"] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": ["r955"] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": ["http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Trademarks and trade names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": ["r64", "r1042", "r1043", "r1044", "r1045", "r1046", "r1047", "r1049", "r1050", "r1051", "r1052"] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": ["r975"] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": ["r977"] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": ["http://mckesson123.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": ["r978"] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": ["r979"] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": ["r979"] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": ["r977"] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": ["r977"] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": ["r980"] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": ["r978"] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": ["http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Average price of shares repurchased (in usd per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": ["r58"] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "terseLabel": "Treasury", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r58"] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical", "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"], "lang": { "en-us": { "role": { "terseLabel": "Treasury shares (in shares)", "negatedPeriodStartLabel": "Beginning balance (in shares)", "negatedPeriodEndLabel": "Ending balance (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r58"] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"], "lang": { "en-us": { "role": { "negatedLabel": "Treasury shares, at cost, 152 and 148 shares at September 30, 2024 and March 31, 2024, respectively", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": ["r58", "r59", "r122"] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": ["http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock repurchased (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": ["r19", "r119", "r164"] }, "us-gaap_TreasuryStockValueAcquiredParValueMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":

```
"TreasuryStockValueAcquiredParValueMethod", "crdr": "debit", "presentation": [ "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased", "label": "Treasury Stock, Value, Acquired, Par Value Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method." } } }, "auth_ref": [ "r19", "r58", "r164" ] },
"mck_TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember": { "xbrltype": "domainItemType", "nsuri": "http://mckesson123.com/20240930", "localname":
"TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember", "presentation": [ "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
], "lang": { "en-us": { "role": { "terseLabel": "True Health Chiropractic Inc., et al. v. McKesson Corporation, et al", "label": "True Health Chiropractic Inc., et al. v. McKesson
Corporation, et al [Member]", "documentation": "True Health Chiropractic Inc., et al. v. McKesson Corporation, et al [Member]" } } }, "auth_ref": [] }, "country_US": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024", "localname": "US", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED
STATES" } } }, "auth_ref": [] }, "currency_USD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2024", "localname": "USD", "presentation": [
"http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "USD",
"label": "United States of America, Dollars" } } }, "auth_ref": [] }, "mck_USPharmaceuticalSegmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://mckesson123.com/20240930", "localname": "USPharmaceuticalSegmentMember", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
"http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
"http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
"http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Pharmaceutical", "label": "U.S.
Pharmaceutical Segment [Member]", "documentation": "U.S. Pharmaceutical Segment [Member]" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype":
"pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security
Market Price Change, Percent" } } }, "auth_ref": [ "r974" ] }, "mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember": { "xbrltype": "domainItemType",
"nsuri": "http://mckesson123.com/20240930", "localname": "UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember", "presentation": [
"http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States ex rel. Hart v. McKesson
Corporation, et al., 15-cv-00903-RA", "label": "United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA [Member]", "documentation": "United States ex rel.
Hart v. McKesson Corporation, et al., 15-cv-00903-RA" } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } },
"auth_ref": [ "r508", "r518", "r864" ] }, "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Unrecognized tax benefits, increase (decrease)", "label": "Unrecognized Tax Benefits, Period Increase (Decrease)", "documentation": "Amount of increase
(decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns." } } }, "auth_ref": [ "r1078" ] }, "us-
gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://mckesson123.com/role/IncomeTaxesNarrativeDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Unrecognized tax benefits that would impact effective tax rate", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
"documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r519", "r864" ] }, "us-
gaap_UnsecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnsecuredDebtMember", "presentation": [
"http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unsecured Debt", "label":
"Unsecured Debt [Member]", "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-
gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [
"http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy
Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted
accounting principles." } } }, "auth_ref": [ "r43", "r44", "r45", "r189", "r190", "r191", "r192" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
"label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r944" ] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": {
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "parentTag": null, "weight": null,
"order": null, "root": true } }, "presentation": [ "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Diluted (in shares)", "totalLabel": "Diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average
number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or
units in the period." } } }, "auth_ref": [ "r297", "r306" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Weighted-average common shares outstanding", "verboseLabel": "Weighted-average common shares outstanding:", "label": "Weighted Average Number of
Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": {
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": { "parentTag": "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
"http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for
contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common
shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r296", "r306" ] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r942" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-
25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230",
"Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(j)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "10A", "Subparagraph": "(k)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-10A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "SubTopic": "10",
"Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-11" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "14", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r10": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification",
"Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-
25" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r14": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "5", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-
5" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic":
"360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-
1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)",
"SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r19": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r21": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10",
"Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "4", "SubTopic": "10", "Topic": "280", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4" }, "r24": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20",
"Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI":
```

```
"https://asc.fasb.org/1943274/2147479876/805-20-55-13" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "420", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481080/718-20-55-12" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-12" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-21" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
```

"Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-7" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-9" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards

Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481138/505-30-25-5" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "470", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r185": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r186": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column C", "Footnote": "5", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column C", "Footnote": "4", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column C", "Footnote": "2", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column F", "Footnote": "7", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Paragraph": "Column A", "Footnote": "4", "Publisher": "SEC" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(A)", "Publisher": "SEC" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(B)", "Publisher": "SEC" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iii)(C)", "Publisher": "SEC" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "a", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "m", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r237": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-

45-23" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name":

```
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/420/tableOfContent" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.b.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":
```

"Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",

"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r503": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r504": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r505": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r506": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":
"740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r510": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" },
"r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r516": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-
10-50-15A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r520": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-
10-65-8" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r524": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r525": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r526": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r527": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-11" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r530": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-
323-65-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479581/805-30-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-
60-65-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-
45-25" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-
10-50-4CCC" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-
65-6" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r553": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r555": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",
"Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r556": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6",

"Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-

```
235-50-23" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI":
```

"https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":

```
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(8))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "2", "Subparagraph", "(SX 210.6-05(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "2", "Subparagraph", "(SX 210.6-05(4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-
45-3" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section", "S99", "Paragraph": "1", "Subparagraph", "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r782": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r783": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r784": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r785": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r786": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r787": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r788": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r789": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r790": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r791": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r792": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5",
"Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r793": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r794": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A",
"Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r795": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r796": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r797": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r798": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B",
"Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r799": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r800": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C",
"Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r801": { "role":
```

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r808": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r809": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3" }, "r810": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r811": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r813": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r814": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1" }, "r815": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r816": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r817": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r818": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r819": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r821": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r822": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r823": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r824": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r825": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r826": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r866": {

```
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r869": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r872": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" }, "r878": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r880": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r881": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r883": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r884": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r885": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r886": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r887": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r888": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r889": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r890": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r891": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r892": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)
(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r893": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r894": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r895": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r896": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r897": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r898": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r899": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r900": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "b-2" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act",
"Number": "240", "Section": "12", "Subsection": "d1-1" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q",
"Number": "240", "Section": "308", "Subsection": "a" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"16", "Subsection": "f", "Paragraph": "a" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection":
"F", "Paragraph": "1", "Subparagraph": "i" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r911": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"D" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph":
"a", "Subparagraph": "1" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-
F", "Section": "19", "Paragraph": "b" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r940": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r949": { "role":
```

```
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r987": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r988": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "SubTopic": "740", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(ii)", "Publisher": "SEC" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "a", "Subparagraph": "(4)(iii)", "Publisher": "SEC" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1025": { "role":
```

```
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4CCC", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",

"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/985-20-50-2" } } } ZIP 84 0000927653-24-000125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000927653-24-000125-xbrl.zip M4$L#!!0 ("2!9UFI2[H"O>D!^/GY'0 0 ;6-K+3(P,C0P.3,P+FAT M;>R]:W?B2+(N_'W_"KW,G#/=:P&E&Q>YNCF+PG:W3Y\H++#B,W\'_] MFU97_Z9@WPX[S*%9T53=GM\VNAA>: M96#=:9DU-&RW:^;PK==0RQK6&NV&AM&PA?667GV^;+7;JF%;K5IC:-@UTVBA MFC74G!JR{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{0[PHD/77R"'2REXW?\)?TE5&0A.P36[HN M$M^-V;BC$2(7*I/OQQA%28@[Z:?TXB^?EJ_-/M-GK#PO(6/X^+"I KOXUK_.M^RP"T3X=Q/LSB7YQ';QX*R,SBH-PS]>N_)Y^>8G]8_2688_=E31+C_BT//I- MLX[P.Q6@%2H25E],K^6BHI^,ASA' M7,_'R>H49\^Z^O:8ZUEDX8I#=Y(@0SF5R8>%ZKN<2.R'&V7RE5W+R(LI\ZOO57,]\0]]KX$R?2: [>L:MYG{GN M:?GHB&-B#FT0W=GE7$]I"=9 AE[8Y4G3%2X%#5FL9]]C9D_-/A&M1+GAXE!A MBP_.]#MZ-W\LVUD??_P^;@N6G3YBA,?M$P![&U*]BQHQ94\G_:,;?S:^]#]-9 MN-6J4;MS^\[*7BN;8/WV**4L5QR57F MRE>F[LQ%GRH"^IN>AZ+H_JD?!_;W[]M+5NC9+;U@3&Q/=B%]SB^:?,A__3HGW M4 W*=&[^')FZ,/&GH+[YCLIG^CSA&KH^=*Q3ZKO\<24- X\7V. M+<"W162<>'0'_CX>X9#>%^(1?=H+OO'M8(REX87Y'L9F7@Q"%BMI8ZH_706D MH?W1_8WHCDM93 L!G$SMZ,Y5 M&52P (S2C^[_26\PBL EV5W94ZVJ(O!*>A>X"$[!,,) fCN?,%[$*R:O2^\V M%Q.OXD9_V5WE4\>+N!%>=C\9@'@1-UX!(>/&-Q>"&[LWMPEG>MH>?B2 M_^@^:W%3DIZK+&2/K)@.1 /<3DD8);N/>N(!LIF*X)+LK6\@>63&\,]5W@00? M(RN(<;+[SB>,%_&*T9G2N\W"Q(NXT5]V5_G4\2)NA)?=3Q8@7L2-%[)O%!<0 M+ ^)&>]F]^F+B1=S(+UA.-<^IR>[9GC#EB=>Q1%-V/[6@E"=>]&_([GN>.N6) M&^%E]QV+- N=X\(D)VGI*E"=NM)?=GRPFY8D;^67W*LM>6ZLANZM9V&&_(I@E MNV];R$& (A@E^V[SZ0_Z%<$ZV1WRH@[Z%<$KZ1WYPCQ>?3&;F-S(M+UA=7YY3D|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fT%Q2M_E >*1'6I9:1+?RD15@G>R^VL$,T M\LJ(L'ZW/,S@)QG">N27>!C?^+0].WA/,:452WU+HAQ=)G@2VRSWQN$*@U> M\._!OYSC,,Q'K-\;.8FS$UA(Q1KV:P9[\+<39Z3* 8F;V.RL-$/D&6>*EO8 MJ K(,C\F"QNK6]^G@2 MLR9\)B?E(L7[RK MJ:ISRRL-;9I.^5C,3XKEBW6=*8OY2;&$<:YV>YG%1%,;9OEXS$^,)0QTG0F/ MN)+Y07$ MBMGUSN-#$" [R-.'Q,#S^*/0%]-LF3]1L@.ACWPW";SX90A)BIT?^WXVOD>UZ-M9/2#28TI>_Y(65Y:=^;-+^$G@OKO]\G%=OANDL>CEH^HBO:9I-;7%1Q=)M%V3+#[T>\fC(O\R\#P4? @G=V(U&#'T'B.[,&"XP#6LH&5 M5T]XK@H;U=_$Z%XP'N/0=I'W@.ATI:&V)FRDOE!JBV!B.,+&S,5A34%^C29L MJ%L@'<7-?-$$CB.'[@N*W1<\-V(>W>C[QT[&88A]^ZW_TUXK? Q9:XY^0Z[_M-8BB+Y^_8?>>36!V+O9.7QW2'B=WU@J.8_G\Z-Z^Q31WB2/W.6TFO_SNV07L M=*/IO?\)'#H(FFD<]3[MPD,E=T/Z#9E-2!S 1\)@0'MQ:/_6ER$&HPNI*P)H! [3SUNVZL!M-NZ'I,@A_ MH-#ID5F%RZW%>(Z&=I[*%I=\&/.P&{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|=)^/CKCR:45,;-:VUP\KS|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|"XXMKX_3&\ABILO+NHE4'8(X@FSNRA8A6@<5T86-?_M 'N0#_+Z*XE,*P0$,X=X>-<3]_.$"ZA&83QGT6\X> [19$3U3,H>.T@(:-Z(_M'5DZ5L@<-!4^C>5#W? +#."5W/011W%(U&<2T@.'O+G%JZ=..[L4OTVPN. M_CZX/%2S4I$ENCP*/-=A2O.&P.5##..>4)A<|Y]GV#D'G[. "DFF*FRT&, I M%#@+6.-,5=A0.3LP3P9+0$,3A='7]N$,$COG^:? _TV9]O=U#I<|/KO)P2V M^"M:|S.[*[M MDUX5=A=AOJ"N_6?B1BX[Y337K*]]]$+@$;V[Z5^_]D]YSV.] MPNXCB,BA G9Z3%78>/B-;P=C/-=YB)@G-NZ/,*:AB*]CN*FZOW0CVPLBLBZ0 M!8)\F 01\GX+@V0R+IQ!V%+1H*=]7TSO(=|\Y+C(?\0Q0I"\A'?!7'V-$H?A2ED,1$V? YR 7)1H+L@7-!] M%Y\/5WC+O!W8T_)Q%%6+2QD+!S05E+=)FRX7]902'Y)D%51",?_@&V';.O'-M?7&=9+931Z$Q& 5C%#T&SC,.R[F1P-2$BJ<++PIPBE*HF7'RY(&8L=VQ>I.\A M%:I-3;@@Z#KZ? L5=W^^/W7A44K4C7++!3!$X4HG,$"VH6P8G#%,A<.K^0?QC-W6'+;@_-E]VAH6.;5FO8;+?:EH9M;-DMPWKZ M%UT%YK^)XC>/'[*|L^K41=I[\86|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|5IZ_(CMFL;9PY?)^M@BCFF":,!TX MBNLK;APIHAAY C^+/8-H- +751IE8WC++,XQBXO).:T M=5//I$EU:9X24<\LMZZ7'FGO$PE(!+I+F:,)V'P0I\S]RI;EN="RS9NAJ2[>;&PG,&\BI4N!-Q?9. M1/R)P5$AAG5 +.M0^7<2NI'CV10^OPS#3QVB:=U%^+);PV?DN_]AGW\N$'N% M$NZF_ECOUY6K\<0+WG#(B+6,+^4NJ/^VC<%7%MSWV)$F/_'D?#H(?[TJA/3L7P85 M)GL)H^TK>]#F/)O^2T2PWZMFWGXO>0C{N3]_^XD7;*FK] 59-2R! MC,FMTIO:DM-I44-R$A*RN1/D*5VPDM0D"^)D*,RNK5?6DRn_(?=Z+02%D^_MB{00WEW'E. =D,.EKAJD)6PM>+L_9P#.E\#HJ0?1H'_P96D>5.FV:R9:57= M'3/+IK5Q"]=[1Q3-/:[__9>VKK4^1TJ,/3RA,U=\-O5%"!'+#4F"H3Z1A-*- M7?+$U-`"(?&M)DD8)=3CB@.%W,$6.4W_:? @SE2,.F>O:\<561M+0R30?_PM M>?RMXUA;(?^9?.$K/T8N^<6:NH3+,,8DD8'W5U]Z^TW3ATQ& MWE??1AHF#NC8 _M[5?FK6E9 MC9TDNEWI:/4&>9IR%\1D9$Z"-9Y)X[PA:FR79(M),A*@RSK*LC9C^:%BR M3I-HZTV]4&K6-)>B2P118 L;TL-G,;=/F1 _3N)8O?I++?W*]>ENV(5NLH.7 MW'.IT^.<&Q- 36223GHJUZ>[3\VQ1YA0@7864'Z,,-OPI%'+A522G[2?TXRP M$8J4)]?#CH(\C]Q!,U1I+/3/Q*61T#A0AGAZ WGP-!B;_E0SZ"9IFIHYC8LN MA%-G/*"Q4GJ9IF82_4"K(+- ,)R&V.0OP.+K"TLPCY2?R/,)P)4KLD1*-_IK9 M,DM[C$9"?\3N)[^D M0YD^C%4E8R-A(T51K%BJX["WJ+Z439=SCZF7A"%YLWA16Z0_9.!?R$L4HS>,\H'?FSUCP^!'/)I=KA/!;.Q.? C)I=G) M'Y8Z07>]=3+--2-DEI7/L]NVWK!^?+,.;_I=$RO7G-6&=WNGZJ*XEK5M-G9MBB M[57?90I^,X1.O'W=K%NZE7?[6K?J;K/!9<[9)7H]\7E2LJY0LW^2]U"M>J// M9W=>U^MZ;_.6^LX;_75+XW.(D#Q)WZG>QI1Y>L8>?5F!WHL#+H6<(YV=5PA[1 M)\]!^);A$K.;F*.QIS,=6I?,UV_QC3VG.$9QR=PKCHED,L- T)MN9G3K%TX8!YEV6)%L]#P,4^N#P; M==[/W9"4L^^^2/IQZF44SV_,&]KDK%]UH)C:S$*0]VM&L6.VGQ\2GD-AED M]BH[&B"- BL6^C/J_<:(UTMIMUT$M!PBP'%#4:\? (8*WG:)I_*[8H.W3:Y?W1E_^MPR6O)]J5?#*$@ 8,7]R(V9<^\FTJ2<3]I$>LZ8X?=HA#UOAG/E)X)>%@0!/*TVLAI@) M08&:,6\K_X$B@O93<(A"=^,YK@;YU+8!MKETW!'O2!2Z(J!YSBJ(_/?-(92$: MH9"\)$ABIG^(IX=X)E*BAM%"?6RI@<@-6GH@\D]B(Q-LFSU'?),"H=36]6+5.MJE9KO)AVS ML7;>*95- E052*#]PB)+"WL"5.G^X,=) MD)HP%R'V6&OIE=X#\W&P :CSGZ!A1#L#K_XDE?$,JS:15>0!;N%UGO:A%$X M=W6><6T88O2]AIYB'%X@[P=ZBR@!H+>" <+T5A#U"GEUU+,>@UR-=P!D/NE^^-M7M%RF[W[N\'5W6"GJOLA?4 19^%;:BM_<5S5X+1MWZXW#3Y,Y'10FS,]M)1 M8-3^ZG1H^U M:&YAYDD7\,UCV7T!IR6?'KJ/ ^6&6? 7ZY^N;N^Y=[Z;[52&^Q_WC[?1E_+BD MYY%A64$MFG;)#]=K1]P:.X&9G#6HJ0LYUCR21DQCQWLIT#PO&\P^7#[\A5^ M[%N=84&?\@(=?PV9/)\&{\7? I[&]6K6IB@5H#'[VHVU:)CG']\[fKf]>V M8O(6S/ OZ\Q9&GCDOLH]B>G9FFF'FNW=$C%N1#Y6HXM;Q@ERO >;Q>4_X;B1 M>Z7DXX7.0B,-'Y_]88/6#- @#53+-#B,.UHS=#$'+66COQ M"_*0;V.E/*8V(]I8I2X*A"6P"/#1/ E\!.%]D@QM&7>PV(H,^0:L!A">5 M<-("N3N%5UB^\RCPR"NB.0:RVEE7^&.G@A\@ M##F$P.2%/F.L.$I-Z1/FNT\$"ZL=.%@S0=PC^< MP-B;JA^=]!HPR\T%K_+>RJ++#M]+J_3UD8=!59=%LC0-J#R8N2 -3_\RK>DZ M(ZV2IG,P!!X]6>$?<12'B1VSAG55Y68\06Y(MWC2CI:/M- 8:W08:T=XN495, M((;5["SR!\$11EB-0!J(-#0:LJ]&= :FU*.G]|'T"_H O4)LJSR"I4$J-RPS M(U4&MK2+S/MV M/EER;/* &ZEHA8'V1V1U*0!U5%A58\\H@Y3HD,\":!}) L,$RI5_SZ!1TJ4=/ MUSS_%Z%]$L2D6=$X&.51L*,LD7Y,E!F$_CB<'W.BEA%]'>*'T5N0#PXB =Y M&&UVXZ-GMK4QM?<%,(9(OO-EGJD^]@.X@ M1TIW&"2QNYIAR Y;S M\O"V=,NY)+JO"\I/ @$0*QT:P%ND1T(>B]K 5]I$&0)K0&/5]7S5Q_0 MLQL1_- VKLC#:./OZL_$C=^4/K;3D"6JLSC/MPC3BU,#$;1D>5 6A+V!$$^ MLN6CJ58ZE_@)L:2(,Q-.$1J+FW \ZX=01.6AM.- LIWCD4,3PL:?#/)A5#JW MY#?$3GS"Q#Q<2(8 #5@:#H,&+$0#-D #2B ?S4KG/A[A4+GQGX)PS!X%NJ\T MO 7=5N5X:N+S$U\^6GJE<_4ZGT"6E1 M#(YCJ9C:V- A9YU,,AAZ>?;]#UF3GEV'XZ;(:SV6>:4O;\:F/%GX MEX[6=7ZM[')VK#+[T2B<"^0SK@U#C+|7T!.9X 7R?J"WB&K?!3J,77\V(%-/ MV'61TB=/E- 4%2I3=/)8<=-:JGO0$,5,KJ)2Q/TLVM<%K0K+E7.K?V'U?]_OV= MTKM_?+A>GJ;TYAQTEC *.^,TG7F:S7Q|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|IX_#%]?&43_PG+QB9!#W3:V:JK$B13_O M+$#90#S:(O7A=9FA,H#0-N^$'X1,XH285'*

*@. M$\]OJO*,?1PBK\JJB")G[/KT!TVT73Q1YCJ@J61HVF)J'@=-1J5CMT<95450[!$*GW%457Q\4+A3 M0C'B&=1$KO^5N&6/M%0*=@;!UW<*]W$<>^P(>8:<- %B=7B[.F&3>?FJST#.!%"KP<9O1%9/SD+U(:.54ZFKJZ<[+!>@RP$5#-; L5[@F6MNAJ M)?]HO%VN"O?79P"K>L3)8*YFCMU4(=!1]Q).Y08L=)R"*Q[GB"W)"*3AI^*

*@. M$\]OJO*,?1PBK\JJB")G[/KT!TVT73Q1YCJ@J61HVF)J'@=-1J5CMT<95450[!$*GW%4557Q\4+A3 M0C'B&=1$KO^5N&6/M%0*=@;!UW<*]W$<>^P(>8:<- %B=7B[.F&3>?FJST#.!%"KP<9O1%9/SD+U(:.54ZFKJZ<[+!>@RP$5#-; L5[@F6MNAJ M)?]HO%VN"O?79P"K>L3)8*YFCMU4(=!1]Q).Y08L=)R"*Q[GB"W)"*3AI^*

M#5/I.MR4/A./=.M9P 5JT[0;FG!:#${#CFW?"!U)29Z@NBQYV6-W@$,3OA"C& M<2*L!V&&-JG1#S&- #(B0F;KP:M#($//5+5!S90-,UN/"QV"&;W2:.|F>0@" MF;/.^1P$,?*48()IT-M_/FP'O8SI*SSMN_L9F:=["U'.S07:44FO-EN'B!+D M2I4%;%L,PX/!9E*P:1{'R!F 37JP,3$I#P8;W0ZfMJQ#*$H0 ;&4!VQ9;]&"P M-2G85%//"9?3DX4F1,/3,=\7U(6",#XDTEDJXCF&BWC 2TRV4# &B7=Y,!Q|& MRI4*"4($9XNI72W1C9AJ5SK6X27[%,EP=2N!N-[Y,-(^]+PA M9+L>S_JB'I\RQ$]!B*=!725&KY#O>HQX[WR?A/R5=I-X"$+ZU&Z<%O2BK;H' M 9$G^MMP0/4X9L*6(5E6I9-5?UJ.$fZ0)W\B(#)O^+-752L?2>$69 7ZRPV^K M87D8_'+M+!+)G"ML>.,QXI2!XH,>RM(@ %4V?.QD2^Z"CT:E M8T 1D-+A8R=K;A=|-_D^2M-^J?@M:[GO O**E<\@'',L[=W=]BP.1 M-CW)/CG5;M$B3K+ZUA#Y.7%8?".4V15.*Z-+!T#I/*&TQ2U9A%*^@" [>Y<5 MZ "DG2?2MC@X>R/-4BG26M+VF#O'T//*O|0=0>Y*JR.@X=?^_MIB6A]GPS:+ ^=<4NK=*"W?.F L\60Y $*5'7"D>]O1Y[\ MV*KD6$9OAI9HT#0,69M%YXI.@-B V.QG\F>(#3U!Q^W((B-(L>'I\.0-TAU6M<1;G#D"J0*KV\P;S2E6;G9?0>?7Z$Y1;8'9V1G*32!;?(,4.OU^@ MA4$[f (0)I>)FT#KTZ3-ZR4=W\A@'^ROLA\4K%/ID&I$RP2&9_WA,E&(T0N%^M01!N>]7P>U%^?]8E_R]=+XFQ>]fG4<3C>f')T>*LUT$T"\|]-M\H$\&4.F8=>M@%P>P#|@_%?8U M7MC7*IUVO;V:6@+8%P8?@/T-X;Y#L*\3FT>K6PVAP0|GT40ZBU;|.6^"\@+ M)REYK1U?4.3;A]27+|ORGS7%|BW_^2(>#"19B[_! AZ\ZH!)L"<,R!=I;L*Q%OLG'"0=;O8!\0+Z8X8ZUR&_08(Y52R M4$<)|@+R GGEO4ND3#[XO12_/|>VS/|D'[!30V14Z!DOIY3Q6OM;G2!7 YN.@C8_^QDR;=%-E,ASB\?Y]2EKD@ MT?U)]!4>DQ'M^H'>R+B9!P @M:?C#P&@NB1%,.L'QRZ!P2)B2#MZ BB MR;Z&6C^2$D*$6<=&Ds;KY1F-NMCYTI =<$B)Y"+R7[&WM-1=>%2$ M|MK2VX<+B3C[+8"?PTV|W?&CIX8>K_(R@[_!\.?H;<[?@Q.KB;@<]8M7D$_'+M+++}G"ML>

M%4PXU2F_LZ8O>@3C!P0;/$H_(9U'AOK@$SE.@;3Q)%^T>A!W%2\,,VGG/0MA!K=JN!'3GY?]*E97 M@'H>.]P!Q@#07SIML>*

<7W5,UQ+;X#4:,8G'H$CD,\W:@M@GB^Y5!%B.25DOL@M@DT%6T4/U=KCZ&Z0I&NA:TA=>TZ[1]H+F@R'O,+S2U#8:TR2H11^UF:=CE+:,1Y M/LU%&:Q?*

*32O,!2LCU13I6VUM5NU8;_(Z6QNM%81-QFMU@*X$<';7:5, V_F MB35>+IHUGB_)4FI,>BDE(:,C(->W:L"V5$"E^317 KN"^3098=:L:C$^H>;KXW@TON,)-9?K!>Y$WI;FY=R M!X2 .F6>3<G<G>8\4 M9ILB:6= V7!LR=_+6!FEWL=),OWB++=XQ5A!%.8)LQ5#4PU)>,. ^H.B*U&-2 M8=FUGZ]H+HCR4IKL<;>RXS*

*+>A[F11C"^D).G*LW$N&T$IDK4\!/63)"M/UCFN-MQ:K9MBL;"MLOUDWCA0UE8[/7#[=8R[-9'C\'3Q3>@[H9!HCR 1X0'O-?;->(E MAX6;&2^=9FTX&%2E=N8'LT5+D)0?*

Q(3(882F ;Z%Z0T5R.?E1N:YC,PTA(A@ M1L;T]N%&9.E&I&LI2ZSU"K+P1V/;s%Y,&)N!RR28<]VK_\,.&3I+(MCPM[WP

*MP("YB*IFPP.I%\+MSN+"%.IA=,BO,69+'X/5F6R612X8AI:GI&WVBWF+10R&1'T:\U0@3=O6_UUA1;6[WWYEFG)H:XB':?(99.UY:\XL=P%IXSW7KU&!'T4M#HB*

MTGH50MJQ=&QU93-=0<$B:_$XSNOI1OJ> X(.EDPNX:R0=X-M(Y$-]!:%:BH MRZ-C9SH-41:4^K5AJ]YMEI!RR\-H:7WJ-,R(-E3L3]?QZ@:?%)>ID$9!TBP6B M!]@9>O:*

*<)17&;&2;>)=88JT%";AYW.+:P//_#[04R5K,?0PIYCR'ZA M]/V]G>!(IAT*ZK9PHZ](.7UN[%8105E/E)6 (-PJ%J_'QKW$,\ +?Z6*G@'.M<{CL6EFGX!G@6*

*I)YSAVL7!MO90N)Y4X(ER2Q?VA45GPB' 9J,32N'6I6X*K M=XH3Q-*

=K/C\L%D2AE2')3V4I&R]$L&2'".RS+0"287DF\O(E_O]ALR+/P5K0$H&&NOU%Z,HXANS&59HLN37+I1GV5P7) MHVB($X&S5ZP,ZM%Q>?

*4A\3NF&K1M/@<\2#56ZF<\IY7BCMRE*B07I7/C$&>5]B"8U9= M;I]^0+-=I"(Z(B\:+MF)^ C(SN!'5!O9O28BN]6]D'IW5^R&Y.E>X@AS\]{9 M!FYEF*

*MA35'RP1R.7%JHN3\05=*KS\ERK=JP4^_VHRS'D]@O'VJ]7I6@)B+4 M>E(TG8B[&%60X@2^+B;_KS&AS@2Q;\2V;X7G%'TA:-0-9*E-3Q;!C'[6&=;O MOV5N)9#"1#^,RXGLB]IK7WP3H?K@+%. ")X C\S8 N N7 MM0WPP?+^]= \ER=!A?BN,Y'L-VP)^(S:FZWI;1N HIKN7"=,@Q>PV.)H>59V*

M_^>!ADTQTER/",S@8H&9NF.@1S_*^LNR6VKTN/%W6;AP$6)2WHF M1XLS,F?DTWFCY7-R_RA>Y\DYF5H=OSHRO,I7M2'/T5N3CMB0NK!N:Y,U#[^U

MB"YC19+/;YKJ+/TU"]WHS:.YN46>PZA=)_F6E6Rl: :=XV";8[\";&.AT3Z MQ%O-@;A A>0KVL"V/3"9VVV27@"6>Q=\S]'6LJ]"^.%D&MS:.5!

M?!Z1E)8\55N=@33OI:7^H$44,E"DIF#Q^?*J3ZMVTM#;A1=aR.I>(_-?-O(:)MWLKZF_QN(/;"BPLKZPU(<F'NR!(L/BI4015(FVC@"H,8L#BID6KZ-RZ6&T' MKX(QR949B[\"T4.|]

(WU|P+B8(2.C#7V'(A+$W&^_RL,*H3-N[K7A=^?7#)/I M9"S<39Z?)\I^CV>-DG#CHD)SHGE9.[)V#UX)L]$T83V:A[F-5I?FG'^/1C_O'MVST2Q5L.?ZSDD M.#,KHQ_Z8V)6R-

*A=P>.5:+;:MDGT1;8U>[)XLH@-*RI[142G0&-M 6:"X8P4 M!8P4;"KY[+:,&HA%[!H_[HM/B#KX)-&"6F&:X1!TYWG?X,@+FTA]18[GD3(L5 MFHNPF85@SR9 [1;9?$#"E]*

*[$*&DV$\);QA4QC+5D!H.X4]*L,O;-6'9FM?8TL"8+P0W H0WS5D*FF,+MCNW-563+5A@=XW)'HIW5:/!L#DF+5.U:.DXUW^E?EKLV!:_@_^:^K>J!\(FBW(]PL*

ML;Q#$4LBZ\Y2P1)N,)M7#1N^Z$0&70TNB IPPVT-QQ1D|=4[DLWN$$S744PD M"IZC6,,,,:R+P)/?WV 2I+&9Y%JV' />R"8VU\SU4@;7!("'XX.YX4X\#&#- M#GE:\#>[0J&_

;U=+ P,:X@.;0J>_OU=/?$QD&J1,>\"9IA{GQ.9:INHI_M93!#N'9)}##\^B\B_.T"CIQW-H:5"?_("EQD:VAYX&WR N:HHB'2$&9 =H_> M6//:MN%2+P'X&$>3]^*FA)#I]-GE9T?*

CSGB3^'K>G<C1Y0W2OF6%W)_8 MDA"7^EUUW.FR%4NC91F%&5&6!K#/R[LP1:^(UGC_Y,Y^=2>PO<)O MIBX(%?BPN8$MTB-J9(.RA*PW!" -K"@L6*

K'EF3+QG'LN>SJG&/);E"/C0RV8:2$@9@<(6I&@R."0;&-P2F;PBH)K8OCY> C#<4PK34#Q@#5 M\,L4'[219"@(UWZ0D"IR;K^3O7%&B^7-X;9VM)@+&L]=/?OH]%3<#<"64-1*

*MIZVVE >*7UKY!,:.MYR=2]+P"(OKNZUSX EP1^J8)X2Q,5IU"01ZF9]KCFIJ MI8$;_'LCV#Z;J)A/%3%0285IBW@LX] S"$4+F(X(L'"%C8.U%6HZ@+JFUYB&/U2$-(4[L=$V*

*MLCVDLV.Y'CK'FT?*CF-I<]?QGY;T)-_F]=!W%RS%79@$TRV:;IR AC_'^^MHA MSXH'^V!,6PES660=$RBJA=@+"4GXEPIP00P"+"<\Y=NW.V:X3N^>'X,+Z/<[0F[7-*

[_4]4L)U!C:!EVD)+#PU*-#'XGH M"UQB;WV)&PI8/T6\)+#/!%P[?]HQ@83\ >)E"4+BU:1ZT;\=O4"0;\]V M:P8>%/BLMDWP?\$]SM(RW9<^F6TN,W56^;,:9[0@69J<%;.MYIXE'*

*R:#1?4/*P=R HP'D"&;/C9DY"O(<IKGU\^K?ZVOA_'O}\;;P]^A!> M;0&NHG+;\(@4C S5M^R$2+=G+/"0!GA6*$B8' 1.V9X1:@?XDDTVQ$1@&5!] M|S"AYY&R#G*

ML;-1@6LOIE6G5IIG4Q%6L0"S,3IEI!L4.8@W(H%/ 'OFKH,K-#?1O[7[QB M2Y_-6&!3OCVKBS>+D> +-KQW(EOL2!TM"S4"Q.M"B*'%LN&[[[+%@"XW6J M"4_-*

*&,KE;PA%M5S.K6I(+(PJ$,..+;R(N&U2VKQB5NZ2PSXO,.YQ,@<Q)-2Z6GITM MKU \A6U"BX2]SC"-AYZ4;Q4K+/F4 6T=GG,;4" H#ICP0=TZS%: % "+6>1+5&,**!:^)/ ME 4Y;-*

*M=L28YS#"065TI&D0(G"T/K.A:LEI(>*NN,"A MXLV^)6^$#C6HKN6KZ4U$@_$+-^%R*@R$"?RB@W74,+BPPSDM;SS,GUI!=,&@T M8.@CS;5F>!2%90*S'-?*

*#G%37D,&B=Y@OGMDK#T<[6&0#>1C8E-HF@?@%,XC@ MQ@#:530.*2QD,9N%?=KYFP!HO@;N9GW+QF%I1/5-[O!"-]^V(P1^DU0_3L0H M:/MO).J5.ABS) H&%*

%+GC#,V=1/855/7(=BX&H*8;B<)[$:#?K@M@4,_0Z M^-"F]B2:LOXZ;C2"1;>YM%>RNWB4BU8R&M3P"+ /M+7LVZ'4 H7OX(4%$!V MMTE,1"\$,WM)H3['-*

\A^O.!/UV";0Y3S0R$T'\AQCZIO1IHWYO*6&QK:4T(#ZBJJU;SY=S#/L/"%:.P;68R^N,U&7C73M8&<"PW#4L%D MI@]WS"I[9$[OI?6I)/H7V+^D76^,(W("-CQ@,,3L:YD&?*

%08^5B&/S'-WXV) M\W?SO/E[Y^:N_&86C D6,Z2:-(X=3C#8HMR51!F- SZ1]@X"/,2L)BARA;(M6-DC14B591$U5&8L@;ME 967A8RH <>A(C:3@E/9P\=6. J?:OTC'G%<(NS1*

MLV#S)EM5+,]TD)QGRE-&>/XQ^1E,S,>]/+$:?K@M@4,_0Z M^-"F]B2:LOXZ;C2"1;>YM%>RNWB4BU8R&M3P"+ /M+7LVZ'4 H7OX(4%$!V MMTE,1"\$,WM)H3[

*@EEZ.V2<7/;CS7UR?W[1M,?P6WXZIOF MH'[LW(RG/WS"HA&'XV61&+IEB]DCAD*W6+P8B .##V=)S-^] XL8UV@:12^=S?' MS)HZVR"S44L)F&KY8E]!(_<"]H1#J,$GO\ ?++T&*

(9R8X7EUM&&"|:H30=K M7LZ:NKN-_-^,CK*-D^^F -ACHGV#GVN)TT#D)LS!W^6A)'21?9 0CT7A MWR' T X5O*.FT(8Y6EUF(C>$!]G"!!D4 W0*-@8V5I]# 0T:-@,_SE"#Z)BS*

*MA"M(Q'Z<(-HDUPK^G1442!(&6V7<\XIF[",*H- /.^*(M!7)9L H332!HPGNW_K,#&^+,=/6WYB7ABSM)7"KP4[4B.+T#8O?03?#0_M7UN!'KN;W"_?*

*2DL+8E9OM*BW0&1EN8EAKXAL>_G_J#@Q0O-V20B;20?3I&& MC[U=_4W*,@86:0:_Q -O.P=&M,T@B &[Q,H3%X,I,#=[XZ,!>H)AO V*

MC_$#CX[F>"GGOG_M_X(D8FH!TR9^KG79"-0!B+S@&FRA9F^\ -/)A>F/-%7" MB])3[8*2C;Z/)G6Q] AB8W8,V2%2N?]A7=\"HQ_R]I!P0E7#H$Y7G@(ZI'.V M=(M,-

*V1PZR"\+1@*TOLZ.C8-DNN?_1/)U"_=&Z:[7]UU(]OV09)B#3LW6I] M#BDD!(!%EB!8D8>\&_S+'IC$12T4-@3O0U+HT]2=.TRGB/ONBFE[FXZ!%F):S)*

<63$!N#&R?]=A6B*>5XODP M/(QR)5]O/(DF99!H%1$F%QC$R)))CXZ]+C53'U;.P M_6I$Y4-2K$;=LA\[C M:W%?5]\265 .L(>)-$9+?

WTF.FW8,3:!FIKMFU9+E+]4CNW.S6#0D_I5Q%f]%@2KQ=LT?X;R.TIG>8AW#SC[@A,/RQX41BPM$K3.NN9TKJ7N?E& M_6/%!OC93MWQ+/2-*

U+5FY_ES6\GO.#)4_^PIIW<21:,=+Z\EM#VU$5_!$=8, MV\M) ^\H]FO#!=6 V*A/ MPAMM:^)H++D N%W7B?'B/P=DIJ;25.3%YBA.;B$;9-"P@0)%=5PW]CTFNNB@

*MH_7@Y9[L69F&!]@*MAZ!R&Z0F8/SIU?MS"UF0W[! Y!O"9; ;JUF';5G)%Y[MAF[D\]HU$OI&8,HG0$E6K?QX+FLN?CB-4@O*?"?6"[!D0(V%--K@LA0P?3S MU9P=,@-*

*CQ&=1LWBA2N%": W@^3OM-AL$Q=EO8+IA]<2UO8E_6V2G:.UWPU;3VN#< M*S4(-0N+E]#:CT%-.3O@3L^@TX/;&#%1G""4B7N%KX1Y!^Q0G,S&%S]-BKN*

*MP1$Y_S)O_?!5KNT51-D^I"&8"MC$WIDUFDB^-55:@^95UG2]7>DQ^-6*J!K= MWI.]^#>UOW.2$TX-I"CKOCE_& M1L#0.7ZR<8. IMNR%?3",,:A)_3>;R\0?*

9L72U<%F>75Z^8;,Z.X0W\K=/<'M<-.85\NP?(<9S2!RHOU:&\7@\IF+@FOA# IE%!^B=VPR.5OJ/ MJ-W.I.'"4]]-C"727%#MA09B=N:9Q'9OHOUL#$B]VIUCIC%/Q-*

*"@2Y$R M)["2\+=*9[,BA%T?<"J^8D=(R"RTZ&N#4)}UC!C+Y-Q5.6LZY^X;_0O5D|\+ M^>0/@'9#D;|CB#@O0OG1W7HHA!,AC=U)1?+!+/!L;C '*/1B'B!,>6*

*M62SE#H2]*F^VDO%/3<8S> ZHF!W$;I^V9A(#(T"N]2R1 ^T!?*HSGUZ!T?M*P M&&B6?^8IWHSG,?<5; ,;5RN\XH*!!Z'V(%8+Z%'?>Z7F9'?C,5\]9HKW2^PG5*

*MG&&]=7KZ"*4>3/C-M/ZBI^OE-:>)W4UQ("FWZH->^TH. 0?+]L'24N=P;>_M/U5X&N!BMJ7ITPB[;R'K>_>XSE9Y0C^CIDZM[UBWS7,08[TW))EW66BR.O;T M?*

S$P8RC/<7_!HR^L05'A]7O]<29B MWEW\D$,>,AM+P2E. 3D4PDA1W5]+-IV!81INDIQB.-//43SGPE(F\&/WG?2A;B7&;@GRV;7JA MK^"D^7X(-V++"H7QZ@5QHV.Z7@5,

/S,R;Z2LU1C IO MV<0VUM76:=3%X^VPW@Y\9+1+L1U)\"IF&S^1)[P_BBJ'IA2;O97,OT-?VA-0W M H:&T(XARU"#IX+'_)Z,:L"3" (G%[3X@>,*C(7G"? \@3:P)X]2Z*ZM.MEQG>W]HH/-DL0#R]%S)*D?.3+445!Y?>_N=U^*[',G[PFG'I%N:+0+0X-@*Q-<>RCZ@>RB{(@8YUK'*(L#9%CFRSN\VG]E M#1R#E &\4Z\+;TL-T"E32>4P(,)C02;AZX-*

S<4%K8ZR&@[%"7<.@7#WT(+)8 M:(I&#.7=Z\[S2@MI8YC/ZY%(S\PY%I%72"4Z0M-ZD6'TE%O\@%IXAGA$?P!A M8?\2D_?`5NH+LV\%,3\L)XMKO&

*[$"O/8KE]2'SGAY8[05'P"HR##+)I) ^K_>!-8 /2D*2BI-^SYBH7H985F6=8%E-S0K=N MW1'N);?,1CMD;=@^PP&KOUCRBD78=YK?S6&H[AP #%_35N*4^8E#Z^IOI%>_*

M<7S=\@F=6_S&2 WQE..BF:UQ*6<9DW*IF36UZ+7%=,,-=F V>D1<%](OF#? MH"|H-%,>B4A[^IT^\)T+6<9K|O,"=:%N:6*0.CL #*$<CFI7+>5X%?3^AD<@*

*M*E;SBC8&O=&I5C37CK;:47?U31,PJM^98:NA E_0QNC825HS%I;L0Y1X3@BJ-ML6 =]RFR';T4&-1++(JMT7VVCNWPQN!V@=]=#)&.H%>GSS|ETTW"4U^@4JR"7 M5/,-WO5?*

[U5^@UX/TD#,PZ17NVSIE=)Z,EZ,Y-1?@]HPJ;S?X4&G@Z)A^08N M-F'@29F3L?)0LWW-MAMX2A"-#/4"H9NU,2(N(L,H-8%@W,)D8%XBBVCV=DS2 M'Q=U0+.HU\Z.

*[W=@MZ,I!E&T4U%7C D7BZV8]EU/=\'L?F2&,/%A@4\J?U!$U M:!E(,EDMPZ*X%+;3MM3Z"!H-'MM?*V%!*;C=:.@)9"77C4(->CDK_OMCOE M#*K5Z(OYYG>"034.8K-*

7M4%5D5#QJ#5KMR8,M+^QL*E]HR:42G[MG4G9AP0IFZ<-U9[I^\KI)/,?Y ^5'M1BK/SN6M5*L*%$B0O+G:@L5]R -#BS+ ME5Z4*\^RIE51.007%1003V!6*Y:VIA[*;!/M#@*WI?*

#(,8AY:4R6'!N_1%X3 MJ\YKEP8/FD-N>'&]RP.$4'$X5%#T!@&.RHK8"A-'I\;=]4=CRN&2->MH]K M#&+-8XYRGPZ9;4>#X^"\+R?"""C;Q@XY[0=$K*6H S&@2-*=#:%3'-J_*E&*

*(_7 M;IBS%&>]:99*R:],1%IXHV>A_23]S7^)<:Q6AM/#?3%EOB9,QQG,,YP7GIY M2@YO!AW6P?,Z9973X$S%?X+KRF2HE%,V %NMR+<89CC/<+LEY!]GT&*]DI"*

*M<9;B+'7Q+)62=I>!HR2T"\MJPG[T1A/'[CH (]_3N6]PCL9,SP22AZT<(]VL MV,MK2?6I_3$;4I49R/SBG=1":.0W6?NEF:PEU28MLWL,!T]:R*X8> 8N3HE1B,I-DP /AT&E%;*

<=MO)NR%RC)S2]\^& M#-R(+=Q.E^.C@OA(<62SP;/-2D%&AZEEM8_)'F'N;+G6/=1["FY364%99Z M,<%]TVQ!7GD_M\>'A7WC,^($Q;Y&VK?AX@=QS7Q-7/;4V>_,'-*

*<C]\L3E^Y M^.F6EQW%X5,E^"2Y?47@DSFFT.Z5O8?*P54I<"7LO]\&7!('UU6#*\';+%?Q M]6O#LC;,.`RJ!)\$9[1<] QJ0ZDJ9G>EVEN=SW&-'L[A':P.R<;@':P.V+[-*

*MG"*N@TV4"^= G;K,S:P0987--REN4L M>^8DJZP3V"XGIW[^GO$VVL 43T>Y>_A_+<NBO#;.VVR9,^YYQ\JP%F= M8553*.TIO.K0)IQ@VNU>?*

*3UH:L>BZ8R@V7L^UVL&@5)*5A3+!?%/^TJP7UG/ M+= VKF7!+2B$3=<1%BYMS8,-!,V5IL U!EEH#FVH8_Y)%(<^UM5I.YT%{5[+ M.J]}#@Z'/9[\7#/1R5I?TI?*

*L=F.*M)7>Z2B]A3&/%AW_O6;$U!;-727 M!\GFYA9Y;B.PDV])*G4[_&UNH4F7P .GKY ;#]\6.Z[5//MW:6T.G+^0F[E%MY+]NY*

*4,IE;6W^1W&VW6,%\#!WL/EY"I=TF6,,/%HI09QC4R9U)"O1Y(%"2W M<(Z(Q7^H/6D0A T5J#Q;_ MD6K#&>VV GQZ9]+>66!+R%5"6GQ#^>_*OQ^FT\E8N)L\/TV>1I/'R3A-1; ^*

MV$G..>L3\>QQ_,/A_I<\V]XJT_GT8SSZ_!JY!|YMITO3DS<7ZK2Z!S07$L5|[5OV M-

!=JIG1=R=,)IEM:RYQ.WIRN>R9L+7651_IBP7V5[&EQ:7Y#4!CV7V#V&=VK#X3D,%9E>:V"5(QMLU,Y MPEV:D(]VLN%LS1O:|*

(8VE4[Q^*@U?P>=HD5?.U)MV]\R5=>.1IFSU*E8]GNL M5@"=\NJ];N;Y W$,MO=B+S=3=$P M9Z;2X-W8H^"\8/P5P",E9)<-'AW>D^1*X9$28,H&CVX)[28Y/*H(CS+Z373+*

MZ$;*X5%%>:!S0:B*#ZDV["%X7"$\2D%"RS3PIOP)<&#-ZOAS6J.Y.^=I|_ MM_1=/UZ1O5+@2O#V3@*N7I.#ZZK!E> KG@9_U<'!5"EQ':,":1'5PB!]=5 M@^L(#0*S@ZO-P77-*

X#HKMCI5PQ9OD<.;Y)28P\'KDQZPY9NQ0&FO6T)C-EY1 MF',LY]BBN_!9.;97WCX\YUC.L9QC#TZ,R,JQ4GE[WYQC.<=RCCTX5R4KQ_;+ M2T?

*@':LYEG/LP>E#63EVD*7T.!4<@WW2ZOO MNZ?-^Y&+!!#18=5S@9<>/47^>%|$^>H'W2RSQGUJA@<,CA,KUEP.(W0Z)58-# M!45OM*H^)>UHJT7@!?*

*5Y/GY>5. ^ENI.!H73FI54*5*5ZID;/4M; 4W'&LVJA2 MZ4<:.<=QCKL"CFL5UF)8*[%3.*F7JST$ZZNAJ>*LQ1/;0,J]\Q\$2%\GUI'5XU_^15\]N\;G[18&9<;=+L M-*

*JM4FLW*Z]H6$#RI8;M,E6VE/B^J*ZWX2#$ELN&CQ&-M'|_'QL>G@O$2&V8 MGPV"2K\9MZ\6R6KD(#DW2$KU\+-:[=<"[>CY_"H(D#*@(=8&XJ%,[V5'!J>*

*M779[7^US^67>D&>4;J[#F96U__)]HKR:?24R*WA-I0.V8C.6%>OC=DGWLHN*\3* G&4O@653+\ S\N#R=61MR MEN4LRUGV_#D)65D6-Q2[96T9<;,E3,N9]O!S-?*

%,FSE>,'"COD"AG:.[0G$+ M)_5DU<+MVE#D?64XSW*>/7>>55:.Q2W_XJ?&S\NR52AZGTB3PM@I5 W_O.,]*

*M9IG\F*B@DU>6%%PS=\;@G?"'Z_PI6F]AW+@L+SW/_,IUUQJ49$F(T.-WJC: M-J(-=W6CFLZ-[_X]N[6AKVDTOQ>G5E:75X5CG.B+!MX;W4&!,G7@/_Y23'S(V-6#?VW8R%A3?*

TL8#I:)X^SHZG-6WP4:O%1[3X4W5[K@#X4K92J^!D;&70:O5;^ M1^UK&M IK;N"6+E!-1MBL[R.'==-J5Y']MB@!HUV2G,,WH@BMA%%FS>B+D1 M105AL*?71.7]7U];#?*

*G49@Z7YsF_=_7(#X1D7X?S&N_7< G]&BX-#D$$!RD9B M/X;(Y8TH>",*7?]QM$D4W,*5&@>]\HZHG3]#@M<^Y3Q5F*=ZQZK@/2BO&B+G M.,YQU\-QTM$XKL]YCG,N7B-YVJ'*

*MY;+AHUU>F0V.CVKA(R6(E T?'=YIXEKQD1+RR(;/,@F[91P?E<3' 7VPHOC M@K&%V!YQ@%%00(*7 0ZH-,[S)O)8[>HYUYTTFCNVUG:+(>Z]9^NX>++[)<+70E M^'RG0=>*

*H^NZT97@,9X$7:TF1]=UHRO!WRRS1'ROU>(-*JX5/R?HW]5K8;Q< MX@"Z0@"=:!#Y8?*]PN(-WJ. =*JJ7<\$K :ZR2YNM!F"OU0&*

*[I;#AP]MV^6E,W'6Y2S+6?;P_)*L+"N5D;',>9;S M+.?9PCD_67FV7QMVN)E/,MY]MQ16%DY=E ;]B^]=5M,"P[<#Y)+,UP:LH_[M)G3\QUN$#L:SHR=;_'JR=*

(5"=WGS;&YND>^W7^4](2UN M[K7A=^?2#]/19"S<39Z?)L^CV>-DG%:"'T7+SH[46>?PJ7$\&M\CKX)X\GL M82I\NIN,9X_C'P_WOZ1-)=Q-H"K3^?1C//IQ_SB+#)_]NR-?_?

((S=Y-FZDN M^(6H(\?_ME-+O$=LW8C1>^#;=NT,W84*T[=0$ZZ&3O+V;73F<395BVZ]1V]@M M3KI/K1^Q-4/73)G BQ..5V;=\5; M2-J"O3YV5[,2K0[W4YY

&5)5%R'^],?;,U6UQW'8,.951UV\0%]8NFZ^ M(0R\)BSN"B8 #[&IO5ZSWL.2$; 7-7FNZ> 1H$"T;1/3ACS\O#,MXAZW]%9F[8]

XOLC=&KW%%&C/I&DQGVN1K,=:N#3KY>)XG- M0-J-MM0NJ1E(7\SWI#UM4YHY^XH'IVJ;__5LG;9:S1R;IUZ8)&;S5&R54>3D ,ERME*EN9,.;)=|8"YK ME<-E8@GH|S).)-*

=)Y.)Y3!9^P05MSF3<2:KRL3S,5F[":,#PYZ%D^TXEW$N MNTXNZY3#9=W:4.2ZC',9Y[+8HQ[E,%D/G++\,I*:BEQB=4]M]:R'BKSR3*: M@EPJ=C]*

]MDJJ.3G!ZEI6JO"U&J#7N\]/XU(@3N`/H1/V#'1.Z M TJ+<:;O@_L6Q7PDWS@GI'B-X;")I_KE@\QG;A6C!PPE0/,\1RY?7C);K=W M>_.$2X-*

*43AET0"Y'1AG4BTOOX##+HT@%S0%Y"1L!{3]H_QW+C @AK^7W%*OE\J,VZ4CW>X^&7TUK'_9QX![4AD4\/AC"-MJR) 4CV^' CI-(NY>!PAU41(BKI,@Y 6*$B.D*M#2(K'E@GC'"*

*(7#I'R (*1YFCBT,D!BH)_Q0SCT]+SX MRVY-.KZ#F,?%_M&$"\"E+T&1FP3!U6G5D9*@4*",5"!PA)\'9Z\/0C$> -MYC$QU.;/C!>!H:-O,Z8@)_.&8T?*

B&XZ7'!ZB[NLO'51L5CL74)>.H8B#>TP, M#;B2NT(,G1!W6;!(S)#F[3"):,\Z%7FJKJ!:(UZ(UK2^Q#R!OVZC.OZ*

*M8<]JETZ?:@O.?!43\C2A3SI,W6VQUDY;P*6:Z%.$)K.*DS+ZM_'&9DS1Q:A,%<{'G(\Y'Y^&C .T]]_#Q[C36]K).L]G),Y)^?EY#Q=[/=P M#C MF*[WO#7RJ7K6LCFSL.,O=-*

*:=.6W4ZV&H(6WHB H4YV!P0WF1;^.<9RG1VI=@R MG7Z,O#K.XFVIP2SRC4XL:?C]6*WJ#X^2S2(*LI$J:(; V2AB\S/+O*0=?^'I M4+M5^GOK,ZUNF7-"Y22JZ YJPW8TDR_;A*

PL\()MA TG;E)P>5SWV#L3^1/[M$,,G*F)H44]O6TV8+@EQ&AG[S>_(B4(=LL\A)\2JR0FVL&M+P[!^'COVB?9: MJKLKEVTK"LYF!UN0@ZUKF_8+AC7?ZF#""K?2.Q;$HBVN%50,ES'^E.'<%/W MW@:;#$NYD0U8U((E%X&)=P,Z^[@V"'"O7:4=:E;G@T+)G@%=$JT<[VOVYU MJ<_5Z;Y;RWS6N()KRF2HE%\D7Q&|XH^D;DTF ,1_?>W+1)$\YZV\?!H.:*S.2?]Y]M*

MZ;M6F0&EW_13>6O#1K:#&=_9Z*.:\[?!@!Y*SA<8 I@JU^6$"/ UKQ>TL MQ=;*[2S4V5)5%D?6DI0OCR#\%PF9..1C^MS!UW7RS;_.H*

MX>@\85K4+0S\5^:&PO1T>6V36__#9[0"=/G]5C/H(.E-G[=?$9/L1%_(?O[L MM2-O-AM-YM%[&6W>F_=W^^V&ZWVH^1F[%U)K%R#>=#ZFK&/JE=&T/C:]=G"I M+8N7%B'"=*

[AN:0L/!FKV;>NP:^ G2M<7,5/N9F2P9@7/6('+@.1'WFI@ZGM=`ME@SK>@3CX_."!>=<9@G8DBSDNTH4E-R7.EQ!'W5,IT4S]=7Q&]VN7U?[\B MJG 4%4'1H6?]#R)

(Y;;VHJ9\;;YOKGJC,]_DKV<7,R4|,,$CC@L)T7R$:$6I MDANP5:,%8;G]#3EO72%OI23LY> MK*30:G/>XKS%>2M3C:H>E@LB(+)-@$S/0.Y[(C.)A!FLB86W?KXW"!N$!,,[']6^=9J?

L/MKDT?)O_M' ^?)(],226C)&>GLUQ(4)0M?N"IR M5H>$;CE>U;NE$93) 3N8(7TT W;HC1O-$"#4O6:^=A7USOX[Z:NG-S",YGFF MCKX+,1W'$'(9ESY&*-YE/#':;G6V(E":@23%IX"2=8!OSI["*F<$' MVZ91V\18T-PN7#G13#0TD0\54U@X2?;(C?.=K2 +_F3'QD)A"2W/,5@:2|<&/.!26 ||PS>!1Z)Y"+07H MNVS.;_\';RW@X/@@03Z2,$4%6@$=[H;'\,1;_)+&=,[" YXL0-D1LUUQ*&(Z M6L632H49B-M63,6F"F?3<-T7%-'\]+)/)3R4=% RP[7A-1NKY14G8C$4>6:Y M@#S_"4!8X"!)(L+@ZEH'O? C0XMCTFZ#HTD=\L!E(X@H!T7/BL6#G[_\6Z%-_MH7HW%C(>E5ML_XEE=YNG.NM?D9 >=<)GQ9P>RP..EGK2Y&LC@KD VY=C"S&& M/P.PC>%?@Y;V-7"1X<21'%!{IK.DDWXT?V;>|GWXM<+GW6F<=W+/&T"Z&R$X MK@4< P@@YKPDMG7M/'&O5>BQ{JY(_DLY+)R/9T+@GP3YNC%]1V[[&!A0[Y48 MD(X{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{)0K:OK&I@H\M _"F4P24VP!\64/=(S0&+ "YUEST6?CC/Q@0GTO!$ B M2_,R3;K[Q=)%3B'T4T]5CMZ]7UUU5%Z@8A M=]D"{(],_AM #1D)\A%B(VA'X\7O(11-PH!/#%'!WO@55[UX;LU_F>N$6E<[-MTKH&Q;I1C2NYB6&Q38PJN8E1L4T,*[F)<>/<=A(Z_!87A,L&-)++(8Q/Q#.)} M1=A-R*.$0G;'P)ZP'YK:U/)X_!H^VM0>@ NXQ[))CQE3X*;X,UDW/*\'5B*T MM0!9%<-+EU_:VDW-@_4=_K-%(1& MKK1@A)?9!E2WRPVH)KWALMNZ36A#F>KJ_*0;T%$*,NU)")_'2 M=4S&IEP'FS'$3N0P]IWH/ 0C3G=]JY $3KLVQ5(`DI%4>EF@_7?BE5=*7P M:TD4!49H?I@&{@NHB1&T*97LWZU/ >K_8@U1ZD?_246]E>-2K?SN^.\DP M"R=Z'(D73FVA"AO5/L<4Q5/RS$4[58*Z6/?I9Z?YH][#:V_H;S[]'Q3.I21F MC1F@B8"EA0H"8HWPR8C]0C4JK,33+%N$@F/Q_\LLYQ(WBB)'V]KUAL;W*4XM2-6.=ZN<=P M8{)RI]M/5.YLN;YKYD=E,G*1.RZN=T1E16N1A;<@O>,NI=^X&TG-?E(95YI+M23CCZ06_%>(,,8AK',3<%,)0#6EQS{<MOWR4?34LF\!!+#WV,GUE*\UZ/[X[,U]>?8?ZI5YUCWH1#L3\67QI^\ MWN^V.MUZDQ_M5B?U>M:KQJW^4"_TINSK({U;K^F5US18^Z:<1CEKF_N.$[=5 MK4UO>G/_>_(|_\5]OU]2?+\;].T]2<#<6;\V!LN&B'/0WJ;CXLH-P>'=E2VS MM[S?-D &(06P-+US'/VKT\|?W=*E;#>O%_CIP*N[*Z\X2:C46+0+%FT[96;,@7@%.BE56$M-+#6Q[%.\=*LC7D:-\TZR(JX6+U7_JE.FF&($MTSNX>]E3LE$EI$O&U:J^H:6255I!WL6C^_V_.G9D9/(*:&A2:'T7UUE59Y,_ M)=>/<#;[YIZH8YQ1W.F845SDP$Y-;4O;8K65MH)F3K\$,Z=H'6%"<^NUP<+IM[6#AI+..O5DX:Q2#FEB.B5B*T4I&IY[7(9%.X[R;U1:GIL*X-(ITTE!H9(IH MB3V(4-%KH5(32^6%2D:Q].N02+>,@$Q)=').7I%TU/BZVH1(-#9(9"Z$ -"+ M 2"5^H^=1'(*V?=+(CT@D8HXERB5%(O)YW]8"&+KUGMLXXO M;*&E!RTV8@U%S_8D^48BT:D*?&-4&M_8@G[W]>+9;"V%Y5R-S(#,.R0A[0^9MQS4RU$]\3{G8K,50.9^NT;F&IFW0.9#]I_[.9R< SX2N;)>^K.4G@*_>#8 MIM!WJC;%7K1Q\C9H^D,V"N]+{FC'U"OOHPS$;\9YH/-,QIRO73@/B<<8AC3C\M[/*)CX&\FS/F_P&XO(0=)_LZ]?53Z>NDMQ]RV8A3F5?M/B<,K77$S7T?<4 M/@V,2LO;O!O3IC/^Cf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{Z:DL"V+:0]T:9K=6O_79ZW5G_JM'FN-&F!(5E@"5]S>&PQJ63 MQ*5^3F^N++:76 -N"MDS7]]?"I9II47G*AQZKAQJH!,&Y3AX:G6&.K3 ML\KK]+A:?E0'Q-?PB)S!567K,94,;EI!B:N$3UOI,77 JL:I'#UF3,8.WPZ07S:1N"..C5.U3A5T'-2Z17]-IAM.+WP/,_.MN#7L5]R+S3KLVQ=N'#N]<+-6ZJ?6P*A$R)P2HRK6&=)+XTM=G/=;5AEE M">?S"H[KFF!K@]TZP7Z+LI?2]+;?,.^^RI3NXR7:XWUYS6XJ=E,.NRG6%S&5 MTV_;+VLUD$GRFI[@JT)\I4)-D<_&-3ZP>%$>,'V$'4WB3=Y5WWL,_*N^MC?MY%UTI.]]8{)@\+]3Z^E<2N?KX!&DNGG^.UR43S\;[H-EAV,Y],C:]^_\ZW9 M2RP]KC.BD=*OK.'HJ.& \L)T.P8DVFO-QY.:[/A:-QA)AN;P^YX]B_;_Q]MV89M6L8*YQO'L9' 7]FUH#H\:,A8^UOYCA!2Y!++SF@W:V'K$WROU MT9#91\=EFF7S$#9:&?!__IQY3'9)F.">]K-< =/M(-'90>MT!P(F1(.)98=MT)MB;$E\N(:)A^:NW,+2>&!G$Y<9^,_M&>SP@[%X-EX\%#&]_ #A(58T1,&Q"N=|\^C$E.0#\NB":RG &1KG]RC/-6>F M7:(=;V.NLU$E]$S;>^\+_,?7^[N;JZURYOOMS??+^ZO;JXS%RU4$33P5R+Y M!]W#UZOKB^O+]XMOVO7-_9<[[=WES?7]U?6/+Y]_R]M*AE9UT.V\^W%|\>/SMU7UB^9ML0CDB_/>!MC!N:=R_E/SS]YBFN^+TZ]PZN<}$K<^69RX/=$_M:>&8/R,7UY!{ST!0L>F%+P:&G551#/EAYAG&DLD-S< U(AN+6$^AT#^W8+5CYPZRPL M\X7_F;+X4ME;+K_NB-'RP?0&QNL.,L],1=*OA_2 VSI>&Q*#">6\PU7'/^@ACH61XL%T2@ M#X*3:0OVQ!;T;\M>!O"+/X<#>C1>M G3 H]-T5 41ZN^T_! D5TLG&?OPX;\ M>X!*<'>]GF$@Y$-_U.KG(_A9K]TZ'()_0 :H'>U,^T\ 1MU46P)_@=<3V](6 M#:;R?R*;HUIOX8K1.2YQ'ZXIJ-\Z?4CI "D/%FC- RVSQN|,,X$7OI$NA<'-MU]G$0-3B*+YY8Y!5Q?=13L3I/0$R;&&KZAML5]$O%BKZ!&4: #9JA\&:O;CW$$Q+HL@Z&'] M6P69]D4DB90XGG3&4Q1)"E\'L6UHWT,[_),+'-+';5BGK]+PYL3%$S\"R(0 MH 77[YVQY8^>?VPN79!ZNIMO4>.W_H620^MVQ"7+-A?!E&CWB7D^%W[#1\= MF[U(7)V!>48RY6_%HJDY4Y;^PF_\19_XBE^X\"|-UWV!0Z*#2XNKCAOG_=XX M$5C5 +@+7_.NL-@B!SEC.XHO1<7G);/ MD",R^)[RT2G\/^>(<$DZQA8OFC<'N)XA;.!'T?5A"(1E570;P-=RZ4 %#]9T* M9(8?\603;>.,FIDRM;-)IS3+]*HGLD%,!D2#]R4Q+47^N(M"KCM^$@\0.2P0WB$D)/0W?0#H$=QCB3F32=83+6Y 3=,&+/A(<"__\)Z')?? M\ R\A+]_ ?'4!H;=6!X7VX'#L*D&AXPVHP"Z,/:(%6Q@=]>J;&C)HO?WQ M[VSZ@/SO J4OJ;%-^J?5L1"\K9DB8"}6FXQT)<3.-,R4*V8/5E?6JKZQN;.8 M>]L*%"HI_@N7 VSB:QZ;'-PR 2,_HW77TAY!I 8ZZ%'5S@92!!27,*\"4I:O 5$X +4H0?NN$#PST$,^'/3H##D% #G\H5PM)6YN@$J9HF<5TI1SBC*_T.[OPCU__>?UU;5CBXT4;8 \QIFIPZQZS:VU_4Z. MLE_RO3&N=[+ZN$<;F)#4RUN-I#[3%I+A(.@Y0-% >9+OR">LL$M/JH.4[Q9JG*D)*T2/,>HT$:4;"NKUY#@71(M+QTD6W0-P=\H9=- +>^3L2#W M\-V5"M0G/ Q4R-F<.5M"7\TYDB2$C5 M8M-FR?91")PE',&.*O8"?8Z.!1S":DNDWN MNY@IWI.0>R+]?7>6@*/S"#8B4.QFK/,.S$9A<,)7;H#/D1[F\]DB$Q=4U >; M^(O$C3CE01Y1" "S X6 MW/1'G ; &?II!LG12P$-67\XU+Q4S9MQ%!XQ68QG?!SA$|TWC#$*=9)56! MT'$98^NP00YAPCK0-6$SZ!DD??NF6;X* #K@I>N8C&WAI,W9ZJUX[U?7>;R# M/=W,TC:?MN$1,,-D WJYWSHR$48F0+|T3S$X<66C24,)A\1%TK,'PJ#6HP(B MU===M<_XCX#-!^#13^4U6>@)}1 O/T;Q@\F\0H;@66P5Y5EZF[@>S@;LN2."* M=Y,/'K,;TM<9>R\M%94X0_X(MVD0@?4NW*3_ 56BHOAL7JQ!',!?[%F%B[M-[-OP1F\!:2?[RLK6I"EZ&!\$7[P0*,$4/\(LU@XCB1A0.>YY@6\5?*2"'T M,6PP?PSDO+YA+=!UNW0 C&BC!\NU<'8M6\57?-_">48G]"PAL=SUA+(17[C MP,,A]-IC6YZKK3M,I/'KBNM-'"H*ME:*URTK(WM-X4B=H;UAAK;>G:%=)UO7 MR=9ULO7;3;,.SKG5UV3DCE(S-N1@8 @<%4;8;#)-)VE5YX0:A#?;1[XE@Y45:%&S8CK2)&BW-26BX#49'AO M@,K=B\9S @"2MB?O+@\ZD_] F#1O@O@Y{9GF'"A@86+K_,L.#+/#E5[W,C+3KD!BI&^;@5EIQ<)H/@*K'GZ$R\563!+3}(>RFY^6[FEF,9.Y8]-M9QA,@%?$$BIYSH[&DTR!YM4$2#5#P8?C_\L9.E'QP5@2 M2(${"O&/C']XP5FO'1&[#0$E]OO-.(SS-N-TP=`6]WA[NPU4<.BD5R=H:Z<& M)V,"Q: VO!XWA[UY,ZPA666A7 M6C9L(4BKYCW68U==ZJ%(]U9E%V>L8 03%);&$$DXB+:R:5URAP"\C[;2TA-,= MJLSNS#F;!N@"CR4 >Q?V(M$IK2S<,FYQ/_*MH964_)2K3Q.%%S5EWVN"G. MA#[9A6,_#V3*-VD M%B&18X;Z3@$(%\;28Q_D7S[*]B*638"@AS[&W]=/SLNBD^(_1UZ*5IM[*D1/ M&O%E\7,+?GJ?O-X?M(;C7NI/[58G]7K6[T:MP;A?Z$W9UP?#8>76--*}{\VF M4=Z;?]MSTMH>;^/$;56;J99P51!5)I6?#3K5GR0DXOK>E#8*Y(=M!GGN+BY M0"|\=V7+^.+>WT5S"37L[5AQUI+[$C:12-I[72/)${!>9EKNRG=.#38U5KX)5 M>V'C>^YU6^D>S=]BQHI: R>]&,+78+'$Z-97 %_=Z/HM-++H>Y.3}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`\$W^EO?I.6PP?BYQ[IK=_2^/MXC{_TX3%7#LV9 MP*)Y#S&T.C%*31LR*8P7+3Q Y>71!+$>/*A1*NUU#-_-78OQ8BES85B/ MHB2+/6"=$&\!I;6<0L]_$?606F0!!\|Z6/P8;]-1QX>8E_(644[BX=% ^8MT1 M?ZNL\44++,VH\@E8##SR@QFKC7I-VCG*O:O486(/ J;VX6X,T?X31; .(3+W0 MR$ECN+QO$7>M\(\K>U1VITT!@UQK O"<,#3_N#%1]W?94&6:^_[2^_#^_?/S M<\MC9@M.|_V%:\ZQI_![-GTPW/EU]..GTV_JL8Q]];G_8-F?_TGN]1,N8 MSE >]ZH#G^HA+VP;/<7?R>.4T[5Y]1.2%9CV*M@V'@48=B@V^88-AEWV6A] M#GK&:6_]MG;_$N160R4&%4_K MM,_^7PVE$\C$&C@QX,BF[_\0%Y3)O#>$5JT/OTSL)E2T758EBUC0$J],G4X M\;_N$;)2'[-0NW%\&SD&.>;(CS?#CAERE(ZBCSU9#X[K!YU;ID)S0D4&K:8M:0;UG,:^=0YH=8KV0M_!:XH:T]+N%'>TB!.%#6CX[4*#((UI1>L)'9C*V@+;_M"TQT*%03%$CO^82 M+I!%ZOD&5Q2[X!'NA9L45=6R_QW8/-\"]O\>O@Z_*8:I<7:0[$WS#H6Z[M&+Z&O4>*,#\)}3AL*&TVI]"!8@,9V#M\$0T<|)^&(%^Z,"?O $D!1.=J*_O M:?C;?|@4|2=]'GRL,#:H*L",,4P\&T5\!6]I{L84/<#\MI;^(M2E-.@1]R8B8(PYV2>4E-JK 7B(&H83L8@(:"'5(+73,78#GX[M,!W@NK"@GXPZQ-I\B(]T0J01B!9#LY;VOQB"4A$]ULPC0FZ>6R/P4<%T@10K M:$XD8/DBB(2]:\,#XHAM*UE$_%Q6;&OLQPO?>+((+52Y1R$S2S2*"'+\:TK>Z M9, 'P0Y<%##=O,?SI.G^)=A.48Y&+58TS-Y15E7*#EC^1DO&"M?@)SG>2&4JP&LZ)$PMRP0@8Tf+%+K'<7RE@0NR+ *+NBR46N2K"-<^6FXN1@V1:FG(?@B3/Y3C MQ)7]!,P%U:_/%O8ZFH0$WV1KK-8X+ES1<4\E<91..ZT*(G."WB+9:X&=G+\M*&46&7PCS1!%O M@IA9B"6;> 67#G?9T@L*ZCM-=L"_T@PI+G_ 2D Y39-%FUQQ.$/%X06U:D=N M#5,9@(<'\+CLE!C; D$;SIQ;,&(?V-&'X7SCA=0_#D8*@_4;!(Y(I:OE._7M;@,X?$?I;ID.IRELVVW(KRE I]Z^\Z?I]/Z[%@(54#Q[:).1:P5U0\VB])U MXDYK5,@\]D0:Z,JG29@] <(Q&._(119H=6|Z?]1C82(=@90*X\YQ[)(]M,ZE=UC<0/RLZ.*IJ4@N'|HV13H1(;"|6C4'U-6@VV M"Q9 @15)PS>:\8W).*;IHB?82C$2C3C0!2|$[V\,\K]_0NXCI-]2K,6@U% M."1K-KI]S<;5]5<9[']PT?W[D491:/(%U*,)M40EG=G+P4:?=`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|D?!GDSS.P:1C81NK+I#,)6,.&7T#$4@F8Q>XMJB>_"@/(T)429 MZ%(!VOC4DUD@JXA*'YZ4^F]_C-P+6]|\7CUM>/?JJ[*X7Y%@VZ= : -<\=F*=$"3+A3 M]H0>/F)TU'F"# .&RC34!VVLC=(L'6&8CQ79(A6JX96#[R M4^[?D8="4V6V:;WLG@R;/P7N8"\SWFS'X1T(/?LTZV]EH|.MQS>ADNV"#,VH[$FK[V7RDB:]& P6Q)>R;H[PW:;S$%A>FDF8TD*Q#3S#+5$ H(7BF 0 M/U"28>"*E$;,2R%=R451K[!MH&VV:NS$<-<09K)!3|2$Z)$T,?20=(<$*E95Y&Y)S+5B+A+Y\&F MCH]K<$2!B.EI,B2/9!Y]8$U0/HQYI;]O-Q-_^(H^CF'CO-/1J^;D&!W4R3%[MG(^RID\DG15Z<-=8^[A8K#UKH[?,Q9 #]%WLWODS]$S,BA_[WR7L>_/7-E* MC\;/UT?C.?>W-HC);T(K>1'YDV7]CGT6DV*W,K/@9#D[=CEYFY|@FI!3ND MF0W&;99\U+, ^9LW?\EI1#N%K09%),UQO-\Y[:9EDJP^$LNDKBBT(T]$F*!(MWWJB9.$P922]FRL[=9Y+0?P#H\UUHN(,Q^$6HP-GJ47[.P4B#*%(3(ADK5*! M-P&B5KQ4!\@]D_RP MM$?2%Z)94+0:W* M-EO-?:]W[>HNOW3&9^UV;ZB3\"N24K'0AOB>>^"^M*=(7>ZI%GS!5)?JA/YX: M6/.WB?3MU16&ZS@-!G2LM0&ZOEEM0*P8@!P9+G;89M3K:DGAD4C@>-P9$&^G M3[8'?I\55NH0=Q/558%/76=9)$UYVJ7P8&.%=2(K,?*"D,R&G95%W"$*\'\R2 MEZ)*-RK[%6JO1-0ZL['\S,9 ^G=E8@;74F8UU9N,Q939VTS,,>T>R^-]97FJ=.|C?-,+YF/I$DOW>Y=-E)Z:ZRTUB*$SB,(C M%-NBP2$\PFJDZ3A:!AH!W5"4 M(7$"E\(.F<9^+466"\":,NRL*[JNWKWWU85^0 ;:?9'6>!M+!' JIN,B63H\ M3!]%Q-E&4U@2"/G<3HEHA;58Z9BY2=C064[=W/&1)-^<-*2+M=AM8GP-5B7K MT7DS76JGP%UQ3P:?@>(%8)*9%O?PAODM I0<4,$)5OOQO2=>&0@[(.%E:K< MX)-\2"U@16;X% N%71H>7(,F^;@-GL(U"0;7LD&^>),7>&O54 $Z MI*D-;YF2:R>]0O3=/RY}U2'M%A@V>I#(M-Y- 6A8!10[\AH7AAPSVV\LE6- MM)QD1?7(8).9 A4CX6&A%+%,/\KV6DDBN/VZIS[JG/>'>8>ZN0)#9YVB!#0E M=5!?B]=0"=++PZ&#*95KC++81[FZ]}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{1}!]@#;ZK6/.1J/UZK36Z@\9Y/Z6"):+6U1GSLU4JC0-EF MT/CVBQ8R>EW1I"ML<(MA]TI^?S)0HUV@{{J&46&"%4#D%,H+QR@]?78Y76&5,_5[$'-UTD2. MZ$. "Y=*B,ZZC\<'(AO9D/3@NDJ8 8WOQ'85XI,M[<97)B$RV9LNT64DV8"+ M+TTFRR:']]->$_/#/\)S+C6?L5]6)C>N3KU.G5?-&^A-<6B-TID 'K79@^-$MZ:W,,X^MP8NFV)M.L)B*;GYXD5&YBGRO\;O$]-.;?M.6;7 >)[-!FDC<5V+OH=:|$%=BUZ!M=2UZ'4M^C'5HO?2 M:|'\Z\H"]]N'Y+}3Y]}>ADE$'IA>M,T3/1.<;UUNP# #>^R1-M?-._I"7)43CS:D:!LP*6?WE%2[(N02HP W8\1@4MGLW8*)5E78YMUQGR=I/_MB[95X<1PZ@P5UF/2U-R`&"FQ15$]RL#2 >;^_^_L=OHH(L:HF$'>(T M/N3=4?]W4Q^X@HZYAVL1.?2.S)};YG[3XF4(@"18AZ/TUUQ.+047&>OO'46 MG&[<:S?..\W4;8""KY#FZH.'@Y26-1Q17?`]6%.-$<5# M.B]23=F90)IH:$BDN5+7%4(9V&8/WFH]>>=6YS3)-M)BDN.\0:]9,&,H6 SFZJ.1]|=E.-7C>C,:>$*_"4WG]2N0R/<>1>NM9"TX=\ MJH?4YK@6%B@CF)+OQ/$2,X.4.G2(,29'-4T"%Z"-%SWD,@K[PH[?`H%\(.? M-L4'X1}}KB9X -BY.$ E&NR'I;+B@[|+T+(5@EC.L(H6'G)?C(8N:$A5BOP6 MX."!SN*-&T;#8FM8.K.XC$#77UBL++#FMU2GDS+\P+& MVT4PX?;%)C&3B4=ZOVKY>7H3N4>[C1]^S"ROVX M38+$ C@\99AVSRD_+8CCNHEXIHG,EX(1^@$8(@)(Q1.EM#HQL8%+QH=TN& M_F/T#W^J^FXT%AQ"NRE'MJ2%2=FK6@L'V.)/R_R)Z4)AW@>/ MP'Q2;=H+'%'_#_$0[2.P12A*#!4!^W3AR?DKB,4\&O($6{]A#$[\:$;WB) * M9[*R6X'LK"TX07.%,5!1CC^! %HR&^=ET5-R&) DNAD3PX1,Q^-N?@^X 1GW MN"FPX_&X23T(FL9T/LV8Q7O(D[B)UG{!=-;N MML<#[=W=GV -WX,3>YLI^_^\&%]#4,O!,T+ W 3)D' ^+!"U(_Q@7\K,QU7AG'% ;N MBY1C&JL,3%*<0L@>'3Y'&8X>X,9]_ZBON M\L;^1(NYF:4:(_W&N9ZL&N1Z@1=:!S$'OK. K^ 0!#%U.=TS"%X-E3GQ%C'6 M\|NWRV;(EY9+&[8Z^.:UM9[K4,W6AGO8A/RW&>K-B\|YTG@<)Y"#)C M\<+'U/].LR'YZ4C%5K@BX9W 99Q'T@R8K1:=9@Z0POH@P%5GD[_S'PZ.[?' M[>[9|PLNNN)[D;C,'2$'P2G#)5?]D4WQ)/MI=@3SFHE)ZFXCDRZ<;.8#'!'E1R1P14AK12 {OX*1B1?T&;3:AV XH+Z!*08@Z,V&$P&X_9B1P?XELGHLHH'IW.,"UO M#/JG15(LW2I_"(3G= ?P93>Z% -.MK025JLE)H;2*'2\&^/[f6.$"ZH"H+.&%.@XIL6(-M,6P Q[]20HFLX^,OQX(DSWED/D%/1'_YSO%)-INASDKJ'IP"+V:!{TDW/[%,`MKHE,&$_>H!Y,B;F+@#39&\!W@ZX]#6=F@;T>#D^0Y86Nl.8#[,QP\@'7+8^#4 M[5+,/34.1BN&;>C%4X\0O1^;,ZHNIN-)X%+10C\?X[[MD|>O)B*V:FXT%AO"NRE'MJ2%2=FK6@L'V.)/R_R)Z4)AW@>/ MP'Q2;=H+'%'_# _

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}IU)1P*VIK2]$]\%7[T-E --1 MC "#.N3F$.X5N> <5K2FN^SP;+ ^]HM'6N)6 7L'.#)?ZQ-&GR61P ,NM.>],\ZI\S?I/YUQ\S Y6,&O R"16,[NK!U2K?'P>MCL(E]5;D+2NXO MRL%%7Q5V70BD4XQ X2GWQA4|+%2E("'S:<|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|OT7X^[+#GJ$:,Y7&7_J&K"S;.&N8E#AV,N 3GPU0N4\.QZU,+Z7% MV&GH 5]F,S&.ZD_#@C IN)-"DB%SR78(8M=0W)LH_36PS0R%$:L0XS2DEU&.M,,55Z_P?[!- CP9O04T2Y72+S6IC(KNR9:-+TG6%8[PK,/!\=)R)OZF!G4@) MER078VSD0N,)#&HRR+,=ITGRZ5&]@LC.-;DWBV*=']HV@"K/)L}].$"O%;8#AY?A4!2X5Z;8<4F_HM#2$("?7U* M#H?L$<4HZ6A%E-R'2R5>5(H H7;>.5EMM+^[E%6*Y*65(YPZE Y(>V09Z"<= M>]):1;81=Z/+\U;%/%6YP.,Z8(H99/OS-]\8O,1XQE8>BR9CTTX1Z (*S'&4S M?45%63Y8?GF"C? 2$D.P$^.I.R$BH7<4?TM*4B=[}>5$T-F_QLO-1#0;0,) + < M.TF?U.H N.*G9%W7.T QC\EWG6%YR)1#_ &VAT.ZH5Z6L&:PN/Z , ,YBCB?K ^ M-I0.ZK#>@=3SZ)XO>D !IMTU$H*($W ML$2@%%C@^R0;GIV2&^K{)#*E9^E M$R[PU> QX-49G.,A'W/9%@7FEK8;$Y+).H7J#(PYZ C+]C-3/D2?2CVG2L; MT)GAQRA++*7V8)@VDFC82]8>5+(@T," <;6RVPE#,?>+X%+VE6CHJG&9BQH\+Y M@&IVA(TMZ&S?=18+7HCL,TQK\)HBS63IV&3X2&Y53-'E[D Y--K[L'XD=)TI M6T:F[+CNOU*!M=1)KW72Z]$DO7(F28XL7INC3*4)F[A_QGT7+&H]. MHWX?N9;OPO|/X8<%0VL!]-XGKW<[K5%OD/13N15)O9[UJDZ[-2[XJNSK@V'Z M1PZZJ%&G7\ZB]!9@7@VIC2 UZH[7ONH]HI3M'>2]Y C_3P,LF% +H)KF#VVM M QKM^_AMX\1M^O(7WICD=JL$R&GO]7D@*29?'1?^:6L\B&WB*$EXFXB\7%!; MYY'+6,$@ >E6\#G2VS9$B92SQLKWUSGI<7$[E8[^W94M Q#>;QN$!GW5:*]\)8 M'N.Z_[O.JL]SR[GG4-6;0)P?-MB'"Z]=09\+H[H$Q!'>1XH]=__.IM1ZM$\DT^*.R^/$&F/#V>U M=]W71-H**])_AFAX&7D684#_L1L-K-\7H?9U&+_)'?'@K<'QG(@)@F\0@8A#*.M471Q,,2#BQ-%S\1&3)-QV> QC^,:+]$$ 3$>1FV#QE%87=#O^UI M\'JF?? Q>I7;]KDADM]M.9(5A03#\+;|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{ 2,,^-C!XIG4\<_$2M)X3K)@W.1(8TXW M+_ *8XW=$ 3CA&-8Y3;3D)&FZL+(S20>;!VPLO:;V/+?,N6:XC!X%0(I$/M_X MI4W$^,&BX-UKF^#TPCOXKW>3!&24Y_?"IUW:SI/TWD9V4(X*A8GQ>Z+Q'4P MM;(Z?Z:0N(F3:V=REPL!5 M=Q-UI]7'/LB_?)0A?\LF;D /?8QSU)19P/0]_O/'9VO]SS^,QZU1OX_9+R)? M0'R8_]II 6]![G[S>[;2&[4[]3^U6^O6L5W7;K7%O4.A5V==G?X)+TIO==K# MJBVJHI :C'MK7Y63(K,V.6Z5(NDGAL?P!8US3?%<<05D MIW//H:HW@3@_,)?!,OX+VN\?I-F_^T96TF\;({B2N28L1 MCFO'A^2*FRT7QPO*A]/"UQ2$14M1^RJM6EYA6F/MJV!M]S6QMH(::38CC5 1 M#73'EC&*3\(K<+N SS:UV'])*?W6X'GO@$*H*:VA%1A&!>,(XQB$=JP7*%'8 M'[18X,_ 9M(!VMW38-F33BUX4]D#B:8PKYX]T.DWSH>C\K("*I,-5 ^ZKDER M&Y(\^.CY3@=$\LM+WJLIJ,(:NVZ($4>?/1\IS.L*;*FR)HB)45NFI:Q1XK$ M!/=::ZTIJ9(HLA- ,:V2)&8AMX;59QD2VKNR*FFG4(VL3S'<8K7MMIM'R>4 MKZ1,4A8)2]NT?3S"'CX%26^/F6)K1E5TI#;26SVUOOKX5 R=V\|O*&C MUZ.Z3ASQ/:?KQ!$OQW Y&.+50IJ.#O&*.?/RI)QR,2\%PT9IAD]A M%WJ-5I5"JU>5HRE(-:X$4M6CM;PU97-O;5#" 8(LZVBD6U(TY?#Y!/54C@-& M8- :B6)FAEAK/CA_/2IC"GHIG9<9A:CP[>CS,)7:SC97<[99F)==(6&$D?/6P MSUJFA_&=2@_W>U.1GV_\SY$Q;E6Q@G;L:1"/|)687,Y9D=KP^A&!=/M+RL MRA3OX&<.!)TXIB7*5*N#>W4LZ,1Q;U_#TTO O3H<=.*XEZ@\K_NCGK<.V7< M*$'N2_,&U<-\^JRGO5E/:OFUU_F/\ \<^PZ%K@S=CD 93(T}_#Q8 MW*LHJSSVD)@<3P*K9]E{6]^UVUT|FU=/W2U6CE;..U;$P.LMNW?6L^-K>?& MYNDMAQ\'W^LWSD>#79P)!9#HFMAK8L\G]M&[A:|+W:HWS>AY\3>HUJ>^9U_M# [XW;)S74KTF]9K4]TS]AQ_>T"NW"VY-ZS6MU[2>2NN'GPK1P_ZZH^'1$COY M&= 3ME-&P<6G3G?A",457,D _BD^S\?3=T9Q@L,IF];L)9ZH@S?M;?1[%FH MA%O1L,Q7_WH<4,-67TB4VS<"%@ M;4P-:O%UC3/;7[#.PTE]T&5+I W{(1SSWM2417C9L_7HDWWV-!&KQK:* W< MD"]_,1F*)^C/7<:T1WCIW-.8C3\EO>>8A@:LCVD/-)8/L.9O19BNOF/9030_ME091XFQ _&6UVP90A1I5M90<]U),?58K-WFM3(F]K9S(<-AR-YS3\D1.9 MZ<)WSR1N;IZSL?2.VO(<,N>;X3)Z%* CLO9\XY?&?BUA1ZPPS/.1/C@+-)W& M>39D-B79CG[D--NM:39&LSMDI>$,61PANP.YZHWS;G/&!-0.@,_^O&%&<2F!$_ /G%1S\$:.UF/O:+A01RCVUX!$_(G+A?/RIH, MQZ-);VAVC.FTUQL/)X/1<#3N,);- S6%W//O7&+BO>&CNRBTLC0=V-G&9\?/, MF,$./Q@+T+L\U+Y5!@RL5JQHB-QW%_&Y59BP8L%&CV?_+/9]@XOZ=|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|"MTFCPUM]*]A MC=+)#/G"M-8=SXTGH^09X0T?RO"<_5NH]YBN[!--%#2QC3B1$?)9;6+ V^Y MEU'#- $K/\Y&$@37]H<:[O-G,AZV\TSG-!J2DYOIPG?/)(YKWK.O])K:\]PR MYYKA,GH4P'1RQ'SCES81<_R* F^O'7"@UW:QI6:7C3:, ?'L;D:^)XUUG<.'9<*=>2[N?,X)A88EL[<]-EG- E6W#/;6T9/\+D"2M_C/WH\MJ;^_.-XW!KU^YBG*S((QO?YKYT6<,3WR>O=3FO8[]3^_MU&ZE7\]Z5;?=&O<&A5Z5??W4Z9_PHO16ISVLY(["JG!N+?V53E).VLSM<9' M.CCYJV#UEY+5W]OPM@7Q3.UBBIR+K,/R!TL?O6T;HL1!O86A$DDO_&#Y\#%S M$U_9E2WEW}]..(I'M_2AUSE2K\KTT%2&KFM[L0V2#;_35KQEPV_%EY71\KO(MN>=0U9M G!^XRV 9_P6[^-O@=Y](^OJ-PT0!W$E/& M<7US'"\H'TX=7]$$U;Y*. ^ #]@IS8L5^$5%RPC>&(1V+!HH4;X?M&+@ M+\,UYU]W0 [2]IZFN9YT@L%,RB$8'#Z'8$PY_\,]C[(MG;/4TZ5KDLPDR4V[MK.Z1)/NIH:F:(FN*?),4N6G2QOQXI"I M]Y'I#A)M9U]GMO<8TX]W<=NL0>X*=RPZ0GP]ADX[- *PLCD5ZN]TX3_+L[7I5 MUIA4+4Q*M)C8+R9UP$1.Y@W7]%1-5"HHY,IH';D-4NF[C3VMT:F"G&F'0:#; MH% WM1{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}IM3 UJTG6-$]IQ?L)## M27W094ND#?LA'/K>U)1%>"N3T)$"D&@L.Z#/15U14$L IX>C[Y)S\>34: KJ M*$\)3&Q'CQ@3H(; SWXD,9=M^YGKK\P1"6N[G14P*W_.7;F.I?'' SB8N,WZ> M&3-8[=-C 6? K(86KY R4*UX^O/'TJR++W.%LMA]//U(& 1JXN,.O] .PI\N:R M8>_&Y59BS9W4>]XU>C+C549CD>3WM#L&)-IKS<<3@:CX6C<828;F\/N>/8O4//N M*6D/Z/$2Y16- RC:JA&EI>V^<_V7^X\O=W7-[??? X\OFWO*T(UM+1*[2===S^N-M+W\YOKJ/+)__N<)?I5+2'O;.NEQ9@[8],(/+_<:\4_U1JA!)9Z"R\/&YE!.M]]BT KUJ6H'281/5OBFF>9.]JQ? VB,|-JZ0^+PZYZZ>R]OYY=#=/9U>A MG$29T[P!S"O";=:=2@[X1P?F53LT6\%IYCC,?'LVU>T #6[&ITP?FC%;) A(F R>Y]"@/]YQ]:41_%U^?;)S@:>"\E6&'[f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|H4P|<1NH";:$#|*] M7P|P$?BG'!T6! (1BBD67<94Y6 X]QZ $QSR!:Y\/$\A,8(XN QP"K87TS8ENF2(&YQ@)A3APXS$=8HPG[E|L+ M9TB.&5#R&H@ ;!,GKC^S KH/5LR5#13 $;_ M1- Q,G@CR2.:B@+@P71@0ZM*^%0D\T[M27A/UG&A-TJF& H38<\(TB "IB2L M2!9S$_:, ^#@&NA_QH65;B-1X+GP$YR*0$Y@38 3"(>T>N,(,7B6^!XP%A.L/ M9 ^<#* 4,DM4 MYN!O$+M11,:Q&PO.3K.7! 1R!#E(B,/\D1V@A?L:TQX E,"f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|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~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|@#+RN:@6C+W&>[9F*JE8HW=6:#07(#Q':DW.,1'R5V0W43*BCI M/QSZULCBGH7RB.BP<1:-01^- LU_JR:ACRS95M$@'O"1ZY M8_WU:&"ZL0N)QS@[#'*B#"RW%SYB6SP)S#,D<8R6>W9N B)@ (6U*=57N3.M,4WW$8.D>6?12=-T0SX"N P#OSB%K[M47QBDQH[[111> +I[C&4S<+\4VJJQ MYXEE3A)+'W5@&"0$S<5&+1H_>QR RM5B$8#">B))<)E3A!;'THWGY3O".,D M+O"I'&I$%>B'B I#]TE(Q1H1Q,/5/EO!!%!)8?&|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~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|@#+RN:@6C+W&>[9F*JE8HW=6:#07(#Q':DW.,1'R5V0W43*BCI M/QSZULCBGH7RB.BP<1:-01^- LU_JR:ACRS95M$@'O"1ZY M8_WU:&"ZL0N)QS@[#'*B#"RW%SYB6SP)S#,D<8R6>W9N B)@ (6U*=57N3.M,4WW$8.D>6?12=-T0SX"N P#OSB%K[M47QBDQH[[111> +I[C&4S<+\4VJJQ MYXEE3A)+'W5@&"0$S<5&+1H_>QR RM5B$8#">B))<)E3A!;'THWGY3O".,D M+O"I'&I$%>B'B I#]TE(Q1H1Q,/5/EO!!%!)8?&|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

<${RV()HU57=K6/W|<::!MFE/8[NR7EO54T# M=1R+X3_X%-HRO(B)3V-N>>P)O2^,CY#.X^A/;IYD8NZ9Z3VD?"4+[A1N-KN4-MYA .>O>3W?,G&,)/[AW5V->OEY2C98M>E%NW">)\8#MS?>2G-^I EP5O/:P)@FTR)1=1RNC>_[-/5 M8:Q*N-CV'<;]fS^<4G;FV:T"\WSY3NJfVW${LLT=0CIK4J4^6_[,];G]3\|-.M9X"U\%G9|&(46R5H|?T3M-1;YS?/"L1G|)G)Y6^#HDD%;_)Y|KFX9N/DO#,H-MA-P3>4SMQ-'>;QG<8>/+(Z98@&W;&2SM'B\$!G.<-+24MGD97L$v4^%/B#+VQ:AZ%>C36W>DNLN1FSYG\)>T3D>0\84!?X#NZP7N7%OS]A-MURN;L%O5Y4G?BVRCKW=K?:"[H;^7W)RH_'AB M@-!D?B 7[@/W-%;.&DPJ72MLGM<3!/D_6M?!5S./\!F/A1FH'/;!P&LH?96$#,[U^Z:S'KUR'O#7DR5FO1V@U M0:L). ^VPLBF&KZ,F:/FSG?Q!S>!17:(OZ+M;XZB7H<5[888>V5=?GFXLM.]DMS_I"WO5FZ^1\[-'RK9R_QQ35G>B[4B+Q9Q1G]>#-X7%'Y .j1 D5].9@ 3/EC M=,<9'U.^0(G@=C Q.57Z'P%]>G,M %XO2ZY(/.F*L)5!E1$N:B<|++L JBM.>E5WFOV\NFUI'Q32;FOW(<]70%N8A\6@=6@ZIR2-Q*-MJ\]+?YU[%BS^Y5N2KUT8*KL<00[M:G3!A0?YS!>?HC_.,&Q@\|_DGRZ'MTFMG63&/6++0_;_?K@T;^3XVZD?0\#D.M:0JZ;7O/0]Q8:Y3HQMK+.:G? MC;4WOOE$1+9PS6*I_U>L'>'BJG3RV]N1|%J<{1"|OOM\|_X='9VP:YA(@\)Y M\A/AFFF?HV\^GKS\>[J/|=7OZV^IU26%:^YW+B#-K.9>F!@B>N-KH.N,*XC M2QJ_.= 98C,NEMS>,(2N)CVPR_\|D/20!.T=+F\(Q9&_S]+"C2XO73CTEYN1?DN5KLY5=LOX=LR5ATP]^! M]V1V]\"\X5H2:)X\232_4$W>>SU+*V%(21+&RR*PL%+DG!/"FM>A\Q#*<\% MU[*Y\HQI..?_E'T 5JC-QV,.O1^(MCHOV4":16B$*H)0W9/SVR?L AK B75 M#3T67:/7/.-H0*QYAN89^T.HP,(9R:2O7Q3V+7"HG' V(6WW-,S3/V!="=:,\&C%RDI/8_)2Y';(M]4; ^8D#PHH* N\%Y$,AX B*;T2+AP/E X*<-P:H28X5-R082VV)(ZZPPP M*9HG;Q!$HJ3K5+P#-_J8$U*9-GA*M3&^PY1;PV=!YQ5.*#(GMM2X:BC&+E6? MAD.#(XY@J;1R G' ?XH7KJWKFE0;UJ3JK*Y)IVPGRI-MLSOTTZ$!^"J%?C=;>VF">?LJ.3MHIU/)EPH]VVW076*C4IOH5GIU<>EBN|C M:W$<>^}],;6(#^)857&^3-BI2,QJK6.6O 'CT*,@FY5D/P!3>^0>FQ@M .QY@ M6#;PK&&(;I&AQS'<6&./6G,FO,GPE$5,S\'5JN"NTJ)RNH^J> C*=TRP!P M-1;$OL<;, ^%T:'%^../CD,N+ 5A^{)s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{K[%(#99AW7%(B8V9 ME!69&1 WIT\M,4H)(5)#M:4F.0LI&&K V+9.C(>T3IZ(N=1FHR#\G?B)V7__MDBQKC2EQ,B%X.\IR00\&IL.@)T*F9U.F8K/1[-1P;&(:Y+1 M=0I6^^@)F6P G]'@(0111X(+_@V^JYL\MKE$&F<^QJEU"FQJ::@,N;!G;#\= MSM*FH/%)21+}]&'"HLG8B?)B!2O8>132;*AH^$_)V^RBSB'(4H|F6A;M#/-IR4)YP63&-6=Q'-E-MTZJ"V!'YC83 <}:ED48K<;=E^M%QP$6X8 M_1E@7D^ HRD]'UGH#*CZ)[72!=WE@1'N9UKT4KZ,ASY2=/WQ=&/B;KN5W\T7 MV(^0U+!)7U\$?1>5E21E)DYP@GUB?VK*M9$)0"|N%I\?8W_K)^IO39G/8+L% M?G1@\C3B(:6'ALZ&_HR%!H>#Z&0WA^D[BWC%;"T?(Q897ZIS)0+(>W1FD7SFC"HB/B%XG]@W8V7F!^_V@^Y M1!9Z%L[6'ZMQ,=>+6#)F!^.0D3?84IELZ;0F4X!QB*IXA%WZ\([A#9*O8-5 +8 MXRB>$^_*-[SP93VC16PEHI$P6[_RXA;>|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|"$YXG%2?)TP4>L\NF.#WI_*YV9DE$K<;FR M@\YNJF8HU>F5/ |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{QDJG[-1A_UCMSFFL"*7'4S=575ED9,IE^?_1*M-4G5VQO]F2@[S0ZC.H51_Z]6YT0G1%4E/S M6^LW%.^$CJL3-;OYE=3828PI0/HGLM75N@IU&+5UZC;_B%;S R@O"Z,VPEJMQ74=M9*B1=9DMGU63VK6VX.8I)'"8=F/(;;LH.'"ZLR1W-I.[JT#*_H27YV3 MK>A(P52<*\C>*:^QS-& J+9M;&Z'"2K1X_&IS\ FPHN7M85.@%'/D.AE689%MW6Q?;Y#D7G1/HW;CN^F$3:/TS733AB-'@-1A&Z_'/$D&TLVS%#F-@$A' %/5^5 M$6&=Z1(KE/;NFB$N\)>$ //@$%(*T1=0;#QX[<'5+M-# M4#U"O-3Z<9.@"HS%[DW$5#2AC$#2RK60"!!T];5=1:GL\"6-2&IVBPG)-\'_ME5@R794P@!9P9A48O1N/\Y:)31V3I2W@ENY:LG.6?F[UEGZ!F\[H?->Y_3]WM7R=AZ]Q^G=NO<_MU;G\))/[^<_LKU*ET52I D;H9Y;Q;MG(SZP89*$=3*VLI M_R;52YT:RF<2>," "E0I2)UPL[>$FI\@J7Y49;NJX%Z,1]677TO"O=.IE>]E M>DE6^"/ZPU(5W,(/A^AT1L_=1\EV?/*VC)6\'AA(*<.GP M4N@%2R7AT6D55=EEWT-8ALON+..5H^,JL->)Y!18L"K#Q..H-@GD*GXPX4\B M*6XFIP.>YWJ.F/NR=PGVM*!0JG3-H+=31KTRO:)QE_"=+++><*NR=|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|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

\#)%9@O F"PPU"&+^&4;UP'RREXP#EE,14I_XZDE,J-MB#(4&5_8N)/=>"3XM]6#(I=:1KB|_>?+@@P3JBI]7!H@F#/C3;"Z[W;K?]*E6+ZDTV3,]C MU+OQ%_MPHW^V,/MFE'AM9{X/XPG#:4"AV+4^SUE0]4'S7T>0[_>'ZC]&_5! M9R\|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|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|S!#U? C1"G6%+,V[,-5R=+^+'?/8L: D+G;DG< 0PVI-K MAWB8U-K;$P&W;!8EK#-NFB!& V8"-;A37#\N V3K2["%(M4-7'9]^FB'=4&5+56L9."%M0K3";S32Z;BQ<-;9N)5@V* M3\@UKB;(Q@:X& M]C|DC-%_$VI{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|Q_M] VY+Y0LXJ.OZ*+=OH#T#A0@CZQ'UB/KD5>.Q<*&G|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}GB>6.6'<$>\OQ M S85W('#&(T'.,. M1S W4+#OIVJEEQ!WS*C3?^JEI(T{(.:SL&W\UPTFPE-%WNC-&AN['G-#CWEB MYGI$TLR7*__W1>&]HT"S;"APNPCZ"$AYU]$4M!+T !C#"[;M/B/3WA,,.^U2 MP_!O? ^DWF]VSDL#1:.-?[5'>|.],3(XL(]$.ST6(PKXT]E@A0A%,P\81@W %M MP?K)IC#+Q&<'CG/$[L4L$-,AT&NK46/-1K/-1B&\X=*+GN ^4+!>6%QPGHB M9J9V0=QOG#,Z'>K8E? _"R+(4!7.?_=?(7.]@:{]?MGFGPX:C='O2&W7ZO/S + .S MUQJ_]<@;E0;#!^JZP/GV&%/1-MRD}%MU4?W$W#]++#2XT3P>XO:4U: M5=[3]M0>G)Q_L1S08E&YOW%!2P6*4PKI71H>-78]G7'+0^DG!=,=XD.7$@]J ML*O@3.DW:2U+D^]AY$I*>&RG+Z0$#:I%D>DW8K,%AY9M!7.I,LTLUQI=1D^; M-K>F"R2,,@>US:-M'EB@9@X'90XV>GE)>VMMKZ*E^8-#G ;?O'1!3CASW+K1 M.X/7_PB14R@-%?51/WA7+N!695S -=S\?]F.?[U;^M%0@ 7B/0K%^%L6DJ=S- M? +EH^,%E9M+? SZT153D/6O6EZ[BL9]P0&]; #273<+RM]#/[#& M\WV#;; .DV$VH4S95/AF<()^-.YH0(CS"XZADG1HP}GB>6.6'<$>\OQ M S85W('#&(T'.,. M1S W4+#OIVJEEQ!WS*C3?^JEI(T{(.:SL&W\UPTFPE-%WNC-&AN['G-#CWEB MYGI$TLR7*__W1>&]HT"S;"APNPCZ"$AYU]$4M!+T !C#"[;M/B/3WA,,.^U2 MP_!O? ^DWF]VSDL#1:.-?[5'>|.],3(XL(]$.ST6(PKXT]E@A0A%,P\81@W %M MP?K)IC#+Q&<'CG/$[L4L$-,AT&NK46/-1K/-1B&\X=*+GN ^4+!>6%QPGHB M9J9V0=QOG#,Z'>K8E? _"R+(4!7.?_=?(7.]@:{]?MGFGPX:C='O2&W7ZO/S + .S MUQJ_]<@;E0;#!^JZP/GV&%/1-MRD}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{(5X@AB/A1FH]*MP&LH?Y8T(-(0\,0$<08X?"&^@F M>-D(US:VMK'?SL,667:'950,3>, MO4EOT7[&8N9SI/FW1E.K^*_ ")O*RR62V9'>+7/%6OCI3FC2QJH/N)56E1>_ M2WK>NW'M:%;Z:*_P>N%16C$3U8 TYD:!$IRJHD4V/D:@:?8.\FRCY(V7V.<# M.:"_23EQM4JG?/+K)#"*R/^RGL:*=\#"^U2>'>50CPK>?B;ZQ(/O\^G6-7$ M@D'F@GM8B@'G!)IEEJ]X*QPD+@FF<,=C$(8?XC7R)+T='9U+H:4HNS"< M(<]B$P Y .?)M<,I59VB\P(R^;,^ ;NM)%LWZ^BE9M9-UD+RX@WZ3-]+/[&3 M,^Y.XHSM=)_Y;Y; PE9'2(P>=GP__=V/*]D$P@@#1A"=->NT Z)4CUW[O7^; M?T\Q%+*[$,X!-GTDQ%@!M<"L$W 7'+\HP,,ZC+*L%^0I=G$-2F7%+%8QBR)F M>L4]ML U1\,PZF4I!U>NRTJ24LNW5RU>'7I#N+2K2GE M"W3)+/F"*_%^..)P1R3=S6_5\93B#]JK@=3!7L9)_]R+_GD^+-38O<4ED M,)-L"X0D=! N:#\,XQ"^@Q-[U 5,/XN=]*C*M] >K!# MPT4[*#7<$Z@CFDU]66B?"LPCNY4G5^(=7XODR^Y,3GN4H:6H-QRR[F(+]O$ M;5?1O.SL=YT-69#WE"L=LJP\NG+@/4]>K>NVJZ15):WV" Y0&IZ9'[N4+NML M1E? 6=RS3LV!JU&24[@W?R8-APVL:1RE*S(QVLI,*GSMGL #>M$H M9B5>]C^7RABJC*'#%.Q:SM+JV#/+;YR:\1\)>"<,MF=3T0DSL8(1_98-M* QW MFCJ14U_Q)([2BV,C,? PZ)5P4NUP3]@=CX{)VV)\^[6/F*>J4A[\NE890:0B' MJR&L!+G9L(J1QMPQG]_50"!I=%ZM6Y9^Q(YN]>0,0XS2-LW?PU\#_X>*4BQ M8]_"2N&\"#M.C_T9I@=(F0?ANOC?Z,X/!3]. MSPZ%\-(?.&$88P5B'!F>'X%$C)(Q0/[%H<%2,.7U2EYMCQVV%N25E%VJ5&KMO:FQO>6KL.C*CF\B,*$V2]BM,A^KA-HJ MH;9*$]*T2:H\GH78>PK)<-E]Z)G 6L#H@[YKQZ>*? WR[@'_^J&8,OY\;9X.O% M#9W:]>6WJL/UT7!?TMN#/I)_F%LG!$'AGUO.R[)&()$N14>YMJ@BDTM,E2C M9(979404T*1/@""GFO/60/5Z NJY7P,U_E90"PZ"L"%/Q \G)),CA'^-V*GK M.O^)G3'Y}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{O7K^!JVZ<-7(6QYY;5J7/6SF*- J@__9+3MIX8L]BIQ[MAQN/9.EYG877C4.XT*\W6N(O\V[=4]VMVY"]2C=9HZ+?PFM=XT;.O4Z_T16E M'1*EO>EU%U3HBL@J(MQ]VGKU[G[8V7-5WH-4 R[(%? ZT&!!L0!_^NQ6.W)6,IW+.W>B*_3V68R7(S3ER4:VF MA#36]+7J:Y!9>53,8S\8]]9M-Z]#*=_!=-]=%S^6G2O*>M2=NL*6:_3]*4 MC#(QQ \9<:.LA4S<.!JWL\A^FO*YB?W+%BJ3/"%J#:XLZ4_&8W:O7N&I=[>QOS KIY M(590*"9;W93]IC1]5GO]&%!U4ZJ;\[/=E-XSW6E[NBHK%$U5#^3YGEA^LP[E MJ6JQ99t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oXYO^V& M_AS[;S?Z3J-_79%\0@2'[BD"#J8YPYKF3EHF-;#BSR$[5.WLO!N=EOH@^_X;QWL7P;1U"JB%"- T0+]QP;AB M^D=[9,9WR1OK>%E&Z$^B!SL06U@4-@0D5]%;< AC:9#A\<#L1D*.F6?U&\F* M-46*>SXP4USH5%\U8]BEYM19T)P.MG4!KJ5_T+-/5-:/%W^0=;EY[2]2:6C MB@I1O#"B>'\YHGB%#9[]O,(&KT"<*VSPG%M<88-7V. 5-OC!8(,?FMB8;82-&JR_BVSEWRP);_%I:<|;>E0U@1A+:.@/E3&+AW!>&!(1 M@8RYMLQ&^V]D#X;D[--&:=,H? 0IGHHG^3^Z?5D]"5B6V_V/QG M_Z8"0">MWT-[$|M;(90V]]2$WZ.MS[YJ2M?]0AD;KY-6-Y9!$U7SI=J48,X+E2 M8>6$S^ @_,P*2ATQ@%4 \V=L^,'@T[@FW%%%TYGY)6%)V!R M"'SNXG,HCW!H I*>2^7,Q6Y@&,S"<\6@OS>S';2R@)<)#%#>|7Y\>=]M(FW M%2VU8XD*>,9OL2?4#C>+$7N_KA_3; [&;'%'O"3IOU;,I%FW36C9.I_G$.)UT MG)IRZ&?O3/&[0?]0?C?K5VRG;K=Y#C&@#@,RU6'971&AH,L2DL,OO5JR!0 [M_)+L"!E#AT^S-Z1!|C+;\|F&'ZA];AEO0"'PO4?X%SO M'%?(=V-['0%9O+DG$RZ_"^=,3'/KWPC2^A219YTEW@6R?];9M2?#

L^)HVZ79%"]L[%1{3AU=_MF>/^@<'#PV^/%L,+?-?G^W2,|1_B[VS%;W.NN?X;Q_MDN|P\-] M.:=HP;-}O9LS+?R6^UEUO]9O],I&TVMK6!/ZO\/1HP;Q;1Q&"¥J4_'@C72IG M*PZ&N?;7),3\8|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{K\@ 5F>V9X\=F#V7 MY(2[V?GEU<*)^L&N_> <75Y=#7*7NW>*0$X!1AVL=!R/Y'Y<7WZ\,@9CO'AT MK+"4^M_HX'D3AL(FT)>D06:F#RT\30-(R&C044_(YC>_]OS W.NIGS$$(UN% M<#(AHC,"7XLC\GVE -.]V9*$S2:T7KHUPI;-J,-1X S9N"2F*N_$,BYH&@,P M(6>/ZJ8E+ 11L^THLD=W\"O@M1]^W#E#^*55-RTCV]&7FQ\4 /8^-$Z[I"N1 MCDOZ7\Z/=¥[O?8E) G+SY[_1"%;?3??XG1^\YBD"(]34(@IM@ MK2ZK@?;"\[@10B4U1_1NXGS0XQAUFXH7!$&.SFQF@U440N_!HROY[^IN\&; M!F-_!@=?|%4]$%D2T_4K8KK^UVGFO;^N_O=AT5(1X"L-25"ZN\,$^%92G&PS MP'M=,Z;^F'JH$#FV"<9XD>#1]ZX_^]J1,/Q"A"-!A@6A02S(`(CZ)59=?PF/3!<' MSOP<3BX=O%E/\]6[*ILN>P5JSWC9A3?^ A]H[&0"F%S0]CB\2V0Q^)KD)2> M]:H,)W+U=S5>_9HVE?P#W?K 3$-J!+VD3YZ'X<.-> \%_?" M]6;+[,)^@G_8'X&H%AH:--YES<).X0VHQFRKL=_&/ M\-I&[#@\;?;TOEI8Q8W<Y=G<1,P6V^O=?#]^+NY_ZD0*HR]@F<$4=Z92"((@Q2UQ;;>O5KJU;OO=52U11_U5V0>9A\68AR9'3 <-0>0 MGKF[XR!T=>2XSZ"W#XF[>^XFM=.,U*,;U,XA\|<-[=%U@.LY$|-VW0S8N=9N M-6_2-O4UG<[;,80#0WQQ)3=4[CV A<&ZA>(VCLDQXH@NY)4T7HW77PUQ=@U<-X^)0Y!E%! M]VX*W=O*3K&"[]V@>X\+NO>@U6BKL:X;W>RLKT8W"ZO17;UBI?],13KG=8N* M= ^[WPX\S[@& 7+W+'TZ_SWS6G2_D!;]CQA.VK@2(;P7/6C/U9F;6]&96_42 MZ,RM%!96V!3-6OM?]-<.G,.=2W3F5N-Q6OSDVO."I=[&4Z@Q6.3F#7D&,.^_]%:/RS=M[WKQX0QAUFXH7!$&.SFQF<4U440N_]HROY[^IN\&; M!F-_!@=?|%4]$%D2T_4K8KK^UVGFO;^N_O=AT5(1X"L-25"ZN\,$^%92G&PS MP'M=,Z;^F'JH$#FV"<9XD>#1]ZX_^]J1,/Q"A"-!A@6A02S(`(CZ)59=?PF/3!<' MSOP<3BX=O%E/\]6[*ILN>P5JSWC9A3?^ A]H[&0"F%S0]CB\2V0Q^)KD)2> M]:H,)W+U=S5>_9HVE?P#W?K 3$-J!+VD3YZ'X<.-> \%_?" M]6;+[,)^@G_8'X&H%AH:--YES<).X0VHQFRKL=_&/ M\-I&[#@\;?;TOEI8Q8W<Y=G<1,P6V^O=?#]^+NY_ZD0*HR]@F<$4=Z92"((@Q2UQ;;>O5KJU;OO=52U11_U5V0>9A\68AR9'3 <-0>0 MGKF[XR!T=>2XSZ"W#XF[>^XFM=.,U*,;U,XA\|<-[=%U@.LY$|-VW0S8N=9N M-6_2-O4UG<[;,80#0WQQ)3=4[CV A<&ZA>(VCLDQXH@NY)4T7HW77PUQ=@U<-X^)0Y!E%! M]VX*W=O*3K&"[]V@>X\+NO>@U6BKL:X;W>RLKT8W"ZO17;UBI?],13KG=8N* M= ^[WPX\S[@& 7+W+'TZ_SWS6G2_D!;]CQA.VK@2(;P7/6C/U9F;6]&96_42 MZ,RM%!96V!3-6OM?]-<.G,.=2W3F5N-Q6OSDVO."I=[&4Z@Q6.3F#7D&,.^_]%:/RS=M[WKQX0QAUFXH7!$&.SFQF@

*M'^\M@MBCE/LIQGD_X*N;Y0N\R]K&D=D4?0*B&TB0U"X@{A9)4"^B8 MFTBT#)(E8-[(L(5/6QO7D'8-#L7*1Y?O8^C1.U.(5@.0Z-8KDTM]^%#"1XPA M(:$GS:1T&H?-=J)$RMC ,G1,H11Y$B0>=lC@1#Q 1>9^6JWP+=&_20^L<,F+05)/X8 M1/Ul.HV?F_%XY8,$)USR,J(4CJY]QPPU-N61,8"=2Q!MK6KX.V.]J&l./ZG M!#.KH;.FLKB?]Q#_%6 MJ+]^.]TQL10K)]X&A*YP\H &0WB.![$'3M.-S-^ZIW1]O!;_'D-\M6BLD(ESP-) MT2:0#N.& M;N3K"+_/?-PNN_@RS"];',/K\PMHVG+,#24;&C\|+7M1E|N\|T4H[==IOO8W MR|_OGJ-;&T&%O-U>)Z52+N^FYY6VNR|XS$F.&>UT3|,G7$*3DWY9,_9&Z%JYYHR2:@-MG11XKaN32"@!6@=K&"F=A.! M&Q"&%/@*_(_O+2F;"FV?Z:YF4E>% XZ_- /,5#I>E#"55+)8<&^HY^1^H,FG,BMG$ M#4NUFYO=1C&DF+:ZY/>*<|"JN?K=)_$W)+H=U95?1A*9Q,:G#RFLK$:* PFC3V_F&-H)PBP7MI:-!THK MIF]W;TH_ILMY|Y19GK;_P:P)4(K]CB]Q2*N_OKCVU[M[-GVB]>#E'&RR*GD\ M?W6K*<6C8JT^IK>7Y5ZUQ>WQ\"QZ<9UQH/F\;CZ+SX_1A^JT;V:)8SU';EMN* M7=V>D:#"&145H/P7JB'Y(WUR82'9%[_M4N53=|$-780%:?G0)WZ>LV>L)VKC%G+]/"Z$M(|GY!{N| GV@]. "|#XY ME4S_JV:"Z^|-\REMPCFB3EIT03E1MN2,@:2 %7F&/R916DY)QVK7T+|\?T;X* M\YY/_[TMG6*?+FI!:N* MI|]%O0<5QFR7YY?=MN71^;2=-_^]B-D<,X)&Q!F[$%$:(G{12]D>+I)R ; . MN&CN0#FIHVM2/PZH:\NO3P),V,V@_- A2"^F8_UEO5[&Y$=WU2!4-999"5C.'U-MOK\V!YIS(,SGDN6D(G%.,J*M"1Z$,HK63A6ZNW73?F/I4H4O&@QNND/>M39(MHV298"9I0G/"I:4 1VDM)9Q[EE)0WO,^1WDWLB$9O9UY<5,9]2"4>BFS6V&[M:MS#/&4T<]*UJY5> G&1(4X1N'?&<1IJWXYY$, AA9('IL\N(NK3C)4-E6;> M;9*@HG_1'>5_O)Z8=SR;- ^>=='2|^CBNB]B:MQE,KF+?]@ZJ|FZF;S*31ZXA4MZ_+1-_LGH4MM|4B&;*31XPX02*F 2F+"KUP%|7W:/AM@.VQZS8|Y-HCOB60-MCKAP.LA,B1"E*"S&(,2ETD&7&BL- !!U<{6VS!P$W;"_Z "(M8O4^C2M7??W ML^D8)3%[F7(3FK6MQ1==ZA;_]Q ;Z*QL6N!*OG5"|@^4%'>#6/(M%=[:W<;7$,RWX=DWDW|6UV&U>SYSK- 2'!&T*"B"|>).@_!X%*CV7.#?HZ 0B M,Y,+9+2L1Q&ZX\NQK.,2!:U MZ==*'H UEF8BDRLR5&Z] +5$T,9<=\"3KVU:HA__)69>]J/IHDM\R,EV^7KYX MF*5__>/_ U!+ P04 "D &UC:R70 *4 %&C:R70 #(T M,#DS,%]0D96HN>&UL|+U;=uO)D32[XWK^BQO,ZX -(," W0$+J7E:1.%(7|9?RO,R,BX +O _^./ M\|%/7W Z&T[&? _T3_S/[TT\X3I,\'' ZZY_^|?%7<'_Z'__Q;__V[_\'P/_^ MY?WKGUY,TL4YCN<_/9]BF&/^Z??A_.RG^1G^],_)]%_#+^&G=Z,P+Y/I,__:?+7__CSN__+A>_S;WW M/R_^]MNOSH;K? I$^EO_\OW|[_2&=X7F X7@V#^-T!0!Z?)Y_^X?7T>B?EW!) MOSH;_F6V^/>O)RG,%P0]N(2?-OY&_0Y6OP,U1\ %2/[G/V;Y3__Q;S_]M)1< MF*;I9(3OL? QT^>4_WK^ZBW0XGO^/YY MA*N?G4VQ;$2_6G(%]2M=Z=+_]-^VL|8SHC(--T$1'HISBN*MX0X[H/WQ_SM\^'' MC"5_F/ MZR,Z/O_F._XXW*#6'W\;))N_ - *H;D^3;_]R(%"*.%C\=9!P.5B?&]W$]%<(E M*GPUQ_/9P',77# &I,X!E.,(.5D/[(UG*EJ73+G+R6S%0S3GS]-OOQ,S_FY MBJ1^L9#-DI4'GKX46;-5?0QQA ,G6+9)2RAT5M!Q9A)XYAWX)"SG+.M26.L5 M+9Y\2,%Q"GGR;3C%.R9>BO%]_I M7[})H,L/\US_-IQ=X]$[;_7*$]=GTIN&G^L6N.G$Q@T\A?!Y\F)-55#_H M^2C,9F_+A_DD_>O9'T,23RHYBIS|6GY\I+6+ *TP@YURK.G'ES'\)VQ.FR%:'K#-MU&^D"'21--2 C2;+'7V5:QD2!+DF7!&*<=9!!@+I+E8U)6 M/5'V;QB 1R2_BXC[(\UR?CX9+P#]MC (!PF=RB5Y$"DI4-S2^H1FD*.T{(J, M+-C6G-\&T9+R=5;T7;[W9>8VT7N)\2[/;%>>R78>/...L3>3.7")7U]" MBB7Q(L"(ZR-LL)"I)YP|< %9QH5]8D4(O"3@RJ!7/DL9_58LKOWX)\|B_B*[RZ+8BT7);T#REY * M&P;C(#=N&Q?4?_I19;"" RNRS*%@\U1_K=@4(G MK!(>N#&$(V0.T64/9 [H;$6RIMQG)&WO1- >G'8]WEWHSL)K>"Q>_'_7(3I M'*>CK^_O\V0Z'S"NA.1DWLL"+'B-M%E8IZ/T@LG<)LQSZ$K3B"$0-]}2,IF806(8:] M"+]!Q!,@=B\AWB54[4_H>_PTG,U)S^9OPCD.L/HA1=0"A(>HPMXR16(B)EA MCMRJ_=[:=4\]&6+W$.9=>3B_%\^O7Y),/ .16D MEA80K2-GFK0P9.DAT183 I? *8@NN[P5Q.M2W$_5=33#[:\+'\,>K3"L?EN$R M/>1R_[%1.QG)5$!A245K@"P419Z<8N08A$Q+W_8OO?O)\-^"_'>Y=WNS_NS MG*2ZN :B8:F&-KW_Z MJ?&]CW#7Q$_V"I/= /9N,IN'T:\W_+RP~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| M!I=%<,]8H/=T;]<\|&2HW5V4:U) &H2H7]IC|:,='G^;3GZ?GSV?G\'XZ\# M&]0L42R*B#4YX=Y L)+<<:.]BR7+Q.1+9]^6XK4//OF]IQ?M&LKWBE)=]N 9 MCD;? X*3H)1,<:H$}+3'4*GWI0)9 FDE_%-;B4+[^S),A>&=!KN%UK[C5I3UX M53[QX2Q.U\,N!+==F-*TY&KQ-KD39P'X:3 MX;V9H-?H08-LK^>TZFD8O1IG_.-_XM0?;@C"=LW O#0C'D MJK>@_N9C3X?M/<2YAN"|@E^K9?XZG*4P^Q\Q3'<E3[GP&BI>B$L&Q2?A0[CAP M-AC05H0@G2DEM,F^OO7@&R*YA4C7T+Q7:.PFIF76\(5^>Y99Z4@D5-'NPM+ M$%*V((7B&HO-LNSG5FU\],E1O:M8UY"I5Z3L&4'*"UBC\&D0>4PADS,0G2 D M2M3*GR(!'2^LE&I!7WXW33DT^_WB9"7OG{UXMG'ER\^?*0_?WOYYN.'M[]^^/CV^? _\^]O7+UZ^__#B MY;^OGK_Z>|/A=KV =GE,@]9|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|?2H^ &]V+F?]'=+:X9C>|;>? M<3F=9C&O08IEO)((16= [5QS]FE:8(9R!|!FIKF-AK;0]FE9AUI>@R2WGJ$N M"PXQ(*I 1T%A@;8_(2UX7@HD{XH/3A5 ;RN.Q\G"02M_'^*L[LR9'[]%IU&.I M5;ZQS,7\XF_3E!:5=V2OA50R'8&IMD63C)/55&+MRN%]=,S@O?W6=PL)W OI M6/7*CU*+[L05VK'90YKA/?!6X[*W -A36?2#X(Y3(MV4TNW590\^CJ{XTDGN M$R;R- 04!U;8GZ5T+Y1&6U1-0FM="?$DA7F@D/]X^M*%AKI'-%F/%478C)? MO^5>UG48[7)B9%/84]O*31$$&R58,BN<$"D)UMH6W!Z>%-*C4F_3Z5Z8]R' M.HK^C8"%RZH2-];5VT7I6(O@A/%I7'G$ Y5'1D>0W%"6;/!V8#GX1UY@""]Y^2*<@34'(G\|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|&>UA|&$G MDWH>OI^&Y-[=?)N$2DJHZ,$4+6H&AP47]V4M32PEZL3<$1W\#:A_Z&9/##>< ML[C#"A96=U(7R)?+F.0@XA% <@'%EQI/<_2.>1)?]B70 H)V\HA.TUK,/ 2S M%W8;3D[\8YET]"D]09G?4:A&3DVY5@P*'6M<@Q&Z5Y\E9V-2B[#A]_3H< M/WT,4-RE28&CW=A)9L% (@636Q@BQ\GW#HK/0R6) V7B;>Q*-*8ZUL_7-81_3 M&7?M-?!-8)*1DCAR\QGCA:0%(1@(!!7I>)G;3A M<=QDO@M?ZPW6RO2- "1EW)@"SGLX!CO3^9Q5!^E#0B^1D;KVG[@WZ\/l\6#W9 M_]IR#Y(;UP/L'-M:B?S;!9I6F]/TUF;_68#392[($<+$FN3(4X&R1P(4K7@L>4SYNPL=Z MW-^)OAZ-ZH:7ZAW? N=>3\:>/.#U?_^X-ZU!6+GP)5H"N0V44'0,0/',@M(W. M!Q\X:]R'YT%,WXDZ'I7*XUZ:WXIFW5A$S,Z&0)N_9)(6P25$*0T@H4=,26?3 M:VGJKL"_$Z4]'M81=.G;N;L@<EK.Q61(%A59S5!*.YS]=ZF4.UB/'N:G'\.XZ\]2R'L^C7+8=NH.H4==0)D-X<4-*0U,B[_^5M M1%;RT]>G[.T>5G\ (S(^PTLXA^:8\,_236C;_>X_TWEZD^<649/>*@ ^GE8(P-MSN]QT>AOV=!O]@;G===C\QEGS6_6^V^-A^[>^:[7211WO:L!Y/IE53;>?X?0+ M7E/6Y+4-EH- /SH)**H(/3('(!W9B%&4UFDSV^#:|^A>M1Y\6VX\[=D5%?3< M,^,"A=<\!F#"T!L3F2$K QFDPIS.@=#[7W'I*1 =XA^KYUEQ;,A~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|OZCB%(*C%3H5E4>?!5DKJ-);9^IM!3)1^UES T[$1 (0-@E;7,1^->->>">O,.W(-MZ7LKN>F6O?SC,Z,+K_F 3*O"N(D04=:25\//!H560G&?DL;M@9.MDYVOQ;H&.M4:+EL:78?;@X/P_3KY.R:H,]2- [=5@@.FHS772;'S- SS ?N1 !;KS&5(F\K M2*!',&4$4RACV"K_(0S]#1#],XG8+Q>Y_H4@%YSA**DL@RE%Z)UW=Q3S=#K MHBW[9.AUH>38&7HUAOU\,IY- 1L\3**NHEH$,&CH:1E2%R90?2A M<$*+2 MY&]HZ7.+VOU3W* >)/$^:RKOOM=U=1)=NZC:8&EZB;|\Q>'OU%AS=2_D> M CX4^2;X{(K+(#QME:HC@- BW(1XC,!,+IY$B_YQ;^4)QWD6L/+M:W*M@/ MRZ-C%43*)6G/#0.6 JV3#'AP]=Z(VAR\S-IXWSJBOP"*8.^\V_ T:2_D7H*S MT\ 3FL?W9C*^1'8)C'.4H,;"\|';FI!7P"L3")VT(B- /:KLLFTY!V@U@3H#_M-H+NX>V_JO.|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{JB0\^'1+31W(AM!I7N]OO34HH# M4=##7<_;F@(=O2I*_]^A1-K%@@+OC8%@"L<44XRWAT-\3R4<^^P:>XN[!^>R M2Y6 %E]2<:0AI&K3* S@7!V(&Z0L06=E8^^M,9] <"4<[A6E'SL9F]H\]!_]9 MF@^_#.=?CYB$?QO"(\C"OU"UGVD@%SBAQ%Q\CTKR7?A1'GB4NF4_B1AM]96_9)P^]"R;'3\+]Y M$]>:K]^(2&'T&I%)R$S3V1$2F8?:< A:><*BUJT/G W87D*\?].W-YPI$/L;AVNRX+5-LAZBOQ1G6@RL,M>]5P:M%Z=2PBAMZQSO3$.[Z*UXNOW6

*YU9G(8[G](HMP#]0KHM:+^;>#VE&S2$>]QTE%ZHWY[%6O&VR-0-V;S9K*0-MEY!M6I:CA*(^2)\RG1N^,-[;Y7X4;O9`"LQCU;(N=/6@7<_)\YNM&BWDW\/.\7$:,IZ'Z;]FS\9Y\4U=[PI<4#F(Z J(FDZH//@2A'`LTY<`M,F=Y\PC.O8!.6T7;<=\'#7=-5BMFB;/[.,)8@W79@X^^YXBO!5]D*24E`M>FN$JEWT2@9GZ"4BE%Z@5[11]CJ[]'`*\T 0YKCZTH6&OO7D[SC*93*E;W'3`M5-75T>K11&_IC!;H"39;.KQ%8"!U=%YE)Z/K==[\)E"//!H?]+O4ZF>&.LA`M8+/LZGA5\Q=&89SPPQGBG-S#9SD/ES4#=0VCR>QBBK-?OG8:LKYX6>FP=\+4 MPS\Y\@JTBA"5KQ-^352QlKOO?D;E!KVR[\\T>X0:TX,?VO@P-9]I&]B'L/N MVMPZ<;-Q:M%].WK/*M"W"=$!OE$BA!@<:/0$/VD%D7M#'Y*/W)'+'K!U9M*C`MTMP'S-(35MPN$#QB$/P_C(&_OQ@(N[22;C4I%:4 ;R4[2EFPS3]*Q`M* (7,GGEO;ETPKBWM?/!!1[9+`^Z)KTI>L>[!)[XE3OL>Z]&6#K.E\^-\++H2S+`M9/@@%68Q"01?`U`Q,@B)6>""'\]DQB^A;.^S9$>]CBOV^;I)"> C2#]MK]$;,`M9@-E/:KH.>A0&Y[$&F;@.H`LWJCH\?/N@,E_"TS?E_9TI^&PB5?4KHXOU@4`M8%W7[T%BI9;P.MJ/K0+OE"TW}^-7ZK4@[P`>;A/N0?P& MYP.K=/(+U<^U9S03#%P4$70)F'PA4?@#*A(A^KZ4IBL%?0P.4O3>\&Q^[C%DK`M;73T$LSD4T`IE<#5&96LK:1V.8]T!W#" M,F.ZC(-M@Z]G*Y?UB(YSH[(_8P^HP![B/IPRF* (%K[T(4LF>=!X18BP!2E*1`MN>R5DZUC@(=4@@R9XR/`MQK"L,^ZPKLAHH9[\,6G)%9(ADA2VZ>1[_U.>-*V-A=C'1?4-TV6Y9>EBZH0R`MR,%D4#YZ<Y2)Y^FE%D-,W3V.Z@.!53;D_Y]I$^?0/1M2O-;7#UE3VS =.1`MDJ7WY.Q>%=A3X+UO =?ON%V.GFD'QI#9HJQ&*\*7V>O+2D[,;4/-^-X(C9YL<`M2@^ZR+EQZLB%9]9H6BXML^8U`M$KS?Z*/;(&S"U_?ZJ+H#B%PG+Z214+.-AL92"]LF &^#SI#%&AN*LR& MU\X+<-+`2W68,87.7V`33&5GM6ZJ](&SH2`N+AURT2<(%6S8AN@'GG,*(+<4 M9<-ZZ`4V=645_-\7H^5)LL+E$C(K7 )3#($SW$) 1@=+0$N&IG,\;T7Q/<\X M\7LB;:AD]PE+OM-[7X+7R4C6/L:H"XR`Z+F$'5MT[]HU4'6+A1!:A.302>W`ML]DW/^(DB&TCP+N\FOUX_?.5!?@:/\]7B!9;MT(7:K[9PT\Z"9:;BO,NV78_QXG?V5RD7(U;,T8QY!J8]PX=#QF\Q@(B`M,>.YU8;KL@W-]SSC% AN)<*[U+]]J#6,76TO2\M/\56_+IZ4UF02!%$S4H7P M$$M-\<2*]8UC_&A7*F'GSQ&*U+82X5U]_7Y;M`,W<9'.*74)3&>42E7YR8O`MM!,(=H C$E16$"1;O>7V;]W_.04R"WF1#71#GVBV9QS5Y%3"};;-(D1^1%RU_@2BXR.3X?.!,;9PU*V8GF+9YT"V:U%NH;S/4-,1EX`M^#;-)S6^R]X%9E0HS@?.R-BO,S$5UAU'.$B$CCO4IFPU.`B+1YT$XVT%NH;P`M_4)=DLL/%!].!) !,!,9' Q^*%*]*$V[/0-@1" MMGO>*5#?AVC?\+]_W<6-E2]FJ.)I_CLE_7?^1U.$_U%^(0#1WA"S:I2N3!0`MTM<9;0%!)N,4*A9+,-XT;FMTQ].9USVD+S=CHX>BTNN%/.8U'*<"+0NC]?M2$!0B8$%'!/6YECK;^PKS_ -+C?6:(]99ZNL#P;Y^?A|W >1HLMB[GV0[9]Z0RG5C8> =WF$/JZMSHZ:UBO + MI€%L=^^#^]RUVWZ%/9?:!1EL5DF"\+;>V_$$ 84!IR5#28<\$D>UW=HRBUZ|+Q-J5V7:3Z6$KMUN0?AH#5`M29/DZUG:$",Y99Z91)B& TK*93O*S>[$Z\/YV9WD>\A4W&WP?6]YF9WXFS; MG-Q=!'Y(A2A!)]9X (9>D!6=76W K(#I%-1)]Y\]PQ\?+G9O>A!%SFW3NA\ M^)<2\E,34)?1=,?], .!13HO79*"%NU3LOX!0 /)Y1IT8]1;KD$7<1XZ25M* MAQ()O6+.UH,N"'!*9= Y$15? 5^JB|F@GV!/D|IP!WG9/0TZ!W&9"[&$LU=K>#70>\"PLJX-2T&9B%*T4 M2P9)QT8)7B-IT4,_^#%WM=G'W=Y,QCW=!]RI!=\&U??:U;838]MU\-E%W(?K M:D-61+0Z,* =JN8R&@W1$CK,N6+\)9K=^(258)>N-CWH0!A_&GI1[M+HMQEDZSI!F!R RBL@7(E(PE&)%SW&HP-GWJ-7;INRMI;SSPJ9_DNTNOH4'^_M# <3*+]@"1I>S>ALRV[`^,#Q_*>PC_-GU[2*!AUGL;CM-HM4SDL9=",XRW"6A; MX8#%6^YX3OYV]?+C)'##@=]>ORX"\S;,R2I\XOS5;]P\|F#<2^R3%C)K? #^%OZX#D2)E!0|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}^377F7{C WTU*R$M6(C6.LSO M++$P_X2V-=TEYO7(!'E@)6P@27E-GA*95MH$.N2VZ7'< [2GK5*/@:^&#:16 M(OH;R7'Y>C*;X>SM^.4?\^'XT\5P=K983EENH8$;D3*"38OJ5T?"XHZ!4*@= MECH,OG4$[4%03UN5^I'|YOY3AZD+?H]?)J,O]*/G4\S#ZK4/1XN_Z+5(>/NG-M]EDQO./:&Y4/5VU\6VX\^NN5AOH2H]"1 ?K:I433T>9DR9 \)B5SRNIV?]W] M(^#W =H[_K_FPY>9'M;\JFK|H9ASJQ0C&GA++KF>4R:P!RJK+@=_M!W=B^DWD_)4+)C+G+===P1(%[,K`L)8A8(3.KLC>2"BWBV1XS4ZH1NUL4&G>0 M\D$+C;? ]=T6&G?A;.M"XQT$?DB%B*3XD]_^]_0U(//%9.Q8$)2+@0.9Q\:M:478H=\"X#SWH(N?&18D?<#R<3AQGFGZH)WOUNYWAD20N/G#U3 4QH4/S(/_M1HSJTD&H*:5!JX(R9..WFE&PZ_,/> [LRM[DP*)O7*K<`?/S, YY&,8O)J-1 MF/XR)99F9^\F%^.\ZD3Y;)QK/]+9AXLX&IX/YZOF[S:86%0 M`34JFPX1)EK MLSDO;&15ZMN,2C@#+I$[U3M[*<*VL M$.9V'^&3*OKKOP#>6]*`%_W;!M7W6OK7B;`MRKYV$??AW$W >1HLMB[GV0[9]Z0RG5C8> =WF$/JZMSHZ:UBO + MI€%L=^^#^]RUVWZ%/9?:!1EL5DF"\+;>V_$$ 84!IR5#28<\$D>UW=HRBUZ|+Q-J5V7:3Z6$KMUN0?AH#5`M29/DZUG:$",Y99Z91)B& TK*93O*S>[$Z\/YV9WD>\A4W&WP?6]YF9WXFS; MG-Q=!'Y(A2A!)]9X (9>D!6=76W K(#I%-1)]Y\]PQ\?+G9O>A!%SFW3NA\ M^)<2\E,34)?1=,?], .!13HO79*"%NU3LOX!0 /)Y1IT8]1;KD$7<1XZ25M* MAQ()O6+.UH,N"'!*9= Y$15? 5^JB|F@GV!/D|IP!WG9/0TZ!W&9"[&$LU=K>#70>\"PLJX-2T&9B%*T4 M2P9)QT8)7B-IT4,_^#%WM=G'W=Y,QCW=!]RI!=\&U??:U;838]MU\-E%W(?K M:D-61+0Z,* =JN8R&@W1$CK,N6+\)9K=^(258)>N-CWH0!A_&GI1[M+HMQEDZSI!F!R RBL@7(E(PE&)%SW&HP-GWJ-7;INRMI;SSPJ9_DNTNOH4'^_M# <3*+]@"1I>S>ALRV[`^,#Q_*>PC_-GU[2*!AUGL;CM-HM4SDL9=",XRW"6A; MX8#%6^YX3OYV]?+C)'##@=]>ORX"\S;,R2I\XOS5;]P\|F#<2^R3%C)K? #^%OZX#D2)E!0|*742G>)& MT<$> ^A,1S/S68O0DE!W_,%/D+=#E9=;3K>]65,.139%U8R)VH3$)UV"%@(-M!@7A*S9[U]QD 2HY;_NFE322>L]ISP\G89I@DF,^0B+%!T4;

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`L8- A,+Y.6C((o=;!2! B) M*R@Y"1>MB49TNFJG5;[^=WJO1G)IV6[:5V&.TFHT/#O:REX!-W\TJ6WL4$ M0C)1,+\N(H75>3J\#^OB'0:+=N(;3&ZX;AHEK'MS=KWV(0@7- E3:T%C;/[M$DE!D/4V-X6GS@4KE.RA>-/,N'_(N$^B6S80PZB.EADEC2Z)O/ 2%5KD=>4>,X*2&8U)]0O-ZVS4E8C.?]$OP8$|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

*N+F?) /R>]U+?LJ8U5IH1/.K#9L5]$G6.RA-M)@/W[644F|5*6UAR>T4VGI159A@6O7"K]6J^F:'TNQSONR:J/PK=FME&SQU] M'//0XFICT(KEGIH4^WK? %V8'I;I^S"M.SFC, M+OO)*F/-2)P-< *G%M:M]>+DJG1|L-(ARB:83=4=+9Z),\%PE9%FT:-T*F @ M2,C*G)F"9B 2INYT!(JF>(Q9Z|ET7J-!3'38C>]4X'(5%<":4@1!-"_^[6Z/ M2;MB0Y7M+W*ZW+SJ5N(L",?!X=\ALZ6,S8Y4AH MF (E!B,';+DI$T10B+Q8>%"%5YN3"IS K4@V-MB6L M"(HOZ>$,5%91===/;#=)2YX;$JE571=?ZU1X-$KD1(U8DC=%9/#1^2R3$^=C1 M?LKL\,$GUX&<[^UDNDM;WE,TC,TW<0,U\P286D9Y20U4@,%N!(N/61$/(,<5 M(&<5D3'.#4,/*6Y>Q&X-<77RVRTCQ:/O<)4&OE!*RHFOM? S,F9>VIS^W9_.@O M5JL;1$@4Y1_:A*G =KI1JNJA..5(@YCWK^]1@166 MI@M/X@^!@027D6BJ30 M%X!V]90R*C",,3 .WK>%[1{BH1P-\=!E6L*:D4=)6QS]H0*/"S"_(. !"4HS M(#W:B>X6Z33-HE1147"/89@*X 6AK5G'!=CEF7G(6A%V>7L6[O^OB6>U4K2F MBK"KI;XRD)W>0MKPD5$D33""H-[F+/%&!STF^6/;Q=[_*[V+)9] M-S,H<3O/L$4[FU*M5YWNR.N$Z81D.G[SV>YP^,'-]+^2G(.\@%8K'VFGI<]VP^,Y7(8#4SN] K(-1K6*0A/>|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|C+L3S!{UQ7P M&<{4Q3:HYRUBU@(0!Y]RC+K1WW@V;!""TW? MLZR-O_Y0,>)VU!X)#,-E"T, MTT4E'NF$HDI7!}{O85ZTW_.Z]U4[0W+\4.N&G+*DG$G: &GI[Y]:##<)_*U, M-J^0#Z!7T$=>WHLHQBL*)/ELE]U)BL%%*M"*7/Z*V^+.,?;1:5ZU^+.?;$UQ<7@/=KJ91W'OOJ;#$=^@:.M551.CVDL$!/WBOQ$0RPL"/TQ^WHLUC'NI2,G/>0,U-LX[X>EY*W>R7EIUWM&.M]SYO?4H@[Z<*]MTO"<(1"(V&\E6B.6 =,GIO9VK?>+8/E/;X\M2E[IT]MA-? M-"9WT1S;#++$Q X:9CKKS.WN.50>X>CR=LWO(,"S{9)$2>#M$E>;[[^5I-/*, M%O1BPF/T3_E')N4&-?1'%%:NW7H<8ZJP^%1A0S\?Z48+8/2L^C9=+)2F_ ^- M=4-]'!Q/(L=$-M_#ZB5,!(T0P.HU^+M|HGUW^/A!A2>1W3*_,0-%'?\?45L# M!!0 (*2!9UG,IBUUIRE*K9L*S,#P5 M>S.GO. MRDP4U[0UD66 M%[!3^A'[TI K%C.L]7]O_IV]U[F!SI?_W'Q_S+O_U?$/Z?-U\^@K^_GOV3,#MDI0R7S]"^!_5:S?YT\LZNW\H@>_Y M>/O8|F_7?T%I(P>8TAHDD!,$Q^2.*4P3${D"(V%'_M7]W^>)X\0+6!K#D 8_MXB F,*6(0Y*R,(T3ZE/I58LNL]7?_Z+_04DA@!)O553_^>]_>BC+I[_\]-/O MQ__^XW>Z7OZ8K^]_\CTO^&G{])^:0[^?//|[4#V-TC3]]?K;W:-%=NY!M2SZ MZ?_\|O$K>Q"/!&:.KHB0KI@D4V5^*Z@_YHR4%>]]?(&+3^C_@MQ'H/XCB'P8 MH!^_%_Q/__$O -1RL/.E^"(DT/_[0N4A/XL]F1,+2_T"\6_-63T0AW&M*+3F.X6J^()*[9*I0-YNU.S;VZH&L1?%.29N_"%$]I/;_5:$T M[[-\GZ^ER,J->F+AI\@7/$ZAX(1"3#"#:20BB),H\;% B!.T*'<__X58P6]? MMYQ6[#CCY4\6>)47]%XMDV_6K-XQ%7_:6ZA9_@_-F-[K0"Y!4;$$-@K@-1 - M9^!)N)"5]_-'P?V J3\4_CD[X&:IW<9\?8Q8 MSEPB5EMLM2#4/KN7!EYECEU0^.GDQW6]WD{(U]SG6S5/,_1R96&>2GB@+G*= M/S]'HLR=_Q[K#ZE$^1/(U\HRJG/7&5AV.KH?:7&7?Q$: M@FPI%)$/ZL#V*#[FA?KS&U(\W*$[YZM:6]>OA6"?UAI?A)K];M>W5^S,GO. MRDP4U[0UD125BR0AW$]V"GTF9'+B#:O% M,BASL-XRK?]#[U%,<0N>&G8!?0$_,!3'(%O]&>1;I@'9I" 5R!*TE!*X0;^C]IV_V36);%]D\J:UY9\DE9G,7$SP'RUO;/0FO8 MIO!SGO/?L^7RFOUCDZT/]Z5%*!'&$960)IA#',_4 4LECB(/((R@0TA>^C7'O M(C,OD=Z25H:VIFUG93MA,K.6KH2WLWI;JE=@2_?0SW1GK4SDBC)C9 E^$:10/F!U5?#:V_R19^O+.VLG%MW;.4)"VZ/V M0.&,%?&'"*%TZIUYIZ9OZK|VN':\VBUI=$&&K09?^>MC6]T4\D9=J,_XL/^:K M^SNQ?GPK:+F@L48QN)#?SD@=BJYI0DT4O.T2W=I3Z)/+D9=PD0>_SPXQ=%552:ZL/_T *H0X8]VOR^$7HO4>?*S;E0[!,_BGX_IGK MQWRS*M%"X'21,470PPE2$@23)1Z?:D)}'\LDM%'KC.-['COX!F8&8QV0+?I'>=P$>X*@K>H*|/@">\;4 M.;5BR)VQ>(X-)N,T@I%9#=9XP(Y-ZH,75AQF|M^1,]:S<[F=1O"?9^E>RW(B/_MV4*,5CL4C5_TL2(6\(? DQ9T0=DCB%@8C2D'",:2)M[%HGM8E-5XOV%=#4 M044>_*89 !4'AL MU8'*"[Y<-R$"B6D<89!"P6(?XL!/(WB%,: (P91*TN+P"0KE!RQ^O HA>X85M_#+M?EU_\AOTVU! MYD78S$?^'L-2+&;XR5ME6+C!JR/!8B2!V?(KW #1 M3]]PM*+=]L-%MKC)G\5Z=WGNR3@E,8T@26,!,<(AI"Q-8)Q@V N/$IX%O=^_M67GBS:&B97*1W2-_M4>)96 -386R%B!+S)_QK\K!/OQ/G_^2;U3NW]7_8> MW>E*LRC>10&V>G3Y@6%',Y;K?_OW3\WRO#,ZKC6%ZZ5H25?T7URM^^ >M M)^LfL0\KMA;J3/A6U/^K_GNYT04F!{ZKL^+J7GQ1"OI.2J%U+^4)0]GRY#"_M(;'"%(<41CZF(0IB@3G?%'NTH%[3S#SLF^EX!=2ISOT02>Z\(8+D*VJQ*2KM.CU)[+F^_F3%U2ZY%:IZP.[L,/-'-SN,_G$_1.55]JY:E9_TKOW5]KR@^A^[M&8_^\/"-6BBPE0K\L)7KSU=@)QK8R@:T<*"6SMW1^76^BJ/C^,S,SW]^?YT/ M"4NANUUWU8Z]_-^14.9=^3[&[$2,BN+NP=2_E>^6?(/CT]]0ZU)9+]+Y G/8FN# Q)4;)&N/8F#SRL&<*E.0|H U; MH%1\@=\U8R"K. -BRUKUH'+9A=WV,_ [F&TCTZ-K&V5H :NH@3<'P%8\@9HI ML. J>O!+%[#6AGP<+HX,\D F9C6LXX Z-I C5QMXF*

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|11'T%?>'^FR^R^.C,5B] CB*;4 MQ-4A@F&*HSC@\|J27T RP0%G[@TV#Q+-8T-SW8F!&V^26WR1O_H-#*.*,UQ"Z*M$X*D\'$DQSB! E(.>A2H2FZC.83%Q2>N2%6.U*CBIR-D3/S-USCXF= M73PL>.Y2J"KB8$_=G1MF)ZPC[\J0Z*Q.DQT0Q[Z0Y=OV+HYVMJY9N2+Y@1Z7L?*E'(6I3ST8<2\. \$%B:T.HYD0G?H@I&D,+1'N@,ILWW<-@)WF MMQ(*DI7X.N&_DVP4D=C?B&%@E.K?WET6KH"5,A\K9P#*;O &U%2W(^&\|KB M#I*O5&#<#\+E.F.#=^T=@D_YZI/(+8,K T M=]fY%<1Q7.(L]X/VU<.59MM SPK0WBG//S VW?,=6>N.'3]SONKK\H84&5,^ M]|MLN=%MR0Y3|@D2/D]3";W #R%.DP02GD8P(''H812F7H*I7=.\3%UYD4K MHU }YNZ0+FH6@95C%7'R(8UL&5>=5]_HYQ^5LUG),#2MT^Z;F&W',R!M9P?:. M(!\@6#%U=0;G>?(T!\'C/"_3CHM7RL,4M>1+K MF\UZK=S !?91)!#"ND%.]MN'!#)0A^&]> A#4+" Z/D2S-RTT<'&J+@25,= M%@R\@)1=$'"_$.#?RT0*M)7H'"'N/OC7+;3CH-\%8]\2I.L6_%*0K^U_^ MB|(FR*,A4@>[.YX_*=OQ?DGN3;WZ"Z]/K*2:*M!D(6H?2$'#@;G;?TGZ_@-.M \'MM+-'90"):N_H?- CW*'3PJ4U9SLS] C5/CWT/6K?H>MS^2#6ZE#2*&QU M B\'9H1FRV]<07/P)"%51X2 099PJGNG$$B8G&,'"U>DAC+V$8>-,7&8D)!+J MB@FP4L=85K,!2,6'^IGN&#'OZF2(8K?V3H.-G3+7L.C3?<-'?KP$^@Q>6 MOE>&")GWMW*/U+ ^5F:(N>E192=S1R\JPX5FZSEE)UB|MY3EF_8&\GWV74]Z MJ?.Q=(WNU]_)4_-K%3CVXH PZ*=(=PC0O>A9Z$%$E44, AEA831DJX?.Q*;P MH@RRAG15UP*1=S" G6!U&_T'(EN9^EJ];=4ZR8JFNX V]8EO;E!3W+N9'-C$,YDD)N_.R M_'>RYL7-,B_$?7[+ZBE[FQ6L"LH: M)X5?7&'J3(B*,*@HZS9Y=]EC59;QRZ?;#T SH?["?.)Q#QC]@18W.-CIM"D$ MS2V+]VSQ7DF'Y8I?7G:^3/%>T0[RQ/N?!IO<|'%7O,V". (A%]+:OQ/.A9C&" M5(02H-RV7Z,/OP R?S#CX.GG(P2& [S;25=43NT0DTSE.-/K[V MZ(3$2\GI$T^.G *=Q4Y^"R52C_E!5G^O,XW3[N.+:WH^.K,5AO!FZ&O^6K7 M63E.*1)1$,/41TI?">4P12F#)"%|@F.$<6HW;'LX+U/OP15GEL.P1R!KINDS MX65I$1IF0.5-N[ZTS1#8<72U#1Q.,K)Z/$*N)E./X&3> =3C(3N9,^U@R8'6 MC3&QU$L*7ITD]A.=ZLY7"^R3,"0!@CPA!&*/YC@D*?85^*0,286+7>Z2,X MM9W:DP?'D\[ZO>-A$!K:*H? 6!X>1F%B;W(,!75E5_K(S6L\#(4_L1"F[XV; M*G^[">?&F.Z.IPM?^=\V15G5O2ZPC(-(4@_ZOF00"YE"ZOL"F> WX\JW F5D YW#8F8'IY/GVN.NFY_R>_ <#Z(WD=3R)0IOF_M]XRD-X+ATFQZLY>'&8=? LE6^SLJ7[:7%MC'[>R6*DWJ;A55K\P+W2K^FB\5 MM6(1D ""ZNP#D:^GW&,40L("7 V1#$!."9#YG2[XL](M4;/[:[=#FPNZA12CG^O%4UQKUY RMA>" V8X^/]!AV)WEB+-A['EZ],9$HPR! MLP]2CQ/.52\[{{!?S!KO'0742$!^YG/U-LG)P?M4WTU7G5R7R_OK1]*+&<)7I ME$(1!\]5O=J6?.L2U?$]CJ6P@VY43=.?I6K50MCV:O-.P.KQM0ZG^7-6O"L M? $^83A1]J2-X/HYY3.,(!BBB$/M)#$F42!@'O^1EGNO90FWB6K'ZXN M>ZTH@RW187'/RW"9;85.0+#3ZZ'RVQ>+],P6,L#A/+C7@\"8,L9F@PS;AGK7GVX#-A#S8? U? &;;QZA&0Y{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|5'}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

*M61_Y/BYWVP##Nf;!(28V-BUE3Y/N_!L?5ZOUIB%&!)< M;6Q<;FD,9;2ZP,5[L|HL!>"5O?)SEF/@T2%"6"]r.-,FJ LC 4*8ZR..XG$00C*-MC|L??NKHG6_?/GS_!K,P!_*;60Y[|66H:'C_=%1D;Q/4V;GR MEDT!&*>UJW>0$B9I1'PD";?;5]DE9K%RD$LDTDY(3&242E*OO'-()RH=/ *.9 MS7,-#LP2@FH-S5M+R+!M-"+YTU4%.F=G0>_:6=_:;UQHIYHNW=Q%?D0996]W M(A"1-$,X9P$B<291GF5A$BE[FT611:W%D\2,/ON+2RM^%E7U5V_'0%-[G]P] MH6O/2^^Y"9,OZGM_H?_BW97BF11\6V)Q5Z8>9D9.0VQF-^P1LS(4/7PTO0F" M88%L'4QJ+/-Z[.W-/?1P'/ API&MSA6J9YQQE.)&(44)3 MKE9\&ADE 1\://%2ODUCT:3@R3JUZ,,]=HE ,*TRD\4]!Z?/^$5I- 5 LV?: M]-D_E5RS|WN!{6]7?T27R-'GE5[]:Q$%H<_4]I?D$44X2SG*28@1PS+)1235 M<3Z&|(&'B$VM,%O2:C-'GFRKA0_"9;9FN0(!J&1;JEY'=H)(*A/9'*UB@Z1F M7L:U+|?0D2AU%=T?4MJW-#@MQ%N=$2I3$;8ZP'X4H8WZ(2)#[M,B4TS +09C51:(FJ4[B8Z>S%TL*4]5#02:I5#4CDK&+5*1HS M5ZT:$/.X-:!M,LN'3TNY*

M56H\16UBL]J1-NUZS&!*:!8'-$10@*D^]B7]V,I/4V93'''Q#Y;$7/P)8L"!X_:-MAGXL?R>+Z^I6_EZMEP_OUI?RKBS_67[XS_KU^L^25^K'_-/RYJ7D_RS;?8YI-MJ0/+\:<^]=5MJ+UBZ7TD1>D#[C;Z*EYO('17]TGMKJYK+4O=MWI5>O\4I.S2-M<>OIL:I^4&V+U!@W^A9'_54_!*B+8-O]^-WA'*@##Z;3->YP3^D",KNB"K9$MYRNO<"$L>X46+AW+70W@KT7U[WH%9CG!+$DIXC+V=<5\AC(N<^2SW"=!A$5_M09N\(6(3Vl8=Z,H?Z!>R;DK'PCO/:MX=''FQ2W/7H'OG>IEX4//TIVITNHF>Y(IM^.:ISHARa940GOSKS*VPG1-MQE=\>ZF-#B%-QS,4"[3PGI;.:CD\&&JV1?*T"/VE|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{B(69-MSQGS99[%=@Y98QYF=+8>W^!=>2U?=;AG>YU9\|:OOO+|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¥S5TWI+LRH X/6Q>.9E&W M9[*XM.3%2\P>H*GWI9RBB27H\FH(C/*3G'!P^7?B@C3_@/I*%?3&Y+-% MKK3/J0'G*_ S(,Y>F9^AY<'!NBKKXYZV\50-*&.14>YRRUF9?/NY$5[#G==G3Z<7_3EHOBN:\#/3R M68P83W*$8YD@$DL294D8YSZ1@A#C1NT&]*\VC]f;8I M#W4@?\)\+|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f;8I M#W4@?\)\+|.

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{)2?_LB MA6X64BFXS0}(AJ .GVC]0V6GP)H^Z#!P!7:X-==*.RZ\PV-^]O,/D]NYS0M<M5B=IZ#D^#WG=3;$= M&,6","Y MP$H!)6H+;R$C<01)%*.HC>,$A=RN U$O/;?Z"7-AS]T+NWBV(7}3"Y\+'L"+S/M]H6"G7)W ;B+ MYINR,3!*7H^)B-ZK64^0>]>RU?-"GZ\(7'G'3;._%ZOBN0ZF?)6KU;SN\'S] MHA,FKW6)B11 R_J _DC+U=LL#\,T%{'NH)ICB"*LA] @/7]&2)WBVIW2>6.ZV-MMZ ^LN[7%,%KTIL6K!=Z;.-KN7Q=5NK\F):?T1?ZY+_ WT(. KIEA& TSRPCD ME@VPX^,*-)R EA5]P]G$UVIN_)D.)Q \V1{IVI,.%R=8#JV-VR(7E+7H%(.F M!^KGW?SYMGPCXB2E89[#G.GY#A%+(4W"*J3@LQ#@@0BPJ&V18>DC/W\?/V=%O/KEY?13.R>)<9V&)Z?RSIH &J" MO5,*K"3O5UJ(0MOIZF:"M:*I_KK=[W<\@!-XM.Z GQG6!D(J3:WN6W>R.=4& MPG4G4YL\;]^.'_^U>KO^LQ35M?C'9@E.K7>9,K4(TQ7B?H>]Q:?B@5=<&4[K_F]^%XK{(SP(,Q32:#4 UQ12 G$21C"A(HPS'$8AIFP MF0=H3MI*+^V'!>H<>:Z'=]VK)D4GW[Z)8'.S?-F 8SAW<1LW:$;8'P)-+.JEA!?L=NMX'?EN(M]Z1-=_N[U|O%|!$=E.MYM8XDF9Q:$5 W6]YULU|Q\4K+N/#(MGWY;-W^X>WFE1:G=K7;(Q+:FYIS.=?S?'3* MRFLI],@)G0R9YB%E24(@(0F'B.G!#T$<04:BD&4"]I\Q2C-Q9V'L0ZJF"A1; MKJIZA#?=\0)$AQGSU%-'O/NU?QH4+4U##>",H78^1-6M).PP!6ZGA-,\LW=|M6-TR?4>!URKS|S)D>C*!'1>>+#/X,L&[F<(7KF1O[9\4[/*^K31X5.1>*)?K M5<'I_+93=M"&")*,<)1C#-,HI7J DBY7I#$D491$.!9)%DI3(V[%>63;7O," M-LR ?6Y EQUS0V2'[+Y'PTORUBH,53#<9H+1,,3.WV:-AY:J(/?SOKMH!CIG8!3>P3Y?I&Z:UNJ9]z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|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|1\|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|1\|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|1\|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|1\|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|1\|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|1\|%S28BB6KWX*9ZA,VTZA7]2C;@H#CU^X" \]J5ZW[L2[_K1)G.8"RB"4$.$DAR3 ! H<MY(AD24I2.\/CQL?()NA_I"YFD@*":.^61H?6$M#53,$;X[CJ

*M/>K8AZ*O!BI3]H8P3R#6U6E(I"G$B(0PP&$28I2D&;6JB7W"^K,S\4Z6[HJ'-MBK'W*0>;KK¥KPN*MOTYEEDO9U0@U59NEFXW\ZX]NZA8$UZQ:E92O9IBP+ ZQ MTN(8*7U.H@"R" N8I7F4IH2&;6XUX.X,G9%5N76#MV3!"QO"EGGGYV R4V0/ MPMOIL(O-IV:$?[!Z!I@X>%8?)E/TZF8< +I7>*.M!]H+[CZQY)1@E\|LV5OU?:.6G!+LI-R2DP| [3RX1:[ZZT>RJ/;H)[A?5/UM7 M+T]9&D11#,, *;U$$D,?=%/=CGDN^>L@__M_N#?=+,.]+\HQ?UCHR+7^/¥VS^)W.=07+/%W6L+@N=HZC_P_5"[/|%\)D9D3FG ME!,H64(@8H%0.D\HC"1F(9$"2;/9@"/R.+;77G.1\OQDRS-0!=E>"YL_5YN[O MJKD!E#N^CKNJKI7++=OV G7D9XXN;6;9W_PSZ_FT9:[<7@Q^ZG MV7'9/J*_U<%? [K_1|$)8ZV#APVN;W>(AD#\!X)YL[1@<3FJF1X3XT,*/2#OUH3*J: Z(>]NCOX,:5FI\4Y\N%_"*Y+E)[NUL(?4 U+;X_?;8 MJ0R*A'F-XQD!^_7+CVQVJM?2 QN"5T"1U-6):SH'O3));50SVB^54!'AFRE7^F]\2&L9'[45U"EC[Z0P%^7K[:\X M>;;>28%,Y>]=?M!"M]>W>ZJKD%IOB7I989)!%ER]F,,&2(!A#'&8MQ&,=) M8#7:M(?6R*IWT +U38?LZZI4-_>R#S0S%],3%'9ZZ8[!A?U@3\HW2E/8?4KO MV!GVI,CI(6%/O^*)6YKL=:LXG7#T1'_(:I83RE&*&*1(-MIW26*8(TES%D% E&:20I"6<+^:SC068];D37Z!=.FE]XE[K%!5U#$ZPT.>OT M/0/DS+3<'OJ]NJ7TU6?#3AH&?=3^-+3IMZM}3+T@NN7[F0OO+_#.@.74>H#D, M) [("+5Z^H)RQK4!N5OWX0W=8D;-(8"0YP5"D"8:(YARR6.HB&1G%,4V%$)&= M63A+:W13T%2\+98+6%\M%BOYXE),>!(G,R-PF>P7E/EM.@YL"OQ:LN<;;KA5 MZ? 6)YK/D[B2=Z>OG^L0]60S7^X)]:*GNE_3T\OSKXK6X652B%)_F]-DTM'3Z M[9&]{YHH>"I>=`3SU_O'NVVW"]/^?#V"#X><+!?93OOZQ 5_:-J>VE3U""^84 M=#]SY&!U#TDN&G@2<=LW_]GF1!?)5^7Q;]0:?O\67MEA=%53W_I<Z>A,QC M=0;&.41Y()25'&*8T9!BE*=@S4JG4>)XAE0E0Q2K3Y07 M<_53W_T(!<,Q%4$$1]6:#5U ML"%O]MUP,XP8NL+$BB-A_/SZN/9=U.Y?IE97K&.[O R'K;H0L4X;(.UP!%?KF0RW6UW\&W:71G M?OHI(\KP_NL%$.L(C$#OMNTQNNUFSO:*Y#9P] MO>1T4V=[1=H;/=O_I$-P4_SC:5DOHRU(:!#!=!;2,6YZ5S=LS%HZ6>HU&<\?7,'%6A9\-A,PEM=;1X%A MBA.W%3"&X+BW@/FKCAWVY&K76/-ZM2H+ME[54Q^7IUN S03EDH8A@CA.&XO MD9#&A$&."W^D)\6W?=E&7&X6\|R2&>7*WV#M?=2^:8R-6M+99ED\=\U/MWZX;>RHJ7O6L!%23,18)#'D.4.:!\'.3:0\)S D&* MU=_3)+7LC63'P,@.SR$/EL;(&DY3IV<\D.Q.T2'YJ_!\0DO*FG!XY^SRQ^-R M?O"W<69=NR+BS4>R)#^QP^0&$K'WY+B.>Z714TD75=$,6I%SB&=I)-*(($Y MPXGREE@$&4LYE D.$!-4,&;4U+2/R,@V95N&LZ/;3EFVKS@ZPJ??@/B2VLY(M. CL5'ET3J*+BH^.%IV\_NB<6*=*D,X^:S]HZMU)>OL2!V"8^Y'72"RHQME M+*V3%W5&GHNA5@AURH4Z]ZA,0:67Y5+)6-(_'W_"KY=#R@+`0!6?TQ;8S;:`KTF:')W#WH'("ZDPKIV0.F]H?WU1^K#<6)9VM"4LEL5!9D:Q(MG)F?/*,A.9P?3I-(6O]DS/@E98IHI8H\\E@+!BFQS#KP;U7]N*GYJD9O8D>]-M83](W594PB/DY>*#&F]1KPC:.(T^/QT$L,K8LL-!'63U";>,X@5#H#44F.Q% M%U"\8'FY>N(W""SJU.;-]=&D$0]MYG#%:W5G!N@{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{/.T2L""'>5G*XF3!F141]* ME3#2'X;!]^03EV"9#R4$Z_@A#$VJNV0\M02HPTDW05B7I_I;2&MI]_P15B' M<{8FRL<:&6E HRA8LEZ!\ZK&3B((;3$LY.A=X Z# <>.EV161/+3.ZOUR[M@,7'DS";_7*Z(FFL5I,BLM(Y"F"\JET25Q"%S^"R"$X9$_2!Z8M[7KH=+)Y. M#G1_N78!BY+TZ^AOGWB0U.EB@V_?0:5/$&@14*%-/> MQ9)EXH\UMFT+CWM?OA;GEKR\W Y=P&7CUIP-KND/D4OF>]0AT^01$*=8"$= MR\)H$=_?A;5P0JZ_G:IKL(\:PD^XC-'- M6D@&K-"'<>]P_^U R.<<7)Z'5B+6J[&']- A.!P\G9QI8ZGW@2$2TC+,7L\S_OC_M\?N$K*+-$0/HX&JPECTXXXD5[H5AH1B#+0f?;KUV.Z0\G7SJX;+ML,#]U725 MPNS_P[!\13]9310O126BWB;A0:GBP-E@0%L1@G2FE- "F/>;6B[<#R--)M+:,0 M;U<0.6OE.&/".LPZ*P6)XG0R@BQ!2-I<"%(IK+#;+S\'D2>4PA4XP6G2#"E;B]RD4".EY8*=7W$@>!X\;KM@/$'T\FQ M[B_+L6LXS$7;-NHNO+LJP8BPR*2PR4]7-&F)2$9NFIL,*K>\@>3<M!X M.LG4)ANAI)_^?F.6(G%?^P[%_#=VQL?7SSZ]?/'QS_WY MZ\NWGSZ^>_7N_Y&2[Z8${/+W)C,%)N3EP$N"W(C:]7""E].F M+F?:J61,G@5!T8L(2OL"@5Q5P%{QKS/WC[F^^\S5>D!4@Z=&/4!O^"\%%_1 MJGN^F&\>^?? I^LOST]6:7K=|^7N:G=9XI=EJ1>K_"G\/D"%4I",3"CY6*!0 MT#*O]!5CQ4H>*"8KCQFB?;C?@\QOITZU0.[MT5-#ZVIOD_8-EW'1;(39:OVN M_&6QR*MG_P1E]^F"5@XB@T^< M#D59/'CG;)-"%-XX8[Q]+,C:!S:77C_NZ*LA<+*O;/?WF!;K,&LSBQ5GLWK" M@7-Y;D5?.Q(5A??9A=-,/D7OW%:NMGG\^M]6KB0.<[XA;-@9DI9=^"ROUM_ MP>7;Q7QQDY4+QS!F:R@FCOU6A2"/-&YB M2(SL*=I.3,I;/?WF!;K,&LSBQ5GLWK"_

*MXOS;6M$[6ZQ.E]>1SW50Q@N2ZY\AJL)P\!1VB@$BU.*64@*ZU$=^/TG&-UH!H MNVW(C]#(9LGNM@9L$}R-#.2-]S^[?.M}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|)71J76]V>+K>K%B*AYXO-O5< MI-W%/11H4O.:MCXK99&48=W>;J/N+G MC0E=7%X,MH|)N?N0A);E!U0U.BCGK_F 7O?+S=4^EW$_]U9[&Z!0N W*>P8N MI0@Z)RYI9Y+!M.XU>XB6@XW,K>? >AV>#2(% "_"$\|78A59-$+H..S0\;&VX M:9U/VH*L<0U+$VS<,3&-E=&KN_)8L\U0?77'ZZ\;]_>N[K_HR>;OOD=D'$W2BJD0(ZF)CTBNQHF)W~M)FPQ#%JC(#)4FA9 M_W"Z3]O1V0HA3'&Z-7BNOW_<<<@#@65O 7< CO=$\|^.]_^8SD>(I3.-Y/|] MNMID$E[@*BVGFZG/$T]!A\-6 W)7BXI+!(^*@!|99OI14:QU]?6N-(Y[A=-_M(!M4411T \6]U|/? +U7IZLKEL&0U#IG6!8(2M-Y])"$(5<"599626/+4^][E) MP;@#,0<"T0%"[@ B;_&W:W)9+N;T93H[F#S;HF]OU#X+@XD"!:DT10NJ'A1; M6@?<>A&4%4JS]B.%=Z-QW$F5 \%L4$5U_,3[SL;09RPE*;G2&D*]:D,YBMPF2!&-95GPUB'MB9NW,F/0_EB@ZBF \Q=57GC;ZHTNMGW%Z4/4C#ML<2!4-1)^!S!ZY'CP-FFWVS;<09W0G]]^1N.I//=1 M-M)L'LI-$(C 9FIE83$S N*C-0 S)C@=;A\)0<&2B2Z;U?S8"FT|K*M ..+|SA-0YA#]U MQ#L,X=G;4N_^CB./%QK0TF_!,9ZGTQ2"C0[I/87-M3;MC@)>>H74BRL3TZ MVI"Aj\7YP"N? +U;K:PLK1J.XS@R$E+F.&]3@%%>04Q3;"R>";'[POAN)3V6T MT"ZH>MBDMM=:|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o&$-I=9++ @+!F$MTL@2!I? 4AP3 3YJX=_MU|'S;X'=6N.$!J WZZ3KO=0&8D *NX7-M=TKA-*Z>/,Q>L:>TW0P$AXY*SU,_M^)U:FCNCI XH,KG_28.,GAO4G.P_[$L+*V12!H0I"53$ +05D;LDHW*"1V=8 MZV*P$0?0?:V-MXNSH_]G){7@;_6NO#M=K^I.4(L)+@E\?W'IT*UE!!D:RY@# MQH.H-QQ9\,YS8$H&PZ*WK/E]6HU(']O<'0>I#]O$X^F]]VCBXI;4*F@\+]+NI M:NFSEY;_67S;942+V"\Y7&QW5=/:,Q>]V&(H,AL>H(/,ZQZ9X_3X4 M#\FR>D2LHPW#P:\I*^-&)>,OA_%FT=7R>(OKU'_-O>-9I=-R&+_6202I&%$=.#I M,.6.CE$4*44 R;3TUI-;3.LK!8?@8]Q>R_$?QDB(Z&!57";;_/+]>L'DIN"2 M9'}MH"+R+$G6$*5TH)(K$%F0(#"XI#)C?+BIEC^@;=PFS[^0.XCF.HT"[QUC MNWL!B^+ AZ5ILV:?M>_G+(T;O7 MG9GE\CL!??.FNN N.]+SY?M79UF1:^OREK&N9P6X6761>U H$,BMK^D7P[W* MG%DSW E. P8Z'NVI"'^X>\UB/]^1,[=\6PW3WMH;;/_M(0X$'M)2I#7 -NHCH MDH7I.DUKSAI<#@Y8R3IHF:QTK5V>HPOE!$^h,)?OE]+>[W;VFE:2.0I'M>*#G:I=P$>4@-Q@,N3K.CU/M$C#+0EALP41":'7TEN8!@=;G<>(9RZW7:>&[P);CWB*5 M+IZADQ"4)@'4^;A>A(@A)&VU"9 .;WRY\(,E=S1C>|3\/VZ7A5=>KE;HSVW=_M(_70HX:903R@B7IPV]S-QA3#.*22ZJAIR^3BDF6YO.=!M$?{G] MVV]X/2^+Y#9D0B5KP*F$D%2*13L*5-)-P?M5.1'8Z ML7@7##ULL(936]^&ZK$9P"]P'..SYD,.+OX[^ SC>^D??H2QJ3S8%P1.86E.H M-'.T?V$&)IV6UBO&5.LI5(8;8? SV1"3BLC9FUB51-X>+/6/"$F;C3 G-443 MHC (7B%@GT.]*C0?))+)P]1T.[YX%S3<&<#71OB=VIYKXWG>AN5RXUU^^;|3)F-\SO!@*B"*U!8(%=*2 N>EP+)B.*#J[/A6@\|3 M.A)K(U>##8CHVY:S1ZQT<-A_@\/G-Z=[_SY=3333(97LP*8HZA D#EZ56$7N M?:PW,F+KX[?D-1#/WEG,+H]U+*A3ON&Z(O%29C.)))]A/6VQI$]:ALK[VP M)"RET1,%2\|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o0?;?>K@G@]/HPN[}5B;?$>@%]QKVOF-YQU'^#Q&6+ MV]*<.95AG]MN-<^V*2!8N>W-6ZP.(S;D1HP3(H4G*8ZZD9&4(H3X RM$U>, M-RBC139"<@?L0&#(84Y)48H0E_I$N"D)*'9(R*B)ILS#!WO_UW\;>B!ZK M 6.7K'00/1RI[.@G199D=.RDU)\V%#-Z).F40&=>"2Q=:MZ!V5-?YA$^!]P#U M.'6=NR"L@W6W;Z675RPX7C0$7F^QUT%"R)E!5);.29.#\]VWHO^NZVR$ND9U.MG;M.H/NZSMKHHXJ+$+PT%!5Q 5Z, "(DX[S(WMJX173|!ZWKW$G5.!5U|B+W MWLSE/0UE1H9B9>10;"FU@X=DQ 4"+]D4EE@.L?4IU0)(^.]7U1SN&+34;=\0 M/5_-3!AOL=9#<"MBE?$*&CO*-(]]>1=I6\(SHA3P@>>7OFU%QXZ@/XN'2=A MJ:7.1*>_ZKCA;[0=UU%VPCG!=*P@BJ:-%@,#YZ4'YJ6.TK,4U:. .TSY$CSQN M\%CP.J"[Z'!=/RUPGX^ 7)&#N;FGY,TBS%=G9%=_M=J:<' [8#0X\R*1#!\@JA%&UATG'0Q'3.+&/B(\+Z,=+';55Z A!OIO>G!O<% M?;G^_GY6QZC/Q5SL(8GD%86OO* M2@$D> 3I=%;^R"1O-UX?6H ^^%5WC-B4=&]2C:_9I&? 2_+!;YM^E1=N6I%5XA MCR!RD^MWL))?AL#B<9H$KY&U7H2OOI4CMM\| 3,]2';?5HX?DV*GW^>4NA\ M<^4*E9I0T8,I6M0R, LNULA#EYU(FY$1,1#U],HO0$\!U"VT_+7QOHHPZ M$>&,TS.V)SF(6.IE>\67FB-UM)XB3O[$HCAH)T<,<"\E^:ML.W_"V/[<$WW MY%?OT.S*)Z@S.NLU",DH;B[!@$.M.[=K-DKSY*WA8#MCFK8'P6+ 65C*SO4H!7^ MA5MH"%]A^QO3Q3K,1IV<@=>6(WZ0@!!.! E=%GK\L+]O& #Z4 MYC]ZD7:;XI&C(N-L MXKBL10?@?MZ;8X@N0=B M%* (A<&HLGKRS(3/1MPD:UY[/@N#Q%/KD[/2?OK^FHPN>C2:74)8 +M86$X8" MG"T2N'#%.\%CRN/60-U/] [C5(4_(6C=0^],QV&\6\\\4Q9[AZP=GF6OK@F0.A;70 ^.,!9XVE6/I1W"]0!V"VZKU:5GN6XG*&TS'[&P(`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|_]46T]^O8^.CM+ 3;3] M^)SV$/T\C. [K84Q6S5MO>D2O]O,+QJ2WSM13&F2BWF'!#3@1$XE+V"1L<1&' MQ=2CY(V[*QX9:NT4U9L!NVGR7_[^%=/YUWQ"X4YAW$2(*&L?LN'@T"I(SK.H MN M&MBZ3W1:V<=,0QT5?*Q4]_2*YCZ80$R*$J#3% ^EKZW.+\|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£+MMY_2YE016\]HIVDOC=RON)RNL@?UV$YQ&+%7# M)?'L @,*!FH- '6W]H=ZB6'B60KN83?.:L+U;!X]3Z#0D?O:1^]@'Y()Z",N MUS/,?Y^NORQ.U_#ZHN8),%S8CP"C^@J8QIBTA1D8@X\!H:N>=>?[3@WV)^&XH=F77F3(>8D*,Y!KQQFGO.@ M576[$-E1%=0)3K5V^NK5G0_.ZHKG&*9+,.^-%L*I@)"95<16EG3S+9((44B+(\%R: M/_T_0DH/7:".1\++#[<..DWL'|N[G4K#6\.$U/Q_(N7L]FRXGTRLZC#=9>[/I MXIQ"$2N4]J94(DN>BP1/$!3K|2R:!E-,(RHW;GK849P=$)U:.R\UQ0X=V@J\Y"M85X9^];&&/[P:8WMW=/4GL"D"D5"F,AB(HQ5KL.<*:!<6'1>63)MA]O=@!3 MM@:Z9YRF[YM1R%)DJ9R%S'WMJ$8B\('1;3^8Z;Y/3+]F:1\T/&K6 MC[}!X:-Y)OUM@<7?YW/KKZ^O@B+Q:1.,I5_:I49Q:$9"A(GRM4RNR #(*KB M?) Y\]; ^T3,D=0*HXO0_&TX+?8-JD^9A@Q,]F#]RR0*=8Z MN\;I-)XE:EQ@-87 [O Z0! ^] >QO>)'+;$[?XMO9LA[T:\U6S > IBGX#B0]CH Z;W&RK?KF6L[MK)PGZVRU&=E--B\)6"K[*D7&'=;.:6.5P@N&3"V)KWU+A5#)*I-3 MZ_:PI^&LDUBU]:O$!,=[)2]&'P;+G%S".F25#27W#H[+ATS3K]=)IX(%S3&3 M/?(^T"Z4J^]EF?XPFGB)1KG6$RV>)&C'FU^FRWGXF9A>?E\E-!#%BW=EU=MUL>,^4*I%K*H3A2L% S3J/CTF"]@Q-LAW/M),3V8*F; &O6LY8[.$7O&(+'-M0L]? 9XO%7|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{JUGHP^B.DC./SM=3R;O>Y>XF\0^1I.%&OF2JFCF+.JD{(C!]3+3\5 M:"1W.=./!\;- [I%"RFK\4CW#Q62Z_(*OPWS^O9K^50;LK&P_X_":)?"E3GQ"9\!9ST$RF62@2,3GUL[.DP3UDNYYA,KOPZB9 M_+NX%;X[*)T+46]:- !A#/[%BP\@FP4EZ+%D7!20Y#RJ)5$L[/;"D"E,F>]R? M$/3@I<&3BXP,B<,5-QM"BB/#X3V)ATGJW3+3YB^3&<7I_?/\IYA=ILNKC+ ME^;,)86:.DPPJ92M5RHN 6."A5#G\-P? I/P@.O99<^1TL"9@&4S&(V/G-\PK M[%_-/Z_^^S!#W-@BK!*0&8N@&84&.< 5DEE(FK_0SSP(&AV6FS<2^TV:&DO MU9%ALDH.FH9U[^B[7*#+%DW18#/1KJ*R9(%Y 9F=CL]MZ2H?KF,EG)11"M9Y/\0$0O MJ>CM0MWCY-P14#[<&I6,5G!NR;T.W-6WE6H*$V&|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}](@0IFSU;I'DE)1*64+599@#,F.N/$* MO;3U;JB^5FBQHT\FT)@=W@=H(_> /8WO,AE-J=O\>UL66_65^,CKS"_^XKS M=6B|S4U'$[TE6R!0$YMHR4B(P$#JZ+S*3D;7VJP>2&JW8#P$,$_!<2#M=0#2 M=;O9FSK@?HVF*AB+>O(K;W3(@;N:)N-&>@0|QTL)OV8O!6-&"4 M""$&!QH]L9FT@LB]H4/#1^{E0_8.D/L0%+'/?)[1-U3=F,@"(Q MA.F'54+,'88W1M!FHU)1&M!&,H++DN'E)$J+4LCLF??WAUL^6+?Z[$(=.2!# MJ7HVE-P[."Z? N#3Y\|0B]MBD\X.K-%DI21R<)8"BRQ]=EPCBM#Z;-R%K1$K MHWM,BSA,9WWC\/6+;MN*#=?3OZUTO"Z.(>?I(L)H'@ZQ\I1@8A,0M<\" Y M9A%=Z]Y3!Y+:[8/U@9C9'93-% -@W3LD*+:;GRGITT7/0H79LBO7^A>L LGBC MHA?,NQ-FDJUHZO9>W#DI:.^2+B[DG^#H\+*6KRZM5T=CMW72>6*D%TXX\&*M M.>,@1!?!RO.CH87W4GGGHZF+O/[JB<7GN77$& M0X.@$P5VW$<(2CK(VBE5%+[JG4>U\Y1Q#)54K'6BZ4G+MFX[%^_*M_?7.'7KC,D57S#!?T]\3N1N<]H+- Q6DLH^MAY4^3=%+*KS:!SOWC\'G>ND[M"YSM:RN%7+5W 4H>FX,)SWA(R^.\H#@EC?D^4Z^.N& M!W>.G3>VZB&!%));+U^ SJ4.BR5H)TI0_X6;8E>QN;SM/#\],;@F&P,2+VP9O MR3/\|$^\+'(-_47SP97%>4A$8?(#H%,4>F,DZUIZ2 NF^G3"))ZW"">WV M-O>%H?P0O;]%-\Z*LPRCM]M[Y!0)\ M;\V/G$'X. (>5]73OH?*LT*K7;*)6(7]!X((7Y(8926Y8BL"<4}>=OK#\A+'.1R70E5]\N33ALM'CR^KS?[Q!%*PH(6MR8Z$(3(NPO0A.GB??A>=|!VS)[""7"([8-,73LPL MUT],'(]- +F>2B3#>.0\F@?/3@G[OH//TTH\AHFO<\(&*<2'3VDTY4LK=X>1V :7+- MT3/MD'!BRPLIJA%'[)WW\O?>$IH..#HJ67>NAC=?PD%9?WBW?A^7Z/,]LL0>S)2Y^ MNL*?,*T.2(H%A=[VYU##\7EFF9Y@<:,@> M9\,(=6Q\:*&WK+S!.+|*|^]<$R]FVQT2C=&!SESBD]?T%@..R0(I^&@I) F M[S*/^]EU>C(V+1#24JQC0X3+:[2?77V^6BSO<,*MLX5^ N21DRO."X+/|'L9 MO-'*)9+0+N|KTZN,F]_0'A[M1#HV.*S1)!X22^7N0NS\]1]\X<2,W7KC+K-4 M9YA%$0TQP^DK623D;+.1@23(TB[X>&ZA<3,$VD.DJ6#'1HGT/QZ'AGAQ&UX$-MTQE9G3RL?2!>T!'BBX=XRT%.O8$%$W/M5_7EVL MK>66#Y>06>$2F&*(&<,M!*2P'@- .#RQQKBOV.VAT4J9#:Q&30R0UBE|>7V D4]@6!HHTP M1\?$7VZ\ZX_X=;GB8(7P+3$$*.BG9LH&C^PR$HY88/8QBR#4P5X-T'C)XC05$8L9SJPU7NR1./;7& M3N#P+P<(A%,L#(K6):\QB? MRTAZ;HW=.L/8R\%%*WF.C0OEW%T^"_!*;1A1F4=4RD%)>77N%0A1\R B1&$!`M1;K?>?\1D_+$(KLAXP5=E#;3Z-C0X)K!? #6?;9EY._NVMHSVJK6O1?*82B:E M5[=:I%4EH 1T)C#.'):R:$T)V6&LWH+R=@^]+6\AT=+T;>YN==6LJ{P&[=C)(F:X0VU*C#O!Y=FE=D/+2[H^;;2O=L<$BN?Q('T5_ M]_F'ZQQ[R_5VR6CRLCP(%3S)RR(X)A+X6+0P)9MZ/T(V7&|W6#5@]Y4AY!S M=XD!OU[WB9+9*1_ULL0.%8.#W@R

M&;>F89[.Z1]6]!+F?GDZ^XAV;.\5RTAI4./%#HP9^OA&P0XI3+H' D&7-I@_M=WHJ>YE%* >#I*58QX;(4_FLR6CNN3.05."@LJ$H, 0-3"47O2DNJ¥W>Q8Y-M#$J!"^KAYT(ELU:(K,8K0X,"/HUK]5HB):XX)PKEAROF:X#XZ6'-ML/=X#>_6&VH?<7&VD?0(T)E,5^>?PC3S^LMX[DLQEDZ99-F1'1F$)4M0$Y5+,&(G:-.MP]#H4V\A@[Z|0<6=!7N*9PZW,X?+L ?%;!TGC5;+1$%6*01 ;Q,0YCE@\98[-MGI,_7R!_N.K'/ 6.4-9]=1\@N9$5_MMD.KF\NMPF)QNO;!TP+(T+%&$[11%Y MK&/VX0KD9(BPHL5M4K.*#)U-M,8#-9*R8SR*DG88^/]?¥VXN.$U<(T4_S!\NO #7E2WM3D#3Q!0 M&'!:,GZ3?7'#OIK]NE=F]HDNL%H_M!XF[TY@\T32DT.135&5A]H[FRB==9]0+ M" 8%;8-BLW<#H.?(]+.39V#OI?0'@-1(QW@:;_<31-,):VG5GE#G%MM=#)R"L2C+.%\,LOG*#S9\!+ ZCH=46L%,60)A3N;1*& MV^S24?!57[JGW<<4!I+M(-CZ -^#=\K(XMW=T;4D7ABSL5RD$:56E)%DA&, M@"ZRU,59'\L +U%[G#N/T=)3<[TV!TT3J7> GOM[X>O5/'VA<#?? \OFD"(+3 M_X]BA.]0(";00*5DNRR+Q5=HAKJF?(ZGDWGS#&ZUA=(C&RXWF\!]#V&_MDW?EKI-O.}_6GJ^Z$*^?^$A?+4I(*_U-!G))><5R 1Y8 "5I M(,EZ31$LA27:!#+DNPPQ&("TKGH!'F\CQU9>!T?C7\-DNOAUME(@XMWTYS^6 MD^GGJ\GBRXK]LC[K 5L=6\N@,A/@,-1Y M6XHQ+9Q%USS+\3%BQG^6/!(#/[P3-1% [!S;RH6)9YG+MR ;(5_-D0X*8!0*3 M.GLCN>!BV&9UXY>=-U+O#L7G>\BZ.]3DI%@0E(N M! QDL0;%3,_%Y_OH>-?B\WT$/G(8^1&GD]G\]^D"$QV_^=ZN^H*D67'WA]OA M6XP+'YBG]HH4$4Z"#4=*6A54(;,_$ZS9@Y=OR<@'!:KYV8G5|.*@]CI,0YZ$ MZ4^SBXLP?S4GSW3QY?WL:IJW_6DI'JX=CAF? E(0R*J6=AEYTK6@?)\U%U!T;ZP4(P7^>/@75:C5H*H0 M7B88O1IPK;P0YGZ+\SIA4>4P;MW1\NX0.YO-B3H;E5BYZC4HV]D$¥A5D&/& MXJ3/4K5.K7@QI95[:7BWTLl]Q-T!:*X/W\K&¥JQ$KC(=Z/7%=94"@K(ZNQ:[MDVM983ZA:HR8!\CH"RZ':;?65M0=H.7NL;O:0C8PB5842"61836E@*_]:T3)·MQ0:D1HC6Q\N/5(R;2S[,23I2UMVA9;.#4F#9Y)C]/#-"O.3DB 4T8)"V5%0E M6=7ZUO8A.L8]78[5[9-0.4#0'8#EX2>&;?SJ1-2HLP=F-&TDG8FMI QMI.0L M#Y)"C-;9#T\2U!-\#M'W#XDTK83? 9(>.HYOWD!]B5'HR !|'?&@: <,GYQ'O9Y>7 M.$ ^3P0M1#'DS])SSM@X'=$¥]V\$7L' MMNR!ZQ,A(2HE8"\3;2+(1-4ZHTK&. #]R&'"'A;2_U/G\-N8^L MNT/+]B)?Q9-UJQ!XK&GP9* <#YP&28JEHE2WR8?'2Z37D7KK=Y1IR'T'W);[MYG[,*(O<>5X[8PE+|--^$> S19!6B;R*D:A#\TOKAPCI"2Z'Z/<^8(X6=@>(-M>2;8C-/LUXW[P.*8Z\9]=-0!_FY?>&T[M@Q"O=T_J<3IZMKH[? MSQ.35=7^X;?E!6EH<8L^L&2;W:YOE[LI9EB<3?,/U#]P_SKG+(V+.W4;KZW76\IX> %OH#>%OOF;CP MS),38%3.Q.'3GK5N33H<-V;_%)P&S_=/^DI0T8'O\2,,Z[M4%91CSD)2G"*_MZ"3XX!/$"63*4D;6B+/4S)N/CL!2>SYDKK$GJ;>UE34N&6G'8M;9T((OTX MP1PJO'}V=W/_0N< H7< GBT#F,\6&¥YN3,CF-MYP8;UC=M%D0ROO:#C1!1U0[]2>CDF>$W?8R:>3S/DM4;I [1_P]M MHJHPM_>B9?)@L M_K';@-$R8H4X<(DG6+4DHPT8@0DM=#;91]6^1%MN MVZ&)+/#@% G)Y @J$2\!!6UAH:TN$5-0[2GLRY))*=)*D[4'@/UYCTF!%Y0*ZVY+Z6UO_\C%;U YU@-WT\5 M.$[<^P/&KP$SI:.W!5SN3 .YX2%$)HVJ4^!1$",])'(8;(;(14I!D_ 6T/F M84K&[BPR$<P.B+V#L^;-:,//.],V2RVQ>-&*"<#'<"\'D9F"]¥YA. X5UX) M66QK#^IA2LB>Y3.0>.|{OO/P/@16+NYUE:NUV[C!|Q8=Q+^.OFZLO/%)*&D MEI"- %J!\1G"L3H#6M$>]L=({@/8#;&RV?32F[M'@ M@)D9VO;!0,B>1)E,IKVKE6E>&O'KL2/5T@&^WN+RERGMYV45 MVH:K[4U,_J9(\CN3" H46@8A6;=Z+&?!HI.N=2W.X]1T<1MVK+IG@\B^BY&- MUT;B+A\NYI"<%\!\S0PTG$,0B8%P5BIN8]2I]=7]PY2,Z_P/@Y\&,N_@'!H= M%E_>7,S^>9<))DSP4=?1(Z) /8HA*/) A4Q&(_%A>/-RA(<(&=?U&@8WQTM\ M1-C4$>_;rFY5&?>6R:*#'!*=C.E-KBS% ,5E]+F06#^>NBQ?8&V+]¥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}V=W/_0N

*()Z"$=.$&8*9B8CSD|!] M.GEFVK%)L7D'PR5"03)NU9ME?GF](RH&"_)N+U)H',;@1C$4LF)-"+"RK6W-MWZ>37\;Y9>DV-(P!Z7>@'7GLZ,%I,+!7E=J;EL3TIU MJ>N'0NIU=U=7$5)M&+=GJS*W!P@Y0]2D$737R!B6R E,(<[3F":I':HYI_#G M5;K2VX$9 '>W#'1[[Z8;XSD5,H9U&,)&2EOX6B 61RG2B<1&\X0ESBM#]ZCC M]W@D@"EX%"%A4NS9Q;Z(89[:X@=1HNTN.(>1*A*&#(F4CK,LC8CKUX9[U-G- MK8V$?!^51MH[_"HMO>^K'JTN"LK;ST+NL,F!*(MMS,7-U!*S%5LKQYSFXY&)4-,1S%*,Y5D MALLY*YK2+QD0/..ACM@-RDSVL]>2T=\O3R_Y3*3)ZWA>2S94>63C7#K/@-V3A<PRC&L8.3SEB=ED!]2__4FYPQ:C8V9++6C^AM)(CMU#' 5<>PHF3GFA"Q'L[%G[ORF57W3_;NC0R)B/(%A3HN9?9,!@D&!60RT2/*4 M*LHX5@-(,Z@QSV&+$[:XMZIGFG3PN2T9N.4DDN$BQ29(02,.^">83D!$D; M2TQ(&F&:#^#& [A;\YE&Y(80C^P40FIY6-<3Q$)(MU2>84L%,CE@2@?H$"T03 MQE'&349)BC5-71>]WE#'![U6MZ?QP85FOFWMT=$T=6NWHYIJ M5J@.E"Xl=5&/6X&S)$0@E4A;9Q)C1#D,$,.RC#/-8"X=E-...33SS,_#5DX_9 MW;KG:>B-ME,<63\X_BR'&]8\TA*BK8PFX%/MPRENDRPL`!4-GJP3"U:,2TE<*S9- (B1SETAX+(@_9(&)8BNQ.N(5A3 M)G==6GJ'*B%19@S&FS<%'!@\ -ZLI|\O5?ERELU9#M-L3A'/K*O-5(R@"QRE M|C*%C'04Y:Z+)NU4QL_&R|&XX\;HG]>F!7;VK[JZJ? G]K0W4.E^L;*HQ%0EB M*DZ@$ZG=U-8QTCFF!F)>'1M!F65[Y]:="GA>1[UA@,,&]]$6ECB>1=6KWFQ MA&B3*\0%)["PH-_=%MO')>$[.LY)/]SZRCXB[5+ WY3E"-C*M94]4D56\[*M M'Z^_7EYCJ4B"XQC11:/[MALL`)5,4&K/(PW<@%9-LF 43Y@NOE_R!WN3;WU8]OGSZ>JA M[P<+(;'PGFEA=THY1\))>$>=1*E-)XBB--]946W>%*5 6S4 6J/5 M$]A*ZYUU*0O=O'\PMMY#=[[Z>/';E)>03,,AGDV7P%>$Z+8QO M#.@ZN7,X=GZK5;WUE'HT;RTI:H#R/DHS! M9T:]KC#5HXY?YW8L!O02;3P?Y1F?W!2QK/\.|<--]=_6H!MN2:.MZ31&X*PE2C L1ABS3XZD6D"?:!;A:,"L,+S%D'@T >#JZ-8.P#M=:/;M*GP0; MV?]_/Z(- G66Z]R>^1(P"_AOCA'$#S#4(JJ%+:^1I*[!TE9%!C&)_EWFP.E8 MA$BHY="SQS;@GP42.K=9!=2."XT1Q=RN8$2S27OG1-X7\M:Z^M;>?2O"]72TIVYWE4:#UOQ^,*2 TZ,*#DU*=5DU![:L[X MKOC?YRZGMCA*3*P1Y]@27BH0HWF&,"6KU?+' *,+$=$,WM5#;PI2)PBC+,)&N1)$%X&D&|O0WZ3Y53-MRJU= Y(@&%W4- G^XD<;"1U)>W6ML4O!.EBL4(>5\'T@>^N*\;/H-1 M-,]OUF6;[<]T>U.9+$0D42YQH!$"NLPIG2&C!1QEK%< M*^?/[(U4U6]4$"+K-E]!?P,*> XI3GG)5<'+BZXFX8L.KZX84I-(& <4(YSDL M#H1@]MA'H%QD-F$IB\";0Q+@]S7D^?GWMX"Z.I,=0W.7IR_*)B]26U*2;)PE M*"<0:R(_(C6#_U#,%@Q*^U%^J=ONL ML%HJ&L:93#62F F4R"2"9ISE!N:8*HR+3;OKKNEW7!5@R7C&,+TT?%(Z 5 MTIZX_/3FPD9I3(S""#G_M-X<5A98PG@Q0 #]>W3I^>15[;#E.(A06-$<<-V- RBE8$2=4;23A)}#8B1P,Z9AO/>H$42OK#3R;*T3")->UDFF,,;9!K*VU00FL M]S6LJQ5/(TWB/"_I\]<77ZOAUTDY@W@_=0ZRM^=S@6UF*1=O]"T^N6;@3RF1 M')E48C".2!#-= (IDRFB&32P-WHCFMYX+[&W(KZ]Q30_WMO5]@+2Z[K[NU8?O M]IL],LN?=!M=9K&B@G%D)24V!=",1)VM5'+C);*I"DXXR$G28-;#*)(WQ&G MJ2/;_W!6L06K2GUC7_,\X/H9XKEI_+'81J4M<=]V5"4O\A2-V M)XG[A&]"Z3 8$<"""X-5K!^>ZMA_P&QW!5$$BG%*.8FI+E'.8-!BLI5&$X=,L M(1"QNKZ"T:=/L.M--SNSSJ (@%8[C\A";/QUQ!BH+] G(B&()] Q$D6&8QZ; MV+C>PYCX?K"/V- -I1S!$ "A8 9X*!HPS,>J?E_-16OFLQ/9E3MIKF,M8V6S MHG:L[`TW 8,CBE/$24J4CB-M$M(.6>7 MNFUG>C%$(B.4CE*#L('H(K%OW;(\UTC%N;*9 $;3(R[M%.?8*,S9[1R T4 MM/14/H#;5?WX^=/'LPL JG[0,)L7E3]HY?6-ODXCHD7,%8H4M[?'8X.$W>3! M6LDL)SKEQG5DM4^G("I-`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|_S5G_D1=VEP4R'9HM,/QF5AV.TXOP>P7HYLA]_^[/M]'1Z M6]IZ&9>M?6*#*- X/ZB!"4-V*775S/0CFZT"O>TV'X+/\':9Q;/3M8N6)9OE=DY M8/+1S39YWO#]M7LUR C_KP_5CA*=# 7EYW':S^.T@[#Y4I5?=.4"E)>2_'T_M]!FZVM/Q@.85#2+OEK>?K7]U-L&\$NS-J8V-#(;8R;?+N[EIEYV:O-OT4I2W MM."Q;&TWA6=\5@[5?;8%(V;C+>=0KVE"$^,O7>;QS-ZE^Y?I4\]Z^;^D/3 M%HO[7R[O3@QJP%O^\%A4#S&;9X3/YBWX^+) [0<6=*!TOOM"\5@L]QHHG GP_M2]?^H=LLS'HMBOVG"MPNW]7%]5R[+^T$!|GUIVH?549WM(;IX.NQTA/,2(<+^>U'-.C.?F7!6=-K4 M%LZ[!S_S;\? OK+E4^-/=O7UH SJP*)KG)G8;UZ*_W :'1#C,LN&L MP%R&>#UB_240.%B$A1GK;5'0\3IZ4ZR?\D".00QK*?U\NfO2#:P++_1?\Z)>- M^Q4W3OF 9@:!'-36U^$V##+Z/SA6!E +R4[R?[I4=9!YL\Y? _R].==U5P*L_ME-IUXL\0^1/&-1AG>]|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|:*^H*Q3ZYWB+.L=YU-MOXV\C\7]JFKY5.7UO4U9WJJDC!YS6VWA'Z$3V<[Y;/9XS@OE"'*AM(KW50QF/-M5X]E?.=4V2- WT+!;-3IRC;MD>BMS,A*X/;;Q'7;N$OI/'FZ<<:=0OU5*!D; M9>XQ3T#H=9H]\Q N0=PFVU]Y$0=8]A@K!%>Z5M6Y0]TIV5]AD"E^=9^AO.?Y MS(OVT3YMLC E+&_NNH?]WA<&E-'06U?H'MB4OSHA(^$>9TK?R\8--.[TTTB WM9MOMJ4,K'S1NEJ'M;4OQ(CH_?NQ#@R,/R_?I3*YK4Z/93*:L[1WOH@QKP5VG&$=;[MS18+$>_W(^M(U!> (>T^W2@\8(;MY&?MK:Z//+ZWMS$(ZI VK@XTGN]1S<5\QNO/1=,Z;K>+740G"%M9^TUD&\M7WN6J3LA.T0.RE8(3.KWS3>=_Y7SM\]@/MD#T(RI*VL@<;R" GJ6?)UX/ZY M:OKRM<;|_/Y2]B 00]G ZC6/]VAG(_*>.ORV"AP$5T@;4'UF\5VAU@94MD>. M -LF;Q!>(6T8]1@EA"U^)Z^-/1S(+'P1B2!L@PTWF M?5Y2A=6+SQ(I MME#H(NI&V0/<8)]? 6!3V53@#&O:MZ]/%G7-F_: MOJ]PL0,P\2F"GF;X*9]6W M6/54SMUKD"M*^V-H9]5V!]681^,S9W\|_KJMKKCS46E;O3V.EWP0YWQ,2.X M V#7;_FL#+W;NM6@KHX&83;5_I_U25E>WA7M[6#CO_H5G^6&_S*A?SF8ZP2*,;S*OJOM7]XXS?3()GETQO MM1T.PVF/2?R?8AT#LQZOWHHV'_;;?I,$X0 [O>S=+]ZZ<((OQ'DKY##&$6XS M1$#.|*]^*UNWOO"92&\E',;[PM<&"&F1'\%&\9XPQWV"_*K#]_OB]HE5!L"_95C&(/4=FL$ =3[^4(Q!Q"M1?DK MKC &G$T+! '+I9;SNF@+W5*(61 OFCE"%L3N;CC@GC>U"N..$B'V"]Y_TEGA4KQZ+MK5YGN_]$ R M)GIQ>WG .:+WL^ M^GYI6]7JKK9IQ_>2B#;_Q-QIK"]3WZ\AOV++\$;_5_ M]G]02P,$% @)(%G6>>=,,+L%P(G#83 !T !M8VM:97AH:6)I=#$P M,3DS,#(P,C0Q,"UQ+FAT;>Rl:7?CMK(H^OW!"KSDG%Q[/5G;DN?Nl*REEM7= M2CQ=R9VWH]KQ M;"&#NTG*VOOM0_9;++#\'! M_^_O@O'9J1CQ=FQ_X&S_L.4?C,9G9|=GXJ;H\.C$$^+L_QZVOH-WX7GU4I(N M0O'O[Z9!M#<1.($W)\?-@_8L?7L? ^.GD36M_[^_JSR:B_I'@^#N^@-S1CN MCF-8G!MQ6$LWWR_3_]BW?VQGP:A(LW_^LVF(]$78E[-HBG//I?C81'R5XB M9#/6#R;!G^)-JP4?IS_OU80.89PPB(298*N- 4^I]F02C(&6M_6;KQW_A\VN6 M]7QSI1'?!"E\S*O,_F3#[(67I4$)6DP7JA+0>0#F;PY@6>VOMS])Z'F=A(D['U_,+QEGU3G|=\MNKUEW MT#OOP[4/@UX/KS683SN")RP>LZMX+]8C(=E)0VV"G13'^>'ITW9[_ZV!SS=:.MSU>BKP.IT5>[\9M.ZTPV1:,W<;[*X2>\/&<5O2R<%6+%F<3H2\#Q+!`MIK$?C .X.I;QE*6P:);&|&\#IB?LO.DRJ"O f0_?"YV\)8BMXK'%!LM&&V5 MG"HMAG)'S]E":.\"0&,0S9?>+R))@#5W8SF+)4HR3P RX#^-Z,RQ2)6$@!C&*%;R"QCV(] MXWL0E@#R^$(@L^P^2"=]>ZBU-@ U82B\)-B+<&'Q+GAG%F,!=@@Y@GL3I'&K MH64!L'8548V#B$=>P$,61*]ZI.3*/8E,0V1_1,2VTN.%F]$=P'[`H_(.4!I MR,#C#?;5[#25\//!9@F2%/GP'$!{AS:6O5#M5*?;N,-&YL'N1ZB1]D84C PY M MW"5Y0<1,V-]M6K,DM^^]@.]#K#!IME,LDX3 #VY1"E!(&;*U!;*&2N[^.`]PY.W7=9/D@RN@^D??. (*I,%M^"0(R-]A MP M#6SBG&]GW/>#Z&XO%./T3;O=W#]$&)T+$,`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`>>*.(V M.XF-P-ID)=M$EA*$12=5OO*)_ZB\&4QUAP8U81H<7ZUX/!AW# (P<@^^:H$0Y0 MC](NV>41]P,>L7-@GUR/CH_FI# M1=1(-L$1O[&\]VZ]B(BDUS/,H?!9,? SQDHW.UC%5J$SO5D!M\VSK=X!)N5 MEU4?,S,8<\H_"XQOF<*GE",0U^W1- .FG74%-88C@03S@ M4HU:-RYWI#]XW$#, /MFEZOM^AN7$K85< IKW(,-=. ^.!%BR8QW$(> "WG',I M T3#TC!\3*]*+>A>+0BX@#I^D6L6?9\OVN@JQ&,B,5&Z&5I_"79 5- [OVL8>M"89^]%09!D3<^8OX#8P|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`>R%M:!-<.$O MA\=+P1,P!D@+1D59ZE>_%X;Q9[GS'206B7?OX\("52NXE>Q^Y+C?.MI3,.5$D%']@6]P1U9+T*54 O]&D)3Z4%D,=\KLRB+2'G-?QV7^4J#?-1$,3.^ M(-]JNL]U?G&9K=4+W[X]^#;,Y>]9'6]QMJA[V_9YE V9VU0+^Q!_5_9ZJBX M")G224ZJ[%(G"%^-- C$N)6G'F/ZGSL=2%"2@<,B5([!$Q&'0,)78ZO$N^78V MN%GKQ1+&]M#*4;/!U//:BG?>SG#&_'CX1<,9\QP7G,NG:A#S.V<0K^B0VAR M%"ASR,839QM@MN'4>^70,_W*I? LZ#M=N%W115((!>UA_21N\-#3>|>=" D4K M ZJ8'GGY<<<@G$>.!249XU_EAF/B"[ASD8OL M*0WW2>OQ@(]H@,'C@"0\IX,%0X-?AOEPV|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fNNNTNKR&W30LT;_9HHR%)/+=- 'AT"F,R'W1AQKVJD\FEDGBP20T3!U2.BT4>W3QM)1J3Y:.>]> MBM)2-DLIX23D]PU6C?H[+[^H<[@>D3C$AS >8880?.#*I MUX^E4H#++5\?2Y M-K*E_\3R,QOB,>"&T?'@<@"05GQO!M'#ATDJL07!1-E$[%/44#I6]6Q\)%1 M^R-6 XCL"DXPJ'G1V 0Z+09+ %767A&%"C3H+)M)&@:4SM3KEXH/Y.8(Y(MHKB<.H7Z"E7TQE\|TF4V$AI%"B*"'"])5W !&#K&.3F'5T)C*&M|_RI;$T#? M$[ZBPA+_".I6NK&U;[4>U#K1>M 'P(#$*MOL@M^_M"+TL3\LM5$;?NQ<7+!W M/?;A^M? >X*IWSM[H\$Z5^>L>WTUO!U\@BOI*!,I=J\'YYVK;H_]UK_]2"7T MV47G-W;IGGX=WG9N>_C'5>\WH_KP2^L]VWEWTL%5;WJ-MR"X[YSWZ-M %R&[|T!N^O!Y?P&,C;_0N_D- ?@&_/W4_JH&?A=-M1/1Z4-X,KG_MG_?. M7Y3#W#7!LW!+_>7_;L^X*MSV_\5_OQ [?\'Z'8:@GN,P"[H#0CRZC]0 /RM M"@FO'?_H>/@*;.H# L7WU@G^B!SWXV;E E*L:/KF!1XI8'O#2:C5; MQQCE@M(/_SC)SYTWED)&G\U:0TB9K-V?'HT7A^&M8AOQIAH%'"<-_0:R\K"%3 M,YYN=|>(G*=_%!ROOK1=:\ VT=-1S2+T%L*MA;HQ[#1S$05"">F5 .EQA&W-_M\#$\N3-6Y1K+]1364429:!>]*?';4(DN.CN+?#&5/B[,O)-H,T]1DO/T;W28 MT9?2> 9 -UM5TG{1X_H?OC]KO1WT+H&? (N<$F7@#[!B$Z"T*N.LKX+'_ >;[M_I:]N^A<_0*/'VR.]OXGQCLX2L:*A]^[_>#)$|/FNW3;Q\D84-7IQ-8 M&[@NH#1>]89#1EVYKM^O; [N$Q_X>)Q:KG%U*9XW5A%1E;@6R5/;F7'E$9X$D MRU'>8SHNYB-0^LE#G8H',IY5';<'ASD(UU.[9:]],5RO2N+FR3Z=@G1_ 31? M7'V1VIMKU'>OKUY^!NLIJ? Z/;+FMY*8MA3(+%TEI_E1OL7T?MIKO=R)[!L% MI=5OXG.5G'N!/$]D[23TDW4^!]'O6.3V/0_YY^ QKOT2@.9|=\6GNA#]TH3Q MYBW&@ZJ[C/V*45$WP(X"WVAFMWD"VE>)3$A351@2PF\?X2&1"IF M[D]D-WCR P)L.4X)+]UFF:S3-E^)#O62ZI =(O"0Y,T[,!O0KNA<[@;];DCTVG.4"C)-)V>/,5'WND2=C>+LYYO+Z\&'SA7K?NP,>PRE MFQ-13]0]3:1]P#Y,5:XY >4$ ME+/%ODIX_=;[N!BR]YW!AVLCN3HJ3(%QA0[E3]B<)'WQ[O_E7?%&(B\/_]73 ^.Q4C MWFI'M'YSM\[;\@']'X[.SX;-P;'1Z=>$*<_=_#D^_^O@9VTEZC?JW@(\?-8[,C M%&Q(?'WKI-$R4*41WP0I?,Q[1,/"6>MNAG'$?A4R@7\WJ(TO1^3KYOT0A^Y] MF00CI,J- 3&'3&AYF)59M[TZ;7>-M^A9OE>V+;V*O6FS/V3V[|;CNUQI.C_OMUQ!5V9)\,B6ZEIQ+6W|IN2W@FVP4 M!@E8O^Q<\)\U/PW[-\I]>73;.CK]=JX,;5_"0,SC<*!DFLG? G#W%|=IJ5[U* M7R@@GCK*\[ITOOM)'-U/@QZOU>U3%K#R7TM1U\PY3X$H><+B,;N*YP+/-M=-A)@[7WV^W&DPX&[5H/'FN3EO@6-5JP=*%>XD1N,\S OS"<*#P38OW7IB MONS^TAL.KZ]8]WIP=_A4;?GHW[)_W.X-^_M;VC11#=NI'>QE/&]D$G#9CZP'N:FGE;GLC?H=[^\$N>;#Y3/^+UH'BQ0F(O MOO+--=&O1+NOX8&D%22K)6@:AA +I+)YT$S>M6KJYU!MV+ MSG]I^/^"B^X#ZK4M<^[V;_MN^VX5I.M[0[^6[7H>>QE;3.4-^^KWZ|<34TGM M/;3(^+T%<_<:,%ZI WN3-6V^$W;#9;I@'X44:?Q/L6W? 7;_OL&&O^VD :*TW-M;+#^5;=ITZ:KJ\RP'\;V.V2G9;^LEEWF&Q>P!RV;_$99_7_MW1EIH&Z\B^//:)!%$5QVA\':/PQ^*/S;RIG;=E!L6Z3#T*TC_:_V]H$*TD* MK:-6L_U(4L*2ZJ9WU-%RO@/&?<,X*1^%HMA]$M3%/:#(D,\2(<:\\M8/DEG(`M%V^"B B+7G]I^H&YD"E8\:%>)2U8W=;4<';2/#H[1H)(8>:I,SZL:-5)M/*O MU%^]UVXW3T\.- M[>;[8VWGMHV./#YF'K9.O#GL&HF^^61_T7 4(!\"=S'CT M[^\.OEO"_IM]HM!EQGO@T?;L"SY[3\<^7[M>7?10S]]|_K]MG=U6YR+_*7UJNUE]8HQMZ6RR" <2PM=B]ZL9P@:;@C,=_25%I M/4$V/02F'SF;2#'^]W??/X'K'G]GS\0[@]M^VBZ_^,_^+*\V_X>=EA^F8F? M]|]WK_KH:!^RSM4YZW2[UY^N;K%,VVUO<#G<%O(M86C? _=2RBV>UVXZ:MS=Q MT&A;EK$KA^"MBLQAG]=BOD-'&\|R9'NPZ1[<&W1H]0)S:COF5&<,JR.K/G*3 MT#104!?,CXWF N=WUXU8'CEUMEYB/CX\L(F9@5P>.?=49PQW/B[,HQ=I&]=2G-M#MJ.0VU7W!Z=642_P*$.'8>J,X8'P)\0N(XS.;]A&Y/RVB6^!,1XXSU1G# M S$64D0>?"N-*

*BP0\':C(IVNH3!TXEK5=8V"_91%! \Z=BRKSAA6GXG'[)PO M"=RM/L(;,;;%M$N<*<3QYWJC.$+D0(GO?9DBAI,T3GE]"A'QX_1\>&!170, MG.K4<:HZ8[CWQ9M@'@(;\%0D/WQ_=/:6=3.)UN""]?I(@CD/A>-XUU.EWD]--UVH?XUQW·WGDZ#%,N97L2\CO&SCD%MF7Q/#BTBWI8+|ZY MAE5968!NTF#=.)JK)FXJ! 3^3H,HHW?HT-5Q,T?K?T?K9S;%BK==-D#-,;P. M8)/B|+9^+,K8L:BM$O!HRZ;&#$XM(N.TR VJ.X1LI9GQ!R0"..SG;?8QVCVPJ8-!V20 UQS F>@>1JGH? M2S80? N:I/XR++EK+V+7#4\>XMD06)S8E"K==?D#-,3PP6A5RJGIZT!V/CO%(MG^W;E#+<==ID!-<B!KJ2V>,*VV? M9@3RI=GR\AAD=UO(CBO5&#K+= M&L.J,^D0!5(YC.7!^ CT? VQ2Q#!S+Q:37 M&L.]>>!CU2\JHR-&];/TCO8=A]HN_9[:%+(,';H%I=<:PS3KC$NO.@1AF&53\VY6H\;YN&VS9%(P.; M;U1?"X2P$1^YJ=]* A90_//%438-B&?VA20#+S*A9S7&\6] M+ZF(§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|-Z;9C'[X_NCL+>OR69#RD'5\\4?&O?JI7BN;MGM->L,>G"=}?[GMGU+'3!:ZZ5U_.IH;9E&=MZ_5Z/(ZM* M?!KWEO-NU1O/@]|-H#?L7=UVE(1+ <\Q_ZPP&G:O,?f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{J:$/";ML#6(9\EH@WYI>W?I#,0KYX$T0$$GKI[>H'EC80[3!U6Z_C M[*1Y='.,2|$B6'|8K(}))JS1[N'*OW62>GAQLO+W?;&V\]|"PQX?-Pl,)UH<[M@U$WWRV/^D1|9)\I='T#@?9V90V=^(2NNN.XFX<@4T7 M^*IA&T5W7 IY)V0- N=61XU;;)>56RZ9,NA.7QUUW%-2^X/3$L.@MT^^1:3:ES M)RZ?N^XH+O>7G&.69/T:>#LNM742/K(I:>[$Y7#'<7U[8_DF-/6*??$IFRY M$Y>T77<4KXL]>]]Y]/%++>M< MG;-! [)WWN_5,/3LU"[.50/Q:O4YG[HPA+JCN#?'[CUJGHB;0+G-YS@"CC_83V1SBSKB?3Z?4/M8ZORJ+4;L/_ MEO%^A^@M(_K\LG_5'IX.5.9IYT/OZK9^W,JU0JHU$9\YUU_=40PZ;AQ$*57% MQFC_3I9.8AG\F6NMG;OE5IZ.=3FZ7D?7IS9EV)TYAV#=4:P*.C(._V<7]_7 MCTNY]DA;)N&#?9O2[YW7>>I4$-&R2=N5]TVR;B0YN(^,PE*]4=0.AVR_-%LH[MY M3H4B^\|*/CPT*:DX:#.7M%1W% \SSQ-)$LO:.M!=L:!M$[!5;0C/7*?)NJX M*H[V)U.A-1.1\IR+E? Y:]MT;55GPC/72++N*+Z*-8]2;]H& MZZ6>XU..B!\AXB.KFA.>N?Z3=4=QQY\&49"DDGIK: WKDB_8^R 4>!X8CRGO MLAOR8.H8F*/NQZC;JL:%9ZXW9=U1W 6,\"!BO4%_V ',E.:UM B/(6)4KS\; MX\BN]H4Z[<9EW=0;SS]\?]9Z.Q PIESX\,=!#3,$7;&P.9.P5;UAI=?ZI?53#;Y%0-[*KJ+?5.+Z* 2$B*44M=.,I-(MTW9WDA^^/SMZR]\Q+@BFZW+OQ MK)9AI;Z^X9;) -BJ3E?(RERF8+UQ?!6SWW@ >%$\JYM-LU=&YK2A^I&+QK'-MTA/3.D:^M_9=789M$[E5_;"0D;E$PGKCN/=E)}\$L#Y[VC,A6M6$!IF3RS*I- X]fR$Q$DK(!3P6[**9!2I\X;N4H^5%*MJH= M 7 KEU)81M4Z]570>00[G)WKC&/6I.UE7%00;FH]WKC>)C)>3#G(?K5!V(&MA^P%Q7P3J>"OW$I>53+ NZ. M:?VV? MJUJ0X#\RX6ZUQO'0P$XX:.@IN=]CD-MFW]MJNV-',K%L-<;Q_^ 2C*. M3VV?AH]M"FE&/N7"UNN-8I#^0JZ2 =$8K&O)=L>KMD_'IS:%-2.O/]MZL_JXBV>W;EGQ-94."= MV!M)P3_0\3$0W!L>WO-%LL1/@)F4$;L>)S_],)++I+],'D^KQ4?$5="&A)VV M!{ ,^2P1;\PO;_T@ 1UA\2;(""3TTMO5#RSM(-IBZK9>Q]E)\^CL&)>B!;_^ ML%YEDU9I-G'E7XO=#TYV'AJOIG;>.`A88\/FX>MDZf/>P:C.KY;'O6)6I&@^ M4^CZ!L+LN=C;@U''G7<7/?;IGG6OKVY5[?#"AM\K0SIX5S1. ^4T>Y!+>M<6 MU6)!==1E)!4:QZH:!VAXO.LC=DM<@WL*_MS)NMX..%Z-FZ;H@\]LHFCD6BX1-Mf=XXOHI9QY\'22P7+);L?>!G7L#ACX%(9G&4!+4I577.;lN$?60382/SN/XY\R_IV>- M5<>=MDZY9S91+G(GEZ)4;QQWO.)1?!*Q.,HZ+|+UA_^GL;L'0_"O7Z$OJU> MKP-&8L0C#UU;_2A)@S2C3(%F#3F;97T<7SW5'^Q;Y,)%SN9RF^J-XX*SJ:BV M@;CC$\'-.M&^#;/9+):I\-G_?M_]f[P%T7RJ]-($/2!_ O'M^*#PT2619Z MTL+|!*4'OP^2!*)NA|fYV\N>L-O32^/FNEW/|6;^ZU-9(+M MB88)4=U6[D3'6I.%L..%2=S'JC,=!&& AGW<|^IQ8LB3JI;5I31T?R'I(4JG.:ME73N8'4_?'_;;IV\3=@UK,<3C;S^8\?W8:D)3&T<2^T!W+3*-?3Z(*5:1YF] M__G8?]>_M84P.YLP^#Z64RK22=2)XO4BYE'NG[5B\N>FSS,5C(:+)MM]-J1G ML,TC3]#.",,8L';#I3]3*L6$!O;R,#-DLX%[@$CK3^ M+I8ROX<2=.T_;RC5ET3,#0I=+!E2U:WD14_M#JK=O/!QU;P MF!B=\/ZC:=KK,AVMF'",,4'_R#6AN5A8,M^?'^)1%/1D8N+["\'31\U1 Z^.M.41>%S0.O]UF>4V ^.4Q,%P(T,T9'^C6^BX>5QUJ$I_;N_Y74R7G8:ZLU>ZW2MRY;NH*88 5!/G\$% M<+++>WAOTSONWK/-AT.M=]JYNO\)145[4{UD"_&U16=7)BS@V6D>P]MM)D+,#E MI;$=].VT"RI]_ID]>'ZP;"^\|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|648R_D69)OR-%MEMQ]+SQ/F2":@3BL_3UA<1X9VG]GPUK&]:Q6FSK>'UF ;HES,4KAQYAGH0W>,2(,% 1,S'7]2EI-CF7* M0<(&(A1S9/C7(T!|+E XNP%Y#+_?3P(/J5->'0G\"^43#*FE@ND!^@9P!OS0*:9,& ^ AQRX# MIS)K#H.G'3YZ*2JKGI4%XDG@Y%A&2" G."E\?2W1U42?:MM7NW^TK%!&6KB#5EUIA.Y#8M286J-F\G2(TKKTU%H5X.A&[/,?V637#;=@V M2E9B2#C%7TYA-(^S'7U4 9>"%#EX[K4=@1@">1-3|'5" L $EB>[N-7P>8_/ MP'@%TQ7]P]6%N% MP1%,*UN\B?"S4###*L'C1H[5E]":6V %-C=44JG00N>0WP!|U2LX*P'EXJRD#@[EWQP2RX\QX}>G;7\;W36 =*1*X.)_ M3T1A"XV4]PCNV<@N_$8, EX6%N^P!K"8SM\EVAM8Z4%Y)${(_70IU_6/^,(MZED(2BG UM#,>]:E/$N-W+ ^C/4UT4.8#K_+24(EC/+Q5?\)-&6=WJ,<(O#._ MB:6A.U:@QR<0\!*VN\F"1S,:X/O5G]#B=NJ;T? 2^>3N&#^H$B2$1(/+?8F\SN M\V*] &O0K;QF,2;_)@%B.$=?!9D-8VS-*$ -J$++P,<\=+\KKR9=*Y^P\8CK MF@GPX'P. P^/SDKN4O1^JK@?0RI%GN!#B-\17X3T OC '%2OZ$Y-H(^D0=Y/MKN9 5'D/CIT2 ,/QK@TF'=KKJX"7\&T %YTY6=',%^3C(4BZ=/3F8^1S0U M\!,;=0OO!U&\60N=@79LS!/L4.73,P92B<$]H1E?]MRY+[CWL!+O D M=Q@R4BK59_1D,6Y;HIDZ(5AQ3G.&(;>KEV1SD2C()$0N#6H4N?X"(;$BC\P M5\/LP?\Z;,#:S'^.^QY9V8LYQ:&S2,4ZYJ-SM/,M+!&(-A#%I0 H3E(§0*]7 M#US 6*3H3M,+9-Q@PY36=*H@"CX ME Z3E0SZKX/&<4D P?^U2'MH.>C(QL0!AO&>2'-8DHCG>SHR#B2;CC%8)QCK MDHAA-SE&.;!WG4=BP2XX7==MH2W2M$*8#9$/F@6ID"Y=W"5?%DF]&NOTH,*@\T 5/2Y" M6|AMC*FO8H6FTH/"E@-'A4PI?!#EI4W.?,I%(])V_53W9TT&KM'1T<[-.G M6^VU# [5.6Z<[^5\>J\.S946L/?ISM.F'R#+NW2^7O9.D$*"VU2#'9 MX,O^JI-\MHI9-VQX_7Z@N'_^9]D[AL=;RAQ7W>I1)(-)IQ)(^+]GL+W\-M0!_ S76FP.8AEV>"L9'JU?FAR(*E*N/)Z /:;11H-K*IPJC|@$|@?] M7[_2S>X$,A\+|/"*-$VF99Y0,$"N,S.:7VN%[E^$%@W(OQ9(2[.OS/-I<'/L MX5G9P|"N:(N5&$.U(221C_@RH|+4=)(TX@EJD7& K(9Q4!'V;2ACB&QT:.O MZWF\=GOQMOIS=;F M5Q\8MGW8/#QK;WW8L-?$!^5,EH8]?-*PC_2,%2:VF[Z/-M==O6W5Y]D\'PWX/FRXI,.+SI_H2(=^ XDP6A>B+/-JG@58@VP71T^!2 MDC75U& %VVJY.W7QA1*G2TPLV6P-6[ZO(X0_?'YR^O:$*'9=Q[",]@!=>1^D MWN3)G6/^@3OJO:E]\5Z(9]]0KP)"Z-K,IQM(4T:=7)5K34KU6K<'/;6K_B'@ M? 8=;/($5<\Z2"A3_R0)P0]\H) 3^,EU_*;BJ&, I8I\>|<-X_^Z1)N V!.MPF9FDJO]:#;=_+J0?BTW8Y:!Y;.GF+7!^J? M/0>E=5 Z<0QI/6!.]YO[CF$[AOT-X'/@=MQ;*_7=N_^/>-/4[SEQ]% [CB8+4. M5F?;9$ZU DS+L6W"MK\))? [=CMO M@W7;ANN[2"UUK&X5=$Y4*\CLMYQ[Y*_"M;@ER3V/<)KUP,XS^2?3W%,3W:('KVZ' !98XJYPU(L#1^K8<"(./VC-0L%)O M[VM//MPFK#"RHZ\1CPYV5=7BJ]O5?O]X_RP1NPQ WL/Q_)#/HD1X&68FA3'L9$0;8&^4_O#]T=E;2VOSS"C1ZF4+ M7JG*?CNM7194NS:H/BI3'E!/).H#6T274RRF[2OC'/DB K\U[0V*73M74[\& MSOQ@#/!92]6W0:1)E,FQ094LU)?-*>0+F]11+6<+G=P*=C8(U""L!N6PDTGLA M5->(":Q<)"IA+8SO\==*O"D6RPR"757"4*G>? V<\76(QO8^KGR&8ZV(?P9R'M0G>5HA8>DT#ZE;6&JA!>.<.D47Q=+DU/X0VS O(\G:)H7F/M>N #JL1BY?K: M; .S8--OA-!?65OI^X#$]F-T57F?R'LL*0D@.P)5>6.3)9&%#*.16SXX>0 MVEBS?D(2C+@*L5"51L217K2.D7GEV_<2:VVEPM%+)VW?]*KY=@"R0C6V8*5 MKBTNF67WI&PMZ/44F^>%3)R2;-N@";Y(U$>D7G5$TC8>&@+$RL%?%%Q4_DI M@@L3[Y6,P?I'2]E[Y>6@3G+XI;.)OG8F@BWE3NIOC 0F)(}B'4=+L8)YZ*<98VXQ#A&"_H"&R^MI*W_8 MW&^!XK4S#UZVGBC58P$FBAQ4=T76/?."1RA:4'U_3";W,VFJ8\Q@&K%/%*M<_HMXTRET%-#?C"U5@#RWV!^LPA+&'YTF8CFXZ*H9< M]7Y,1)]&JI;[P^47>$+- "BEK%>;F#=.#]HJ#&;N\21{@7 ML,D7!H^D2A$P<=A$I:GJ?30=6D:UX2)[$"157TL*8!3+*;Q\Q*//5&5>QK - M,P#K\APT,-VU?9-!U,RS99LV'?K6PF_IJ6:K& 2U*_I=^^TCXSEV*X*+ M-NP<4U!O03/*76FFY@ZINUBNC+J$D,S("R=Q?4"V4508PO99IGV:.BFB'B'3 MR"L>0G=PJJL"+;V1WU2NUWP>23&-)|_7D>PSD*R4J-%*&PZ<3'_3>- S!BG%@ M$*34LZ@?>|>E%_*%[G]Z<|%ML"X\@ I$@UTU;_#(ASCT83)L"!;(?NI3 ML--@/I]TW$88)>P\D@5<^>X&?(&-F3;?4W[J L% MQOG7(*3!U/51"IF.HLB1\3/0L0)MKR=FN,;"#.;SNQBS(>:<<.,L0;4?)2F/ ME*O@#Z,+4AQ!XIT@[WV9!*.@9>=.IZGYW@((2]QFVHT3FVK@XQ92155I8P#[M0 J>Q!%9LV.|_%M\F8DH$>I1/TA&F4Q$428_P@*M]VPPR#5*\2.\NB$&-_[T$C M2 6HKKBRR!,-=!K.N%269PF-ODAY$#9*_%SYG=%S\RA-HEZ>QS[I8WYSRD#N M;"G^P&ZUCND]"|.3P2A3)1G[$08P"3\"6K"&_V$$21Y*URC,-B)(Y9K43 ZT MU@ +LF)M5ZI1+5!M382Y;|I"*G\?/0N3\DT-=HKH(#\X[*GI. M]|!L*+FD" M;.1#&C*9")'F'GG=)#3?)BKRCVYM\@=^Z'1N&M6*M[MK&2XBF$\;>& AXA*N M1T#:)7Z\QO:A2\%GM%1&_^]F7MH5;2]3BLM2/?$<"\;31'(??(>@V=T)W48 M!!VLV/IG(PH=*W@&5I#Y0,4!]3 %C-K8$4C/U(LCBEPG962%7,MBA70IV -# MD%>!,A&<%X >!PD>32R0\M$=X]-+L_G[*#58.W]=KN1A\]9>OB5#R9116X!SI;B.2O?RF(LB* <2P^_7]MZUY/]$Z[N7_\DBC5]K7W-&@7,,8KY /7!1ST Z"G_K.NQTICZE3A7Q?,KZI]] M:$%2C*"QZP]YO2[@8B?46N;U8/6TN?^~ IL=;[8%U^^ ->_U(^Q=9(DR4[!E M\45(+RAL^= ^ LXJ|<^K"A$WVXF@.6PX!0:#.1(3%53IGT?)9#?A,T;)EU?(. M R.>U#%NAP+E*G91/P*B2FFHEVTK;5L4QXWY&-](73Y&/9D/-@\].UOS,9R4 M_%M2\D+68G;@N;+?7ZI!+,1V!8MM%IZI$T3>=J4A6:FV(=1Q M2!X=H=@[#Z0.#F_OMPY)?3TZHWJZGXRVBPTA9O!1=H,&$,]/^W/%.@-A&;X\ M_2G^? =B5"83\OL%D%H*E5'2@1#^P5 T@J"\;Y.STNV*W4\"#&G!J/K$D\&H M2(>_5,0!(QMZ$^:'3%$Q&SS(H34M+&.H7F+4?3QNX_I3US4*K=RD"QI2,,_O MGP&"P)B8*C?CR115>T? $ESJD54"I@B,+*Uj-7M'29Y624631RD+W@7EF41)C ME!QZV0$,^!P&%Y$W<0ZFK()U(*=)<5X\SK6?H-!^$AU@'4C&3?1;PG;4&Y2N MFDYDG-U-0*L"+/KZ */4"4^O2KT1H%=U3I'>%"5-V0):W+Y+%PM^HRDH;NR M6L/1V-+$2M%LZ L'9H!!^K%KJ_T\1))8UN10G1S2X?"":<38.,R_-%.?#-H=% M+\.\G-ER48&*R^Z](+7"8QA#G*@$KEF8)4S5.F[C\ZW_7G+E2>UKZ(M]YK[M?ZLH&MHR2D85S8;R]+0P+_WV!\ >]C1MN91Z"$+8I_NTLEDFP4(5B9)\(&8[M=U*0G-9MRU? F;Z9+51/4X")=M^!2.N.!A^=XJDFZ=O I2.:>^I)0 F&J6J&-NF+(P M%42H5:,"@DY03>(IYCBIO"E2/'2F$CZ Z0PX"B>8T4.J4M@J+:.P.2T@1 !T M'0QER//|"D04#ZZ;E)2BNY&37'5.(DF6JW#<*.LB3 TCXB0W"QFBFJ.#3_.MF/&.EG,"&>LOTQ& ;23P.SFDL9U!M>.;+5+Y>Q#NJ'AT%_T"[UDL9PFM(%2_? MZ? 9%,*@7\@RI$#5?HI81H.FO=8FS)LBM0"=,0PV#NTB][>3),\H3[89'#1;= -M[?:(%IXTLR*QA%4[MCER>4YRL8U(B#2FW"=.PO.4PA*U?&LF99VBJZ.!"=I MICEB7O"@PO10&@#[6FH.6&9J*,D4KDPAJ*:*@35NV_).FH>@87 M+8,;]T:P|@^KFC@%EY(+L*%8*F%,VYS-LSH]= M.N[*ZR'8L$.IB,,,RW11I"EK*.8G5^5=J2KVH2 M2RDO#=9JD\G7;+6Z6%KY_/N;NY%HUDX0GP&0K2HL@_2S*L EA6I/A2^'W 9 M)*4@IC+V,W37+W!,\3O)9Q/FLE^>FV@PUAW&Y$5U/.*4V".79CU[V#3?$5 MZZFA';W>'...O$]@V^SXKNX>4R)B;#,FPO2\1MF8GBFH'H>5+*!I3=HQ%&G07@KTHA MKT:I&OJJ-?A<**QD6*H,CK734((LSW_P!0l\]7Q5%VCTN)I@G&\96C";N! MJ%_[\4*&Y\#-0WC")#9Q/|_BN9"JOF511I65%1(*N.V'$H@'3=^:VO"IOT%J M^/K6Z(P&>P8B8|>=P8?>;=VHQ42A?VN2&.9D"-PUU,X47?IR!3*. &ZVZ4*6U M4HPGDB82/ ^)AA$OXAI'AT?|<.$_$RXXRY\IV3V&80.XU?Y>PUUS+)5WH5Y](MM<_[8^3EZO*O$#8!7IDEYH]4;2S3)E,A7+^CQ#H87*7,N7@\3B8Q&4T XKW-M /1^%J6\#?!//(.B)H0A'B>,O\2(GT0(R_QRNT2VD:]3A<@GS.[;L?Y*8N3F MS;?[\$XI^!FF=A"MPG^ W@B9H,H;*;,U2NJ00>0%,V!X11JGLI],N6GLVCS M5 \|>^? 6_/;>K"Z/N\!4I&B#-\OZ\^JN'S7_RP9(T5EU4.@FY/2C+&33&(LK M8XP@(I>[;?0=%Y=*53/V&,5NT&3 &-D!'V'1X5RV. MP/UX9NJU[DJRVIA4\Z+)R/H2/BEF:R\[_=7**>Y/>|=_TI9,M7A,HXC$-7^; MJD+Y$-KF5QDHNG@K^2OP64\N6$1%$,W#+XCY(#(E0#P83E)ZT.Z7$J;/8]_?>R_1&?0:)MD.@? Y$R@;" MFE3I4I-)-@5D1.HDO-L 2@1N*IMH""|/!OFIMB+QI%M[QM)3TB1! WT(_TGUX8^S+,RR< M/XT\53G,8V $NBE,R:MA-L-&0%24[98H,+72Q!4 $7)H0AW2QVRC7LJ+N M S15X]_0G &C?3I]-4F+MF ML V=-DN%4C2W))X[(HY>R(;BC_B+QB1BS*!*^$XH/YM01JL;=W=LA2Z;IYN(MN>Y(C0.J9"BZ1+5]E6\OE[?KZL[I/A#]G,RD-E&NUFK*TYV.L]G:?!;E.LP2 M?8JB^$S"6@<{OJ]?TCK$WS2%EXXW>|.YV%$2OW5V<-A@HRS59R^:U[*U25E% M\HM*+L.]0>6[RJTL3.V[XAG=0A4V&(Z^ICEE*F% ["%1T3+MO4ZW.SRC[D^1_.MH3'$LN*GQ.F!T 5BFBI^,"WG/B_(6%0@(P58.?O'2C8P6'\?"L1\$'H!.S M5/>(+2V<|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|)ZG#GKNNQHOED&RU7AB4I@RVK^M#7P&3 MHX8=)ZJKKN-8S\"Q8M\R3J6/DT(V0-]W9JJ/H3_TI-B1Q'.0A&EX:0UA-'2Z M0:G[9IH,|.;5.FW|IZLX*P'KZR=0A+-^9<'WX+7F>42PP95C@\'!Q4E<$X<)Q$>1:)@]>G-LB0!W6OE5K?NEFC*_3[G)02 M!N29*9J<6:5\%"W.7K-08EVGQ==!)T5(B4^]#G,NOA18+2-I:1+ MW$;.]4KJ>Z1;*"=)[64148#Y8VH&_#S]M]JJ"O=Z\$?N]]&O3?70 ,0*A# M4'FN89XB1EJ[\O$]+ [#/NEJC7W(WFZD8R*I4B_Q0B#(V C-S31YY4\V\B_;& M1XN%//JH6NC31E2 >/19#;C''USR!180!"IR.D*W.R8%4@6D<=X2V71+5_6< M=*YK7M:IW+>Y;)*="F\",B0/JI0QI\37>":DR1B<1SX M)IO6CI-1VG>_7Y7RBD65FHTO/+%4XS*8,#DX]_:'$I&G;Z%!DJC8K7*JNVI MK& %RU!$=RGY8<,X_CSBWF=,8 # <)+O+BKY2H'-'L!|D'B@W>D4;U7^5+9]@ M#UK%VZMCDU*R&&P!*<8A;>AR$C<=>BRE2NNXL]*^0K+82524.8PT0WHQ_U4X-M0BFO^J'}UJ', M? DH=|>T@%?;3D,/)\U\=5*O/C\$ EB-AYK S1\"(2'"GQ;#":M9O3D6K,U^J M?V92]M3LR"]U'GL9WMMUYL2S:!,&;?T(SV79+?]BD4K!KHDP2M.D^>F]*"F9 M/=:=KREPEB>9;CT<",<;#7;KN2/)92#*)P\ G/,#WKG|f_J(^MB4-UX0,*#'<8)797@')Z6V4 M\V7UH*56XRS,7G2O4Z]3E!98)M//BC(K6E^@+-0OJ1)"NEHK%7@M%$\"\@8L MZ.85&=GM.\$NZ0GY<]E6*K[.1>2+Y*]KZR^0(A_^9<'WX+7F>42EQIG M>W[ZL8GSQ5+ M+40R0^49

*M()MB%83-WZ7"8Z?IHPF4\%#E&Y]>YUF:!+[JV15+^#C;ZEZ,U=C)3V5H89DP-MJ2C-%PU>13>P6,G-&-W"E42'F-2%[,(H2S)>VF-&F'!/3W#Y*T]UZ>&^6!EV MM7*Z%_)@JKY7(#V@JN:ZYM9_M1K-I@5S^M#IW.P:&\$L8APD'H#BCXQ+K&2#X9,^.Q>>RE\Z:%$"TS[Y-MH*5-#U*U0GVJKR)&W'^.IT^G>+_-H2-5MY1\F(B)ZI%*

<+#N*C9DI\D!XNJE;8[1-M4VT.79KD6[@<:,$&8-E?K{0[<>E^]Z>YX$*UCECFO?(Q=>\"7UD])"[_2WH*I-MH'=\L?ZKBHGHM}03#W-H[.3^"B;59-!QA2T[C+:RE;6E7DI^5I$I5*K%&:2-M-Y]FG5+6?R(N:,>);,2-IJ\)EPF[RRRUAV@$?I*E*ES:C^COP(K2LD'2TDSS-MUR6.@#V8!AN;IKAN@D4A-(-=H&-=T55)>GT,I2RC,#K<-^5?:,::1*@%$8F-M7KT$?^<++>UY?6,%C+/:'(<64/:],:^N<%,;NENDHH78>E"GXKNZ*T86B#5%BI-MVB-KLGY0)+M2MT\ITD6';@5_RG4?],JIF*E5)"+R;E01M9WUQ31\YYW=/)5

M8L!%O<**F#5!?"K3B^I<((B/RDUNL53)%3#5:0 &%]T\(>:,\%)]R[R#SWB5-MP#3KKD]VT9,6"U0FL2IK7DHK+^:E$MAE4MM8$U>9<.1X(]+EIL)<5-V0T'4

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

MYUW]^/MA_YM]^^"TW<1U.\;_#%M1G4STF!F0V&0K5FZ]&J OHOTI6K)=5Y4 MQEI>H:.],T]5YV*4HJ"VI%[07{3>BH2+@;/AGIM\,--,A($88[TD'-4,+$[4(-$N1H0761Y!3@3^6". MM.$[ZB09WFN@?84C!-D4NZ!Q*3&[3OG"L+1P.!=Z=!XLVJ9\;\""!5 M70>4H8H[!P8P*RV%]>8Z7$-OP]3P-8IS\[M@KD.55-0H)M(VUO42I-T] 1F

M_7VFU$[@OG^(W-M*D%KR5*EW'O5D[.XH?LNEXKN.=!N-*TI7]C^;PQG DA&V=2%OCU6DM!.V.@<-M]1>/"ERMXL,W%,-4?Q;Y7*N&7 LI4-1+=M+XT-

&K#3NX_H]S'IVT0 ,O>5^?@=M$CK"-#)XT]=%,:U_I,%\1=2LU<-#K#8JHWB8U%HJ3.7(\-G(${N*MW;0(HZ-M'C')1K]K+FPG\(A:PZW5E=+66[JDL1-HY0AW]9@'NLGB.--!S*7*3>EDM1\0-M%NQZ2@\;*O$5Z"#HD:#QE40)TB)AEC@!'N',(%LH:UDW0*9\PS_-9ZI-CLC%X89[C96W3-'YM MPT -KXS%/U>G$H?+#.E]!7O$N M<7;,-

A\)$17]^52F74$EA:)11T,N,+QA&$A@=8BUP30BNJF)ENL*8"SJQ80Ff M%!S_E\CD?B(P"'TWDE* R#A6GH"[F=W'LXQH-EGZ0S#*TM"@'L%BKIABU%TS1 MY,;7+7&9IF I?

BP2W=8==*"Q:*Z7;+11F;4+9:Y0$+ M@=5.-1G1!1,<5E!W31[=>=\IXQ<\8MOPEE3*7%.JEZGUH(@JK'<44+U$!M;/$MT@V4][38:7GV((9EYF>YC(>&*Q>5B[1PQ9-7;

[0K2D/,8[%W69M3?RK3.!T=C.@7ZBNHOH M<, 497RHUF!#$6XT#DCA*^H.EJK?]:5Q55'Z(>Y@!L9]_+!]RFXHT:V=4M\& M.

[ZTN30[4L3K'6WQH17*5I2[2O\&]D9HTI9RJLIF*KE9!+-"&)K"#)HHU/9\ MJ+]!:25"+5AF!S7?9S+_;-1UZ!R%R;S2;UZ,/>/!DOWR@I--45'D&W[#H

M\OF3JLR0!Q>8A)4\OYLRKCV83DS!M,"FL+*)3I:&?B\ 71AG(G584Q533*&'\<4<2:1H>C]$0T#7T_E0=>6CEA7G<=F&-S;U6+&+/D1.)1DG00F=S4:_5QB!2 M56X)*)6-

J9C==)I%,+0Z,)Q4SQ&)KF) 8%(P\C5GD?I[FLU>|*DL?^>^7>Z MW++"DK:IJ#*0]!W1QEH@H0P=D*84,7F:.R.7<#U,=E4M7-QY>+0ZRWQ5<16R9@U?

XR8JGW;)6.7:/5R2V(B&HG\13,:,"-M%)/-NC3I,-#1T0]AK-J55]>L&#.TCSF'2N%4,:AEY1PVXG268]EA$}*Z9EK. MO_0<_B44I;QH8661A\GPJ2(#O9QI7BW90-

S#9+H#]=X%V@->O5OOM."F4U]?4 M*:OUC4I NL89MN!ZS39DO50G5L2>_"]>TBVCE^XW=SF?>0"B.T((/Y&APON M@-B>$%VI9_=Z

HB=5/^+4OWGDE_!!IE>I.-4_!GJR)+,,,\@OH!WX\;, /8, ^1][Z/T@R[P5]D7\1T%&?RKI%N8;PK M.@+ >Z6([FH8=[E9IS(RR8QTFNG+T+]W9E+13.=8NH,O->UC0;ZJ]=9)TD

MR:.J>5?>@.IM,+?!W .[^@WV/L?3F250I,>^\AMHG_,)K+33E$G EF4ZEJS M0LI A;BH,)9$A&,3,%@)1%C0 ,,4$ZQ>@IM0OXGER8<\4G9&P_0X",%>Z68C M-&LD+ 8#%.

[T.?"GSY+#)-&>P22#JUBF$_8++B0: K1Q^,]#$_"B,UL M C/_S&Y$/ M%'DHU$"HT:?GQ\S@2Z>;'25G]74SD6X^4P!,BPV#\G?TX"#H/=J<"V?#EN!;R^W$6LBFH&'D 1<7KZ]C+

<[$?UOLC^-8\M,3-8^K*%PI HU0>,\VKY-% M2IVJ49"K%26-?4?D%O^9#$C M_'JI3A)84&]820(7OG]6*S"0E7K%[VIAK-8)Q_O ME"92;0]' H 8\XT6NJ3CNA."=@[KRE3

Y#GE&)LPYUDFO0E7G:?,$HM0S76PJ7H-&NVM%*R-W0WX,FGK-K!!:X//W:O'>U\>]K]I3KLOGJTR4,[MC4*]V8RVCRH &Q1S5&\]J4KH]#RLXS*.L,TOCD6RX-]!:R22H#KXS-

3Z,%IC-;-4!6.KH"Y$D];AG>>]*4@ MXW;_|^S^*BW8L^U+1=RG:HHZ;51?Q*HK,S0]P(# K=#W3'A'(+P)%HE.A2E& M<17+>^YTD6>BJ'7LTBZZ,J[LJB+._RNHFTCNA\!WU)U-

R86]C+XTU29ZF4 MCR]"<2>3)C7-=/=^Y?B6S<[7]XG<6^N@HJ8?HE+@/97RGS'<6%RH0:YDYP>M'V/A_+#M:_]!:]HU6A@7;=M8P*2<&(Y)\-*$3ZL\(M6\%3GJ[JS>T*M@Y=?

PM-= Q_0RA*1]WJ'9R?\3R[|."C M%."*BZ6\>)ZHL/-,C$-% ("7Z0],(-Y"^FY\]571;P]_2!DPN77&5'(@DZ^.4='FC_-P'JS.J>CSAHER=

M!_Y2!71P>F268LT1*A%'A;CR, ^)Y$(>\XB195@H;U6+K]MR:FGB6@##8V 5D? M4G&H%)2=!"M@ZMM)&F.74KPA>&K4$]P=&">]1A)^\&.N6%P:[:11%"$77^!A

MK";ICY$7/$\N=+\TQ5SID52X#9Y#]]:VIWF=1 :]YE+9ZL5*,A<2:0+ ?O<\-S;VF M%#Y4U$^D>:V4X^ZKJUYON!MZ#92;0]' H 8\XT6NJ3CNA."=@[KRE3

Y#GE&)LPYUDFO0E7G:?,$HM0S76PJ7H-&NVM%*R-W0WX,FGK-K!!:X//W:O'>U\>]K]I3KLOGJTR4,[MC4*]V8RVCRH &Q1S5&\]J4KH]#RLXS*.L,TOCD6RX-]!:R22H#KXS-

3Z,%IC-;-4!6.KH"Y$D];AG>>]*4@ MXW;_|^S^*BW8L^U+1=RG:HHZ;51?Q*HK,S0]P(# K=#W3'A'(+P)%HE.A2E& M<17+>^YTD6>BJ'7LTBZZ,J[LJB+._RNHFTCNA\!WU)U-R86]C+XTU29ZF4 MCR]"<2>3)C7-=/=^Y?B6S<[7]XG<6^N@HJ8?HE+@/97RGS'<6%RH0:YDYP>M'V/A_+#M:_]!:]HU6A@7;=M8P*2<&(Y)\-*$3ZL\(M6\%3GJ[JS>T*M@Y=?

PM-= Q_0RA*1]WJ'9R?\3R[|."C M%."*BZ6\>)ZHL/-,C$-% ("7Z0],(-Y"^FY\]571;P]_2!DPN77&5'(@DZ^.4='FC_-P'JS.J>CSAHER=

M!_Y2!71P>F268LT1*A%'A;CR, ^)Y$(>\XB195@H;U6+K]MR:FGB6@##8V 5D? M4G&H%)2=!"M@ZMM)&F.74KPA>&K4$]P=&">]1A)^\&.N6%P:[:11%"$77^!A

MK";ICY$7/$\N=+\TQ5SID52X#9Y#]]:VIWF=1 :]YE+9ZL5*,A<2:0+ ?O<\-S;VF M%#Y4U$^D>:V4X^ZKJUYON!MZ#92;0]' H 8\XT6NJ3CNA."=@[KRE3

Y#GE&)LPYUDFO0E7G:?,$HM0S76PJ7H-&NVM%*R-W0WX,FGK-K!!:X//W:O'>U\>]K]I3KLOGJTR4,[MC4*]V8RVCRH &Q1S5&\]J4KH]#RLXS*.L,TOCD6RX-]!:R22H#KXS-

3Z,%IC-;-4!6.KH"Y$D];AG>>]*4@ MXW;_|^S^*BW8L^U+1=RG:HHZ;51?Q*HK,S0]P(# K=#W3'A'(+P)%HE.A2E& M<17+>^YTD6>BJ'7LTBZZ,J[LJB+._RNHFTCNA\!WU)U-R86]C+XTU29ZF4 MCR]"<2>3)C7-=/=^Y?B6S<[7]XG<6^N@HJ8?HE+@/97RGS'<6%RH0:YDYP>M'V/A_+#M:_]!:]HU6A@7;=M8P*2<&(Y)\-*$3ZL\(M6\%3GJ[JS>T*M@Y=?

PM-= Q_0RA*1]WJ'9R?\3R[|."C M%."*BZ6\>)ZHL/-,C$-% ("7Z0],(-Y"^FY\]571;P]_2!DPN77&5'(@DZ^.4='FC_-P'JS.J>CSAHER=

M!_Y2!71P>F268LT1*A%'A;CR, ^)Y$(>\XB195@H;U6+K]MR:FGB6@##8V 5D? M4G&H%)2=!"M@ZMM)&F.74KPA>&K4$]P=&">]1A)^\&.N6%P:[:11%"$77^!A

MK";ICY$7/$\N=+\TQ5SID52X#9Y#]]:VIWF=1 :]YE+9ZL5*,A<2:0+ ?O<\-S;VF M%#Y4U$^D>:V4X^ZKJUYON!MZ#92;0]' H 8\XT6NJ3CNA."=@[KRE3

Y#GE&)LPYUDF00

M3)\U;2R&@2@>$)[<=&OH2]DFGP((4XJ?)<"E^*+SG6%82K7EV=K\|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|'^N^(T\C+"=%LVP"X]POG :/"M*2(T4T-JUO'"2GKCS!G]TI](FW@C1L@M?OP!P_&&V4+S2CCL$39!L$U0D2V7:9)OG&^K&+" M;7N/V_YYPFU/N.T)MSTY(=_,"<$[(:_]1>*QQ-B)P._VN:V)*B+W!;AB^S;*K!,_MYCABCJ]/@W_\CS_FB.V!&Y^7P=NWYTB\^ HIKS]#6;OVLR"MFPA.'?6M5+\ZJE+5,"*9JS31VO\X7^F#MQLFIH;UBUKK>T2L<.AM-YKT#\ZY*3+U'P142IGECZ'US(VB,<,4XDC51L*@$ MK'UD4#.$##8+M'@\)X$G"/AU5%>8CRK91">T"=O5;F!EQMD3?((_B="9DZ.T2MRU>8HD:DTVH["6YIW\3OM-99Z28:T1L%K==),P=O?+814C85M7WEWRL7-M(*|(0^-DFY(B&S3XGAHH*_RB/!4< (FY;-065V/-0\KLG(d\|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|<(1EY2^EP%C5>$GR0$.VPIJ,PCDA!MHI'O.INW] A5W$T)!>'TL"HP0_\L'*#GAQ/CT^^?)00\YM\8'+W^C<*UIX&@ MQ>02I2],$0^,;TNHPH(11T42!K!144UX)W;-J=P;*4%3MZKC#"7ID W[36B7 MQJKF.)IOS2N3R#DWI8+7M!B\!7ML6E>7H7"*VYD*KTIN1:7P.?41VG2D!+ MLF1EDMDLH'JV!\$9H7*MN*6J)6D.WU64E1#LMZ$P9VH2H9KJF7IOV'54-BXQ+E0S*0 .3"M!6L,%'/%1 MX]!R?!BN2,$L:B[%$<-SM"3PM2B"]\=?%.H6&D)I^%S=W]#/AEYARR;#DY@:M=Y[^!8N!QTPGIETLMW=1WOK(G+)1&IZ-).1P,9=0[:]_?0[SWP)3ST_4BG?-MR$ 5^<$]&?FGM2@)FD?UMJZ!N"MPD?^3>H6(-&7HN:CW2=U=K<(9D

M^!&,O3^82!¥|RU?V,¥[<20G0~7O?&'EQL=>:0$K4A10&=&:%'$>7-4J$1E8^,(O)TR[&/;IE,"97*95C)<-*

*M'C7^\GST4HK}S/LG5;HN4_1S/=H&P[O0W*JZ7@=X/AALG7*OM;Y&F2F>(`MWT"D]C &FL"_8!]-BTZE)\1C672;G+AZX1H-"()A;4CIKAV+,Y9&V16C^*

*,JH1+TVF4]*EJ>|O4|QU;@,H9*PS38CX)?96A3<2DB>(& MK1|E6,L&68?AC]=56="D4UFU\=3*A."9$#P3@F="\!P,@L>W1*]'P=2OJ0OR MK'LDT6NJ$@:S4!1#*

(N?,O:WC'>ID\F@&#:,5U R&&"\M<#G+ZV\D0-I?ID6 MZ2+LZA;CQ_IDC*5O!!QV2BR#DP\)?Q8\!^2&LFB//"IG@4>!2#/8](T$ZP6=;-MS")"*01L@,,(=?)"8H.4[ZZY8";.6\(%X7?J>I908"C M1DN'*I4Q^NVA> 1/%1,N(AMQJH\/&\&IT MO=B"Q*I"DVYLH8 CN=Q1*K.[,R=@\<1:YB O[#:J&^ID?1TJJ!<8>\|SLSV M_(>5[IRHWG$07*

*T>2*PGC@II]G!PR3BAS69]S0CSKQ'!&OOZFD1%>[#@&B;&[8140_[@:#!TV:ALR2 MT=W0 PM[%@U!.Q[0@^/UW#E'J[0F.^?R@W/K!S:XQ/W5*^M7!?+7D(>;)!4^*

M3M4'6\=T]^H+7Z^I$^=/BU'\0K5HT5N6&?I_H99M&PL+M!?=@(E M?'"YU\1.X'YG"QS&)]L^!!=*

[&/G,R23B4=-66PRAW:,O,W+Z1'93@$YB[TBFYW/$G>"])XF;7G>A0;,7'=D;PE1 M9KGEW#EWC-X>TWY@R:K&?_7'1NQ,0Q/R=3BZ=W+3%VT%;_:,M2#=NW$ZLUIDI

*M20(3!8X8#Z9]<"T?!)O90S)KV3;\&>*MX[;9Q^K!3A$.@L&VVQWVF)Q"?XX9 MRBG\H!+4'-^QM5*&0LF.ES58NL@\:.A;,%C0!\?X;&[TT%F(LB 966CBS"3I*

M!R^]M6G=Q7TH!EG76,(5?5@?U-,,@,3:NCLB?[K'F)4"&I8L %PRTZ/]QX-GA8'F'(`M/Q?(15LCXH+%FFH4,ZI0[$LFR:K"^NPX)27*Y1+>F ^2^NQKGS72H6/UD*B.*

*M+0W)L68<%RSP]#H-V:A!@*PZ;$S_#XU705>;'R+;ZM7LJV+$%19_1OLT-(MNT?X;\%.1X840YQKI +NQDR?Z2?@VV,@XIK5;RC[F8YHQP[L.V1 M"]>>4.&.(EX\H@*2(L;CI-*

*[$^ZJI8B(T\QT.>3K!(28RHFWI@IZ3=>V4EIWD/PC29QOP%IM[;"6;?G0VWD>H!9GX$-*X Q)@-'_MJPJO'70/*UA+[J//@U2Q_IN1_8T-F-)@6DC8C1T/S-G!'*

*S&:WAMI2"$4SK)ZP$9 MYX<(!PYAR9NPEQYC+|>#/FB-8MT#9U^[_&(D :37N:2SSLD*P3=O4E::&UL" MPZ};_^^R6JV!1]*

6E@5(D]E{^08E[EA:V,J6]_"5=3#WRXSB/&IAP3:%H/LT M&]R:E/C_9;GXYZ&&JCG;E%0UDG!RQG%$%]B);EIORRPU?#$;.U3#U65B@Z*

M"#OKIZ/GAJ[JR%BR5B\FPXQ+J12M4-I/;YN=105[XW2;IX5V=?|_%:<|DE[N MMI_21W5O-$>RMRE<2^-^O\4TPK=(&5PK?6X#Z-GPRO.

*<6B*B%XOZ/#A#G8INY0# ^CZWZTXKO4).7>* MJHU,8.<@U)/80JM(#^745KZM3A"K?1 M+N5TE44!WS%I6OQ-5U'#CO@B,W&&G[G!I]509UYQY#7D%68.K_RW?|T1LV&(*

*MEVF1_V"OOY-BI2^IT;##NK;%LJYDD48I€'$@; >>*7/1+#V5E]JH|LKPKJ*L2_1A MKR-AH*5-*/1FR%#,U`@]>(><)YEG&3=M<8LA2UR& P1R&Z|_#K!=9IY101D/5? MU?*

Y'8(W+KHF1=0_9F&/08I_CV[X2J8[H,>DJEE0Y,1ZU5BF=MYRT V8:X--E MH?:\@30E?HRJ'^@'TFHB],0^E8)95%G00V?TW51EN$L";KTH3M5Q M$#!ZRLPU7&Y>0E0=*;96-*

A3B;#T;W]G%#[" + :1UMN'TMWQ'+$6M*$?I9ZQK M[:P0R@5TKN|[%@JLTV/=_DKG9W8 ")^/=B^RH$?&Y@Z[?9] S8561C/|HV< M'VCO>8V:0,F=:^M9(MT=;:', 3[*E%[>*

*0X/WNM_<$+Y$E_(!,2LQ*QU-?!98'<]XC1GR<)C\!@;) MBY&0SR:>B@/D%?7@&"[X'-/I&J63P?G$JK<6(@EV 06[$\< M;]NRSTQR"'"#AGI'N7234CARRH#77B-0)XQV+|\"68V2%*

3H.T8;LF1IX-D)P MF:XWASVK5!5X<,,HIBH0W>$"%BN9^YBV$'}08VH+ ^=< "F-HQ5 8:%PY,:,. M4A\%+$U%K#A3-T8,YVE,,/OI-//5.U,<%9) "TF!A]+!4J1>?=:C^XLM#OUE!*

*MY)/).'^0$1XQ SV88GC(>FCR*L,)1:N!?V^'21P/PK !*LWW)%U2RJXI;SC[M1EFQC/2YZF;F\/43-RU_H79A4;XC^^Q'S:V556_-5E!N#SH"!^B0[=DCZYJL*

M&@M7E@_]GQ>RJYY&?. I:ANLJ:E/;^Y5EROJ[0#.!X+[?>)/WKTCA8|%DN>,RLA^&QMOQ^F 1ZTZ#PPQF!1=P^!H8*%+ M0&BKPS2^6BV&4-*

>AV<^6(Q4!WKX47HU17IV@@QNL6LJJNGID=9Z/XPS(&"L MJ__=F5H/3-5Z.\,C2Z@=J^OI?1#,!PE9T^4JCS23@;>SWX-9'UJTXI+)[M-V M6LZ'*

*H11X%1.44A:GU5QNV0U!9M#6Z/+'"*ANFQ7 MS(N;1 M4V-+5LL*W(?SGEE.#47>F;[B)4.5AP&S&SQ/.X>,#6%!9Z.5-;L'Q MP?>O2RS5'Z'!L+V,AO:>&HKUEA:76()XZ8]O/K??*

G!YJK0\%;\DVXLRUP'I=(MUAF,>E2I8ZXL=5B_>U;>2 9A(H+PF0ABZ.BXQ4(^.5A?;(E8C>^&D:>HTA_. MD>O\^#C@^8'4^3LJ]

*SET#@P+\%:Q82VHLQFIHU_Y]/SF'[WSF]^H&E4^TBK$-E-E?M$N.X5>9MMYC\[_=(RBU!8W62BUZ+_(MVT+'N3!8Y6W-*X?*

35R%7Z]1$Z8']?'(F(1%6)3F1(<:))*O'2AM1J:PL"C$V MS8>MUQJ$L3GR9\,K&_A0LI'+F4B-^8.#/5B^K2(+!55%2\N<(MFZ4R1;V@0- MH(B+E7%3+K(%&DH>_P!2\?*

Z$P9^@"'"D,E539Z(_^5ZFX!\%R)G%HVG%@#@8"W%;&KUL)>1!.P'X=@&PQ[O_*2-5? MX @/IU^G\B#/RX-^F,]#IO*@J3S(Z_(@6A-AVQQ"4)55_P1UI(;3 Z)V=QJ*

*M@XZE'6FS$TH@3J3OY%)G78GUPCLA+>!9FJ_ ^3.I#5(;,+ZS#=*7OQ-UJX*?9 MO.4*?@=7!PR/4I^:VOB. ^[4J^O.43CID ^UBUR5+!L@Y$W;$7F\B+[JVVXZ8158MH*2<[-*

X4+ZVDZ&([-]'<,<@CQOY.3XZ?/ MIYO9L59XRT0%/=#D3(%WA5UY&G=^[$FHK7-H/-38|\;4C%=1>MO$&K?L!.8 MW&\Y?]*1N%L_V.A$%S5I$|_/CBG:<4LR5+%,-\@??*

J>PH912F-Q7K?M)F,#[M037N_K]M[C(A:+2.:$1_(]=X;]U551;,#'%]89.#C;WY@_%Z((9FC\F9G&_W M&G3K&N ?3,[20N'R@X*(P+01;,1M.%5"4--19K/7SRJT?3/0\?*

9DWZ&_=QFK:[5@ MHPMS5.#'$8BC+G3? %@T2O,6 M.B L6$C]P:.+'YBROY]F4G.W%P8$3@#.QM,Y@&Q_ WP<3!-Z-H\K7GX1*YIZ8!^ M18F^K"P':$3-Q 8^<4%]*

9;.5DQ8&>GEUQ!""GF5(9<P M(2\((\S)>B=1K"93(DL?ZO,1K6BRB>&=P2TXS'2B VN_P2C-HHK:I,W)TK" M%FFQC__'WKLNMXUDV<*OPIB>[B C8(=EEUWVZ?*

A.A;J6:52GNEQANV;._/H" M)$$)91#@X"))9_0G|RUS9R)!4G+9!-WLB.ZV)!*7O.SN MFL!,H35/L[8,A>9#|XQ\"!2V,1X_/$3T?,B;01V(ŋP]1GL4<

*MJ;A%@"^V[C8M,)0OLWE;U69A/=J8#9+A3H">CR:_*K/,1NMS/*.P6E_@#2N@-MY2YRLRE,N%S5B632:G4*9VXP;W!'5?CT@'JI+/K^8:>]=K?QU*E)'"=RT.'@-M4FI;*

<;J;7[!:5Y^\!P#J:O)+>OO=;=+QA+^R21D)9=:)L;&+Z[2\RL06&R\@ MNX'D5/:9_P FO6%E-O3C",)EO7GO6U'R7\[!O#;;$IVCGM/G+FXQM) OFPG_ ME+7-Y,JLT-

*H$?'>R7[^G)3(^-*_58G6 #3-U;1SYK*1]C?02W;>Y)S0VY6 MU<>M=!.6]3K[G(*8J1DND0@;S@7A7Y1$&A<@A4F"'>Q6HA$!?L35!,@53>0 MU>A+/*95/[_#-*

*L*6_2ATX5C(GFF05+KJS/IR)BCQ: N6-C7@5$5!\VTDPEV M>O\:!PCTGP_8.:X3;%,9:-#>[,A7CW*@;40QI7@#U>X.!K1J-&3688B6L/ M&-*

UAIS1IOAQ>D2^B.'%K]LEX;5=FXL3P9Q,AY SE$'J*S.VY3S M3#8[I+LG\81&[Y&S:RIO0 57^1HJ:.@![*H<7Y)0O_@>6>L]HIVC+D4LU#F ME4D++FTDTM'E#\]*+:R&*

(Y6ZY9&E#-^UUU6M BK.(&2?LT77Q68L!AIFGC/"W!WCIQ? %:440\LA).IFP!>L6XFP-3,K M8?V>AS]4^"95'>M!,U-"ON>SX0V=U-]5#3G/,KLRIZY0*X"\NNH*$]\T4# U*

*M#B[<423BA,-O474U)7N,=VO^9L,XCZ[.FV5,-SF(%O>, ,V[T926&I]%78' 7^>.>RR_&$X#@!32?F MB6-@GL"]'J[@#9'?48(:<%#E$K>'QD*8/T$?8@8)D4%-5T=^".@Q*PV+-58Z*

*MST!$= FF.@4JL3B1S/ >28&"^!9^J5|_>)S:4N)OGC%5L\R(G,$G?3E=4I, M2QZ6D:!!S=R=E!HZ3'8T<,:BW&.S7CIJ-BMQ2H>3E*EFT.7FL-*

SAJ@0&HH!%J9K$]Q#\G"URF]% MAG7RS*Z-0FGL5M!::/X);1I=@]]+OI+,&8OKI D6<7[-"\;8OY/KBI1, GVI,#V\NGXPJ,[MC*XM<,4%V"H<$^^FY@B:7 ?^P:_,RT?

*=QV*BF_P$[!4!#HLJ\@U51&CU5;5K MXF*X/.9%;J^K@D<%?1IAVX89P[UI)T,ARJ#&A)E?;6';)V\F]=M ,:,UMYAP M]6"K3-O'CE-*

&PCXC'7^2FPGNN"G0_&.B^RE@^8081^/IZNW]P .QV)0B%!=(@LP5V@P15%RMM:@#]?"2'WB=A/-! M43VFF65B!-"M" J!9/+R8W;QBZ(#8C#7X]^#%D-

*)|+ZK%)^C:;**ORD7TXD%"" M(>L_4COY*2VQ^^Y\;<9^D1ZE/S,"=^:83.Z([*W1OUQ[YK9OP- D+_6'S$^!-M57;$HL(BH!D3M&,/OQ@(S,*1U[F-#X]|[61U"!S-:6M;>*EN2K2-C?*

*>*_N 2 M9 OA&MEGFR,JQ[T?NCDF_RC&5&2F\#-EZ@!M<%MYBJ -)SJQ$V033@#[:%D+ M"(9:2,\NB4F-O]_ &/N"J*AL"@!F5;_Y#\:HT]%R_P'<:\R.-SWV\EC28^?L MN%AP"2,I82*

XAF\O M-<6+Q6>Y/EQU343'?Z@NQH^W ,9);KRG$WJKDIFV@$&.7$U!M@+&ZD-0#>? MFSQ__,25RSK3!H=;R_N']2W<:,O,8DSZJ...#M_Z]S-'%?(V\R.0$_58#$,KJ M)+-':IQ-

*NB:YN.N{(8ZG$DHE&]BBS;6;A,N2>X8P;?/Z.EW/^;FJM?%D%ID@ MN!!D:KM8TW1*N\|_O05]";*8O3K+'4P_E=NX>*

*M'@G4QADG@Z]PT*G&L5]F(!ZQ3C_GZVXML8^G@0%*RDKY<8"\)NRN)54G[ZIY M$\2)VZX(";H/\(?80FA1*^1ZTT&$7H'O:U9!,3YMWFB>-CF%>K6QBG6SY^4B*

MXN&$E"FAA)<69A&GM1FT.T?<16XNT0QR998_QD^3D,=7+C5PS2]O&QXG)!*$ MCA%HQ% H(.M%#K,:\//MJDA+W&"&_]NN1$!V+.BO\#(<:,5ZB8/IQ+3X,(' MI>1-

*KJ/!AMW^],$#KKNBS8D_6&A6@IWV2;MJ=IM;0'S]/*#X3CQDUS"'!\3 M7@C(>1V+XM&&XF=/1G/0G6T_Z-I658FQY-N,5J,.Q2A.LS(WK[$QWAP*O G- MUAA5L]GN]*

(2;,3QJB5:0C)+Z/O%26/0.?/#Y[^GSR M5\4T>CH!Q_8),>+GL0O.*8&+C-P/-%9HG.LZA0YXJ,1+ [1*.J92Q.WQX0- MJ#*Z7.\@)Y\;>(= -/CI5F;/'3WX\L,6\=+BG8>3[%YE/+.ZP'-*

*J=79Z)AZ1.M%#\(\D*CQZKTU6"S)>\/F(A,:\!'-UQ3?2#9I%*IA..C -=BUCZK5HPW418&@=M> /T+XWB-*SLHS7J:1K *)?9;5]8?R'ZOK&LRXC QPU!JCO_.S5+!@K(^EZ%*

M4VEG;]>X/=OII-'ZN(%$\X,5^^&A@(M8IB8+!O_:SY15F6=@5^7*[#%&E 1-K8>W!VV/>$>>=YZUMUDF@1>T#^CNR8AMU#^X,62 M_M?(KB"JORJ.>.6-*

*AX)WQ\K[O9D=/D4'3W3]ZO=D<0!*K("& M3P\MW:H.[-HIR(-KN@UT:\BZ]#GYD?4KC^FF <+'\?OM.AWGEFM=5%BW*F[MQ3@N8!_& G?,*>Z)*

(9U(B\M>_.AR0486#>9[#3<-9C.>@1I >B'6-[03H]Z+Q@[5U!=G<'M#!CK %N$5@8D6=!EQ>;"5<6;F)-A*CRZNH+VMS;,)\U!R\9K>@KAQL"M3FS^=_M;\;'/:*%/OZ2XAT+_TT&?*

*7^VUS+@"SQH*14S^.OT+O'Y\C#N;2P6ZDQ|)~M,HZ3MD'F70\R3:=WT!E.U\,:XOJGFN4D]$6OBKBRV1YWJ5.+MGF3T]H M2;U:=.H&7(D^03*:?9YZ>`]TI=,\?;?*

Z@&5HS%?76C_G KC2.GOX)0H;L92/IE MP-.;43R0VS9?A'HSDK;?P@VP497]$8I-BOHS7XV0I|TFDI+*OI1H_>PU=^?+5B_\K;U'CR^_@-AS7>[TI],&^*.(PE|S+'N-Y M[!!X+-*

*ID^>[5#K4Y7\Y142*YZ94WAE.T#_6DC-&^K8'QK!27B2N::%Q'RXYS M\?DZGYL1^S\'70\BO>*+J2*%1&;A\!B|*?H$K,B;68FT8',$'<>T"D5S-+@^ M(2+'CHC\2K6%$R)R/)C#*

<3_=1%GC|\V'GIAW+ED!J9':MHS!IZO9%<'/$O MD3NE4!-?)IK%]JD4@QL.!\JTJ;.,O.J:7OZABGU/R@DG4,Q^L 5&IM2Z<,[E]_)R\|#(KN/&G92QV MSI[YSHU% +U>#

*[^UF(/0+2,J1-/0\.Y$Q%F)\5!W!3SEO$SNZ93;=LJ% MA5K+NAFR;,(_B)Z K)_/Q.5.2,X\/WL"4.Z&*X%/):*!7NN0[Z'.B)8ODA,> M #WPWG5K(?;=6$LTD2-*

*(6H+YC*GE#2G:.V)+L=H.GRN 4TE#R63,D(R,TAQ M#W[,FM83E>Y>?+%E9?E .1DBTZHFT2X,-^S<1TIM$W2(>?8C0 V$GMG @MSU M/;I),[H?E+W$X1%Y*#R#T0*

*M>54.R1'V]9U @BULWW;678GU^/O/QU[*U-=V9WGI2HY?;TL*KN(G*(Q@3P(T M$Y-$ T8)(WDGX.507,!1C%L.@]+" Y8,BF!3[_C$6TO9C--T:CW-J'(#NQP M5:P)5R/^?+%*

*(*4#Y,5";&_.95R1#"IW@*]EX4;G%CYWE_1L#-W<-3)S>GCX#$ M$N"<-/HD:QFM>R/Y!H9#W]+R&[WUP+V,,XJ$\/7-?32$#%1C.E(;.W!=P;P MOZS?0F0G\-*

N1H&.?"X9;2Z%_MCN!^?+_-^Y=\|>IE-D^?GCUY]NK)#V?+9_/5 MJUFA^>_;?VP_M.#9_[9CR.?^6]5M-QWYG\S81OAN9NQ3?D11'S/ M(>

*(,3<"'(W8,,C^*RM^'N%POL4#H#@*8@*&67L=(O#$+:*9T,@_<@QZ4_Z8J M.NBI ^C7!A=7Z%,$$1D1\F]+M&ZNL\Z[.(O9V5<8#7'X.P*\/"Y7^CKV\I M+$H=.VL>8#*

*M<28TO=-SIPF390'SEDT:85L).\/^92ZZNK++:UNB8DCMJ[GME5FC*I-EO @,MGMST)[[?JNKJKW:[B&QWSK[C]+5(WI0,?(S=9]#/IL7L,PMQ:E-[/73.-5P+*

*M)LJX_L8Y+U1'V;\^3\PB@_^2XC/M+^YQQ@?\US/[*6C!^;P@'C+]6[AJ=$ + ME#NC/KX68HC>K>0+V%NO7%6AJM2KCQUWX_E)HGTI+7A!*YQZ>TES?+S;H*0$*

*MIO{(C$6&AG+4>(%\R7@6MZH?6S5G3G=K]DA;&1FF>&RX!6X/6L5;]^C3 3C MN@~.B?Z;40@<53A&T)^^S/E")32*Z,]^V6 MTEI $]A;H>G 5G+W*

P])!NXP1XS"HM%W>%C,7LGK2;HTJNNB-&!(CE(=[F4 M<"1,//#DRZ[6U+-8-NEC9$@< G?R\KX.M#1KI1VU#%S-\(M1]JA ,*

*[>>#]@<"2,\0@4'3Q]5\6D86P[_1O(*QIVMW)6<6#-J,ET.=-\<93E M^%BU9K\I_LG&,^>6]B(M)\'N(ZTZL*+GO"B(W>UQ[,+ M_&)'B>3HAG8\W:8X$C9-V?_?RZ^M/G"?3-*

*^0*D'D\W=?49D@=@*'O&?;=(T2R MJ]&,'UAV"TVX148S=4P$-O=)/M>X4&2'3H#U-65;WF/571_TT;.Q!]= M QE/SQK]^"W*H;T1.7N^Y;1T:?"H15!(//)D8/YA*

"6[!.TGWAE[,+NGH5O?!2M\./CWM%S ML\M9WF'+JJR@=C>Z]5!+MB@_J^K1 !$D0\YZBP(*A/D+>;UNV MP]97XN+[?A_>4=:.5VKW"0"1F^\UW,#B$/0" -L/^JB#_=2?*

*GPUNEO.JAO\8 ;PB"'*0J>A.99 M-B.MIG^D+>G:OA'/9'O\!UNAAX90V9"J=#D0\S@/78FOGCP9^4K\5@*,^ZI$ M2P0/'73]'64Z^.7X$,SFI/^#G1"JWQK'N9$6DW$ZJRKEV/+-!7*

*EC(EG>A^2 MYULP>\ZFM 8'<+9?_J9"P*M2=W,\;9"%!GUSN[AQMZI>.U(^,#QV%% MB"918*T>KE;+<|*$0YW@.%"G(>N)ZK; CIV*OT(X"+4-F93J^&J3A>2*6UF*

*M0*Q)"%8H';48SZS9Y4CP01,+K,AJZ_Y;,.5X.6B3O!^N6LRO4G/C?';Y=2455 M1E:\FZGM0*@M-P-]0T7X_]+J0[_$VV2B&=3F,T;L/!\O&3L^EJAH'[M03,LU5A'"D?H8-*

EP')P965),/AF&.VF+=H8:VK_$AA3^"!T>>-S>995ENM[M%@R"WP';"RZ"BB8MYA+I/)A[V_:7]!:"ZK===#0\(':+][S9DSRV(G[ZW=3+0 MKVX&RK8F+*

*F/H<&BDS]>=='W'=:N/8@#/.0< AW)7HO'4,[@!7D)L,V#PONI6 MCWY.?CD;[E+ .6*YIA/P;N3 N[.3\.X$O#L!{T;NQH\,>'>I3@;*4GLM9>&! MX)0.[1=<,,GI2E+]*

<|>7+!WHS(./#5ID9(#5TCG.V&LU>/<.[''JH^-5+& M1K87/>4+!6ZO>4V9=&/X$4KY:.,K2RAP/@]S#DB58K@A;=)9P M8A-Q@>.[76,<8Y;,.Y"Y1QBC?3^AP)I<^/0D\T7?

*XC3^-)!:;JD)41%1'NK[M]?GG8JA6)LA529%9.G&!]-T"P,1#DZ_7$PN M_^.PYQU*Z+;3=<:>Z*''7Z\3%(\YXP"+1SJN;[%X;\8%ZX?A[7@A@P=M&Q2:*

*M69+&S+9E2V1\=J,G>AG;%-1L>+> :'M:.++HBM2+LX;OUM-CI0B?/):B#K$ MWX07NDV;+VE]&(N_,*K"US93\@Z#VA$$(B#UM,-E(.;*NK&,-MN14/!#6\623QSH"^]#8U/CX-*

0Q$SPBB)\CM>Q.P82X\ <5 /5,U8(_=V- MA@+0@AN+7^#4>?9Y8YZN,5^R53Z0#!?"%@'1,\IY/;X-?NHJ8#LX%Y,Q5L@ MKX*]E[!#XRF0+2E7UW/5(SUX)+L5^:*

*<,AKRF!DWTN/N8D"'"76CZ7;LC9V)3F-43;'29*TXH22,9G77%'0*T UQ!)Y&6'2Y)P&Z2V MJ,Q*X/2DX6JD'4\N\EV;|@2LB/^U*9H9/M/JI M&$-+B&LV(--!5 !B6'H$F3]91]DMVK1*

*S^?H7S$-51#?;)=>UV2:8Y<-|3C M.8@^/RL:>&SW@-,EI:;(PJ=UCEK7QI,ZM3=-U-=@6:9-TXE$A[!O=2IHG8ZJ M4K6^NR98C*5IQFY[GSP]>,1J$G5C\j;(<>*

0EDQE/)B3#;$QQZ<|5H1,C3FJ MP16NZ%BUWL(E7Q935M0^HV<9%A?T']>+ECVX5]V>Z-WP\M&E2+(J/1C!8.$4 M"N#(^XOH9ZEB>XO;^GM-:X]V]#UX^],L0%1[QA3]76-

LQ@ R+:|_3@I7O-M!5B 4P@:'M-"!QI'?DAY=TLBQ)57EFJHDQV<=^HAWYEQ+V%)M.MI?C^[==@.1/QZI_FH_/2%B@Z9!2V:FTD0>X-HB&G.1-4#JC.+S"[.4KD(. M2"[!!O*

MW4(+UK##+16+<.JG,#!3F!@@-QIZMI'>66<>^SE!9LM:\Y O_I,@,%/XM"/? MM62/|!A"UO.2P!|!V<5(K9 /5I3T<-8Q[!\|9KXS"'@##2=J;2S=;S=:*

*MR2UO:KTX29UMZNP/LS=))@&399 E&_P^:)CH7Z17;5X'+$B&B,Y/\X *(A* M1/VH4(_1B2OK!,8X@3%,8(SC V,,N)V10|;Q5'F> @QN'K&,'4432111HM*

*M=%HEIWQMU!4)$KT)>\18/DYT|U#$>]24TI.DA)T)56LNRACQC$6@W) M2>X5;ODNG!NQ98AO540A["S)UP_(@L}'CD|.-]W0.-YKC5QD]@-MY!A-|O#^]TN$/3BZ*AV-,T?*

*4=/.&H]+I?'9X]S/2_[!_J]6QI)?'PW1YI@CK M+63^$P#'XIE7JGY)*9(Z(H?2,UY9C3,;-N$1R&N,>(=8&J3+PZ(*;2*&*Y!" MB[1W?LY+2,TSI^.IR*CZ7P\[B@ Z0X?F>-&@(V.N:LP#-*

EBK-?OF-D6O=PI& MUGY^K,I:KB|U!@.EZ7QI%;:18X+XG-'HEO@0,- E\ >8TGU Nj+CB|>R> (MJSS.72KEj..SQT|^F'X.S*$.9Q(OX'C"-MOOW#%2M95:CKD=^GOC-*

j>5/Z%Q8,_!CV44R&1IGH1"PZ'O+_?L5---::Z5EB^ZL.SA->.+U6 M7KI&DPNK4=M?3|=j,6Y[^O_)>X5>4MJ-ZJ4:N)5J 1V.?GX[+OOU:@47\E ML. 06 0T+18LL!:5'/L],

*5T'>E\U+-.P?5Q4T!PD|05VZB=(Y%*UU)2B&G M81:8F2,+A*%OB70E+29=Z-[LA4#BZ@L?YL&M$&=/GCP?>R_$MPK1]NV% PC M8VBD++>0G.I&0=6PM":&N>L7N2-*

*M=@UYL2=^)RU MCZK5*0S(+#69*WHL/$W-H*LBI0Z/2SX :S-8:8FFU9QK5T$LT*_]YVMC;W*B M^INFG+M1"M!#9#@4/J0+IM.U:1]|8MA4O#Z5FH@38V&^0U-*

E_H9I39P4;LW MW3Q^E?O-)EQ{@$)-=8Z4& W<205SM;L*74J8M30;..4Z? OV'36<]C MMZ@"[RWB3VCV!ZX"'OQ4IGO]M[!\?_7WD3IYLJN3@WIWXQP;)C5TQ:QV?-*

/\(F9>0Y$'K6DG5/G&B+L)EGM>+;@V4ZM SF.<4S71 MP6A19_!^LR2(*\DH M8HHOM=)Z%)\LP--?.C8B+QZ)"}!'S*?L X9Z+>B1$@.D>?85T#]VU14=MURR

*ME$}K3Q)$=!=U8*C@L.34F<*@(7{8[O2K1)Q!"8V<'T)$^M,%^;$GGB\U M4DMVR%-?Z2=)@Y"3JY;>8L$R|!XJCD5ZFSBG"OT9<))@=S2Z;CGU*Z)]MPM* MGT?*

*#K0@FY^3#**FF7?:0&7A2B>@2;?QT;>9NPA+V*..H8H7[*LHUMXI&4B@#3V[.OAG$>X#,5S+\1=L54/5LX.# M^G&2\E(D,Q[L=TC*

(7&#:S_JI3J9Q$*2U@%Y%QHCQ641K%)|8IXF,/>$T<:O M2!-6PO$\!-+XL6;6#.P5;B_*EYHSO4F$0JY)&"T#_T!;@#L)%4Y:)JE>=V6^ MX"T6V5@G#/) WS")\PP$>#

*3X42,V2#L38357< S_J5)ES:_BSV(_#WCCF MI6QZLQ]O6$^O,H=!7@*QR6V9U5OO\P4E@:R?OAQJ/6;,U4PW'<> M+\L%$'<@7%:I*AZPK!D[L(ZB'OQ\?*

(Q6OTF!"L9QL:.!90[LWV2KMBC8A M,#YCC;>)DWI!KNY'[$=5LT0*+RACMA8,N89F6U^=+]_<B1<6E6-4KY,-P+M4\0#@!0S>7&,^BVDCTI)-*

YF49G0!P#8I$!=:I^7BFD(\XN5:ST6N(;3GF3'K M26H?BM,&4]%=P#A%0H\9HC<@E4U$'?]ZE!@)E_!"?Z33LZ)<$;4&\"(\"5/U M@V):NJER@N29KRVK;MXF&L=ADX1.KE2JB-

C^GF=O(<4[%/GDPVC}>/I9UIE:^,M?I)A+3?0.>3Y4#?TB:(0899";9@`M:Q>&>Q38M>:CDBX.HX4.R8@3)P-C51,2^QV`,M1YXW!:00J:4\Y"+[XM002= M@6VFFOZ%_+]WT

[P%IV=\6G#R<6=FE8QB(YY*3;=2TU&6FOI03LUP`M:8^[&>,S>[!-_6EVB6:V:E6B?A_G-(WID)3Z]KIG5,T+2EK[%K^24_7KSZM^`MS;lV\0N5!>PR^2HK,
{JBMA7;3"1=9PW)&]TPEO4;EM^H?WZ/-_L,"W0,^O/& M'Y<'XNGON4#V'DBJ!A;0O=D&1<%=Z_-^]XDO13!,,;@'V5], W4H$\U1V_==WQ MNRT\+F:34^7Q>"N;?WZ|\
<')\&A}C_>6L?0?V)&I>^>/8)#?Y/ET"/N@2G;/H] MQNB46O&J#>_5XV`W_6I6/P%_}?T9Y!",(L6I:PV45S$W+:B6H-6=4MTPE"9FRD:_'' MT0WUJ:QSB++.";,V=LS;2;
[QA%D[8=;&7F7^X5BJS*X]fF*_'$_YI$1"$T0`M'?&ZPK0Q"?-+|^$LGWY>M-@>D1RQ(`_;'%MXEU($F0L]f+^=B0BPE"QDO`M4Q!CC-
RT0G7.:A%F!D#O9I&=&L_W:3SW^27OSPK&T?8T>FL>DG4FA,{GA:-? MBNT*YKB^S[P"UY0MCMDXW>.DWA+R?R=D/H-0E:PPHT+|%@@\8>D=S&WTS0,F
M2BH]=*2BYP;83 (hF'YZ\E?DUC6M\ 8GYX\M9@F,7E>8#X.U\-K,&0A;IK-*>RV(0*)S(.$_,K<6T^*\B#/ MS6A--6Y1'2_6_F8O/#_^=I&0;45&'1=-H(5 L4YRR2'LK]$A(0V"[P%*\/-
M_#?\ [?.D*Z*,2"K1RM0JO0Z]'0V=]&E2NL:Y%]AG1\QG)"?>Y'1*OZ&;>'-MBT$\.WL^:O'#B?^?9X]_F,3_S/]Z"(F\'_@V(L6=S7Z29' M;3D$-RX.*V!XM#M_5$3JVXXR?
U4TD\\SXZA#96PZMW$P7:4L' BXL1B<1*Q"O G_'21$U]6Q5D7[!"JE;6L60M>2 MW!{!/KZXF6&$IF \K6O^035AC3FG,=TW!QB2#BL1]WS$HBJ7.3'!(FMY!0*H MH+8H[+Q4*@]
{R8(>X7M4ZL:5[*)#/:L4%BD+"GMGENWRR,3:(/[PL[W7H0 M";11'S(:"YAS/KBK,*$A@'Q+-[(IR&]O\$>>D[G3T:@N% *@;UC%T6AOA 2?WCF+ZQ320X>,E- M59AS%?,KL/@Q%95
+JI"XBZ44:.&)'RNQ<*$Z36_BF #H8?R@6R48UDVHT)7 MT+)9<;|}B!U&FSNSU6^3!{>C\..,HV,+%T>KA'SH\Z#XXP')D5P?.LZO44_
M&)?'(';.IB,AN48^HED]85ZXC/>@,>RXL2RZ39V/BG'O,RQ[&)^ M+:ON(?#@42V;427K:-FD#91.[,KXLX\;&Q7T"AB"2IS[W\|ZAS;.^%G29V?& MPWA^V.Z >]K0 ZW}(:2$SQ *
[JD'&V=-^-7*&:DAEBV5MGB =6V*RAHU*&4! MH!?@O=:=1>-'0%/3K-,64R1jPNZZ MU-UI'NVX%\;(_!9<&^DAPBR'-LY]^CGXK5XN@H27V;+41PJ"Y4WMAQ9[!RM+ MFYOHC\;Q]C-
9 2AE7 [S7^;UE11?YT6N7F0.D\Y/[.UXT56IV?O&[LE?SZ> MQ<.6'%U0DOW8&+\!M;;-YU@]12*6*WTN<_R9P!Q93?8/:6UFM$DG/[5IEYBU M)6Z,6TGP?6<\?
L[*#$1]7IO0JLF*P(0D7QHT.YU*=!363$]QVTEB:.&=..'6 M;#F-^7|8'SX',LR__>79R[]/WE;FRM H]\LOOR64R$"U$'HO?DC[7BGZ,+ ? M@2U,GLN\/4SR?
U7UV\A[_>5G6_BI9Q.A>;,1'CHEG\>GC>C\VIH,NXH M*DEWU*)VC/ HUON8\6WXOA-5LU72G&/!:4UA+.D,U#7P_V4-L@82UZ'Q3N/&
M6_S'*)K!HU$J>#EMS0)1YAUJ<+4!JU84%FDOJ@)~-!6MY/_T:*&<,LV6,56% M.:Z6=Q-0(+/^NEP>0WJ^I=QI-N'@(`7ZC4O4NL)S$5MX46TB_K$'/RC+L8': M0BN":$@P-
L^RDNXH[A_7 1;NN>0)O+|\&?GW2 S$>$(),1!E)1QL,\'7-XP(.MDM]EGW.2NR!%;-4P0WTJC'NV 87QL9 YF[?PZR-)W6IS+]Q-RBVON#>
MER8';_D?:6TVSK.S9/+TR=.GH+*D&Q+(A=N M!5:/:'W3NB]+WKOA-X["O3>...S_>/Q\LO[+<'!7*>;_339OHD;@B.$1<_3_VWK6Y;62[&OXK]"1/2]R"
M?9;O\YZJITICRQ.E'MN1/'.>\Q$D00EC$&!PD8;Y]>^^=N\&0(F2/2:HPZKD MC"610*/1O7M?UEZKIG00(D&DNG);!8);'D.6 @<;,=<>;2F_V,#,P#OVD8;@ M^<@ 89Z>P
M=>MMJW=1CN<08&X,ADV3=+E;D)M-R8"D Y%;XT!G,,-5D:[A0W7C0KC!PFBX M/&11|!: 4S0NJT%4R2IO;Z$*[5/IP>TI TJ4Y=2(MA.1F.$O@!O!0#3^,8C
M@>$A37L*L9H;)#D^"Q-<:KSZ"BDJZ3QNOMX@DI*N3$]*O9/.2=RM$!T.Y& MY\21ME"U08RGFYM4U)5=Y"PEA$$IU_W=,^->]F-%,7&Q*X&!O=KO*I9-IF MY3*-
OA3(HWL+]&|_7]QXT"FN:65F&I7%1.7B_VA?.+PW+$O@ACM/K\N=;G!W9]#Q$A[":X.'X!"_UH M,=D4)V_JD1]:L1AI(DU7P!6L@NCHV:33&^".1++Z>4E*@V^YL F7U%#!@S;[
M_/C6^ZS2RS8GO62'U<:2O6BJ>D0>=G4]??(WM%31NFRK: 8O 6P7,=P\/68T M$]:['RU+/#+SA"Z|@ZO;/%5* +H9(*)AB(`^R:>35^=G'S]')[.&*K19/8";
M8@3!#8X1OG:+]V"F$;:-T?&3K6?1T?1]W9M0F5K&D=.QKO7UFG'L,J&D8!0Q M7+XWI]Y;_)P6*;>*11]O"C!55]D*+(=.IUU/3M:"?'#;!<++>AVL%J1\^2]B*.M.CBD-
RYN%8YL3@5%5%^7O^#;/_9XAR@)G,EIG+!%P%$E%Z'<3]7F<05T3E_VYM7OZGCUYM5+C]N%0.!W,UW! M5\2 [:KGKR6>]Y$2.]??R H7OCM [EI,M.%FP+
[M$:'B05:)MO/;T>'_(G)+S MV)0#I\>V_#4OQ\Y?\[W2EMORUVP1]^P4?Q$=)>*"?QQ(S^SOQ-LR"%7..ZW! MEBT4G7]_R,P%?#&9.O0"%FUE&CJUY7!4G
M(6.]YBVG.:.;S7M34S6OLUBV^[ET*D30E0$4HB"ZOW&5L]\22H3?79T&SW&=`-M#QK%9 S4ZEN>.D\?/WFYVU--6X0QO%W8A ?\E!,]:N.2%]U21 %G4UTG?+BA MGHBV+
<*/!)=*)\YTC/,|[%AG4=|!'TGB@]NVOP+N-ADQLG'-KUOA.0R"U+%N8 MC]_PA+;E)=V9)_2]:F4/8_+#1=W-FNZ;T>]S3]\L".\@7BL+*>Z*6#9K97>3 MOT<3SITA ?
ZP1\#P/@?Z;0< (SC@0B.>W3[&#<;27WV:A:3UTE M]!W^LT47+R2=H!%HP!;A_#!C.)77-IVT59%5E]AZ9O#@@9&&#GAOI"A"0,# M2MV70O?$B6
7)8R_S=4EF;23M.L_Q1!N8E9U(P[NCK6KG:FDGE6E"U4S!&\. ME@[\Q+VL6 ZEMZ.2+^N1SZ)IO@V?A/6V>,IPDKH5H!&3]9ML_[/=RYOLOU'4 M^7SQ^,GK7;?
V#56\W":$Z5ZBPIX0#%$G.F,U13W4=O3PT4MXR32]W MWT@9JQF%T#3?2VU =B1'!LK_X/D)>*\3(P$J(CT& DEV2KVR>^CO[SI0$29] 4QVX.#$2/)X+ 5EU!YH%;=')[PFM
]JL1J6PI!M5[W7KP;'PPZK-%ER/0*D@F M0Z*MHF/>P?SL#E&U\W>G*28>GCXJW53?CXY42F[[+(A"D%:?.?2ZG,C5G:9GQE@":;@$&CK M;0B\49?YB#[D&7B]<03.'6-
_Y[MR\KCNYS=6P)0QG'KH6,^O]T=&(*OYO3I&`M[B>K=G[ZZ?STXO3#YQ/65COY\#;Z^\GY^G_U]>VO/G)UWNSY((=2F MY>2V-,- -LE=V1C%?D9LC6ODR*5
3(HZNP8,.2H9MS>.:^CN$8,.]TK8@?*[JF=O\R195RNA*]BY 6Y6>#H$. ^!$Q:Y7^TF<[P8=_'"MRT `>F 0;HC[DEZV-K,%U"B7.NM*6KDHBR7EFK67YBGF[:Q1
MF^*6ERQG(2N0,<^>P80SMR[E-Z\';>O\ @OR^ M)[\CQYWKIMR$H$4*4@3(DQ86[=%,D/I(P"J_FD\&*5H(4I=D>8N$*V4T+[%? ME$E;D:)B,W$KA:T;.5L?#E%]\?
+UR!WDL37K> ?YQ)Z1,%L^E!!N%1#5(&6O MS1#L)!]8%4^<@DR(8?NVAZZM&VG:S;3/H3L*55[13N M];5GE=Z$_ ?\(D:.H>,7!DV_2"GBVLT\)LJO.&]X/-A7N* N>,.6#V-V9X
M.KZ88:8+G;FCL&VG[N8BG%CM1^/L>T?N3]B/A@!\>]W!X0(!ZP_O=`0'/ 6 M!\/(DA!P.BP@[&!HB]:(:Z0$X(:"IS;Y8LL#X2Q%V\6]L0`Q_1-) P"!GX M?R M&&!CC3HJ_IX=L%G3(G.*
[]1Q/DJ0*_?9 X?2K>@.6?%'6X@W@8PX^..17P.!V,RU6> M$KTP@H4,(H\BY>|!")22>RJ(;DPC6?!Q?K7B. C>RU;AIH$#F.50:O MS=D!MJ-@OI(C+9L02)TR="GW
%)+'!4R3XDO5KIH9==3497Z-]"ZR!**>S-6, MA-ZAD]58(P&/-2-P4,EL*<>O_A95,/>U4M51<942;6"DF QJ567@M;YR(BS/
M12;@{(S*_;JL^.1[]4109%HK[!/&EFH.]^G6"'#CL"B%*>C1K.?88'54%_'M6&_(ED0G/_]58NRW:N4MET<>0:P*2(!I$;;3I_/+U%7E+.@7@ZW4G3Q0% [X0 M@5EC8K%,,]C7C-
:NM)U5TZSQQ?PAD=_L]1N<]MS-:; *(C^V)&5WJ!ZS(]*]&)H64'!HW-',ZE],GC_Z+8[ANB@;,&*PP M'%T]j.E%;"$3FE)&)TCO: JG2)\69#AIH!FVM)R556Y6M4AS-P0S\FF<8?
W M'Q#.2;Z+1K!MZ-$ON=VQT^99Y.P1*2T',\ZI(N!!XC;C<37R3WXfY.2URR6S MJM<#G]/+?(4C\N+IR\V1]R5UOZTCXGOF=!\IV4I<>*.8,+9(J*X&K.6/)A20 M7:.N -
SM9$B6,H8@/Q-$L[=E5&&YSF5HCAJA"]fX)44LN6G],%DR M='9@T6;S5GWXIKQ.:3P.[,)]VWQCPL]HE0$=%.>4K#CLR!.]T2#S> "KYZ-W A^+_&V;8W@;]S: M\$GD--
A%_)7FRUW#SCX$/K]OXP8UD">2U8/.WZ/K498X>V$*]6XY]HH7)XVFN MQD\8\?+Q)9-='TA;GP4^]Y(6E\FE=5X=:.!3Q!6TU_^^/O42&+N_ 995=-.7L
M2]!D..2\4O,+6OL6:ESC5R:40\8T+^6_.#/4?2-;WOXK+,Y/ST=N<5Z/S.*\-MRPIPQ4FK1[LM=[S%\E4ID%W]MN(":!Y9-PSKMMY@-M^HTX=Z63H
,)U"%7.6UV#EYG)4G&:+K#)]K) MNMQD-?F(X'K6.5]T1C^<%;'CY.PT_>&_VR*1I6'(<4B%)X)+&', ^/Q%@]-> MIPG6MK ?! U2,D=8]19 O+U80^/)P/ :@BFO\K6*;VXF!Z,RL-
O6KLW.4)\[MX<%.^V88*EC>;@[%Z. ^NHZ+Y9I#@LCQHTA\@F0=(YDA C^.>W3Y_L=Q+HT' M'L?G4GU5WH1'$4[7%%P(UZC) 4^>~<0E:B@<*:-;.@b(R2L]##9Q0Z1F6>S2FI
MO.V!Y9]HF!U14VEPVI7/K)#Z6H8RTI@M?3A/&,]J+U+:\H72C9+\3X\7GUU-M/&ZUA!>/?QI9O"I9,-@WIRAP'1MLU]F9LD@[1H%Q*"'+^9G+T> ^F(^?
C&8U'S,I8?)G6N^X8?)T:Z1F M72+BE_$R)!5]+P1FW$'5#49W=|_D^<;TL=YKEE VF?<"_Q8\W?I'+,=;,*XFM8@K<(0@CN&4CY 1"\7" MPC.YSV%*\7L8^E?
7^B;IX'1%4W>C8*_$-Q<>B14?'M^8@>Q5'tCVRDHYY M?%&6O837V%^+W61=:KG,Z">S6^ HGX\7H'%:&PPC%=ODB89#-]IT+ QO4Y2A$("&"]2B]*EV M>NSY)1S6X,?
+Q2*;"2 1<6KE.G7QR7VNF%SRD<%;@S<@=I\G,]?[-DM6R0RA M0P-]"@[70UL"%< -G$(+2?!M C6#Z0(CQS3HFEC.R"?RF 5N9R#Y]! <.OW2!-)=4P#,TJ1\HD0GCB:/_^/6S^\Y;
M&W']!4RQ1.\=?;8Q"{]1Z ^^#//V7JFIB3!/L=|X/4%ETQ3ASA@OZSBT! 6&S8GB#9@'^4_#B/:8,RP=@K-AIT 9-U)R2 V=:9"9]BKR;&%G](9-ON#_]A"? MLG$1@&GNM
5X_B_MSGS!L;G8E^MXVC-YN?Y,/C8YB1>5C#'IZ@XD&$Y0_<5KV M6?HW>4E(L;>D\\7P:NH>D -'W&G)=-[)8#VA#]6\?FS3-]##<2\;S$:'I#>/Y
MR;MW9^>_GGP^^_TT>O/Q]L,/)Q\^_R!$YQ?L$V'P47>! M(B^C)4^?QU87UW9C\/D6B?FQOQ,[:B6$Z/CX\9/GNU.X,]+R58I.F*GC:KL MM8LE'?"1O*-:LZK:
[NQ/0?,FOY5RNN6F[4%Y9'AL;:%TUUP@?;[M&FX*4L4 M%H+OEFVC]+(Q?#U'EQ4'=ZZ):UY?X*@G6>@@HG=<9?B4?\+=)$E"K,W%3$Z-D"]%+[F5XRF!]VY==D]F[4@^RZ0>,
MW0%C]\|Q'#!V8\+8!1:4]?)DK0.T$^#RUB7J28'#= V'!4=6TJ85?U*]20@D M9=63: [OSO1K(CI?Z3ED_YU0^[U24PBRFR8Y>3SU5D9(Y
M9>R.+Y6U"^YHV@T"B#G)G%7I59GS2<=<;PC]V!;@#6*< MZYKB:#*HZ4$RMHFI==9V=;=\D1Z^B3,ZD>Z)R"O+W; M(XZTT8*SD8PQ$DWN1*D+**F[D^ ?
>BW:5ZB%EST[_Z(/7?HL\E/&P:O7__MB3U?|H\+*6F1$/FLO.3;$>XO9'(A/!.\]21V#.]VC&[?%N 44YY*Y**Z]W=Z M3W(V&Z4\AEE5-\0BE.J>@=]==-52,V+DY MDZ'LP*+)G1U
B(P3LH7TGQ<*=M.4X,Y:#0"\V]B%BFI5Z]*;DOM#%&&,V0Z MW;R%%^@\R .,KC=L9$3/Z=IUAI_ZR'B,WLNOH["Q2J&D RU4\7 3U'W>YS9+ M;^.!X: 0!3/O%)BLY7EY--
B%Y^89XK94.&$69=E@.V#-N6"QR#;5BXD<)HV$ MD65VF(!<0>-"D3S?O> MOAC.@ZDB3.)%8N 1^=)M+P6T]M8-
MCPOL1J4I6706K.DRIV%ZD94K=(P!58 M72'SM)YA67]7.K+;+8P:5\8QJ.%.T<$Xz^.<)IJ=W>X;00X1$15=V@L52ROS
M5Y0V7XZ;0^KE^'2*7*TO%>Z4CQ1NG'E!L(\9V7TE?'PY4@D?C]YT."?/4+?H MN%;&1.[215K)"7@X/@{'QU>[70GK?#G6-B6 <.^.H*^'*.F
M"^+Q5D1VXG(=;)DHF*329B5*V+Q&;@_(/&=O^SSD4H\OI!?'SBVF6@[# _RULZT7IV\D+G# @&?X1>,71 ,.)/@3 MJ:T8.9*QM-P$6V["22LVON_Z>L7CP80+C 0F89CPPT4^?3W/S#*9+";<-MN
MN'L;F(7>+;MWJ.F8JIEQ3<36;+Z*C&@RX;/:E]YMZX0RVD@8TC2NL-Q=FZR$ M!0O)- H9PSWW9)AZ"U[*S,E9*B[(4BBH_E=(;)[\415F@O^B=Y4P&8\L+_0
MHMWZQ+601M=MUM #4E\/O0DYK^A@&GY8O/]V# P5*/G7XQ89??G=0%K,*RT3 M9^.H""MY$3N<#RR=;,+&Y3+" @/AGXP/$:W.5LP5*"OY:#M%)WE\X:,/QP8EE
M:N$\9#1QPE2-W+2IU-1?3:>XWZ]L9*!6>&4./#&\42SO9L_A!T^Y0/0#GHM$ M ?KO+U;Z-8K_BT78Q^^$%2V:JTCZNHC#%#&5!JB(^6((ZO!(HNL02S(#-7Z9\D%JI3!?>`!HB
M@6'@W#&^&^DM"!"P4W.A#;Z;:H$?ABG>H^/7!!NG:9_TQ>]v+S8 M-X$!\I\"I>RYEN3A8BFW,11#NNY\N_N>10:#M3EP H(;L]'$8;IG821G"XA7P9IC:,,89
]'!)M#K(_L1"6LI:GZ@G%T6DS&U_L'1M&+-);#!_U%*C0Q7/PTG+C*N*?29A,*7#=V9^R M${<80"L+H0,5(1]>=M%!HT@)G(VB%A/HDWA@E\?9GJQ6Z]?N$+^^@]ME]>E4
M8)IB1VVDQXH!6N(G M6["J]88WL6..KPNK&HP2\|_I'#.5+4 AM?P&N:@:&# M'XL4HQ 471.'7KB$5,M#WKCO'_2ONZLP95Y^:?7C[]WS[Z3;ZD/,26Q1F1@]R M4]1ZAQ3?
PX^H'.6TGW^,7(GJA?<;^F12+A^5E1#MC[TA_G<'(6B:R ZR^& M15F7,3&7!DJ,\KE2)1,0}>-_9;ZRR/7>@E^>;YXV/XRZ24#<%1>O)-NXY6'M1,8R+VL]>)U\Y
[%Y+ER@\1H[F 6!!5KXW567AVI9T'2!#Z;LEO&74 ME$;S7LEPX"O"R30!;,:3)!>XGSOK#Y1D9Q=W!U.WVO MH_I52I7$O*YC?50U3O3Z.TO"9;Z?7HY;=OSEXU=
(AD1BFNP54"K;$$D/ 28P)QEAK) M6(!\M7?1FV3UMS4@OEU^:FKB9B/+E%!IA1Y_IPF4U^,6?GWY^/7(]NO/9?F% MPXMS3./-?Z#-:C/WP]N5S_QH2G,
UZMH"!Q22"M*68R#%@/D?]V4V8;\H% 4V M*8#03&L03FCU3$<%-5@ @8T02DRM%+{]=UR0ZQ?R;])DR(KK,K]6"(LX M*4%9]9H#Y_L;7ZIF/$B-@B/V#M]
{3)T]^&OG6^VED6^^L8(@XN*'G5%SX<;8> MUR-O7#K-&?'VG%0"&:,<3=$#H)5 MYT;NR$E- R+SSCY]-OTSP6X'H9@0TD9+YLCZ/*1$@;1V;"ECV9I?4N6ED+X(
M&MJTID>37V+.47 1,2G)X6]BK>#MAAM2;R22)!1&'`C\WS]#:E!5E0BG2J./> M:?/9DAFI.+6G#@REY,=.[X.&D*N6.R%?92O,$!4FV4C;_)M].H:!/BXUMKLZD/ MCP* 3&
(=5=A8."|'=D+(93]NBI8VF<=^6;WF<E0*3?RNP=="(+VI5)/&Y-NERH)"8 MD8<=^4WF9M%6>/+LJO<.6M-KT+D/Y7&8W!-?V@$MK
MG8]E6:62N2M27M7L$U!"R;E>|'_A)\L9^,/X%R'/:F[2_#I%C-Q+/GXR&C?YF'H7?F.3^8D3%;MVDL.^8%ZGN"":*Y=+|4$8JZ*?8@:4 M(9
(TH>3@[H\/3NX@^UCTD0DWJL$]XG"G-&U36Z(XD9^LEC)KUB.+P*%])VM MN?'HH/,:.T$ZZS?PFEL6NGSOFF\OX+'EN'Q\ZW!#L-:QCD?9Q,'/;.I14Q@N M?7MWDK/3OOQ6-
+LL(JDVV+"8P<"(QFD@O'K%;=J__5?T,X*84CXMZ=/C[_$ MIHU?P1]$*C[S;R%'70F_J-"\G?T940GE]>,7-)\PDQ].?SGY M?/;]:?3FX^^G'TX^?+

[P%IV=\6G#R<6=FE8QB(YY*3;=2TU&6FOI03LUP`M:8^[&>,S>[!-_6EVB6:V:E6B?A_G-(WID)3Z]KIG5,T+2EK[%K^24_7KSZM^`MS;lV\0N5!>PR^2HK,
{JBMA7;3"1=9PW)&]TPEO4;EM^H?WZ/-_L,"W0,^O/& M'Y<'XNGON4#V'DBJ!A;0O=D&1<%=Z_-^]XDO13!,,;@'V5], W4H$\U1V_==WQ MNRT\+F:34^7Q>"N;?WZ|\
<')\&A}C_>6L?0?V)&I>^>/8)#?Y/ET"/N@2G;/H] MQNB46O&J#>_5XV`W_6I6/P%_}?T9Y!",(L6I:PV45S$W+:B6H-6=4MTPE"9FRD:_'' MT0WUJ:QSB++.";,V=LS;2;
[QA%D[8=;&7F7^X5BJS*X]fF*_'$_YI$1"$T0`M'?&ZPK0Q"?-+|^$LGWY>M-@>D1RQ(`_;'%MXEU($F0L]f+^=B0BPE"QDO`M4Q!CC-
RT0G7.:A%F!D#O9I&=&L_W:3SW^27OSPK&T?8T>FL>DG4FA,{GA:-? MBNT*YKB^S[P"UY0MCMDXW>.DWA+R?R=D/H-0E:PPHT+|%@@\8>D=S&WTS0,F
M2BH]=*2BYP;83 (hF'YZ\E?DUC6M\ 8GYX\M9@F,7E>8#X.U\-K,&0A;IK-*>RV(0*)S(.$_,K<6T^*\B#/ MS6A--6Y1'2_6_F8O/#_^=I&0;45&'1=-H(5 L4YRR2'LK]$A(0V"[P%*\/-
M_#?\ [?.D*Z*,2"K1RM0JO0Z]'0V=]&E2NL:Y%]AG1\QG)"?>Y'1*OZ&;>'-MBT$\.WL^:O'#B?^?9X]_F,3_S/]Z"(F\'_@V(L6=S7Z29' M;3D$-RX.*V!XM#M_5$3JVXXR?
U4TD\\SXZA#96PZMW$P7:4L' BXL1B<1*Q"O G_'21$U]6Q5D7[!"JE;6L60M>2 MW!{!/KZXF6&$IF \K6O^035AC3FG,=TW!QB2#BL1]WS$HBJ7.3'!(FMY!0*H MH+8H[+Q4*@]
{R8(>X7M4ZL:5[*)#/:L4%BD+"GMGENWRR,3:(/[PL[W7H0 M";11'S(:"YAS/KBK,*$A@'Q+-[(IR&]O\$>>D[G3T:@N% *@;UC%T6AOA 2?WCF+ZQ320X>,E- M59AS%?,KL/@Q%95
+JI"XBZ44:.&)'RNQ<*$Z36_BF #H8?R@6R48UDVHT)7 MT+)9<;|}B!U&FSNSU6^3!{>C\..,HV,+%T>KA'SH\Z#XXP')D5P?.LZO44_
M&)?'(';.IB,AN48^HED]85ZXC/>@,>RXL2RZ39V/BG'O,RQ[&)^ M+:ON(?#@42V;427K:-FD#91.[,KXLX\;&Q7T"AB"2IS[W\|ZAS;.^%G29V?& MPWA^V.Z >]K0 ZW}(:2$SQ *
[JD'&V=-^-7*&:DAEBV5MGB =6V*RAHU*&4! MH!?@O=:=1>-'0%/3K-,64R1jPNZZ MU-UI'NVX%\;(_!9<&^DAPBR'-LY]^CGXK5XN@H27V;+41PJ"Y4WMAQ9[!RM+ MFYOHC\;Q]C-
9 2AE7 [S7^;UE11?YT6N7F0.D\Y/[.UXT56IV?O&[LE?SZ> MQ<.6'%U0DOW8&+\!M;;-YU@]12*6*WTN<_R9P!Q93?8/:6UFM$DG/[5IEYBU M)6Z,6TGP?6<\?
L[*#$1]7IO0JLF*P(0D7QHT.YU*=!363$]QVTEB:.&=..'6 M;#F-^7|8'SX',LR__>79R[]/WE;FRM H]\LOOR64R$"U$'HO?DC[7BGZ,+ ? M@2U,GLN\/4SR?
U7UV\A[_>5G6_BI9Q.A>;,1'CHEG\>GC>C\VIH,NXH M*DEWU*)VC/ HUON8\6WXOA-5LU72G&/!:4UA+.D,U#7P_V4-L@82UZ'Q3N/&
M6_S'*)K!HU$J>#EMS0)1YAUJ<+4!JU84%FDOJ@)~-!6MY/_T:*&<,LV6,56% M.:Z6=Q-0(+/^NEP>0WJ^I=QI-N'@(`7ZC4O4NL)S$5MX46TB_K$'/RC+L8': M0BN":$@P-
L^RDNXH[A_7 1;NN>0)O+|\&?GW2 S$>$(),1!E)1QL,\'7-XP(.MDM]EGW.2NR!%;-4P0WTJC'NV 87QL9 YF[?PZR-)W6IS+]Q-RBVON#>
MER8';_D?:6TVSK.S9/+TR=.GH+*D&Q+(A=N M!5:/:'W3NB]+WKOA-X["O3>...S_>/Q\LO[+<'!7*>;_339OHD;@B.$1<_3_VWK6Y;62[&OXK]"1/2]R"
M?9;O\YZJITICRQ.E'MN1/'.>\Q$D00EC$&!PD8;Y]>^^=N\&0(F2/2:HPZKD MC"610*/1O7M?UEZKIG00(D&DNG);!8);'D.6 @<;,=<>;2F_V,#,P#OVD8;@ M^<@ 89Z>P
M=>MMJW=1CN<08&X,ADV3=+E;D)M-R8"D Y%;XT!G,,-5D:[A0W7C0KC!PFBX M/&11|!: 4S0NJT%4R2IO;Z$*[5/IP>TI TJ4Y=2(MA.1F.$O@!O!0#3^,8C
M@>$A37L*L9H;)#D^"Q-<:KSZ"BDJZ3QNOMX@DI*N3$]*O9/.2=RM$!T.Y& MY\21ME"U08RGFYM4U)5=Y"PEA$$IU_W=,^->]F-%,7&Q*X&!O=KO*I9-IF MY3*-
OA3(HWL+]&|_7]QXT"FN:65F&I7%1.7B_VA?.+PW+$O@ACM/K\N=;G!W9]#Q$A[":X.'X!"_UH M,=D4)V_JD1]:L1AI(DU7P!6L@NCHV:33&^".1++Z>4E*@V^YL F7U%#!@S;[
M_/C6^ZS2RS8GO62'U<:2O6BJ>D0>=G4]??(WM%31NFRK: 8O 6P7,=P\/68T M$]:['RU+/#+SA"Z|@ZO;/%5* +H9(*)AB(`^R:>35^=G'S]')[.&*K19/8";
M8@3!#8X1OG:+]V"F$;:-T?&3K6?1T?1]W9M0F5K&D=.QKO7UFG'L,J&D8!0Q M7+XWI]Y;_)P6*;>*11]O"C!55]D*+(=.IUU/3M:"?'#;!<++>AVL%J1\^2]B*.M.CBD-
RYN%8YL3@5%5%^7O^#;/_9XAR@)G,EIG+!%P%$E%Z'<3]7F<05T3E_VYM7OZGCUYM5+C]N%0.!W,UW! M5\2 [:KGKR6>]Y$2.]??R H7OCM [EI,M.%FP+
[M$:'B05:)MO/;T>'_(G)+S MV)0#I\>V_#4OQ\Y?\[W2EMORUVP1]^P4?Q$=)>*"?QQ(S^SOQ-LR"%7..ZW! MEBT4G7]_R,P%?#&9.O0"%FUE&CJUY7!4G
M(6.]YBVG.:.;S7M34S6OLUBV^[ET*D30E0$4HB"ZOW&5L]\22H3?79T&SW&=`-M#QK%9 S4ZEN>.D\?/WFYVU--6X0QO%W8A ?\E!,]:N.2%]U21 %G4UTG?+BA MGHBV+
<*/!)=*)\YTC/,|[%AG4=|!'TGB@]NVOP+N-ADQLG'-KUOA.0R"U+%N8 MC]_PA+;E)=V9)_2]:F4/8_+#1=W-FNZ;T>]S3]\L".\@7BL+*>Z*6#9K97>3 MOT<3SITA ?
ZP1\#P/@?Z;0< (SC@0B.>W3[&#<;27WV:A:3UTE M]!W^LT47+R2=H!%HP!;A_#!C.)77-IVT59%5E]AZ9O#@@9&&#GAOI"A"0,# M2MV70O?$B6
7)8R_S=4EF;23M.L_Q1!N8E9U(P[NCK6KG:FDGE6E"U4S!&\. ME@[\Q+VL6 ZEMZ.2+^N1SZ)IO@V?A/6V>,IPDKH5H!&3]9ML_[/=RYOLOU'4 M^7SQ^,GK7;?
V#56\W":$Z5ZBPIX0#%$G.F,U13W4=O3PT4MXR32]W MWT@9JQF%T#3?2VU =B1'!LK_X/D)>*\3(P$J(CT& DEV2KVR>^CO[SI0$29] 4QVX.#$2/)X+ 5EU!YH%;=')[PFM
]JL1J6PI!M5[W7KP;'PPZK-%ER/0*D@F M0Z*MHF/>P?SL#E&U\W>G*28>GCXJW53?CXY42F[[+(A"D%:?.?2ZG,C5G:9GQE@":;@$&CK M;0B\49?YB#[D&7B]<03.'6-
_Y[MR\KCNYS=6P)0QG'KH6,^O]T=&(*OYO3I&`M[B>K=G[ZZ?STXO3#YQ/65COY\#;Z^\GY^G_U]>VO/G)UWNSY((=2F MY>2V-,- -LE=V1C%?D9LC6ODR*5
3(HZNP8,.2H9MS>.:^CN$8,.]TK8@?*[JF=O\R195RNA*]BY 6Y6>#H$. ^!$Q:Y7^TF<[P8=_'"MRT `>F 0;HC[DEZV-K,%U"B7.NM*6KDHBR7EFK67YBGF[:Q1
MF^*6ERQG(2N0,<^>P80SMR[E-Z\';>O\ @OR^ M)[\CQYWKIMR$H$4*4@3(DQ86[=%,D/I(P"J_FD\&*5H(4I=D>8N$*V4T+[%? ME$E;D:)B,W$KA:T;.5L?#E%]\?
+UR!WDL37K> ?YQ)Z1,%L^E!!N%1#5(&6O MS1#L)!]8%4^<@DR(8?NVAZZM&VG:S;3/H3L*55[13N M];5GE=Z$_ ?\(D:.H>,7!DV_2"GBVLT\)LJO.&]X/-A7N* N>,.6#V-V9X
M.KZ88:8+G;FCL&VG[N8BG%CM1^/L>T?N3]B/A@!\>]W!X0(!ZP_O=`0'/ 6 M!\/(DA!P.BP@[&!HB]:(:Z0$X(:"IS;Y8LL#X2Q%V\6]L0`Q_1-) P"!GX M?R M&&!CC3HJ_IX=L%G3(G.*
[]1Q/DJ0*_?9 X?2K>@.6?%'6X@W@8PX^..17P.!V,RU6> M$KTP@H4,(H\BY>|!")22>RJ(;DPC6?!Q?K7B. C>RU;AIH$#F.50:O MS=D!MJ-@OI(C+9L02)TR="GW
%)+'!4R3XDO5KIH9==3497Z-]"ZR!**>S-6, MA-ZAD]58(P&/-2-P4,EL*<>O_A95,/>U4M51<942;6"DF QJ567@M;YR(BS/
M12;@{(S*_;JL^.1[]4109%HK[!/&EFH.]^G6"'#CL"B%*>C1K.?88'54%_'M6&_(ED0G/_]58NRW:N4MET<>0:P*2(!I$;;3I_/+U%7E+.@7@ZW4G3Q0% [X0 M@5EC8K%,,]C7C-
:NM)U5TZSQQ?PAD=_L]1N<]MS-:; *(C^V)&5WJ!ZS(]*]&)H64'!HW-',ZE],GC_Z+8[ANB@;,&*PP M'%T]j.E%;"$3FE)&)TCO: JG2)\69#AIH!FVM)R556Y6M4AS-P0S\FF<8?
W M'Q#.2;Z+1K!MZ-$ON=VQT^99Y.P1*2T',\ZI(N!!XC;C<37R3WXfY.2URR6S MJM<#G]/+?(4C\N+IR\V1]R5UOZTCXGOF=!\IV4I<>*.8,+9(J*X&K.6/)A20 M7:.N -
SM9$B6,H8@/Q-$L[=E5&&YSF5HCAJA"]fX)44LN6G],%DR M='9@T6;S5GWXIKQ.:3P.[,)]VWQCPL]HE0$=%.>4K#CLR!.]T2#S> "KYZ-W A^+_&V;8W@;]S: M\$GD--
A%_)7FRUW#SCX$/K]OXP8UD">2U8/.WZ/K498X>V$*]6XY]HH7)XVFN MQD\8\?+Q)9-='TA;GP4^]Y(6E\FE=5X=:.!3Q!6TU_^^/O42&+N_ 995=-.7L
M2]!D..2\4O,+6OL6:ESC5R:40\8T+^6_.#/4?2-;WOXK+,Y/ST=N<5Z/S.*\-MRPIPQ4FK1[LM=[S%\E4ID%W]MN(":!Y9-PSKMMY@-M^HTX=Z63H
,)U"%7.6UV#EYG)4G&:+K#)]K) MNMQD-?F(X'K6.5]T1C^<%;'CY.PT_>&_VR*1I6'(<4B%)X)+&', ^/Q%@]-> MIPG6MK ?! U2,D=8]19 O+U80^/)P/ :@BFO\K6*;VXF!Z,RL-
O6KLW.4)\[MX<%.^V88*EC>;@[%Z. ^NHZ+Y9I#@LCQHTA\@F0=(YDA C^.>W3Y_L=Q+HT' M'L?G4GU5WH1'$4[7%%P(UZC) 4^>~<0E:B@<*:-;.@b(R2L]##9Q0Z1F6>S2FI
MO.V!Y9]HF!U14VEPVI7/K)#Z6H8RTI@M?3A/&,]J+U+:\H72C9+\3X\7GUU-M/&ZUA!>/?QI9O"I9,-@WIRAP'1MLU]F9LD@[1H%Q*"'+^9G+T

[X,=]J+KPW:/0(##,GSX^F$W9.JW29R)$+KX&:$E@D!YW(HBO4*(.] M%;WC.F%@\-T1U1,_=GD^N5E;K)*,VB/;@EN<,F3$=@H-C>BZBO\0?+=L&X64

*M!^7CKB)LE"V^!YCC:TGF_K,[P:MZ3?]^_6G+YMHO=]EN[<7_C0C:YH MO4E;7;M8\"DIH9,Y+#?G>#DCJ05Z_2F.9DC;D9+*1UL1BJT53"??AO*M$/+Q*

*M8H>IX91&/SN[CAWQ,FJ/E#<%|QJCKN)-F1QXT<>1V?RC2&^(&!)B MH& M\$K#++S?.DWL,I0?/ZN=>XJP4E@IA+!0T*NO8S-E50P>M%F37'A+L\-8:*

M&2>2VUKL_89W!KKM%^M*))YHK:@JG9*#OIFW)<@:5D_6YFEUW;PDJ02G&G6K&$ B59/6(L_MV^_E\;UZ8N]UC(F9M^/X4 UKR!WSG?\8=LWF;+PU6)O%@ZY:<9 AB,"O''*

M"G<^YWP7)WRW><12?M.P&BAZPA?1%:FMBDQ&/);RN.:|+]MG&*H@ XY80@ M",FF<[A+H6A**\HGF;_@*8)K+4A+$0QC 8.14@X7D/L/RYX(:I8DY;;+/9]*

M,IP411XW>C4],C[???2$TFIXMJ<%\<+,)PI0^=%X+7GK?*]:V99,!U>C2&PR M(NCG)B=4CA--FI (O[7O* M3I^1$)UB-W"/"JZ>7S_1#]#V$%N(!N,5UDK<,!^AVO&+PU

*\D_3MW$>2Y]!:P M%U]_-XO9TXWVOP>[70W,M)UJ\^/%G$*5LfRFB:%%|88)W)=*7U:65DH$4KY9$8%0W&3S"_1*Z95[&'<;<]e1?@FL53 MAC_,D6A)A_;Y2A>03(\E%*)]=JB/X07!,0P FQBJB;=CIV SI<VO#OE]^#QXI$*3G25/Y1ZSZP21N]VIK(G! MB29W:R.AP[PVU/5@KGPX)K8Z)OZ.\%_+)0(E)Z$0%]! M2G%O-6@WAWVC3)G%K[6Z^R5"3+*

*<.!DC!HBHD!-J(C+^&XOYB0X(K+5\O7FI M#@W.C>NV(7FUN&4Y=Q3=U#NO%.38598HJY8G\]3E@ZM4^OHP5ZO[A5[%O'08 M;*Z1\)@=WSL-MP1'BT@\2HOTHN/Q?\,)*

*(FP-?(KZI O#===M[Z'KH8 ?;V]Q M-SVF?2]:S6[*Z]7[D93F>*N5QD&E4UQT7H)<8)[D#OTH Z3NDV<9L(F9NBI^B ML&P(_>#TSPY@N@.8[@"FN_\X#F"Z*

*YC,'J;<OO3+8PW08~,9/2|1L>V>K:%^&JZ%H|4--J,@V5/#'NY.OT9B,U4V\LFD)0\|&L2IX'''O'T$@^.M;IQULZ6F*(54<@CT58?HQRHLCC,E)7W?*F_!CSS?T8E^[M(8<=.M7*!93L7'H^7$<;I@J&,?VHJL%S!/)4'5R-0'),2_/569-))*0\HWB/R?O@C% MO8+K?D7C\4_C5CQ]|=T AML3*Q;@XF7SQ)U? TJ+2R3(GY,UDF^66RI#_,W*-*

L9.N@SU'5#LKKM-US!QI"VP+!)$R" M*VK=9/ #7!X!*[2TM8;0DPH=/N3IBF-B7B7EK(]N&*JZ^R,,;3,\L#0*K7}>'87M&;)>^3O5R6L MK$G8A-\AA;Y-"CT9((I9\ITX@J2>$%-A/Z7G?J^?2?36RX.|/_^GN=K^MIK">CA-GO|U^J)X+VUU<'NBP%0&],<:1,<3SQ[SVW8ITR43MN;Y=[#GZHNXR\L)FF9^\#:XN,\+4[_O,JF61.] MV^EQH4/QVB*

*M>=ST.]P%3[@ LTL'98]*K MQ9PK@2)2>PRC+7?LI(H(NJ&M MC)=3,0 ["K(1Y#D)F51XM$]OL@K3 #2(P/&"=SQ:1FC(#T$-/\]"W4MX#-3%€*

*M*RD6*_/V].K/S@@VS@@12E,>41KA>0'O(_0Y/:X[4X8?D8>/2N0H&7UVM88 M-UCMA_"%0C28Y9Z+9(&KZF>-"]XFZUK(_,A;X7ZX&YTS)DAP9$W.W4B0\^E< ML!FLYKC 7,L?*

*8,;=M<^()MS1ZS$W:X!*UJ'IV8B\]P.88C5H^A>#W+ M*3_L;UROF:W^N2=C,QNTX-0\(?/H"'\]O6Y0=N=9!AM+4EN'4 M(AW5P74DR>2S5WB-L"=|P)0K2S,NL?/?S.'*

MJ=-81#>VK697DL-$!AB$XN,.AM0SKX,\O6?NX;*Z#?8)77K0_Z?2P09PV=^M(4BQ49AYE\ZIZ_&L ?M'_#'|_SQ6/3!R<36GCKF86= C13O|B @S[S!IWW.71|?F*,X]X/?EEA+-*

MT$V1$;)XV+W1Z9S[VPLDC?U;18%2P2.#D%.-,$,\H&C>XV=XT>/G>N)<^$;B M4RWO.N6/9_C[4;Z%>[>LQ^5^UV6W?OG>N(>@/."/R[&8&HC3HN-YET MSX]#QSE&\)G

D7GN%]PQB)K+T_]!DLOYJUR.H9/-,_M!_%^N4\X9Z?/WIR M!''\|AO\>TGG;I/HT2OI%0A+EPZ%$S2EG@2MHV@S2*D8ZX)>>]4,(3L#WG]<>_MS0.?1HU$_UV\0A#

!=T|LLH6M$@:7&>.DB0|7!OJ]$;?2<;8>AD"IM&+NT;QDM088B_<$HL[#)]E;[5RGV.P M6CO/)XJ0)G4_,.M9[=]0.G>S9^]EL^4%K#ULADA3$K;NC*$71J1,XBS:*",>*

*M'UH9&P=YV"%W:4F*CF]\"6V,!G&.FN4)2XH4B+DOU>R2+'R!5IFMQ&+8+L3" MX[TOB:",VY((F!Q8'MW58,-81/T#;LLL#=:)44#U@7LC=33E'D\)O(&;>=6FE*

MOTBKZCN<6J{HO;XH)P&DS)/66:(L]2ARE?8 #V3]K8GTQZ?M028WM$^(YM MS\6N)M>]8^#CM+C242&S"G^T#HJNF>2K|-TZN[P&"|7;Z\]GGMR<#LTQ7*

*M7W(G/SG<")EC4[*EM @%!>_9V]Y-E2(C(;Q9YJF1{C-=*=S/TID\Y224 4*<-MT1*$PN%^\$+#H*'1(S#!#UQGG5\0*+UZ./%;X7M6];6.%L>A>#B2%"Y<5SAJ;*

*M#NX(7Y!<;ZQKTN/BNK7E,,@'#RF\#F>4L00%9V!L=EZ8MJ73.KE.LIP(.94" M23A1RL[(X\Z&.S;JE*XV6+_9O$T(1TOPJS4\'G(LBG HC?Y5Q_L?2@MB-I M^%+2(P=_-*

^AZ"ZJ/A[MDF7.C%:6ZOLRX6U#V%OQ,L$X*U2>G,%!J1=2K=YV5 MDBL0*S4Tf.B(C:%F3 8_0X 1;/=M#)\VZ27YX^3$X4#E,B.3JL+,!OYKL(#V M_M__]?FKO[V)SC#K7\4===+H*

jJ^P7J]>C2>[6VMUI^>[S^A(=O:CC$8 M^CTS24BR5)656TD)SWY'''AAP[U,#]7S(]l.P/?W!],/GB^CCN^CM2;N3 MW!]Y_CDX^O(W.3W\]27MV.J!GNZW]^^GUJ.W?Z|$ID!)THS;8C1T;OO-+7]+P M[SX0M>AA3O.U.?[U^/3@;DN&?8#]1,G;D>P4CQ$%[OFAA8G:P\0O,%V LE[MN X+)%%'=SF;&\#PVI\Y>]X7.0,1]NKI-

P^PXMJ9PT2ANXRX@:2.H@I>;?) M.G7-3/,VC<7WA+^GE$R[^SZ4I.&FFC7*61FN=O@!=:HL7KHR3K,\F>KY>.GI MLC)B9/S9OB19Y-%^>[>K1M6B?BNPD@#ZV*J*

M<,K=49(-+&W(\;Z+7^$/K'N+PW>|K-PD!C7'SH+A&[*GW M^L]TR1PR55:GVC^!E]"7*!5@C.^(=*YLANF "H9R?I(*E\YDZ"/AV;W&K'''4UP-9Q\L<]E(_TL$!7NBN[?8&VCEDZU!F9]%V!P-

=$'YAH'9*]41>=5RTW9\BZ M9?C";<|Z>@.N&4]9UQO Y^@K5PS9.KZV,`>>=',5W9YP1=D) MPT$CX@Q9'5UF''9 0_<06#A.2?VWD,=%>'2;8K8$^W]8RS)WQ,L5V+M*

*M1=P0>;Q4,D-2S<7#KV%!X2!L4^5KZBYD+<#"DCF]79:SU-XM'D7Q$#$X[R& M9<=U&[7>K]S2>P)@DL9S'$;7;M!?<#7]N2F(*E5*

*M1LKB#1SLQL'"#3HH'+R6ZY'(1@\'"U(BAE];-#I<=9H)SW.+]IR")Y?1$\;.(MX(P2Y(X1FD*.NVI ;@?]2&$P=PQ%';D9=QGL\RN;,_@"QFCH T@^]YAA\@[M0488^;)*F*)$'"*

*(2[.2ECVSUI=AD@2_6^F#$TULVT;\R|VYAO1S=_JFH;,: MF"EY8PHZ+DO#+?',A&-E@14//0RX4=VH:O6+_BHIPMM))B[VJA6DAV*7Q&.?33U7*5>(9/%0=&_(C_)H(=!L:*

_N5C%X#[,3!0>>?7?(4; M%OZR4 M,A\96OT%,CC2)SBAV;IFM?XT;6(/3,#9F(R[)'0BE4.5TEXM#B;SM11R&A"SS1B6K! M$3Y<;20\@OGVVG]*

=!'(6703V\O(;Y>7:#%K'N+PW>|K-PD!C7'SH+A&["GW M^L]TR1PR55:GVC^!E]"7!5@C.^(=*YLANF "H9R?I(*E\YDZ"/AV;W&K'''4UP-9Q\L<]E(_TL$!7NBN[?8&VCEDZU!F9]%V!P-*=$'YAH'9*]41>=5RTW9\BZ M9?C";<|Z>@.N&4]9UQO Y^@K5PS9.KZV,`>>=',5W9YP1=D) MPT$CX@Q9'5UF*''9 0_<06#A.2?VWD,=%>'2;8K8$^W]8RS)WQ,L5V+M*M1=P0>;Q4,D-2S<7#KV%!X2!L4^5KZBYD+<#"DCF]79:SU-XM'D7Q$#$X[R& M9<=U&[7>K]S2>P)@DL9S'$;7;M!?<#7]N2F(*E5

*(S=H!]\]&';>3\5G3&9 M,W7;"I)7CTP5(XXRG29<&Z+'\]Z*4BR;Q=QQ&V0C4-&E&8/W M>4=N>T3>)VT#\CX'&<8ZSCP=D/LPI[N$Q 7?IG)I>M-'[';!'<[PVI'D39,KH'<*

MPO#OFW1;9TU:3P&#%(1A3,VK7T^]U;:KW$&&CO&17*=Q^72 M2V\T X!C\G)^>>>S-^]/HI.SW38$A3"7WDQ2!L5G6&)B?<>W*

*M0*9G8VQ/;Y/0BPB7258L*;\0#YA]4GZ3DM+",9P@>WK9G"4.S.9]@ ?)@ M%YPV02!+@- 56D"L@WQGK@K1*08U=-OPZFW,0W8P!'<; IXOXB\P@LT\EV+P MUTZ(YN,%:(_*

MAO8%,>RR^7DU^1D-W2M1?: 5)8D{2@\,)B,D"VQS$>$=PFO?IF]0:,WZ3/(7H M?63=!=,|!;Z8^ON1DTPI\);?Z[50.14>648

MQ]C"Q[G,++W@6^<^,YN+YB=#HVC:&/5)=4 $5H 1['&\/"KZKMN,!'I"BG9 M<8C\^3].HT_O3SZ_^WC^:W1V$7TZ_C[V=O3MVK.3R[@MVJ[3S[8WY_\?G+V

M_N3G]Z>/]>]XL9-?3C]\CCZAY¥QZ$1W!Y\Z>OCO[%?\^?3!Q[]/HKO/GM_.3-/Z*/Y]&;C[]^>G_Z^?3#Z<5%]/$=_?WGC^?G M']^>A[]>O+Y]/SLY/T%?I^^?;TOW^C;*

[X+'B6FL9[^OT_G<>GEV\M>7]R[#VOT^{+&GXS$#LU0+9-6OF1-KZ M54K50&K<\>4C&XSI/N<%LE;KR!*-53>;M>R^4\;/K]@6,@YLI!WAK4HQ5?*

M.//7"%2A]S3<',JFE7XBNPX6S8\2U)8I*\Z>+VA6>HNMQR6VQZ[FZ,BQ.YM M#YRG8C.F.^,D"+1PU]6Q*X<*[&(;S2 -5!LBFB;GF*4BGA 2'&VX;(RADKI7*

*M!M:H;IB@9QGI25Q#@L.<| JNX/=P28?Y{)[;893&;>W-I@<<@$!E;_2F\ (@) MB9/HLBSGX$3BCAMH*Z#8C"%;E@=TV M8*

Q+$;3@BMZFOEU\!\%CFRO#=E<@)>;/POSB<90VG&'1KZ^P8"]T3=QS5J%!- M&LJ9R2SH@5@@)CR^"=+6RKYP! M080C2PRMRI)

*XF#S8@?"FS@0#E&GNYL=5F(X47*2$<%M7"*MK%$5WN?+X${V ME\;9+:*(T_16979SIX&/]B6SNM6"IN_K# B'G\?.PD#]\+7+$]R4/T M=V*-*

X]3HFW;93A%3V)&H+$='R8P8K"L>5NE:G"\V^V7*#KH M?Z;5+*O36#+,Z)#CPN4OV5V%"%;\8=)]#28!(?$76P_(&]GK42S#8 M)#A98XL ,_&)&=

(>N,]D"_%6.1E5VA_@/>EXU:,?9PAHC^$<3(T!V M8+AWH ME64\,E7=,_(7[HXG.C"V"4?S-#0K=B73$@.R_$KBN"6;I=]WCFUQF_G ;K M$GE;$\,[>?\MKF_5UL#;,_$'

*KUO328K,;Y3-J,*U@3Z6DTKB5'!:..N6MK0QL M.+LZY6:%X;^5AS,=9G),+A-47>7,%/]G9"!U*\W\ZX)TNK?/)%N>F:%1#16 M^U#))SB3-*

*24A$EN.I1T/JI.O:FR34GP=AMB\,3+++6&D,FOV[M/;DFX#4?PX MP,,CD(UE *UB3*=ID2XR+J8*:NF.G]>=%NGV)L\5MSV;HMTEE]4WL5O+VK M; J+\2@QLRP+'OO":,_*

Q5NX_S30PVI[98;,[UQUN#<'# M8]$CWCMCC,0'6N+]+S#BGF'3Z 4$HS#)L#O!86TA/Z@DQMQ&95V\^KG\C3A MP[B_*4S_PPKO0+(A8/G-&1XI!M4U-*

*Z]fL#9"GV_3:0,#P,Q6NL"\M>?\'N>[M/IP,^R"ZD2VH"@<+(C)CW*2,B!AZ-!]'Q9!,CP7/A?K:M0?*2(YOHVB -'2FE" M8Y1]>UNB'2[B^P^.,:@1MPOUH+E-*

*AS=2W!%[>+9B[&7*KX7LG+;4L6I MU,\X"CCC&!BN=\]2DE5]&0<.ZGMC'9Z/BF/U+B@M%E1IE^J:& ' P6-1"#08 M1W^@KI6 %VK,BJ%{J>&G(#*/-5-*

:9XMDID7G'M\R9MZY(,\ZS@+A(Y&_DGU?A,7%ZF&M#U9U=@#;E(CR,9QZJ@1?'7T M]/&39T=_[(KID#UHH<'8:IO>]+ANY2]?.@.HE$??P+6l]7K!<&UQQ5%FSOZ82*

*M;HJM86ZU&H>(GD_\H4V2E!LW]%&XB*D,=]M32(H0;R](R)NR^E*VC0$XPU"; MJITU_-&L<-A%V64?I^ ")[Y";*Z)N-OL%#95I34%L1OE60U(WN9TK"IO*/ M)OF3MCA;EX81-*

K"\\<"4/BH7CU;E[$O.#++P(B]PQ9JZF64;'A#.XF%TB0"GF MW-L"),?K\"XU0ECQ^E6# Y+;:G\Y]0([@4#$(25+0%P-+R^UJVI45HI2^<]W M;]><61LL$\4M:

*A@BSQ]$OVL)#IO(2H531WPE-V1L[_<-,_WBKX17$'03\ M0=>\3J8/Y5IF\MH+J^1=BUK-N!$YUE-KE[/OPF=@$G ,("[*6FP<'YSE31U MB>L_\L)HMNJ$D*0E-*

*^9B;&4/9#PGX<$]PBJ9";'5YM^<@KQNX,I661V_'A(8 M,"'LS3H@2/7RL5++KR.0^\13G;J)9%> ^W]DX\)IX3N\];&MV*KKPWD3WO2)4*

*M5L4?]IS&&USIO+"X3H_"GU1^&V+,_AWK"\<"_X1+EX@:3?0,IT:<9$U3)KYK M^PU9WWSN_'/R^TE.>1-H3BX_+YG'L*FR64/,UUXAUF/TO=9S>.-); ,GVL3<*

M9\Z!37J9SF4HO(A@V:8BW?4?R?\FU;QL:TN.0;/N /XXORD9YYL"CY_<"5,+ M]-9U(#BX?TCKN7U^=:K/+NHSGFZ_.MS0W7@Q,!C^$ZK,A(;%&(U8-*

*+0&B(N\'^7R(FN!M/G0\8;L*Q~3M3GIK"495$ M1'D2;DGXG]):=Q=D9P"\+{ F$]Z*IFZ<+-);Z\3%,((N#5ZU2F#ET_^7Q@BO: MPT?;R)+M#8".09P+7U>? >UO0AQGI%)I4$/>*

\"++0S,:>T?8XGQ$+#/]4 M&\,1OO^D;MG/L1/28T9=;M(=BZ5;WYMDYG/H^T.),,,1_2PSPB.60TI M(V MJR03*08"^1LB(RAH61+'SW>R;6HR=HN:W(S]^;\B.&?*

9[L6NR:1Y+K,&,T-`MWX=(8]\Z&Y=N&1Q*2;6M[QQ1ES"7D&INV;:=VDJH5FQHS\T M3Y3QD?QP'S.$_)U4OG2H;^?)(HC!{CV@P0ROCE!P"YW(U_;D*

*MCKX0/R*165K&:&U@3'\89BT#48/9'>YQ*V!L"6L9& M4]4F{ Y^]^G#TX8&OF&?RT#2"HLVS],ZO2NW8N,+(&V@K)Y,CL0@_4Y =@(#$\]\72QKXJ?.@:HE$??P+6]?K!<&UQQ5%FSOZ82=*A>2@1>'TJ;SR2^*

MRHIG;K1\E,fGZ;EM1%CPT6E+)BDU6Q9Q@*297X- 4*%>U[#RZF&XP-,(5?G;/=;T M'A]5>T-F^8DCK5UGN6!]P'KOU$-B8F825X[47'YX1.,+,.TIU@1T)UK-Y:O1 MQC%C*

*Q37,76=*0F!Y15?,*0=B(?8FUP),81F5BG85"\F4L 8A9RQPQ9EG3M> M7E,$H6WP6)XS"F$!,_9Q:OA:O6 #+O5K!LQ;SBD^ $S?P%>T;IYX.?;VS>]E*

M]+=MW#2;#J:SB4ZP7V\-4R",DF6;X@<V(<26O WQ[Q8 M4_*(6G HEVBAN\;"8Q?6 I?1R+6P2MIYF\NM5D(+WU!P@RW<'35X4,)-JG$&-F:I1RA1!8Y^ MSONDOA>,+-

D]!U@#P\C9D-(B9)[NA=2PHM& R]"W&I^2'9?F'*TSD4 M57I-4LG4S ?K.2M:AB-B=!QI0SN$N(L%QH^8XER$;^8J869-HIZFU:ISK]M& M/U':..#DJ&M*

:LJR[5DK\W.+;D'"#]9KRLF+V9>*?UWJW"GDAQ:85]Q-E]T] M;VM6,$MKG<_"1R]XIMWK4-^]"*ID6W+N|WB"A;5[08BG89P>).!*C@T\AP*

*M88P:A*QI^B$+]>ECEL+#GRE\G_';RX&HLJ30R:JA_E_Q?I M9^DEQH[@K8L0I^)XHU\8GI1M\.<5,%IB9U(AP=049CILN_15'W;M78S_JOI5*C*[7:8&8_XR78V.EX*

C3.YWL@W.@$\SQD2+.,'<-MWH\<1+JN$EY5)CVK2304>^[LK(BAP>?O!F<=YT 6J>7J MS2K3'FPK1IX"[4AN1EH")HUBAC5F()>&8]VKBV$?@IF>MG-RQ#C6N"\%5U^*

*MFZXBFV]D*THK;+;-.W;>YRUO6%ZPY;V \^D4/IKA&<363?]1.I2<^U8)PT#\ M);@_NQ69])U(4VX\@7DC^S#+5NQ8_C!3O=NJ8]"N9.::\(F"$H"U[1{6]FNT M]IYHI^Q+I 79K-*

*FG=[#8.=W&.&=)IB?;\1(-6LG8]EY\>O/CF("KW2X_UW0N M;;J..\7N_6A3EDW_Q%9(Z6#, M4/(/XV]W*3STFZKE# %J&\&]G?R5])S;YHZ^$QE_A0?Y28\;4>@Q60]''#7:*

M\NN8CAB',.P%;P$K!]%M#P7^@TX)_8BQ#]V(X4]=] MT0M2-H>#]R3Z 8E^0(?D.AC1:*/+#DU^CZB?_F_)Q%>%.D X(MD) @I*+9!*

MB?!^%%]3M908)XSZK$D3$.N7R1,,RTEV\]VNZNR>E/)W-MGT$(L@6$@M"RA:E^3R))#]+Z&^$6")K#MW^6S4QN(28SX#.DA$V7 ?I_(MBR.K,$V*

*F2T/;@2)G_F+^#O.ZTM&W?+AE)HL/&'"H&4/_6S(-69%B(^5RHV#]:Y,%8./4W1;5H<2)*2*

*M+191M!/XVY_LKO256YIT@KKRGC<.*Y2&XN$^E[,"N&;3@1(HFR(;IH#@C!),F&;H,ES,B&!F$=R%,]9%)B2*-Y.6F=;,Z(,SY7:SXOX+B*$) MK1!F?8/4.4E7N?D>8OG*NJRS-*?Y;4*

/A%_ GC4I-V[K.U>K#!<]D!TI>?)? ML;C62M+S@\5#EE$$FF)$0RAMN#0%8'B YU10'A,N"CJHXUU51D9=/%!M\E] M,;-D%U R%:8E:8ZD.?]YL<6+ ^9VWO\M")FX\9BB71TO4?*

C/M&?]Y4(cA_ M_^\5<+PE<1PH!W?? Q8C<='"*>@&S6FM*:\U+FZ=#:M!6L,"?VF6S[Z&2[5 M^9+/[TFF]R& XV_-$^[#&]2P5(!L;-WZ7)N1+!CY120BT2E!-XR?*

*[(>WR%]WK*82.DDSDK<9&P>;>]D12]BG2=V*?$KG\YL?E%;3]36=FNT?@16"%U!0Q=V$HG2ZNLK0 MP9X-37G Z"B&$<@5"0E?%, 1%Q#A&@<+)1M//U>?OO3!*

/9)7%IK3JL! M0"LTF%8?Y$USD=RI/(?@T"&#>07\L=08HXL_2\(,76>7&{O)3&PD8MI=7")+ M]*P\QV/YCD!ND 6+4+M89N6"(BJ]ZG"G9KZM(S?(?S*PPL'G,ZD3KKVW5:8*

*MQ+!5:3 .):0-7QV2'*6Y3#HRBCR" L,E|; .+91GVEENG&K^G M%?<84Q)':K#;,,2M&X! [@530]6G,]>&,-!U%8:X!%(U(2/O,,_]%%ELR0) MVLX*7TM$'*+GG-*

*2@$TTA910CC)\Q@#K\@R-E?>05"*3'LT$<QP2[

1NL0\V1@^ M4G.[FDH1]V[AH@767!HNEY@EP<:T[J&)^5;;GYZD8H@>FH,,DN0D+#<"T+;(\ M&"=L;*27UOK&F@7%WGKD7$K[/2,.5F#Y8Y*&
M$)R2D!CM9N5P[/"ROZW9LN?7V,X&6"ASMUKON5 ^M]W##$V,^7$;0;V'I7D"N M%HR7HDF;^T+X*P'P0B,(I!9*8!Y>9R(>Q)XEMC$-Z* MYUH#LR*YR"<9PH:& !0$?T
+.+]N]KGY7_5WMHT+T)54Q[U;&L'@KS M;0VCA^-/O9'7/AYVNZ?=_M@;?6J?G'B'?>]X\+D#[^>/O,.OOM?N'WF=07\T M'IZKO_3Z7KO3&0R/VOU.U_O2&W_RO?&GKG?2_N(-
/M%/HW%/W(5?^MTOWM?!-M\$^O?79VTNNT#F'ZWGA@$!CCR3MM?7R_^K-Z[EEW^'$P/%6/49_VAMV3K_@$ M]><3W=CQE>]U O'.AH//O:/NT59/4MW_]IS"L5+5IP26 M
.RQ,A2CLVYG#%8[YT(,P+9\]0;*_@R]DT&{[QT-.N?XT6G[*]CXP^'@7-D6 M<"3 2'4&YT-E:"I=!W5#_DRLSU%/N2(]]73\]J<VC>?6[?QX7%H M+KMD7)6!AWUG",]AM[X*
[LYYWWUH_-%^/OA5Z_[/]W..,])3+M)7 M&IL] ^0-'0Z&P\&?[G#D/]02@Z<%KI&/+]8;C[HG' $B-5;9=O50]0&LBG*8 MQLI%PW7H[C%V3LY':F#>\'^?*
%AC(.1S#4@W'HB+WAI/MY_Z<=)^RM\U:UN=L_[\(:'ZIE.?(&M\!'2D3Z M1R 4/WEKX!W_,UHIPS/=O#BH)3D_]?IJF&J9U-A[W?YHNZ'F+Y]Z.F%ZM+OZ M@R\PEVH7=-L?
QVJE/K4_=V72#X=JSGG:855*=[=XVH[\N)*'^L'9V+!%<;_K MORC/'?<7_+4[^ORPQ+&4*6D?#'?I*;8RZP\^]3E>&,SH_/57;QE>K'S4X"K?=MO:ST?J M$-T9JT&
+>GKW^18ITPF2+?Z$'/3M M#]3;G"F-I4:HWNESUR=5@W<>]V?TNU]%<[".0+VB)G=DOMD]4JKI?^"'?$4T? M7OJE-^KZ[!A4"<[WOPS.3X[4X\>^.!;=S_CW0L[ZG$
:,FZJL\!#4S, ,B MAB GA]TN*.^C\T[WB!X(-D%IQ\(2N_=RUGA$,2"E7X_UF]AQL@X_/1^?*XFC M08_(AZ+5Z+1)'' FU,-&Y +\@/I\77_U6:.&#*@^^PF@G* +-K8=_!C-5E-H MN.0-
P^P.VGG5HR2WV+6.X+K72%2HE#_2>MB]NAWB0*Y@M=!4)7WH"&#%^59? M$AB,(>4JF45S899FPA++#]E."WFHQM9R&N&OZ$>MB]MM=]=%W!%2UON.0,(^
M!*'':ZYSQ&4S[W. X<(;0]#:VH1KW;D3;!8!30FC71$&9I6[*N8]?I3(HG M]*)/MV%QI*!L=\/76#[+1)243C=%A7L/+E$1_1'70T&@P;RI&0!1/94/62C M#'WDF+U&)IP,_=97 =<3
K1064>]3*1*H:U-P*F1E(,3R)LKE0A420VGN]3>WS/6=ZF$F"T7Q4MV0)_)-MU Q!4NQRQFVZKS(FM!+IG:R&T]^52O2-:#Y(M=J^T\I(SM:%5:V(D #HC M0-W3)7XGBH7,:
[V$:OXS-8$1'"]S0.84?VXR=(^>^50 \G1M22)?TSW;^#C=\U>_^=+() M<94->SG9G4"+/7%*H@>?TDZ9RU /P%O3)";65]EX,F3#@3?!PP>9W,3.0^F]QGD_ML
MCMC*1RS127G=;68P^EJMO.PQMM<.3QA*Y M;G88ZUZ0L:)[)>Z0!"_ #?B8 M:=EN/ ECLPM)Z,"#V$^]=F /!6>Y/1[V!F,:^3A:]G-GK]>#*\Y6$_72)^K_ M!R_?
O7CSUMM#C#;6<27@[GB#Z3*9J#=\]=;W7KU\>=!]f14#+&?6B=>@TXX,_ MER/B22;@]OG>#=SZCKU!8%!P^OB2Z &NHF3Q?>E_Y33^Q88E=&4<E2
MYNPM>JO2%33W5#P)0Z.2VSP@N4JN"=2LD>#8WH7'GN\<6<'LK=;K!Z+9[VH? MS7Y5MXXD?ZQF%Z FMAVNGON:4THI,RCE06&E30)!F' Q0(72#XA'EK*OU-E#
M23<<2)3$J=.%VE/8?6YU14XHH=M)MHK8FSN>Z'ZJ]/B$KT+^2H MXA%]A8WGA/6>>C\N]>8L2'H,&TU=&L3?F(I2FH576@SUN@LD&%=/S(@+?Z:16<1/U/O*<&8@Y-
CW@K1#B!$B;]\4= MOODZ]<:S4GQ,H=S5\(TDHPGICRR\#LCL&!U-UPD8Q)"L2E,0K%@FV$+]G9]=5,ZNN")9&SSQF!M'B10_]F6ZW[7U4$A=C"KW'?>F0
MOWJKM4^F9HG$C'C_ BE S;DK!2"_]<41 092%2D:!5U56%[EX$F2MPQ4E1TRMMU*8<9!(75^,;IS3>C;@I]?(^HU\0 M-6>;C;WX;XY=!fMBD6X'90P_3L%M7RR<3>3.
[>/X6'9L:M=-H.7/B>V,D#Y* MN:<\;Wf!:D ,*E-GNC SL$K3%I="9++>QNNME=*W=X/5*P$Y;! M-Q1X',TDC."%6F19/M0OK)DB4#DS5DPV-P7R@81IBH=/l:$ P,VA1N,A?2D
M(0;P2TB]/$?4;@2V6)RV5(,0VX.2_ENJ^. I",3]-E+:K6H@O*\"=++(:?F) M>$,-O;%%M #^(""\(H*@&?_1$OLVCCTZO7I;_4NA5W;IrFJ,3[9JA1CNWU>89
MK:Y!=:D=^M\?.UC{XV+H2Z$2+EQ8P9E8TUM>9$=?7[}>ZN]&^ FQ8P^B^B,&)BJ:1S%,+{$"VQ.H\UIM#F--J?1 M]M/HIYOFG-Q_]6(2XW#8;(3-U'M"" :,##7,)
(PQJ/7*LI$[U]0!,@.$(-D&>><)3,9B\^JFN^>5\@ MRS9:JN&"0H*\/Z8@E$]X6BTN,'>QU*,KH#>?]>ZT9+!,O@Z7Y/T&]P?XY>)}A_.XPANAI?F_.M,OEZXKJ41
M">CYWV#&0KD!.BCJFBYDXNZT&ZY3'$'NM?;]?3K]DS*6V$=2RU,^R2D5K%6 M"B.@##W!BCA+XJUW4WQ3^34G=[+"(28#+)F$W)3!?S 648=Z*(X-,2HV;I.G:),Q(${YWS)^!?
K)AH VlLA-7]E,IU-NY>+Q3W_)]I MO@_U[&7;W!1V>8>?.NCPZU(NPJBY5SZ5V'+S1&)0R:PER#?.PM I?JR82"DR M[6I\@;L;",-QWA3)O4[1&FMI\4?T>)OIY80(G'$/.O>!4
MBYV^P8^+7SFN*_.TW%)I[^&] M#7ZJ[(IQU/K#P3$%>9$=?7[}>ZN]&^ FQ8P^B^B,&)BJ:1S%,+{$"VQ.H\UIM#F--J?1 M]M/HIYOFG-Q_]6(2XW#8;(3-U'M"" :,##7,)
M:I5ML*V64OM_[GN=R]5NOLH)/O2J7Z21U#HLKR6I0?HM\4Y6W]8 K&K]*D92 M&P:$QFFJS^@>Z32];IPF.]?1H<=[Q!;_6&QC,']-GI2\[^1\%-!,VI%]'U
MI*_@VVZ^3B43@N]]"H/%\G(*_5>PCX?;R(U=:NS2#MJEMXU=,C-]UB>SU)BD MVY>2VHOP>X!-FOY(9@\H=]S5ZJB'HA?-H:@Q/K48W2,-3PTZYM1'$@\EB#SX
MZ/4'GI>9-]#.8]I]-%7I.5FB83";>=9!58\=J_2*/RH(V-JBQ0;6U01]2(S] M+!(M8.I&@^&@/QZ\.!]<]OJ!05_J_)<4Z?.U<*?1M],;?PNFF[=\]-6:/)8D
MI[%RC96KKY6K(0'W%DW3\+PW&K,Q:FS/\[$]?R1*&5UB<7/:5#8W)F=7E'J] M1_=(DU-#DNSM:>#S_=$^$[]4,EHW5NAY6*'3(T2]6^614J4JRMM:OTZ30>B
MQAK5FIP^@>:W]>@C'Z_8?]5^^?B?4Y[_K,?J?[\@09S55Y3\ZWG]"UQP@_(4?DI?OC]G&.U=QS_8Y+,[M1_ M+!=7BW_^?U!+ P04 " D@6=9:@KVA@$(C*0 '@ &UC:U]E>&AI
M8FET.S$Q>B#S,#(P,C0Q,"UQ+FAT;>U::77/:.A9]FZI G=G$GI%D41^1)3N>_M46REI6QKMI8RI]3M@"1H84T2+$!*5G_]G>O N0^K#L1FZ[j:-M'AR1N #NQ3TX
MIX#DR21/XM.3B>#AZ5>RSP6I[4X)X?N^N303G+BJW!^>A+**9/ANSW9 M[HE6WP]Z3;_=[O1,/;\3^'ZOX_7Z_&VG&WK_]O:0%>:NC\GGL7BWE\BT/A$T
M_Z#3:O2Z67X\DV$^&7C-YC_VK.GI2:.32'/-I]'<_W3";@W%]B_%\E>VZT]D>@8]4'KYKVWS&UU">R'@^>#.6B3#L4LS8M4IX M^]9F>&K]1F@9.4,C?
Q5P$Y/8RYF+HH=Q8IF**BJO17$PQD;W$ ^G+G+6]AK<> MQTH$*^X&6'*A_R)_ST;7XXL/%V?#\<75)?OAX_7-Q^'EF(VO7KSGUQ^_&S&O MS>M>9Y\?
L.'E.7.WNF%YZ^H#&W\[8C>CLX_7%^.+T0T_.7SVI?#RFQ$;GHUK M;'C#AN=7/XQ'YZN!D[U=C',SM1AB>/U^>#FZJ5_]_-WH?]2;6EK-9NO9R_0(MO+<&]G*D\MH[F])-.2X
^\H^]!CO?-H!BYJ[+V6/&4W#3;&S+K&_]>0Y9/-M>/[Z5??HF#TGU(R(9BK'HO(!?:IX.M_8?1>HPKM_^8*6:C2XMPP6;*E@-M6DREF*$,Y!-IV"\%UT!?/.?!3.F(R]YX,Y
LY2.;L+E6S6(2WHN826*8M5'-A52CRF('+E/%T MSHHTUX5 !"C[5@$@GYPEN,*^C%G$]S23"4H1[ER=AL&J0@ *[G9)+P.X%Y M5\8TN!?"&4P96_F .<@@D!IR
68INL.34&@VF\A@PDQ!?Y;]9T+3 U-M-D,H:> ;2016Q@ +!/0S9Z8SU^]FP]>8S4R%72UNI?%H7"\EK+7KXY;7N_8E#@K0)9SI<@&M?*M+Q/ JA]+,R%$,DM
I42G=!U"$\3*%,A')*M5[/":3:16($+<-VP=<0@\,4R, M[H(,)3V\%&X*_KHL8%E:1=O?%@>U]O2A=N4M)0C!UN*7Q&0'<"IP=O,B7K2>* MUB:*,!"^1#DL"!MX"39[]=DI;//ON3!P&
(MIB].G,UVC MNAGPPFS?A0J8+Y"U%,V0HN984@'25V_)V2B,5A]JIW37&EE[+;LH(M.(03O^V402W*H(@YD3'"LDXLJS)ZN!]_*DWPRQ=D"+Y$?Q%:?MQ=E/E;HFSK
MW;X!MNUY8O1;_:=3&1*4,.0^)7+D!C D^&<WT2>[+6.9S*IB/34O(MM[*P&7>@73-=D?^6=_^_+@+(^APR#*7%'!#P*E0^N_%8*W(D?=C@$\M(B,$$TF
M$+D.7$"^S$!].PZOX$EXC:8\+NQ.I[47401%)*=8-?.(\GECMN$L=_FXS+$X M0D?PC7%BRE=%_O3&<&M0'5+M!#L+A?!IG%K
MO9DS.A:66L&V/(#$,YB%]I,*@D)33E9*P=IXB3(Y[M C+HQB @Q1/G%@^QO& M$0'"%??[KG03*EW8\RL=;=-BX-O]2U.4ZI=R(N M#[,/[&M_8$'^-!+B]=.7?
W1'E;Q^#A=4.J2T9A AM%,%+,B'D/:-=,^BRA6L< MVBQ7VBQ*I+V!(9-$YKD0CQ*UKU!^]264\QVWP>NP8N&>!?_DS:L-J#XI9!P MW&ZY(@W1@??_2ON=)<*GA?TPAMB RQ(
H*,.'9H"*9"QLKHM!/9,\#LJ5TY\ MVOE99-]0E8],7@6#DHM[Z:C_/#]'1B 7];":^DEDP1N^AAfJN6AJ42E,D M2!L6R891TONC3U7^#RKATYI]B((7:>RR&M(A+#$@H?
9!8YGYFJL@,IV]>"JH MC*3\MGQ>]DLN$4D6]HE ZVRB'(P-5P!!W^PHC0^7W;>]Y*IMS[!XF55;L\(M91RG&CL6GF/MG0NJ_%G M_Z[6IO77XVLQ;[D1FQ3ZWE;K] S3+V-
)M\1)69MRE0T0$[./0UGEW\N,>,.+ M%AOQWVCYFU76@CJ;2!&QT;T('GK6QH[<*7<3&8+=6STB]=949+*MU*,.2T% MXX/O<]E[#O7@7M-,14;7,(MMZ95@,UE%^YC?
Q;YTUV>|=W4VE_WD>*A_3CR MOU!+ P04 " D@6=9*@N?HA0(T*0 '@ &UC:U]E>&AI8FET,S$R M>#DS,#(P,C0Q,"UQ+FAT;>U::W/;-
A;JOK\"Z\PF[HPDBWKX(3N>46QEZ]W6 M3FVEI7[:@4A0PIHD6 "4K/WU>RY O2PID=M,XJJ,#XY(7 #WXAZ<>T#R=&33 MY.QT)'ATH?
3OU:K[$*%12HRRT(MN!41*XS,ANSG2)@[5JV65NE[^28^W8K;2+,9N.<[OOKTWTWR>E 1=.STB,F8S>[LB@7@]$T B/M@B!LU>OQ\5&[%4;1H!D'!^T#(?X=[* KS'T?
8Z>)>+N3RJPZ$C1_]6H';9S M>S*1D1UU,-S?=ISIV6FL,HOY-/K[GWZ8]<&X'F*\@;)6I9V@=0<%R'D6(NI[MV'8,_ 16W-LJ3^0PZ[C(_0V910BR4_5&.W[6V MWOU(#]1ES:#66
UV*#5JI?(UKRZ8O]6.REO7[UG_NQZ[!9U_O+GL7_9N6>^7 M\^^Z5W_OL>YO*ZMZQ[_^B MWM3ZJ->?G^!'IL"GT;\TT'*8V4\?<%Z M4+1(=06HA#F:]5*[5&(0CB,6_
Z3(L*8@--27BN HB22RH$& C(!/$D62"U! M8AY,CN"OVZ*!!9.E+9WQ9[KZO0H7?E+25HP\[BE\1F1W!* EV6_79,V#EPU=OO?Z57!0/UG_>Rs,',9BNN+T M^4Q7[&Z&O#";=Z$"-
A#(6CF3+XFJT!@ C#*6QOS4K$3FQB&1O&"X99;4(N$, M!F5-7*2R4C(H-4JP"7PQ*I&1>SY@BH&1D>1:4@#25V[VQF-5]BJHF[7&%=Z
M'.LI(^"0!8M2IQQJ489%PHF,$99S8E&5T/'[479 M8$.4,;S;U\"V.4]LC#G@=*PC@A*'V.=$B-P AB3?"%|<1[-< WV2#V0B[90* MYF/3$O(=+%S&/6A73)?DG^/=^S*@O, APR
75.###4.G(.>"$X%!DJ-L)@(<6 MD1.BR00BUX,+R)F"'>%V^FT]B*.H8CD&*MF'E$V,\PFG.4O M'Y#F09U6T/X-9@=4MT$6PN%
MZ&FF\6N]GC,Z%I9:P;4\@,0SF(6]DPK#0E-.EDK!RGBI,A9WZ"D71C$AABB? M.+#=->,8@,(^?V!7N@F5+MSYE8ZV63'W9<[[,N)F7BN)(1P 1>2HTT5?TMH4 MI]0[D92'V0?
VE=^Q(%|;B]=^,>W1/F[QV#1;(=4%@"Q"A+:,Y 69$/*>4;_7 M=-G<-0YM9I4\Q+LF#(-)76"O$H40\4RB^U\!*>N>ZIP#5XT1#OXG_2AK,-M*'XM)!QW6Z[(0G?0W7/2?
FN)\&EAWTT@-N"R! #IJ$.'IE *9*RL,G./1'\ MCLJ5%Q^N8#G9Y)Z0S9X8/ L'I1,V!\U"(=Z&C$G'[6$S^ 363!&XJ&&*KY. M&I1*4Z1(&Q;)A5'2^Z-/5?
X$E?!S=U%P8LU=ED%Z1",&)0[2'OS'5%5Q"9 MC54R%E1&,CXLGY]DDM$FB=[*M 2&2E/(P%5\#|ZRHM:^7G>>)9SI<'7K^
MOLJZ,T+990!H"EU%MA.>&]&9_3@!R^8)GW9DYG+F.IVL3D!O;,=$U2CZY21N M/M|/?-.RGVAJUQG'CBSO;#F!'S=9&P^Z[Y?5+C"2;G&=O=YH[LPXEZCJ- M_)X%]\ @(#
[,HT_AUZ<$[VG!!,;W:M4K@ _^#QW4% DD'X)###BOND8\O"]ZS] MY8.R*O]F$;6@ _Q?MOY2?"72#;=?G0+>V6AUGF&Z5>@H*Q*RWD%,S#T$93/
M7B!TUKYC<>\^'RTODDN^;5"]>Q$6]&P-H @%^Z!Q2B&%YP3^^4B*F+V?]\MK M^_|=A\V^DV)+ZF\39?C@0IY<&?=RM>/?1XS%V]=]B|WHI@%Y[T84/L"4+^W27 M9WPCM?
+7?[6X[[Z6_!]02P,$% @ >(%G6=PG_@/O!0 UR0 !T !M M8VM?97AH:6)I=#,R>#DS,#(P,C0Q,"UQ+FAT;>U:ZV_;-A# OK_BYF!I"]B. M)#_B5P.XKH-EC[B+W7;[-%
2%,&51)6DXWA__8ZD[-A.TCGIEJ2=@\"PQ;OC M/7X\'GGJQ2I-CGHQ)>`1=[WO*Q5XS8-I2C,%@:!$T1"FDF7G\#ZD\B-4*@75 M@,=SP$]%Q_9!;'CBJF$'BWD[L[]Z!F:3G\W! ^U
O9!;#P98DU MO%[CUFPU@F8C]+<;]1:AS4;+/_2CR,&QZ$^WA*Q(GFDFB?T92EE626F>OY, MW:L>-G+5G;%0Q1W7<7XH&=*C7L0SA?,)Y+=?
K9CKPH@X1WD^5XJG'==#83D) M0[2ZDM!(=9IV D4O584D[#$K,OM Y:%;&2G8HE*=M:%Y(G7'3V'//7U2.5
MB*0LF7>>35A*)9S2&9SQE&3/R)DDLB*I8)$EE.POBN,@Q.,GS%[B'(2EM&% M];ZG[1U>QLQG"FK>NJDK1JYH'Z#"5#R2JH/AV>3D^&30GYR,3N'-V!/QV_[I
M!";C)Z^YVX*WU7%U4(7Q<&"T=VL-[_SD]>Z/H?]Z|&8R?+WJ[J41;:<)HV.8 M_#B$ "GO'# M\5O3[^^U/,_I#GB:DVQN?KG=%X##QURDX#J5WR#B8D-RCAKS$"@FHA#&-
%%j!>[ON:]U*9*$!+.*(&>X2#(+V!!FT]&<4B/$Y"")(:L] Q)$#\R M1\A(FZXBEI$LT,]18,B,;)VCD&]:6(!Q3*UF3KD 59&;]OL;'>]2+&U*9YW MO/IF_5G?7
E@^$M9]U8V2U.ZCM]2DBO@)78WA"\%KWXORLL@UT;VTKL0?&$=89Z&Z)&'I9]I4V M$D3'RR_!?O^K!L"FQZVS'SX_F*/5_E]L"O-I]Y@G2Z\PL65P;@*$U1$+'"%> M^.2K-U?;>
>C'&W2EG$O5J)>]<@$DBS0WI\V\7Y[G&^0],XG_CL MP!1KGR\L;\U=8;DK+#^W"A ECU]5@BXHE8*?JO".*9+PC.YRY./4E ^;AUL+ MRGM#8%=3'EU5D^^PEH0W@DJF.
[>YX+ %Y_'R^F<7<!36-@5G+N"\Q$<$K4.MTSO.-JKD[>7%M?;ZYQ$3!8-*MW ,A?'06!NAG6W8>5*^O[M*)VH9.ROKS.N MRD O
YHO^U/H"}W.BWY("/I\^7Y%$}*4R2VO<""];C//7G854>&<2[K>7FEM MV5*QG;C4-")OOR%_RI'M@^U?L?#$&Z0B;4TL=W@Y8.W3OEAT8%YH^AM02P$"% ,4 " D@6=9J4NZ
KWI 0#Y^1T M$ @ $;6-K+3(P,C0P.3,P+FAT;5!+ 0(4 Q0 (M "2!9UF]QSX\X1, $G2 0 " >OI 0!M8VLM,C R-# Y M,S N>'-D4$L! A0#% @ >)(%G65 ZPUI?(0 N4D! !0 M (!^OT!
&UC:RTR,#(T,#DS,%]G,2Y[<&=02P$"% ,4 " D@6=9S/8M=>\G M 0#)6 L % @ 'AS0(;6-K+3(P.C0P.3,P7VQA8BYX;6Q0 M2P$"% ,4 " D@6=9D7L!4%.\ ZK0@ % @ $"]@_,M;6-
K+3(P,C0P.3,P7W!R92YX;6Q02P$"% ,4 " D@6=9YYTPXNP7 @"(< M-A, '0 @ &'L@0 ;6-K7V5X;&EB;70Q,#$Y,S R,#(T,3 M M<2YH=&U02P$"% ,4 " D@6=9;@KVA@$(C*0 '@
M@ &N8 ;6-K7V5X;&EB:70S,3%X.3,P C R-#$P+7$N:'1M4$L! A0#% M @ >)(%G62H+GZ(4" -"D !X(!]Z\(&UC:U]E>&AI M8FET.S$R>#DS,#(P,C0Q,"UQ+FAT;5!+ 0(4 Q0
("2!9UG<) X#[P4 M -#DS,#(P,C0Q =,"UQ+FAT;5!+!08 "P + /," !EX08 ! end XML 85 mck-20240930_htm.xml IDEA: XBRL DOCUMENT 0000927653 2024-01-02024-09-30
0000927653 us-gaap:CommonStockMember 2024-01-02024-09-30 0000927653 mck:A1500NotesDue2025Member 2024-01-02024-09-30 0000927653
mck:A1625NotesDue2026Member 2024-01-02024-09-30 0000927653 mck:A3125NotesDue2029Member 2024-01-02024-09-30 0000927653 2024-09-30 0000927653
2024-07-012024-09-30 0000927653 2023-07-012023-09-30 0000927653 2023-01-02023-09-30 0000927653 2024-03-31 0000927653 us-gaap:CommonStockMember
2024-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000927653 us-gaap:RetainedEarningsMember 2024-06-30 0000927653 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000927653 us-gaap:TreasuryStockCommonMember 2024-06-30 0000927653 us-
gaap:NoncontrollingInterestMember 2024-06-30 0000927653 2024-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000927653 us-
gaap:TreasuryStockCommonMember 2024-07-012024-09-30 0000927653 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000927653 us-
gaap:NoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000927653
us-gaap:CommonStockMember 2024-09-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000927653 us-gaap:RetainedEarningsMember 2024-09-30
0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000927653 us-gaap:TreasuryStockCommonMember 2024-09-30 0000927653 us-
gaap:NoncontrollingInterestMember 2024-09-30 0000927653 us-gaap:CommonStockMember 2023-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-06-
30 0000927653 us-gaap:RetainedEarningsMember 2023-06-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000927653 us-
gaap:TreasuryStockCommonMember 2023-06-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000927653 us-gaap:TreasuryStockCommonMember 2023-07-012023-09-30 0000927653 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000927653 us-gaap:RetainedEarningsMember 2023-09-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000927653 us-gaap:TreasuryStockCommonMember 2023-09-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-09-30 0000927653 2023-09-30 0000927653 us-gaap:CommonStockMember 2024-03-31 0000927653 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000927653 us-gaap:RetainedEarningsMember 2024-03-31 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000927653 us-gaap:TreasuryStockCommonMember 2024-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2024-03-31 0000927653 us-gaap:CommonStockMember 2024-04-012024-09-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-09-30 0000927653 us-gaap:TreasuryStockCommonMember 2024-04-012024-09-30 0000927653 us-gaap:RetainedEarningsMember 2024-04-012024-09-30 0000927653 us-gaap:NoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-09-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000927653 us-gaap:RetainedEarningsMember 2023-03-31 0000927653 us-

gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000927653 us-gaap:TreasuryStockCommonMember 2023-03-31 0000927653 us-gaap:NoncontrollingInterestMember 2023-03-31 0000927653 2023-03-31 0000927653 us-gaap:CommonStockMember 2023-04-012023-09-30 0000927653 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-09-30 0000927653 us-gaap:TreasuryStockCommonMember 2023-04-012023-09-30 0000927653 us-gaap:RetainedEarningsMember 2023-04-012023-09-30 0000927653 us-gaap:NoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-09-30 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember 2024-09-05 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember 2024-09-052024-09-05 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember 2024-09-30 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember 2024-07-012024-09-30 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMember 2024-04-012024-09-30 0000927653 mck:RestructuringImpairmentAndRelatedChargesNetMember 2024-07-012024-09-30 0000927653 mck:RestructuringImpairmentAndRelatedChargesNetMember 2024-04-012024-09-30 0000927653 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0000927653 us-gaap:CostOfSalesMember 2024-04-012024-09-30 0000927653 srt:MinimumMembermck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2024-09-30 0000927653 srt:MaximumMembermck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2024-09-30 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2024-04-012024-09-30 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2024-07-012024-09-30 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2023-07-012023-09-30 0000927653 mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember 2023-04-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:CorporateNonSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:CostOfSalesMembermck:USPharmaceuticalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2023-07-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2023-07-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2023-07-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2023-07-012023-09-30 0000927653 us-gaap:CorporateNonSegmentMember 2023-07-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:CorporateNonSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:CostOfSalesMembermck:USPharmaceuticalSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:CorporateNonSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2024-03-31 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2024-03-31 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2024-03-31 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2024-03-31 0000927653 us-gaap:CorporateNonSegmentMember 2024-03-31 0000927653 us-gaap:OperatingSegmentsMembermck:USPharmaceuticalSegmentMember 2024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:PrescriptionTechnologySolutionsSegmentMember 2024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:MedicalSurgicalSolutionsSegmentMember 2024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:InternationalSegmentMember 2024-09-30 0000927653 us-gaap:CorporateNonSegmentMember 2024-09-30 0000927653 us-gaap:AccruedLiabilitiesMember 2024-03-31 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember 2024-03-31 0000927653 us-gaap:AccruedLiabilitiesMember 2024-09-30 0000927653 us-gaap:OtherNoncurrentLiabilitiesMember 2024-09-30 0000927653 2023-04-012023-06-30 0000927653 us-gaap:EmployeeStockOptionMember 2024-07-012024-09-30 0000927653 us-gaap:EmployeeStockOptionMember 2023-07-012023-09-30 0000927653 us-gaap:EmployeeStockOptionMember 2024-04-012024-09-30 0000927653 us-gaap:EmployeeStockOptionMember 2023-04-012023-09-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2024-07-012024-09-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2023-07-012023-09-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-09-30 0000927653 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-09-30 0000927653 mck:USPharmaceuticalSegmentMember 2024-03-31 0000927653 mck:PrescriptionTechnologySolutionsSegmentMember 2024-03-31 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2024-03-31 0000927653 mck:InternationalSegmentMember 2024-03-31 0000927653 us-gaap:CorporateMember 2024-03-31 0000927653 mck:USPharmaceuticalSegmentMember 2024-09-30 0000927653 mck:PrescriptionTechnologySolutionsSegmentMember 2024-09-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2024-09-30 0000927653 mck:InternationalSegmentMember 2024-09-30 0000927653 us-gaap:CorporateMember 2024-09-30 0000927653 us-gaap:CustomerRelationshipsMember 2024-09-30 0000927653 us-gaap:CustomerRelationshipsMember 2024-03-31 0000927653 us-gaap:ServiceAgreementsMember 2024-09-30 0000927653 us-gaap:ServiceAgreementsMember 2024-03-31 0000927653 us-gaap:TrademarksAndTradeNamesMember 2024-09-30 0000927653 us-gaap:TrademarksAndTradeNamesMember 2024-03-31 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-09-30 0000927653 us-gaap:TechnologyBasedIntangibleAssetsMember 2024-03-31 0000927653 us-gaap:OtherIntangibleAssetsMember 2024-09-30 0000927653 us-gaap:OtherIntangibleAssetsMember 2024-03-31 0000927653 mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A090NotesDueDecember32025Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A525NotesDueFebruary152026Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A130NotesDueAugust152026Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A765DebenturesDueMarch12027Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A765DebenturesDueMarch12027Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A395NotesDueFebruary162028Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A475NotesDueMay302029Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A475NotesDueMay302029Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A600NotesDueMarch12041Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A488NotesDueMarch152044Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A488NotesDueMarch152044Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A150EuroNotesDueNovember172025Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A150EuroNotesDueNovember172025Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A163EuroNotesDueOctober302026Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember 2024-09-30 0000927653 mck:A313SterlingNotesDueFebruary172029Memberus-gaap:LoansPayableMember 2024-03-31 0000927653 mck:LeaseAndOtherObligationsMember 2024-09-30 0000927653 mck:LeaseAndOtherObligationsMember 2024-03-31 0000927653 mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember 2024-09-10 0000927653 mck:A4.25NotesDueSeptember152029Memberus-gaap:LoansPayableMember 2024-09-102024-09-10 0000927653 mck:A525NotesDueFebruary152026Member 2024-09-10 0000927653 mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember 2023-06-15 0000927653 mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember 2023-06-15 0000927653 mck:A490NotesDueJuly152028Memberus-gaap:LoansPayableMember 2023-06-152023-06-15 0000927653 mck:A510NotesDueJuly152033Memberus-gaap:LoansPayableMember 2023-06-152023-06-15 0000927653 mck:A380NotesDueMarch152024Member 2023-06-15 0000927653 srt:MinimumMemberus-gaap:LoansPayableMember 2023-06-152023-06-15 0000927653 srt:MaximumMemberus-gaap:LoansPayableMember 2023-06-152023-06-15 0000927653 us-gaap:LoansPayableMember 2023-06-152023-06-15 0000927653 mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember 2023-06-162023-06-16 0000927653 mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember 2023-06-16 0000927653 mck:A380NotesDueMarch152024Memberus-gaap:LoansPayableMember 2023-04-012023-09-30 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMemberus-gaap:UnsecuredDebtMember 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMember 2022-11-07 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMember 2023-04-012023-09-30 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMember 2024-04-012024-09-30 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMember 2024-03-31 0000927653 us-gaap:RevolvingCreditFacilityMembermck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMemberus-gaap:UnsecuredDebtMember 2024-09-30 0000927653 us-gaap:CommercialPaperMember 2024-09-30 0000927653 us-gaap:CommercialPaperMember 2024-04-012024-09-30 0000927653 us-gaap:CommercialPaperMember 2023-04-012023-09-30 0000927653 us-gaap:CommercialPaperMember 2024-03-31 0000927653 currency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 currency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 currency:GBPus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 currency:GBPus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 currency:EURus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 currency:EURus-gaap:CurrencySwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 currency:USDus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 currency:USDus-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 currency:GBPus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 currency:GBPus-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 currency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-06-30 0000927653 currency:CADus-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SubsequentEventMember 2024-10-31 0000927653 us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-03-31 0000927653 us-gaap:InterestRateSwapMemberus-gaap:FairValueHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 us-

gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2022-04-012023-03-31 0000927653 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-04-012023-06-30 0000927653 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-06-15 0000927653 us-gaap:InterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-04-012024-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-07-012024-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-04-012024-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-04-012023-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-07-012024-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-04-012024-09-30 0000927653 us-gaap:CurrencySwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-04-012023-09-30 0000927653 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-07-012024-09-30 0000927653 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000927653 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-04-012024-09-30 0000927653 us-gaap:ForwardContractsMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-04-012023-09-30 0000927653 mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-07-012024-09-30 0000927653 mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-07-012023-09-30 0000927653 mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-04-012024-09-30 0000927653 mck:FixedInterestRateSwapMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember 2023-04-012023-09-30 0000927653 mck:CurrentAssetLiabilityMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 mck:CurrentAssetLiabilityMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 mck:OtherNonCurrentAssetsLiabilitiesMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 mck:OtherNonCurrentAssetsLiabilitiesMemberus-gaap:CurrencySwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 mck:OtherNonCurrentAssetsLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 mck:OtherNonCurrentAssetsLiabilitiesMemberus-gaap:InterestRateSwapMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 mck:CurrentAssetLiabilityMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 mck:CurrentAssetLiabilityMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 us-gaap:OtherNoncurrentAssetsMemberus-gaap:ForwardContractsMemberus-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2024-09-30 0000927653 us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000927653 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000927653 us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000927653 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0000927653 us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:NationalPrescriptionOpiateLitigationMembermck:ThreeLargestUSPharmaceuticalDistributorsMember 2024-04-012024-09-30 0000927653 mck:StateOfAlabamaAndSubdivisionsMembermck:NationalPrescriptionOpiateLitigationMember 2024-04-012024-09-30 0000927653 mck:StateOfWestVirginiaAndSubdivisionsMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember 2024-04-012024-09-30 0000927653 mck:CherokeeNationMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember 2024-04-012024-09-30 0000927653 mck:NativeAmericanTribesOtherThanCherokeeNationMembermck:NationalPrescriptionOpiateLitigationMembermck:ThreeNationalPharmaceuticalDistributorsMember 2024-04-012024-09-30 0000927653 mck:NativeAmericanTribesOtherThanCherokeeNationMembermck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 country:USmck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:IndividualClaimantMembercountry:USmck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2023-04-012024-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMemberus-gaap:CorporateMember 2023-04-012024-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMembermck:USPharmaceuticalSegmentMember 2023-04-012024-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2023-04-012024-03-31 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2024-04-012024-09-30 0000927653 mck:NationalPrescriptionOpiateLitigationMembermck:CorporateSegmentAndU.S.PharmaceuticalSegmentMember 2024-04-012024-09-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:NationalPrescriptionOpiateLitigationMember 2024-03-31 0000927653 mck:SettlingGovernmentalEntitiesAndCherokeeNationMembermck:NationalPrescriptionOpiateLitigationMemberus-gaap:SettledLitigationMember 2024-04-012024-09-30 0000927653 country:CAmck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:IndividualClaimantMembercountry:CAmck:NationalPrescriptionOpiateLitigationMember 2024-09-30 0000927653 mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMembersrt:MinimumMember 2013-05-172013-05-17 0000927653 mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMembersrt:MaximumMember 2013-05-172013-05-17 0000927653 mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember 2019-08-13 0000927653 2021-10-082021-10-08 0000927653 mck:TrueHealthChiropracticInc.etal.v.McKessonCorporationetalMember 2022-04-272022-04-27 0000927653 mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15Cv00903RAMember 2020-07-31 0000927653 2024-04-012024-06-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2024-07-012024-09-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2024-09-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2024-04-012024-06-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-07-012023-09-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-09-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-04-012023-06-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2024-04-012024-09-30 0000927653 mck:OpenMarketShareRepurchaseTransactionsMember 2023-04-012023-09-30 0000927653 2023-04-012024-03-31 0000927653 2024-07-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2024-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedTranslationAdjustmentMember 2024-07-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2024-07-012024-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2024-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-06-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedTranslationAdjustmentMember 2023-07-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2023-07-012023-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2024-03-31 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-03-31 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-

gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedTranslationAdjustmentMember 2024-04-012024-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2024-04-012024-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-03-31 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedForeignCurrencyAdjustmentAttributableToNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossAttributableToNoncontrollingInterestMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedTranslationAdjustmentMember 2023-04-012023-09-30 0000927653 mck:AOCIAccumulatedGainLossNetInvestmentHedgesPortionAttributableToParentMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-04-012023-09-30 0000927653 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember 2023-04-012023-09-30 0000927653 mck:USPharmaceuticalSegmentMember 2024-07-012024-09-30 0000927653 mck:USPharmaceuticalSegmentMember 2023-07-012023-09-30 0000927653 mck:USPharmaceuticalSegmentMember 2023-04-012023-09-30 0000927653 mck:PrescriptionTechnologySolutionsSegmentMember 2024-07-012024-09-30 0000927653 mck:PrescriptionTechnologySolutionsSegmentMember 2023-07-012023-09-30 0000927653 mck:PrescriptionTechnologySolutionsSegmentMember 2023-04-012023-09-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2024-07-012024-09-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2023-07-012023-09-30 0000927653 mck:MedicalSurgicalSolutionsSegmentMember 2023-04-012023-09-30 0000927653 mck:InternationalSegmentMember 2024-07-012024-09-30 0000927653 mck:InternationalSegmentMember 2023-07-012023-09-30 0000927653 mck:InternationalSegmentMember 2023-04-012023-09-30 0000927653 us-gaap:CorporateMember 2024-07-012024-09-30 0000927653 us-gaap:CorporateMember 2023-07-012023-09-30 0000927653 us-gaap:CorporateMember 2023-04-012023-09-30 0000927653 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:ProductConcentrationRiskMembermck:USPharmaceuticalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:ProductConcentrationRiskMembermck:PrescriptionTechnologySolutionsSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:ProductConcentrationRiskMembermck:MedicalSurgicalSolutionsSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMemberus-gaap:ProductConcentrationRiskMembermck:InternationalSegmentMember 2024-07-012024-09-30 0000927653 country:US 2024-07-012024-09-30 0000927653 mck:USPharmaceuticalSegmentMember 2023-04-012024-03-31 0000927653 us-gaap:OperatingSegmentsMembermck:RestructuringInitiativesQTDMembermck:USPharmaceuticalSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:RestructuringInitiativesQTDMembermck:USPharmaceuticalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:OperatingSegmentsMembermck:NationalPrescriptionOpiateLitigationMembermck:USPharmaceuticalSegmentMember 2024-04-012024-09-30 0000927653 mck:RxSavingsSolutionsLLCMember 2023-07-012023-09-30 0000927653 mck:RxSavingsSolutionsLLCMember 2023-04-012023-09-30 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMembermck:InternationalSegmentMember 2024-04-012024-09-30 0000927653 us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMembermck:CanadianRetailDisposalGroupMembermck:InternationalSegmentMember 2024-07-012024-09-30 0000927653 us-gaap:CorporateNonSegmentMembermck:CanadianRetailDisposalGroupMember 2024-04-012024-09-30 0000927653 us-gaap:CorporateNonSegmentMembermck:CanadianRetailDisposalGroupMember 2024-07-012024-09-30 0000927653 us-gaap:CorporateNonSegmentMembermck:NationalPrescriptionOpiateLitigationMember 2024-04-012024-09-30 0000927653 mck:ThomasRodgersMember 2024-04-012024-09-30 0000927653 mck:ThomasRodgersMember 2024-07-012024-09-30 0000927653 mck:ThomasRodgersMember 2024-09-30 0000927653 mck:LeAnnSmithMember 2024-04-012024-09-30 0000927653 mck:LeAnnSmithMember 2024-07-012024-09-30 0000927653 mck:LeAnnSmithMember 2024-09-30 shares iso4217:USD iso4217:USD shares mck:segment pure iso4217:CAD iso4217:GBP iso4217:EUR mck:distributor mck:state mck:case mck:subdivision mck:plaintiff mck:faxNumber mck:fax mck:settlement mck:vote0000927653--03-312025Q2falseP366DP365D10-Qtrue2024-09-30false1-13252McKESSON CORPORATIONDE94-3207296655 5 State Hwy 161IrvingTX75039972446-4800Common stock, $0.01 par valueMCKNYSE1.500% Notes due 2025MCK25NYSE1.625% Notes due 2026MCK26NYSE3.125% Notes due 2029MCK29NYSEYesYesLarge Accelerated 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-881000000152000000148000000263100000002411900000-3017000000-197100000037500000037200000-2642000000-15990000007242900000006744300000027900000030000008126000000158100000091300000014900000-247810000003740000001381000000320000003200000063000000630000003000001529000000152900000024100000046000000287000000230000002300000.719000000090000000450000004890000000152000000-263100000003750000000-264200000027800000030000007824000000131820000000-848000000143000000-217630000003620000000-124000000027000000-100000026000000480000004800000020000008400000008400000006640000003900000070300000-39000000-390000000.628400000084000000380000003800000010000000-1000000027800000030000007899000000137610000000-887000000145000000-226040000003640000000-146400000027800000030000008048000000149780000000-881000000148000000-241190000003720000000-159900000010000005400000-134000000-800000001190000001190000004000000205700000020570000001156000000910000001247000000-9000000-90000001.331730000001730000008800000088000000200000020000002790000003000000822100000015959000000-890000000152000000-263100000003750000000-264200000027700000030000007747000000122950000009050000001410000000-209970000003670000000-149000000010000005400000-940000004000000091000000910000004000000151300000015130000001622000000780000001700000000180000001800000001.161570000001570000007700000077000000-7000000-100000040000000-400000027800000030000007899000000137610000000-887000000145000000-226040000003640000000-146400000012470000001700000000124000000129000000208000000187000000760000002800000-125000000271000000-400000087000000113000000122000000890000001600000063800000000-169000000243000000-174000000-710000003499000000320700000033100000002349000000622100000043070000000-196000000-166000000-145000000-76000000-386000000-529000000408000000347000000720000000-870000002420000001530000001430000001110000001000000093000000500000008000000010100000-373000000-315000000687600000020000000068760000002000000004980000009910000005010000002710000000647000000540000005400000020190000001505000000162000000278000000-225000000-2408000000-175200000001000000-1000000-140000000-2074000000-215500000045850000004679000000251100000025240000002000000025090000002524000000Significant Accounting Policies Nature of Operations: McKesson Corporation together with its subsidiaries (collectively, the "Company" or "McKesson,") is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions ("RxTS"), Medical-Surgical Solutions, and International. Refer to Financial Note 12, "Segments of Business," for additional information. Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and therefore do not include all information and disclosures normally included in the annual consolidated financial statements. The condensed consolidated financial statements of McKesson include the financial statements of all majority-owned or controlled companies. For those consolidated subsidiaries where the Company's ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as "Net income attributable to noncontrolling interests" in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. Net income attributable to noncontrolling interests includes third-party equity interests in the Company's consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity ("VIE"). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Fiscal Period: The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means the Company's fiscal year. Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation. Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the

Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented. The results of operations for the three and six months ended September 30, 2024 and 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024, previously filed with the SEC on May 8, 2024 (the "2024 Annual Report"). Recently Adopted Accounting Pronouncements There were no accounting standards adopted during the six months ended September 30, 2024 that had a material impact to the Company's condensed consolidated financial statements or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment's profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures. Recent Securities and Exchange Commission Final Rules Not Yet Implemented In March 2024, the SEC adopted final rules under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which would have required the Company to provide certain climate-related information in annual reports and registration statements beginning with its Annual Report on Form 10-K for the year ended March 31, 2026. In April 2024, the SEC stayed these rules pending the completion of judicial review of consolidated petitions challenging the validity of the rules. The Company is currently evaluating the impact of these rules in light of those legal challenges and monitoring the status of the stay and judicial review. 4 Basis of Presentation: The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission ("SEC") and therefore do not include all information and disclosures normally included in the annual consolidated financial statements. The condensed consolidated financial statements of McKesson include the financial statements of all majority-owned or controlled companies. For those consolidated subsidiaries where the Company's ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as "Net income attributable to noncontrolling interests" in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. Net income attributable to noncontrolling interests includes third-party equity interests in the Company's consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity ("VIE"). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. Fiscal Period: The Company's fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year means the Company's fiscal year. Reclassifications: Certain prior period amounts have been reclassified to conform to the current year presentation. Use of Estimates: The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented. Recently Adopted Accounting Pronouncements There were no accounting standards adopted during the six months ended September 30, 2024 that had a material impact to the Company's condensed consolidated financial statements or disclosures. Recently Issued Accounting Pronouncements Not Yet Adopted In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 improves the transparency of income tax disclosures by requiring, on an annual basis, consistent categories, and greater disaggregation of information in the rate reconciliation as well as income taxes paid disaggregated by jurisdiction. ASU 2023-09 is effective for the Company for fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update should be applied prospectively, however, retrospective application is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 expands reportable segment disclosures by requiring disclosure, on an annual and interim basis, of significant segment expenses that are regularly provided to the chief operating decision maker ("CODM") and included within each reported measure of segment profit or loss as well as an amount and description of other segment items. ASU 2023-07 also requires interim disclosures of a reportable segment's profit or loss and assets, disclosure of the title and position of the CODM, and an explanation of how the CODM uses the reported measure of segment profit or loss in assessing performance and allocating resources. ASU 2023-07 is effective for the Company for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The amendments in this update are required to be applied retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact that this guidance will have on its disclosures. In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 requires disclosure of certain costs and expenses on an interim and annual basis in the notes to the financial statements. ASU 2024-03 is effective for the Company for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on its disclosures. Recent Securities and Exchange Commission Final Rules Not Yet Implemented In March 2024, the SEC adopted final rules under SEC Release Nos. 33-11275 and 34-99678, The Enhancement and Standardization of Climate-Related Disclosures for Investors, which would have required the Company to provide certain climate-related information in annual reports and registration statements beginning with its Annual Report on Form 10-K for the year ended March 31, 2026. In April 2024, the SEC stayed these rules pending the completion of judicial review of consolidated petitions challenging the validity of the rules. The Company is currently

evaluating the impact of these rules in light of those legal challenges and monitoring the status of the stay and judicial review. Held for Sale Assets and liabilities to be disposed of by sale ("disposal groups") are classified as "held for sale" if their carrying amounts are principally expected to be recovered through a sale transaction rather than through continuing use. The classification occurs when the disposal group is available for immediate sale and the sale is probable. These criteria are generally met when management has committed to a plan to sell the assets within one year. Disposal groups are measured at the lower of carrying amount or fair value less costs to sell, and long-lived assets included within the disposal group are not depreciated or amortized. The fair value of a disposal group, less any costs to sell, is assessed during each reporting period it remains classified as held for sale, and any remeasurement to the lower of carrying value or fair value less costs to sell is reported as an adjustment to the carrying value of the disposal group. When the net realizable value of a disposal group increases during a period, a gain can be recognized to the extent that it does not increase the value of the disposal group beyond its original carrying value when the disposal group was reclassified as held for sale. The Company determined that the disposal group discussed below did not meet the criteria for classification as discontinued operations. Rexall Health and Well.ca On September 5, 2024, the Company announced an agreement to sell its Rexall and Well.ca businesses in Canada ("Canadian retail disposal group"). The adjusted purchase price of approximately $148 million, net of working capital and other adjustments, includes a payment of $27 million to be made upon closing, and a note of $121 million accruing interest upon satisfaction of certain conditions, measured at fair value, payable to the Company at the end of six years. As of September 30, 2024, the Canadian retail disposal group, consisting of $631 million of assets and $371 million of liabilities within the Company's International segment, was classified as "Assets held for sale" and "Liabilities held for sale," respectively, in the Condensed Consolidated Balance Sheet. The transaction is anticipated to close in the second half of fiscal 2025, pursuant to the satisfaction of customary closing conditions, including receipt of regulatory approvals, as applicable. During the three and six months ended September 30, 2024, the Company recorded a charge of $643 million, within "Selling, distribution, general, and administrative expenses" in the Condensed Consolidated Statements of Operations, to remeasure the Canadian retail disposal group to fair value less costs to sell. The remeasurement adjustment includes a $15 million loss related to the accumulated other comprehensive balances associated with the Canadian retail disposal group. The Company's measurement of the fair value of the Canadian retail disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreements. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.</div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt">The total assets and liabilities of the Canadian retail disposal group that have met the classification of held for sale in the Company's Condensed Consolidated Balance Sheet are as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Receivables, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventories, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prepaid expenses and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Property, plant, and equipment, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">283 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Intangible assets, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Remeasurement of assets of businesses held for sale to fair value less costs to sell(1) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(643)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">631 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Drafts and accounts payable</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Current portion of operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Long-term operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">249 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-

align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total liabilities held for sale</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
1480000002700000012100000OP6Y631000000371000000643000000643000000150000001500000 The total assets and liabilities of the Canadian retail disposal group that have met the classification of held for sale in the Company's Condensed Consolidated Balance Sheet are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:81.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Assets</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current assets</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Receivables, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Inventories, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">219 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prepaid expenses and other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Property, plant, and equipment, net</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">62 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">283 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Goodwill</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Intangible assets, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">419 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">160 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt">Remeasurement of assets of businesses held for sale to fair value less costs to sell(1)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(643)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total assets held for sale</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">631 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Liabilities</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Current liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Drafts and accounts payable</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Current portion of operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">61 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">42 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Long-term operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">249 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Other non-current liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom">Total liabilities held for sale</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes intercompany trade accounts payable of $142 million, primarily related to purchases of inventories from McKesson Canada. These balances are expected to be assumed by the buyer upon divestiture and are excluded from Drafts and accounts payable above as they are fully eliminated in the Company's consolidated financial statements.
1400000065000000219000000500000062000000283000000470000004190000001600000006430000006310000001500000061000000420000002490000004000000500000006300000063100000064000000650000006600000067000000680000006900000070000000710000007200000073000000740000007500000076000000770000007800000079000000800000008100000082000000830000008400000085000000860000008700000088000000890000009000000091000000920000009300000094000000950000009600000097000000980000009900000100000001010000010200000103000001040000010500000106000001070000010800000109000001100000011100000112000001130000011400000115000001160000011700000118000001190000012000000121000001220000012300000124000001250000012600000127000001280000012900000130000001310000013200000133000001340000013500000136000001370000013800000139000001400000014100000142000001430000014400000145000001460000014700000148000001490000015000000151000001520000015300000154000001550000015600000157000001580000015900000160000001610000016200000163000001640000016500000166000001670000016800000169000001700000017100000172000001730000017400000175000001760000017700000178000001790000018000000181000001820000018300000184000001850000018600000187000001880000018900000190000001910000019200000193000001940000019500000196000001970000019800000199000002000000201000002020000020300000204000002050000020600000207000002080000020900000210000002110000021200000213000002140000021500000216000002170000021800000219000002200000022100000222000002230000022400000225000002260000022700000228000002290000023000000231000002320000023300000234000002350000023600000237000002380000023900000240000002410000024200000243000002440000024500000246000002470000024800000249000002500000025100000252000002530000025400000255000002560000025700000258000002590000026000000261000002620000026300000264000002650000026600000267000002680000026900000270000002710000027200000273000002740000027500000276000002770000027800000279000002800000028100000282000002830000028400000285000002860000028700000288000002890000029000000291000002920000029300000294000002950000029600000297000002980000029900000300000003010000030200000303000003040000030500000306000003070000030800000309000003100000031100000312000003130000031400000315000003160000031700000318000003190000032000000321000003220000032300000324000003250000032600000327000003280000032900000330000003310000033200000333000003340000033500000336000003370000033800000339000003400000034100000342000003430000034400000345000003460000034700000348000003490000035000000351000003520000035300000354000003550000035600000357000003580000035900000360000003610000036200000363000003640000036500000366000003670000036800000369000003700000037100000372000003730000037400000375000003760000037700000378000003790000038000000381000003820000038300000384000003850000038600000387000003880000038900000390000003910000039200000393000003940000039500000396000003970000039800000399000004000000401000004020000040300000404000004050000040600000407000004080000040900000410000004110000041200000413000004140000041500000416000004170000041800000419000004200000042100000422000004230000042400000425000004260000042700000428000004290000043000000431000004320000043300000434000004350000043600000437000004380000043900000440000004410000044200000443000004440000044500000446000004470000044800000449000004500000045100000452000004530000045400000455000004560000045700000458000004590000046000000461000004620000046300000464000004650000046600000467000004680000046900000470000004710000047200000473000004740000047500000476000004770000047800000479000004800000048100000482000004830000048400000485000004860000048700000488000004890000049000000491000004920000049300000494000004950000049600000497000004980000049900000500000005010000050200000503000005040000050500000506000005070000050800000509000005100000051100000512000005130000051400000515000005160000051700000518000005190000052000000521000005220000052300000524000005250000052600000527000005280000052900000530000005310000053200000533000005340000053500000536000005370000053800000539000005400000054100000542000005430000054400000545000005460000054700000548000005490000055000000551000005520000055300000554000005550000055600000557000005580000055900000560000005610000056200000563000005640000056500000566000005670000056800000569000005700000057100000572000005730000057400000575000005760000057700000578000005790000058000000581000005820000058300000584000005850000058600000587000005880000058900000590000005910000059200000593000005940000059500000596000005970000059800000599000006000000601000006020000060300000604000006050000060600000607000006080000060900000610000006110000061200000613000006140000061500000616000006170000061800000619000006200000062100000622000006230000062400000625000006260000062700000628000006290000063000000631000006320000063300000634000006350000063600000637000006380000063900000640000006410000064200000643000006440000064500000646000006470000064800000649000006500000065100000652000006530000065400000655000006560000065700000658000006590000066000000661000006620000066300000664000006650000066600000667000006680000066900000670000006710000067200000673000006740000067500000676000006770000067800000679000006800000068100000682000006830000068400000685000006860000068700000688000006890000069000000691000006920000069300000694000006950000069600000697000006980000069900000700000007010000070200000703000007040000070500000706000007070000070800000709000007100000071100000712000007130000071400000715000007160000071700000718000007190000072000000721000007220000072300000724000007250000072600000727000007280000072900000730000007310000073200000733000007340000073500000736000007370000073800000739000007400000074100000742000007430000074400000745000007460000074700000748000007490000075000000751000007520000075300000754000007550000075600000757000007580000075900000760000007610000076200000763000007640000076500000766000007670000076800000769000007700000077100000772000007730000077400000775000007760000077700000778000007790000078000000781000007820000078300000784000007850000078600000787000007880000078900000790000007910000079200000793000007940000079500000796000007970000079800000799000008000000801000008020000080300000804000008050000080600000807000008080000080900000810000008110000081200000813000008140000081500000816000008170000081800000819000008200000082100000822000008230000082400000825000008260000082700000828000008290000083000000831000008320000083300000834000008350000083600000837000008380000083900000840000008410000084200000843000008440000084500000846000008470000084800000849000008500000085100000852000008530000085400000855000008560000085700000858000008590000086000000861000008620000086300000864000008650000086600000867000008680000086900000870000008710000087200000873000008740000087500000876000008770000087800000879000008800000088100000882000008830000088400000885000008860000088700000888000008890000089000000891000008920000089300000894000008950000089600000897000008980000089900000900000009010000090200000903000009040000090500000906000009070000090800000909000009100000091100000912000009130000091400000915000009160000091700000918000009190000092000000921000009220000092300000924000009250000092600000927000009280000092900000930000009310000093200000933000009340000093500000936000009370000093800000939000009400000094100000942000009430000094400000945000009460000094700000948000009490000095000000951000009520000095300000954000009550000095600000957000009580000095900000960000009610000096200000963000009640000096500000966000009670000096800000969000009700000097100000972000009730000097400000975000009760000097700000978000009790000098000000981000009820000098300000984000009850000098600000987000009880000098900000990000009910000099200000993000009940000099500000996000009970000099800000999000010000000100100

Condensed Consolidated Statement of Operations, for each of the three and six months ended September 30, 2024, respectively. Restructuring Initiatives During the second quarter of fiscal 2025, the Company approved enterprise-wide initiatives to modernize and accelerate the technology service operating model, which are intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives will also include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions, and U.S. Pharmaceutical segments to help realize long-term sustainable growth. The Company anticipates total charges related to these initiatives of $650 million to $700 million, consisting primarily of employee severance and other employee-related costs as well as facility, exit and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. For the three and six months ended September 30, 2024, the Company recorded charges of $227 million related to the initiatives, which primarily includes severance and other employee-related costs as well as facility exit and other related costs, including long-lived asset impairments. During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives included headcount reductions, primarily consisting of employee severance and other employee-related costs within the RxTS segment, and the exit or downsizing of certain facilities. For the three and six months ended September 30, 2023, the Company recorded charges of $3 million and $39 million related to this program, respectively, which primarily included real estate and other related asset impairments and facility costs within Corporate. This restructuring program was substantially complete in fiscal 2024.</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following: </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">U.S. Pharmaceutical (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Medical-Surgical Solutions (2)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">International(3)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">149 </td><td style="background-color:#ceeeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Exit and other-related costs (3) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceeeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceeeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#ceeeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-

align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.</div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's Medical-Surgical Solutions segment.</div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Prescription Technology Solutions (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Corporate</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Exit and other-related costs (2) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's technology solutions. (2) Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Pharmaceutical(1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medical-Surgical Solutions (2) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> International </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt">Exit and other-related costs (3)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's Medical-Surgical Solutions segment. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Prescription Technology Solutions (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> International </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net

</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Exit and other-related costs (2) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">46 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. The following table summarizes the activity related to the liabilities associated with the Company's restructuring initiatives for the six months ended September 30, 2024: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-

align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Balance, March 31, 2024 (1) </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Restructuring, impairment, and related charges, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Non-cash charges</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cash payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Other (2) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> Balance, September 30, 2024 (3) </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td>

<td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">188 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet. (2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves. (3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in “Other accrued liabilities” and $28 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.</div>2340000002800000024400000080000000171000000181000000630000006300000065000000070000000022700000002270000003000000390000000<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Restructuring, impairment, and related charges, net for the three months ended September 30, 2024 and 2023 consisted of the following: </div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.199%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.913%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.476%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">U.S. Pharmaceutical (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Medical-Surgical Solutions (2)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">International </div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">149 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Exit and other-related costs (3) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0

1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">63 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">73 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">147 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">234 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations.</div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's Medical-Surgical Solutions segment.</div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Prescription Technology Solutions (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Corporate</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-

color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Exit and other-related costs (2) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's technology solutions. (2) Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Restructuring, impairment, and related charges, net for the six months ended September 30, 2024 and 2023 consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:20.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.492%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Pharmaceutical (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medical-Surgical Solutions (2) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> International </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:100%">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">148 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Exit and other-related costs (3) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">64 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">76 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's U.S. Pharmaceutical segment, including an inventory impairment of $63 million within "Cost of sales" in the Condensed Consolidated Statement of Operations. (2)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's Medical-Surgical Solutions segment. (3)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:20.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.612%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td

style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, 2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Prescription Technology Solutions (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> International </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Severance and employee-related costs, net </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Exit and other-related costs (2) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">40 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Asset impairments and accelerated depreciation</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">28 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top">Total</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">46 </td><td style="background-

color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">80 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company's technology solutions. </div>(2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.10000000144000000040000001490000000033000000-10000001000000012000000630000001000000009000000730000006400000010000001470000000-10000002300000023400000063000000800000002000000010000001000000300000040000004000000060000001800000000000009000000300000040000006000000060000010000001200000020000006400000020000001000000900000076000000650000005000000150000000024000000244000000630000009000000020000001000000120000style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt">The following table summarizes the activity related to the liabilities associated with the Company's restructuring initiatives for the six months ended September 30, 2024:</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">International</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Balance, March 31, 2024 (1)</div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">21 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">55 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top">Restructuring, impairment, and related charges, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">65 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Non-cash charges</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(64)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(76)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Cash payments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(25)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Other (2) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2) </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"> Balance, September 30, 2024 (3) </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">144 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">188 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)As of March 31, 2024, the total reserve balance was $55 million, of which $24 million was recorded in “Other accrued liabilities” and $31 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet. (2)Other primarily includes cumulative translation adjustments within International, and transfers to certain other liabilities, including Canadian retail disposal group reserves. (3)As of September 30, 2024, the total reserve balance was $188 million, of which $160 million was recorded in “Other accrued liabilities” and $28 million was recorded in “Other non-current liabilities” in the Company’s Condensed Consolidated Balance Sheet.
1800000050000001000000100000002100000055000000650000005000000150000000024000000244000000640000002000000010000009000000760000004000000210000000-1000000-20000000-5000000-2000000-1000000014000000400000014400000020000002400000018800000055000000240000003100000018800000016000000028000000Income Taxes Income tax expense was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax expense</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">247 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">213 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">307 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Reported income tax rate</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.9 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table> Fluctuations in the Company's reported income tax rates were primarily due to non-cash charges related to remeasuring the value of its Canadian retail disposal group held for sale to fair value less costs to sell, changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters. During the three months ended September 30, 2024, the Company sold certain intellectual property between McKesson wholly-owned legal entities based in foreign tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result, a discrete tax benefit of $44 million was recognized in the second quarter of fiscal 2025. During the three and six months ended September 30, 2024, the Company recorded non-cash pre-tax charges of $643 million to remeasure the Canadian retail disposal group to fair value less costs to sell, as described in Financial Note 2, "Held for Sale". The Company's reported income tax rates for the three and six months ended September 30, 2024 were unfavorably impacted by these charges given that no net tax benefit was recognized for these charges. During the six months ended September 30, 2024, the Company also recognized discrete tax benefits of $58 million related to an election to change the tax status of a foreign affiliate, $38 million related to the tax impact of share-based compensation, and $47 million related to the reduction in unrecognized tax benefits due to a change in case law, partially offset by a discrete tax expense of $37 million related to interest expense accrued on unrecognized tax benefits. During the three months ended September 30, 2023, the Company recognized a net discrete tax expense of $12 million primarily related to interest expense accrued on unrecognized tax benefits. During the six months ended September 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, Intra-Entity Transfers of Assets Other Than Inventory, a net discrete tax benefit of $147 million was recognized during the three months ended June 30, 2023. As of September 30, 2024, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year.</div>The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year.<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Income tax expense was as follows:</div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income tax expense</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">247 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">213 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">371 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">307 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Reported income tax rate</td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">46.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.9 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">15.3 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom">%</td></tr></table>
2470000002130000003710000003070000000.4630.2330.2290.153-4400000006430000006430000000-58000000-38000000-4700000037000000120000001470000001400000000130000000Earnings Per Common Share Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than one million of potentially dilutive securities for the three and six months ended September 30, 2024 and 2023 were excluded from the computation of diluted earnings per common share as they were anti-dilutive. The computations for basic and diluted earnings per common share were as follows: <table

<table>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td colspan="3">Three Months Ended September 30,</td><td></td><td colspan="3">Six Months Ended September 30,</td><td></td></tr>
<tr><td>(In millions, except per share amounts)</td><td>2024</td><td></td><td>2023</td><td></td><td>2024</td><td></td><td>2023</td><td></td></tr>
<tr><td>Net income</td><td>$</td><td>287</td><td></td><td>$</td><td>1,247</td><td></td><td>$</td><td>703</td><td></td></tr>
<tr><td>Net income attributable to noncontrolling interests</td><td></td><td>(46)</td><td></td><td>(39)</td><td></td><td>(91)</td><td></td><td>(78)</td><td></td></tr>
<tr><td>Net income attributable to McKesson Corporation</td><td>$</td><td>241</td><td></td><td>$</td><td>1,156</td><td></td><td>$</td><td>664</td><td></td></tr>
<tr><td>Basic</td><td></td><td>128.7</td><td></td><td></td><td>134.1</td><td></td><td></td><td>129.3</td><td></td><td></td><td>134.8</td><td></td></tr>
<tr><td>Effect of dilutive securities:</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>Stock options</td><td></td><td>0.1</td><td></td><td></td><td>0.2</td><td></td><td></td><td>0.2</td><td></td><td></td><td>0.2</td><td></td></tr>
<tr><td>Restricted stock units</td><td></td><td>0.1</td><td></td><td></td><td>0.2</td><td></td><td></td><td>0.2</td><td></td><td></td><td>0.2</td><td></td></tr>
</table>

family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">135.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share attributable to McKesson Corporation: (2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Diluted</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1.87 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">4.92 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8.89 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">11.95 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Basic</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1.88 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4.95 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">8.94 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">12.03 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes dilutive effect from restricted stock units and performance-based restricted stock units. (2)Certain computations may reflect rounding adjustments. 10000001000000100000010000000 The computations for basic and diluted earnings per common share were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions, except per share amounts)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px

0;text-align:right;vertical-align:bottom">287 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">703 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,247 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,700 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income attributable to noncontrolling interests</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(46)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(91)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Net income attributable to McKesson Corporation</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">241 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">664 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,156 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,622 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average common shares outstanding:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Basic</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">128.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive securities:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Stock options</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Restricted stock units (1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Diluted</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">134.8 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">130.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">135.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-

align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Earnings per common share attributable to McKesson Corporation: (2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

#000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,449 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,132 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill acquired</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Disposals (1)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Foreign currency translation adjustments, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,123 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,024 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,507 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,404 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3"

style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,087 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt">(1)Goodwill related to the Canadian retail disposal group discussed in Financial Note 2, "Held for Sale." This amount was included under the caption "Assets held for sale" in the Condensed Consolidated Balance Sheet as of September 30, 2024.</div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt">Intangible Assets</div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt">Information regarding intangible assets was as follows:</div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-
Average
Remaining
Amortization
Period
(Years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">11</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,480 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(604)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">876 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(701)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Service agreements</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">9</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(707)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">422 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(676)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">450 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks and trade names</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">13</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">384 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(268)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">759 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(395)</td><td style="background-

color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">364 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">10</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(125)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Total </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,311 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,738)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,573 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">(1)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,033 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,923)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,110 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Excludes net intangible assets of approximately $419 million related to the Canadian retail disposal group discussed in Financial Note 2, "Held for Sale." This amount was included under the caption "Assets held for sale" in the Condensed Consolidated Balance Sheet as of September 30, 2024. Amortization of these assets ceased upon classification as held for sale in the second quarter of fiscal 2025. All intangible assets, except for those classified as held for sale, were subject to amortization as of September 30, 2024 and March 31, 2024. Amortization expense of intangible assets was $60 million and $62 million for the three months ended September 30, 2024 and 2023, respectively, and $123 million and $124 million for the six months ended September 30, 2024 and 2023, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $102 million, $177 million, $171 million, $166 million, and $164 million for the remainder of fiscal 2025 and each of the succeeding years through fiscal 2029, respectively, and $793 million thereafter. Changes in the carrying amount of goodwill were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.157%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.457%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Pharmaceutical</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> International </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Corporate</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2024</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,123 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,024 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,536 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,449 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,132 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Goodwill acquired</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Disposals (1) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(47)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Foreign currency translation adjustments, net</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(29)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top">Balance, September 30, 2024</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,123 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,024 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt

solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,507 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,404 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">29 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">10,087 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Goodwill related to the Canadian retail disposal group discussed in Financial Note 2, "Held for Sale." This amount was included under the caption "Assets held for sale" in the Condensed Consolidated Balance Sheet as of September 30, 2024.
4123000000202400000025360000001449000000010132000000000000000047000000047000000000200000002000000000-290000000290000000412300000020240000002507000000140400000029000000100870000000 Information regarding intangible assets was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:23.093%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.404%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.017%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.119%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(Dollars in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted-
Average
Remaining
Amortization
Period
(Years)</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Net
Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">11</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,480 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(604)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">876 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,830 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(701)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Service agreements</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">9</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,129 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(707)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">422 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,126 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(676)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">450 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3"

style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks and trade names</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:center;vertical-align:bottom">13</td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">384 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(268)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">116 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">759 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(395)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">364 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Technology</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">10</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(133)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">151 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">284 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(125)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">159 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="3" style="background-color:#ceceff;padding:2px 1pt;text-align:center;vertical-align:bottom">6</td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">34 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(26)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td colspan="2" style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Total </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"> </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3,311 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,738)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,573 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top">(1)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">4,033 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(1,923)</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,110 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Excludes net intangible assets of approximately $419 million related to the Canadian retail disposal group discussed in Financial Note 2, "Held for Sale," This amount was included under the caption "Assets held for sale" in the Condensed Consolidated Balance Sheet as of September 30, 2024. Amortization of these assets ceased upon classification as held for sale in the second quarter of fiscal 2025.
P11Y1480000000604000000876000000183000000070100000011290000000P9Y1129000000070700000042200000011260000006760000004500000000P13Y3840000000
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Debt and Financing Activities Long-term debt consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td>

</tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Dollar notes (1) (2) </td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.90% Notes due December 3, 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% Notes due February 15, 2026 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.30% Notes due August 15, 2026 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 7.65% Debentures due March 1, 2027 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.95% Notes due February 16, 2028 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">343 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">343 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.90% Notes due July 15, 2028 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.75% Notes due May 30, 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.25% Notes due September 15, 2029 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.10% Notes due July 15, 2033 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">597 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">596 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.00% Notes due March 1, 2041 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.88% Notes due March 15, 2044 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency notes (1) (3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.50% Euro Notes due November 17, 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">667 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">646 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.63% Euro Notes due October 30, 2026 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">540 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.13% Sterling Notes due February 17, 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">602 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">568 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease and other obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">261 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td

colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,744 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,629 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Current portion</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,691 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,579 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)These notes are unsecured and unsubordinated obligations of the Company. (2)Interest on these U.S. dollar notes is payable semi-annually. (3)Interest on these foreign currency notes is payable annually. Long-Term Debt The Company's long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At September 30, 2024 and March 31, 2024, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $53 million and $50 million, respectively, was included under the caption "Current portion of long-term debt" in the Company's Condensed Consolidated Balance Sheets. Public Offerings On September 10, 2024, the Company completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million (the "2029 Notes"). Interest on the 2029 Notes is payable semi-annually on March 15th and September 15th of each year, commencing on March 15, 2025. Proceeds received from the issuance of the 2029 Notes, net of discounts and offering expenses, were $496 million. The Company utilized the net proceeds from the offering of the 2029 Notes together with cash on hand to redeem its $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 (the "2026 Notes"), which became callable on or after February 15, 2024, prior to maturity at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest through the redemption date. The total loss recognized on the debt extinguishment of the 2026 Notes described above for the three and six months ended September 30, 2024 was not material and is included within "Interest expense" in the Company's Condensed Consolidated Statements of Operations. On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the "2028 Notes") and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the "2033 Notes" and, together with the 2028 Notes, the "Notes"). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the portion of the Company's then outstanding 3.80% Notes due March 15, 2024 (the "2024 Notes") that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes was available for general corporate purposes. Each of the 2029 Notes, the 2033 Notes and the 2028 Notes, constitutes a "series," is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company's existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. Each series is governed by an indenture and officers' certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days' and not more than 60 days' notice to holders of the applicable series of the notes, the Company may redeem such series of the notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers' certificate. If there were to occur both (a) a change of control of the Company and (b) a downgrade of the applicable series of the notes below an investment grade rating by each of the Ratings Agencies (as defined in the applicable officers' certificate) within a specified period, then the Company would be required to make an offer to purchase that series at a price equal to 101% of the then outstanding principal amount of that series, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers' certificate for each series, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders' consent. The indenture also contains customary events of default provisions. Concurrent Tender Offer of the 2024 Notes On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the "Concurrent Tender Offer"). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. Satisfaction and Discharge of the 2024 Notes On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the "2024 Notes Indenture") U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647 million principal amount of the 2024 Notes as it became due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company's obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. The total gain recognized on the debt extinguishment of the 2024 Notes described above for the six months ended September 30, 2023 was $9 million and was included within "Interest expense" in the Company's Condensed Consolidated Statement of Operations. Revolving Credit Facilities On November 7, 2022, the Company entered into a Credit Agreement (the "2022 Credit Facility"), that provides a syndicated $4.0 billion senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility was scheduled to mature in November 2028. On November 7, 2024, the maturity date of the 2022 Credit Facility was extended from November 2028 to November 2029. There were no borrowings under the 2022 Credit Facility during the six months ended September 30, 2024 and 2023 and no amounts outstanding at September 30, 2024 or March 31, 2024. At September 30, 2024, the Company was in compliance with all covenants under the 2022 Credit Facility. Commercial Paper The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the six months ended September 30, 2024, the Company borrowed and repaid $6.9 billion under the program. During the six months ended September 30, 2023, the Company borrowed and repaid $2.0 billion under the program. At September 30, 2024 and March 31, 2024, there were no commercial paper notes outstanding. Long-term debt consisted of the following: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.098%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Dollar notes <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-

weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2) </td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 0.90% Notes due December 3, 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.25% Notes due February 15, 2026 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.30% Notes due August 15, 2026 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">499 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 7.65% Debentures due March 1, 2027 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">150 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.95% Notes due February 16, 2028 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">343 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">343 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.90% Notes due July 15, 2028 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">399 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.75% Notes due May 30, 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">196 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.25% Notes due September 15, 2029 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">500 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 5.10% Notes due July 15, 2033 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">597 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">596 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 6.00% Notes due March 1, 2041 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">218 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 4.88% Notes due March 15, 2044 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">255 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency notes (1) (3) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.50% Euro Notes due November 17, 2025 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">667 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">646 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 1.63% Euro Notes due October 30, 2026 </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">557 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">540 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> 3.13% Sterling Notes due February 17, 2029 </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">602 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">568 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Lease and other obligations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">261 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">220 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total debt</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,744 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px

1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,629 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less: Current portion</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">53 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">50 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Total long-term debt</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,691 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,579 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)These notes are unsecured and unsubordinated obligations of the Company. (2)Interest on these U.S. dollar notes is payable semi-annually. (3)Interest on these foreign currency notes is payable annually.
0.009050000000050000000000.052504990000000.013049900000049900000000.076515000000015000000000.039534300000003430000000.049039900000039900000006 style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Activities In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company's policy, derivatives are only used for hedging purposes. The Company does not use derivatives for trading or speculative purposes. The Company uses various counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties. Foreign Currency Exchange Risk The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars. Changes in foreign currency exchange rates could have a material adverse impact on the Company's financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use foreign currency forward contracts and cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. Interest Rate Risk The Company has exposure to changes in interest rates, and it utilizes risk programs which use interest rate swaps to hedge the changes in debt fair values caused by fluctuations in benchmark interest rates. The Company also enters into forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances. These programs reduce but do not entirely eliminate interest rate risk. Derivative Instruments At September 30, 2024 and March 31, 2024, the notional amounts of the Company's outstanding derivatives were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Currency</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Maturity Date(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as net investment hedges:(2) </td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (3) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">CAD</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Apr-25 to Jun-26</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">C$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">C$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as fair value hedges: (2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (4) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">GBP</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nov-28</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">450 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (4) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">EUR</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Aug-25 to Jul-26</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Floating interest rate swaps (5) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">USD</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Aug-27 to Sep-29</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as cash flow hedges: (2) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency forwards (6) </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">GBP</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Oct-24 to Jul-25</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> (1)The maturity date reflected is for outstanding derivatives as of September 30, 2024. (2)There was no ineffectiveness in these hedges for the three and six months ended September 30, 2024 and 2023. (3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts. (4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. (5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. (6)The Company entered into agreements with financial institutions to hedge the variability of foreign currency exchange fluctuations in future cash payments due to a third party in the United Kingdom for capital expenditures. Net Investment Hedges The Company uses cross-currency swaps to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company's net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings. In the first quarter of fiscal 2025, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$2.5 billion to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps mature in April 2025 and June 2026. Further, the Company terminated C$1.5 billion of cross-currency swaps designated as net investment hedges with original maturity dates in November 2024 and extending through March 2025. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-

size:10pt;font-weight:400;line-height:120%">In October 2024, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$1.0 billion to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps will mature in October 2026. Fair Value Hedges The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The Company also uses floating interest rate swaps to hedge the changes in the fair value of its U.S. dollar notes resulting from changes in benchmark interest rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains and losses from the changes in the Company's fair value hedges recorded in earnings were largely offset by the gains and losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive loss. In fiscal 2023, the Company entered into floating interest rate swaps designated as fair value hedges to convert $1.3 billion of its fixed rate debt to floating rate in order to hedge the changes in fair value caused by fluctuations in the benchmark interest rate. In fiscal 2025, $500 million of the $1.3 billion floating interest rate swaps with original maturity dates in February 2026 and callable at any time after February 2024 were terminated. Refer to Financial Note 7, "Debt and Financing Activities," for additional information on the public offering of the 2029 Notes.
 Cash Flow Hedges The Company uses cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency exchange rates. The Company also uses forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances and to offset the potential income statement effects from obligations denominated in non-functional currencies. The effective portion of changes in the fair value of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. There were no gains or losses reclassified from accumulated other comprehensive loss and recorded in "Selling, distribution, general, and administrative expenses" in the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023. In fiscal 2023, the Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges with a combined notional amount of $450 million, and in the first quarter of fiscal 2024 with a notional amount of $50 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500 million cash flow hedges were terminated and the proceeds are being amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, "Debt and Financing Activities," for additional information on the public offering of the 2033 Notes.</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Derivatives Not Designated as Hedges</div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt">Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in "Selling, distribution, general, and administrative expenses" in the Condensed Consolidated Statements of Operations. The Company did not enter into or have any outstanding derivative instruments not designated as hedges during the periods presented.</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Other Information on Derivative Instruments</div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Gains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows:</div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as net investment hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swaps</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as cash flow and other hedges:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Cross-currency swaps (1)</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td

*style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ceceff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ceceff;padding:0 1pt"></td><td style="background-color:#ceceff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ceceff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ceceff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forwards</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Fixed interest rate swaps </td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges. Information regarding the fair value of derivatives on a gross basis were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet
Caption</td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value of
Derivative</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Dollar Notional</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value of
Derivative</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Dollar Notional</td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Asset</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Liability</td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Asset</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Liability</td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Derivatives designated for hedge accounting:</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cross-currency swaps (current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Prepaid expenses and other/Other accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">69 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,690 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,122 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cross-currency swaps (non-current)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Other non-current assets/liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-*

height:100%">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,771 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements. At September 30, 2024 and March 31, 2024, the notional amounts of the Company's outstanding derivatives were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.346%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.266%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Currency</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Maturity Date(1) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Notional</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as net investment hedges: (2) </td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (3) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">CAD</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Apr-25 to Jun-26</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">C$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">2,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">C$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,500 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as fair value hedges: (2) </td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (4) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">GBP</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nov-28</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">450 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">450 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (4) </td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">EUR</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Aug-25 to Jul-26</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">€</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,100 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Floating interest rate swaps (5) </td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">USD</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Aug-27 to Sep-29</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">750 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">1,250 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Derivatives designated as cash flow hedges: (2) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3"

style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign currency forwards (6) </td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">GBP</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Oct-24 to Jul-25</td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">£</td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">39 </td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> (1)The maturity date reflected is for outstanding derivatives as of September 30, 2024. (2)There was no ineffectiveness in these hedges for the three and six months ended September 30, 2024 and 2023. (3)The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts. (4)Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. (5)Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. (6)The Company entered into agreements with financial institutions to hedge the variability of foreign currency exchange fluctuations in future cash payments due to a third party in the United Kingdom for capital expenditures. 2500000000150000000045000000045000000011000000001100000000750000000125000000027000000039000000 Net Investment Hedges The Company uses cross-currency swaps to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company's net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings. In the first quarter of fiscal 2025, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$2.5 billion to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps mature in April 2025 and June 2026. Further, the Company terminated C$1.5 billion of cross-currency swaps designated as net investment hedges with original maturity dates in November 2024 and extending through March 2025. In October 2024, the Company entered into cross-currency swaps designated as net investment hedges with a total notional amount of C$1.0 billion to hedge portions of the Company's net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. These cross-currency swaps will mature in October 2026. Fair Value Hedges The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The Company also uses floating interest rate swaps to hedge the changes in the fair value of its U.S. dollar notes resulting from changes in benchmark interest rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains and losses from the changes in the Company's fair value hedges recorded in earnings were largely offset by the gains and losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive loss. In fiscal 2023, the Company entered into floating interest rate swaps designated as fair value hedges to convert $1.3 billion of its fixed rate debt to floating rate in order to hedge the changes in fair value caused by fluctuations in the benchmark interest rate. In fiscal 2025, $500 million of the $1.3 billion floating interest rate swaps with original maturity dates in February 2026 and callable at any time after February 2024 were terminated. Refer to Financial Note 7, "Debt and Financing Activities," for additional information on the public offering of the 2029 Notes.
 Cash Flow Hedges The Company uses cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency exchange rates. The Company also uses forward contracts to hedge the variability of future benchmark interest rates on any planned bond issuances and to offset the potential income statement effects from obligations denominated in non-functional currencies. The effective portion of changes in the fair value of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. There were no gains or losses reclassified from accumulated other comprehensive loss and recorded in "Selling, distribution, general, and administrative expenses" in the Condensed Consolidated Statements of Operations for the three and six months ended September 30, 2024 and 2023. In fiscal 2023, the Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges with a combined notional amount of $450 million, and in the first quarter of fiscal 2024 with a notional amount of $50 million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500 million cash flow hedges were terminated and the proceeds are being amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, "Debt and Financing Activities," for additional

information on the public offering of the 2033 Notes. Derivatives Not Designated as Hedges Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in “Selling, distribution, general, and administrative expenses” in the Condensed Consolidated Statements of Operations. The Company did not enter into or have any outstanding derivative instruments not designated as hedges during the periods presented.
2500000000015000000001000000000130000000050000000013000000000000450000000500000005000000000P10Y Gains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as net investment hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swaps</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as cash flow and other hedges:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (1) </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forwards</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Fixed interest rate swaps
</td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges. Gains (losses) from derivatives included in other comprehensive income (loss) in the Condensed Consolidated Statements of Comprehensive Income were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td

style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as net investment hedges:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cross-currency swaps</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(20)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(13)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Derivatives designated as cash flow and other hedges:</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Cross-currency swaps (1) </td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">33 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">27 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Foreign currency forwards</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Fixed interest rate swaps </td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">16 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges. -2000000027000000-1300000007000000-1400000033000000-1400000027000000200000002000000000016000000 Information regarding the fair value of derivatives on a gross basis were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Balance Sheet
Caption</td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-

weight:700;line-height:100%">Fair Value of
Derivative</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Dollar Notional</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value of
Derivative</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S. Dollar Notional</td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Asset</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Liability</td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Asset</td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Liability</td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Derivatives designated for hedge accounting:</td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cross-currency swaps (current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Prepaid expenses and other/Other accrued liabilities</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">69 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">15 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,690 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,122 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Cross-currency swaps (non-current)</td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom">Other non-current assets/liabilities</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">97 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,771 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">108 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,638 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Foreign currency forwards (non-current)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Other non-current assets</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"

any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information. There were no other material assets or liabilities measured at fair value on a nonrecurring basis at September 30, 2024 and March 31, 2024. Other Fair Value Disclosures At September 30, 2024 and March 31, 2024, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments. The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance. The Company's long-term debt is recorded at amortized cost. The carrying value and fair value of the Company's long-term debt was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt, including current maturities</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,744 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,808 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,629 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,488 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The estimated fair value of the Company's long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future. Goodwill Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow ("DCF") model to determine the fair value of each reporting unit. Long-lived Assets The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement. The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, Fair Value Measurements and Disclosures. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows: Level 1 - quoted prices in active markets for identical assets or liabilities. Level 2 - significant other observable market-based inputs. Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement. Assets and Liabilities Measured at Fair Value on a Recurring Basis Cash and cash equivalents at September 30, 2024 and March 31, 2024 included investments in money market funds of $549 million and $705 million, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature. Fair values of the Company's interest rate swaps, cross-currency swaps, and foreign currency forward contracts were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information. These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, "Hedging Activities," for fair values and other information on the Company's derivatives. The Company holds investments in equity and debt securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $175 million and $240 million at September 30, 2024 and March 31, 2024, respectively. These investments primarily consist of equity securities without readily determinable fair values and are included in "Other non-current assets" in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains and losses as well as impairment charges related to these investments were a net loss of $15 million and gain of $95 million for the three and six months ended September 30, 2024, respectively, and an immaterial loss for the three and six months ended September 30, 2023, all of which are included within "Other income, net" in the Condensed Consolidated Statements of Operations. The net gain recognized for the six months ended September 30, 2024 primarily relates to a recapitalization event of one of the Company's investments in equity securities which resulted in an increase to the carrying value of this investment. The Company recognized a net gain of $100 million related to this event and sold a portion of its investment for proceeds of $92 million. <div

style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company's assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell. At September 30, 2024, the assets and liabilities associated with the Canadian retail disposal group classified as held for sale were measured at the lower of carrying value or fair value less costs to sell, as discussed in Financial Note 2, "Held for Sale." The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information. Goodwill Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow ("DCF") model to determine the fair value of each reporting unit. Long-lived Assets The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement. The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value. 549000000705000000175000000240000000-150000009500000000100000000092000000 The Company's long-term debt is recorded at amortized cost. The carrying value and fair value of the Company's long-term debt was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying Value</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">Fair Value</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term debt, including current maturities</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,744 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,808 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,629 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">5,488 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 57440000005808000000562900000054880000000Commitments and Contingent Liabilities In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Company's 2024 Annual Report and Financial Note 9 to the Companys 10-Q filing for the quarterly period ended June 30, 2024, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations. Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within "Claims and litigation charges, net" in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. I. Litigation and Claims Involving Distribution of Controlled Substances The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds,

*third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. These plaintiffs have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act ("RICO"), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. *

State and Local Government Claims

*The Company and two other national pharmaceutical distributors (collectively "Distributors") entered into a settlement agreement (the "Settlement") and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the "Settling Governmental Entities"). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $2.0 billion as of September 30, 2024, and additionally will pay the Settling Governmental Entities up to approximately $5.9 billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs' attorneys' fees and costs and will be paid out through 2030. Pursuant to the Settlement, the Distributors are in the process of establishing a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $75 million as of September 30, 2024, and additionally will pay approximately $99 million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $53 million as of September 30, 2024, and additionally will pay approximately $99 million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company's favor on July 4, 2022. Those subdivisions appealed that decision. Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions' claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision. A trial of its claims against the Company and another national pharmaceutical distributor began on September 16, 2024 in the Circuit Court of Maryland for Baltimore City, Mayor and City Council of Baltimore v. Purdue Pharma LP, No. 24-C-18-000515, Baltimore claims that the defendants' distribution of controlled substances to certain pharmacies in the City of Baltimore and Baltimore County caused a public nuisance. Baltimore is seeking monetary damages and other relief. The district attorneys of the City of Philadelphia, Pennsylvania, and Allegheny County, Pennsylvania did not participate in the settlement and sought to bring separate claims against the Company, notwithstanding the settlement with the state of Pennsylvania and its attorney general. On January 26, 2024, the Commonwealth Court of Pennsylvania ruled that the Pennsylvania attorney general had settled and fully released the claims brought by those district attorneys under Pennsylvania's Unfair Trade Practices and Consumer Protection Law. The district attorneys have appealed that decision to the Supreme Court of Pennsylvania. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities. Native American Tribe Claims The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $112 million as of September 30, 2024, and additionally will pay approximately $84 million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic. Non-Governmental Plaintiff Claims The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above. One such case was brought by a group of individual plaintiffs in Glynn County, Georgia Superior Court seeking to recover for damages allegedly arising from their family members' abuse of prescription opioids. Poppell v. Cardinal Health, Inc., CE19-00472. On March 1, 2023, the jury in that case returned a verdict in favor of the defendants, including the Company. Plaintiffs appealed the jury verdict. On September 4, 2024, the Supreme Court of Georgia affirmed the judgment in favor of the Company. The Company and two other national distributors have reached proposed settlements with representatives of nationwide groups of acute care hospitals and certain third-party payors. The claims of remaining U.S. non-governmental plaintiffs are not included in the charges recorded by the Company. With respect to the acute care hospitals, for the year ended March 31, 2024, the Company recorded a charge of $149 million within "Claims and litigation charges, net" in the Consolidated Statement of Operations to reflect its portion of a proposed settlement with a nationwide class of acute care hospitals, of which $75 million was recorded within Corporate expenses, net, and $74 million was recorded within U.S. Pharmaceutical. The corresponding liability was included within "Other accrued liabilities" in the Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by hospitals. On October 30, 2024, the U.S. District Court for the District of New Mexico granted preliminary approval to the proposed settlement. The trial for one of those acute care hospital cases, Fort Payne Hospital Corporation et al. v. McKesson Corp., CV-2021-900016, has been stayed as to the Company. With respect to the third-party payors, for the six months ended September 30, 2024, the Company recorded a charge of $114 million within "Claims and litigation charges, net" in the Condensed Consolidated Statement of Operations to reflect the Company's portion of the proposed settlement with representatives of a nationwide group of certain third-party payors, of which $57 million was recorded within Corporate expenses, net and U.S. Pharmaceutical, respectively. The corresponding liability was included within "Other accrued liabilities" in the Condensed Consolidated Balance Sheet. The proposed settlement is subject to, among other things, court approval and sufficient participation by third-party payors. On September 3, 2024, the U.S. District Court for the Northern District of Ohio granted preliminary approval to the proposed settlement. The Company's estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, and certain non-governmental plaintiffs, including a proposed settlement with a nationwide class of acute care hospitals and certain third-party payors, was as follows:

<table>
<tr><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td colspan="3">(In millions)</td><td colspan="3">September 30, 2024</td><td>March 31, 2024</td></tr>
<tr><td>Current litigation liabilities (1)</td><td>$</td><td>775</td><td>$</td><td>665</td></tr>
<tr><td>Long-term litigation liabilities</td><td></td><td>5,617</td><td></td><td>6,113</td></tr>
<tr><td colspan="3">Total litigation liabilities</td><td>$</td><td>6,392</td></tr>
</table>

size:10pt;font-weight:400;line-height:100%">6,778 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)These amounts, recorded in "Other accrued liabilities" in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date. During the six months ended September 30, 2024, the Company made payments totaling $500 million associated with the Settlement and the separate settlement agreements. Canadian Plaintiff Claims The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, municipal governments, a group representing indigenous people, as well as one case brought by an individual. Defense of Opioids Claims The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the accruals described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company's financial position, cash flows or liquidity, or results of operations. II. Other Litigation and Claims On May 17, 2013, the Company was served with a complaint filed in the United States District Court for the Northern District of California by True Health Chiropractic Inc., alleging that McKesson sent unsolicited marketing faxes in violation of the Telephone Consumer Protection Act of 1991 ("TCPA"), as amended by the Junk Fax Protection Act of 2005 ("JFPA"), True Health Chiropractic Inc., et al. v. McKesson Corporation, et al., No. CV-13-02219 (HG). The plaintiffs seek statutory damages from $500 to $1,500 per violation plus injunctive relief. True Health Chiropractic later amended its complaint, adding McLaughlin Chiropractic Associates as an additional named plaintiff and McKesson Technologies Inc. as a defendant. Both plaintiffs alleged that defendants violated the TCPA by sending faxes that did not contain notices regarding how to opt out of receiving the faxes. On August 13, 2019, the court granted plaintiffs' renewed motion for class certification. After class notice and the opt-out period, 9,490 fax numbers remain in the class, representing 48,769 faxes received. On October 8, 2021, the court de-certified the class citing the plaintiffs lacked class-wide proof identifying the manner of receipt, thus leaving two named plaintiffs remaining in the case. On April 27, 2022, the Court found that the named plaintiffs had failed to meet their burden to show defendants willfully or knowingly violated the TCPA and therefore were not entitled to treble damages. The Court found McKesson liable for statutory damages in the amount of $6,500. The Company appealed the finding of liability and the plaintiffs cross-appealed the denial of class certification and the ruling denying treble damages. On October 25, 2023, the U.S. Court of Appeals for the Ninth Circuit affirmed the decision of the district court. On October 4, 2024, the Supreme Court of the United States granted plaintiffs' petition for certiorari on the issue of whether the Hobbs Act required the district court to accept the FCC's legal interpretation of the TCPA in determining whether to certify the class. On June 17, 2014, U.S. Oncology Specialty, LP ("USOS") was served with a fifth amended qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that USOS, among others, solicited and received illegal "kickbacks" from Amgen in violation of the Anti-Kickback Statute, the federal False Claims Act, and various state false claims statutes, and seeking damages, treble damages, civil penalties, attorneys' fees and costs of suit, all in unspecified amounts, United States ex rel. Hanks v. Amgen, Inc., et al., CV-08-03096 (SJ). Previously, the United States declined to intervene in the case as to all allegations and defendants except for Amgen. On September 17, 2018, the court granted USOS's motion to dismiss. Following the relator's appeal, the United States Court of Appeals for the Second Circuit vacated the district court's order and remanded the suit to the district court, directing it to consider the question of whether the suit should be dismissed for lack of jurisdiction. The district court granted the relator leave to amend the complaint for a seventh time. The relator filed the seventh amended complaint on November 30, 2020. On September 18, 2024, the district court dismissed the False Claims Act claim for lack of subject matter jurisdiction. In July 2020, the Company was served with a first amended qui tam complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the United States, 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, United States ex rel. Hart v. McKesson Corporation, et al., 15-cv-00903-RA. The United States and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. The relator filed the second amended complaint on June 7, 2022, which was dismissed by the district court on March 28, 2023. On March 12, 2024, the U.S. Court of Appeals for the Second Circuit affirmed the dismissal of claims under the Anti-Kickback Statute and federal False Claims Act, vacated the dismissal of the remaining claims, and remanded for further proceedings. On June 7, 2024, the relator filed a petition seeking review by the U.S. Supreme Court, which was denied on October 7, 2024. On October 17, 2024, the Company was served with a qui tam complaint filed in the United States District Court for the Eastern District of New York by a relator alleging that, from 2010 through at least 2012, the Company submitted false certifications to the government in support of Horizon Clinicals, an Electronic Health Record product. United States ex rel. James Thompson v. McKesson Corporation, No. 16-CV-2891. The United States has declined to intervene in the case. The complaint seeks relief under the False Claims Act including damages, treble damages, civil penalties, attorney fees, and costs of suit. III. Government Subpoenas and Investigations From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business. In July 2024, the United States Department of Justice served a Civil Investigative Demand issued pursuant to the False Claims Act on the Company seeking documents and information related to administration of copay coupon programs associated with certain Sun Pharmaceutical Industries Inc. drugs. V. Antitrust Settlement During the second fiscal quarter of 2025, the Company received proceeds of $63 million related to its share of two antitrust settlements. The lawsuits were filed against a brand manufacturer alleging that the manufacturer, by itself or in concert with others, took improper actions to delay or prevent generic drugs from entering the market. The Company was not a named party to either litigation but was a member of the representative classes of those who purchased directly from the pharmaceutical manufacturer. The Company recognized a gain in that amount within "Cost of sales" in the Condensed Consolidated Statement of Operations in the second quarter of fiscal 2025 related to the settlements. In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in Financial Note 17 to the Company's 2024 Annual Report and Financial Note 9 to the Company's 10-Q filing for the quarterly period ended June 30, 2024, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations. Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within "Claims and litigation charges, net" in the Condensed Consolidated

*Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. 2482300200000000059000000000.8575000000990000005300000099000000111200000084000000.8540012-149000000750000007400000001-114000000-57000000 The Company's estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, and certain non-governmental plaintiffs, including a proposed settlement with a nationwide class of acute care hospitals and certain third-party payors, was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.303%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.736%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.738%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30, 2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">March 31, 2024</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Current litigation liabilities (1) </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">775 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">665 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Long-term litigation liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,617 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,113 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top">Total litigation liabilities</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,392 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">6,778 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)These amounts, recorded in "Other accrued liabilities" in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.
77500000066500000056170000006113000000639200000067780000005000000004150015009490487692650027630000002Stockholders' Deficit Each share of the Company's outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company's Board of Directors (the "Board"). In July 2024, the Company's quarterly dividend was raised from $0.62 to $0.71 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. Share Repurchase Plans The Board has authorized the repurchase of common stock. The Company may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company's stock price, corporate and regulatory requirements, tax implications, restrictions under the Company's debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions. During the three months ended September 30, 2024, the Company repurchased 2.9 million shares of common stock for $1.5 billion through open market transactions at an average price per share of $533.46, of which $22 million was accrued within "Other accrued liabilities" in the Company's Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2024 and settled in early October 2024. During the three months ended June 30, 2024, the Company repurchased 1.0 million shares of common stock for $528 million through open market transactions at an average price per share of $548.20. During the three months ended September 30, 2023, the Company repurchased 2.0 million shares of common stock for $840 million through open market transactions at an average price per share of $422.39, of which $23 million was accrued within "Other accrued liabilities" in the Company's Condensed Consolidated Balance Sheets for share repurchases that were executed in late September 2023 and settled in early October 2023. During the three months ended June 30, 2023, the Company repurchased 1.8 million shares of common stock for $673 million through open market transactions at an average price per share of $379.14. Effective January 1, 2023, the Company's repurchase of common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the Inflation Reduction Act of 2022. Excise taxes incurred on share repurchases of an entity's own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders' equity within "Treasury shares" in the Company's Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders' Deficit. Excise taxes do not reduce the Company's remaining authorization for the repurchase of common stock. Excise taxes of $15 million and $8 million were incurred and accrued for shares repurchased during the three months ended September 30, 2024 and 2023, respectively. Excise taxes of $16 million and $12 million were incurred and accrued for shares repurchased during the six months ended September 30, 2024 and 2023, respectively. As of September 30, 2024 and March 31, 2024, the amounts accrued for excise taxes were $41 million and $25 million, respectively, within "Other accrued liabilities" in the Company's Condensed Consolidated Balance Sheets. In July 2024, the Board approved an increase of $4.0 billion in the authorization for the repurchase of common stock. The total remaining authorization outstanding for repurchases of common stock at September 30, 2024 was $8.6 billion. Accumulated Other Comprehensive Loss Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended September 30, 2024 and 2023 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign Currency Translation Adjustments, Net of Tax (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Losses on Net Investment Hedges, Net of Tax (2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-*

weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2024</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(892)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(913)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(843)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>

<td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(890)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the three months ended September 30, 2024 include losses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million. (3)Amounts recorded for the three months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Foreign Currency Translation Adjustments, Net of Tax (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Net Investment Hedges, </div><div style="text-align:center">Net of Tax (2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Cash Flow and Other Hedges, </div><div style="text-align:center">Net of Tax (3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(780)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(29)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(29)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(848)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2023</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(864)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(887)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the three months ended September 30, 2023 include gains of $27 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $7 million. (3)Amounts recorded for the three months ended September 30, 2023 include gains of $33 million related to cash flow and other hedges from cross-currency swaps, which are net of income tax expense of $8 million. Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the six months ended September 30, 2024 and 2023 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign Currency Translation Adjustments, Net of Tax (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Losses on Net Investment Hedges, Net of Tax (2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-

weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2024</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(856)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(881)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt">Amounts reclassified to earnings and other(3)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(843)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt

solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(890)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Europe into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2024 include losses of $13 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $3 million. (3)Amounts recorded for the six months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.</div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify">
</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Foreign Currency Translation Adjustments, Net of Tax (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Net Investment Hedges, </div><div style="text-align:center">Net of Tax (2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Cash Flow and Other Hedges, </div><div style="text-align:center">Net of Tax (3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(847)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(905)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2023</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(864)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(887)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2023 include gains of $7 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $2 million. (3)Amounts recorded for the six months ended September 30, 2023 include gains of $27 million related to cash flow and other hedges from cross-currency swaps and gains of $16 million related to cash flow hedges from fixed interest rate swaps. These amounts are net of income tax expense of $11 million.10.620.712900000150000000000533.462200000010000005280000000548.20200000084000000422.39230000001800000673000000379.1415000000800000016000006 style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended September 30, 2024 and 2023 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.846%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.670%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:1.0%"></td><td style="width:12.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign Currency Translation Adjustments, Net of Tax (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Losses on Net Investment Hedges, Net of Tax(2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-

weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (3) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2024</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(892)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(7)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(913)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">49 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(15)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">23 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(843)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>

<td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(890)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the three months ended September 30, 2024 include losses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million. (3)Amounts recorded for the three months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Foreign Currency Translation Adjustments, Net of Tax (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Net Investment Hedges, </div><div style="text-align:center">Net of Tax (2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Cash Flow and Other Hedges, </div><div style="text-align:center">Net of Tax (3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, June 30, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(780)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(29)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(848)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(38)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(84)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(39)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2023</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(864)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(887)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the three months ended September 30, 2023 include gains of $27 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $7 million. (3)Amounts recorded for the three months ended September 30, 2023 include gains of $33 million related to cash flow and other hedges from cross-currency swaps, which are net of income tax expense of $8 million. Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the six months ended September 30, 2024 and 2023 was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.928%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.819%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Foreign Currency Translation Adjustments, Net of Tax (1) </td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Losses on Net Investment Hedges, Net of Tax (2) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-

weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2024</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(856)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(12)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(16)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(881)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt">Amounts reclassified to earnings and other(3)</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">13 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2024</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(843)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt

solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(22)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(6)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(19)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(890)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Europe into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2024 include losses of $13 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $3 million. (3)Amounts recorded for the six months ended September 30, 2024 include losses of $14 million related to cash flow and other hedges from cross-currency swaps and gains of $2 million related to cash flow hedges from foreign currency forwards. These amounts are net of income tax benefit of $3 million.</div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify">
</div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:31.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.107%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.815%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.694%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Foreign Currency Translation Adjustments</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Foreign Currency Translation Adjustments, Net of Tax (1)</div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Net Investment Hedges, </div><div style="text-align:center">Net of Tax (2)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center">Unrealized Gains (Losses) on Cash Flow and Other Hedges, </div><div style="text-align:center">Net of Tax (3)</div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Total Accumulated Other Comprehensive Loss</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, March 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(847)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(14)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(36)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(8)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(905)</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) before reclassifications</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Amounts reclassified to earnings and other</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-

align:left;vertical-align:bottom">Other comprehensive income (loss)</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Less: amounts attributable to noncontrolling interests</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom">Other comprehensive income (loss) attributable to McKesson</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(17)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">32 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(2)</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance, September 30, 2023</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(864)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(9)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(4)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(10)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(887)</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Primarily results from the conversion of non-U.S. dollar financial statements of the Company's operations in Canada and Norway into the Company's reporting currency, U.S. dollars. (2)Amounts recorded for the six months ended September 30, 2023 include gains of $7 million related to net investment hedges from cross-currency swaps, which are net of income tax expense of $2 million. (3)Amounts recorded for the six months ended September 30, 2023 include gains of $27 million related to cash flow and other hedges from cross-currency swaps and gains of $16 million related to cash flow hedges from fixed interest rate swaps. These amounts are net of income tax expense of $11 million.-892000000-700000030000000-17000000-913000000490000000-15000000-9000000-1000000240000000001000000100000049000000-15000000-9000000-2000000230000000000049000000-15000000-9000000-2000000023000000-843000000-22000000-6000000-19000000-890000000-20000000-5000000-1400000002000000-3000000-780000000-29000000-29000000-10000000-848000000-840000002000000025000000100000038000000001000000100000-840000002000000025000000-390000000000-840000002000000025000000-39000000-864000000-9000000-4000000-10000000-887000000270000007000000330000000000000-856000000-120000003000000-16000000-881000000130000000-10000000-9000000-2000000-800000000010000001000000130000000-10000000-9000000-3000000-900000000000130000000-10000000-9000000-3000000-9000000-843000000-22000000-6000000-19000000-890000000-13000000-3000000-1400000002000000-3000000-847000000-14000000-36000000-8000000-905000000-17000000500000032000000-10000001900000000010000001000000-17000000500000032000000-200000018000000000000-17000000500000032000000-200000018000000-864000000-9000000-4000000-10000000-887000000700000002000000270000001600000011000000Segments of Business The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments and operations. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services. The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national

brand medical-surgical products as well as McKesson's own line of high-quality products through a network of distribution centers in the U.S. The International segment includes the Company's operations in Canada and Norway, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company's Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and include Rexall Health retail pharmacies. The Company's Norwegian operations provide distribution and services to wholesale and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. In the second quarter of fiscal 2025, the Company entered into an agreement to sell the Canadian retail disposal group. Refer to Financial Note 2, "Held for Sale," for more information. Financial information relating to the Company's reportable operating segments and reconciliations to the condensed consolidated totals was as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.484%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"> Segment revenues (1) </td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Pharmaceutical</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">85,726 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">69,766 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">157,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">136,926 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,265 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,140 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,506 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,384 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,948 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,445 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,709 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,475 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,400 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Total revenues</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">93,651 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">77,215 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-

top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">172,934 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">151,698 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Segment operating profit (loss) (2) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Pharmaceutical (3) </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,075 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">593 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,420 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Prescription Technology Solutions (4) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">408 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">469 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medical-Surgical Solutions (5) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">471 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> International (6) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(508)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(418)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">861 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,123 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,483 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate expenses, net (7) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(249)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(164)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(352)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(368)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(153)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(108)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td

colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">534 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">916 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,618 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,007 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment's total revenues, less than 40% of the RxTS segment's total revenues, less than 1% of the Medical-Surgical Solutions segment's total revenues, and less than 1% of the International segment's total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. Corporate reflects revenues from services derived in the U.S. related to certain technology operations and were not material for the three and six months ended September 30, 2024. (2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company's reportable segments. (3)The Company's U.S. Pharmaceutical segment's operating profit includes the following: •a credit of $203 million for the three and six months ended September 30, 2024 due to the Company's reassessment of its initial fiscal 2024 estimates of the previously reserved $725 million prepetition balance owed by the Company's customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid"). Rite Aid filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in October 2023. The Company recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid. The amounts described above were recorded within "Selling, distribution, general, and administrative expenses" in the Company's Condensed Consolidated Statements of Operations. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August, 2024; •cash receipts for the Company's share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively. These gains were recorded within "Cost of sales" in the Company's Condensed Consolidated Statements of Operations; •a credit of $2 million and a charge of $55 million related to the last-in, first-out method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million for the six months ended September 30, 2024 and 2023, respectively. These amounts were recorded within "Cost of sales" in the Company's Condensed Consolidated Statements of Operations; •restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net;" •a charge of $57 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, "Commitments and Contingent Liabilities;" and •a loss of $43 million for the six months ended September 30, 2024 related to one of the Company's equity method investments, which was recorded within "Other income, net" in the Company's Condensed Consolidated Statement of Operations. (4)The Company's RxTS segment's operating profit for the three and six months ended September 30, 2023 includes gains of $48 million and $76 million, respectively, resulting from fair value adjustments of the Company's contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022. (5)The Company's Medical-Surgical Solutions segment's operating profit for the three and six months ended September 30, 2024 includes restructuring charges of $144 million for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net." (6)The Company's International segment's operating profit (loss) for the three and six months ended September 30, 2024 includes a charge of $593 million to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, "Held for Sale." (7)Corporate expenses, net includes the following: •a charge of $50 million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, "Held for Sale;" •a net gain of $95 million for the six months ended September 30, 2024 related to the Company's investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, "Fair Value Measurements;" <div

style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt">•a net charge of $51 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, "Commitments and Contingent Liabilities;" and •restructuring charges of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net."</div>4<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt">Financial information relating to the Company's reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.479%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.814%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> </td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three Months Ended September 30, </td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Six Months Ended September 30, </td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(In millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Segment revenues (1)</div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">U.S. Pharmaceutical</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">85,726 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">69,766 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">157,441 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">136,926 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Prescription Technology Solutions</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,265 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,140 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,506 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,384 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Medical-Surgical Solutions</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,948 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,834 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,584 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5,445 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">International</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,709 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3,475 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7,400 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6,943 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Corporate</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Total revenues</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">93,651 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">77,215 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">172,934 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">151,698 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Segment operating profit (loss) (2) </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> U.S. Pharmaceutical (3) </td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,075 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">593 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,856 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1,420 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Prescription Technology Solutions (4) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">205 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">408 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">469 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Medical-Surgical Solutions (5) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">244 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">277 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">471 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> International (6) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(508)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">66 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(418)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">123 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom">Subtotal</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">861 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1,141 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,123 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2,483 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Corporate expenses, net (7) </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(249)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(164)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(352)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(368)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Interest expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(78)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td>

<td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(61)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(153)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(108)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom">Income before income taxes</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">534 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">916 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">1,618 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">2,007 </td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> (1)Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment's total revenues, less than 40% of the RxTS segment's total revenues, less than 1% of the Medical-Surgical Solutions segment's total revenues, and less than 1% of the International segment's total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S. Corporate reflects revenues from services derived in the U.S. related to certain technology operations and were not material for the three and six months ended September 30, 2024. (2)Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company's reportable segments. (3)The Company's U.S. Pharmaceutical segment's operating profit includes the following: •a credit of $203 million for the three and six months ended September 30, 2024 due to the Company's reassessment of its initial fiscal 2024 estimates of the previously reserved $725 million prepetition balance owed by the Company's customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid"). Rite Aid filed a voluntary petition for reorganization under Chapter 11 of the Bankruptcy Code in October 2023. The Company recognized a provision for bad debts of $210 million for the three and six months ended September 30, 2023, which represented the uncollected trade accounts receivable balance as of September 30, 2023 due from Rite Aid. The amounts described above were recorded within "Selling, distribution, general, and administrative expenses" in the Company's Condensed Consolidated Statements of Operations. Rite Aid's restructuring plan was approved by the court and the company successfully emerged from bankruptcy in August, 2024; •cash receipts for the Company's share of antitrust legal settlements of $63 million and $79 million for the three months ended September 30, 2024 and 2023, respectively, and $153 million and $197 million for the six months ended September 30, 2024 and 2023, respectively. These gains were recorded within "Cost of sales" in the Company's Condensed Consolidated Statements of Operations; •a credit of $2 million and a charge of $55 million related to the last-in, first-out method of accounting for inventories for the three months ended September 30, 2024 and 2023, respectively, and a credit of $4 million and a charge of $87 million for the six months ended September 30, 2024 and 2023, respectively. These amounts were recorded within "Cost of sales" in the Company's Condensed Consolidated Statements of Operations; •restructuring charges of $64 million for the three and six months ended September 30, 2024 for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net;" •a charge of $57 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, "Commitments and Contingent Liabilities;" and •a loss of $43 million for the six months ended September 30, 2024 related to one of the Company's equity method investments, which was recorded within "Other income, net" in the Company's Condensed Consolidated Statement of Operations. (4)The Company's RxTS segment's operating profit for the three and six months ended September 30, 2023 includes gains of $48 million and $76 million, respectively, resulting from fair value adjustments of the Company's contingent consideration liability related to the acquisition of Rx Savings Solutions, LLC completed in November 2022. (5)The Company's Medical-Surgical Solutions segment's operating profit for the three and six months ended September 30, 2024 includes restructuring charges of $144 million for restructuring initiatives that commenced in the second quarter of fiscal 2025 as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net." (6)The Company's International segment's operating profit (loss) for the three and six months ended September 30, 2024 includes a charge of $593 million to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, "Held for Sale." (7)Corporate expenses, net includes the following: •a charge of $50 million for the three and six months ended September 30, 2024 related to the effect of accumulated other comprehensive loss components from the Canadian retail disposal group, as discussed in Financial Note 2, "Held for Sale;" <div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-

indent:-18pt">•a net gain of $95 million for the six months ended September 30, 2024 related to the Company's investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 9, "Fair Value Measurements;" •a net charge of $51 million for the six months ended September 30, 2024 related to the estimated liability for opioid-related claims, as discussed in Financial Note 10, "Commitments and Contingent Liabilities;" and •restructuring charges of $46 million for the six months ended September 30, 2023 for restructuring initiatives as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net."
8572600000069766000000157441000000136926000000126500000011400000002506000000238400000029480000002834000000558400000054450000003709000650800000006600000041800000012300000008610000001141000000212300000024830000002490000001640000003520000036800000078000000610000001530000001080000005340000009162000000550000004000000870000006400000064000000570000004300000048000000760000001440000001440000005930000005930000005000000095000000510000004600000falsefalsefalseOn August 17, 2024, Thomas Rodgers, our Executive Vice President and Chief Strategy and Business Development Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 4,080 shares of the Company's common stock. The duration of the trading arrangement is until August 18, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Mr. Rodgers represented to us that he intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards.August 17, 2024Thomas RodgersExecutive Vice President and Chief Strategy and Business Development Officertrue4080August 18, 2025On September 9, 2024, LeAnn Smith, our Executive Vice President and Chief Human Resources Officer, adopted a Rule 10b5-1 trading arrangement for the sale of up to 3,592 shares of the Company's common stock. The duration of the trading arrangement is until September 9, 2025, or earlier if all transactions under the trading arrangement are completed or if the trading arrangement is otherwise terminated according to its terms. The trading arrangement was entered into during an open trading window period and Ms. Smith represented to us that she intended for it to satisfy the requirements for the affirmative defense of Rule 10b5-1(c) of the Exchange Act. The number of shares subject to the arrangement includes shares that may be withheld by the Company to satisfy income tax withholding and remittance obligations in connection with the net settlement of equity awards.September 9, 2024LeAnn SmithExecutive Vice President and Chief Human Resources Officertrue3592September 9, 2025

<:JKL6$Q-MH(ER&'L3F8+ZHL2DD-3JKGB-K5Y5>_^B4?#2?^ILB-UX\^&&&,^6>/KD\0L2-MX3$,3QEC"5!?^E))*\C?3^HZ;9SL]Y&P:U .(TT*26)HL\BSH^=/)_@++MJ*V M"DB_MH2Y/\LZ^I0GO3Z8@-S*=8FF1+,V8UKY.&QJB9"KVBI,*A7X/*19#ZI. M&Y"XLJR76>,;EKLHL1IJ98XG;ZDKDT#/V%(H6)+TSW2YZK.YV^7TZ?-I+2WR M8,3AI^CU\T?'SZ,CJH_6M;D&6C(5*S!WZ6IV6!XQH0%)]>BZ8/@U5E-Q

-

ESM.J M\H\@V65L_Z+>?-IVSYNE"XB*8VP\FAB3Z=7DT2=7&)!(?74F<8C42]0>=NH M+DH3V[3@Q^2@-*2BWR3\^]BB^*$3K6X3Y10#.^O3%O_MB?A#BD Z<;"H G&% MQ[#[SFY<'-6!F(C850C2^?Y\E2-F8AR4@AB],+*NO;D(+9H?GK)/J1]&'-8> M4^5 .9+8S3J?B-M3N#N]$CEN@[}B,KK5)-^?%_5BS?F%QP?/Y-&Y7[?K_#GC@K]Y^5;HN.N.V'[MU")"$?-DC*%DOE)5IC27XA1!$;(D])@7>%&*6AQ$QIS4E;Z?&. ,>?MFZI-MQW22Y%/#BN[E],-&ATNSU9],#2K(CB/K*36F(O)OI_C30V9D#C5]56GK;1NW; M%K762(M^\U(9,MK$$P-YD&U/"8N(AYRG4L*8H03B-MQ,:F+-4$ADRRVE7EBQ.[4K4-7WJ-LF&XE'*)$< M2E_]+\<^@10*#*;T]@FF(DZH5:`.14I3!XX;NB,N@`]P.,,C3J2U,Q?'E[_-MK;C[4TNO;%/<_!{0>;U[WW/B=M{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fO .$4L1 ""T|81IC*D""1(ZH8]AACB/HM"JTGDP)Q,;@]NU@"7Y#L3W)[$] MU-ZW%O65BG(.1%%FC|5_Z&E3]2"OW?2I<;-F+++[$($=B&GS'^1>@84I/]-&<

M@"TKX(U,GF!\4,E#=X_WOXCR M(>?|6U\#.}?Q^M2G$DT5W&6/.HY7DS8S+5T2=QL-1\+:F8,SY:D7#MBL#/TVW89@><#N;T>3C-=EY-3N@YF<[UTZC7O&DO8IM E_%U]0X MFM] 3XOGL"O1-?"UNJ8>#DO'O?6 16>[R!XN\0]HO[4W9KH>Z/K]?K- MRX<5KY*$3)VI<<`],:)D;DD#1U%F*50U(-_]{(*S.59=XK2]L[G:8)-FZ.@6]>?FERGVNOM{[MM? C'ICHO55%71*7G(0]RCTF(8ZK\[" @,$E(@(G S.-6,WD,:.$ZLHBVR8$=W M4/S5!#^ST(EC5.PT>! @]GTFS45TU6K2@.^\W2;-(3AI.&GQZM NT:U]O6YZ M]WE3%B6IY@,OPL#S4S*(,-Z :#E 4RPAZ'PXB!,?'6>"A*[5M%=Y*;^?]G; M)1^ZH#43H,6%;=OH3@"[#8%[6"SO8T8B,]"/M(F@(Y!)=RX_52LL^HVHC:Q]G_[\>N/X&V^7!*=_-D,(R$Y:LZ]0R ;03,/=WAD>=C[^)UMG M8^IDS :0GD;,]AF9)A*Z2K?LI#5O+[6)V"">)DD8OV9^=&]XRW2^V(0ZV9]PM^6IDG.9!\(W>H7]3O("&4>' M3 NQ!YTY3=:?

[0AJ(6SI1&KSVL!VR?H3"UZ\5^R^U<43:EM4'_RS?+,I% FE M+L6"AD$0"L^#C#-=QN"E, D9ABE+";*"!PFU&MIN0'/B++>NF;?-3L0'TIP)\ MSXAE*V4#!,TV+

<=XV!F"VP.T6N1UB'C/@,,>R^;2NNJU.$!QWI[+YA"<[%ZV M>'689?A6J-7>-5T!EBTJWH+?P&_-?\[23'X>>DG1XK.JY'G! MCK7OPE.3EQG^G.?\]VRYO&G&VHDX)#QE

B9,Y^_IB7^4$!_&$1>19&DJN-$5 M_'A6)E;@+;7)2@F/D34\9LZ"E^49U+I\<,O:%;AYQ;K!"P#-7S%XS,@?M5;P M F CJ@0OK3C,KFT]D6JP2Y%5+=+K&2_B;? Y(LM6"Q9XR4E$,DT0RB)&G^_GI MTT7 XB!)21PAJZFEO10GME);^]#%P&[&D "_U4Q87H'UPVAFJYR'8V>2QN)B M;?:,,975D7?KIS6I$C,4_MA7F+PZ87(#C<-[@_"7P% (IT^DCC"02/(QA)'T" M<9+]X(*'H!*F29",H\;U2'TI)E8_?&/<7@XM> %!%[5G#ZUZ-7?@5.WICN4 MWDZ_VX*_/1)\R+2"#@0L9A6X06)8ZET7(H[F%/2+US6EH./M^684}(MP,*'

MX/$!U03\;W>Y+L>Z?BR-2PA;[TQL4Q2I35%6B2-E7A7SB571^.TVLUM/1.V_ MEQ@J!9WMN"R@LRNS2\(,*Q-H+S1?;< 9]@* L[]O;TRM*Z_OPB6/XOUBZ5J M7%YAZI"^Q2_'1NY^/7$CLIW6M&B"+='IE*=?PD&]U+'L;(K5+U!;S0R>=M!M MNLI"VXY#O25U5EI=ZK-0!^88IYQ 21,!<40)) %*H8@2YON,I4%L5:)O2GAB

M[6WRH%HCBD=TI>["S^RL/ 4J=@I^W+.Z(K]?5WP%%"/U_95$%IK8FT@_|1-.MK;O(OEZ/:P.P.EM>F[SOX [A9DF*(1.9JW:'"D>;.,ZC6%D.&2<)Q#R.(0TB

M"FFD_H(3/Y"IE=GHH3>QM3@,<8-#^H/RS/OP&W =, Z5,3%_2T#&!?4OB5E% MY/X,M=<+SU\6O3,&W_':@./K_7UY\["ZOUT5*V5./JR^;AX?:Z^D*%=W=/D^ M7U_+>GRO]=-!,7TC&N[\-0'X?0[==6^K^E.KYO3W]8UMLT^>-0M_8U8"9T%MU:CPZ^42W.INV$H;;M6RA7*:G_)U60V, 5HR]:G< 9 MZ5&Q+0== 7X6^?V:/#THIWY9'1@CYN-0\A

2GR6ZE2:'B1|S2%,OB' JN4B- M;K0[J4RL=FUR5J?J;FBZ]]]BR* M9R3>5OO,'AX[_^U@),CUBG^I^SS>Y$59[/NF^6$@L1=RR%.IE)-A#Q(6"!A[MW,.!$@$W\QT'TI]8.0]XN (?U&Z2K37J5U515\,2J'@;.I?-#&>SJ-F$Z-G9 M@,,1/B=8S3I=S0H$Y]/4S*B_TO0T*V@N3TNS6V9 0R5"-TNR_[@5Y=%@0M.N M2[<6F-AR-'2!)GQE&P&

[+'6_@^U$8,L+MI:LDVBVD5$=NBE=7'6^EDI@AWT M5>I]>+*^U]MR#LQ3[#'AP32F1.WX$L.$(@+|*,1Q&/"4I&CQ+-8T=]C]>D"I M1YL%\P-

C,VWK3/_JS+;6S0)3L]U&ISL=/UT!L.N2;7SBA=[>>=K0?TJ%2WV M@ QH,CVN8D5GEWX5JRQ??ULI{M9*V=_5]6OB>LZ@)_]R 4WO[A'S;W. G! M(HB]! 8)]R":

<0"3F$>041G',DR%H,.YZT.9F#H|V(+[/@"-0](@RP3XH7P0 M.K?9/_X;BS:W@S] MQV."U8[BS0"T0$)]8.A-<^VGP/B8:GX4_QXK3+UQT+3 MD<8_>.G9&.M)!

E2.PKV.6(H#!(4=K-N"?-M'?PVK+;^5_HZ'1[#W!S-YFB\$M1M_^2U6!@6?LBE.B>=3RN^"3*.5!'1L0G M09A E@0(XC#@.$5Q"JGD?L@CZ4LF;:[&SE*9_)L1_.K&S;CY{'Q2S8-

5I: MVPNKE]"?=+M1Y^&L3HD<1.[.TY@U2-4IYG$\JOOA$,#2@*GK MG3@:;7DH[@67X)';0H@UJXLU 1>?SFHU%=3F>O9/>_(/:3<0_.f+=Z$?[*^1W M_RA?KG]?\\)=08?%DE,?

Y?7%|#^OB7*\W^I_W;O>53O#>GAQ/4UP.]'=="RXA'Z$8X@C$4(B$@DE#:7GJQ.#[QG-+.HB,K456JD?N]WLY(M^@-W+@2U,P>M 6%;D@.NCRZ*;!ZFNRX-

[_046$64AB:#DTH.8T@BFT]>0^K$Z"WD442]>E'E)EF;' M'2.J5I9G1|L\]4R_,F&VSC&&9B<>Y\C8F:I++<^2GSLRY(."D23G'-/_^3@7 M8#!+Q;GT\C##4"TJ^,>]4FR#

<$E,/J<"^@EJ8 XC1-(8L@@F,9Q+/Q :MJ M$,5%.,F!4M!:.FI#|?^R7"9,;P3\2W/)XW,+9H3!"U[!7.DW9?IS*K1O>(> M:W'_"P.U5O&GBTW>M+25YVD4.W!

JKN^"1%[5LAIYD M7/5_;B9\>50=++1(602&Y[F4324B))R%'411*&<><6,U#=<+5Q!;A-B\5_!E9 M+E_EE=0I)@%HN%V.ZM&/:'^0S2LMJ;3_[#4?9;+!|(R3+US^^T,#<_<7\32

M2+78 WO^P+N#C|!BL0JK;+^%'J1>L=G;H-/>KKG$S94-=,+3O/;2)8PGMM7I MXO8AFX^[8\5749;+ZM*XBO75*]_E;\2W0O W+U4QYO6*?U0_N^7/NI?A2C^[

M"%BDG*D$01'$$F(6IS E'$'L,1P@=9#U<6@:VAG+S.16=[U5WV+'!5?9+3_M 15@HZ]?Z LH-']52.#6TB6XW[&XR53C66Z+?E#&F*F_L$A]'OW-^F-/RDT'1"K>X_"E*(=]_U19-

8\""-F4XY(LKU MAS@,4T@X0S!D?HR)3'0&M(WG?Y,*Q'O*IWP%F1XOF6^)@Z6FKESXBKR=5WX>_M9S.O>[3T=G9\1PY4]*[_NQZ!K=W?3H$>QN=C\|<"8L>=$J

M7E2YAZU2^47BAVDB1 +C2'>137D DRA1_J&/J4B)TEK*MBE(9AIZB=2 I",[M-.TGP#;4+0>^7H+'3"U'B3QLM&M#L'W#,T^JNMN4JE/R9+IO-O-C>SP?,CXCG0\SU0*4TQ#!-TPAZ/ I#+IB/ MS=)X^TE-O)U6Q"M'LR[ZR?T+9S|K ,3D_,(+ \&^VDKZ\,6J0'W./WP&!Q MHG&&Q\#SRF58"!T_C 3L.EQT+S#?T<%(D(.#@=:D;PSR+P^K,9GPA"CP4|@F% M*;

(>Q F)(47J/T5,,,<4!R2RNM4[1V1B*W5<4CQLTN-9=,R1RY$F=)S.I&=_EY{$)T/CM0&94+K/|/)X0^DZ5V4"KO)-/M,?5?5*VQ MVG_0>G+!4TZD3 4,E()"S#A3IW:"8>+S%"&/;>)

(/57)T%]+LBX-=?<,3S8_M^&/.K X.5Z ZX8L]Z;JUWGK'6?T ^0$5]|E*1_AUD+DF:FD41GTEG_O*M*HC M6A+3$&(L$TB0.KO%/)"4AI&,,+))GYKM^PQ(J[+\,D+

[E*_Q30PM^EQ(6YK^.M"N3J/RN#?*>%5_,4K=///C#]AL.MPH70+G:4T;Q,N_FXD*VDUW*R:(#DT^* M0I3;1)9KJH@05BZ$[Z=8< *3@X@17

*4101'$LJD4!6R23GJ$SM73;] MW4A%VS*MXRPJ9B9HM*QVIJ4FMTL' {]M23KT*SM%9"QT M/CQ,&7_.<_Y[MEPN4AGX?NS',)9(NXD)@BD//!@F08I1Q-(_93;ZMUUX8I7;

MDK%3MIW4(0LDC[T4RD3&$',.P]3C"?1)PKD,*4NCU-XY'B+[8# WS%?/6!V'@9FY'2*5G87M_55;V]-CGAV9T-VRLUK-8V&.#>7)W]L/C+C)5T6^ MS'@54_M0BL>B'L[(*

<49R%Y8]Y$1W?*.F!=Q8>'9AD5T'];>%-'SY)|)+0?% M^K=K/B#B\7I3/N3K{)^B27M!"X^G;>(1!$."N.!FBF#B21_&W,<>IE@+LSG MMAC1G%@U]_1:XY4!J;.Z?

M@\|@3(W3%6TP,%?:R= QTZ-JWS;5]\-T+!P!?9, MN,OA'B#RJ,DP9I1FG!-C)?KAU!B[5QU,8+^I^L_40\D7D8@PEY)!*8@<4(1 MI)PED#'BQCS&$,4(-MJ>-CZL%$HA3&

<80HPE+&/CF$T?CHV!I$D4>]*? S.VJYT4.[+6>G@A7-*U!3 MO:KKA1S&Q'M%S,.N;"8N3EDI8EWDX8EL.4)\(W013/',.D[-L48V'+6 MZU&Y .,,;.R!J9UEF Q.JXY.8S 9U)H$,'9>C2-

@:/=K&G4.@-SN-=ZU7]\1O=PZ[=\ZL:U;YK8UN9RL]/ M52[8{AY)(ASZNB=+&'@"8B(13 .6PD"Y?QQ[RD&65MUB9^%ZV&#8OG7/PO.\2?YS?H:3BH%9B0_;8MX]/BWS

M%R%:2S>9'XL48*),)KV4)C;E=2?>_,FB MW* ?'#.+7ZU-3T2HD ?'0+CO86#!W34"-A75DI2[3F=6R]{H[_WZ7Q@[-_N3*#^1_MGD51ZB_]5\'OA3(=&4,'E&?)'ZM1!4?37OU42$HI@BC

$<0Z@D4|@B&3*<(B-M"E!D-T%@"B;GMAL-R]K+4$R#/=>@9ENWV>T;6U+SW@PN&3JGV^%W-;-,K_VU-M+$V>\P\UTY!P]^_ZGR3ND,57&C?

N'N3+,\DGH#4N<^]+OM2=I'5+")U$&S", M/.@EL3KF"S^$"0D|&*61YQ$I?&YV*=Y!8Z9\/O"-I@D:HI;U6>>@;,,*(P6V

M,VJVL@\:^CHCC>A\KS:%5TD%.R/BI:RP]I=C#9J:GKL"P-MC/T/QL%;=4T$=*3#G:1F5683H0^UVNB=8>K]5JA-G-7=XA82^9RRD$)9-6KP MD&ZI$@D8\CB*!4%Q**R:G;87GUA|VZ3I-./4 3/-'"]7G28:B62M=.=X=Z1D M!TO/JE3GA#I6HK/C+_;K53[=SB]|F*K%BVNKIF9?

9<]=MB69A,1C&"8XIDG,_(3:;9.6]"=6O8KI\.1D$P#M+X8OJ1157]95I6AF1 S?Q!)"NK(UFD+-<9 MW915(*O,P2_L/T51Y"MPDZ^?|\O6 #;|\+3#-#XP@B.Z/2$>>KYJTVR3A7X/H(

ML5OB=I"!@?2N*M@I*,U;G]XO\DGUN<$K0[T/(<5Z+7AU U-?PW]>E$5)IES6 M1>Q%%(LXA-Q'&.(PDC'1H8#"CWE"TX0DGE65>0^]B;V+'74ZB>5]FS">[5D8

MGK7;!Z6IW^$,(%L_8XM-D\);TP8MXBY["B,IG?D0W=1F!AF,1#_U$'LS,# M7&2+H?_RIOO{$%?B7\BCV*11HE(SP2,84.SLF\$;:.&81|6.>_89X8E89<M(C#U/65#$FQI

DW43)\O8M*MP"XDM;SCLQ/26$G|).G(AU6OU@JI_F6OAQ<7 MG$7Q^L39:EKO<_:]3,\45.J7N]X71?GMZZU2VD?"Q*,,&%F^S8K:M'8B8GCT:*Z7#$!H:AC

GBD4B047:1/>F)U,%B!C3<@&_?OT1"(& MVBR0]_VTQ+=;@:=%S4ZU|0 ;T#'5$CGS#JK3(3BLHZJCGYV5D]5A&'0T7;5< M<+8FK,,$;3=E'.C"P$9.^@KS3KU;M5\(//!KS0#=VY

&'&.E81\(0Q%Y,8R8% M0B&Q:J#57GUB@UH/,-$K)I1G ?"[& R6#P[RVYVN1W:_]_EKLY4Y7A"PKZ_PSR58ZF+1@P@\P"P2,*%>: MA6D"28HI%(C$2^X;\9 *SAH*Z'J5D

A/]M4^<[%5=@)0PK M @?.;Z;YTX!F!]9;']I_%KDM&Z#*%!]",]"6&#L!],9?2<;*/>%7R0$R!^12 M;I#%"@/'*75D!VY#H,VPNW;H^B[_I'#(5Z6"1;U^_V&E=%RY&(N((Z&V]PC&

MNNML%EDD"$^9AZ&.6XCB0":;#U2 FM_Q-,+4^BJ+X2],AISBY#5D=L 2RAB?+ M^A#77\S,QKWB=[SA+UYUH?W+IM!CL?W,(=[L@RW?#D=230.H]V%6CKF;=PS6 M--">#-

":B,PP0]X:R?U9JI/=4UZ0Y<_K?/.TJ^33"6F*,K;:"-Y,_U*L;?,< M4P|[GE#GL{@37/=;)9!X40Q3%GII(H*8AKZ-Y1[+T-2F>L^>G?T=#;29P9T3 M/CL+NV4&5-RTBYS;#

{$=1U>@)S,ZNU=_7>L7ETMNXP>_A% M/ NU;CTV>U6M^%]9^7"C#H[*1J]OUSG?L%+70(OU<\;$&^5?/SR2]=^;B*R4 M+$D#XBGW51VJL?0EI+HK6<*91Y Z= MN-

~~5MH)#\36\.&N^U\^IH_\+MB$&PY MO (-C]6 AH9+L&/3SHB,_3IF-G1&S.U,Z'BX)ZBE=H26(R,ZE!M9;.@CZ(Y- MJ*ME!R=.*¥M#Z 16_H# HR=P)E9+E=PV)FE/1(5W0](=WL@ M/G4 ,23KN5="=RG.ETG-G<_<*_29Y.7^=P9V<:@&N//1/>M[\,H)DD:08&$ MGOTE*$P%BI2N\Y2&).$QMBJ!N$!G\AREBBK8Df7LA7-!'3,-=B"SG?*>BCN! MC] CE;M6 !>HS%O-WRWJ24%^S^/#-/27,)7K?*E=M!8QA A)$@4;J0KJE6K* MU(<1PRCP=8%O8-52^IC Q#KYR4D(_05,Y4<(ZN=+FH,K;?1V:/*ET1TD)@G MR\^JD9>$.U;%B_9)QCJ6.Y-%:*XU_=OGS9:IS_+&U*(XFU6/&9%(?B"BE#(M@(20I%77,K^;2(QAQ'VI%>_-XC0+O4UZJQ3;B>G._*4H4*C"CQE..F/#B M4'DG'M+=?U""*((T{AB(5Q] ! (<0SRD[J)S6Q040_!MZ_@H!\U5Z[9@"@\ IH M'LP5O0>P?NOG#@8[L]=&X.TI @,RI'N@,#=V[B 99N5ZH'%CV=*N'|8UDDRJSI)IB3?G15L6]Z .X,)SMZ-+.">Y)K; I#I:[I? MY[+: @*+&F]'5\[-.!A=/ZI^!9_77TO=?['!74KUE5)Z8+!*&/F$JE-B$NJC M8]CG'D@/QFF$*8IP[$6AI2WIHSFQ+6E/+;@"3V0-G]N&9+K.F^?+)5D7X$E9 MFZKFV[+DVP118V/B$B=K8Z(A:NJ^%7WULP(U!TWW-L5#70_NU%J82NS.6O12-MG-M;F$)PQEH8OSIZXM.[[_KFL1GF\D&9*3WW@]71,R_[/LK#1CZ9+3ZQD3@> M4G0%6FSIO?28L<%#G@RQ[+8:L\!H9T.L$02_.>TD/1H2%U.>#"F^UI@G.T Z MY€Q9+C0@YN_JH)%^]X3MZB+DY^_9AD2IW'P(BVC6[!]D6-3+Z8=Q%"-S"EU7 M+,T-H? EB;DZ!.8C-N5UY<*IWOGQ6J]ZL!<_*]X15^V2C>AY*@U2HG8G'NL,: M"SQ(5G;C].HC@E''FVB=R7]4V_>QH@YHXV%*WSK[N ,5L0.T,!KO]X"(" MTR1$]XOH+MVY@];SNCKDK3(SI@?A<^]. MK*![8D!3,S_%GI6S_Y Z5D0[Y;M;DZK.JS7;#9A*;'70[!)KT#GR[(*S'1,[MQ&F? CN?& [8WJIWXAA0/M^O\.>."OWGY5@C^857OS@==C_?777&4A,@34"[* M(18I@RF1'D2"AQY!213&5B7\]BQ,K*0?/OWZ[NO=AT_@^N;NP^_?KC[\.ZK MW08Z %6S775;K.RT7;OPFAFPY0;0%_"#9@AD]S^#'4^MINB37'L-Q\31WCR M@5DWI.$`>_B(U8;U^KH>]7(E.K7E]&EN"X*41;[\2D['8I8D.,]'S#@-- W M:#%,//4/7U 62XH8QU;-DJVH3VR4=K.W=-'-GAM0L],;[S-XRI$=UF;V:C($ M[4R54_ &]S^R L%Q"R0SVJ_2!,,9]^>6($KHJ!%%7P1Y6:] M M=5]S&+R,-YV0UB#Z/%MHP^#)38+O+0*=2PV,/Y)>>+/G2*=!!_Z'YR=%9< M/57A0U%L!%_$:L_T DZ@A_0$!!:FD(92PM0/$2S 7=,_MTQB^-^(^6ZWT;DN)^@LFW(.&/%]REE 81PG1]S\^I%S_)PTP3A/.4\(;T-ZM M^,R0;2F:!YCK(3]3H67FG#F0W\[V'Y90UC2O00$UUDI3)K4KEN;_-'DJT64M((.R^$/(XPQ$HG(8W2 *9I'& :<1'& MGNDTG/;"4]_V5*3 ;S4QPW#,B?#=*C=&)#L=,Y7&:LI-.=8'S;@ZGQ?@.MV3_;W M>5ZN]LCYJ"3R:4U9SN:] C5/IOT/3KT<*)X MU)W5=!#L2U;_5;L!]1^0>X$6D8QBS",?AD&L WYA" (DD*90^(IZ71*G/+.O^ M+A.,/G&H:CBHD.F>U=&D:CQ8U%WCU._V:<<(^($\/:WS[]DC*<7R11>J+$51 M@/*!K*Q=S YL3?U,-XC9.ILMJD"3O0) [PB[=S7[IG/F<':1F=CS[A3[U/@W> M&=HV>R4^RZ.D):)^_IO'-_EZG?^N4YK(D_J;\D5G1GA1Z$G("(T@#BB':1#K MN2LQ2A+!$B\([%IDFQ.?.HY19]/)AHLK\%CS >B6$< :3FS;95L ;&85IH+-.MSDIH+O2UR5$>XA5H6 $[7L!-'W(#.E[;0^"LN[4%Z9D[6=N#L :=J9G M.|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|2V|Sl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~~

_"